{"title":"Nootropics","description":"\u003cp\u003e\u003cspan\u003eBeyond traditional nootropics like racetams and herbal adaptogens, there is a growing class of research chemical nootropics and neuropeptides studied for their roles in cognitive enhancement, neuroprotection, mood regulation, and neurogenesis.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eThese compounds are often experimental or investigational, making them especially important in cutting-edge neuroscience and longevity research.\u003cbr\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eResearch Chemical \u0026amp; Experimental Nootropics\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eBromantane (Ladasten)\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eA unique actoprotector and mild stimulant with anxiolytic properties.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eIncreases dopamine synthesis without typical stimulant side effects.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eStudied for fatigue resistance, motivation, and performance under stress.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eNSI-189\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eExperimental neurogenic compound derived from nicotinamide and pyrazine.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003ePromotes hippocampal neurogenesis in animal studies.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eInvestigated for major depressive disorder, cognitive decline, and neuroregeneration.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCerebrolysin\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eA peptide mixture from porcine brain proteins with neurotrophic effects.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eStudied for stroke recovery, traumatic brain injury, Alzheimer’s, and dementia.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eEnhances neuroplasticity and nerve repair.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePhenibut HCl (β-Phenyl-GABA)\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eA GABA analogue with anxiolytic and mood-stabilizing effects.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eIncreases sociability, reduces stress, and supports sleep.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eOriginally developed in Russia for anxiety and space medicine.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eNeuropeptide \u0026amp; Nasal Nootropics\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSemax\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eSynthetic peptide derived from ACTH fragments.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eEnhances BDNF expression, neuroplasticity, and recovery from cognitive decline.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eStudied for stroke, memory, and learning enhancement.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSelank\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eAnxiolytic peptide with serotonergic and GABAergic activity.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eReduces stress and anxiety, while improving focus and memory stability.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCerebrolysin (Peptide Injection)\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003e(as above, but worth repeating in neuropeptide category).\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eSupports cognitive resilience and neuroprotection.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eN-Acetyl Semax Amidate (NA-Semax)\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eA modified form of Semax with stronger cognitive and mood-regulating effects.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAdditional Experimental Nootropics\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eColuracetam – enhances high-affinity choline uptake (HACU); studied for depression and memory support.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eFasoracetam – interacts with GABA and metabotropic glutamate receptors; studied for attention deficit and cognitive flexibility.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eSunifiram (DM-235) – potent ampakine-like compound; supports learning and memory.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eUnifiram (DM-232) – closely related to sunifiram, with stronger cognitive-enhancing activity.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003ePRL-8-53 – experimental nootropic studied for short-term memory enhancement.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eNoopept (GVS-111) – peptide-like nootropic, stronger than piracetam; studied for neuroprotection, learning, and memory.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eMood \u0026amp; Anxiolytic Research Nootropics\u003cbr\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eTianeptine (Sodium \/ Sulfate) – atypical antidepressant with neuroplasticity-promoting effects.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eAgmatine Sulfate – neuromodulator with anti-anxiety, neuroprotective, and antidepressant potential.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003ePicamilon – combination of niacin and GABA; studied for vasodilation and stress relief.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003ePhenylpiracetam Hydrazide – derivative of phenylpiracetam with longer-lasting stimulant and cognitive effects.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eApplications of Research Nootropics\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eCognitive Enhancement: Improving memory, focus, and executive function.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eNeuroprotection: Supporting recovery in traumatic brain injury, stroke, and neurodegeneration.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eNeurogenesis \u0026amp; Plasticity: Compounds like NSI-189 and Semax promote new neuron growth.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eMood \u0026amp; Stress Regulation: Selank, Phenibut, and Tianeptine reduce anxiety and stabilize mood.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eLongevity \u0026amp; Regeneration: Cerebrolysin, Semax, and nootropic peptides support anti-aging brain research.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSummary of the Research Nootropic Family\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eThe advanced nootropic family includes:\u003cbr\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eActoprotectors \u0026amp; Neurogenic Agents: Bromantane, NSI-189.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eNeuroprotective Peptides: Semax, Selank, Cerebrolysin.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eAnxiolytic Compounds: Phenibut, Tianeptine, Agmatine.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eExperimental Racetam Derivatives: Coluracetam, Fasoracetam, Sunifiram, PRL-8-53, Noopept.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eTogether, they represent the frontier of cognitive science, neuroregeneration, and mood research, with applications ranging from memory enhancement and depression treatment to neurodegenerative disease models.\u003c\/span\u003e\u003c\/p\u003e","products":[{"product_id":"noopept-10mgx90","title":"Noopept 100x10mg","description":"\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e\u003cstrong data-end=\"392\" data-start=\"377\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                       \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"text-decoration: underline; color: rgb(255, 42, 0);\"\u003eFOR HUMAN CONSUMPTION\u003cmeta charset=\"UTF-8\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"86\" data-end=\"665\"\u003e\u003cstrong\u003eNoopept \u003c\/strong\u003eis a small dipeptidomimetic \u003cstrong data-start=\"155\" data-end=\"168\"\u003enootropic\u003c\/strong\u003e developed in Russia. After oral dosing it is rapidly \u003cstrong data-start=\"222\" data-end=\"267\"\u003ehydrolyzed to cyclo-L-prolylglycine (cPG)\u003c\/strong\u003e and related fragments that \u003cstrong data-start=\"295\" data-end=\"331\"\u003emodulate glutamatergic signaling\u003c\/strong\u003e, enhance \u003cstrong data-start=\"341\" data-end=\"379\"\u003eneurotrophin expression (BDNF\/NGF)\u003c\/strong\u003e, and exert \u003cstrong data-start=\"391\" data-end=\"424\"\u003eantioxidant\/anti-inflammatory\u003c\/strong\u003e effects. In clinical practice (primarily Eastern Europe), it has been used for \u003cstrong data-start=\"504\" data-end=\"539\"\u003emild cognitive impairment (MCI)\u003c\/strong\u003e and \u003cstrong data-start=\"544\" data-end=\"578\"\u003epost-injury cognitive symptoms\u003c\/strong\u003e. It is \u003cstrong data-start=\"586\" data-end=\"610\"\u003enot FDA\/EMA-approved\u003c\/strong\u003e; evidence outside Russia is limited and heterogeneous.\u003c\/p\u003e\n\u003chr data-start=\"667\" data-end=\"670\"\u003e\n\u003ch3 data-start=\"672\" data-end=\"730\"\u003eAdditional Benefits of Noopept Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"732\" data-end=\"2936\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"732\" data-end=\"760\"\u003e\n\u003ctr data-start=\"732\" data-end=\"760\"\u003e\n\u003cth data-start=\"732\" data-end=\"742\" data-col-size=\"sm\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-start=\"742\" data-end=\"760\" data-col-size=\"xl\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"771\" data-end=\"2936\"\u003e\n\u003ctr data-start=\"771\" data-end=\"1060\"\u003e\n\u003ctd data-start=\"771\" data-end=\"808\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"773\" data-end=\"807\"\u003e1 Cognitive performance in MCI\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"808\" data-end=\"1060\" data-col-size=\"xl\"\u003eSmall randomized and open-label trials report \u003cstrong data-start=\"856\" data-end=\"908\"\u003eimproved memory, attention, and global cognition\u003c\/strong\u003evs baseline and \u003cstrong data-start=\"925\" data-end=\"956\"\u003epiracetam-class comparators\u003c\/strong\u003e over 1–3 months. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Neuroscience \u0026amp; Behavioral Physiology; Zhurnal Nevrologii i Psikhiatrii\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1061\" data-end=\"1302\"\u003e\n\u003ctd data-start=\"1061\" data-end=\"1106\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1063\" data-end=\"1105\"\u003e2 Anxiolytic and anti-asthenic effects\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1106\" data-end=\"1302\" data-col-size=\"xl\"\u003eReductions in \u003cstrong data-start=\"1122\" data-end=\"1172\"\u003etrait anxiety, emotional lability, and fatigue\u003c\/strong\u003e have been observed alongside cognitive gains, with good daytime tolerability. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;CNS Drugs; Human Psychopharmacology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1303\" data-end=\"1547\"\u003e\n\u003ctd data-start=\"1303\" data-end=\"1346\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1305\" data-end=\"1345\"\u003e3 Post-TBI\/stroke cognitive recovery\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1346\" data-end=\"1547\" data-col-size=\"xl\"\u003eAnimal models and small clinical series show \u003cstrong data-start=\"1393\" data-end=\"1431\"\u003ebetter learning, faster processing\u003c\/strong\u003e, and \u003cstrong data-start=\"1437\" data-end=\"1464\"\u003eimproved daily function\u003c\/strong\u003e during rehabilitation. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Brain Research; Stroke \u0026amp; Vascular Neurology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1548\" data-end=\"1756\"\u003e\n\u003ctd data-start=\"1548\" data-end=\"1583\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1550\" data-end=\"1582\"\u003e4 Neurotrophic up-regulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1583\" data-end=\"1756\" data-col-size=\"xl\"\u003eHippocampal \u003cstrong data-start=\"1597\" data-end=\"1626\"\u003eBDNF and NGF mRNA\/protein\u003c\/strong\u003e increase after Noopept\/cPG, supporting \u003cstrong data-start=\"1666\" data-end=\"1689\"\u003esynaptic plasticity\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Molecular Neurobiology; Journal of Neurochemistry\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1757\" data-end=\"1983\"\u003e\n\u003ctd data-start=\"1757\" data-end=\"1798\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1759\" data-end=\"1797\"\u003e5 Anti-amyloid \u0026amp; synaptoprotection\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1798\" data-end=\"1983\" data-col-size=\"xl\"\u003eAttenuates \u003cstrong data-start=\"1811\" data-end=\"1834\"\u003eAβ-induced toxicity\u003c\/strong\u003e, normalizes synaptic markers, and improves task performance in AD-like models. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Journal of Alzheimer’s Disease; Neurobiology of Aging\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1984\" data-end=\"2248\"\u003e\n\u003ctd data-start=\"1984\" data-end=\"2030\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1986\" data-end=\"2029\"\u003e6 Antioxidant\/anti-inflammatory actions\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2030\" data-end=\"2248\" data-col-size=\"xl\"\u003eLowers \u003cstrong data-start=\"2039\" data-end=\"2067\"\u003elipid peroxidation (MDA)\u003c\/strong\u003e, restores \u003cstrong data-start=\"2078\" data-end=\"2097\"\u003eglutathione\/SOD\u003c\/strong\u003e, and \u003cstrong data-start=\"2103\" data-end=\"2136\"\u003edown-shifts NF-κB\/TNF-α\/IL-1β\u003c\/strong\u003e, contributing to neuroprotection. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Free Radical Biology \u0026amp; Medicine; Journal of Neuroinflammation\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2249\" data-end=\"2476\"\u003e\n\u003ctd data-start=\"2249\" data-end=\"2287\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"2251\" data-end=\"2286\"\u003e7 Visual and sensory processing\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2287\" data-end=\"2476\" data-col-size=\"xl\"\u003eNormalization of \u003cstrong data-start=\"2306\" data-end=\"2336\"\u003eevoked-potential latencies\u003c\/strong\u003e and contrast sensitivity reported in MCI\/vascular cognitive impairment subgroups. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Clinical Neurophysiology; Vision Research\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2477\" data-end=\"2675\"\u003e\n\u003ctd data-start=\"2477\" data-end=\"2510\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"2479\" data-end=\"2509\"\u003e8 Sleep\/circadian symptoms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2510\" data-end=\"2675\" data-col-size=\"xl\"\u003eExploratory data suggest \u003cstrong data-start=\"2537\" data-end=\"2567\"\u003ereduced daytime sleepiness\u003c\/strong\u003e without stimulant-type disruption of sleep architecture. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Sleep Medicine; Psychopharmacology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2676\" data-end=\"2936\"\u003e\n\u003ctd data-start=\"2676\" data-end=\"2707\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"2678\" data-end=\"2706\"\u003e9 Safety in older adults\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2707\" data-end=\"2936\" data-col-size=\"xl\"\u003eShort-course use (10–30 mg\/day) generally \u003cstrong data-start=\"2751\" data-end=\"2769\"\u003ewell tolerated\u003c\/strong\u003e with \u003cstrong data-start=\"2775\" data-end=\"2798\"\u003elow discontinuation\u003c\/strong\u003e; comparative safety vs racetams favorable in small programs. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Drugs \u0026amp; Aging; International Journal of Geriatric Psychiatry\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"2938\" data-end=\"2941\"\u003e\n\u003ch2 data-start=\"2943\" data-end=\"2978\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-start=\"2980\" data-end=\"3006\"\u003e2.1 Pharmacodynamics\u003c\/h3\u003e\n\u003cul data-start=\"3007\" data-end=\"3569\"\u003e\n\u003cli data-start=\"3007\" data-end=\"3164\"\u003e\n\u003cp data-start=\"3009\" data-end=\"3164\"\u003e\u003cstrong data-start=\"3009\" data-end=\"3027\"\u003eProdrug → cPG:\u003c\/strong\u003e Oral Noopept yields \u003cstrong data-start=\"3048\" data-end=\"3073\"\u003ecyclo-L-prolylglycine\u003c\/strong\u003e, which modulates \u003cstrong data-start=\"3091\" data-end=\"3104\"\u003eAMPA\/NMDA\u003c\/strong\u003e tone and \u003cstrong data-start=\"3114\" data-end=\"3134\"\u003eCa²⁺ homeostasis\u003c\/strong\u003e, improving LTP\/LTD balance.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3165\" data-end=\"3316\"\u003e\n\u003cp data-start=\"3167\" data-end=\"3316\"\u003e\u003cstrong data-start=\"3167\" data-end=\"3185\"\u003eNeurotrophins:\u003c\/strong\u003e Up-regulates \u003cstrong data-start=\"3199\" data-end=\"3211\"\u003eBDNF\/NGF\u003c\/strong\u003e and \u003cstrong data-start=\"3216\" data-end=\"3233\"\u003eTrk-dependent\u003c\/strong\u003e pathways (CREB\/MAPK), supporting dendritic spine maintenance and synaptogenesis.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3317\" data-end=\"3438\"\u003e\n\u003cp data-start=\"3319\" data-end=\"3438\"\u003e\u003cstrong data-start=\"3319\" data-end=\"3342\"\u003eRedox\/Inflammation:\u003c\/strong\u003e Enhances \u003cstrong data-start=\"3352\" data-end=\"3375\"\u003eantioxidant enzymes\u003c\/strong\u003e, reduces \u003cstrong data-start=\"3385\" data-end=\"3410\"\u003eROS\/NO overproduction\u003c\/strong\u003e, and modulates \u003cstrong data-start=\"3426\" data-end=\"3435\"\u003eNF-κB\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3439\" data-end=\"3569\"\u003e\n\u003cp data-start=\"3441\" data-end=\"3569\"\u003e\u003cstrong data-start=\"3441\" data-end=\"3465\"\u003eAnti-excitotoxicity:\u003c\/strong\u003e Limits glutamate-driven damage and stabilizes \u003cstrong data-start=\"3512\" data-end=\"3548\"\u003emitochondrial membrane potential\u003c\/strong\u003e in stressed neurons.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"3571\" data-end=\"3598\"\u003e2.2 Down-stream Biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"3600\" data-end=\"4103\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"3600\" data-end=\"3642\"\u003e\n\u003ctr data-start=\"3600\" data-end=\"3642\"\u003e\n\u003cth data-start=\"3600\" data-end=\"3610\" data-col-size=\"sm\"\u003ePathway\u003c\/th\u003e\n\u003cth data-start=\"3610\" data-end=\"3631\" data-col-size=\"md\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-start=\"3631\" data-end=\"3642\" data-col-size=\"sm\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"3657\" data-end=\"4103\"\u003e\n\u003ctr data-start=\"3657\" data-end=\"3744\"\u003e\n\u003ctd data-start=\"3657\" data-end=\"3692\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3659\" data-end=\"3691\"\u003ecPG → AMPA\/NMDA tuning; CREB\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3692\" data-end=\"3722\" data-col-size=\"md\"\u003e↑ LTP, memory consolidation\u003c\/td\u003e\n\u003ctd data-start=\"3722\" data-end=\"3744\" data-col-size=\"sm\"\u003eHippocampus\/cortex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3745\" data-end=\"3834\"\u003e\n\u003ctd data-start=\"3745\" data-end=\"3775\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3747\" data-end=\"3774\"\u003eBDNF\/NGF → Trk\/ERK\/PI3K\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3775\" data-end=\"3813\" data-col-size=\"md\"\u003e↑ Synaptic plasticity, neurogenesis\u003c\/td\u003e\n\u003ctd data-start=\"3813\" data-end=\"3834\" data-col-size=\"sm\"\u003eLearning circuits\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3835\" data-end=\"3943\"\u003e\n\u003ctd data-start=\"3835\" data-end=\"3870\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3837\" data-end=\"3869\"\u003eAntioxidant (SOD\/GSH) \u0026amp; Nrf2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3870\" data-end=\"3923\" data-col-size=\"md\"\u003e↓ ROS\/lipid peroxidation, mitochondrial protection\u003c\/td\u003e\n\u003ctd data-start=\"3923\" data-end=\"3943\" data-col-size=\"sm\"\u003eOxidative stress\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3944\" data-end=\"4024\"\u003e\n\u003ctd data-start=\"3944\" data-end=\"3979\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3946\" data-end=\"3978\"\u003eNF-κB\/TNF-α\/IL-1β down-shift\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3979\" data-end=\"4001\" data-col-size=\"md\"\u003e↓ Neuroinflammation\u003c\/td\u003e\n\u003ctd data-start=\"4001\" data-end=\"4024\" data-col-size=\"sm\"\u003eInjury\/degeneration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"4025\" data-end=\"4103\"\u003e\n\u003ctd data-start=\"4025\" data-end=\"4054\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"4027\" data-end=\"4053\"\u003eAβ toxicity mitigation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"4054\" data-end=\"4085\" data-col-size=\"md\"\u003ePreserves synapses, behavior\u003c\/td\u003e\n\u003ctd data-start=\"4085\" data-end=\"4103\" data-col-size=\"sm\"\u003eAD-like models\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"4105\" data-end=\"4108\"\u003e\n\u003ch2 data-start=\"4110\" data-end=\"4132\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-start=\"4134\" data-end=\"4623\"\u003e\n\u003cli data-start=\"4134\" data-end=\"4221\"\u003e\n\u003cp data-start=\"4136\" data-end=\"4221\"\u003e\u003cstrong data-start=\"4136\" data-end=\"4155\"\u003eAbsorption\/BBB:\u003c\/strong\u003e Rapid oral absorption; \u003cstrong data-start=\"4179\" data-end=\"4198\"\u003ebrain-penetrant\u003c\/strong\u003e small peptide ester.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4222\" data-end=\"4332\"\u003e\n\u003cp data-start=\"4224\" data-end=\"4332\"\u003e\u003cstrong data-start=\"4224\" data-end=\"4243\"\u003eOnset\/Duration:\u003c\/strong\u003e Subjective effects within \u003cstrong data-start=\"4270\" data-end=\"4278\"\u003edays\u003c\/strong\u003e; steady neurotrophic changes accrue over \u003cstrong data-start=\"4320\" data-end=\"4329\"\u003eweeks\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4333\" data-end=\"4425\"\u003e\n\u003cp data-start=\"4335\" data-end=\"4425\"\u003e\u003cstrong data-start=\"4335\" data-end=\"4349\"\u003eHalf-life:\u003c\/strong\u003e Short (hours) for parent; \u003cstrong data-start=\"4376\" data-end=\"4396\"\u003eactive fragments\u003c\/strong\u003e may persist longer in CNS.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4426\" data-end=\"4532\"\u003e\n\u003cp data-start=\"4428\" data-end=\"4532\"\u003e\u003cstrong data-start=\"4428\" data-end=\"4450\"\u003eDosing in studies:\u003c\/strong\u003e \u003cstrong data-start=\"4451\" data-end=\"4467\"\u003e10–30 mg\/day\u003c\/strong\u003e in \u003cstrong data-start=\"4471\" data-end=\"4492\"\u003e1–3 divided doses\u003c\/strong\u003e for \u003cstrong data-start=\"4497\" data-end=\"4511\"\u003e1–3 months\u003c\/strong\u003e, sometimes cyclic.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4533\" data-end=\"4623\"\u003e\n\u003cp data-start=\"4535\" data-end=\"4623\"\u003e\u003cstrong data-start=\"4535\" data-end=\"4551\"\u003eElimination:\u003c\/strong\u003e Hydrolysis to amino-acid derivatives; renal\/hepatic peptide catabolism.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4625\" data-end=\"4628\"\u003e\n\u003ch2 data-start=\"4630\" data-end=\"4675\"\u003e4. Pre-clinical and Translational Evidence\u003c\/h2\u003e\n\u003ch3 data-start=\"4677\" data-end=\"4722\"\u003e4.1 Cognitive impairment (vascular\/MCI)\u003c\/h3\u003e\n\u003cp data-start=\"4723\" data-end=\"4909\"\u003eSmall RCTs and open-label trials (primarily Russia\/Eastern Europe) show \u003cstrong data-start=\"4795\" data-end=\"4824\"\u003eimproved memory\/attention\u003c\/strong\u003e and \u003cstrong data-start=\"4829\" data-end=\"4846\"\u003eglobal scales\u003c\/strong\u003e vs baseline and vs \u003cstrong data-start=\"4866\" data-end=\"4879\"\u003epiracetam\u003c\/strong\u003e, with favorable tolerability.\u003c\/p\u003e\n\u003ch3 data-start=\"4911\" data-end=\"4951\"\u003e4.2 Neuroprotection (ischemia\/TBI)\u003c\/h3\u003e\n\u003cp data-start=\"4952\" data-end=\"5081\"\u003eRodent models demonstrate \u003cstrong data-start=\"4978\" data-end=\"5004\"\u003ereduced neuronal death\u003c\/strong\u003e, better \u003cstrong data-start=\"5013\" data-end=\"5033\"\u003espatial learning\u003c\/strong\u003e, and \u003cstrong data-start=\"5039\" data-end=\"5057\"\u003emotor recovery\u003c\/strong\u003e when given peri-injury.\u003c\/p\u003e\n\u003ch3 data-start=\"5083\" data-end=\"5117\"\u003e4.3 Alzheimer-like pathology\u003c\/h3\u003e\n\u003cp data-start=\"5118\" data-end=\"5251\"\u003eIn Aβ-infusion\/APP models, Noopept \u003cstrong data-start=\"5153\" data-end=\"5181\"\u003ereduces amyloid toxicity\u003c\/strong\u003e, normalizes \u003cstrong data-start=\"5194\" data-end=\"5215\"\u003esynaptic proteins\u003c\/strong\u003e, and improves \u003cstrong data-start=\"5230\" data-end=\"5250\"\u003ebehavioral tasks\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cblockquote data-start=\"5253\" data-end=\"5461\"\u003e\n\u003cp data-start=\"5255\" data-end=\"5461\"\u003e\u003cstrong data-start=\"5255\" data-end=\"5281\"\u003eEvidence quality note:\u003c\/strong\u003e \u003cstrong data-start=\"5282\" data-end=\"5337\"\u003eHuman data are limited, regional, and heterogeneous\u003c\/strong\u003e; many studies are small and short. Larger \u003cstrong data-start=\"5380\" data-end=\"5415\"\u003emulticenter, placebo-controlled\u003c\/strong\u003e trials using harmonized endpoints are needed.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-start=\"5463\" data-end=\"5466\"\u003e\n\u003ch2 data-start=\"5468\" data-end=\"5501\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"5503\" data-end=\"6099\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"5503\" data-end=\"5541\"\u003e\n\u003ctr data-start=\"5503\" data-end=\"5541\"\u003e\n\u003cth data-start=\"5503\" data-end=\"5511\" data-col-size=\"sm\"\u003eField\u003c\/th\u003e\n\u003cth data-start=\"5511\" data-end=\"5523\" data-col-size=\"md\"\u003eRationale\u003c\/th\u003e\n\u003cth data-start=\"5523\" data-end=\"5541\" data-col-size=\"sm\"\u003eCurrent status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"5556\" data-end=\"6099\"\u003e\n\u003ctr data-start=\"5556\" data-end=\"5667\"\u003e\n\u003ctd data-start=\"5556\" data-end=\"5601\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5558\" data-end=\"5600\"\u003ePost-concussive\/long-COVID “brain fog”\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5601\" data-end=\"5646\" data-col-size=\"md\"\u003eAnti-inflammatory + neurotrophic signaling\u003c\/td\u003e\n\u003ctd data-start=\"5646\" data-end=\"5667\" data-col-size=\"sm\"\u003ePilot\/exploratory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5668\" data-end=\"5776\"\u003e\n\u003ctd data-start=\"5668\" data-end=\"5704\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5670\" data-end=\"5703\"\u003eVascular cognitive impairment\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5704\" data-end=\"5742\" data-col-size=\"md\"\u003eAntioxidant\/vasculoneuronal support\u003c\/td\u003e\n\u003ctd data-start=\"5742\" data-end=\"5776\" data-col-size=\"sm\"\u003eSmall RCTs; replication needed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5777\" data-end=\"5880\"\u003e\n\u003ctd data-start=\"5777\" data-end=\"5818\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5779\" data-end=\"5817\"\u003eChemo-related cognitive impairment\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5818\" data-end=\"5851\" data-col-size=\"md\"\u003eSynaptic rescue, redox balance\u003c\/td\u003e\n\u003ctd data-start=\"5851\" data-end=\"5880\" data-col-size=\"sm\"\u003ePreclinical → feasibility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5881\" data-end=\"5986\"\u003e\n\u003ctd data-start=\"5881\" data-end=\"5917\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5883\" data-end=\"5916\"\u003eAge-related cognitive decline\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5917\" data-end=\"5960\" data-col-size=\"md\"\u003eBDNF\/NGF up-shift with good tolerability\u003c\/td\u003e\n\u003ctd data-start=\"5960\" data-end=\"5986\" data-col-size=\"sm\"\u003eEarly clinical signals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5987\" data-end=\"6099\"\u003e\n\u003ctd data-start=\"5987\" data-end=\"6025\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5989\" data-end=\"6024\"\u003eAnxiety with cognitive symptoms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6025\" data-end=\"6076\" data-col-size=\"md\"\u003eAnxiolytic + procognitive in dysexecutive states\u003c\/td\u003e\n\u003ctd data-start=\"6076\" data-end=\"6099\" data-col-size=\"sm\"\u003eSmall trials\/series\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"6101\" data-end=\"6104\"\u003e\n\u003ch2 data-start=\"6106\" data-end=\"6135\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-start=\"6137\" data-end=\"6833\"\u003e\n\u003cli data-start=\"6137\" data-end=\"6278\"\u003e\n\u003cp data-start=\"6139\" data-end=\"6278\"\u003e\u003cstrong data-start=\"6139\" data-end=\"6150\"\u003eCommon:\u003c\/strong\u003e \u003cstrong data-start=\"6151\" data-end=\"6163\"\u003eHeadache\u003c\/strong\u003e, \u003cstrong data-start=\"6165\" data-end=\"6181\"\u003eirritability\u003c\/strong\u003e, \u003cstrong data-start=\"6183\" data-end=\"6200\"\u003emild insomnia\u003c\/strong\u003e or \u003cstrong data-start=\"6204\" data-end=\"6218\"\u003esomnolence\u003c\/strong\u003e, \u003cstrong data-start=\"6220\" data-end=\"6240\"\u003enausea\/dyspepsia\u003c\/strong\u003e—usually transient and dose-related.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6279\" data-end=\"6385\"\u003e\n\u003cp data-start=\"6281\" data-end=\"6385\"\u003e\u003cstrong data-start=\"6281\" data-end=\"6297\"\u003eLess common:\u003c\/strong\u003e \u003cstrong data-start=\"6298\" data-end=\"6316\"\u003eBP sensitivity\u003c\/strong\u003e, \u003cstrong data-start=\"6318\" data-end=\"6335\"\u003eallergic rash\u003c\/strong\u003e, \u003cstrong data-start=\"6337\" data-end=\"6353\"\u003erestlessness\u003c\/strong\u003e in stimulant-sensitive users.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6386\" data-end=\"6564\"\u003e\n\u003cp data-start=\"6388\" data-end=\"6564\"\u003e\u003cstrong data-start=\"6388\" data-end=\"6433\"\u003eDrug interactions (theoretical\/observed):\u003c\/strong\u003e Additive CNS effects with \u003cstrong data-start=\"6460\" data-end=\"6474\"\u003estimulants\u003c\/strong\u003e, \u003cstrong data-start=\"6476\" data-end=\"6488\"\u003eracetams\u003c\/strong\u003e, or \u003cstrong data-start=\"6493\" data-end=\"6515\"\u003ehigh-dose caffeine\u003c\/strong\u003e; consider spacing with \u003cstrong data-start=\"6539\" data-end=\"6561\"\u003esedative-hypnotics\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6565\" data-end=\"6703\"\u003e\n\u003cp data-start=\"6567\" data-end=\"6703\"\u003e\u003cstrong data-start=\"6567\" data-end=\"6591\"\u003eSpecial populations:\u003c\/strong\u003e Insufficient data in \u003cstrong data-start=\"6613\" data-end=\"6626\"\u003epregnancy\u003c\/strong\u003e, \u003cstrong data-start=\"6628\" data-end=\"6645\"\u003ebreastfeeding\u003c\/strong\u003e, \u003cstrong data-start=\"6647\" data-end=\"6679\"\u003esevere hepatic\/renal disease\u003c\/strong\u003e—avoid outside trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6704\" data-end=\"6752\"\u003e\n\u003cp data-start=\"6706\" data-end=\"6752\"\u003e\u003cstrong data-start=\"6706\" data-end=\"6726\"\u003eAbuse potential:\u003c\/strong\u003e \u003cstrong data-start=\"6727\" data-end=\"6734\"\u003eLow\u003c\/strong\u003e (non-euphoric).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6753\" data-end=\"6833\"\u003e\n\u003cp data-start=\"6755\" data-end=\"6833\"\u003e\u003cstrong data-start=\"6755\" data-end=\"6775\"\u003eDiscontinuation:\u003c\/strong\u003e Generally uncomplicated; no withdrawal syndrome reported.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"6835\" data-end=\"6864\"\u003e\u003cstrong data-start=\"6835\" data-end=\"6864\"\u003eComparative safety matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"6866\" data-end=\"7506\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"6866\" data-end=\"6940\"\u003e\n\u003ctr data-start=\"6866\" data-end=\"6940\"\u003e\n\u003cth data-start=\"6866\" data-end=\"6876\" data-col-size=\"sm\"\u003eConcern\u003c\/th\u003e\n\u003cth data-start=\"6876\" data-end=\"6890\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6878\" data-end=\"6889\"\u003eNoopept\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6890\" data-end=\"6906\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6892\" data-end=\"6905\"\u003ePiracetam\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6906\" data-end=\"6923\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6908\" data-end=\"6922\"\u003eAniracetam\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6923\" data-end=\"6940\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6925\" data-end=\"6938\"\u003eModafinil\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"6963\" data-end=\"7506\"\u003e\n\u003ctr data-start=\"6963\" data-end=\"7101\"\u003e\n\u003ctd data-start=\"6963\" data-end=\"6975\" data-col-size=\"sm\"\u003eMechanism\u003c\/td\u003e\n\u003ctd data-start=\"6975\" data-end=\"7015\" data-col-size=\"sm\"\u003ecPG → glutamate tuning; neurotrophins\u003c\/td\u003e\n\u003ctd data-start=\"7015\" data-end=\"7045\" data-col-size=\"sm\"\u003eAMPA\/NMDA modulation (weak)\u003c\/td\u003e\n\u003ctd data-start=\"7045\" data-end=\"7071\" data-col-size=\"sm\"\u003eAMPA-positive modulator\u003c\/td\u003e\n\u003ctd data-start=\"7071\" data-end=\"7101\" data-col-size=\"sm\"\u003eWake-promoter (DAT\/orexin)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7102\" data-end=\"7216\"\u003e\n\u003ctd data-start=\"7102\" data-end=\"7120\" data-col-size=\"sm\"\u003eEvidence in MCI\u003c\/td\u003e\n\u003ctd data-start=\"7120\" data-end=\"7148\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7122\" data-end=\"7147\"\u003eSmall RCTs (regional)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"7148\" data-end=\"7175\" data-col-size=\"sm\"\u003eExtensive legacy (mixed)\u003c\/td\u003e\n\u003ctd data-start=\"7175\" data-end=\"7199\" data-col-size=\"sm\"\u003eSmall studies (mixed)\u003c\/td\u003e\n\u003ctd data-start=\"7199\" data-end=\"7216\" data-col-size=\"sm\"\u003eNot indicated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7217\" data-end=\"7307\"\u003e\n\u003ctd data-start=\"7217\" data-end=\"7230\" data-col-size=\"sm\"\u003eAnxiolysis\u003c\/td\u003e\n\u003ctd data-start=\"7230\" data-end=\"7250\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7232\" data-end=\"7249\"\u003eYes (signals)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"7250\" data-end=\"7260\" data-col-size=\"sm\"\u003eNeutral\u003c\/td\u003e\n\u003ctd data-start=\"7260\" data-end=\"7276\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7262\" data-end=\"7275\"\u003eOften yes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"7276\" data-end=\"7307\" data-col-size=\"sm\"\u003eVariable; can be activating\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7308\" data-end=\"7372\"\u003e\n\u003ctd data-start=\"7308\" data-end=\"7328\" data-col-size=\"sm\"\u003eHeadache\/insomnia\u003c\/td\u003e\n\u003ctd data-start=\"7328\" data-end=\"7335\" data-col-size=\"sm\"\u003eMild\u003c\/td\u003e\n\u003ctd data-start=\"7335\" data-end=\"7342\" data-col-size=\"sm\"\u003eMild\u003c\/td\u003e\n\u003ctd data-start=\"7342\" data-end=\"7349\" data-col-size=\"sm\"\u003eMild\u003c\/td\u003e\n\u003ctd data-start=\"7349\" data-end=\"7372\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7351\" data-end=\"7370\"\u003eInsomnia common\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7373\" data-end=\"7506\"\u003e\n\u003ctd data-start=\"7373\" data-end=\"7393\" data-col-size=\"sm\"\u003eRegulatory status\u003c\/td\u003e\n\u003ctd data-start=\"7393\" data-end=\"7424\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7395\" data-end=\"7423\"\u003eApproved regionally (RU)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"7424\" data-end=\"7444\" data-col-size=\"sm\"\u003eVaries by country\u003c\/td\u003e\n\u003ctd data-start=\"7444\" data-end=\"7471\" data-col-size=\"sm\"\u003eSupplement\/drug (varies)\u003c\/td\u003e\n\u003ctd data-start=\"7471\" data-end=\"7506\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7473\" data-end=\"7504\"\u003eApproved (narcolepsy, etc.)\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"7508\" data-end=\"7511\"\u003e\n\u003ch2 data-start=\"7513\" data-end=\"7539\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-start=\"7541\" data-end=\"7789\"\u003e\n\u003cli data-start=\"7541\" data-end=\"7633\"\u003e\n\u003cp data-start=\"7543\" data-end=\"7633\"\u003e\u003cstrong data-start=\"7543\" data-end=\"7569\"\u003eRussia\/Eastern Europe:\u003c\/strong\u003e Marketed prescription \u003cstrong data-start=\"7592\" data-end=\"7605\"\u003enootropic\u003c\/strong\u003e for cognitive impairment.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7634\" data-end=\"7789\"\u003e\n\u003cp data-start=\"7636\" data-end=\"7789\"\u003e\u003cstrong data-start=\"7636\" data-end=\"7652\"\u003eUS\/EU\/UK\/CA:\u003c\/strong\u003e \u003cstrong data-start=\"7653\" data-end=\"7669\"\u003eNot approved\u003c\/strong\u003e as a medicine; appears on \u003cstrong data-start=\"7696\" data-end=\"7729\"\u003eresearch-chemical\/“nootropic”\u003c\/strong\u003e markets—quality varies and clinical claims are unregulated.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"7791\" data-end=\"7794\"\u003e\n\u003ch2 data-start=\"7796\" data-end=\"7819\"\u003e8. Future Directions\u003c\/h2\u003e\n\u003cul data-start=\"7821\" data-end=\"8426\"\u003e\n\u003cli data-start=\"7821\" data-end=\"7958\"\u003e\n\u003cp data-start=\"7823\" data-end=\"7958\"\u003e\u003cstrong data-start=\"7823\" data-end=\"7843\"\u003eMulticenter RCTs\u003c\/strong\u003e in \u003cstrong data-start=\"7847\" data-end=\"7858\"\u003eMCI\/VCI\u003c\/strong\u003e with validated composites (e.g., \u003cstrong data-start=\"7892\" data-end=\"7918\"\u003eADAS-Cog, CDR-SB, SAGE\u003c\/strong\u003e) and \u003cstrong data-start=\"7924\" data-end=\"7945\"\u003edigital cognitive\u003c\/strong\u003e endpoints.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7959\" data-end=\"8072\"\u003e\n\u003cp data-start=\"7961\" data-end=\"8072\"\u003e\u003cstrong data-start=\"7961\" data-end=\"7976\"\u003eBiomarkers:\u003c\/strong\u003e CSF\/plasma \u003cstrong data-start=\"7988\" data-end=\"8000\"\u003eBDNF\/NGF\u003c\/strong\u003e, inflammatory panels, \u003cstrong data-start=\"8023\" data-end=\"8034\"\u003eEEG\/ERP\u003c\/strong\u003e and \u003cstrong data-start=\"8039\" data-end=\"8060\"\u003efMRI connectivity\u003c\/strong\u003e readouts.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8073\" data-end=\"8160\"\u003e\n\u003cp data-start=\"8075\" data-end=\"8160\"\u003e\u003cstrong data-start=\"8075\" data-end=\"8091\"\u003eHead-to-head\u003c\/strong\u003e vs \u003cstrong data-start=\"8095\" data-end=\"8114\"\u003epiracetam-class\u003c\/strong\u003e agents and vs \u003cstrong data-start=\"8129\" data-end=\"8157\"\u003estandard cognitive rehab\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8161\" data-end=\"8285\"\u003e\n\u003cp data-start=\"8163\" data-end=\"8285\"\u003e\u003cstrong data-start=\"8163\" data-end=\"8187\"\u003eFormulation science:\u003c\/strong\u003e \u003cstrong data-start=\"8188\" data-end=\"8210\"\u003eControlled-release\u003c\/strong\u003e or \u003cstrong data-start=\"8214\" data-end=\"8228\"\u003eintranasal\u003c\/strong\u003e routes to optimize CNS exposure and reduce GI effects.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8286\" data-end=\"8426\"\u003e\n\u003cp data-start=\"8288\" data-end=\"8426\"\u003e\u003cstrong data-start=\"8288\" data-end=\"8315\"\u003eCombination strategies:\u003c\/strong\u003e Pair with \u003cstrong data-start=\"8326\" data-end=\"8357\"\u003eaerobic\/resistance exercise\u003c\/strong\u003e or \u003cstrong data-start=\"8361\" data-end=\"8386\"\u003emultidomain lifestyle\u003c\/strong\u003e programs to potentiate neuroplasticity.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"8428\" data-end=\"8431\"\u003e\n\u003ch3 data-start=\"8433\" data-end=\"8456\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-start=\"8458\" data-end=\"9357\"\u003e\n\u003cli data-start=\"8458\" data-end=\"8602\"\u003e\n\u003cp data-start=\"8460\" data-end=\"8602\"\u003e\u003cem data-start=\"8460\" data-end=\"8532\"\u003eNeuroscience \u0026amp; Behavioral Physiology; Zhurnal Nevrologii i Psikhiatrii\u003c\/em\u003e — Clinical studies of Noopept in MCI\/vascular cognitive impairment.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8603\" data-end=\"8706\"\u003e\n\u003cp data-start=\"8605\" data-end=\"8706\"\u003e\u003cem data-start=\"8605\" data-end=\"8642\"\u003eCNS Drugs; Human Psychopharmacology\u003c\/em\u003e — Anxiolytic and procognitive profiles of peptide nootropics.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8707\" data-end=\"8826\"\u003e\n\u003cp data-start=\"8709\" data-end=\"8826\"\u003e\u003cem data-start=\"8709\" data-end=\"8760\"\u003eMolecular Neurobiology; Journal of Neurochemistry\u003c\/em\u003e — BDNF\/NGF signaling and synaptic plasticity under Noopept\/cPG.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8827\" data-end=\"8932\"\u003e\n\u003cp data-start=\"8829\" data-end=\"8932\"\u003e\u003cem data-start=\"8829\" data-end=\"8884\"\u003eJournal of Alzheimer’s Disease; Neurobiology of Aging\u003c\/em\u003e — Anti-amyloid and synaptoprotective effects.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8933\" data-end=\"9020\"\u003e\n\u003cp data-start=\"8935\" data-end=\"9020\"\u003e\u003cem data-start=\"8935\" data-end=\"8980\"\u003eBrain Research; Stroke \u0026amp; Vascular Neurology\u003c\/em\u003e — Neuroprotection after TBI\/ischemia.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9021\" data-end=\"9136\"\u003e\n\u003cp data-start=\"9023\" data-end=\"9136\"\u003e\u003cem data-start=\"9023\" data-end=\"9086\"\u003eFree Radical Biology \u0026amp; Medicine; Journal of Neuroinflammation\u003c\/em\u003e — Antioxidant and anti-inflammatory mechanisms.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9137\" data-end=\"9236\"\u003e\n\u003cp data-start=\"9139\" data-end=\"9236\"\u003e\u003cem data-start=\"9139\" data-end=\"9182\"\u003eClinical Neurophysiology; Vision Research\u003c\/em\u003e — Evoked-potential and sensory-processing findings.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9237\" data-end=\"9357\"\u003e\n\u003cp data-start=\"9239\" data-end=\"9357\"\u003e\u003cem data-start=\"9239\" data-end=\"9301\"\u003eDrugs \u0026amp; Aging; International Journal of Geriatric Psychiatry\u003c\/em\u003e — Tolerability in older adults and comparative context.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":50937976094984,"sku":"","price":30.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0937\/9053\/5944\/files\/Noopept_10mg.png?v=1756663670"},{"product_id":"cerebrolysin-60mg-vial","title":"Cerebrolysin 60mg vial","description":"\u003cp\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e               \u003c\/span\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                            \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003e\u003cstrong data-start=\"377\" data-end=\"392\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"text-decoration: underline; color: rgb(255, 42, 0);\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003ca href=\"https:\/\/www.cerebrolysin.com\/\" data-cke-saved-href=\"https:\/\/www.cerebrolysin.com\" target=\"_blank\"\u003eCerebrolysin\u003c\/a\u003e\u003c\/strong\u003e is\u003cmeta charset=\"UTF-8\"\u003e a \u003cstrong data-start=\"97\" data-end=\"170\"\u003estandardized porcine brain–derived peptide and amino-acid preparation\u003c\/strong\u003e (low–molecular-weight neuropeptides \u0026lt;10 kDa) formulated for \u003cstrong data-start=\"231\" data-end=\"249\"\u003eparenteral use\u003c\/strong\u003e. It exerts \u003cstrong data-start=\"261\" data-end=\"291\"\u003eneurotrophic-like activity\u003c\/strong\u003e—functionally mimicking \u003cstrong data-start=\"315\" data-end=\"327\"\u003eBDNF\/NGF\u003c\/strong\u003esignaling—promoting \u003cstrong data-start=\"348\" data-end=\"415\"\u003eneuronal survival, synaptogenesis, neurogenesis, and plasticity\u003c\/strong\u003e while dampening \u003cstrong data-start=\"432\" data-end=\"491\"\u003eexcitotoxicity, oxidative stress, and neuroinflammation\u003c\/strong\u003e. It is \u003cstrong data-start=\"499\" data-end=\"519\"\u003enot FDA-approved\u003c\/strong\u003e; it is marketed in several countries (ex-US\/UK) for \u003cstrong data-start=\"572\" data-end=\"621\"\u003estroke recovery, traumatic brain injury (TBI)\u003c\/strong\u003e, and \u003cstrong data-start=\"627\" data-end=\"651\"\u003ecognitive impairment\u003c\/strong\u003e based on regional evidence and guidelines.\u003c\/p\u003e\n\u003chr data-start=\"696\" data-end=\"699\"\u003e\n\u003ch3 data-start=\"701\" data-end=\"764\"\u003eAdditional Benefits of Cerebrolysin Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"766\" data-end=\"3340\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"766\" data-end=\"794\"\u003e\n\u003ctr data-start=\"766\" data-end=\"794\"\u003e\n\u003cth data-start=\"766\" data-end=\"776\" data-col-size=\"md\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-start=\"776\" data-end=\"794\" data-col-size=\"xl\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"805\" data-end=\"3340\"\u003e\n\u003ctr data-start=\"805\" data-end=\"1165\"\u003e\n\u003ctd data-start=\"805\" data-end=\"854\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"807\" data-end=\"853\"\u003e1 Post-ischemic stroke functional recovery\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"854\" data-end=\"1165\" data-col-size=\"xl\"\u003eMeta-analyses and RCTs report \u003cstrong data-start=\"886\" data-end=\"926\"\u003eimproved global disability and NIHSS\u003c\/strong\u003e with \u003cstrong data-start=\"932\" data-end=\"983\"\u003eearly IV courses (e.g., 30 mL\/day × 10–20 days)\u003c\/strong\u003e, particularly when paired with structured rehab; heterogeneity and risk of bias remain. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Stroke; Journal of Stroke \u0026amp; Cerebrovascular Diseases; European Stroke Journal\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1166\" data-end=\"1498\"\u003e\n\u003ctd data-start=\"1166\" data-end=\"1215\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1168\" data-end=\"1214\"\u003e2 Traumatic brain injury (moderate–severe)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1215\" data-end=\"1498\" data-col-size=\"xl\"\u003eSignals for \u003cstrong data-start=\"1229\" data-end=\"1270\"\u003ebetter Glasgow Outcome Scale-Extended\u003c\/strong\u003e, \u003cstrong data-start=\"1272\" data-end=\"1304\"\u003efaster cognitive\/motor gains\u003c\/strong\u003e, and \u003cstrong data-start=\"1310\" data-end=\"1336\"\u003elower mortality trends\u003c\/strong\u003e in some cohorts using \u003cstrong data-start=\"1359\" data-end=\"1375\"\u003e10–50 mL\/day\u003c\/strong\u003e cycles; larger contemporary trials are needed. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Neurorehabilitation \u0026amp; Neural Repair; Journal of Neurotrauma\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1499\" data-end=\"1762\"\u003e\n\u003ctd data-start=\"1499\" data-end=\"1543\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1501\" data-end=\"1542\"\u003e3 Vascular\/mixed cognitive impairment\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1543\" data-end=\"1762\" data-col-size=\"xl\"\u003eModest \u003cstrong data-start=\"1552\" data-end=\"1586\"\u003eattention\/executive and memory\u003c\/strong\u003e improvements across small RCTs; effects strengthen when combined with \u003cstrong data-start=\"1657\" data-end=\"1688\"\u003emultidomain cognitive rehab\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;CNS Drugs; International Journal of Geriatric Psychiatry\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1763\" data-end=\"2040\"\u003e\n\u003ctd data-start=\"1763\" data-end=\"1805\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1765\" data-end=\"1804\"\u003e4 Alzheimer’s disease (symptomatic)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1805\" data-end=\"2040\" data-col-size=\"xl\"\u003eAdd-on to standard care shows \u003cstrong data-start=\"1837\" data-end=\"1890\"\u003eshort-term cognitive and global-function benefits\u003c\/strong\u003e in mild–moderate AD; durability and disease-modification are unproven. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Alzheimer’s Research \u0026amp; Therapy; Journal of Alzheimer’s Disease\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2041\" data-end=\"2280\"\u003e\n\u003ctd data-start=\"2041\" data-end=\"2080\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2043\" data-end=\"2079\"\u003e5 Aphasia \u0026amp; post-stroke language\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2080\" data-end=\"2280\" data-col-size=\"xl\"\u003ePilot trials indicate \u003cstrong data-start=\"2104\" data-end=\"2142\"\u003egreater gains on aphasia batteries\u003c\/strong\u003e when Cerebrolysin is given \u003cstrong data-start=\"2170\" data-end=\"2216\"\u003econcurrently with intensive speech therapy\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Aphasiology; Neuropsychological Rehabilitation\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2281\" data-end=\"2541\"\u003e\n\u003ctd data-start=\"2281\" data-end=\"2313\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2283\" data-end=\"2312\"\u003e6 Motor plasticity \u0026amp; gait\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2313\" data-end=\"2541\" data-col-size=\"xl\"\u003eEnhanced \u003cstrong data-start=\"2324\" data-end=\"2365\"\u003eFugl-Meyer, Barthel Index, gait speed\u003c\/strong\u003e and \u003cstrong data-start=\"2370\" data-end=\"2401\"\u003eDTI\/fMRI plasticity markers\u003c\/strong\u003e when paired with \u003cstrong data-start=\"2419\" data-end=\"2450\"\u003etask-specific physiotherapy\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Neurorehabilitation \u0026amp; Neural Repair; Restorative Neurology \u0026amp; Neuroscience\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2542\" data-end=\"2792\"\u003e\n\u003ctd data-start=\"2542\" data-end=\"2583\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2544\" data-end=\"2582\"\u003e7 Post-ICU\/encephalopathy recovery\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2583\" data-end=\"2792\" data-col-size=\"xl\"\u003eObservational programs suggest \u003cstrong data-start=\"2616\" data-end=\"2655\"\u003efaster cognitive\/functional rebound\u003c\/strong\u003e after toxic-metabolic encephalopathy; controlled evidence is preliminary. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Critical Care Medicine; Frontiers in Neurology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2793\" data-end=\"3056\"\u003e\n\u003ctd data-start=\"2793\" data-end=\"2828\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2795\" data-end=\"2827\"\u003e8 Neuroprotection biomarkers\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2828\" data-end=\"3056\" data-col-size=\"xl\"\u003eIn models and small human studies: \u003cstrong data-start=\"2865\" data-end=\"2874\"\u003e↑BDNF\u003c\/strong\u003e, \u003cstrong data-start=\"2876\" data-end=\"2884\"\u003e↓NfL\u003c\/strong\u003e, \u003cstrong data-start=\"2886\" data-end=\"2911\"\u003e↓MDA\/oxidative stress\u003c\/strong\u003e, and \u003cstrong data-start=\"2917\" data-end=\"2948\"\u003e↓pro-inflammatory cytokines\u003c\/strong\u003e, paralleling clinical improvements. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Molecular Neurobiology; Frontiers in Aging Neuroscience\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3057\" data-end=\"3340\"\u003e\n\u003ctd data-start=\"3057\" data-end=\"3099\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"3059\" data-end=\"3098\"\u003e9 Combination neurorehab strategies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3099\" data-end=\"3340\" data-col-size=\"xl\"\u003eAdditive effects with \u003cstrong data-start=\"3123\" data-end=\"3166\"\u003erobot-assisted therapy, NMES, rTMS\/tDCS\u003c\/strong\u003e, and \u003cstrong data-start=\"3172\" data-end=\"3194\"\u003eearly mobilization\u003c\/strong\u003e, supporting a \u003cstrong data-start=\"3209\" data-end=\"3241\"\u003e“drug-plus-dose-dense-rehab”\u003c\/strong\u003e paradigm. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Clinical Neurophysiology; Archives of Physical Medicine \u0026amp; Rehabilitation\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"3342\" data-end=\"3345\"\u003e\n\u003ch2 data-start=\"3347\" data-end=\"3382\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-start=\"3384\" data-end=\"3410\"\u003e2.1 Pharmacodynamics\u003c\/h3\u003e\n\u003cp data-start=\"3411\" data-end=\"3886\"\u003eCerebrolysin’s peptide fractions activate \u003cstrong data-start=\"3453\" data-end=\"3487\"\u003eTrk receptors (TrkB\/TrkA-like)\u003c\/strong\u003e and downstream \u003cstrong data-start=\"3503\" data-end=\"3515\"\u003ePI3K–Akt\u003c\/strong\u003e and \u003cstrong data-start=\"3520\" data-end=\"3532\"\u003eMAPK–ERK\u003c\/strong\u003e cascades, enhancing \u003cstrong data-start=\"3553\" data-end=\"3561\"\u003eCREB\u003c\/strong\u003e signaling → \u003cstrong data-start=\"3574\" data-end=\"3605\"\u003esynaptic protein expression\u003c\/strong\u003e (synapsin, PSD-95), \u003cstrong data-start=\"3626\" data-end=\"3647\"\u003eneurite outgrowth\u003c\/strong\u003e, and \u003cstrong data-start=\"3653\" data-end=\"3689\"\u003eanti-apoptosis (Bcl-2↑\/caspase↓)\u003c\/strong\u003e. Additional actions include \u003cstrong data-start=\"3718\" data-end=\"3739\"\u003eNMDA\/GABA balance\u003c\/strong\u003e (anti-excitotoxic), \u003cstrong data-start=\"3760\" data-end=\"3785\"\u003emicroglial modulation\u003c\/strong\u003e (NF-κB down-tuning), \u003cstrong data-start=\"3807\" data-end=\"3832\"\u003emitochondrial support\u003c\/strong\u003e, and \u003cstrong data-start=\"3838\" data-end=\"3875\"\u003eamyloid\/tau pathway normalization\u003c\/strong\u003e in models.\u003c\/p\u003e\n\u003ch3 data-start=\"3888\" data-end=\"3915\"\u003e2.2 Down-stream Biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"3917\" data-end=\"4540\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"3917\" data-end=\"3959\"\u003e\n\u003ctr data-start=\"3917\" data-end=\"3959\"\u003e\n\u003cth data-start=\"3917\" data-end=\"3927\" data-col-size=\"sm\"\u003ePathway\u003c\/th\u003e\n\u003cth data-start=\"3927\" data-end=\"3948\" data-col-size=\"md\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-start=\"3948\" data-end=\"3959\" data-col-size=\"sm\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"3974\" data-end=\"4540\"\u003e\n\u003ctr data-start=\"3974\" data-end=\"4069\"\u003e\n\u003ctd data-start=\"3974\" data-end=\"4006\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3976\" data-end=\"4005\"\u003eBDNF\/TrkB → PI3K–Akt–CREB\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"4006\" data-end=\"4047\" data-col-size=\"md\"\u003eNeuronal survival, LTP, synaptogenesis\u003c\/td\u003e\n\u003ctd data-start=\"4047\" data-end=\"4069\" data-col-size=\"sm\"\u003eHippocampus\/cortex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"4070\" data-end=\"4144\"\u003e\n\u003ctd data-start=\"4070\" data-end=\"4085\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"4072\" data-end=\"4084\"\u003eMAPK–ERK\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"4085\" data-end=\"4122\" data-col-size=\"md\"\u003ePlasticity, learning, neurogenesis\u003c\/td\u003e\n\u003ctd data-start=\"4122\" data-end=\"4144\" data-col-size=\"sm\"\u003eNeurorehab windows\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"4145\" data-end=\"4240\"\u003e\n\u003ctd data-start=\"4145\" data-end=\"4174\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"4147\" data-end=\"4173\"\u003eNMDA\/GABA re-balancing\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"4174\" data-end=\"4215\" data-col-size=\"md\"\u003eAnti-excitotoxicity, network stability\u003c\/td\u003e\n\u003ctd data-start=\"4215\" data-end=\"4240\" data-col-size=\"sm\"\u003eAcute\/subacute injury\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"4241\" data-end=\"4330\"\u003e\n\u003ctd data-start=\"4241\" data-end=\"4271\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"4243\" data-end=\"4270\"\u003eNF-κB \/ NLRP3 restraint\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"4271\" data-end=\"4312\" data-col-size=\"md\"\u003e↓ Microglial cytokines, ↓ inflammation\u003c\/td\u003e\n\u003ctd data-start=\"4312\" data-end=\"4330\" data-col-size=\"sm\"\u003eStroke\/TBI, AD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"4331\" data-end=\"4436\"\u003e\n\u003ctd data-start=\"4331\" data-end=\"4362\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"4333\" data-end=\"4361\"\u003eOxidative stress control\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"4362\" data-end=\"4412\" data-col-size=\"md\"\u003e↓ ROS\/lipid peroxidation; mitochondrial support\u003c\/td\u003e\n\u003ctd data-start=\"4412\" data-end=\"4436\" data-col-size=\"sm\"\u003eIschemia–reperfusion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"4437\" data-end=\"4540\"\u003e\n\u003ctd data-start=\"4437\" data-end=\"4461\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"4439\" data-end=\"4460\"\u003eAβ\/tau modulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"4461\" data-end=\"4520\" data-col-size=\"md\"\u003e↓ Amyloid toxicity, ↓ tau hyper-phosphorylation (models)\u003c\/td\u003e\n\u003ctd data-start=\"4520\" data-end=\"4540\" data-col-size=\"sm\"\u003eAD-like settings\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"4542\" data-end=\"4545\"\u003e\n\u003ch2 data-start=\"4547\" data-end=\"4569\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-start=\"4571\" data-end=\"5074\"\u003e\n\u003cli data-start=\"4571\" data-end=\"4655\"\u003e\n\u003cp data-start=\"4573\" data-end=\"4655\"\u003e\u003cstrong data-start=\"4573\" data-end=\"4589\"\u003eComposition:\u003c\/strong\u003e Low-MW neuropeptides and free amino acids; \u003cstrong data-start=\"4633\" data-end=\"4652\"\u003eparenteral only\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4656\" data-end=\"4778\"\u003e\n\u003cp data-start=\"4658\" data-end=\"4778\"\u003e\u003cstrong data-start=\"4658\" data-end=\"4673\"\u003eBBB access:\u003c\/strong\u003e Peptides \u003cstrong data-start=\"4683\" data-end=\"4694\"\u003e\u0026lt;10 kDa\u003c\/strong\u003e and fragments \u003cstrong data-start=\"4709\" data-end=\"4726\"\u003ecross the BBB\u003c\/strong\u003e; pharmacodynamic effects outlast plasma exposure.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4779\" data-end=\"4889\"\u003e\n\u003cp data-start=\"4781\" data-end=\"4889\"\u003e\u003cstrong data-start=\"4781\" data-end=\"4795\"\u003eHalf-life:\u003c\/strong\u003e \u003cstrong data-start=\"4796\" data-end=\"4821\"\u003eShort (minutes–hours)\u003c\/strong\u003e for peptide components; signaling changes persist for days–weeks.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4890\" data-end=\"5074\"\u003e\n\u003cp data-start=\"4892\" data-end=\"5074\"\u003e\u003cstrong data-start=\"4892\" data-end=\"4914\"\u003eDosing in studies:\u003c\/strong\u003e \u003cstrong data-start=\"4915\" data-end=\"4942\"\u003eIV infusion 5–50 mL\/day\u003c\/strong\u003e (often \u003cstrong data-start=\"4950\" data-end=\"4963\"\u003e30 mL\/day\u003c\/strong\u003e) for \u003cstrong data-start=\"4969\" data-end=\"4983\"\u003e10–20 days\u003c\/strong\u003e, repeated \u003cstrong data-start=\"4994\" data-end=\"5014\"\u003eevery 1–3 months\u003c\/strong\u003e in subacute\/chronic phases; IM 5 mL used in some protocols.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"5076\" data-end=\"5079\"\u003e\n\u003ch2 data-start=\"5081\" data-end=\"5126\"\u003e4. Pre-clinical and Translational Evidence\u003c\/h2\u003e\n\u003ch3 data-start=\"5128\" data-end=\"5144\"\u003e4.1 Stroke\u003c\/h3\u003e\n\u003cp data-start=\"5145\" data-end=\"5430\"\u003eRodent and primate stroke models show \u003cstrong data-start=\"5183\" data-end=\"5203\"\u003esmaller infarcts\u003c\/strong\u003e, \u003cstrong data-start=\"5205\" data-end=\"5233\"\u003ebetter neurologic scores\u003c\/strong\u003e, and \u003cstrong data-start=\"5239\" data-end=\"5275\"\u003eenhanced peri-infarct plasticity\u003c\/strong\u003e. Human RCTs\/meta-analyses suggest \u003cstrong data-start=\"5310\" data-end=\"5333\"\u003efunctional benefits\u003c\/strong\u003e with early use + rehab, but \u003cstrong data-start=\"5362\" data-end=\"5385\"\u003etrial heterogeneity\u003c\/strong\u003e(timing, dose, endpoints) tempers certainty.\u003c\/p\u003e\n\u003ch3 data-start=\"5432\" data-end=\"5464\"\u003e4.2 Traumatic Brain Injury\u003c\/h3\u003e\n\u003cp data-start=\"5465\" data-end=\"5637\"\u003eImproved \u003cstrong data-start=\"5474\" data-end=\"5499\"\u003econsciousness metrics\u003c\/strong\u003e, \u003cstrong data-start=\"5501\" data-end=\"5514\"\u003ecognition\u003c\/strong\u003e, and \u003cstrong data-start=\"5520\" data-end=\"5550\"\u003eactivities of daily living\u003c\/strong\u003e reported in several trials\/series; \u003cstrong data-start=\"5586\" data-end=\"5617\"\u003emulti-center, modern-design\u003c\/strong\u003e RCTs are warranted.\u003c\/p\u003e\n\u003ch3 data-start=\"5639\" data-end=\"5668\"\u003e4.3 Cognitive Disorders\u003c\/h3\u003e\n\u003cp data-start=\"5669\" data-end=\"5845\"\u003eIn \u003cstrong data-start=\"5672\" data-end=\"5701\"\u003evascular\/mixed impairment\u003c\/strong\u003e and \u003cstrong data-start=\"5706\" data-end=\"5726\"\u003emild–moderate AD\u003c\/strong\u003e, repeated courses yield \u003cstrong data-start=\"5751\" data-end=\"5797\"\u003emodest cognitive and global-function gains\u003c\/strong\u003e; disease-modifying effects remain \u003cstrong data-start=\"5832\" data-end=\"5844\"\u003eunproven\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cblockquote data-start=\"5847\" data-end=\"6075\"\u003e\n\u003cp data-start=\"5849\" data-end=\"6075\"\u003e\u003cstrong data-start=\"5849\" data-end=\"5875\"\u003eEvidence quality note:\u003c\/strong\u003e The totality of evidence is \u003cstrong data-start=\"5904\" data-end=\"5936\"\u003esupportive but heterogeneous\u003c\/strong\u003e (regional RCTs, varying quality). Benefits appear \u003cstrong data-start=\"5987\" data-end=\"6050\"\u003egreatest when combined with early, intensive rehabilitation\u003c\/strong\u003e and standardized dosing.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-start=\"6077\" data-end=\"6080\"\u003e\n\u003ch2 data-start=\"6082\" data-end=\"6115\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"6117\" data-end=\"6644\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"6117\" data-end=\"6155\"\u003e\n\u003ctr data-start=\"6117\" data-end=\"6155\"\u003e\n\u003cth data-start=\"6117\" data-end=\"6125\" data-col-size=\"sm\"\u003eField\u003c\/th\u003e\n\u003cth data-start=\"6125\" data-end=\"6137\" data-col-size=\"md\"\u003eRationale\u003c\/th\u003e\n\u003cth data-start=\"6137\" data-end=\"6155\" data-col-size=\"sm\"\u003eCurrent status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"6170\" data-end=\"6644\"\u003e\n\u003ctr data-start=\"6170\" data-end=\"6275\"\u003e\n\u003ctd data-start=\"6170\" data-end=\"6204\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6172\" data-end=\"6203\"\u003eAphasia\/upper-limb recovery\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6204\" data-end=\"6250\" data-col-size=\"md\"\u003eTrophic plasticity + task-specific training\u003c\/td\u003e\n\u003ctd data-start=\"6250\" data-end=\"6275\" data-col-size=\"sm\"\u003ePhase 2–style signals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6276\" data-end=\"6378\"\u003e\n\u003ctd data-start=\"6276\" data-end=\"6313\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6278\" data-end=\"6312\"\u003ePost-ICU cognitive dysfunction\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6313\" data-end=\"6355\" data-col-size=\"md\"\u003eAnti-inflammatory\/mitochondrial support\u003c\/td\u003e\n\u003ctd data-start=\"6355\" data-end=\"6378\" data-col-size=\"sm\"\u003eObservational\/pilot\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6379\" data-end=\"6459\"\u003e\n\u003ctd data-start=\"6379\" data-end=\"6413\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6381\" data-end=\"6412\"\u003eLong-COVID cognitive issues\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6413\" data-end=\"6444\" data-col-size=\"md\"\u003eNeuroinflammatory modulation\u003c\/td\u003e\n\u003ctd data-start=\"6444\" data-end=\"6459\" data-col-size=\"sm\"\u003eExploratory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6460\" data-end=\"6549\"\u003e\n\u003ctd data-start=\"6460\" data-end=\"6504\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6462\" data-end=\"6503\"\u003ePerioperative neurocognitive disorder\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6504\" data-end=\"6526\" data-col-size=\"md\"\u003eSynaptic resilience\u003c\/td\u003e\n\u003ctd data-start=\"6526\" data-end=\"6549\" data-col-size=\"sm\"\u003eConcept\/feasibility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6550\" data-end=\"6644\"\u003e\n\u003ctd data-start=\"6550\" data-end=\"6594\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6552\" data-end=\"6593\"\u003eParkinson’s-related cognitive decline\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6594\" data-end=\"6627\" data-col-size=\"md\"\u003eSynaptic\/mitochondrial support\u003c\/td\u003e\n\u003ctd data-start=\"6627\" data-end=\"6644\" data-col-size=\"sm\"\u003eEarly studies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"6646\" data-end=\"6649\"\u003e\n\u003ch2 data-start=\"6651\" data-end=\"6680\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-start=\"6682\" data-end=\"7338\"\u003e\n\u003cli data-start=\"6682\" data-end=\"6851\"\u003e\n\u003cp data-start=\"6684\" data-end=\"6851\"\u003e\u003cstrong data-start=\"6684\" data-end=\"6695\"\u003eCommon:\u003c\/strong\u003e \u003cstrong data-start=\"6696\" data-end=\"6724\"\u003eInjection-site reactions\u003c\/strong\u003e, \u003cstrong data-start=\"6726\" data-end=\"6757\"\u003etransient agitation\/anxiety\u003c\/strong\u003e, \u003cstrong data-start=\"6759\" data-end=\"6772\"\u003edizziness\u003c\/strong\u003e, \u003cstrong data-start=\"6774\" data-end=\"6786\"\u003eheadache\u003c\/strong\u003e, \u003cstrong data-start=\"6788\" data-end=\"6800\"\u003eflushing\u003c\/strong\u003e, \u003cstrong data-start=\"6802\" data-end=\"6814\"\u003esweating\u003c\/strong\u003e, \u003cstrong data-start=\"6816\" data-end=\"6828\"\u003einsomnia\u003c\/strong\u003e; generally \u003cstrong data-start=\"6840\" data-end=\"6848\"\u003emild\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6852\" data-end=\"6967\"\u003e\n\u003cp data-start=\"6854\" data-end=\"6967\"\u003e\u003cstrong data-start=\"6854\" data-end=\"6875\"\u003eLess common\/rare:\u003c\/strong\u003e \u003cstrong data-start=\"6876\" data-end=\"6898\"\u003eAllergic reactions\u003c\/strong\u003e, \u003cstrong data-start=\"6900\" data-end=\"6927\"\u003eblood-pressure lability\u003c\/strong\u003e; avoid in \u003cstrong data-start=\"6938\" data-end=\"6964\"\u003eknown hypersensitivity\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6968\" data-end=\"7064\"\u003e\n\u003cp data-start=\"6970\" data-end=\"7064\"\u003e\u003cstrong data-start=\"6970\" data-end=\"6987\"\u003eSeizure risk:\u003c\/strong\u003e Use caution in \u003cstrong data-start=\"7003\" data-end=\"7028\"\u003euncontrolled epilepsy\u003c\/strong\u003e (excitability symptoms possible).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7065\" data-end=\"7214\"\u003e\n\u003cp data-start=\"7067\" data-end=\"7214\"\u003e\u003cstrong data-start=\"7067\" data-end=\"7089\"\u003eDrug interactions:\u003c\/strong\u003e No major CYP interactions expected; monitor with \u003cstrong data-start=\"7139\" data-end=\"7153\"\u003eCNS-active\u003c\/strong\u003e regimens (sedatives\/stimulants) and \u003cstrong data-start=\"7190\" data-end=\"7211\"\u003eantihypertensives\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7215\" data-end=\"7338\"\u003e\n\u003cp data-start=\"7217\" data-end=\"7338\"\u003e\u003cstrong data-start=\"7217\" data-end=\"7247\"\u003eGeriatrics\/polymedication:\u003c\/strong\u003e Good short-course tolerability in studies; continue routine \u003cstrong data-start=\"7308\" data-end=\"7330\"\u003eBP and neurostatus\u003c\/strong\u003echecks.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"7340\" data-end=\"7369\"\u003e\u003cstrong data-start=\"7340\" data-end=\"7369\"\u003eComparative safety matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"7371\" data-end=\"7807\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"7371\" data-end=\"7448\"\u003e\n\u003ctr data-start=\"7371\" data-end=\"7448\"\u003e\n\u003cth data-start=\"7371\" data-end=\"7381\" data-col-size=\"sm\"\u003eConcern\u003c\/th\u003e\n\u003cth data-start=\"7381\" data-end=\"7400\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7383\" data-end=\"7399\"\u003eCerebrolysin\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"7400\" data-end=\"7431\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7402\" data-end=\"7430\"\u003eCiticoline (CDP-choline)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"7431\" data-end=\"7448\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7433\" data-end=\"7446\"\u003eEdaravone\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"7467\" data-end=\"7807\"\u003e\n\u003ctr data-start=\"7467\" data-end=\"7510\"\u003e\n\u003ctd data-start=\"7467\" data-end=\"7475\" data-col-size=\"sm\"\u003eRoute\u003c\/td\u003e\n\u003ctd data-start=\"7475\" data-end=\"7494\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7477\" data-end=\"7493\"\u003eIV\/IM cycles\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"7494\" data-end=\"7504\" data-col-size=\"sm\"\u003eOral\/IV\u003c\/td\u003e\n\u003ctd data-start=\"7504\" data-end=\"7510\" data-col-size=\"sm\"\u003eIV\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7511\" data-end=\"7629\"\u003e\n\u003ctd data-start=\"7511\" data-end=\"7528\" data-col-size=\"sm\"\u003eEvidence focus\u003c\/td\u003e\n\u003ctd data-start=\"7528\" data-end=\"7563\" data-col-size=\"sm\"\u003eStroke\/TBI, VCI\/AD (symptomatic)\u003c\/td\u003e\n\u003ctd data-start=\"7563\" data-end=\"7592\" data-col-size=\"sm\"\u003eStroke recovery, cognition\u003c\/td\u003e\n\u003ctd data-start=\"7592\" data-end=\"7629\" data-col-size=\"sm\"\u003eALS (JP), stroke (select regions)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7630\" data-end=\"7713\"\u003e\n\u003ctd data-start=\"7630\" data-end=\"7636\" data-col-size=\"sm\"\u003eAEs\u003c\/td\u003e\n\u003ctd data-start=\"7636\" data-end=\"7657\" data-col-size=\"sm\"\u003eMild CNS\/vasomotor\u003c\/td\u003e\n\u003ctd data-start=\"7657\" data-end=\"7679\" data-col-size=\"sm\"\u003eGI, headache (mild)\u003c\/td\u003e\n\u003ctd data-start=\"7679\" data-end=\"7713\" data-col-size=\"sm\"\u003eInfusion reactions, renal risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7714\" data-end=\"7807\"\u003e\n\u003ctd data-start=\"7714\" data-end=\"7721\" data-col-size=\"sm\"\u003eRole\u003c\/td\u003e\n\u003ctd data-start=\"7721\" data-end=\"7756\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7723\" data-end=\"7755\"\u003eNeurotrophic + rehab adjunct\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"7756\" data-end=\"7781\" data-col-size=\"sm\"\u003eMembrane\/choline donor\u003c\/td\u003e\n\u003ctd data-start=\"7781\" data-end=\"7807\" data-col-size=\"sm\"\u003eFree-radical scavenger\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"7809\" data-end=\"7812\"\u003e\n\u003ch2 data-start=\"7814\" data-end=\"7840\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-start=\"7842\" data-end=\"8156\"\u003e\n\u003cli data-start=\"7842\" data-end=\"8000\"\u003e\n\u003cp data-start=\"7844\" data-end=\"8000\"\u003e\u003cstrong data-start=\"7844\" data-end=\"7855\"\u003eStatus:\u003c\/strong\u003e \u003cstrong data-start=\"7856\" data-end=\"7880\"\u003eNot FDA\/EMA-approved\u003c\/strong\u003e; \u003cstrong data-start=\"7882\" data-end=\"7915\"\u003emarketed in several countries\u003c\/strong\u003e as an injectable neuropeptide preparation for \u003cstrong data-start=\"7962\" data-end=\"7997\"\u003estroke\/TBI\/cognitive impairment\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8001\" data-end=\"8156\"\u003e\n\u003cp data-start=\"8003\" data-end=\"8156\"\u003e\u003cstrong data-start=\"8003\" data-end=\"8016\"\u003eGuidance:\u003c\/strong\u003e Best supported as an \u003cstrong data-start=\"8038\" data-end=\"8083\"\u003eadjunct to structured neurorehabilitation\u003c\/strong\u003e with \u003cstrong data-start=\"8089\" data-end=\"8109\"\u003eearly initiation\u003c\/strong\u003e and \u003cstrong data-start=\"8114\" data-end=\"8131\"\u003erepeat cycles\u003c\/strong\u003e where locally permitted.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"8158\" data-end=\"8161\"\u003e\n\u003ch2 data-start=\"8163\" data-end=\"8186\"\u003e8. Future Directions\u003c\/h2\u003e\n\u003cul data-start=\"8188\" data-end=\"8945\"\u003e\n\u003cli data-start=\"8188\" data-end=\"8365\"\u003e\n\u003cp data-start=\"8190\" data-end=\"8365\"\u003e\u003cstrong data-start=\"8190\" data-end=\"8225\"\u003eModern, adequately powered RCTs\u003c\/strong\u003e with \u003cstrong data-start=\"8231\" data-end=\"8285\"\u003estandardized dosing (e.g., 30 mL\/day × 10–20 days)\u003c\/strong\u003e and \u003cstrong data-start=\"8290\" data-end=\"8311\"\u003ecore outcome sets\u003c\/strong\u003e (mRS\/NIHSS, Fugl-Meyer, language batteries, PROMs).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8366\" data-end=\"8485\"\u003e\n\u003cp data-start=\"8368\" data-end=\"8485\"\u003e\u003cstrong data-start=\"8368\" data-end=\"8389\"\u003ePrecision timing:\u003c\/strong\u003e Initiation \u003cstrong data-start=\"8401\" data-end=\"8416\"\u003ewithin days\u003c\/strong\u003e of stroke\/TBI; evaluate \u003cstrong data-start=\"8441\" data-end=\"8458\"\u003edose–response\u003c\/strong\u003e and \u003cstrong data-start=\"8463\" data-end=\"8482\"\u003ecycle frequency\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8486\" data-end=\"8648\"\u003e\n\u003cp data-start=\"8488\" data-end=\"8648\"\u003e\u003cstrong data-start=\"8488\" data-end=\"8513\"\u003eBiomarkers \u0026amp; imaging:\u003c\/strong\u003e \u003cstrong data-start=\"8514\" data-end=\"8532\"\u003eSerum\/CSF BDNF\u003c\/strong\u003e, \u003cstrong data-start=\"8534\" data-end=\"8541\"\u003eNfL\u003c\/strong\u003e, \u003cstrong data-start=\"8543\" data-end=\"8566\"\u003einflammatory panels\u003c\/strong\u003e; \u003cstrong data-start=\"8568\" data-end=\"8580\"\u003eDTI\/fMRI\u003c\/strong\u003e for network plasticity; \u003cstrong data-start=\"8605\" data-end=\"8635\"\u003edigital mobility\/cognition\u003c\/strong\u003e endpoints.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8649\" data-end=\"8802\"\u003e\n\u003cp data-start=\"8651\" data-end=\"8802\"\u003e\u003cstrong data-start=\"8651\" data-end=\"8675\"\u003eCombination therapy:\u003c\/strong\u003e Pair with \u003cstrong data-start=\"8686\" data-end=\"8710\"\u003ehigh-intensity rehab\u003c\/strong\u003e, \u003cstrong data-start=\"8712\" data-end=\"8730\"\u003espeech therapy\u003c\/strong\u003e, \u003cstrong data-start=\"8732\" data-end=\"8744\"\u003erobotics\u003c\/strong\u003e, \u003cstrong data-start=\"8746\" data-end=\"8759\"\u003erTMS\/tDCS\u003c\/strong\u003e; examine \u003cstrong data-start=\"8769\" data-end=\"8780\"\u003esynergy\u003c\/strong\u003eand \u003cstrong data-start=\"8785\" data-end=\"8799\"\u003esequencing\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8803\" data-end=\"8945\"\u003e\n\u003cp data-start=\"8805\" data-end=\"8945\"\u003e\u003cstrong data-start=\"8805\" data-end=\"8831\"\u003eReal-world registries:\u003c\/strong\u003e Safety, adherence, and comparative effectiveness vs \u003cstrong data-start=\"8884\" data-end=\"8920\"\u003eciticoline, memantine, donepezil\u003c\/strong\u003e, and \u003cstrong data-start=\"8926\" data-end=\"8944\"\u003estandard rehab\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"8947\" data-end=\"8950\"\u003e\n\u003ch3 data-start=\"8952\" data-end=\"8975\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-start=\"8977\" data-end=\"9913\"\u003e\n\u003cli data-start=\"8977\" data-end=\"9128\"\u003e\n\u003cp data-start=\"8979\" data-end=\"9128\"\u003e\u003cstrong data-start=\"8979\" data-end=\"9060\"\u003eStroke; European Stroke Journal; Journal of Stroke \u0026amp; Cerebrovascular Diseases\u003c\/strong\u003e — Acute\/subacute stroke trials and meta-analyses of Cerebrolysin.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9129\" data-end=\"9278\"\u003e\n\u003cp data-start=\"9131\" data-end=\"9278\"\u003e\u003cstrong data-start=\"9131\" data-end=\"9218\"\u003eNeurorehabilitation \u0026amp; Neural Repair; Archives of Physical Medicine \u0026amp; Rehabilitation\u003c\/strong\u003e — Functional recovery, motor outcomes, and rehab synergy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9279\" data-end=\"9373\"\u003e\n\u003cp data-start=\"9281\" data-end=\"9373\"\u003e\u003cstrong data-start=\"9281\" data-end=\"9321\"\u003eJournal of Neurotrauma; Brain Injury\u003c\/strong\u003e — TBI cohorts and functional\/cognitive endpoints.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9374\" data-end=\"9504\"\u003e\n\u003cp data-start=\"9376\" data-end=\"9504\"\u003e\u003cstrong data-start=\"9376\" data-end=\"9436\"\u003eCNS Drugs; International Journal of Geriatric Psychiatry\u003c\/strong\u003e — Vascular\/mixed cognitive impairment and safety in older adults.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9505\" data-end=\"9625\"\u003e\n\u003cp data-start=\"9507\" data-end=\"9625\"\u003e\u003cstrong data-start=\"9507\" data-end=\"9573\"\u003eAlzheimer’s Research \u0026amp; Therapy; Journal of Alzheimer’s Disease\u003c\/strong\u003e — Add-on symptomatic effects in mild–moderate AD.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9626\" data-end=\"9777\"\u003e\n\u003cp data-start=\"9628\" data-end=\"9777\"\u003e\u003cstrong data-start=\"9628\" data-end=\"9687\"\u003eMolecular Neurobiology; Frontiers in Aging Neuroscience\u003c\/strong\u003e — Mechanistic work: neurotrophic signaling, inflammation, oxidative stress, biomarkers.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9778\" data-end=\"9913\"\u003e\n\u003cp data-start=\"9780\" data-end=\"9913\"\u003e\u003cstrong data-start=\"9780\" data-end=\"9846\"\u003eRestorative Neurology \u0026amp; Neuroscience; Clinical Neurophysiology\u003c\/strong\u003e — Plasticity measures (DTI, fMRI) and combination neuromodulation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":50937997492488,"sku":"","price":75.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0937\/9053\/5944\/files\/Cerebrolysin.png?v=1758644905"},{"product_id":"methylene-blue-60ml-usp-grade","title":"Methylene blue USP grade 100x10mg","description":"\u003cp\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                          \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003eFOR HUMAN \u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eCONSUMPTION\u003cmeta charset=\"UTF-8\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"48\" data-end=\"681\"\u003e\u003cstrong\u003eMethylene blue\u003c\/strong\u003e is a phenothiazine \u003cstrong data-start=\"120\" data-end=\"133\"\u003eredox dye\u003c\/strong\u003e with multiple pharmacologies. Clinically it’s \u003cstrong data-start=\"180\" data-end=\"227\"\u003eFDA-approved for acquired methemoglobinemia\u003c\/strong\u003e (it accepts electrons from NADPH-methemoglobin reductase as \u003cstrong data-start=\"288\" data-end=\"311\"\u003eleucomethylene blue\u003c\/strong\u003eand reduces Fe³⁺→Fe²⁺ to restore O₂ carriage). Beyond this, MB \u003cstrong data-start=\"375\" data-end=\"444\"\u003einhibits nitric-oxide synthase and soluble guanylyl cyclase (sGC)\u003c\/strong\u003e (countering pathologic vasodilation), acts as a \u003cstrong data-start=\"493\" data-end=\"512\"\u003ephotosensitizer\u003c\/strong\u003e for antimicrobial photodynamic therapy (aPDT), \u003cstrong data-start=\"560\" data-end=\"598\"\u003eshuttles electrons in mitochondria\u003c\/strong\u003e, and is a \u003cstrong data-start=\"609\" data-end=\"646\"\u003epotent reversible MAO-A inhibitor\u003c\/strong\u003e (important for drug interactions).\u003c\/p\u003e\n\u003chr data-start=\"683\" data-end=\"686\"\u003e\n\u003ch3 data-start=\"688\" data-end=\"753\"\u003eAdditional Benefits of Methylene Blue Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"755\" data-end=\"3342\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"755\" data-end=\"783\"\u003e\n\u003ctr data-start=\"755\" data-end=\"783\"\u003e\n\u003cth data-start=\"755\" data-end=\"765\" data-col-size=\"md\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-start=\"765\" data-end=\"783\" data-col-size=\"xl\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"794\" data-end=\"3342\"\u003e\n\u003ctr data-start=\"794\" data-end=\"1121\"\u003e\n\u003ctd data-start=\"794\" data-end=\"844\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"796\" data-end=\"843\"\u003e1 Vasoplegic shock rescue (sepsis\/post-CPB)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"844\" data-end=\"1121\" data-col-size=\"xl\"\u003eIV MB can \u003cstrong data-start=\"856\" data-end=\"899\"\u003eraise MAP and reduce catecholamine dose\u003c\/strong\u003e by blocking \u003cstrong data-start=\"912\" data-end=\"927\"\u003eNO–sGC–cGMP\u003c\/strong\u003e signalling; early use in \u003cstrong data-start=\"953\" data-end=\"967\"\u003evasoplegia\u003c\/strong\u003e (post-cardiac surgery, septic shock) shows hemodynamic benefit in RCTs\/series; mortality data remain mixed. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Critical Care; Anesthesiology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1122\" data-end=\"1403\"\u003e\n\u003ctd data-start=\"1122\" data-end=\"1164\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1124\" data-end=\"1163\"\u003e2 Ifosfamide-induced encephalopathy\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1164\" data-end=\"1403\" data-col-size=\"xl\"\u003eCase series and protocols support \u003cstrong data-start=\"1200\" data-end=\"1223\"\u003e1–2 mg\/kg IV q4–8 h\u003c\/strong\u003e to reverse neurotoxicity, likely via \u003cstrong data-start=\"1261\" data-end=\"1281\"\u003eredox re-routing\u003c\/strong\u003e (NAD⁺\/NADH) and \u003cstrong data-start=\"1298\" data-end=\"1330\"\u003emonoamine oxidase modulation\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Journal of Clinical Oncology; Supportive Care in Cancer\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1404\" data-end=\"1730\"\u003e\n\u003ctd data-start=\"1404\" data-end=\"1448\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1406\" data-end=\"1447\"\u003e3 Tau aggregation \u0026amp; neurodegeneration\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1448\" data-end=\"1730\" data-col-size=\"xl\"\u003eMB\/LMTM (leuco-methylthioninium) \u003cstrong data-start=\"1483\" data-end=\"1511\"\u003einhibits tau aggregation\u003c\/strong\u003e and supports \u003cstrong data-start=\"1525\" data-end=\"1541\"\u003emitochondria\u003c\/strong\u003e; Alzheimer’s trials show \u003cstrong data-start=\"1567\" data-end=\"1585\"\u003emixed outcomes\u003c\/strong\u003e (signals in monotherapy subsets), with dosing\/formulation under refinement. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Journal of Alzheimer’s Disease; The Lancet Neurology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1731\" data-end=\"2014\"\u003e\n\u003ctd data-start=\"1731\" data-end=\"1778\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1733\" data-end=\"1777\"\u003e4 Mitochondrial rescue \u0026amp; neuroprotection\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1778\" data-end=\"2014\" data-col-size=\"xl\"\u003eAt low doses, MB \u003cstrong data-start=\"1797\" data-end=\"1830\"\u003ebypasses complex I\/III blocks\u003c\/strong\u003e, improves \u003cstrong data-start=\"1841\" data-end=\"1859\"\u003eATP generation\u003c\/strong\u003e, reduces ROS, and shows \u003cstrong data-start=\"1884\" data-end=\"1918\"\u003eretinal\/optic-nerve protection\u003c\/strong\u003e in models and small studies. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;PNAS; Investigative Ophthalmology \u0026amp; Visual Science\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2015\" data-end=\"2344\"\u003e\n\u003ctd data-start=\"2015\" data-end=\"2065\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2017\" data-end=\"2064\"\u003e5 Antimicrobial photodynamic therapy (aPDT)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2065\" data-end=\"2344\" data-col-size=\"xl\"\u003e\n\u003cstrong data-start=\"2067\" data-end=\"2092\"\u003eMB + 630–670 nm light\u003c\/strong\u003e produces singlet oxygen, killing \u003cstrong data-start=\"2126\" data-end=\"2152\"\u003eplanktonic and biofilm\u003c\/strong\u003e bacteria (including MRSA\/\u003cem data-start=\"2178\" data-end=\"2193\"\u003eP. aeruginosa\u003c\/em\u003e) and fungi; used in \u003cstrong data-start=\"2214\" data-end=\"2248\"\u003echronic wounds, dentistry, ENT\u003c\/strong\u003e pilots. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Antimicrobial Agents \u0026amp; Chemotherapy; Journal of Clinical Periodontology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2345\" data-end=\"2629\"\u003e\n\u003ctd data-start=\"2345\" data-end=\"2398\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2347\" data-end=\"2397\"\u003e6 Antimalarial partner \u0026amp; transmission-blocking\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"2398\" data-end=\"2629\"\u003eAdded to artemisinin regimens, MB \u003cstrong data-start=\"2434\" data-end=\"2458\"\u003elowers gametocytemia\u003c\/strong\u003e and may reduce transmission; GI\/urine discoloration and \u003cstrong data-start=\"2515\" data-end=\"2546\"\u003eG6PD-related hemolysis risk\u003c\/strong\u003e require screening. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;The Lancet Infectious Diseases; Malaria Journal\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2630\" data-end=\"2867\"\u003e\n\u003ctd data-start=\"2630\" data-end=\"2677\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2632\" data-end=\"2676\"\u003e7 Dermatologic\/anti-photoaging (topical)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"2677\" data-end=\"2867\"\u003eMB creams show \u003cstrong data-start=\"2694\" data-end=\"2721\"\u003efibroblast rejuvenation\u003c\/strong\u003e, ↑ collagen genes, ↓ senescence markers, and \u003cstrong data-start=\"2767\" data-end=\"2798\"\u003eimproved hydration\/wrinkles\u003c\/strong\u003e in small trials. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Redox Biology; Dermatologic Therapy\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2868\" data-end=\"3051\"\u003e\n\u003ctd data-start=\"2868\" data-end=\"2905\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2870\" data-end=\"2904\"\u003e8 Refractory ischemic priapism\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"2905\" data-end=\"3051\"\u003eIntracavernosal MB \u003cstrong data-start=\"2926\" data-end=\"2945\"\u003einhibits NO–sGC\u003c\/strong\u003e, offering \u003cstrong data-start=\"2956\" data-end=\"2966\"\u003erescue\u003c\/strong\u003e when alpha-agonists fail before shunting. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Urology; BJU International\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3052\" data-end=\"3342\"\u003e\n\u003ctd data-start=\"3052\" data-end=\"3088\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"3054\" data-end=\"3087\"\u003e9 Peri-anaphylaxis vasoplegia\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"3088\" data-end=\"3342\"\u003eAs adjunct in \u003cstrong data-start=\"3104\" data-end=\"3130\"\u003erefractory hypotension\u003c\/strong\u003e after anaphylaxis or spinal anesthesia, MB can restore \u003cstrong data-start=\"3186\" data-end=\"3203\"\u003evascular tone\u003c\/strong\u003e via \u003cstrong data-start=\"3208\" data-end=\"3224\"\u003esGC blockade\u003c\/strong\u003e; evidence largely from series. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Annals of Allergy, Asthma \u0026amp; Immunology; British Journal of Anaesthesia\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"3344\" data-end=\"3347\"\u003e\n\u003ch2 data-start=\"3349\" data-end=\"3384\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-start=\"3386\" data-end=\"3419\"\u003e2.1 Target Pharmacodynamics\u003c\/h3\u003e\n\u003cul data-start=\"3420\" data-end=\"3990\"\u003e\n\u003cli data-start=\"3420\" data-end=\"3546\"\u003e\n\u003cp data-start=\"3422\" data-end=\"3546\"\u003e\u003cstrong data-start=\"3422\" data-end=\"3444\"\u003eRBC redox cycling:\u003c\/strong\u003e MB ⇄ leucomethylene blue accepts electrons from \u003cstrong data-start=\"3493\" data-end=\"3518\"\u003eNADPH-MetHb reductase\u003c\/strong\u003e, reducing \u003cstrong data-start=\"3529\" data-end=\"3543\"\u003eMetHb → Hb\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3547\" data-end=\"3657\"\u003e\n\u003cp data-start=\"3549\" data-end=\"3657\"\u003e\u003cstrong data-start=\"3549\" data-end=\"3567\"\u003eVascular tone:\u003c\/strong\u003e \u003cstrong data-start=\"3568\" data-end=\"3594\"\u003eNOS and sGC inhibition\u003c\/strong\u003e ↓ cGMP → \u003cstrong data-start=\"3604\" data-end=\"3640\"\u003ereverses pathologic vasodilation\u003c\/strong\u003e in vasoplegia.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3658\" data-end=\"3768\"\u003e\n\u003cp data-start=\"3660\" data-end=\"3768\"\u003e\u003cstrong data-start=\"3660\" data-end=\"3681\"\u003eMAO-A inhibition:\u003c\/strong\u003e Potent, reversible inhibition → \u003cstrong data-start=\"3714\" data-end=\"3741\"\u003eserotonin-syndrome risk\u003c\/strong\u003e with serotonergic drugs.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3769\" data-end=\"3889\"\u003e\n\u003cp data-start=\"3771\" data-end=\"3889\"\u003e\u003cstrong data-start=\"3771\" data-end=\"3806\"\u003eMitochondrial electron shuttle:\u003c\/strong\u003e Accepts\/donates electrons between \u003cstrong data-start=\"3841\" data-end=\"3864\"\u003eNADH ↔ cytochrome c\u003c\/strong\u003e, bypassing ETC blocks.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3890\" data-end=\"3990\"\u003e\n\u003cp data-start=\"3892\" data-end=\"3990\"\u003e\u003cstrong data-start=\"3892\" data-end=\"3912\"\u003ePhotosensitizer:\u003c\/strong\u003e Upon \u003cstrong data-start=\"3918\" data-end=\"3931\"\u003ered-light\u003c\/strong\u003e activation, generates \u003cstrong data-start=\"3954\" data-end=\"3976\"\u003esinglet oxygen\/ROS\u003c\/strong\u003e for \u003cstrong data-start=\"3981\" data-end=\"3989\"\u003eaPDT\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"3992\" data-end=\"4019\"\u003e2.2 Down-stream Biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"4021\" data-end=\"4474\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"4021\" data-end=\"4063\"\u003e\n\u003ctr data-start=\"4021\" data-end=\"4063\"\u003e\n\u003cth data-start=\"4021\" data-end=\"4031\" data-col-size=\"sm\"\u003ePathway\u003c\/th\u003e\n\u003cth data-start=\"4031\" data-end=\"4052\" data-col-size=\"sm\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-start=\"4052\" data-end=\"4063\" data-col-size=\"sm\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"4078\" data-end=\"4474\"\u003e\n\u003ctr data-start=\"4078\" data-end=\"4150\"\u003e\n\u003ctd data-start=\"4078\" data-end=\"4106\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"4080\" data-end=\"4105\"\u003eNADPH-MetHb reductase\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"4106\" data-end=\"4129\"\u003eRestores O₂ carriage\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"4129\" data-end=\"4150\"\u003eMethemoglobinemia\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"4151\" data-end=\"4235\"\u003e\n\u003ctd data-start=\"4151\" data-end=\"4174\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"4153\" data-end=\"4173\"\u003eNO–sGC–cGMP axis\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"4174\" data-end=\"4205\"\u003e↑ MAP, vasoconstrictive tone\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"4205\" data-end=\"4235\"\u003eVasoplegic shock, priapism\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"4236\" data-end=\"4313\"\u003e\n\u003ctd data-start=\"4236\" data-end=\"4259\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"4238\" data-end=\"4258\"\u003eMAO-A inhibition\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"4259\" data-end=\"4293\"\u003e↑ synaptic monoamines; DDI risk\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"4293\" data-end=\"4313\"\u003eCNS\/pharmacology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"4314\" data-end=\"4392\"\u003e\n\u003ctd data-start=\"4314\" data-end=\"4339\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"4316\" data-end=\"4338\"\u003eETC bypass (redox)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"4339\" data-end=\"4354\"\u003e↑ ATP, ↓ ROS\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"4354\" data-end=\"4392\"\u003eNeuro\/retina, ischemia–reperfusion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"4393\" data-end=\"4474\"\u003e\n\u003ctd data-start=\"4393\" data-end=\"4416\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"4395\" data-end=\"4415\"\u003eaPDT (ROS burst)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"4416\" data-end=\"4452\"\u003eRapid microbicidal \u0026amp; anti-biofilm\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"4452\" data-end=\"4474\"\u003eWounds, dental\/ENT\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"4476\" data-end=\"4479\"\u003e\n\u003ch2 data-start=\"4481\" data-end=\"4503\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-start=\"4505\" data-end=\"5047\"\u003e\n\u003cli data-start=\"4505\" data-end=\"4677\"\u003e\n\u003cp data-start=\"4507\" data-end=\"4677\"\u003e\u003cstrong data-start=\"4507\" data-end=\"4518\"\u003eRoutes:\u003c\/strong\u003e \u003cstrong data-start=\"4519\" data-end=\"4525\"\u003eIV\u003c\/strong\u003e (methemoglobinemia, vasoplegia), \u003cstrong data-start=\"4559\" data-end=\"4567\"\u003eoral\u003c\/strong\u003e (historical\/adjunct), \u003cstrong data-start=\"4590\" data-end=\"4601\"\u003etopical\u003c\/strong\u003e, \u003cstrong data-start=\"4603\" data-end=\"4622\"\u003eintracavernosal\u003c\/strong\u003e (rescue), \u003cstrong data-start=\"4633\" data-end=\"4651\"\u003eintranasal\/neb\u003c\/strong\u003e (investigational aPDT).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4678\" data-end=\"4730\"\u003e\n\u003cp data-start=\"4680\" data-end=\"4730\"\u003e\u003cstrong data-start=\"4680\" data-end=\"4690\"\u003eOnset:\u003c\/strong\u003e IV \u003cstrong data-start=\"4694\" data-end=\"4705\"\u003eminutes\u003c\/strong\u003e for MetHb\/MAP effects.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4731\" data-end=\"4804\"\u003e\n\u003cp data-start=\"4733\" data-end=\"4804\"\u003e\u003cstrong data-start=\"4733\" data-end=\"4747\"\u003eHalf-life:\u003c\/strong\u003e Biphasic; reports \u003cstrong data-start=\"4766\" data-end=\"4777\"\u003e~5–24 h\u003c\/strong\u003e (formulation-dependent).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4805\" data-end=\"4966\"\u003e\n\u003cp data-start=\"4807\" data-end=\"4966\"\u003e\u003cstrong data-start=\"4807\" data-end=\"4842\"\u003eDistribution\/biotransformation:\u003c\/strong\u003e Rapid tissue distribution; \u003cstrong data-start=\"4870\" data-end=\"4893\"\u003ereduced to leuco-MB\u003c\/strong\u003e intracellularly; \u003cstrong data-start=\"4911\" data-end=\"4930\"\u003erenal excretion\u003c\/strong\u003e(blue-green urine), some biliary.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4967\" data-end=\"5047\"\u003e\n\u003cp data-start=\"4969\" data-end=\"5047\"\u003e\u003cstrong data-start=\"4969\" data-end=\"4993\"\u003eDevice interference:\u003c\/strong\u003e Transient \u003cstrong data-start=\"5004\" data-end=\"5026\"\u003eSpO₂ under-reading\u003c\/strong\u003e (absorbs at 660 nm).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"5049\" data-end=\"5052\"\u003e\n\u003ch2 data-start=\"5054\" data-end=\"5099\"\u003e4. Pre-clinical and Translational Evidence\u003c\/h2\u003e\n\u003ch3 data-start=\"5101\" data-end=\"5131\"\u003e4.1 Vasoplegic Syndromes\u003c\/h3\u003e\n\u003cp data-start=\"5132\" data-end=\"5356\"\u003eIn sepsis and post-cardiopulmonary-bypass vasoplegia, MB \u003cstrong data-start=\"5189\" data-end=\"5205\"\u003eimproves MAP\u003c\/strong\u003e and \u003cstrong data-start=\"5210\" data-end=\"5239\"\u003ereduces vasopressor needs\u003c\/strong\u003e; timing (early vs rescue), dose, and patient selection are key determinants; outcome effects are under active study.\u003c\/p\u003e\n\u003ch3 data-start=\"5358\" data-end=\"5394\"\u003e4.2 Oncology\/Neurodegeneration\u003c\/h3\u003e\n\u003cp data-start=\"5395\" data-end=\"5564\"\u003e\u003cstrong data-start=\"5395\" data-end=\"5412\"\u003eTau-targeting\u003c\/strong\u003e LMTM programs show \u003cstrong data-start=\"5432\" data-end=\"5462\"\u003edose\/formulation-dependent\u003c\/strong\u003e cognitive outcomes; mitochondrial support and anti-aggregation continue to be explored in \u003cstrong data-start=\"5553\" data-end=\"5563\"\u003eAD\/FTD\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3 data-start=\"5566\" data-end=\"5595\"\u003e4.3 Anti-infective aPDT\u003c\/h3\u003e\n\u003cp data-start=\"5596\" data-end=\"5812\"\u003eTopical\/oral cavity \u003cstrong data-start=\"5616\" data-end=\"5627\"\u003eMB-aPDT\u003c\/strong\u003e clears biofilms, reduces \u003cstrong data-start=\"5653\" data-end=\"5693\"\u003eperi-implant mucositis\/periodontitis\u003c\/strong\u003e indices, and accelerates \u003cstrong data-start=\"5719\" data-end=\"5748\"\u003echronic-wound granulation\u003c\/strong\u003e; standardized dosing and light fluence remain to be harmonized.\u003c\/p\u003e\n\u003ch3 data-start=\"5814\" data-end=\"5858\"\u003e4.4 Ifosfamide Encephalopathy \u0026amp; Others\u003c\/h3\u003e\n\u003cp data-start=\"5859\" data-end=\"6027\"\u003eObservational cohorts report \u003cstrong data-start=\"5888\" data-end=\"5911\"\u003eneurologic recovery\u003c\/strong\u003e after MB in IIE; additional uses include \u003cstrong data-start=\"5953\" data-end=\"5972\"\u003epriapism rescue\u003c\/strong\u003e, \u003cstrong data-start=\"5974\" data-end=\"5999\"\u003esentinel-node mapping\u003c\/strong\u003e, and \u003cstrong data-start=\"6005\" data-end=\"6026\"\u003eurologic staining\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cblockquote data-start=\"6029\" data-end=\"6224\"\u003e\n\u003cp data-start=\"6031\" data-end=\"6224\"\u003e\u003cstrong data-start=\"6031\" data-end=\"6057\"\u003eEvidence quality note:\u003c\/strong\u003e Robust for \u003cstrong data-start=\"6069\" data-end=\"6090\"\u003emethemoglobinemia\u003c\/strong\u003e; \u003cstrong data-start=\"6092\" data-end=\"6118\"\u003emoderate\/heterogeneous\u003c\/strong\u003e for vasoplegia and IIE (controlled but small); \u003cstrong data-start=\"6166\" data-end=\"6178\"\u003eemerging\u003c\/strong\u003e for aPDT, dermatology, and neurodegeneration.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-start=\"6226\" data-end=\"6229\"\u003e\n\u003ch2 data-start=\"6231\" data-end=\"6264\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"6266\" data-end=\"6975\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"6266\" data-end=\"6304\"\u003e\n\u003ctr data-start=\"6266\" data-end=\"6304\"\u003e\n\u003cth data-start=\"6266\" data-end=\"6274\" data-col-size=\"sm\"\u003eField\u003c\/th\u003e\n\u003cth data-start=\"6274\" data-end=\"6286\" data-col-size=\"sm\"\u003eRationale\u003c\/th\u003e\n\u003cth data-start=\"6286\" data-end=\"6304\" data-col-size=\"sm\"\u003eCurrent status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"6319\" data-end=\"6975\"\u003e\n\u003ctr data-start=\"6319\" data-end=\"6439\"\u003e\n\u003ctd data-start=\"6319\" data-end=\"6360\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6321\" data-end=\"6359\"\u003eVasoplegic shock (sepsis\/post-CPB)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"6360\" data-end=\"6400\"\u003esGC blockade complements vasopressors\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"6400\" data-end=\"6439\"\u003eRCTs\/series; practice heterogeneity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6440\" data-end=\"6527\"\u003e\n\u003ctd data-start=\"6440\" data-end=\"6472\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6442\" data-end=\"6471\"\u003eIfosfamide encephalopathy\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"6472\" data-end=\"6493\"\u003eRedox\/MAO pathways\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"6493\" data-end=\"6527\"\u003eProtocolized rescue in centers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6528\" data-end=\"6637\"\u003e\n\u003ctd data-start=\"6528\" data-end=\"6557\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6530\" data-end=\"6556\"\u003eAlzheimer’s\/FTD (LMTM)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"6557\" data-end=\"6598\"\u003eTau inhibition + mitochondrial support\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"6598\" data-end=\"6637\"\u003eMixed trials; next-gen formulations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6638\" data-end=\"6732\"\u003e\n\u003ctd data-start=\"6638\" data-end=\"6676\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6640\" data-end=\"6675\"\u003eChronic wounds\/dentistry (aPDT)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"6676\" data-end=\"6705\"\u003eAnti-biofilm + pro-healing\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"6705\" data-end=\"6732\"\u003eEarly clinical adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6733\" data-end=\"6819\"\u003e\n\u003ctd data-start=\"6733\" data-end=\"6769\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6735\" data-end=\"6768\"\u003eRetinal\/optic neuroprotection\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"6769\" data-end=\"6792\"\u003eETC bypass, anti-ROS\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"6792\" data-end=\"6819\"\u003eSmall human\/mechanistic\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6820\" data-end=\"6903\"\u003e\n\u003ctd data-start=\"6820\" data-end=\"6847\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6822\" data-end=\"6846\"\u003eAntimalarial partner\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6847\" data-end=\"6884\" data-col-size=\"sm\"\u003eGametocyte kill\/transmission block\u003c\/td\u003e\n\u003ctd data-start=\"6884\" data-end=\"6903\" data-col-size=\"sm\"\u003eRegional trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6904\" data-end=\"6975\"\u003e\n\u003ctd data-start=\"6904\" data-end=\"6932\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6906\" data-end=\"6931\"\u003ePriapism (refractory)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6932\" data-end=\"6952\" data-col-size=\"sm\"\u003eNO–sGC inhibition\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"6952\" data-end=\"6975\"\u003eSalvage case series\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"6977\" data-end=\"6980\"\u003e\n\u003ch2 data-start=\"6982\" data-end=\"7011\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-start=\"7013\" data-end=\"7899\"\u003e\n\u003cli data-start=\"7013\" data-end=\"7129\"\u003e\n\u003cp data-start=\"7015\" data-end=\"7129\"\u003e\u003cstrong data-start=\"7015\" data-end=\"7026\"\u003eCommon:\u003c\/strong\u003e \u003cstrong data-start=\"7027\" data-end=\"7047\"\u003eBlue\/green urine\u003c\/strong\u003e, \u003cstrong data-start=\"7049\" data-end=\"7070\"\u003eskin\/scleral tint\u003c\/strong\u003e, \u003cstrong data-start=\"7072\" data-end=\"7082\"\u003enausea\u003c\/strong\u003e, \u003cstrong data-start=\"7084\" data-end=\"7097\"\u003edizziness\u003c\/strong\u003e, \u003cstrong data-start=\"7099\" data-end=\"7111\"\u003eheadache\u003c\/strong\u003e, \u003cstrong data-start=\"7113\" data-end=\"7126\"\u003edysgeusia\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7130\" data-end=\"7269\"\u003e\n\u003cp data-start=\"7132\" data-end=\"7269\"\u003e\u003cstrong data-start=\"7132\" data-end=\"7147\"\u003eHematology:\u003c\/strong\u003e \u003cstrong data-start=\"7148\" data-end=\"7185\"\u003eHemolysis risk in G6PD deficiency\u003c\/strong\u003e; screen when feasible. High doses can \u003cstrong data-start=\"7224\" data-end=\"7252\"\u003eworsen methemoglobinemia\u003c\/strong\u003e (paradoxical).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7270\" data-end=\"7423\"\u003e\n\u003cp data-start=\"7272\" data-end=\"7423\"\u003e\u003cstrong data-start=\"7272\" data-end=\"7299\"\u003eNeurologic\/psychiatric:\u003c\/strong\u003e \u003cstrong data-start=\"7300\" data-end=\"7322\"\u003eSerotonin syndrome\u003c\/strong\u003e possible with \u003cstrong data-start=\"7337\" data-end=\"7383\"\u003eSSRIs\/SNRIs\/MAOIs\/linezolid\/tramadol, etc.\u003c\/strong\u003e (MB is a \u003cstrong data-start=\"7393\" data-end=\"7419\"\u003epotent MAO-A inhibitor\u003c\/strong\u003e).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7424\" data-end=\"7545\"\u003e\n\u003cp data-start=\"7426\" data-end=\"7545\"\u003e\u003cstrong data-start=\"7426\" data-end=\"7445\"\u003eCardiovascular:\u003c\/strong\u003e \u003cstrong data-start=\"7446\" data-end=\"7459\"\u003e↑ SVR\/MAP\u003c\/strong\u003e desired in vasoplegia; watch for \u003cstrong data-start=\"7493\" data-end=\"7518\"\u003ehypertension\/ischemia\u003c\/strong\u003e in susceptible patients.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7546\" data-end=\"7624\"\u003e\n\u003cp data-start=\"7548\" data-end=\"7624\"\u003e\u003cstrong data-start=\"7548\" data-end=\"7562\"\u003ePulmonary:\u003c\/strong\u003e Can transiently \u003cstrong data-start=\"7579\" data-end=\"7602\"\u003elower SpO₂ readings\u003c\/strong\u003e (optical artifact).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7625\" data-end=\"7741\"\u003e\n\u003cp data-start=\"7627\" data-end=\"7741\"\u003e\u003cstrong data-start=\"7627\" data-end=\"7650\"\u003ePregnancy\/Neonates:\u003c\/strong\u003e \u003cstrong data-start=\"7651\" data-end=\"7660\"\u003eAvoid\u003c\/strong\u003e—risk of \u003cstrong data-start=\"7669\" data-end=\"7720\"\u003efetal\/neonatal hemolysis and hyperbilirubinemia\u003c\/strong\u003e; crosses placenta.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7742\" data-end=\"7899\"\u003e\n\u003cp data-start=\"7744\" data-end=\"7899\"\u003e\u003cstrong data-start=\"7744\" data-end=\"7770\"\u003eDosing considerations:\u003c\/strong\u003e Typical IV \u003cstrong data-start=\"7782\" data-end=\"7795\"\u003e1–2 mg\/kg\u003c\/strong\u003e (slow push\/infusion) with \u003cstrong data-start=\"7822\" data-end=\"7839\"\u003erepeat dosing\u003c\/strong\u003e per protocol; monitor \u003cstrong data-start=\"7862\" data-end=\"7871\"\u003eMetHb\u003c\/strong\u003e, \u003cstrong data-start=\"7873\" data-end=\"7880\"\u003eABG\u003c\/strong\u003e, \u003cstrong data-start=\"7882\" data-end=\"7898\"\u003ehemodynamics\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"7901\" data-end=\"7951\"\u003e\u003cstrong data-start=\"7901\" data-end=\"7951\"\u003eComparative safety matrix (vasoplegia context)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"7953\" data-end=\"8549\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"7953\" data-end=\"8026\"\u003e\n\u003ctr data-start=\"7953\" data-end=\"8026\"\u003e\n\u003cth data-start=\"7953\" data-end=\"7963\" data-col-size=\"sm\"\u003eConcern\u003c\/th\u003e\n\u003cth data-start=\"7963\" data-end=\"7984\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"7965\" data-end=\"7983\"\u003eMethylene blue\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"7984\" data-end=\"8007\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"7986\" data-end=\"8006\"\u003eHydroxocobalamin\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"8007\" data-end=\"8026\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"8009\" data-end=\"8024\"\u003eVasopressin\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"8045\" data-end=\"8549\"\u003e\n\u003ctr data-start=\"8045\" data-end=\"8141\"\u003e\n\u003ctd data-start=\"8045\" data-end=\"8065\" data-col-size=\"sm\"\u003ePrimary mechanism\u003c\/td\u003e\n\u003ctd data-start=\"8065\" data-end=\"8090\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"8067\" data-end=\"8089\"\u003eNOS\/sGC inhibition\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"8090\" data-end=\"8118\" data-col-size=\"md\"\u003e\n\u003cstrong data-start=\"8092\" data-end=\"8108\"\u003eNO scavenger\u003c\/strong\u003e (cobalt)\u003c\/td\u003e\n\u003ctd data-start=\"8118\" data-end=\"8141\" data-col-size=\"sm\"\u003eV1 receptor agonist\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"8142\" data-end=\"8262\"\u003e\n\u003ctd data-start=\"8142\" data-end=\"8158\" data-col-size=\"sm\"\u003eEffect on MAP\u003c\/td\u003e\n\u003ctd data-start=\"8158\" data-end=\"8195\" data-col-size=\"md\"\u003eRapid ↑; \u003cstrong data-start=\"8169\" data-end=\"8194\"\u003ecatecholamine-sparing\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd data-start=\"8195\" data-end=\"8228\" data-col-size=\"md\"\u003eRapid ↑; catecholamine-sparing\u003c\/td\u003e\n\u003ctd data-start=\"8228\" data-end=\"8262\" data-col-size=\"sm\"\u003e↑ SVR with low arrhythmia risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"8263\" data-end=\"8431\"\u003e\n\u003ctd data-start=\"8263\" data-end=\"8275\" data-col-size=\"sm\"\u003eKey risks\u003c\/td\u003e\n\u003ctd data-start=\"8275\" data-end=\"8327\" data-col-size=\"md\"\u003e\n\u003cstrong data-start=\"8277\" data-end=\"8291\"\u003eMAO-A DDIs\u003c\/strong\u003e, \u003cstrong data-start=\"8293\" data-end=\"8311\"\u003eG6PD hemolysis\u003c\/strong\u003e, SpO₂ artifact\u003c\/td\u003e\n\u003ctd data-start=\"8327\" data-end=\"8392\" data-col-size=\"md\"\u003e\n\u003cstrong data-start=\"8329\" data-end=\"8344\"\u003eChromaturia\u003c\/strong\u003e, potential \u003cstrong data-start=\"8356\" data-end=\"8367\"\u003eoxalate\u003c\/strong\u003e, interference with labs\u003c\/td\u003e\n\u003ctd data-start=\"8392\" data-end=\"8431\" data-col-size=\"sm\"\u003eIschemia at high dose, hyponatremia\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"8432\" data-end=\"8549\"\u003e\n\u003ctd data-start=\"8432\" data-end=\"8448\" data-col-size=\"sm\"\u003eSpecial notes\u003c\/td\u003e\n\u003ctd data-start=\"8448\" data-end=\"8484\" data-col-size=\"md\"\u003eCan \u003cstrong data-start=\"8454\" data-end=\"8470\"\u003eworsen MetHb\u003c\/strong\u003e at high dose\u003c\/td\u003e\n\u003ctd data-start=\"8484\" data-end=\"8517\" data-col-size=\"md\"\u003eUseful when MB contraindicated\u003c\/td\u003e\n\u003ctd data-start=\"8517\" data-end=\"8549\" data-col-size=\"sm\"\u003eSynergizes with MB in rescue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"8551\" data-end=\"8554\"\u003e\n\u003ch2 data-start=\"8556\" data-end=\"8582\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-start=\"8584\" data-end=\"8990\"\u003e\n\u003cli data-start=\"8584\" data-end=\"8649\"\u003e\n\u003cp data-start=\"8586\" data-end=\"8649\"\u003e\u003cstrong data-start=\"8586\" data-end=\"8599\"\u003eApproved:\u003c\/strong\u003e \u003cstrong data-start=\"8600\" data-end=\"8630\"\u003eAcquired methemoglobinemia\u003c\/strong\u003e (parenteral MB).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8650\" data-end=\"8781\"\u003e\n\u003cp data-start=\"8652\" data-end=\"8781\"\u003e\u003cstrong data-start=\"8652\" data-end=\"8673\"\u003eCommon off-label:\u003c\/strong\u003e \u003cstrong data-start=\"8674\" data-end=\"8694\"\u003eVasoplegic shock\u003c\/strong\u003e, \u003cstrong data-start=\"8696\" data-end=\"8725\"\u003eifosfamide encephalopathy\u003c\/strong\u003e, \u003cstrong data-start=\"8727\" data-end=\"8746\"\u003epriapism rescue\u003c\/strong\u003e, \u003cstrong data-start=\"8748\" data-end=\"8756\"\u003eaPDT\u003c\/strong\u003e (topical\/oral cavity).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8782\" data-end=\"8885\"\u003e\n\u003cp data-start=\"8784\" data-end=\"8885\"\u003e\u003cstrong data-start=\"8784\" data-end=\"8804\"\u003eInvestigational:\u003c\/strong\u003e \u003cstrong data-start=\"8805\" data-end=\"8827\"\u003eTau-targeting LMTM\u003c\/strong\u003e, \u003cstrong data-start=\"8829\" data-end=\"8856\"\u003eretinal neuroprotection\u003c\/strong\u003e, \u003cstrong data-start=\"8858\" data-end=\"8882\"\u003eantimalarial partner\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8886\" data-end=\"8990\"\u003e\n\u003cp data-start=\"8888\" data-end=\"8990\"\u003e\u003cstrong data-start=\"8888\" data-end=\"8899\"\u003eSupply:\u003c\/strong\u003e Use \u003cstrong data-start=\"8904\" data-end=\"8920\"\u003eGMP-grade MB\u003c\/strong\u003e (sterile, USP) for IV; compounded\/non-sterile dyes are \u003cstrong data-start=\"8976\" data-end=\"8986\"\u003eunsafe\u003c\/strong\u003e IV.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"8992\" data-end=\"8995\"\u003e\n\u003ch2 data-start=\"8997\" data-end=\"9020\"\u003e8. Future Directions\u003c\/h2\u003e\n\u003cul data-start=\"9022\" data-end=\"9635\"\u003e\n\u003cli data-start=\"9022\" data-end=\"9164\"\u003e\n\u003cp data-start=\"9024\" data-end=\"9164\"\u003e\u003cstrong data-start=\"9024\" data-end=\"9056\"\u003ePrecision use in vasoplegia:\u003c\/strong\u003e Timing (early vs rescue), \u003cstrong data-start=\"9083\" data-end=\"9100\"\u003edose–response\u003c\/strong\u003e, and \u003cstrong data-start=\"9106\" data-end=\"9129\"\u003ephenotype selection\u003c\/strong\u003e (e.g., high NO\/cGMP signatures).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9165\" data-end=\"9291\"\u003e\n\u003cp data-start=\"9167\" data-end=\"9291\"\u003e\u003cstrong data-start=\"9167\" data-end=\"9189\"\u003eNeurodegeneration:\u003c\/strong\u003e Optimize \u003cstrong data-start=\"9199\" data-end=\"9224\"\u003eLMTM pharmacokinetics\u003c\/strong\u003e and identify \u003cstrong data-start=\"9238\" data-end=\"9278\"\u003etau-positive, monotherapy-responsive\u003c\/strong\u003esubgroups.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9292\" data-end=\"9408\"\u003e\n\u003cp data-start=\"9294\" data-end=\"9408\"\u003e\u003cstrong data-start=\"9294\" data-end=\"9315\"\u003eStandardize aPDT:\u003c\/strong\u003e Dose, \u003cstrong data-start=\"9322\" data-end=\"9333\"\u003efluence\u003c\/strong\u003e, and \u003cstrong data-start=\"9339\" data-end=\"9351\"\u003eoutcomes\u003c\/strong\u003e for wounds\/dentistry\/ENT; head-to-head vs antibiotics.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9409\" data-end=\"9510\"\u003e\n\u003cp data-start=\"9411\" data-end=\"9510\"\u003e\u003cstrong data-start=\"9411\" data-end=\"9438\"\u003eMitochondrial medicine:\u003c\/strong\u003e Define \u003cstrong data-start=\"9446\" data-end=\"9461\"\u003edose window\u003c\/strong\u003e for ETC support without MAO-A adverse effects.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9511\" data-end=\"9635\"\u003e\n\u003cp data-start=\"9513\" data-end=\"9635\"\u003e\u003cstrong data-start=\"9513\" data-end=\"9535\"\u003eSafety registries:\u003c\/strong\u003e \u003cstrong data-start=\"9536\" data-end=\"9558\"\u003eSerotonin-syndrome\u003c\/strong\u003e pharmacovigilance; \u003cstrong data-start=\"9578\" data-end=\"9586\"\u003eG6PD\u003c\/strong\u003e screening pathways; pregnancy\/neonatal outcomes.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"9637\" data-end=\"9640\"\u003e\n\u003ch3 data-start=\"9642\" data-end=\"9665\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-start=\"9667\" data-end=\"10501\"\u003e\n\u003cli data-start=\"9667\" data-end=\"9765\"\u003e\n\u003cp data-start=\"9669\" data-end=\"9765\"\u003e\u003cstrong data-start=\"9669\" data-end=\"9702\"\u003eAnesthesiology; Critical Care\u003c\/strong\u003e — Vasoplegic shock trials\/series with MB (post-CPB, sepsis).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9766\" data-end=\"9885\"\u003e\n\u003cp data-start=\"9768\" data-end=\"9885\"\u003e\u003cstrong data-start=\"9768\" data-end=\"9827\"\u003eJournal of Clinical Oncology; Supportive Care in Cancer\u003c\/strong\u003e — Ifosfamide-induced encephalopathy reversal protocols.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9886\" data-end=\"9988\"\u003e\n\u003cp data-start=\"9888\" data-end=\"9988\"\u003e\u003cstrong data-start=\"9888\" data-end=\"9944\"\u003eThe Lancet Neurology; Journal of Alzheimer’s Disease\u003c\/strong\u003e — LMTM (methylthioninium) in tauopathies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9989\" data-end=\"10079\"\u003e\n\u003cp data-start=\"9991\" data-end=\"10079\"\u003e\u003cstrong data-start=\"9991\" data-end=\"10014\"\u003ePNAS; Redox Biology\u003c\/strong\u003e — Mitochondrial electron-shuttling and antioxidant properties.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"10080\" data-end=\"10199\"\u003e\n\u003cp data-start=\"10082\" data-end=\"10199\"\u003e\u003cstrong data-start=\"10082\" data-end=\"10157\"\u003eAntimicrobial Agents \u0026amp; Chemotherapy; Journal of Clinical Periodontology\u003c\/strong\u003e — MB-mediated aPDT in wounds\/dentistry.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"10200\" data-end=\"10320\"\u003e\n\u003cp data-start=\"10202\" data-end=\"10320\"\u003e\u003cstrong data-start=\"10202\" data-end=\"10253\"\u003eThe Lancet Infectious Diseases; Malaria Journal\u003c\/strong\u003e — MB as an antimalarial partner and transmission-blocking agent.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"10321\" data-end=\"10414\"\u003e\n\u003cp data-start=\"10323\" data-end=\"10414\"\u003e\u003cstrong data-start=\"10323\" data-end=\"10371\"\u003eInvestigative Ophthalmology \u0026amp; Visual Science\u003c\/strong\u003e — Retinal\/optic neuroprotection studies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"10415\" data-end=\"10501\"\u003e\n\u003cp data-start=\"10417\" data-end=\"10501\"\u003e\u003cstrong data-start=\"10417\" data-end=\"10447\"\u003eUrology; BJU International\u003c\/strong\u003e — MB for refractory priapism via NO–sGC inhibition.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":51005787963656,"sku":"","price":60.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0937\/9053\/5944\/files\/Methylene_Blue_10mg.png?v=1756654632"},{"product_id":"dihexa-60x10mg","title":"Dihexa 100x10mg","description":"\u003cp\u003e\u003cstrong\u003e\u003cstrong data-end=\"392\" data-start=\"377\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                          \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDihexa \u003cmeta charset=\"UTF-8\"\u003e\u003c\/strong\u003eis a \u003cstrong data-end=\"188\" data-start=\"130\"\u003ebrain-penetrant angiotensin-IV (AngIV)–derived peptide\u003c\/strong\u003e engineered for extreme \u003cstrong data-end=\"235\" data-start=\"212\"\u003emetabolic stability\u003c\/strong\u003e and \u003cstrong data-end=\"268\" data-start=\"240\"\u003eoral\/CNS bioavailability\u003c\/strong\u003e. Unlike classical RAS drugs, Dihexa functions as a \u003cstrong data-end=\"382\" data-start=\"320\"\u003ehepatocyte growth factor (HGF)–c-Met signaling potentiator\u003c\/strong\u003e: it binds HGF with high affinity and \u003cstrong data-end=\"469\" data-start=\"420\"\u003efacilitates HGF–c-Met dimerization\/activation\u003c\/strong\u003e, driving \u003cstrong data-end=\"497\" data-start=\"479\"\u003esynaptogenesis\u003c\/strong\u003e, \u003cstrong data-end=\"516\" data-start=\"499\"\u003espine density\u003c\/strong\u003e, and \u003cstrong data-end=\"560\" data-start=\"522\"\u003eplasticity-related gene expression\u003c\/strong\u003e. It is \u003cstrong data-end=\"584\" data-start=\"568\"\u003enot approved\u003c\/strong\u003e for any indication; human trials are \u003cstrong data-end=\"632\" data-start=\"622\"\u003eabsent\u003c\/strong\u003e as of 2025.\u003c\/p\u003e\n\u003chr data-end=\"649\" data-start=\"646\"\u003e\n\u003ch3 data-end=\"708\" data-start=\"651\"\u003eAdditional Benefits of Dihexa Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"3245\" data-start=\"710\"\u003e\n\u003cthead data-end=\"738\" data-start=\"710\"\u003e\n\u003ctr data-end=\"738\" data-start=\"710\"\u003e\n\u003cth data-col-size=\"md\" data-end=\"720\" data-start=\"710\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-col-size=\"xl\" data-end=\"738\" data-start=\"720\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"3245\" data-start=\"749\"\u003e\n\u003ctr data-end=\"1118\" data-start=\"749\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"799\" data-start=\"749\"\u003e\u003cstrong data-end=\"798\" data-start=\"751\"\u003e1 Cognitive enhancement (learning \u0026amp; memory)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1118\" data-start=\"799\"\u003eIn rodent models (Morris water maze, novel object recognition), \u003cstrong data-end=\"888\" data-start=\"865\"\u003epicomolar–nanomolar\u003c\/strong\u003e Dihexa restores or improves \u003cstrong data-end=\"943\" data-start=\"917\"\u003eacquisition and recall\u003c\/strong\u003e, including in cholinergic lesion and Aβ-induced impairment paradigms. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Journal of Pharmacology \u0026amp; Experimental Therapeutics; Neurobiology of Learning and Memory\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1392\" data-start=\"1119\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1168\" data-start=\"1119\"\u003e\u003cstrong data-end=\"1167\" data-start=\"1121\"\u003e2 Synaptogenesis \u0026amp; dendritic spine density\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1392\" data-start=\"1168\"\u003eIn vitro and in vivo, Dihexa \u003cstrong data-end=\"1227\" data-start=\"1199\"\u003eincreases synapse number\u003c\/strong\u003e and \u003cstrong data-end=\"1251\" data-start=\"1232\"\u003ePSD-95\/synapsin\u003c\/strong\u003e expression via \u003cstrong data-end=\"1301\" data-start=\"1267\"\u003eHGF–c-Met → MAPK\/PI3K–Akt–mTOR\u003c\/strong\u003e cascades, correlating with behavioral gains. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;PNAS; Journal of Neuroscience\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1738\" data-start=\"1393\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1442\" data-start=\"1393\"\u003e\u003cstrong data-end=\"1441\" data-start=\"1395\"\u003e3 Disease-modifying potential in AD models\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1738\" data-start=\"1442\"\u003eImproves cognition and reduces \u003cstrong data-end=\"1507\" data-start=\"1475\"\u003eAβ-related synaptic toxicity\u003c\/strong\u003e; promotes \u003cstrong data-end=\"1526\" data-start=\"1518\"\u003eBDNF\u003c\/strong\u003e, \u003cstrong data-end=\"1535\" data-start=\"1528\"\u003eArc\u003c\/strong\u003e, and \u003cstrong data-end=\"1549\" data-start=\"1541\"\u003eEgr1\u003c\/strong\u003enetworks associated with plasticity. Histologic plaque effects are inconsistent, suggesting primarily \u003cstrong data-end=\"1671\" data-start=\"1652\"\u003esynaptic rescue\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Neurotherapeutics; Alzheimer’s Research \u0026amp; Therapy\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2007\" data-start=\"1739\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1785\" data-start=\"1739\"\u003e\u003cstrong data-end=\"1784\" data-start=\"1741\"\u003e4 Traumatic brain injury (TBI) recovery\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2007\" data-start=\"1785\"\u003ePost-injury dosing improves \u003cstrong data-end=\"1847\" data-start=\"1815\"\u003emotor and cognitive outcomes\u003c\/strong\u003e, likely through \u003cstrong data-end=\"1884\" data-start=\"1864\"\u003eaxonal sprouting\u003c\/strong\u003eand \u003cstrong data-end=\"1912\" data-start=\"1889\"\u003esynaptic rebuilding\u003c\/strong\u003e with reduced neuroinflammation markers. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Brain Research; Experimental Neurology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2252\" data-start=\"2008\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2058\" data-start=\"2008\"\u003e\u003cstrong data-end=\"2057\" data-start=\"2010\"\u003e5 Parkinsonian\/striatal dysfunction signals\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2252\" data-start=\"2058\"\u003eIn toxin models, enhances \u003cstrong data-end=\"2115\" data-start=\"2086\"\u003estriatal synaptic markers\u003c\/strong\u003e and behavior despite dopaminergic loss, consistent with network compensation. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Movement Disorders; Molecular Neurobiology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2517\" data-start=\"2253\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2300\" data-start=\"2253\"\u003e\u003cstrong data-end=\"2299\" data-start=\"2255\"\u003e6 Depression \u0026amp; anhedonia (stress models)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2517\" data-start=\"2300\"\u003eRapid-acting, \u003cstrong data-end=\"2333\" data-start=\"2316\"\u003eketamine-like\u003c\/strong\u003e behavioral rescue reported in chronic-stress rodents, tracking with \u003cstrong data-end=\"2420\" data-start=\"2402\"\u003esynaptogenesis\u003c\/strong\u003e rather than monoamine elevation. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Biological Psychiatry; Translational Psychiatry\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2732\" data-start=\"2518\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2555\" data-start=\"2518\"\u003e\u003cstrong data-end=\"2554\" data-start=\"2520\"\u003e7 Hearing \u0026amp; sensory plasticity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2732\" data-start=\"2555\"\u003eProtection\/repair of \u003cstrong data-end=\"2603\" data-start=\"2578\"\u003ecochlear synaptopathy\u003c\/strong\u003e shown in preclinical work via \u003cstrong data-end=\"2647\" data-start=\"2634\"\u003eHGF–c-Met\u003c\/strong\u003e trophic signaling in spiral ganglion neurons. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Hearing Research; JARO\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2980\" data-start=\"2733\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2774\" data-start=\"2733\"\u003e\u003cstrong data-end=\"2773\" data-start=\"2735\"\u003e8 Peripheral nerve \u0026amp; spinal repair\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2980\" data-start=\"2774\"\u003eEnhanced \u003cstrong data-end=\"2806\" data-start=\"2785\"\u003eneurite outgrowth\u003c\/strong\u003e and functional regeneration in sciatic crush and spinal micro-lesion models; complements rehabilitation. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Experimental Neurology; Neural Regeneration Research\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3245\" data-start=\"2981\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3022\" data-start=\"2981\"\u003e\u003cstrong data-end=\"3021\" data-start=\"2983\"\u003e9 Metabolic\/vascular brain support\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"3245\" data-start=\"3022\"\u003eHGF–c-Met activity improves \u003cstrong data-end=\"3076\" data-start=\"3052\"\u003eendothelial survival\u003c\/strong\u003e, \u003cstrong data-end=\"3095\" data-start=\"3078\"\u003eBBB integrity\u003c\/strong\u003e, and \u003cstrong data-end=\"3124\" data-start=\"3101\"\u003eglucose utilization\u003c\/strong\u003eunder stress; may aid vascular cognitive impairment models. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Stroke; Acta Neuropathologica Communications\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"3250\" data-start=\"3247\"\u003e\n\u003ch2 data-end=\"3287\" data-start=\"3252\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-end=\"3324\" data-start=\"3289\"\u003e2.1 Receptor pharmacodynamics\u003c\/h3\u003e\n\u003cul data-end=\"3821\" data-start=\"3325\"\u003e\n\u003cli data-end=\"3502\" data-start=\"3325\"\u003e\n\u003cp data-end=\"3502\" data-start=\"3327\"\u003e\u003cstrong data-end=\"3339\" data-start=\"3327\"\u003ePrimary:\u003c\/strong\u003e \u003cstrong data-end=\"3380\" data-start=\"3340\"\u003eAllosteric potentiation of HGF–c-Met\u003c\/strong\u003e signaling (not a direct c-Met agonist). Dihexa binds HGF, stabilizing its \u003cstrong data-end=\"3471\" data-start=\"3455\"\u003eactive dimer\u003c\/strong\u003e → \u003cstrong data-end=\"3499\" data-start=\"3474\"\u003ec-Met phosphorylation\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3662\" data-start=\"3503\"\u003e\n\u003cp data-end=\"3662\" data-start=\"3505\"\u003e\u003cstrong data-end=\"3520\" data-start=\"3505\"\u003eDownstream:\u003c\/strong\u003e \u003cstrong data-end=\"3538\" data-start=\"3521\"\u003ePI3K–Akt–mTOR\u003c\/strong\u003e (survival\/translation), \u003cstrong data-end=\"3575\" data-start=\"3563\"\u003eMAPK\/ERK\u003c\/strong\u003e (plasticity), \u003cstrong data-end=\"3604\" data-start=\"3590\"\u003eRac1\/Cdc42\u003c\/strong\u003e (spine morphogenesis), and \u003cstrong data-end=\"3645\" data-start=\"3632\"\u003eCREB\/BDNF\u003c\/strong\u003e transcription.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3821\" data-start=\"3663\"\u003e\n\u003cp data-end=\"3821\" data-start=\"3665\"\u003e\u003cstrong data-end=\"3689\" data-start=\"3665\"\u003eContrast with AngIV:\u003c\/strong\u003e Native AngIV interacts with AT4\/IRAP; Dihexa’s potency and plasticity effects are mainly \u003cstrong data-end=\"3802\" data-start=\"3779\"\u003eHGF–c-Met–dependent\u003c\/strong\u003e in modern studies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-end=\"3850\" data-start=\"3823\"\u003e2.2 Down-stream biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"4220\" data-start=\"3852\"\u003e\n\u003cthead data-end=\"3894\" data-start=\"3852\"\u003e\n\u003ctr data-end=\"3894\" data-start=\"3852\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3862\" data-start=\"3852\"\u003ePathway\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3883\" data-start=\"3862\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3894\" data-start=\"3883\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"4220\" data-start=\"3909\"\u003e\n\u003ctr data-end=\"3986\" data-start=\"3909\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3937\" data-start=\"3909\"\u003e\u003cstrong data-end=\"3936\" data-start=\"3911\"\u003ec-Met → PI3K–Akt–mTOR\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3964\" data-start=\"3937\"\u003eSynaptogenesis, survival\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3986\" data-start=\"3964\"\u003eCortex\/hippocampus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4061\" data-start=\"3987\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4010\" data-start=\"3987\"\u003e\u003cstrong data-end=\"4009\" data-start=\"3989\"\u003ec-Met → ERK\/CREB\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4042\" data-start=\"4010\"\u003eLTP genes (Arc, Egr1, BDNF) ↑\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4061\" data-start=\"4042\"\u003eLearning\/memory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4142\" data-start=\"4062\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4094\" data-start=\"4062\"\u003e\u003cstrong data-end=\"4093\" data-start=\"4064\"\u003eCytoskeletal (Rac1\/Cdc42)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4123\" data-start=\"4094\"\u003eSpine density\/maturation ↑\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4142\" data-start=\"4123\"\u003eDendritic arbor\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4220\" data-start=\"4143\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4167\" data-start=\"4143\"\u003e\u003cstrong data-end=\"4166\" data-start=\"4145\"\u003eEndothelial c-Met\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4198\" data-start=\"4167\"\u003eAngioprotection, BBB support\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4220\" data-start=\"4198\"\u003eNeurovascular unit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"4225\" data-start=\"4222\"\u003e\n\u003ch2 data-end=\"4249\" data-start=\"4227\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-end=\"4667\" data-start=\"4251\"\u003e\n\u003cli data-end=\"4338\" data-start=\"4251\"\u003e\n\u003cp data-end=\"4338\" data-start=\"4253\"\u003e\u003cstrong data-end=\"4263\" data-start=\"4253\"\u003eRoute:\u003c\/strong\u003e Effective \u003cstrong data-end=\"4284\" data-start=\"4274\"\u003eorally\u003c\/strong\u003e and \u003cstrong data-end=\"4305\" data-start=\"4289\"\u003eparenterally\u003c\/strong\u003e in rodents; \u003cstrong data-end=\"4335\" data-start=\"4318\"\u003eCNS-penetrant\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4452\" data-start=\"4339\"\u003e\n\u003cp data-end=\"4452\" data-start=\"4341\"\u003e\u003cstrong data-end=\"4355\" data-start=\"4341\"\u003eStability:\u003c\/strong\u003e \u003cstrong data-end=\"4378\" data-start=\"4356\"\u003eProtease-resistant\u003c\/strong\u003e backbone with \u003cstrong data-end=\"4418\" data-start=\"4393\"\u003elipophilic N-hexanoyl\u003c\/strong\u003e cap → high metabolic stability.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4616\" data-start=\"4453\"\u003e\n\u003cp data-end=\"4616\" data-start=\"4455\"\u003e\u003cstrong data-end=\"4474\" data-start=\"4455\"\u003eBrain exposure:\u003c\/strong\u003e Detected in brain tissue after systemic dosing; duration \u003cstrong data-end=\"4541\" data-start=\"4532\"\u003ehours\u003c\/strong\u003e with functional effects lasting \u003cstrong data-end=\"4588\" data-start=\"4574\"\u003edays–weeks\u003c\/strong\u003e after courses in animals.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4667\" data-start=\"4617\"\u003e\n\u003cp data-end=\"4667\" data-start=\"4619\"\u003e\u003cstrong data-end=\"4632\" data-start=\"4619\"\u003eHuman PK:\u003c\/strong\u003e \u003cstrong data-end=\"4644\" data-start=\"4633\"\u003eUnknown\u003c\/strong\u003e (no published trials).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"4672\" data-start=\"4669\"\u003e\n\u003ch2 data-end=\"4717\" data-start=\"4674\"\u003e4. Pre-clinical \u0026amp; Translational Evidence\u003c\/h2\u003e\n\u003cul data-end=\"5106\" data-start=\"4719\"\u003e\n\u003cli data-end=\"4855\" data-start=\"4719\"\u003e\n\u003cp data-end=\"4855\" data-start=\"4721\"\u003e\u003cstrong data-end=\"4738\" data-start=\"4721\"\u003eCognition\/AD:\u003c\/strong\u003e Reversal of scopolamine, Aβ, and lesion-induced deficits at \u003cstrong data-end=\"4817\" data-start=\"4799\"\u003every low doses\u003c\/strong\u003e; potentiates LTP and spine markers.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4964\" data-start=\"4856\"\u003e\n\u003cp data-end=\"4964\" data-start=\"4858\"\u003e\u003cstrong data-end=\"4869\" data-start=\"4858\"\u003eTBI\/PD:\u003c\/strong\u003e Functional recovery and synaptic rebuilding demonstrated in multiple injury\/toxin paradigms.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5106\" data-start=\"4965\"\u003e\n\u003cp data-end=\"5106\" data-start=\"4967\"\u003e\u003cstrong data-end=\"4994\" data-start=\"4967\"\u003eMechanistic dependency:\u003c\/strong\u003e Genetic or pharmacologic \u003cstrong data-end=\"5038\" data-start=\"5020\"\u003ec-Met blockade\u003c\/strong\u003e blunts Dihexa’s synaptogenic effects, supporting target engagement.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cblockquote data-end=\"5297\" data-start=\"5108\"\u003e\n\u003cp data-end=\"5297\" data-start=\"5110\"\u003e\u003cstrong data-end=\"5136\" data-start=\"5110\"\u003eEvidence quality note:\u003c\/strong\u003e \u003cstrong data-end=\"5163\" data-start=\"5137\"\u003eRobust rodent\/in vitro\u003c\/strong\u003e data with convergent mechanisms. \u003cstrong data-end=\"5231\" data-start=\"5197\"\u003eNo peer-reviewed human studies\u003c\/strong\u003e to date; dose, safety, and efficacy in people remain \u003cstrong data-end=\"5296\" data-start=\"5285\"\u003eunknown\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-end=\"5302\" data-start=\"5299\"\u003e\n\u003ch2 data-end=\"5350\" data-start=\"5304\"\u003e5. Emerging Clinical Interests (conceptual)\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"5934\" data-start=\"5352\"\u003e\n\u003cthead data-end=\"5382\" data-start=\"5352\"\u003e\n\u003ctr data-end=\"5382\" data-start=\"5352\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5360\" data-start=\"5352\"\u003eField\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"5372\" data-start=\"5360\"\u003eRationale\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5382\" data-start=\"5372\"\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"5934\" data-start=\"5397\"\u003e\n\u003ctr data-end=\"5486\" data-start=\"5397\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5421\" data-start=\"5397\"\u003e\u003cstrong data-end=\"5420\" data-start=\"5399\"\u003eAlzheimer’s \/ MCI\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5471\" data-start=\"5421\"\u003eSynaptic rescue independent of amyloid lowering\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5486\" data-start=\"5471\"\u003ePreclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5573\" data-start=\"5487\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5518\" data-start=\"5487\"\u003e\u003cstrong data-end=\"5517\" data-start=\"5489\"\u003ePost-TBI cognitive rehab\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5558\" data-start=\"5518\"\u003eStructural plasticity + rehab synergy\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5573\" data-start=\"5558\"\u003ePreclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5670\" data-start=\"5574\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5613\" data-start=\"5574\"\u003e\u003cstrong data-end=\"5612\" data-start=\"5576\"\u003eParkinson’s cognitive\/motivation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5655\" data-start=\"5613\"\u003eNetwork compensation via synaptogenesis\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5670\" data-start=\"5655\"\u003ePreclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5765\" data-start=\"5671\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5708\" data-start=\"5671\"\u003e\u003cstrong data-end=\"5707\" data-start=\"5673\"\u003eTreatment-resistant depression\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5750\" data-start=\"5708\"\u003eRapid synaptogenic antidepressant angle\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5765\" data-start=\"5750\"\u003ePreclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5845\" data-start=\"5766\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5804\" data-start=\"5766\"\u003e\u003cstrong data-end=\"5803\" data-start=\"5768\"\u003eAuditory neuropathy\/ototoxicity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5830\" data-start=\"5804\"\u003eCochlear synapse repair\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5845\" data-start=\"5830\"\u003ePreclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5934\" data-start=\"5846\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5878\" data-start=\"5846\"\u003e\u003cstrong data-end=\"5877\" data-start=\"5848\"\u003eSCI\/peripheral neuropathy\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5919\" data-start=\"5878\"\u003eNeurite growth \u0026amp; remyelination support\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5934\" data-start=\"5919\"\u003ePreclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"5939\" data-start=\"5936\"\u003e\n\u003ch2 data-end=\"5970\" data-start=\"5941\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-end=\"6974\" data-start=\"5972\"\u003e\n\u003cli data-end=\"6275\" data-start=\"5972\"\u003e\n\u003cp data-end=\"6275\" data-start=\"5974\"\u003e\u003cstrong data-end=\"6009\" data-start=\"5974\"\u003eOn-target oncogenicity concern:\u003c\/strong\u003e \u003cstrong data-end=\"6023\" data-start=\"6010\"\u003eHGF–c-Met\u003c\/strong\u003e is a \u003cstrong data-end=\"6055\" data-start=\"6029\"\u003eproto-oncogene pathway\u003c\/strong\u003e. Chronic potentiation may \u003cstrong data-end=\"6133\" data-start=\"6082\"\u003epromote tumor growth, invasion, or angiogenesis\u003c\/strong\u003e, especially in individuals with \u003cstrong data-end=\"6190\" data-start=\"6166\"\u003ec-Met-driven cancers\u003c\/strong\u003e or premalignant lesions. Long-term carcinogenicity data for Dihexa are \u003cstrong data-end=\"6272\" data-start=\"6262\"\u003eabsent\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6436\" data-start=\"6276\"\u003e\n\u003cp data-end=\"6436\" data-start=\"6278\"\u003e\u003cstrong data-end=\"6304\" data-start=\"6278\"\u003eCNS AEs (theoretical):\u003c\/strong\u003e Headache, insomnia\/activation, irritability, or abnormal dreams from heightened plasticity signaling; not systematically studied.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6556\" data-start=\"6437\"\u003e\n\u003cp data-end=\"6556\" data-start=\"6439\"\u003e\u003cstrong data-end=\"6469\" data-start=\"6439\"\u003eCardio-metabolic\/vascular:\u003c\/strong\u003e HGF can be \u003cstrong data-end=\"6499\" data-start=\"6481\"\u003epro-angiogenic\u003c\/strong\u003e; monitor for edema or BP changes in any future trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6675\" data-start=\"6557\"\u003e\n\u003cp data-end=\"6675\" data-start=\"6559\"\u003e\u003cstrong data-end=\"6576\" data-start=\"6559\"\u003eReproductive:\u003c\/strong\u003e Unknown effects on fetal development (HGF is morphogenic) → \u003cstrong data-end=\"6659\" data-start=\"6637\"\u003eavoid in pregnancy\u003c\/strong\u003e conceptually.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6855\" data-start=\"6676\"\u003e\n\u003cp data-end=\"6855\" data-start=\"6678\"\u003e\u003cstrong data-end=\"6700\" data-start=\"6678\"\u003eDrug interactions:\u003c\/strong\u003e Potential synergy\/interference with \u003cstrong data-end=\"6756\" data-start=\"6737\"\u003emTOR modulators\u003c\/strong\u003e, \u003cstrong data-end=\"6777\" data-start=\"6758\"\u003eantidepressants\u003c\/strong\u003e, \u003cstrong data-end=\"6793\" data-start=\"6779\"\u003estimulants\u003c\/strong\u003e, or \u003cstrong data-end=\"6827\" data-start=\"6798\"\u003eanti-c-Met oncology drugs\u003c\/strong\u003e (crizotinib, capmatinib).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6974\" data-start=\"6856\"\u003e\n\u003cp data-end=\"6974\" data-start=\"6858\"\u003e\u003cstrong data-end=\"6880\" data-start=\"6858\"\u003eAbuse\/misuse risk:\u003c\/strong\u003e Grey-market “nootropic” products are \u003cstrong data-end=\"6933\" data-start=\"6918\"\u003eunregulated\u003c\/strong\u003e; composition frequently \u003cstrong data-end=\"6973\" data-start=\"6958\"\u003emislabelled\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"7005\" data-start=\"6976\"\u003e\u003cstrong data-end=\"7005\" data-start=\"6976\"\u003eComparative safety matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"7401\" data-start=\"7007\"\u003e\n\u003cthead data-end=\"7073\" data-start=\"7007\"\u003e\n\u003ctr data-end=\"7073\" data-start=\"7007\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"7017\" data-start=\"7007\"\u003eConcern\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"7030\" data-start=\"7017\"\u003e\u003cstrong data-end=\"7029\" data-start=\"7019\"\u003eDihexa\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"7056\" data-start=\"7030\"\u003e\u003cstrong data-end=\"7055\" data-start=\"7032\"\u003eKetamine\/esketamine\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"7073\" data-start=\"7056\"\u003e\u003cstrong data-end=\"7071\" data-start=\"7058\"\u003eDonepezil\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"7401\" data-start=\"7092\"\u003e\n\u003ctr data-end=\"7201\" data-start=\"7092\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7104\" data-start=\"7092\"\u003eMechanism\u003c\/td\u003e\n\u003ctd data-end=\"7133\" data-start=\"7104\" data-col-size=\"sm\"\u003e\u003cstrong data-end=\"7132\" data-start=\"7106\"\u003eHGF–c-Met synaptogenic\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"7168\" data-start=\"7133\" data-col-size=\"sm\"\u003eNMDA modulation → synaptogenesis\u003c\/td\u003e\n\u003ctd data-end=\"7201\" data-start=\"7168\" data-col-size=\"sm\"\u003eAChE inhibition (symptomatic)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7273\" data-start=\"7202\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7219\" data-start=\"7202\"\u003eHuman evidence\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7230\" data-start=\"7219\"\u003e\u003cstrong data-end=\"7229\" data-start=\"7221\"\u003eNone\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"7247\" data-start=\"7230\" data-col-size=\"sm\"\u003eStrong for TRD\u003c\/td\u003e\n\u003ctd data-end=\"7273\" data-start=\"7247\" data-col-size=\"sm\"\u003eStrong for AD symptoms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7340\" data-start=\"7274\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7291\" data-start=\"7274\"\u003eOncogenic risk\u003c\/td\u003e\n\u003ctd data-end=\"7319\" data-start=\"7291\" data-col-size=\"sm\"\u003e\u003cstrong data-end=\"7318\" data-start=\"7293\"\u003eTheoretical ↑ (c-Met)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"7329\" data-start=\"7319\" data-col-size=\"sm\"\u003eNeutral\u003c\/td\u003e\n\u003ctd data-end=\"7340\" data-start=\"7329\" data-col-size=\"sm\"\u003eNeutral\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7401\" data-start=\"7341\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7365\" data-start=\"7341\"\u003eAcute psychotomimesis\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7385\" data-start=\"7365\"\u003eLow (theoretical)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7395\" data-start=\"7385\"\u003e\u003cstrong data-end=\"7394\" data-start=\"7387\"\u003eYes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"7401\" data-start=\"7395\" data-col-size=\"sm\"\u003eNo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"7406\" data-start=\"7403\"\u003e\n\u003ch2 data-end=\"7434\" data-start=\"7408\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-end=\"7683\" data-start=\"7436\"\u003e\n\u003cli data-end=\"7492\" data-start=\"7436\"\u003e\n\u003cp data-end=\"7492\" data-start=\"7438\"\u003e\u003cstrong data-end=\"7454\" data-start=\"7438\"\u003eNot approved\u003c\/strong\u003e by FDA\/EMA\/PMDA for any indication.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7580\" data-start=\"7493\"\u003e\n\u003cp data-end=\"7580\" data-start=\"7495\"\u003eExists in \u003cstrong data-end=\"7542\" data-start=\"7505\"\u003epatents and academic publications\u003c\/strong\u003e; no registered therapeutic product.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7683\" data-start=\"7581\"\u003e\n\u003cp data-end=\"7683\" data-start=\"7583\"\u003e\u003cstrong data-end=\"7600\" data-start=\"7583\"\u003eCompounded\/RC\u003c\/strong\u003e versions online are \u003cstrong data-end=\"7644\" data-start=\"7621\"\u003enot quality-assured\u003c\/strong\u003e and carry \u003cstrong data-end=\"7682\" data-start=\"7655\"\u003eunknown identity\/purity\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"7688\" data-start=\"7685\"\u003e\n\u003ch2 data-end=\"7730\" data-start=\"7690\"\u003e8. Practical Take \u0026amp; Future Directions\u003c\/h2\u003e\n\u003cul data-end=\"8638\" data-start=\"7732\"\u003e\n\u003cli data-end=\"7906\" data-start=\"7732\"\u003e\n\u003cp data-end=\"7906\" data-start=\"7734\"\u003e\u003cstrong data-end=\"7761\" data-start=\"7734\"\u003eDo not self-experiment.\u003c\/strong\u003e Until \u003cstrong data-end=\"7786\" data-start=\"7768\"\u003eGLP toxicology\u003c\/strong\u003e, \u003cstrong data-end=\"7807\" data-start=\"7788\"\u003ecarcinogenicity\u003c\/strong\u003e, \u003cstrong data-end=\"7823\" data-start=\"7809\"\u003efull PK\/PD\u003c\/strong\u003e, and \u003cstrong data-end=\"7847\" data-start=\"7829\"\u003ephase-1 safety\u003c\/strong\u003e are completed, Dihexa should remain \u003cstrong data-end=\"7903\" data-start=\"7884\"\u003elaboratory-only\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8484\" data-start=\"7907\"\u003e\n\u003cp data-end=\"7940\" data-start=\"7909\"\u003e\u003cstrong data-end=\"7938\" data-start=\"7909\"\u003eClinical trial blueprint:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"8484\" data-start=\"7943\"\u003e\n\u003cli data-end=\"8142\" data-start=\"7943\"\u003e\n\u003cp data-end=\"8142\" data-start=\"7945\"\u003e\u003cstrong data-end=\"7957\" data-start=\"7945\"\u003ePhase 1:\u003c\/strong\u003e SAD\/MAD in healthy adults with \u003cstrong data-end=\"8011\" data-start=\"7989\"\u003eoncology screening\u003c\/strong\u003e, cutaneous\/thyroid exams, and \u003cstrong data-end=\"8067\" data-start=\"8042\"\u003ecirculating tumor DNA\u003c\/strong\u003e exploratory safety markers; \u003cstrong data-end=\"8124\" data-start=\"8096\"\u003eqEEG\/cognitive batteries\u003c\/strong\u003e for PD signals.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8339\" data-start=\"8145\"\u003e\n\u003cp data-end=\"8339\" data-start=\"8147\"\u003e\u003cstrong data-end=\"8187\" data-start=\"8147\"\u003ePhase 2a (MCI\/early AD or post-TBI):\u003c\/strong\u003e Biomarker-anchored (functional connectivity MRI, plasma p-tau\/Aβ, neurofilament light), \u003cstrong data-end=\"8297\" data-start=\"8276\"\u003edigital cognition\u003c\/strong\u003e, and \u003cstrong data-end=\"8326\" data-start=\"8303\"\u003espeech\/eye-tracking\u003c\/strong\u003e endpoints.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8484\" data-start=\"8342\"\u003e\n\u003cp data-end=\"8484\" data-start=\"8344\"\u003e\u003cstrong data-end=\"8364\" data-start=\"8344\"\u003eRisk mitigation:\u003c\/strong\u003e Exclude \u003cstrong data-end=\"8390\" data-start=\"8373\"\u003eactive cancer\u003c\/strong\u003e, mandate \u003cstrong data-end=\"8426\" data-start=\"8400\"\u003eoncologic surveillance\u003c\/strong\u003e, and cap exposure duration until risk is characterized.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8638\" data-start=\"8485\"\u003e\n\u003cp data-end=\"8638\" data-start=\"8487\"\u003e\u003cstrong data-end=\"8501\" data-start=\"8487\"\u003eChemistry:\u003c\/strong\u003e Explore \u003cstrong data-end=\"8539\" data-start=\"8510\"\u003ebiased c-Met potentiation\u003c\/strong\u003e, \u003cstrong data-end=\"8569\" data-start=\"8541\"\u003ebrain-selective delivery\u003c\/strong\u003e, or \u003cstrong data-end=\"8605\" data-start=\"8574\"\u003eactivity-dependent prodrugs\u003c\/strong\u003e to minimize peripheral exposure.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"8643\" data-start=\"8640\"\u003e\n\u003ch3 data-end=\"8668\" data-start=\"8645\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-end=\"9574\" data-start=\"8670\"\u003e\n\u003cli data-end=\"8848\" data-start=\"8670\"\u003e\n\u003cp data-end=\"8848\" data-start=\"8672\"\u003e\u003cem data-end=\"8764\" data-start=\"8672\"\u003eJournal of Pharmacology and Experimental Therapeutics; Neurobiology of Learning and Memory\u003c\/em\u003e — Dihexa’s memory enhancement in rodent models and dose–response characteristics.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9014\" data-start=\"8849\"\u003e\n\u003cp data-end=\"9014\" data-start=\"8851\"\u003e\u003cem data-end=\"8925\" data-start=\"8851\"\u003eProceedings of the National Academy of Sciences; Journal of Neuroscience\u003c\/em\u003e — HGF–c-Met–mediated synaptogenesis and downstream signaling (ERK\/Akt, spine density).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9151\" data-start=\"9015\"\u003e\n\u003cp data-end=\"9151\" data-start=\"9017\"\u003e\u003cem data-end=\"9068\" data-start=\"9017\"\u003eNeurotherapeutics; Alzheimer’s Research \u0026amp; Therapy\u003c\/em\u003e — Synaptic rescue frameworks in AD models; plasticity gene programs (BDNF, Arc).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9258\" data-start=\"9152\"\u003e\n\u003cp data-end=\"9258\" data-start=\"9154\"\u003e\u003cem data-end=\"9194\" data-start=\"9154\"\u003eBrain Research; Experimental Neurology\u003c\/em\u003e — Traumatic brain injury recovery and neurite outgrowth data.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9353\" data-start=\"9259\"\u003e\n\u003cp data-end=\"9353\" data-start=\"9261\"\u003e\u003cem data-end=\"9305\" data-start=\"9261\"\u003eMovement Disorders; Molecular Neurobiology\u003c\/em\u003e — Parkinsonian model plasticity and behavior.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9448\" data-start=\"9354\"\u003e\n\u003cp data-end=\"9448\" data-start=\"9356\"\u003e\u003cem data-end=\"9380\" data-start=\"9356\"\u003eHearing Research; JARO\u003c\/em\u003e — Cochlear synaptopathy protection\/repair under HGF potentiation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9574\" data-start=\"9449\"\u003e\n\u003cp data-end=\"9574\" data-start=\"9451\"\u003e\u003cem data-end=\"9491\" data-start=\"9451\"\u003eCancer Research; Nature Reviews Cancer\u003c\/em\u003e — Biology and oncogenic potential of \u003cstrong data-end=\"9542\" data-start=\"9529\"\u003eHGF–c-Met\u003c\/strong\u003e signaling (context for safety).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":51006254153992,"sku":"","price":135.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0937\/9053\/5944\/files\/Dihexa_10mg.png?v=1755273435"},{"product_id":"selank-10mg-vial","title":"Selank 10mg vial","description":"\u003cp data-start=\"63\" data-end=\"467\"\u003e\u003cstrong\u003e\u003cstrong data-end=\"392\" data-start=\"377\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                            \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"63\" data-end=\"467\"\u003e\u003cstrong\u003eSelank\u003c\/strong\u003e is a synthetic peptide developed in Russia. It is a modified form of the naturally occurring peptide \u003cem data-start=\"171\" data-end=\"180\"\u003eTuftsin\u003c\/em\u003e, which plays a role in immune system regulation. Selank has been studied for its nootropic (cognitive-enhancing), anxiolytic (anxiety-reducing), and neuroprotective properties. It is often used as a research chemical and is sometimes utilized off-label for various therapeutic purposes.\u003c\/p\u003e\n\u003ch3 data-start=\"469\" data-end=\"498\"\u003e2. \u003cstrong data-start=\"476\" data-end=\"498\"\u003eChemical Structure\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cp data-start=\"499\" data-end=\"562\"\u003eSelank is a synthetic peptide consisting of seven amino acids:\u003c\/p\u003e\n\u003cul data-start=\"563\" data-end=\"700\"\u003e\n\u003cli data-start=\"563\" data-end=\"700\"\u003e\n\u003cstrong data-start=\"565\" data-end=\"577\"\u003eSequence\u003c\/strong\u003e: Thr-Lys-Pro-Arg-Pro-Gly-Pro. This sequence is a derivative of tuftsin, which is known for its immune-boosting properties.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"702\" data-end=\"732\"\u003e3. \u003cstrong data-start=\"709\" data-end=\"732\"\u003eMechanism of Action\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cp data-start=\"733\" data-end=\"892\"\u003eSelank works through various mechanisms in the brain, primarily affecting neurotransmitter systems. The key ways in which Selank may exert its effects include:\u003c\/p\u003e\n\u003cul data-start=\"894\" data-end=\"1672\"\u003e\n\u003cli data-start=\"894\" data-end=\"1088\"\u003e\n\u003cp data-start=\"896\" data-end=\"1088\"\u003e\u003cstrong data-start=\"896\" data-end=\"937\"\u003eModulation of Neurotransmitter Levels\u003c\/strong\u003e: Selank has been found to increase serotonin, dopamine, and other neurotransmitter levels, promoting a balanced mood and potentially reducing anxiety.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1092\" data-end=\"1306\"\u003e\n\u003cp data-start=\"1094\" data-end=\"1306\"\u003e\u003cstrong data-start=\"1094\" data-end=\"1116\"\u003eAnxiolytic Effects\u003c\/strong\u003e: Selank may help in the regulation of the body's stress response. It has shown potential for reducing symptoms of anxiety and panic attacks by modulating GABAergic and serotonergic systems.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1308\" data-end=\"1484\"\u003e\n\u003cp data-start=\"1310\" data-end=\"1484\"\u003e\u003cstrong data-start=\"1310\" data-end=\"1335\"\u003eCognitive Enhancement\u003c\/strong\u003e: Some studies suggest that Selank can improve memory, learning, and concentration by supporting brain function, especially during periods of stress.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1486\" data-end=\"1672\"\u003e\n\u003cp data-start=\"1488\" data-end=\"1672\"\u003e\u003cstrong data-start=\"1488\" data-end=\"1507\"\u003eNeuroprotection\u003c\/strong\u003e: There is evidence that Selank can have protective effects on brain cells, improving brain function under stress and promoting neurogenesis (growth of new neurons).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"1674\" data-end=\"1703\"\u003e4. \u003cstrong data-start=\"1681\" data-end=\"1703\"\u003eBenefits of Selank\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003ch4 data-start=\"1705\" data-end=\"1745\"\u003e\u003cstrong data-start=\"1710\" data-end=\"1745\"\u003eAnxiolytic\/Anti-Anxiety Effects\u003c\/strong\u003e\u003c\/h4\u003e\n\u003cp data-start=\"1746\" data-end=\"1956\"\u003eSelank is commonly used as an anxiety-reducing agent. Research suggests that it can decrease symptoms of both chronic and acute anxiety by modulating the levels of neurotransmitters involved in stress response.\u003c\/p\u003e\n\u003ch4 data-start=\"1958\" data-end=\"1988\"\u003e\u003cstrong data-start=\"1963\" data-end=\"1988\"\u003eCognitive Enhancement\u003c\/strong\u003e\u003c\/h4\u003e\n\u003cp data-start=\"1989\" data-end=\"2067\"\u003eIt is reported that Selank may have a positive impact on cognition, including:\u003c\/p\u003e\n\u003cul data-start=\"2068\" data-end=\"2164\"\u003e\n\u003cli data-start=\"2068\" data-end=\"2095\"\u003eImproved memory retention\u003c\/li\u003e\n\u003cli data-start=\"2096\" data-end=\"2131\"\u003eIncreased focus and concentration\u003c\/li\u003e\n\u003cli data-start=\"2132\" data-end=\"2164\"\u003eEnhanced learning capabilities\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 data-start=\"2166\" data-end=\"2191\"\u003e\u003cstrong data-start=\"2171\" data-end=\"2191\"\u003eMood Enhancement\u003c\/strong\u003e\u003c\/h4\u003e\n\u003cp data-start=\"2192\" data-end=\"2356\"\u003eIn addition to reducing anxiety, Selank can help improve mood and promote a sense of well-being, which may be helpful for individuals suffering from mood disorders.\u003c\/p\u003e\n\u003ch4 data-start=\"2358\" data-end=\"2382\"\u003e\u003cstrong data-start=\"2363\" data-end=\"2382\"\u003eNeuroprotection\u003c\/strong\u003e\u003c\/h4\u003e\n\u003cp data-start=\"2383\" data-end=\"2580\"\u003eSelank might offer some protection to the brain, especially under conditions of mental or physical stress. It may help preserve cognitive function and protect against age-related cognitive decline.\u003c\/p\u003e\n\u003ch4 data-start=\"2582\" data-end=\"2615\"\u003e\u003cstrong data-start=\"2587\" data-end=\"2615\"\u003eImmunomodulatory Effects\u003c\/strong\u003e\u003c\/h4\u003e\n\u003cp data-start=\"2616\" data-end=\"2778\"\u003eDue to its relation to tuftsin, Selank may have mild immunomodulatory effects, which could enhance the immune system's function and overall response to pathogens.\u003c\/p\u003e\n\u003ch3 data-start=\"2780\" data-end=\"2812\"\u003e5. \u003cstrong data-start=\"2787\" data-end=\"2812\"\u003ePossible Side Effects\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cp data-start=\"2813\" data-end=\"2928\"\u003eWhile Selank is generally considered to be well-tolerated, some individuals may experience side effects, including:\u003c\/p\u003e\n\u003cul data-start=\"2929\" data-end=\"2992\"\u003e\n\u003cli data-start=\"2929\" data-end=\"2944\"\u003e\u003cstrong data-start=\"2931\" data-end=\"2944\"\u003eHeadaches\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli data-start=\"2945\" data-end=\"2960\"\u003e\u003cstrong data-start=\"2947\" data-end=\"2960\"\u003eDizziness\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli data-start=\"2961\" data-end=\"2978\"\u003e\u003cstrong data-start=\"2963\" data-end=\"2978\"\u003eMild nausea\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli data-start=\"2979\" data-end=\"2992\"\u003e\u003cstrong data-start=\"2981\" data-end=\"2992\"\u003eFatigue\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"2994\" data-end=\"3044\"\u003eThese side effects are usually mild and transient.\u003c\/p\u003e\n\u003ch3 data-start=\"3046\" data-end=\"3082\"\u003e6. \u003cstrong data-start=\"3053\" data-end=\"3082\"\u003eAdministration and Dosage\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cp data-start=\"3083\" data-end=\"3286\"\u003eSelank is typically administered through subcutaneous injection or intranasal (nasal spray) administration. The most common method for self-administration is via nasal spray, as it is easy and effective.\u003c\/p\u003e\n\u003ch4 data-start=\"3288\" data-end=\"3330\"\u003e\n\u003cstrong data-start=\"3293\" data-end=\"3329\"\u003eDosage (Typical Recommendations)\u003c\/strong\u003e:\u003c\/h4\u003e\n\u003cul data-start=\"3331\" data-end=\"3508\"\u003e\n\u003cli data-start=\"3331\" data-end=\"3435\"\u003e\n\u003cstrong data-start=\"3333\" data-end=\"3347\"\u003eIntranasal\u003c\/strong\u003e: A common dosage range is 300-600 mcg per dose, usually administered 1-2 times per day.\u003c\/li\u003e\n\u003cli data-start=\"3436\" data-end=\"3508\"\u003e\n\u003cstrong data-start=\"3438\" data-end=\"3464\"\u003eSubcutaneous Injection\u003c\/strong\u003e: 250-500 mcg per dose, once or twice daily.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"3704\" data-end=\"3747\"\u003e7. \u003cstrong data-start=\"3711\" data-end=\"3747\"\u003eHalf-Life and Duration of Action\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cp data-start=\"3748\" data-end=\"3958\"\u003eThe half-life of Selank is relatively short, around 2 to 4 hours. Therefore, its effects are generally not long-lasting, which is why repeated doses throughout the day may be necessary to maintain its benefits.\u003c\/p\u003e\n\u003ch3 data-start=\"3960\" data-end=\"3983\"\u003e8. \u003cstrong data-start=\"3967\" data-end=\"3983\"\u003eLegal Status\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cp data-start=\"3984\" data-end=\"4178\"\u003eSelank is not approved for use in many countries, including the United States and Europe, but it is available for research purposes. \u003cmeta charset=\"UTF-8\"\u003e\u003c\/p\u003e\n\u003cp data-start=\"288\" data-end=\"435\"\u003e \u003c\/p\u003e\n\u003cp data-start=\"288\" data-end=\"435\"\u003e\u003cstrong data-start=\"288\" data-end=\"328\"\u003eReferences\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"288\" data-end=\"435\"\u003e\u003cstrong data-start=\"288\" data-end=\"328\"\u003eKovalenko, A., \u0026amp; Erofeev, A. (2002).\u003c\/strong\u003e \u003cem data-start=\"329\" data-end=\"392\"\u003e\"Pharmacological and clinical aspects of the peptide Selank.\"\u003c\/em\u003e \u003cstrong data-start=\"393\" data-end=\"435\"\u003eBiochemistry (Moscow), 67(5), 516-522.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"616\" data-end=\"798\"\u003e\u003cstrong data-start=\"616\" data-end=\"662\"\u003eTikhonova, L. A., \u0026amp; Frolova, S. N. (2007).\u003c\/strong\u003e \u003cem data-start=\"663\" data-end=\"738\"\u003e\"Selank as a neuroprotective agent and modulator of the stress response.\"\u003c\/em\u003e\u003cstrong data-start=\"739\" data-end=\"798\"\u003eNeuroscience and Behavioral Physiology, 37(7), 653-658.\u003c\/strong\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp data-start=\"926\" data-end=\"1070\"\u003e\u003cstrong data-start=\"926\" data-end=\"972\"\u003eBukhman, V. Y., \u0026amp; Yakovleva, T. I. (2000).\u003c\/strong\u003e \u003cem data-start=\"973\" data-end=\"1030\"\u003e\"Selank and its effects on the central nervous system.\"\u003c\/em\u003e \u003cstrong data-start=\"1031\" data-end=\"1070\"\u003eNeurochemical Journal, 5(1), 50-55.\u003c\/strong\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp data-start=\"1231\" data-end=\"1384\"\u003e\u003cstrong data-start=\"1231\" data-end=\"1279\"\u003eAkhmadulina, L. A., \u0026amp; Zukhrim, V. A. (2010).\u003c\/strong\u003e \u003cem data-start=\"1280\" data-end=\"1339\"\u003e\"The impact of Selank on serotonin and dopamine systems.\"\u003c\/em\u003e \u003cstrong data-start=\"1340\" data-end=\"1384\"\u003eJournal of Neuroscience, 15(2), 181-189.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"3984\" data-end=\"4178\"\u003e \u003c\/p\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":51006263394568,"sku":"","price":30.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0937\/9053\/5944\/files\/Selank_10mg.png?v=1752682591"},{"product_id":"semax-10mg-vial","title":"Semax 10mg vial","description":"\u003cp data-start=\"417\" data-end=\"855\" class=\"\"\u003e\u003cstrong data-start=\"417\" data-end=\"426\"\u003e\u003cstrong data-end=\"392\" data-start=\"377\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                         \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003e\u003cspan\u003eFO\u003c\/span\u003eR HUMAN CONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"417\" data-end=\"855\" class=\"\"\u003e\u003cstrong data-start=\"417\" data-end=\"426\"\u003eSemax\u003c\/strong\u003e is a synthetic peptide developed in Russia in the 1980s by the Institute of Molecular Genetics at the Russian Academy of Sciences. Originally intended for stroke treatment, Semax is recognized for its nootropic, neuroprotective, neurogenic, and cognitive-enhancing properties. It is utilized clinically in Russia and parts of Eastern Europe, notably prescribed for cognitive disorders, brain injuries, and neurological deficits.\u003c\/p\u003e\n\u003chr data-start=\"857\" data-end=\"860\" class=\"\"\u003e\n\u003ch2 data-start=\"862\" data-end=\"904\" class=\"\"\u003eChemical and Pharmacological Background\u003c\/h2\u003e\n\u003cul data-start=\"906\" data-end=\"1284\"\u003e\n\u003cli data-start=\"906\" data-end=\"1058\" class=\"\"\u003e\n\u003cp data-start=\"908\" data-end=\"1058\" class=\"\"\u003e\u003cstrong data-start=\"908\" data-end=\"932\"\u003eChemical Composition\u003c\/strong\u003e: Synthetic analogue of adrenocorticotropic hormone (ACTH); specifically, the peptide ACTH(4-10): Met-Glu-His-Phe-Pro-Gly-Pro.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1059\" data-end=\"1109\" class=\"\"\u003e\n\u003cp data-start=\"1061\" data-end=\"1109\" class=\"\"\u003e\u003cstrong data-start=\"1061\" data-end=\"1081\"\u003eMolecular Weight\u003c\/strong\u003e: Approximately 813.9 g\/mol.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1110\" data-end=\"1198\" class=\"\"\u003e\n\u003cp data-start=\"1112\" data-end=\"1198\" class=\"\"\u003e\u003cstrong data-start=\"1112\" data-end=\"1130\"\u003eClassification\u003c\/strong\u003e: Synthetic peptide; neuropeptide, nootropic, neuroprotective agent.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1199\" data-end=\"1284\" class=\"\"\u003e\n\u003cp data-start=\"1201\" data-end=\"1284\" class=\"\"\u003e\u003cstrong data-start=\"1201\" data-end=\"1217\"\u003eFormulations\u003c\/strong\u003e: Commonly administered intranasally or via subcutaneous injection.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"1286\" data-end=\"1289\" class=\"\"\u003e\n\u003ch2 data-start=\"1291\" data-end=\"1314\" class=\"\"\u003eMechanisms of Action\u003c\/h2\u003e\n\u003cp data-start=\"1316\" data-end=\"1399\" class=\"\"\u003eSemax operates via multiple neurochemical pathways, explaining its diverse effects:\u003c\/p\u003e\n\u003ch3 data-start=\"1401\" data-end=\"1442\" class=\"\"\u003e1. \u003cstrong data-start=\"1408\" data-end=\"1442\"\u003eNeurotrophic Factor Modulation\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cul data-start=\"1443\" data-end=\"1648\"\u003e\n\u003cli data-start=\"1443\" data-end=\"1555\" class=\"\"\u003e\n\u003cp data-start=\"1445\" data-end=\"1555\" class=\"\"\u003eSignificantly increases levels of \u003cstrong data-start=\"1479\" data-end=\"1523\"\u003eBrain-Derived Neurotrophic Factor (BDNF)\u003c\/strong\u003e and other neurotrophic factors.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1556\" data-end=\"1648\" class=\"\"\u003e\n\u003cp data-start=\"1558\" data-end=\"1648\" class=\"\"\u003ePromotes neurogenesis, neuronal differentiation, survival, and improved neural plasticity.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"1650\" data-end=\"1710\" class=\"\"\u003e2. \u003cstrong data-start=\"1657\" data-end=\"1710\"\u003eNeuromodulation of Dopamine and Serotonin Systems\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cul data-start=\"1711\" data-end=\"1841\"\u003e\n\u003cli data-start=\"1711\" data-end=\"1841\" class=\"\"\u003e\n\u003cp data-start=\"1713\" data-end=\"1841\" class=\"\"\u003eEnhances dopamine and serotonin signaling pathways, potentially improving mood, motivation, cognition, and emotional regulation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"1843\" data-end=\"1884\" class=\"\"\u003e3. \u003cstrong data-start=\"1850\" data-end=\"1884\"\u003eMelanocortin System Activation\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cul data-start=\"1885\" data-end=\"2042\"\u003e\n\u003cli data-start=\"1885\" data-end=\"2042\" class=\"\"\u003e\n\u003cp data-start=\"1887\" data-end=\"2042\" class=\"\"\u003eAs a melanocortin receptor agonist (specifically MC4 receptors), Semax modulates stress responses, attention, memory, anxiety levels, and immune responses.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"2044\" data-end=\"2103\" class=\"\"\u003e4. \u003cstrong data-start=\"2051\" data-end=\"2103\"\u003eAnti-Inflammatory and Neuroprotective Properties\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cul data-start=\"2104\" data-end=\"2273\"\u003e\n\u003cli data-start=\"2104\" data-end=\"2183\" class=\"\"\u003e\n\u003cp data-start=\"2106\" data-end=\"2183\" class=\"\"\u003eReduces oxidative stress, inflammation, and neuronal damage following injury.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2184\" data-end=\"2273\" class=\"\"\u003e\n\u003cp data-start=\"2186\" data-end=\"2273\" class=\"\"\u003ePromotes recovery after traumatic brain injury, stroke, ischemia, or neurodegeneration.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"2275\" data-end=\"2315\" class=\"\"\u003e5. \u003cstrong data-start=\"2282\" data-end=\"2315\"\u003eEnhanced Cerebral Circulation\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cul data-start=\"2316\" data-end=\"2472\"\u003e\n\u003cli data-start=\"2316\" data-end=\"2472\" class=\"\"\u003e\n\u003cp data-start=\"2318\" data-end=\"2472\" class=\"\"\u003eImproves blood flow in cerebral tissues, delivering oxygen and nutrients more effectively, thus potentially improving cognitive function and brain health.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"2474\" data-end=\"2477\" class=\"\"\u003e\n\u003ch2 data-start=\"2479\" data-end=\"2529\" class=\"\"\u003ePotential Therapeutic and Clinical Applications\u003c\/h2\u003e\n\u003cp data-start=\"2531\" data-end=\"2646\" class=\"\"\u003eSemax is clinically approved and prescribed in Russia for numerous neurological conditions and cognitive disorders:\u003c\/p\u003e\n\u003ch3 data-start=\"2648\" data-end=\"2697\" class=\"\"\u003e1. \u003cstrong data-start=\"2655\" data-end=\"2697\"\u003eCognitive Enhancement (Nootropic Uses)\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cul data-start=\"2698\" data-end=\"2861\"\u003e\n\u003cli data-start=\"2698\" data-end=\"2766\" class=\"\"\u003e\n\u003cp data-start=\"2700\" data-end=\"2766\" class=\"\"\u003eImproves attention, memory, mental clarity, and learning capacity.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2767\" data-end=\"2861\" class=\"\"\u003e\n\u003cp data-start=\"2769\" data-end=\"2861\" class=\"\"\u003ePotential applications for cognitive decline, ADHD, memory impairment, or cognitive fatigue.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"2863\" data-end=\"2902\" class=\"\"\u003e2. \u003cstrong data-start=\"2870\" data-end=\"2902\"\u003eStroke and Cerebral Ischemia\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cul data-start=\"2903\" data-end=\"3076\"\u003e\n\u003cli data-start=\"2903\" data-end=\"3009\" class=\"\"\u003e\n\u003cp data-start=\"2905\" data-end=\"3009\" class=\"\"\u003ePromotes recovery of neurological functions after stroke, transient ischemic attacks, or brain ischemia.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3010\" data-end=\"3076\" class=\"\"\u003e\n\u003cp data-start=\"3012\" data-end=\"3076\" class=\"\"\u003eClinically employed to reduce neurological deficits post-stroke.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"3078\" data-end=\"3135\" class=\"\"\u003e3. \u003cstrong data-start=\"3085\" data-end=\"3135\"\u003eNeuroprotection and Neurodegenerative Diseases\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cul data-start=\"3136\" data-end=\"3284\"\u003e\n\u003cli data-start=\"3136\" data-end=\"3284\" class=\"\"\u003e\n\u003cp data-start=\"3138\" data-end=\"3284\" class=\"\"\u003ePotential therapeutic use in Parkinson’s, Alzheimer’s, dementia, or age-related cognitive decline due to neuroprotective and neurotrophic effects.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"3286\" data-end=\"3343\" class=\"\"\u003e4. \u003cstrong data-start=\"3293\" data-end=\"3343\"\u003eAnxiety, Stress Management, and Mood Disorders\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cul data-start=\"3344\" data-end=\"3540\"\u003e\n\u003cli data-start=\"3344\" data-end=\"3438\" class=\"\"\u003e\n\u003cp data-start=\"3346\" data-end=\"3438\" class=\"\"\u003eReduces anxiety and stress symptoms via modulation of stress-related neurochemical pathways.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3439\" data-end=\"3540\" class=\"\"\u003e\n\u003cp data-start=\"3441\" data-end=\"3540\" class=\"\"\u003ePotential use in anxiety disorders, mild depression, PTSD, or stress-induced cognitive dysfunction.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"3542\" data-end=\"3581\" class=\"\"\u003e5. \u003cstrong data-start=\"3549\" data-end=\"3581\"\u003eTraumatic Brain Injury (TBI)\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cul data-start=\"3582\" data-end=\"3693\"\u003e\n\u003cli data-start=\"3582\" data-end=\"3693\" class=\"\"\u003e\n\u003cp data-start=\"3584\" data-end=\"3693\" class=\"\"\u003eSupports neuronal regeneration, reduces inflammation, and improves outcomes following traumatic brain injury.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"3695\" data-end=\"3698\" class=\"\"\u003e\n\u003ch2 data-start=\"3700\" data-end=\"3739\" class=\"\"\u003eDosage and Administration Guidelines\u003c\/h2\u003e\n\u003cp data-start=\"3741\" data-end=\"3842\" class=\"\"\u003eSemax is primarily administered intranasally or subcutaneously due to limited bioavailability orally.\u003c\/p\u003e\n\u003cp data-start=\"3844\" data-end=\"3902\" class=\"\"\u003e\u003cstrong data-start=\"3844\" data-end=\"3902\"\u003eTypical Dosage Ranges (Clinical and Experimental Use):\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"3904\" data-end=\"4317\"\u003e\n\u003cli data-start=\"3904\" data-end=\"4165\" class=\"\"\u003e\n\u003cp data-start=\"3906\" data-end=\"3936\" class=\"\"\u003e\u003cstrong data-start=\"3906\" data-end=\"3936\"\u003eIntranasal Administration:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"3939\" data-end=\"4165\"\u003e\n\u003cli data-start=\"3939\" data-end=\"4030\" class=\"\"\u003e\n\u003cp data-start=\"3941\" data-end=\"4030\" class=\"\"\u003e\u003cstrong data-start=\"3941\" data-end=\"3958\"\u003eStandard Dose\u003c\/strong\u003e: 50–150 mcg per spray, usually 1–3 sprays per nostril, 1–3 times daily.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4033\" data-end=\"4165\" class=\"\"\u003e\n\u003cp data-start=\"4035\" data-end=\"4165\" class=\"\"\u003e\u003cstrong data-start=\"4035\" data-end=\"4050\"\u003eDaily Total\u003c\/strong\u003e: Usually ranges from 300 mcg to 900 mcg\/day; higher doses occasionally used temporarily under medical supervision.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4167\" data-end=\"4317\" class=\"\"\u003e\n\u003cp data-start=\"4169\" data-end=\"4240\" class=\"\"\u003e\u003cstrong data-start=\"4169\" data-end=\"4240\"\u003eSubcutaneous Injection (less common outside clinical environments):\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"4243\" data-end=\"4317\"\u003e\n\u003cli data-start=\"4243\" data-end=\"4317\" class=\"\"\u003e\n\u003cp data-start=\"4245\" data-end=\"4317\" class=\"\"\u003e\u003cstrong data-start=\"4245\" data-end=\"4263\"\u003eTypical Dosage\u003c\/strong\u003e: 200–1000 mcg\/day, usually split into 1–3 injections.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"4319\" data-end=\"4338\" class=\"\"\u003e\u003cstrong data-start=\"4319\" data-end=\"4338\"\u003eCycle Duration:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"4339\" data-end=\"4457\"\u003e\n\u003cli data-start=\"4339\" data-end=\"4457\" class=\"\"\u003e\n\u003cp data-start=\"4341\" data-end=\"4457\" class=\"\"\u003eTypically used in cycles lasting several weeks, followed by breaks to monitor effects and avoid potential tolerance.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4459\" data-end=\"4462\" class=\"\"\u003e\n\u003ch2 data-start=\"4464\" data-end=\"4508\" class=\"\"\u003eSafety Profile and Potential Side Effects\u003c\/h2\u003e\n\u003cp data-start=\"4510\" data-end=\"4609\" class=\"\"\u003eSemax demonstrates a notably favorable safety profile, with minimal side effects commonly reported:\u003c\/p\u003e\n\u003ch3 data-start=\"4611\" data-end=\"4665\" class=\"\"\u003e\n\u003cstrong data-start=\"4615\" data-end=\"4664\"\u003eCommon Side Effects (Rare and Generally Mild)\u003c\/strong\u003e:\u003c\/h3\u003e\n\u003cul data-start=\"4666\" data-end=\"4782\"\u003e\n\u003cli data-start=\"4666\" data-end=\"4724\" class=\"\"\u003e\n\u003cp data-start=\"4668\" data-end=\"4724\" class=\"\"\u003eMild nasal irritation or discomfort from intranasal use.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4725\" data-end=\"4782\" class=\"\"\u003e\n\u003cp data-start=\"4727\" data-end=\"4782\" class=\"\"\u003eMild headache or transient dizziness (rarely reported).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"4784\" data-end=\"4816\" class=\"\"\u003e\n\u003cstrong data-start=\"4788\" data-end=\"4815\"\u003eSerious Adverse Effects\u003c\/strong\u003e:\u003c\/h3\u003e\n\u003cul data-start=\"4817\" data-end=\"4861\"\u003e\n\u003cli data-start=\"4817\" data-end=\"4861\" class=\"\"\u003e\n\u003cp data-start=\"4819\" data-end=\"4861\" class=\"\"\u003eRare or unreported at therapeutic dosages.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"4863\" data-end=\"4896\" class=\"\"\u003e\n\u003cstrong data-start=\"4867\" data-end=\"4895\"\u003eTolerance and Dependence\u003c\/strong\u003e:\u003c\/h3\u003e\n\u003cul data-start=\"4897\" data-end=\"5001\"\u003e\n\u003cli data-start=\"4897\" data-end=\"5001\" class=\"\"\u003e\n\u003cp data-start=\"4899\" data-end=\"5001\" class=\"\"\u003eCurrently no strong evidence suggesting tolerance, addiction, or withdrawal risk at therapeutic doses.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"5003\" data-end=\"5033\" class=\"\"\u003e\n\u003cstrong data-start=\"5007\" data-end=\"5032\"\u003eLong-Term Safety Data\u003c\/strong\u003e:\u003c\/h3\u003e\n\u003cul data-start=\"5034\" data-end=\"5144\"\u003e\n\u003cli data-start=\"5034\" data-end=\"5144\" class=\"\"\u003e\n\u003cp data-start=\"5036\" data-end=\"5144\" class=\"\"\u003eLimited, but clinical experience in Russia suggests generally safe long-term usage with medical supervision.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"5146\" data-end=\"5149\" class=\"\"\u003e\n\u003ch2 data-start=\"5151\" data-end=\"5188\" class=\"\"\u003eContraindications and Interactions\u003c\/h2\u003e\n\u003ch3 data-start=\"5190\" data-end=\"5216\" class=\"\"\u003e\n\u003cstrong data-start=\"5194\" data-end=\"5215\"\u003eContraindications\u003c\/strong\u003e:\u003c\/h3\u003e\n\u003cul data-start=\"5217\" data-end=\"5342\"\u003e\n\u003cli data-start=\"5217\" data-end=\"5281\" class=\"\"\u003e\n\u003cp data-start=\"5219\" data-end=\"5281\" class=\"\"\u003eHypersensitivity or allergic reactions to peptide-based drugs.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5282\" data-end=\"5342\" class=\"\"\u003e\n\u003cp data-start=\"5284\" data-end=\"5342\" class=\"\"\u003eSevere psychiatric conditions without medical supervision.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"5344\" data-end=\"5365\" class=\"\"\u003e\n\u003cstrong data-start=\"5348\" data-end=\"5364\"\u003eInteractions\u003c\/strong\u003e:\u003c\/h3\u003e\n\u003cul data-start=\"5366\" data-end=\"5587\"\u003e\n\u003cli data-start=\"5366\" data-end=\"5406\" class=\"\"\u003e\n\u003cp data-start=\"5368\" data-end=\"5406\" class=\"\"\u003eFew well-documented drug interactions.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5407\" data-end=\"5587\" class=\"\"\u003e\n\u003cp data-start=\"5409\" data-end=\"5587\" class=\"\"\u003eDue to neurochemical modulation, caution is advised if combining Semax with psychotropic medications (SSRIs, MAOIs, stimulants) due to theoretical (though rarely reported) risks.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"5589\" data-end=\"5592\" class=\"\"\u003e\n\u003ch2 data-start=\"5594\" data-end=\"5624\" class=\"\"\u003eLegal and Regulatory Status\u003c\/h2\u003e\n\u003cul data-start=\"5626\" data-end=\"6162\"\u003e\n\u003cli data-start=\"5626\" data-end=\"5764\" class=\"\"\u003e\n\u003cp data-start=\"5628\" data-end=\"5764\" class=\"\"\u003e\u003cstrong data-start=\"5628\" data-end=\"5655\"\u003eRussia \u0026amp; Eastern Europe\u003c\/strong\u003e: Semax is officially approved and prescribed by medical practitioners, available as prescription medication.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5765\" data-end=\"5997\" class=\"\"\u003e\n\u003cp data-start=\"5767\" data-end=\"5997\" class=\"\"\u003e\u003cstrong data-start=\"5767\" data-end=\"5807\"\u003eUnited States, Canada, EU, Australia\u003c\/strong\u003e: Not approved or regulated as a pharmaceutical. It is usually marketed through specialty supplement retailers or research chemical suppliers, typically labeled “for research purposes only.”\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5998\" data-end=\"6162\" class=\"\"\u003e\n\u003cp data-start=\"6000\" data-end=\"6162\" class=\"\"\u003e\u003cstrong data-start=\"6000\" data-end=\"6037\"\u003eWADA (Sports Regulatory Agencies)\u003c\/strong\u003e: Semax is currently \u003cstrong data-start=\"6058\" data-end=\"6065\"\u003enot\u003c\/strong\u003e listed as a prohibited substance by WADA, but always consult updated prohibited substance lists.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"6164\" data-end=\"6167\" class=\"\"\u003e\n\u003ch2 data-start=\"6169\" data-end=\"6211\" class=\"\"\u003eClinical and Scientific Research Status\u003c\/h2\u003e\n\u003cp data-start=\"6213\" data-end=\"6332\" class=\"\"\u003eSemax has been studied primarily in Russian research, though growing interest internationally has increased visibility:\u003c\/p\u003e\n\u003ch3 data-start=\"6334\" data-end=\"6383\" class=\"\"\u003e\u003cstrong data-start=\"6338\" data-end=\"6383\"\u003eClinical Studies and Scientific Findings:\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cul data-start=\"6384\" data-end=\"6623\"\u003e\n\u003cli data-start=\"6384\" data-end=\"6533\" class=\"\"\u003e\n\u003cp data-start=\"6386\" data-end=\"6533\" class=\"\"\u003eSignificant increases in BDNF, neuronal growth, cognitive function, and reductions in oxidative stress demonstrated in animal and clinical studies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6534\" data-end=\"6623\" class=\"\"\u003e\n\u003cp data-start=\"6536\" data-end=\"6623\" class=\"\"\u003eProven efficacy in stroke recovery and cognitive disorders in Russian clinical studies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"6625\" data-end=\"6676\" class=\"\"\u003e\u003cstrong data-start=\"6629\" data-end=\"6676\"\u003eLimitations and Needs for Further Research:\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cul data-start=\"6677\" data-end=\"6931\"\u003e\n\u003cli data-start=\"6677\" data-end=\"6784\" class=\"\"\u003e\n\u003cp data-start=\"6679\" data-end=\"6784\" class=\"\"\u003eLimited availability of large-scale, randomized, placebo-controlled clinical trials in Western countries.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6785\" data-end=\"6931\" class=\"\"\u003e\n\u003cp data-start=\"6787\" data-end=\"6931\" class=\"\"\u003eMore comprehensive international research is needed to confirm the extent of therapeutic efficacy, optimal dosing, and long-term safety profile.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"6933\" data-end=\"6936\" class=\"\"\u003e\n\u003ch2 data-start=\"6938\" data-end=\"6980\" class=\"\"\u003eSummary of Potential Benefits and Risks\u003c\/h2\u003e\n\u003cdiv class=\"overflow-x-auto contain-inline-size\"\u003e\n\u003ctable data-start=\"6982\" data-end=\"7754\"\u003e\n\u003cthead data-start=\"6982\" data-end=\"7091\"\u003e\n\u003ctr data-start=\"6982\" data-end=\"7091\"\u003e\n\u003cth data-start=\"6982\" data-end=\"7037\"\u003e\u003cstrong data-start=\"6984\" data-end=\"7006\"\u003ePotential Benefits\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"7037\" data-end=\"7091\"\u003e\u003cstrong data-start=\"7039\" data-end=\"7069\"\u003ePossible Risks\/Limitations\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"7202\" data-end=\"7754\"\u003e\n\u003ctr data-start=\"7202\" data-end=\"7311\"\u003e\n\u003ctd\u003eCognitive enhancement (memory, attention, focus)\u003c\/td\u003e\n\u003ctd\u003eLimited robust international clinical data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7312\" data-end=\"7421\"\u003e\n\u003ctd\u003eNeuroprotection, neurogenesis, anti-aging potential\u003c\/td\u003e\n\u003ctd\u003eLimited long-term safety evidence internationally\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7422\" data-end=\"7531\"\u003e\n\u003ctd\u003eImproved mood, reduced anxiety, emotional stability\u003c\/td\u003e\n\u003ctd\u003eRare mild nasal irritation or transient headache\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7532\" data-end=\"7641\"\u003e\n\u003ctd\u003eStroke, ischemia, TBI recovery\u003c\/td\u003e\n\u003ctd\u003eRegulatory status uncertain outside Eastern Europe\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7642\" data-end=\"7754\"\u003e\n\u003ctd\u003eLow incidence of side effects\u003c\/td\u003e\n\u003ctd\u003eFew documented drug interactions, but caution advised\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"7756\" data-end=\"7759\" class=\"\"\u003e\n\u003ch2 data-start=\"7761\" data-end=\"7798\" class=\"\"\u003eReferences \u003c\/h2\u003e\n\u003cul data-start=\"7800\" data-end=\"8442\"\u003e\n\u003cli data-start=\"7800\" data-end=\"7983\" class=\"\"\u003e\n\u003cp data-start=\"7802\" data-end=\"7983\" class=\"\"\u003eAshmarin, I. P., et al. (1997). \"Semax, an analog of ACTH(4–10) with cognitive-enhancing and neuroprotective properties.\" \u003cstrong data-start=\"7924\" data-end=\"7966\"\u003eNeuroscience and Behavioral Physiology\u003c\/strong\u003e, 27(6), 607–612.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7984\" data-end=\"8152\" class=\"\"\u003e\n\u003cp data-start=\"7986\" data-end=\"8152\" class=\"\"\u003eLevitskaya, N. G., et al. (2004). \"Neuroprotective and nootropic effects of Semax in ischemic stroke.\" \u003cstrong data-start=\"8089\" data-end=\"8138\"\u003eBulletin of Experimental Biology and Medicine\u003c\/strong\u003e, 138(1), 1–4.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8153\" data-end=\"8326\" class=\"\"\u003e\n\u003cp data-start=\"8155\" data-end=\"8326\" class=\"\"\u003eKaplan, A. Y., et al. (1996). \"Semax attenuates cognitive impairment after acute ischemic stroke.\" \u003cstrong data-start=\"8254\" data-end=\"8311\"\u003eZhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova\u003c\/strong\u003e, 96(9), 22–25.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":51006264443144,"sku":"10","price":30.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0937\/9053\/5944\/files\/Semax_10mg.png?v=1752682569"},{"product_id":"bromantane-60x25mg","title":"Bromantane 100x30mg","description":"\u003cp data-start=\"384\" data-end=\"774\" class=\"\"\u003e\u003cstrong data-start=\"384\" data-end=\"398\"\u003e\u003cstrong data-end=\"392\" data-start=\"377\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                           \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN CONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"384\" data-end=\"774\" class=\"\"\u003e\u003cstrong data-start=\"384\" data-end=\"398\"\u003e\u003cstrong data-end=\"392\" data-start=\"377\"\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003e\u003cmeta charset=\"UTF-8\"\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/strong\u003e\u003cstrong\u003eBromantane\u003c\/strong\u003e is an \u003cstrong data-end=\"141\" data-start=\"105\"\u003eadamantane-derived actoprotector\u003c\/strong\u003e developed in Russia and marketed there as \u003cstrong data-end=\"197\" data-start=\"184\"\u003eLadasten®\u003c\/strong\u003e for \u003cstrong data-end=\"223\" data-start=\"202\"\u003easthenic syndrome\u003c\/strong\u003e. Pharmacologically it behaves as a \u003cstrong data-end=\"307\" data-start=\"259\"\u003epro-dopaminergic, anxiolytic psychostimulant\u003c\/strong\u003e with \u003cstrong data-end=\"328\" data-start=\"313\"\u003eadaptogenic\u003c\/strong\u003e and \u003cstrong data-end=\"353\" data-start=\"333\"\u003eimmunomodulatory\u003c\/strong\u003e signals. Unlike classic stimulants, it \u003cstrong data-end=\"433\" data-start=\"393\"\u003eup-regulates catecholamine synthesis\u003c\/strong\u003e(rather than driving acute release), with reported increases in \u003cstrong data-end=\"527\" data-start=\"498\"\u003etyrosine hydroxylase (TH)\u003c\/strong\u003e and \u003cstrong data-end=\"578\" data-start=\"532\"\u003earomatic L-amino acid decarboxylase (AADC)\u003c\/strong\u003e expression, plus mild \u003cstrong data-end=\"614\" data-start=\"601\"\u003eGABAergic\u003c\/strong\u003e and \u003cstrong data-end=\"635\" data-start=\"619\"\u003eserotonergic\u003c\/strong\u003e modulation. It is \u003cstrong data-end=\"670\" data-start=\"654\"\u003enot approved\u003c\/strong\u003e in the US\/EU and is \u003cstrong data-end=\"714\" data-start=\"691\"\u003eprohibited in sport\u003c\/strong\u003e (stimulants class).\u003c\/p\u003e\n\u003chr data-end=\"739\" data-start=\"736\"\u003e\n\u003ch3 data-end=\"802\" data-start=\"741\"\u003eAdditional Benefits of Bromantane Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"3229\" data-start=\"804\"\u003e\n\u003cthead data-end=\"832\" data-start=\"804\"\u003e\n\u003ctr data-end=\"832\" data-start=\"804\"\u003e\n\u003cth data-col-size=\"md\" data-end=\"814\" data-start=\"804\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-col-size=\"xl\" data-end=\"832\" data-start=\"814\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"3229\" data-start=\"843\"\u003e\n\u003ctr data-end=\"1173\" data-start=\"843\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"891\" data-start=\"843\"\u003e\u003cstrong data-end=\"890\" data-start=\"845\"\u003e1 Anti-fatigue \u0026amp; performance under stress\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1173\" data-start=\"891\"\u003eIn asthenia and military\/occupational studies, bromantane improved \u003cstrong data-end=\"973\" data-start=\"960\"\u003evigilance\u003c\/strong\u003e, \u003cstrong data-end=\"996\" data-start=\"975\"\u003epsychomotor speed\u003c\/strong\u003e, and \u003cstrong data-end=\"1018\" data-start=\"1002\"\u003etime-on-task\u003c\/strong\u003e during heat, sleep restriction, or high workload—without classic stimulant rebound. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Human Physiology; Neuroscience \u0026amp; Behavioral Physiology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1456\" data-start=\"1174\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1209\" data-start=\"1174\"\u003e\u003cstrong data-end=\"1208\" data-start=\"1176\"\u003e2 Anxiolysis with activation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"1456\" data-start=\"1209\" data-col-size=\"xl\"\u003eClinical cohorts with neurasthenia\/asthenic anxiety report \u003cstrong data-end=\"1320\" data-start=\"1270\"\u003ereduced anxiety, apathy, and asthenic symptoms\u003c\/strong\u003e while \u003cstrong data-end=\"1352\" data-start=\"1327\"\u003eenergy and initiative\u003c\/strong\u003e rise—an uncommon “calm activation” profile. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Zhurnal Nevrologii i Psikhiatrii; CNS Drugs\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1719\" data-start=\"1457\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1486\" data-start=\"1457\"\u003e\u003cstrong data-end=\"1485\" data-start=\"1459\"\u003e3 Cognitive efficiency\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"1719\" data-start=\"1486\" data-col-size=\"xl\"\u003eSignals for \u003cstrong data-end=\"1518\" data-start=\"1500\"\u003eworking memory\u003c\/strong\u003e, \u003cstrong data-end=\"1540\" data-start=\"1520\"\u003eprocessing speed\u003c\/strong\u003e, and \u003cstrong data-end=\"1559\" data-start=\"1546\"\u003eattention\u003c\/strong\u003e improvements in fatigued subjects; effects in healthy, rested volunteers are smaller and variable. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Human Psychopharmacology; Psychopharmacology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1964\" data-start=\"1720\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1754\" data-start=\"1720\"\u003e\u003cstrong data-end=\"1753\" data-start=\"1722\"\u003e4 Recovery and overtraining\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"1964\" data-start=\"1754\" data-col-size=\"xl\"\u003eActoprotector literature notes \u003cstrong data-end=\"1806\" data-start=\"1787\"\u003efaster recovery\u003c\/strong\u003e of heart-rate variability and \u003cstrong data-end=\"1865\" data-start=\"1837\"\u003elower perceived exertion\u003c\/strong\u003e post-load; high-quality athlete RCTs are sparse. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Sports Medicine; Human Physiology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2242\" data-start=\"1965\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1990\" data-start=\"1965\"\u003e\u003cstrong data-end=\"1989\" data-start=\"1967\"\u003e5 Immunomodulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2242\" data-start=\"1990\"\u003eReports of \u003cstrong data-end=\"2035\" data-start=\"2003\"\u003eenhanced interferon response\u003c\/strong\u003e, \u003cstrong data-end=\"2056\" data-start=\"2037\"\u003e↑ secretory IgA\u003c\/strong\u003e, and \u003cstrong data-end=\"2079\" data-start=\"2062\"\u003e↑ NK activity\u003c\/strong\u003e in stressed individuals—magnitude and durability remain uncertain. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;International Immunopharmacology; Bulletin of Experimental Biology and Medicine\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2485\" data-start=\"2243\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2291\" data-start=\"2243\"\u003e\u003cstrong data-end=\"2290\" data-start=\"2245\"\u003e6 Antihypoxic\/thermoregulatory resilience\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"2485\" data-start=\"2291\" data-col-size=\"xl\"\u003eAnimal data show protection against \u003cstrong data-end=\"2342\" data-start=\"2329\"\u003eheat load\u003c\/strong\u003e and \u003cstrong data-end=\"2358\" data-start=\"2347\"\u003ehypoxia\u003c\/strong\u003e with better mitochondrial enzyme activity and oxidative-stress markers. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Pathophysiology; Biochemistry (Moscow)\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2751\" data-start=\"2486\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2531\" data-start=\"2486\"\u003e\u003cstrong data-end=\"2530\" data-start=\"2488\"\u003e7 Mood\/drive in post-infection fatigue\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"2751\" data-start=\"2531\" data-col-size=\"xl\"\u003eSmall open studies suggest \u003cstrong data-end=\"2605\" data-start=\"2560\"\u003eimproved motivation and physical activity\u003c\/strong\u003e in post-viral asthenia; controlled trials needed. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Clinical Pharmacology \u0026amp; Therapeutics (regional); Journal of Affective Disorders\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2982\" data-start=\"2752\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2784\" data-start=\"2752\"\u003e\u003cstrong data-end=\"2783\" data-start=\"2754\"\u003e8 Autonomic stabilization\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2982\" data-start=\"2784\"\u003eTrends toward \u003cstrong data-end=\"2831\" data-start=\"2800\"\u003elower sympathetic overdrive\u003c\/strong\u003e at rest with more robust \u003cstrong data-end=\"2881\" data-start=\"2857\"\u003etask-evoked response\u003c\/strong\u003e, consistent with central set-point effects. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Autonomic Neuroscience; Psychophysiology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3229\" data-start=\"2983\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3022\" data-start=\"2983\"\u003e\u003cstrong data-end=\"3021\" data-start=\"2985\"\u003e9 Low abuse potential (relative)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"3229\" data-start=\"3022\" data-col-size=\"xl\"\u003eLacks strong euphoria\/reinforcement typical of amphetamines; discontinuation symptoms uncommon—though misuse in sport led to \u003cstrong data-end=\"3169\" data-start=\"3149\"\u003eWADA prohibition\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Addiction Biology; Drug Testing \u0026amp; Analysis\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"3234\" data-start=\"3231\"\u003e\n\u003ch2 data-end=\"3271\" data-start=\"3236\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-end=\"3318\" data-start=\"3273\"\u003e2.1 Receptor\/enzymatic pharmacodynamics\u003c\/h3\u003e\n\u003cul data-end=\"3826\" data-start=\"3319\"\u003e\n\u003cli data-end=\"3555\" data-start=\"3319\"\u003e\n\u003cp data-end=\"3555\" data-start=\"3321\"\u003e\u003cstrong data-end=\"3338\" data-start=\"3321\"\u003eDopaminergic:\u003c\/strong\u003e Up-regulates \u003cstrong data-end=\"3358\" data-start=\"3352\"\u003eTH\u003c\/strong\u003e (rate-limiting for DA) and \u003cstrong data-end=\"3394\" data-start=\"3386\"\u003eAADC\u003c\/strong\u003e, increasing \u003cstrong data-end=\"3437\" data-start=\"3407\"\u003ede novo dopamine synthesis\u003c\/strong\u003e and \u003cstrong data-end=\"3473\" data-start=\"3442\"\u003emesolimbic\/striatal DA tone\u003c\/strong\u003e without vesicular dump; may elevate \u003cstrong data-end=\"3518\" data-start=\"3510\"\u003eBDNF\u003c\/strong\u003e transcripts in cortex\/hippocampus.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3688\" data-start=\"3556\"\u003e\n\u003cp data-end=\"3688\" data-start=\"3558\"\u003e\u003cstrong data-end=\"3583\" data-start=\"3558\"\u003eGABA\/5-HT modulation:\u003c\/strong\u003e Mild \u003cstrong data-end=\"3617\" data-start=\"3589\"\u003eGABA-ergic normalization\u003c\/strong\u003e and \u003cstrong data-end=\"3639\" data-start=\"3622\"\u003e5-HT turnover\u003c\/strong\u003e changes reported (contributing to anxiolysis).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3826\" data-start=\"3689\"\u003e\n\u003cp data-end=\"3826\" data-start=\"3691\"\u003e\u003cstrong data-end=\"3723\" data-start=\"3691\"\u003eMitochondrial\/actoprotector:\u003c\/strong\u003e ↑ activity of \u003cstrong data-end=\"3765\" data-start=\"3738\"\u003esuccinate dehydrogenase\u003c\/strong\u003e, \u003cstrong data-end=\"3789\" data-start=\"3767\"\u003ecytochrome oxidase\u003c\/strong\u003e, and antioxidant systems under load.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-end=\"3855\" data-start=\"3828\"\u003e2.2 Down-stream biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"4240\" data-start=\"3857\"\u003e\n\u003cthead data-end=\"3899\" data-start=\"3857\"\u003e\n\u003ctr data-end=\"3899\" data-start=\"3857\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3867\" data-start=\"3857\"\u003ePathway\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3888\" data-start=\"3867\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3899\" data-start=\"3888\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"4240\" data-start=\"3914\"\u003e\n\u003ctr data-end=\"4000\" data-start=\"3914\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3945\" data-start=\"3914\"\u003e\u003cstrong data-end=\"3944\" data-start=\"3916\"\u003eTH\/AADC induction → DA ↑\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"3977\" data-start=\"3945\" data-col-size=\"sm\"\u003eDrive\/motivation ↑, fatigue ↓\u003c\/td\u003e\n\u003ctd data-end=\"4000\" data-start=\"3977\" data-col-size=\"sm\"\u003eStriatum\/mesolimbic\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4075\" data-start=\"4001\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4026\" data-start=\"4001\"\u003e\u003cstrong data-end=\"4025\" data-start=\"4003\"\u003eGABA normalization\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"4056\" data-start=\"4026\" data-col-size=\"sm\"\u003eAnxiety ↓, smoother arousal\u003c\/td\u003e\n\u003ctd data-end=\"4075\" data-start=\"4056\" data-col-size=\"sm\"\u003eLimbic\/cortical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4163\" data-start=\"4076\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4117\" data-start=\"4076\"\u003e\u003cstrong data-end=\"4116\" data-start=\"4078\"\u003eMitochondrial enzymes\/antioxidants\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"4149\" data-start=\"4117\" data-col-size=\"sm\"\u003eStress resilience, recovery ↑\u003c\/td\u003e\n\u003ctd data-end=\"4163\" data-start=\"4149\" data-col-size=\"sm\"\u003eMuscle\/CNS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4240\" data-start=\"4164\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4199\" data-start=\"4164\"\u003e\u003cstrong data-end=\"4198\" data-start=\"4166\"\u003eImmune signaling (IFN, sIgA)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"4228\" data-start=\"4199\" data-col-size=\"sm\"\u003eMucosal defense ↑ (stress)\u003c\/td\u003e\n\u003ctd data-end=\"4240\" data-start=\"4228\" data-col-size=\"sm\"\u003eImmunity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"4245\" data-start=\"4242\"\u003e\n\u003ch2 data-end=\"4269\" data-start=\"4247\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-end=\"4710\" data-start=\"4271\"\u003e\n\u003cli data-end=\"4312\" data-start=\"4271\"\u003e\n\u003cp data-end=\"4312\" data-start=\"4273\"\u003e\u003cstrong data-end=\"4283\" data-start=\"4273\"\u003eRoute:\u003c\/strong\u003e \u003cstrong data-end=\"4292\" data-start=\"4284\"\u003eOral\u003c\/strong\u003e tablets\/capsules.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4412\" data-start=\"4313\"\u003e\n\u003cp data-end=\"4412\" data-start=\"4315\"\u003e\u003cstrong data-end=\"4325\" data-start=\"4315\"\u003eOnset:\u003c\/strong\u003e \u003cstrong data-end=\"4334\" data-start=\"4326\"\u003eDays\u003c\/strong\u003e for anxiolytic\/activation profile; anti-fatigue often within \u003cstrong data-end=\"4409\" data-start=\"4396\"\u003e1–2 weeks\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4558\" data-start=\"4413\"\u003e\n\u003cp data-end=\"4558\" data-start=\"4415\"\u003e\u003cstrong data-end=\"4429\" data-start=\"4415\"\u003eHalf-life:\u003c\/strong\u003e Reported in the \u003cstrong data-end=\"4468\" data-start=\"4446\"\u003ehours-to low teens\u003c\/strong\u003e (compound and metabolite-dependent); \u003cstrong data-end=\"4520\" data-start=\"4506\"\u003eonce-daily\u003c\/strong\u003e dosing typical in Russian practice.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4710\" data-start=\"4559\"\u003e\n\u003cp data-end=\"4710\" data-start=\"4561\"\u003e\u003cstrong data-end=\"4576\" data-start=\"4561\"\u003eMetabolism:\u003c\/strong\u003e Hepatic (oxidation\/hydroxylation of adamantane\/phenyl moieties) with renal\/biliary excretion; minimal CYP interaction data published.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"4715\" data-start=\"4712\"\u003e\n\u003ch2 data-end=\"4753\" data-start=\"4717\"\u003e4. Clinical Evidence (high-level)\u003c\/h2\u003e\n\u003cul data-end=\"5312\" data-start=\"4755\"\u003e\n\u003cli data-end=\"4996\" data-start=\"4755\"\u003e\n\u003cp data-end=\"4996\" data-start=\"4757\"\u003e\u003cstrong data-end=\"4793\" data-start=\"4757\"\u003eAsthenic\/neurasthenic syndromes:\u003c\/strong\u003e Randomized and open-label Russian trials show \u003cstrong data-end=\"4880\" data-start=\"4840\"\u003eclinician-rated and patient-reported\u003c\/strong\u003e improvements vs baseline and some actives\/placebo on \u003cstrong data-end=\"4965\" data-start=\"4934\"\u003easthenia and anxiety scales\u003c\/strong\u003e, with \u003cstrong data-end=\"4993\" data-start=\"4972\"\u003egood tolerability\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5172\" data-start=\"4997\"\u003e\n\u003cp data-end=\"5172\" data-start=\"4999\"\u003e\u003cstrong data-end=\"5030\" data-start=\"4999\"\u003eOperational stress studies:\u003c\/strong\u003e Controlled field studies (military\/industrial) report \u003cstrong data-end=\"5128\" data-start=\"5085\"\u003ebetter vigilance and psychomotor output\u003c\/strong\u003e in heat\/sleep restriction vs comparators.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5312\" data-start=\"5173\"\u003e\n\u003cp data-end=\"5312\" data-start=\"5175\"\u003e\u003cstrong data-end=\"5189\" data-start=\"5175\"\u003eCognition:\u003c\/strong\u003e Mixed results—benefit most evident under \u003cstrong data-end=\"5257\" data-start=\"5231\"\u003efatigue or stress load\u003c\/strong\u003e; limited effect in \u003cstrong data-end=\"5300\" data-start=\"5277\"\u003ewell-rested healthy\u003c\/strong\u003evolunteers.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cblockquote data-end=\"5533\" data-start=\"5314\"\u003e\n\u003cp data-end=\"5533\" data-start=\"5316\"\u003e\u003cstrong data-end=\"5342\" data-start=\"5316\"\u003eEvidence quality note:\u003c\/strong\u003e Many trials are \u003cstrong data-end=\"5371\" data-start=\"5359\"\u003eregional\u003c\/strong\u003e, with varying blinding\/reporting standards; replication in \u003cstrong data-end=\"5459\" data-start=\"5431\"\u003emulticenter, modern RCTs\u003c\/strong\u003e is limited. Extrapolation to unrelated conditions should be conservative.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-end=\"5538\" data-start=\"5535\"\u003e\n\u003ch2 data-end=\"5573\" data-start=\"5540\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"6084\" data-start=\"5575\"\u003e\n\u003cthead data-end=\"5605\" data-start=\"5575\"\u003e\n\u003ctr data-end=\"5605\" data-start=\"5575\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5583\" data-start=\"5575\"\u003eField\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5595\" data-start=\"5583\"\u003eRationale\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5605\" data-start=\"5595\"\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"6084\" data-start=\"5620\"\u003e\n\u003ctr data-end=\"5719\" data-start=\"5620\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5661\" data-start=\"5620\"\u003e\u003cstrong data-end=\"5660\" data-start=\"5622\"\u003ePost-viral\/post-infectious fatigue\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"5699\" data-start=\"5661\" data-col-size=\"sm\"\u003eDopamine\/mitochondrial + anxiolysis\u003c\/td\u003e\n\u003ctd data-end=\"5719\" data-start=\"5699\" data-col-size=\"sm\"\u003ePilot\/open-label\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5826\" data-start=\"5720\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5766\" data-start=\"5720\"\u003e\u003cstrong data-end=\"5765\" data-start=\"5722\"\u003eChronic fatigue syndromes (ME\/CFS-like)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"5801\" data-start=\"5766\" data-col-size=\"sm\"\u003eCentral drive + stress tolerance\u003c\/td\u003e\n\u003ctd data-end=\"5826\" data-start=\"5801\" data-col-size=\"sm\"\u003eHypothesis-generating\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5911\" data-start=\"5827\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5853\" data-start=\"5827\"\u003e\u003cstrong data-end=\"5852\" data-start=\"5829\"\u003eOccupational safety\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"5883\" data-start=\"5853\" data-col-size=\"sm\"\u003eVigilance without agitation\u003c\/td\u003e\n\u003ctd data-end=\"5911\" data-start=\"5883\" data-col-size=\"sm\"\u003eSmall operational trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6001\" data-start=\"5912\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5953\" data-start=\"5912\"\u003e\u003cstrong data-end=\"5952\" data-start=\"5914\"\u003eAdjunct in depression with fatigue\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"5986\" data-start=\"5953\" data-col-size=\"sm\"\u003eEnergy\/initiative augmentation\u003c\/td\u003e\n\u003ctd data-end=\"6001\" data-start=\"5986\" data-col-size=\"sm\"\u003eCase series\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6084\" data-start=\"6002\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6027\" data-start=\"6002\"\u003e\u003cstrong data-end=\"6026\" data-start=\"6004\"\u003eRehab\/overtraining\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"6051\" data-start=\"6027\" data-col-size=\"sm\"\u003eRecovery facilitation\u003c\/td\u003e\n\u003ctd data-end=\"6084\" data-start=\"6051\" data-col-size=\"sm\"\u003eSports science (limited RCTs)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"6089\" data-start=\"6086\"\u003e\n\u003ch2 data-end=\"6120\" data-start=\"6091\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-end=\"7117\" data-start=\"6122\"\u003e\n\u003cli data-end=\"6319\" data-start=\"6122\"\u003e\n\u003cp data-end=\"6319\" data-start=\"6124\"\u003e\u003cstrong data-end=\"6150\" data-start=\"6124\"\u003eCommon (usually mild):\u003c\/strong\u003e \u003cstrong data-end=\"6164\" data-start=\"6151\"\u003eDry mouth\u003c\/strong\u003e, \u003cstrong data-end=\"6192\" data-start=\"6166\"\u003einsomnia (early weeks)\u003c\/strong\u003e, \u003cstrong data-end=\"6206\" data-start=\"6194\"\u003eheadache\u003c\/strong\u003e, \u003cstrong data-end=\"6218\" data-start=\"6208\"\u003enausea\u003c\/strong\u003e, \u003cstrong data-end=\"6236\" data-start=\"6220\"\u003erestlessness\u003c\/strong\u003e, \u003cstrong data-end=\"6250\" data-start=\"6238\"\u003esweating\u003c\/strong\u003e; often resolve with dose-timing (morning) or brief dose reduction.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6433\" data-start=\"6320\"\u003e\n\u003cp data-end=\"6433\" data-start=\"6322\"\u003e\u003cstrong data-end=\"6338\" data-start=\"6322\"\u003eLess common:\u003c\/strong\u003e \u003cstrong data-end=\"6354\" data-start=\"6339\"\u003eTachycardia\u003c\/strong\u003e, \u003cstrong data-end=\"6368\" data-start=\"6356\"\u003eBP drift\u003c\/strong\u003e, \u003cstrong data-end=\"6380\" data-start=\"6370\"\u003etremor\u003c\/strong\u003e, \u003cstrong data-end=\"6398\" data-start=\"6382\"\u003eirritability\u003c\/strong\u003e; rare \u003cstrong data-end=\"6413\" data-start=\"6405\"\u003erash\u003c\/strong\u003e or \u003cstrong data-end=\"6430\" data-start=\"6417\"\u003edyspepsia\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6614\" data-start=\"6434\"\u003e\n\u003cp data-end=\"6614\" data-start=\"6436\"\u003e\u003cstrong data-end=\"6457\" data-start=\"6436\"\u003eNeuropsychiatric:\u003c\/strong\u003e Generally \u003cstrong data-end=\"6482\" data-start=\"6468\"\u003eanxiolytic\u003c\/strong\u003e, but activation can \u003cstrong data-end=\"6521\" data-start=\"6503\"\u003eunmask anxiety\u003c\/strong\u003e in some—monitor if panic-prone. \u003cstrong data-end=\"6573\" data-start=\"6554\"\u003eMania\/psychosis\u003c\/strong\u003e is rare; caution with bipolar history.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6708\" data-start=\"6615\"\u003e\n\u003cp data-end=\"6708\" data-start=\"6617\"\u003e\u003cstrong data-end=\"6643\" data-start=\"6617\"\u003eDependence\/withdrawal:\u003c\/strong\u003e Low relative to amphetamines; no classic rebound when tapered.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6822\" data-start=\"6709\"\u003e\n\u003cp data-end=\"6822\" data-start=\"6711\"\u003e\u003cstrong data-end=\"6729\" data-start=\"6711\"\u003eHepatic\/renal:\u003c\/strong\u003e Routine labs typically stable; avoid with \u003cstrong data-end=\"6803\" data-start=\"6772\"\u003esignificant hepatic disease\u003c\/strong\u003e until more data.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6963\" data-start=\"6823\"\u003e\n\u003cp data-end=\"6963\" data-start=\"6825\"\u003e\u003cstrong data-end=\"6847\" data-start=\"6825\"\u003eDrug interactions:\u003c\/strong\u003e Limited data; be cautious with \u003cstrong data-end=\"6888\" data-start=\"6879\"\u003eMAOIs\u003c\/strong\u003e, strong \u003cstrong data-end=\"6914\" data-start=\"6897\"\u003edopaminergics\u003c\/strong\u003e, and \u003cstrong data-end=\"6938\" data-start=\"6920\"\u003eCNS stimulants\u003c\/strong\u003e (additive activation).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7017\" data-start=\"6964\"\u003e\n\u003cp data-end=\"7017\" data-start=\"6966\"\u003e\u003cstrong data-end=\"6990\" data-start=\"6966\"\u003ePregnancy\/lactation:\u003c\/strong\u003e Insufficient data—avoid.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7117\" data-start=\"7018\"\u003e\n\u003cp data-end=\"7117\" data-start=\"7020\"\u003e\u003cstrong data-end=\"7042\" data-start=\"7020\"\u003eSport\/anti-doping:\u003c\/strong\u003e \u003cstrong data-end=\"7061\" data-start=\"7043\"\u003eBanned by WADA\u003c\/strong\u003e (stimulants). Detection persists \u003cstrong data-end=\"7103\" data-start=\"7095\"\u003edays\u003c\/strong\u003e after dosing.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"7141\" data-start=\"7119\"\u003e\u003cstrong data-end=\"7141\" data-start=\"7119\"\u003eComparative matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"7528\" data-start=\"7143\"\u003e\n\u003cthead data-end=\"7209\" data-start=\"7143\"\u003e\n\u003ctr data-end=\"7209\" data-start=\"7143\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"7153\" data-start=\"7143\"\u003eFeature\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"7170\" data-start=\"7153\"\u003e\u003cstrong data-end=\"7169\" data-start=\"7155\"\u003eBromantane\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"7186\" data-start=\"7170\"\u003e\u003cstrong data-end=\"7185\" data-start=\"7172\"\u003eModafinil\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"7209\" data-start=\"7186\"\u003e\u003cstrong data-end=\"7207\" data-start=\"7188\"\u003eMethylphenidate\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"7528\" data-start=\"7228\"\u003e\n\u003ctr data-end=\"7351\" data-start=\"7228\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7245\" data-start=\"7228\"\u003ePrimary action\u003c\/td\u003e\n\u003ctd data-end=\"7293\" data-start=\"7245\" data-col-size=\"md\"\u003e\n\u003cstrong data-end=\"7265\" data-start=\"7247\"\u003eDA synthesis ↑\u003c\/strong\u003e, actoprotector, anxiolytic\u003c\/td\u003e\n\u003ctd data-end=\"7327\" data-start=\"7293\" data-col-size=\"sm\"\u003eWake-promoter (DA\/NE transport)\u003c\/td\u003e\n\u003ctd data-end=\"7351\" data-start=\"7327\" data-col-size=\"sm\"\u003eDA\/NE reuptake block\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7400\" data-start=\"7352\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7362\" data-start=\"7352\"\u003eAnxiety\u003c\/td\u003e\n\u003ctd data-end=\"7372\" data-start=\"7362\" data-col-size=\"md\"\u003eOften ↓\u003c\/td\u003e\n\u003ctd data-end=\"7391\" data-start=\"7372\" data-col-size=\"sm\"\u003eNeutral\/slight ↑\u003c\/td\u003e\n\u003ctd data-end=\"7400\" data-start=\"7391\" data-col-size=\"sm\"\u003eCan ↑\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7452\" data-start=\"7401\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7419\" data-start=\"7401\"\u003eAbuse potential\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7431\" data-start=\"7419\"\u003e\u003cstrong data-end=\"7430\" data-start=\"7421\"\u003eLower\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7442\" data-start=\"7431\"\u003eModerate\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7452\" data-start=\"7442\"\u003eHigher\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7528\" data-start=\"7453\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7467\" data-start=\"7453\"\u003eWADA status\u003c\/td\u003e\n\u003ctd data-end=\"7484\" data-start=\"7467\" data-col-size=\"md\"\u003e\u003cstrong data-end=\"7483\" data-start=\"7469\"\u003eProhibited\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"7514\" data-start=\"7484\" data-col-size=\"sm\"\u003eProhibited (in-competition)\u003c\/td\u003e\n\u003ctd data-end=\"7528\" data-start=\"7514\" data-col-size=\"sm\"\u003eProhibited\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"7533\" data-start=\"7530\"\u003e\n\u003ch2 data-end=\"7561\" data-start=\"7535\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-end=\"7809\" data-start=\"7563\"\u003e\n\u003cli data-end=\"7620\" data-start=\"7563\"\u003e\n\u003cp data-end=\"7620\" data-start=\"7565\"\u003e\u003cstrong data-end=\"7582\" data-start=\"7565\"\u003eApproved use:\u003c\/strong\u003e \u003cstrong data-end=\"7597\" data-start=\"7583\"\u003eRussia\/CIS\u003c\/strong\u003e (asthenic syndrome).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7716\" data-start=\"7621\"\u003e\n\u003cp data-end=\"7716\" data-start=\"7623\"\u003e\u003cstrong data-end=\"7633\" data-start=\"7623\"\u003eUS\/EU:\u003c\/strong\u003e Not approved; available only as \u003cstrong data-end=\"7694\" data-start=\"7666\"\u003eresearch chemical\/import\u003c\/strong\u003e (quality variable).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7809\" data-start=\"7717\"\u003e\n\u003cp data-end=\"7809\" data-start=\"7719\"\u003e\u003cstrong data-end=\"7729\" data-start=\"7719\"\u003eSport:\u003c\/strong\u003e \u003cstrong data-end=\"7744\" data-start=\"7730\"\u003eProhibited\u003c\/strong\u003e substance (stimulants). High-profile positives drove early bans.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"7814\" data-start=\"7811\"\u003e\n\u003ch2 data-end=\"7858\" data-start=\"7816\"\u003e8. Practical Use \u0026amp; Dosing (where legal)\u003c\/h2\u003e\n\u003cul data-end=\"8399\" data-start=\"7860\"\u003e\n\u003cli data-end=\"8047\" data-start=\"7860\"\u003e\n\u003cp data-end=\"8047\" data-start=\"7862\"\u003e\u003cstrong data-end=\"7881\" data-start=\"7862\"\u003eTypical ranges:\u003c\/strong\u003e \u003cstrong data-end=\"7906\" data-start=\"7882\"\u003e50–100 mg once daily\u003c\/strong\u003e (morning) for \u003cstrong data-end=\"7934\" data-start=\"7921\"\u003e2–4 weeks\u003c\/strong\u003e, extend to \u003cstrong data-end=\"7960\" data-start=\"7946\"\u003e8–12 weeks\u003c\/strong\u003e if needed; some protocols use \u003cstrong data-end=\"8009\" data-start=\"7991\"\u003e100–200 mg\/day\u003c\/strong\u003e in divided doses under supervision.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8260\" data-start=\"8048\"\u003e\n\u003cp data-end=\"8260\" data-start=\"8050\"\u003e\u003cstrong data-end=\"8069\" data-start=\"8050\"\u003eTitration tips:\u003c\/strong\u003e Start \u003cstrong data-end=\"8089\" data-start=\"8076\"\u003e50 mg qAM\u003c\/strong\u003e, advance after \u003cstrong data-end=\"8117\" data-start=\"8105\"\u003e3–7 days\u003c\/strong\u003e if insomnia or jitteriness absent. Pair with \u003cstrong data-end=\"8180\" data-start=\"8163\"\u003esleep hygiene\u003c\/strong\u003e, \u003cstrong data-end=\"8195\" data-start=\"8182\"\u003ehydration\u003c\/strong\u003e, \u003cstrong data-end=\"8213\" data-start=\"8197\"\u003eelectrolytes\u003c\/strong\u003e, and \u003cstrong data-end=\"8230\" data-start=\"8219\"\u003eprotein\u003c\/strong\u003e during heavy training\/work.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8399\" data-start=\"8261\"\u003e\n\u003cp data-end=\"8399\" data-start=\"8263\"\u003e\u003cstrong data-end=\"8286\" data-start=\"8263\"\u003eWhen to avoid\/stop:\u003c\/strong\u003e Persistent \u003cstrong data-end=\"8310\" data-start=\"8298\"\u003einsomnia\u003c\/strong\u003e, \u003cstrong data-end=\"8331\" data-start=\"8312\"\u003etachyarrhythmia\u003c\/strong\u003e, \u003cstrong data-end=\"8351\" data-start=\"8333\"\u003emarked anxiety\u003c\/strong\u003e, or \u003cstrong data-end=\"8370\" data-start=\"8356\"\u003eBP \u0026gt;140\/90\u003c\/strong\u003e despite timing\/dose changes.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"8404\" data-start=\"8401\"\u003e\n\u003ch3 data-end=\"8429\" data-start=\"8406\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-end=\"9224\" data-start=\"8431\"\u003e\n\u003cli data-end=\"8599\" data-start=\"8431\"\u003e\n\u003cp data-end=\"8599\" data-start=\"8433\"\u003e\u003cstrong data-end=\"8491\" data-start=\"8433\"\u003eNeuroscience \u0026amp; Behavioral Physiology; Human Physiology\u003c\/strong\u003e — Actoprotector concept, performance under heat\/sleep restriction; mitochondrial and antioxidant markers.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8754\" data-start=\"8600\"\u003e\n\u003cp data-end=\"8754\" data-start=\"8602\"\u003e\u003cstrong data-end=\"8649\" data-start=\"8602\"\u003eZhurnal Nevrologii i Psikhiatrii; CNS Drugs\u003c\/strong\u003e — Clinical studies in \u003cstrong data-end=\"8697\" data-start=\"8672\"\u003easthenia\/neurasthenia\u003c\/strong\u003e: anxiolysis with activation, clinician-rated outcomes.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8914\" data-start=\"8755\"\u003e\n\u003cp data-end=\"8914\" data-start=\"8757\"\u003e\u003cstrong data-end=\"8829\" data-start=\"8757\"\u003eBiochemistry (Moscow); Bulletin of Experimental Biology and Medicine\u003c\/strong\u003e — Up-regulation of \u003cstrong data-end=\"8860\" data-start=\"8849\"\u003eTH\/AADC\u003c\/strong\u003e, dopaminergic signaling, and mitochondrial enzymes.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9021\" data-start=\"8915\"\u003e\n\u003cp data-end=\"9021\" data-start=\"8917\"\u003e\u003cstrong data-end=\"8953\" data-start=\"8917\"\u003eInternational Immunopharmacology\u003c\/strong\u003e — \u003cstrong data-end=\"8977\" data-start=\"8956\"\u003eInterferon\/IgA\/NK\u003c\/strong\u003e changes (stress-linked immunomodulation).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9124\" data-start=\"9022\"\u003e\n\u003cp data-end=\"9124\" data-start=\"9024\"\u003e\u003cstrong data-end=\"9068\" data-start=\"9024\"\u003eAutonomic Neuroscience; Psychophysiology\u003c\/strong\u003e — Autonomic balance and vigilance metrics under load.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9224\" data-start=\"9125\"\u003e\n\u003cp data-end=\"9224\" data-start=\"9127\"\u003e\u003cstrong data-end=\"9165\" data-start=\"9127\"\u003eDrug Testing \u0026amp; Analysis; WADA Code\u003c\/strong\u003e — Anti-doping status, detection windows, historical cases.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"8363\" data-end=\"8531\" class=\"\"\u003e \u003c\/p\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":51061689319688,"sku":"10","price":60.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0937\/9053\/5944\/files\/bromantane_30.png?v=1767647659"},{"product_id":"phenibut-hcl-90x200mg","title":"Phenibut HCL 100x200mg","description":"\u003cp data-start=\"425\" data-end=\"900\" class=\"\"\u003e\u003cstrong data-start=\"425\" data-end=\"468\"\u003e\u003cstrong data-end=\"392\" data-start=\"377\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                           \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN CONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"425\" data-end=\"900\" class=\"\"\u003e\u003cstrong data-start=\"425\" data-end=\"468\"\u003ePhenibut (β-phenyl-γ-aminobutyric acid)\u003c\/strong\u003e is a synthetic derivative of the neurotransmitter gamma-aminobutyric acid (GABA). Developed in the Soviet Union in the 1960s, phenibut was originally utilized clinically to treat anxiety, insomnia, stress, and other psychiatric or neurological conditions. Phenibut hydrochloride (Phenibut HCl) is the most commonly available formulation, notable for its improved water solubility and bioavailability compared to the free acid form.\u003c\/p\u003e\n\u003chr data-start=\"902\" data-end=\"905\" class=\"\"\u003e\n\u003ch2 data-start=\"907\" data-end=\"946\" class=\"\"\u003eChemical and Pharmacological Profile\u003c\/h2\u003e\n\u003cul data-start=\"948\" data-end=\"1199\"\u003e\n\u003cli data-start=\"948\" data-end=\"1011\" class=\"\"\u003e\n\u003cp data-start=\"950\" data-end=\"1011\" class=\"\"\u003e\u003cstrong data-start=\"950\" data-end=\"967\"\u003eChemical Name\u003c\/strong\u003e: β-phenyl-γ-aminobutyric acid hydrochloride\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1012\" data-end=\"1050\" class=\"\"\u003e\n\u003cp data-start=\"1014\" data-end=\"1050\" class=\"\"\u003e\u003cstrong data-start=\"1014\" data-end=\"1035\"\u003eMolecular Formula\u003c\/strong\u003e: C₁₀H₁₃NO₂·HCl\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1051\" data-end=\"1130\" class=\"\"\u003e\n\u003cp data-start=\"1053\" data-end=\"1130\" class=\"\"\u003e\u003cstrong data-start=\"1053\" data-end=\"1071\"\u003eClassification\u003c\/strong\u003e: GABA analog; central nervous system depressant\/anxiolytic\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1131\" data-end=\"1199\" class=\"\"\u003e\n\u003cp data-start=\"1133\" data-end=\"1199\" class=\"\"\u003e\u003cstrong data-start=\"1133\" data-end=\"1151\"\u003eAdministration\u003c\/strong\u003e: Oral, typically as powder, capsule, or tablet.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"1201\" data-end=\"1204\" class=\"\"\u003e\n\u003ch2 data-start=\"1206\" data-end=\"1228\" class=\"\"\u003eMechanism of Action\u003c\/h2\u003e\n\u003cp data-start=\"1230\" data-end=\"1317\" class=\"\"\u003ePhenibut primarily exerts its effects by modulating GABAergic and dopaminergic systems:\u003c\/p\u003e\n\u003ch3 data-start=\"1319\" data-end=\"1353\" class=\"\"\u003e1. \u003cstrong data-start=\"1326\" data-end=\"1353\"\u003eGABA-B Receptor Agonism\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cul data-start=\"1354\" data-end=\"1524\"\u003e\n\u003cli data-start=\"1354\" data-end=\"1416\" class=\"\"\u003e\n\u003cp data-start=\"1356\" data-end=\"1416\" class=\"\"\u003ePhenibut acts as a selective agonist at the GABA-B receptor.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1417\" data-end=\"1524\" class=\"\"\u003e\n\u003cp data-start=\"1419\" data-end=\"1524\" class=\"\"\u003eActivation of GABA-B receptors produces anxiolytic (anti-anxiety), sedative, and muscle-relaxing effects.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"1526\" data-end=\"1572\" class=\"\"\u003e2. \u003cstrong data-start=\"1533\" data-end=\"1572\"\u003eIndirect Effects on Dopamine Levels\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cul data-start=\"1573\" data-end=\"1747\"\u003e\n\u003cli data-start=\"1573\" data-end=\"1638\" class=\"\"\u003e\n\u003cp data-start=\"1575\" data-end=\"1638\" class=\"\"\u003ePhenibut has mild stimulatory effects on dopamine transmission.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1639\" data-end=\"1747\" class=\"\"\u003e\n\u003cp data-start=\"1641\" data-end=\"1747\" class=\"\"\u003eElevated dopamine levels in select brain regions may enhance motivation, cognition, mood, and sociability.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"1749\" data-end=\"1792\" class=\"\"\u003e3. \u003cstrong data-start=\"1756\" data-end=\"1792\"\u003eMild Effects on GABA-A Receptors\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cul data-start=\"1793\" data-end=\"1915\"\u003e\n\u003cli data-start=\"1793\" data-end=\"1915\" class=\"\"\u003e\n\u003cp data-start=\"1795\" data-end=\"1915\" class=\"\"\u003ePhenibut may have minimal action at GABA-A receptors, primarily at higher dosages, potentially contributing to sedation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"1917\" data-end=\"1920\" class=\"\"\u003e\n\u003ch2 data-start=\"1922\" data-end=\"1962\" class=\"\"\u003eClinical and Therapeutic Applications\u003c\/h2\u003e\n\u003cp data-start=\"1964\" data-end=\"2087\" class=\"\"\u003eHistorically and clinically (particularly in Eastern Europe and Russia), phenibut is used for various therapeutic purposes:\u003c\/p\u003e\n\u003ch3 data-start=\"2089\" data-end=\"2130\" class=\"\"\u003e1. \u003cstrong data-start=\"2096\" data-end=\"2130\"\u003eAnxiety Reduction (Anxiolytic)\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cul data-start=\"2131\" data-end=\"2268\"\u003e\n\u003cli data-start=\"2131\" data-end=\"2268\" class=\"\"\u003e\n\u003cp data-start=\"2133\" data-end=\"2268\" class=\"\"\u003eUtilized clinically to relieve symptoms of social anxiety, generalized anxiety, panic disorders, and stress-related anxiety conditions.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"2270\" data-end=\"2337\" class=\"\"\u003e2. \u003cstrong data-start=\"2277\" data-end=\"2337\"\u003eImprovement of Sleep Quality (Hypnotic\/Sedative Effects)\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cul data-start=\"2338\" data-end=\"2418\"\u003e\n\u003cli data-start=\"2338\" data-end=\"2418\" class=\"\"\u003e\n\u003cp data-start=\"2340\" data-end=\"2418\" class=\"\"\u003ePrescribed to treat insomnia, promote deep sleep, and regulate sleep patterns.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"2420\" data-end=\"2462\" class=\"\"\u003e3. \u003cstrong data-start=\"2427\" data-end=\"2462\"\u003eCognitive and Mood Enhancements\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cul data-start=\"2463\" data-end=\"2602\"\u003e\n\u003cli data-start=\"2463\" data-end=\"2602\" class=\"\"\u003e\n\u003cp data-start=\"2465\" data-end=\"2602\" class=\"\"\u003eAnecdotally used for cognitive enhancement (nootropic), improvement of social confidence, enhanced mood stability, and stress resilience.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"2604\" data-end=\"2644\" class=\"\"\u003e4. \u003cstrong data-start=\"2611\" data-end=\"2644\"\u003eOther Potential Clinical Uses\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cul data-start=\"2645\" data-end=\"2870\"\u003e\n\u003cli data-start=\"2645\" data-end=\"2763\" class=\"\"\u003e\n\u003cp data-start=\"2647\" data-end=\"2763\" class=\"\"\u003eReportedly helpful in managing withdrawal symptoms from alcohol or benzodiazepines (in supervised medical contexts).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2764\" data-end=\"2870\" class=\"\"\u003e\n\u003cp data-start=\"2766\" data-end=\"2870\" class=\"\"\u003eMay alleviate symptoms of post-traumatic stress disorder (PTSD), though clinical studies remain limited.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"2872\" data-end=\"2875\" class=\"\"\u003e\n\u003ch2 data-start=\"2877\" data-end=\"2942\" class=\"\"\u003eDosage and Administration Guidelines (Non-medical \u0026amp; Anecdotal)\u003c\/h2\u003e\n\u003cp data-start=\"2944\" data-end=\"3058\" class=\"\"\u003eTypical dosages used clinically and experimentally (for reference only; individual response varies significantly):\u003c\/p\u003e\n\u003cul data-start=\"3060\" data-end=\"3345\"\u003e\n\u003cli data-start=\"3060\" data-end=\"3149\" class=\"\"\u003e\n\u003cp data-start=\"3062\" data-end=\"3149\" class=\"\"\u003e\u003cstrong data-start=\"3062\" data-end=\"3074\"\u003eLow dose\u003c\/strong\u003e: 250–500 mg\/day (for mild anxiety, stress relief, subtle mood improvement)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3150\" data-end=\"3265\" class=\"\"\u003e\n\u003cp data-start=\"3152\" data-end=\"3265\" class=\"\"\u003e\u003cstrong data-start=\"3152\" data-end=\"3169\"\u003eModerate dose\u003c\/strong\u003e: 500–1500 mg\/day (for more pronounced anxiolytic effects, social anxiety relief, sleep support)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3266\" data-end=\"3345\" class=\"\"\u003e\n\u003cp data-start=\"3268\" data-end=\"3345\" class=\"\"\u003e\u003cstrong data-start=\"3268\" data-end=\"3281\"\u003eHigh dose\u003c\/strong\u003e: 1500–2500 mg\/day (heavy sedation, stronger anxiolytic effects)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"3347\" data-end=\"3373\" class=\"\"\u003e\u003cstrong data-start=\"3347\" data-end=\"3373\"\u003eImportant Usage Notes:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"3374\" data-end=\"3607\"\u003e\n\u003cli data-start=\"3374\" data-end=\"3498\" class=\"\"\u003e\n\u003cp data-start=\"3376\" data-end=\"3498\" class=\"\"\u003ePhenibut has a delayed onset of action, typically \u003cstrong data-start=\"3426\" data-end=\"3439\"\u003e1–3 hours\u003c\/strong\u003e, and a prolonged duration, usually lasting \u003cstrong data-start=\"3483\" data-end=\"3497\"\u003e8–12 hours\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3499\" data-end=\"3607\" class=\"\"\u003e\n\u003cp data-start=\"3501\" data-end=\"3607\" class=\"\"\u003eDue to tolerance and dependence risks, phenibut use is commonly limited to \u003cstrong data-start=\"3576\" data-end=\"3606\"\u003e1–3 times per week maximum\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"3609\" data-end=\"3612\" class=\"\"\u003e\n\u003ch2 data-start=\"3614\" data-end=\"3648\" class=\"\"\u003eSafety Profile and Side Effects\u003c\/h2\u003e\n\u003cp data-start=\"3650\" data-end=\"3743\" class=\"\"\u003ePhenibut presents potential risks and side effects, especially with chronic or high-dose use:\u003c\/p\u003e\n\u003ch3 data-start=\"3745\" data-end=\"3803\" class=\"\"\u003e\n\u003cstrong data-start=\"3749\" data-end=\"3778\"\u003eCommon Acute Side Effects\u003c\/strong\u003e (Low-to-Moderate Doses):\u003c\/h3\u003e\n\u003cul data-start=\"3804\" data-end=\"3932\"\u003e\n\u003cli data-start=\"3804\" data-end=\"3838\" class=\"\"\u003e\n\u003cp data-start=\"3806\" data-end=\"3838\" class=\"\"\u003eSedation or excessive drowsiness\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3839\" data-end=\"3875\" class=\"\"\u003e\n\u003cp data-start=\"3841\" data-end=\"3875\" class=\"\"\u003eDizziness or impaired coordination\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3876\" data-end=\"3915\" class=\"\"\u003e\n\u003cp data-start=\"3878\" data-end=\"3915\" class=\"\"\u003eNausea or gastrointestinal discomfort\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3916\" data-end=\"3932\" class=\"\"\u003e\n\u003cp data-start=\"3918\" data-end=\"3932\" class=\"\"\u003eMild headaches\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"3934\" data-end=\"3968\" class=\"\"\u003e\u003cstrong data-start=\"3938\" data-end=\"3968\"\u003eHigh-Dose Adverse Effects:\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cul data-start=\"3969\" data-end=\"4152\"\u003e\n\u003cli data-start=\"3969\" data-end=\"4014\" class=\"\"\u003e\n\u003cp data-start=\"3971\" data-end=\"4014\" class=\"\"\u003ePronounced sedation or cognitive impairment\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4015\" data-end=\"4043\" class=\"\"\u003e\n\u003cp data-start=\"4017\" data-end=\"4043\" class=\"\"\u003eSevere dizziness or nausea\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4044\" data-end=\"4093\" class=\"\"\u003e\n\u003cp data-start=\"4046\" data-end=\"4093\" class=\"\"\u003eBalance issues, ataxia, impaired motor function\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4094\" data-end=\"4152\" class=\"\"\u003e\n\u003cp data-start=\"4096\" data-end=\"4152\" class=\"\"\u003eAgitation, irritability, anxiety rebound upon withdrawal\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"4154\" data-end=\"4206\" class=\"\"\u003e\u003cstrong data-start=\"4158\" data-end=\"4206\"\u003eTolerance, Dependence, and Withdrawal Risks:\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cul data-start=\"4207\" data-end=\"4624\"\u003e\n\u003cli data-start=\"4207\" data-end=\"4308\" class=\"\"\u003e\n\u003cp data-start=\"4209\" data-end=\"4308\" class=\"\"\u003eChronic or frequent use rapidly leads to tolerance, requiring escalating doses for similar effects.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4309\" data-end=\"4551\" class=\"\"\u003e\n\u003cp data-start=\"4311\" data-end=\"4551\" class=\"\"\u003ePhysical dependence can develop quickly; abrupt cessation after chronic use can trigger severe withdrawal symptoms, including rebound anxiety, insomnia, agitation, tremors, confusion, tachycardia, and in severe cases, psychosis or seizures.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4552\" data-end=\"4624\" class=\"\"\u003e\n\u003cp data-start=\"4554\" data-end=\"4624\" class=\"\"\u003ePhenibut withdrawal can be severe and may require medical supervision.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4626\" data-end=\"4629\" class=\"\"\u003e\n\u003ch2 data-start=\"4631\" data-end=\"4673\" class=\"\"\u003eContraindications and Drug Interactions\u003c\/h2\u003e\n\u003ch3 data-start=\"4675\" data-end=\"4701\" class=\"\"\u003e\n\u003cstrong data-start=\"4679\" data-end=\"4700\"\u003eContraindications\u003c\/strong\u003e:\u003c\/h3\u003e\n\u003cul data-start=\"4702\" data-end=\"4961\"\u003e\n\u003cli data-start=\"4702\" data-end=\"4744\" class=\"\"\u003e\n\u003cp data-start=\"4704\" data-end=\"4744\" class=\"\"\u003eHistory of substance abuse or dependence\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4745\" data-end=\"4809\" class=\"\"\u003e\n\u003cp data-start=\"4747\" data-end=\"4809\" class=\"\"\u003eLiver or kidney impairment (due to potential metabolic strain)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4810\" data-end=\"4856\" class=\"\"\u003e\n\u003cp data-start=\"4812\" data-end=\"4856\" class=\"\"\u003ePregnancy or lactation (safety data lacking)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4857\" data-end=\"4961\" class=\"\"\u003e\n\u003cp data-start=\"4859\" data-end=\"4961\" class=\"\"\u003ePsychiatric disorders (especially bipolar disorder or schizophrenia), unless under medical supervision\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"4963\" data-end=\"4994\" class=\"\"\u003e\n\u003cstrong data-start=\"4967\" data-end=\"4993\"\u003eDangerous Interactions\u003c\/strong\u003e:\u003c\/h3\u003e\n\u003cul data-start=\"4995\" data-end=\"5265\"\u003e\n\u003cli data-start=\"4995\" data-end=\"5154\" class=\"\"\u003e\n\u003cp data-start=\"4997\" data-end=\"5154\" class=\"\"\u003eAlcohol and other central nervous system depressants (benzodiazepines, opioids, barbiturates) significantly enhance sedation and respiratory depression risk.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5155\" data-end=\"5265\" class=\"\"\u003e\n\u003cp data-start=\"5157\" data-end=\"5265\" class=\"\"\u003eStimulants or dopamine-enhancing drugs might lead to unpredictable psychological effects or overstimulation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"5267\" data-end=\"5270\" class=\"\"\u003e\n\u003ch2 data-start=\"5272\" data-end=\"5302\" class=\"\"\u003eLegal and Regulatory Status\u003c\/h2\u003e\n\u003cul data-start=\"5304\" data-end=\"5783\"\u003e\n\u003cli data-start=\"5304\" data-end=\"5422\" class=\"\"\u003e\n\u003cp data-start=\"5306\" data-end=\"5422\" class=\"\"\u003e\u003cstrong data-start=\"5306\" data-end=\"5335\"\u003eRussia and Eastern Europe\u003c\/strong\u003e: Phenibut is approved as a prescription medication (brands: Noofen, Fenibut, Anvifen).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5423\" data-end=\"5656\" class=\"\"\u003e\n\u003cp data-start=\"5425\" data-end=\"5656\" class=\"\"\u003e\u003cstrong data-start=\"5425\" data-end=\"5469\"\u003eUnited States, Canada, Australia, Europe\u003c\/strong\u003e: Sold as an unregulated dietary supplement or \"research chemical.\" Not approved or regulated by FDA or analogous regulatory agencies; availability varies by region, legality is evolving.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5657\" data-end=\"5783\" class=\"\"\u003e\n\u003cp data-start=\"5659\" data-end=\"5783\" class=\"\"\u003eCertain countries have begun regulating or banning phenibut due to health concerns, including Australia and parts of the EU.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"5785\" data-end=\"5788\" class=\"\"\u003e\n\u003ch2 data-start=\"5790\" data-end=\"5816\" class=\"\"\u003eCurrent Research Status\u003c\/h2\u003e\n\u003cul data-start=\"5818\" data-end=\"6159\"\u003e\n\u003cli data-start=\"5818\" data-end=\"5902\" class=\"\"\u003e\n\u003cp data-start=\"5820\" data-end=\"5902\" class=\"\"\u003eLimited robust clinical trials exist, especially in Western scientific literature.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5903\" data-end=\"6017\" class=\"\"\u003e\n\u003cp data-start=\"5905\" data-end=\"6017\" class=\"\"\u003eMost evidence supporting therapeutic benefits is derived from Russian-language literature and anecdotal reports.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6018\" data-end=\"6159\" class=\"\"\u003e\n\u003cp data-start=\"6020\" data-end=\"6159\" class=\"\"\u003eMore controlled trials are required to validate therapeutic claims, determine optimal dosages, and establish long-term safety and efficacy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"6161\" data-end=\"6164\" class=\"\"\u003e\n\u003ch2 data-start=\"6166\" data-end=\"6213\" class=\"\"\u003ePractical Recommendations and Harm Reduction\u003c\/h2\u003e\n\u003cp data-start=\"6215\" data-end=\"6258\" class=\"\"\u003eTo minimize risks associated with Phenibut:\u003c\/p\u003e\n\u003cul data-start=\"6260\" data-end=\"6650\"\u003e\n\u003cli data-start=\"6260\" data-end=\"6324\" class=\"\"\u003e\n\u003cp data-start=\"6262\" data-end=\"6324\" class=\"\"\u003e\u003cstrong data-start=\"6262\" data-end=\"6282\"\u003eUse infrequently\u003c\/strong\u003e (ideally not exceeding 1–2 times weekly).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6325\" data-end=\"6383\" class=\"\"\u003e\n\u003cp data-start=\"6327\" data-end=\"6383\" class=\"\"\u003e\u003cstrong data-start=\"6327\" data-end=\"6343\"\u003eLimit dosage\u003c\/strong\u003e (start with the lowest effective dose).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6384\" data-end=\"6461\" class=\"\"\u003e\n\u003cp data-start=\"6386\" data-end=\"6461\" class=\"\"\u003e\u003cstrong data-start=\"6386\" data-end=\"6407\"\u003eAvoid chronic use\u003c\/strong\u003e due to rapid development of tolerance and dependence.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6462\" data-end=\"6553\" class=\"\"\u003e\n\u003cp data-start=\"6464\" data-end=\"6553\" class=\"\"\u003e\u003cstrong data-start=\"6464\" data-end=\"6494\"\u003eNever abruptly discontinue\u003c\/strong\u003e chronic phenibut use; taper slowly under medical guidance.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6554\" data-end=\"6650\" class=\"\"\u003e\n\u003cp data-start=\"6556\" data-end=\"6650\" class=\"\"\u003e\u003cstrong data-start=\"6556\" data-end=\"6575\"\u003eAvoid combining\u003c\/strong\u003e phenibut with alcohol, benzodiazepines, opioids, or other CNS depressants.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"6652\" data-end=\"6655\" class=\"\"\u003e\n\u003ch2 data-start=\"6657\" data-end=\"6689\" class=\"\"\u003eSummary of Benefits and Risks\u003c\/h2\u003e\n\u003cdiv class=\"overflow-x-auto contain-inline-size\"\u003e\n\u003ctable data-start=\"6691\" data-end=\"7361\"\u003e\n\u003cthead data-start=\"6691\" data-end=\"6784\"\u003e\n\u003ctr data-start=\"6691\" data-end=\"6784\"\u003e\n\u003cth data-start=\"6691\" data-end=\"6736\"\u003e\u003cstrong data-start=\"6693\" data-end=\"6717\"\u003eBenefits (Potential)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6736\" data-end=\"6784\"\u003e\u003cstrong data-start=\"6738\" data-end=\"6761\"\u003eRisks (Significant)\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"6879\" data-end=\"7361\"\u003e\n\u003ctr data-start=\"6879\" data-end=\"6972\"\u003e\n\u003ctd\u003eAnxiety and stress relief\u003c\/td\u003e\n\u003ctd\u003eHigh risk of dependence \u0026amp; withdrawal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6973\" data-end=\"7066\"\u003e\n\u003ctd\u003eSleep improvement\u003c\/td\u003e\n\u003ctd\u003eRapid tolerance development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7067\" data-end=\"7160\"\u003e\n\u003ctd\u003eSocial anxiety reduction\u003c\/td\u003e\n\u003ctd\u003eRisk of severe withdrawal symptoms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7161\" data-end=\"7267\"\u003e\n\u003ctd\u003eMood enhancement\u003c\/td\u003e\n\u003ctd\u003ePotential adverse interactions (alcohol, CNS depressants)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7268\" data-end=\"7361\"\u003e\n\u003ctd\u003eCognitive or motivational boost (anecdotal)\u003c\/td\u003e\n\u003ctd\u003eInsufficient research on long-term safety\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"7363\" data-end=\"7366\" class=\"\"\u003e\n\u003ch2 data-start=\"7368\" data-end=\"7399\" class=\"\"\u003e\u003cbr\u003e\u003c\/h2\u003e\n\u003ch2 data-start=\"7368\" data-end=\"7399\" class=\"\"\u003e References\u003c\/h2\u003e\n\u003cul data-start=\"7401\" data-end=\"8138\"\u003e\n\u003cli data-start=\"7401\" data-end=\"7525\" class=\"\"\u003e\n\u003cp data-start=\"7403\" data-end=\"7525\" class=\"\"\u003e\u003cstrong data-start=\"7403\" data-end=\"7423\"\u003eLapin, I. (2001)\u003c\/strong\u003e. \"Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug.\" \u003cem data-start=\"7491\" data-end=\"7509\"\u003eCNS Drug Reviews\u003c\/em\u003e, 7(4), 471-481.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7526\" data-end=\"7629\" class=\"\"\u003e\n\u003cp data-start=\"7528\" data-end=\"7629\" class=\"\"\u003e\u003cstrong data-start=\"7528\" data-end=\"7565\"\u003eSamokhvalov, A. V., et al. (2013)\u003c\/strong\u003e. \"Phenibut dependence.\" \u003cem data-start=\"7590\" data-end=\"7608\"\u003eBMJ Case Reports\u003c\/em\u003e, 2013:bcr2012008381.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7630\" data-end=\"7780\" class=\"\"\u003e\n\u003cp data-start=\"7632\" data-end=\"7780\" class=\"\"\u003e\u003cstrong data-start=\"7632\" data-end=\"7662\"\u003eOwen, D. R., et al. (2016)\u003c\/strong\u003e. \"Phenibut dependence and withdrawal: an emerging problem.\" \u003cem data-start=\"7723\" data-end=\"7763\"\u003eJournal of Clinical Psychopharmacology\u003c\/em\u003e, 36(6), 686-688.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7781\" data-end=\"7943\" class=\"\"\u003e\n\u003cp data-start=\"7783\" data-end=\"7943\" class=\"\"\u003e\u003cstrong data-start=\"7783\" data-end=\"7809\"\u003eShulgina, G. I. (1986)\u003c\/strong\u003e. \"On neurotransmitter mechanisms of reinforcing effect of phenibut.\" \u003cem data-start=\"7879\" data-end=\"7929\"\u003eEksperimental'naia i Klinicheskaia Farmakologiia\u003c\/em\u003e, 49(5), 7-11.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":51061742174472,"sku":"10","price":45.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0937\/9053\/5944\/files\/Phenibut_HCL_200mg.png?v=1755271498"},{"product_id":"nsi-189-60x30mg","title":"NSI-189 100x30mg","description":"\u003cp class=\"\" data-end=\"920\" data-start=\"352\"\u003e\u003cstrong\u003e\u003cstrong data-start=\"377\" data-end=\"392\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                         \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"\" data-end=\"920\" data-start=\"352\"\u003e\u003cstrong\u003eNSI-189 \u003cmeta charset=\"UTF-8\"\u003e\u003c\/strong\u003eis an \u003cstrong data-start=\"98\" data-end=\"168\"\u003eorally bioavailable, benzylpiperazine-aminopyridine small molecule\u003c\/strong\u003e originally developed to \u003cstrong data-start=\"193\" data-end=\"231\"\u003estimulate hippocampal neurogenesis\u003c\/strong\u003e and improve \u003cstrong data-start=\"244\" data-end=\"266\"\u003emood and cognition\u003c\/strong\u003e. It is \u003cstrong data-start=\"274\" data-end=\"290\"\u003enot approved\u003c\/strong\u003e by any regulator. After \u003cstrong data-start=\"315\" data-end=\"326\"\u003ePhase 1\u003c\/strong\u003e safety and signal-finding studies in \u003cstrong data-start=\"364\" data-end=\"399\"\u003emajor depressive disorder (MDD)\u003c\/strong\u003e, a \u003cstrong data-start=\"403\" data-end=\"414\"\u003ePhase 2\u003c\/strong\u003e program did \u003cstrong data-start=\"427\" data-end=\"439\"\u003enot meet\u003c\/strong\u003e its primary endpoint; development has largely \u003cstrong data-start=\"486\" data-end=\"497\"\u003estalled\u003c\/strong\u003e. Preclinical data indicate \u003cstrong data-start=\"525\" data-end=\"575\"\u003epro-neurogenic, synaptogenic, and neurotrophic\u003c\/strong\u003e effects in hippocampus with downstream impacts on \u003cstrong data-start=\"626\" data-end=\"646\"\u003estress circuitry\u003c\/strong\u003e and \u003cstrong data-start=\"651\" data-end=\"664\"\u003ecognition\u003c\/strong\u003e.\u003c\/p\u003e\n\u003chr data-start=\"667\" data-end=\"670\"\u003e\n\u003ch3 data-start=\"672\" data-end=\"730\"\u003eAdditional Benefits of NSI-189 Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"732\" data-end=\"2832\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"732\" data-end=\"760\"\u003e\n\u003ctr data-start=\"732\" data-end=\"760\"\u003e\n\u003cth data-start=\"732\" data-end=\"742\" data-col-size=\"md\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-start=\"742\" data-end=\"760\" data-col-size=\"xl\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"771\" data-end=\"2832\"\u003e\n\u003ctr data-start=\"771\" data-end=\"1028\"\u003e\n\u003ctd data-start=\"771\" data-end=\"804\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"773\" data-end=\"803\"\u003e1 Hippocampal neurogenesis\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"804\" data-end=\"1028\"\u003eIn vitro and rodent studies show \u003cstrong data-start=\"839\" data-end=\"872\"\u003eproliferation\/differentiation\u003c\/strong\u003e of hippocampal precursors and \u003cstrong data-start=\"903\" data-end=\"920\"\u003espine density\u003c\/strong\u003e increases; memory behaviors improve in stress\/lesion models. \u003cem data-start=\"982\" data-end=\"1026\"\u003eStem Cell Reports; Journal of Neuroscience\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1029\" data-end=\"1306\"\u003e\n\u003ctd data-start=\"1029\" data-end=\"1065\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1031\" data-end=\"1064\"\u003e2 Antidepressant signal (MDD)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"1065\" data-end=\"1306\"\u003eEarly Phase 1b showed \u003cstrong data-start=\"1089\" data-end=\"1117\"\u003eexploratory improvements\u003c\/strong\u003e on depression scales; the \u003cstrong data-start=\"1144\" data-end=\"1155\"\u003ePhase 2\u003c\/strong\u003eRCT failed its primary endpoint but suggested \u003cstrong data-start=\"1202\" data-end=\"1224\"\u003esubset\/time-course\u003c\/strong\u003e signals—insufficient for approval. \u003cem data-start=\"1260\" data-end=\"1304\"\u003eMolecular Psychiatry; Depression \u0026amp; Anxiety\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1307\" data-end=\"1566\"\u003e\n\u003ctd data-start=\"1307\" data-end=\"1371\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1309\" data-end=\"1370\"\u003e3 Cognitive enhancement (processing speed\/working memory)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"1371\" data-end=\"1566\"\u003eRodent data and small human exploratory tasks suggested \u003cstrong data-start=\"1429\" data-end=\"1458\"\u003emodest cognitive benefits\u003c\/strong\u003e, especially in \u003cstrong data-start=\"1474\" data-end=\"1494\"\u003eprocessing speed\u003c\/strong\u003e and \u003cstrong data-start=\"1499\" data-end=\"1518\"\u003everbal learning\u003c\/strong\u003e domains. \u003cem data-start=\"1528\" data-end=\"1564\"\u003eNeuropsychopharmacology; CNS Drugs\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1567\" data-end=\"1790\"\u003e\n\u003ctd data-start=\"1567\" data-end=\"1598\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1569\" data-end=\"1597\"\u003e4 Anhedonia \u0026amp; motivation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1598\" data-end=\"1790\" data-col-size=\"xl\"\u003ePreclinical stress paradigms show \u003cstrong data-start=\"1634\" data-end=\"1656\"\u003esucrose preference\u003c\/strong\u003e and \u003cstrong data-start=\"1661\" data-end=\"1683\"\u003eeffort-based tasks\u003c\/strong\u003eimprovements consistent with mesolimbic normalization. \u003cem data-start=\"1739\" data-end=\"1788\"\u003eBiological Psychiatry; Translational Psychiatry\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1791\" data-end=\"2002\"\u003e\n\u003ctd data-start=\"1791\" data-end=\"1834\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1793\" data-end=\"1833\"\u003e5 Neuroprotection after ischemia\/TBI\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"1834\" data-end=\"2002\"\u003eIn stroke\/TBI models, NSI-189 \u003cstrong data-start=\"1866\" data-end=\"1915\"\u003ereduced lesion-associated behavioral deficits\u003c\/strong\u003e and supported \u003cstrong data-start=\"1930\" data-end=\"1949\"\u003eneurite\/synapse\u003c\/strong\u003e recovery. \u003cem data-start=\"1960\" data-end=\"2000\"\u003eBrain Research; Experimental Neurology\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2003\" data-end=\"2222\"\u003e\n\u003ctd data-start=\"2003\" data-end=\"2052\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2005\" data-end=\"2051\"\u003e6 Anti-inflammatory\/neuroimmune modulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"2052\" data-end=\"2222\"\u003eDown-shift of \u003cstrong data-start=\"2068\" data-end=\"2088\"\u003emicroglial NF-κB\u003c\/strong\u003e and cytokines (IL-1β, TNF-α) reported alongside neurogenesis; causal links remain exploratory. \u003cem data-start=\"2184\" data-end=\"2220\"\u003eGlia; Journal of Neuroinflammation\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2223\" data-end=\"2419\"\u003e\n\u003ctd data-start=\"2223\" data-end=\"2257\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2225\" data-end=\"2256\"\u003e7 Stress-axis normalization\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"2257\" data-end=\"2419\"\u003eRodent work shows \u003cstrong data-start=\"2277\" data-end=\"2289\"\u003eHPA-axis\u003c\/strong\u003e re-tuning with lower corticosterone reactivity and improved \u003cstrong data-start=\"2350\" data-end=\"2374\"\u003ehippocampal feedback\u003c\/strong\u003e. \u003cem data-start=\"2376\" data-end=\"2417\"\u003eEndocrinology; Psychoneuroendocrinology\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2420\" data-end=\"2599\"\u003e\n\u003ctd data-start=\"2420\" data-end=\"2453\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2422\" data-end=\"2452\"\u003e8 Neuroplasticity in aging\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2453\" data-end=\"2599\" data-col-size=\"xl\"\u003eSignals for \u003cstrong data-start=\"2467\" data-end=\"2489\"\u003ehippocampal volume\u003c\/strong\u003e preservation and memory tasks in aged rodents; human aging data absent. \u003cem data-start=\"2562\" data-end=\"2597\"\u003eAging Cell; Neurobiology of Aging\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2600\" data-end=\"2832\"\u003e\n\u003ctd data-start=\"2600\" data-end=\"2644\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2602\" data-end=\"2643\"\u003e9 Adjunct in PTSD\/cognitive syndromes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"2644\" data-end=\"2832\"\u003eConcept: pair neurogenesis with psychotherapy\/rehab to consolidate learning; only preclinical or hypothesis-driven studies so far. \u003cem data-start=\"2777\" data-end=\"2830\"\u003eFrontiers in Psychiatry; Behavioural Brain Research\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"2834\" data-end=\"2837\"\u003e\n\u003ch2 data-start=\"2839\" data-end=\"2874\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-start=\"2876\" data-end=\"2918\"\u003e2.1 Pharmacodynamics (working model)\u003c\/h3\u003e\n\u003cul data-start=\"2919\" data-end=\"3427\"\u003e\n\u003cli data-start=\"2919\" data-end=\"3144\"\u003e\n\u003cp data-start=\"2921\" data-end=\"3144\"\u003e\u003cstrong data-start=\"2921\" data-end=\"2955\"\u003eNeurogenesis \u0026amp; synaptogenesis:\u003c\/strong\u003e Up-regulates \u003cstrong data-start=\"2969\" data-end=\"2977\"\u003eBDNF\u003c\/strong\u003e, \u003cstrong data-start=\"2979\" data-end=\"2987\"\u003eCREB\u003c\/strong\u003e, \u003cstrong data-start=\"2989\" data-end=\"3001\"\u003eMAPK\/ERK\u003c\/strong\u003e, and \u003cstrong data-start=\"3007\" data-end=\"3024\"\u003ePI3K–Akt–mTOR\u003c\/strong\u003e pathways → \u003cstrong data-start=\"3036\" data-end=\"3064\"\u003eprogenitor proliferation\u003c\/strong\u003e, \u003cstrong data-start=\"3066\" data-end=\"3095\"\u003edendritic spine formation\u003c\/strong\u003e, and \u003cstrong data-start=\"3101\" data-end=\"3122\"\u003esynaptic proteins\u003c\/strong\u003e (PSD-95, synapsin).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3145\" data-end=\"3292\"\u003e\n\u003cp data-start=\"3147\" data-end=\"3292\"\u003e\u003cstrong data-start=\"3147\" data-end=\"3180\"\u003eNeuroimmune \u0026amp; HPA modulation:\u003c\/strong\u003e Restraint of \u003cstrong data-start=\"3194\" data-end=\"3203\"\u003eNF-κB\u003c\/strong\u003e signaling and improved \u003cstrong data-start=\"3227\" data-end=\"3254\"\u003eglucocorticoid feedback\u003c\/strong\u003e in hippocampus → stress resilience.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3293\" data-end=\"3427\"\u003e\n\u003cp data-start=\"3295\" data-end=\"3427\"\u003e\u003cstrong data-start=\"3295\" data-end=\"3343\"\u003eNot a monoaminergic reuptake inhibitor\/MAOI.\u003c\/strong\u003e Any serotonergic\/dopaminergic effects appear \u003cstrong data-start=\"3389\" data-end=\"3403\"\u003edownstream\u003c\/strong\u003e of plasticity cascades.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"3429\" data-end=\"3456\"\u003e2.2 Down-stream biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"3458\" data-end=\"3797\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"3458\" data-end=\"3500\"\u003e\n\u003ctr data-start=\"3458\" data-end=\"3500\"\u003e\n\u003cth data-start=\"3458\" data-end=\"3468\" data-col-size=\"sm\"\u003ePathway\u003c\/th\u003e\n\u003cth data-start=\"3468\" data-end=\"3489\" data-col-size=\"md\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-start=\"3489\" data-end=\"3500\" data-col-size=\"sm\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"3515\" data-end=\"3797\"\u003e\n\u003ctr data-start=\"3515\" data-end=\"3601\"\u003e\n\u003ctd data-start=\"3515\" data-end=\"3542\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3517\" data-end=\"3541\"\u003eBDNF–TrkB → ERK\/CREB\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3542\" data-end=\"3586\" data-col-size=\"md\"\u003ePlasticity gene induction, mood\/cognition\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"3586\" data-end=\"3601\"\u003eHippocampus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3602\" data-end=\"3672\"\u003e\n\u003ctd data-start=\"3602\" data-end=\"3622\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3604\" data-end=\"3621\"\u003ePI3K–Akt–mTOR\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3622\" data-end=\"3656\" data-col-size=\"md\"\u003eCell survival, dendritic growth\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"3656\" data-end=\"3672\"\u003eHippo\/cortex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3673\" data-end=\"3739\"\u003e\n\u003ctd data-start=\"3673\" data-end=\"3695\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3675\" data-end=\"3694\"\u003eNF-κB restraint\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3695\" data-end=\"3726\" data-col-size=\"md\"\u003e↓ Pro-inflammatory cytokines\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"3726\" data-end=\"3739\"\u003eMicroglia\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3740\" data-end=\"3797\"\u003e\n\u003ctd data-start=\"3740\" data-end=\"3760\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3742\" data-end=\"3759\"\u003eHPA re-tuning\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"3760\" data-end=\"3782\"\u003eStress reactivity ↓\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"3782\" data-end=\"3797\"\u003eLimbic loop\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"3799\" data-end=\"3802\"\u003e\n\u003ch2 data-start=\"3804\" data-end=\"3826\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-start=\"3828\" data-end=\"4260\"\u003e\n\u003cli data-start=\"3828\" data-end=\"3869\"\u003e\n\u003cp data-start=\"3830\" data-end=\"3869\"\u003e\u003cstrong data-start=\"3830\" data-end=\"3840\"\u003eRoute:\u003c\/strong\u003e \u003cstrong data-start=\"3841\" data-end=\"3849\"\u003eOral\u003c\/strong\u003e (phosphate salt).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3870\" data-end=\"3953\"\u003e\n\u003cp data-start=\"3872\" data-end=\"3953\"\u003e\u003cstrong data-start=\"3872\" data-end=\"3894\"\u003eBrain penetration:\u003c\/strong\u003e Demonstrated in animals; human CNS levels not published.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3954\" data-end=\"4074\"\u003e\n\u003cp data-start=\"3956\" data-end=\"4074\"\u003e\u003cstrong data-start=\"3956\" data-end=\"3983\"\u003eHalf-life\/steady state:\u003c\/strong\u003e \u003cstrong data-start=\"3984\" data-end=\"4016\"\u003eHours to low-teens half-life\u003c\/strong\u003e reported; once- or twice-daily regimens used in trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4075\" data-end=\"4170\"\u003e\n\u003cp data-start=\"4077\" data-end=\"4170\"\u003e\u003cstrong data-start=\"4077\" data-end=\"4092\"\u003eMetabolism:\u003c\/strong\u003e Hepatic oxidative pathways (exact CYP liabilities not fully characterized).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4171\" data-end=\"4260\"\u003e\n\u003cp data-start=\"4173\" data-end=\"4260\"\u003e\u003cstrong data-start=\"4173\" data-end=\"4202\"\u003eFood effect\/interactions:\u003c\/strong\u003e Limited public data; not a classic CYP inducer\/inhibitor.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4262\" data-end=\"4265\"\u003e\n\u003ch2 data-start=\"4267\" data-end=\"4303\"\u003e4. Clinical Evidence (high-level)\u003c\/h2\u003e\n\u003cul data-start=\"4305\" data-end=\"4735\"\u003e\n\u003cli data-start=\"4305\" data-end=\"4435\"\u003e\n\u003cp data-start=\"4307\" data-end=\"4435\"\u003e\u003cstrong data-start=\"4307\" data-end=\"4327\"\u003ePhase 1b in MDD:\u003c\/strong\u003e Generally \u003cstrong data-start=\"4338\" data-end=\"4356\"\u003ewell tolerated\u003c\/strong\u003e; exploratory antidepressant and cognitive \u003cstrong data-start=\"4399\" data-end=\"4410\"\u003esignals\u003c\/strong\u003e across several scales.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4436\" data-end=\"4619\"\u003e\n\u003cp data-start=\"4438\" data-end=\"4619\"\u003e\u003cstrong data-start=\"4438\" data-end=\"4457\"\u003ePhase 2 in MDD:\u003c\/strong\u003e \u003cstrong data-start=\"4458\" data-end=\"4491\"\u003eDid not meet primary endpoint\u003c\/strong\u003e vs placebo; some \u003cstrong data-start=\"4509\" data-end=\"4534\"\u003esecondary\/exploratory\u003c\/strong\u003e outcomes hinted at benefit in subgroups\/time windows—insufficient for advancement.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4620\" data-end=\"4735\"\u003e\n\u003cp data-start=\"4622\" data-end=\"4735\"\u003e\u003cstrong data-start=\"4622\" data-end=\"4645\"\u003eImaging\/biomarkers:\u003c\/strong\u003e Small datasets explored \u003cstrong data-start=\"4670\" data-end=\"4697\"\u003ehippocampal volumetrics\u003c\/strong\u003e and peripheral \u003cstrong data-start=\"4713\" data-end=\"4721\"\u003eBDNF\u003c\/strong\u003e—inconclusive.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cblockquote data-start=\"4737\" data-end=\"4952\"\u003e\n\u003cp data-start=\"4739\" data-end=\"4952\"\u003e\u003cstrong data-start=\"4739\" data-end=\"4765\"\u003eEvidence quality note:\u003c\/strong\u003e Strong \u003cstrong data-start=\"4773\" data-end=\"4801\"\u003epreclinical plausibility\u003c\/strong\u003e with \u003cstrong data-start=\"4807\" data-end=\"4831\"\u003eneurogenesis\/circuit\u003c\/strong\u003e biology; \u003cstrong data-start=\"4841\" data-end=\"4868\"\u003ehuman efficacy unproven\u003c\/strong\u003e after a negative Phase 2. Any clinical use should be confined to research settings.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-start=\"4954\" data-end=\"4957\"\u003e\n\u003ch2 data-start=\"4959\" data-end=\"5005\"\u003e5. Emerging Clinical Interests (conceptual)\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"5007\" data-end=\"5377\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"5007\" data-end=\"5037\"\u003e\n\u003ctr data-start=\"5007\" data-end=\"5037\"\u003e\n\u003cth data-start=\"5007\" data-end=\"5015\" data-col-size=\"sm\"\u003eField\u003c\/th\u003e\n\u003cth data-start=\"5015\" data-end=\"5027\" data-col-size=\"sm\"\u003eRationale\u003c\/th\u003e\n\u003cth data-start=\"5027\" data-end=\"5037\" data-col-size=\"sm\"\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"5052\" data-end=\"5377\"\u003e\n\u003ctr data-start=\"5052\" data-end=\"5131\"\u003e\n\u003ctd data-start=\"5052\" data-end=\"5089\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5054\" data-end=\"5088\"\u003eTreatment-resistant depression\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5089\" data-end=\"5120\" data-col-size=\"sm\"\u003ePlasticity beyond monoamines\u003c\/td\u003e\n\u003ctd data-start=\"5120\" data-end=\"5131\" data-col-size=\"sm\"\u003eConcept\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5132\" data-end=\"5237\"\u003e\n\u003ctd data-start=\"5132\" data-end=\"5170\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5134\" data-end=\"5169\"\u003ePost-stroke\/TBI cognitive rehab\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5170\" data-end=\"5208\" data-col-size=\"sm\"\u003ePairing synaptogenesis with therapy\u003c\/td\u003e\n\u003ctd data-start=\"5208\" data-end=\"5237\" data-col-size=\"sm\"\u003ePreclinical\/early concept\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5238\" data-end=\"5290\"\u003e\n\u003ctd data-start=\"5238\" data-end=\"5249\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5240\" data-end=\"5248\"\u003ePTSD\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5249\" data-end=\"5279\" data-col-size=\"sm\"\u003eExtinction learning support\u003c\/td\u003e\n\u003ctd data-start=\"5279\" data-end=\"5290\" data-col-size=\"sm\"\u003eConcept\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5291\" data-end=\"5377\"\u003e\n\u003ctd data-start=\"5291\" data-end=\"5327\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5293\" data-end=\"5326\"\u003eAge-related cognitive decline\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5327\" data-end=\"5354\" data-col-size=\"sm\"\u003eHippocampal neurogenesis\u003c\/td\u003e\n\u003ctd data-start=\"5354\" data-end=\"5377\" data-col-size=\"sm\"\u003ePreclinical concept\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"5379\" data-end=\"5382\"\u003e\n\u003ch2 data-start=\"5384\" data-end=\"5413\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-start=\"5415\" data-end=\"6166\"\u003e\n\u003cli data-start=\"5415\" data-end=\"5554\"\u003e\n\u003cp data-start=\"5417\" data-end=\"5554\"\u003e\u003cstrong data-start=\"5417\" data-end=\"5442\"\u003eCommon AEs in trials:\u003c\/strong\u003e \u003cstrong data-start=\"5443\" data-end=\"5455\"\u003eHeadache\u003c\/strong\u003e, \u003cstrong data-start=\"5457\" data-end=\"5470\"\u003edizziness\u003c\/strong\u003e, \u003cstrong data-start=\"5472\" data-end=\"5495\"\u003esomnolence\/insomnia\u003c\/strong\u003e, \u003cstrong data-start=\"5497\" data-end=\"5507\"\u003enausea\u003c\/strong\u003e, \u003cstrong data-start=\"5509\" data-end=\"5520\"\u003efatigue\u003c\/strong\u003e—generally \u003cstrong data-start=\"5531\" data-end=\"5551\"\u003emild to moderate\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5555\" data-end=\"5630\"\u003e\n\u003cp data-start=\"5557\" data-end=\"5630\"\u003e\u003cstrong data-start=\"5557\" data-end=\"5577\"\u003eVitals\/labs\/ECG:\u003c\/strong\u003e No consistent safety signal in short-term studies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5631\" data-end=\"5743\"\u003e\n\u003cp data-start=\"5633\" data-end=\"5743\"\u003e\u003cstrong data-start=\"5633\" data-end=\"5654\"\u003eNeuropsychiatric:\u003c\/strong\u003e Activation\/insomnia in a subset; monitor for \u003cstrong data-start=\"5700\" data-end=\"5724\"\u003eanxiety or agitation\u003c\/strong\u003e early in dosing.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5744\" data-end=\"5875\"\u003e\n\u003cp data-start=\"5746\" data-end=\"5875\"\u003e\u003cstrong data-start=\"5746\" data-end=\"5773\"\u003eSuicidality monitoring:\u003c\/strong\u003e Standard for antidepressant investigations—no clear excess signal reported, but vigilance required.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5876\" data-end=\"5941\"\u003e\n\u003cp data-start=\"5878\" data-end=\"5941\"\u003e\u003cstrong data-start=\"5878\" data-end=\"5899\"\u003eLong-term safety:\u003c\/strong\u003e Unknown (no lengthy exposure datasets).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5942\" data-end=\"6166\"\u003e\n\u003cp data-start=\"5944\" data-end=\"6166\"\u003e\u003cstrong data-start=\"5944\" data-end=\"5966\"\u003eDrug interactions:\u003c\/strong\u003e Limited data; because the MOA is \u003cstrong data-start=\"6000\" data-end=\"6021\"\u003enon-monoaminergic\u003c\/strong\u003e, risk of \u003cstrong data-start=\"6031\" data-end=\"6053\"\u003eserotonin syndrome\u003c\/strong\u003e appears low when combined with SSRIs\/SNRIs, but combination evidence is sparse—use caution in research settings.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"6168\" data-end=\"6235\"\u003e\u003cstrong data-start=\"6168\" data-end=\"6235\"\u003eComparative snapshot (neuroplasticity-oriented antidepressants)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"6237\" data-end=\"6654\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"6237\" data-end=\"6306\"\u003e\n\u003ctr data-start=\"6237\" data-end=\"6306\"\u003e\n\u003cth data-start=\"6237\" data-end=\"6247\" data-col-size=\"sm\"\u003eFeature\u003c\/th\u003e\n\u003cth data-start=\"6247\" data-end=\"6261\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6249\" data-end=\"6260\"\u003eNSI-189\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6261\" data-end=\"6287\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6263\" data-end=\"6286\"\u003eKetamine\/Esketamine\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6287\" data-end=\"6306\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6289\" data-end=\"6304\"\u003eSSRIs\/SNRIs\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"6325\" data-end=\"6654\"\u003e\n\u003ctr data-start=\"6325\" data-end=\"6438\"\u003e\n\u003ctd data-start=\"6325\" data-end=\"6342\" data-col-size=\"sm\"\u003ePrimary action\u003c\/td\u003e\n\u003ctd data-start=\"6342\" data-end=\"6382\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6344\" data-end=\"6381\"\u003eNeurogenesis\/BDNF–CREB (putative)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6382\" data-end=\"6415\" data-col-size=\"sm\"\u003eRapid glutamatergic plasticity\u003c\/td\u003e\n\u003ctd data-start=\"6415\" data-end=\"6438\" data-col-size=\"sm\"\u003eMonoamine transport\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6439\" data-end=\"6499\"\u003e\n\u003ctd data-start=\"6439\" data-end=\"6447\" data-col-size=\"sm\"\u003eOnset\u003c\/td\u003e\n\u003ctd data-start=\"6447\" data-end=\"6465\" data-col-size=\"sm\"\u003eGradual (weeks)\u003c\/td\u003e\n\u003ctd data-start=\"6465\" data-end=\"6490\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6467\" data-end=\"6489\"\u003eRapid (hours–days)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6490\" data-end=\"6499\" data-col-size=\"sm\"\u003eWeeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6500\" data-end=\"6587\"\u003e\n\u003ctd data-start=\"6500\" data-end=\"6511\" data-col-size=\"sm\"\u003eEvidence\u003c\/td\u003e\n\u003ctd data-start=\"6511\" data-end=\"6542\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6513\" data-end=\"6541\"\u003eNegative Phase 2 primary\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6542\" data-end=\"6564\" data-col-size=\"sm\"\u003eRobust TRD efficacy\u003c\/td\u003e\n\u003ctd data-start=\"6564\" data-end=\"6587\" data-col-size=\"sm\"\u003eRobust MDD efficacy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6588\" data-end=\"6654\"\u003e\n\u003ctd data-start=\"6588\" data-end=\"6606\" data-col-size=\"sm\"\u003eAbuse liability\u003c\/td\u003e\n\u003ctd data-start=\"6606\" data-end=\"6623\" data-col-size=\"sm\"\u003eLow (expected)\u003c\/td\u003e\n\u003ctd data-start=\"6623\" data-end=\"6647\" data-col-size=\"sm\"\u003eModerate (controlled)\u003c\/td\u003e\n\u003ctd data-start=\"6647\" data-end=\"6654\" data-col-size=\"sm\"\u003eLow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"6656\" data-end=\"6659\"\u003e\n\u003ch2 data-start=\"6661\" data-end=\"6687\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-start=\"6689\" data-end=\"6916\"\u003e\n\u003cli data-start=\"6689\" data-end=\"6759\"\u003e\n\u003cp data-start=\"6691\" data-end=\"6759\"\u003e\u003cstrong data-start=\"6691\" data-end=\"6707\"\u003eNot approved\u003c\/strong\u003e (no active late-stage programs publicly ongoing).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6760\" data-end=\"6916\"\u003e\n\u003cp data-start=\"6762\" data-end=\"6916\"\u003eAny availability is via \u003cstrong data-start=\"6786\" data-end=\"6807\"\u003eresearch channels\u003c\/strong\u003e; consumer “nootropic” products are \u003cstrong data-start=\"6843\" data-end=\"6858\"\u003eunregulated\u003c\/strong\u003e and may be \u003cstrong data-start=\"6870\" data-end=\"6887\"\u003emisidentified\u003c\/strong\u003e—avoid outside formal trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"6918\" data-end=\"6921\"\u003e\n\u003ch2 data-start=\"6923\" data-end=\"6963\"\u003e8. Practical Take \u0026amp; Future Directions\u003c\/h2\u003e\n\u003cul data-start=\"6965\" data-end=\"7635\"\u003e\n\u003cli data-start=\"6965\" data-end=\"7062\"\u003e\n\u003cp data-start=\"6967\" data-end=\"7062\"\u003e\u003cstrong data-start=\"6967\" data-end=\"6986\"\u003eCurrent stance:\u003c\/strong\u003e NSI-189 remains \u003cstrong data-start=\"7003\" data-end=\"7019\"\u003eexperimental\u003c\/strong\u003e with \u003cstrong data-start=\"7025\" data-end=\"7059\"\u003einsufficient clinical efficacy\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7063\" data-end=\"7333\"\u003e\n\u003cp data-start=\"7065\" data-end=\"7333\"\u003e\u003cstrong data-start=\"7065\" data-end=\"7095\"\u003eIf pursued scientifically:\u003c\/strong\u003e Target \u003cstrong data-start=\"7103\" data-end=\"7123\"\u003ebiotype-enriched\u003c\/strong\u003e populations (low hippocampal volume, high inflammation, high anhedonia), use \u003cstrong data-start=\"7201\" data-end=\"7227\"\u003eadaptive trial designs\u003c\/strong\u003e, and anchor outcomes with \u003cstrong data-start=\"7254\" data-end=\"7277\"\u003eobjective cognition\u003c\/strong\u003e, \u003cstrong data-start=\"7279\" data-end=\"7302\"\u003edigital phenotyping\u003c\/strong\u003e, and \u003cstrong data-start=\"7308\" data-end=\"7319\"\u003eMRI\/EEG\u003c\/strong\u003e biomarkers.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7334\" data-end=\"7489\"\u003e\n\u003cp data-start=\"7336\" data-end=\"7489\"\u003e\u003cstrong data-start=\"7336\" data-end=\"7363\"\u003eCombination hypotheses:\u003c\/strong\u003e Pair with \u003cstrong data-start=\"7374\" data-end=\"7397\"\u003epsychotherapy\/rehab\u003c\/strong\u003e, \u003cstrong data-start=\"7399\" data-end=\"7411\"\u003eexercise\u003c\/strong\u003e, or \u003cstrong data-start=\"7416\" data-end=\"7452\"\u003esleep-based plasticity protocols\u003c\/strong\u003e to exploit a pro-neurogenic state.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7490\" data-end=\"7635\"\u003e\n\u003cp data-start=\"7492\" data-end=\"7635\"\u003e\u003cstrong data-start=\"7492\" data-end=\"7516\"\u003eTranslational needs:\u003c\/strong\u003e Clear \u003cstrong data-start=\"7523\" data-end=\"7555\"\u003etarget engagement biomarkers\u003c\/strong\u003e, refined \u003cstrong data-start=\"7565\" data-end=\"7574\"\u003ePK\/PD\u003c\/strong\u003e, and \u003cstrong data-start=\"7580\" data-end=\"7605\"\u003elonger blinded trials\u003c\/strong\u003e in precisely defined cohorts.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"7637\" data-end=\"7640\"\u003e\n\u003ch3 data-start=\"7642\" data-end=\"7665\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-start=\"7667\" data-end=\"8312\"\u003e\n\u003cli data-start=\"7667\" data-end=\"7782\"\u003e\n\u003cp data-start=\"7669\" data-end=\"7782\"\u003e\u003cem data-start=\"7669\" data-end=\"7713\"\u003eStem Cell Reports; Journal of Neuroscience\u003c\/em\u003e — NSI-189-driven neurogenesis and synaptogenesis in vitro\/in vivo.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7783\" data-end=\"7923\"\u003e\n\u003cp data-start=\"7785\" data-end=\"7923\"\u003e\u003cem data-start=\"7785\" data-end=\"7840\"\u003eMolecular Psychiatry; Depression \u0026amp; Anxiety; CNS Drugs\u003c\/em\u003e — Phase 1\/2 clinical results in MDD (safety, exploratory signals, Phase 2 miss).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7924\" data-end=\"8039\"\u003e\n\u003cp data-start=\"7926\" data-end=\"8039\"\u003e\u003cem data-start=\"7926\" data-end=\"7977\"\u003eNeuropsychopharmacology; Translational Psychiatry\u003c\/em\u003e — Plasticity markers, cognition, and stress-model outcomes.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8040\" data-end=\"8132\"\u003e\n\u003cp data-start=\"8042\" data-end=\"8132\"\u003e\u003cem data-start=\"8042\" data-end=\"8078\"\u003eGlia; Journal of Neuroinflammation\u003c\/em\u003e — Neuroimmune modulation accompanying neurogenesis.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8133\" data-end=\"8231\"\u003e\n\u003cp data-start=\"8135\" data-end=\"8231\"\u003e\u003cem data-start=\"8135\" data-end=\"8176\"\u003eEndocrinology; Psychoneuroendocrinology\u003c\/em\u003e — HPA-axis changes linked to hippocampal plasticity.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8232\" data-end=\"8312\"\u003e\n\u003cp data-start=\"8234\" data-end=\"8312\"\u003e\u003cem data-start=\"8234\" data-end=\"8274\"\u003eBrain Research; Experimental Neurology\u003c\/em\u003e — Post-stroke\/TBI recovery paradigms.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":51061766095112,"sku":"","price":90.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0937\/9053\/5944\/files\/NSI-189_30mg.png?v=1755272500"},{"product_id":"9-mbc-60x25mg","title":"9-MBC 100x25mg","description":"\u003cp class=\"\" data-end=\"467\" data-start=\"0\"\u003e\u003cstrong\u003e\u003cstrong data-start=\"377\" data-end=\"392\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                         \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"\" data-end=\"467\" data-start=\"0\"\u003e\u003cstrong\u003e9-Methyl-β-carboline \u003cmeta charset=\"UTF-8\"\u003e\u003c\/strong\u003e(9-MBC) is a synthetic \u003cstrong data-start=\"116\" data-end=\"131\"\u003eβ-carboline\u003c\/strong\u003e derivative investigated as a \u003cstrong data-start=\"161\" data-end=\"195\"\u003eneurotrophic, pro-dopaminergic\u003c\/strong\u003e research compound. In cell and rodent models it promotes \u003cstrong data-start=\"253\" data-end=\"325\"\u003edopaminergic neuron survival, differentiation, and neurite outgrowth\u003c\/strong\u003e, with signals of \u003cstrong data-start=\"343\" data-end=\"368\"\u003emitochondrial support\u003c\/strong\u003e and \u003cstrong data-start=\"373\" data-end=\"419\"\u003eanti-inflammatory microglial reprogramming\u003c\/strong\u003e. It is \u003cstrong data-start=\"427\" data-end=\"443\"\u003enot approved\u003c\/strong\u003e for human use; evidence is \u003cstrong data-start=\"471\" data-end=\"486\"\u003epreclinical\u003c\/strong\u003e.\u003c\/p\u003e\n\u003chr data-start=\"489\" data-end=\"492\"\u003e\n\u003ch3 data-start=\"494\" data-end=\"550\"\u003eAdditional Benefits of 9-MBC Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"552\" data-end=\"2801\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"552\" data-end=\"580\"\u003e\n\u003ctr data-start=\"552\" data-end=\"580\"\u003e\n\u003cth data-start=\"552\" data-end=\"562\" data-col-size=\"sm\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-start=\"562\" data-end=\"580\" data-col-size=\"xl\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"591\" data-end=\"2801\"\u003e\n\u003ctr data-start=\"591\" data-end=\"906\"\u003e\n\u003ctd data-start=\"591\" data-end=\"624\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"593\" data-end=\"623\"\u003e1 Dopaminergic neurotrophy\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"624\" data-end=\"906\" data-col-size=\"xl\"\u003eIn primary midbrain cultures and lesion models, 9-MBC increases \u003cstrong data-start=\"690\" data-end=\"711\"\u003eTH⁺ neuron counts\u003c\/strong\u003e, \u003cstrong data-start=\"713\" data-end=\"731\"\u003eneurite length\u003c\/strong\u003e, and \u003cstrong data-start=\"737\" data-end=\"765\"\u003edopamine synthesis genes\u003c\/strong\u003e (TH, DAT), suggesting true trophic action rather than mere MAO inhibition. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Journal of Neurochemistry; Molecular Neurobiology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"907\" data-end=\"1167\"\u003e\n\u003ctd data-start=\"907\" data-end=\"945\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"909\" data-end=\"944\"\u003e2 Protection in PD toxin models\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"945\" data-end=\"1167\" data-col-size=\"xl\"\u003eAttenuates loss of dopaminergic neurons and motor deficits after \u003cstrong data-start=\"1012\" data-end=\"1022\"\u003e6-OHDA\u003c\/strong\u003e or \u003cstrong data-start=\"1026\" data-end=\"1039\"\u003eMPTP\/MPP⁺\u003c\/strong\u003e, linked to \u003cstrong data-start=\"1051\" data-end=\"1081\"\u003emitochondrial preservation\u003c\/strong\u003e and \u003cstrong data-start=\"1086\" data-end=\"1116\"\u003eoxidative-stress buffering\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Neuropharmacology; Brain Research\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1168\" data-end=\"1426\"\u003e\n\u003ctd data-start=\"1168\" data-end=\"1198\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1170\" data-end=\"1197\"\u003e3 Mitochondrial support\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1198\" data-end=\"1426\" data-col-size=\"xl\"\u003eImproves \u003cstrong data-start=\"1209\" data-end=\"1235\"\u003ecomplex I\/III activity\u003c\/strong\u003e and \u003cstrong data-start=\"1240\" data-end=\"1262\"\u003emembrane potential\u003c\/strong\u003e, raises \u003cstrong data-start=\"1271\" data-end=\"1291\"\u003ePGC-1α\/NRF1\/TFAM\u003c\/strong\u003esignaling, and lowers \u003cstrong data-start=\"1314\" data-end=\"1323\"\u003emtROS\u003c\/strong\u003e, pointing to a bioenergetic mechanism. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Redox Biology; Journal of Neuroscience Research\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1427\" data-end=\"1668\"\u003e\n\u003ctd data-start=\"1427\" data-end=\"1457\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1429\" data-end=\"1456\"\u003e4 Microglial modulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1457\" data-end=\"1668\" data-col-size=\"xl\"\u003eShifts microglia toward a \u003cstrong data-start=\"1485\" data-end=\"1512\"\u003epro-resolving phenotype\u003c\/strong\u003e, lowering \u003cstrong data-start=\"1523\" data-end=\"1538\"\u003eTNF-α\/IL-1β\u003c\/strong\u003e and increasing trophic cues (e.g., \u003cstrong data-start=\"1574\" data-end=\"1587\"\u003eBDNF\/GDNF\u003c\/strong\u003e signals) in injured striatum. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Glia; Journal of Neuroinflammation\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1669\" data-end=\"1933\"\u003e\n\u003ctd data-start=\"1669\" data-end=\"1704\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1671\" data-end=\"1703\"\u003e5 Adult neurogenesis signals\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1704\" data-end=\"1933\" data-col-size=\"xl\"\u003eIn hippocampal paradigms, increases \u003cstrong data-start=\"1742\" data-end=\"1756\"\u003eDCX⁺\/BrdU⁺\u003c\/strong\u003e indices and dendritic maturation; behavioral readouts suggest \u003cstrong data-start=\"1819\" data-end=\"1843\"\u003ememory consolidation\u003c\/strong\u003e benefits in stress models. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Hippocampus; Neurobiology of Learning \u0026amp; Memory\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1934\" data-end=\"2093\"\u003e\n\u003ctd data-start=\"1934\" data-end=\"1962\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1936\" data-end=\"1961\"\u003e6 Synaptic plasticity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1962\" data-end=\"2093\" data-col-size=\"xl\"\u003eUpregulates \u003cstrong data-start=\"1976\" data-end=\"1996\"\u003ePSD-95, synapsin\u003c\/strong\u003e, and \u003cstrong data-start=\"2002\" data-end=\"2014\"\u003eCREB\/ERK\u003c\/strong\u003e pathways; improves LTP readouts ex vivo. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Synapse; Neuroscience\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2094\" data-end=\"2350\"\u003e\n\u003ctd data-start=\"2094\" data-end=\"2122\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"2096\" data-end=\"2121\"\u003e7 Anti-excitotoxicity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2122\" data-end=\"2350\" data-col-size=\"xl\"\u003eMitigates \u003cstrong data-start=\"2134\" data-end=\"2152\"\u003eglutamate\/NMDA\u003c\/strong\u003e injury via \u003cstrong data-start=\"2164\" data-end=\"2181\"\u003eCa²⁺ handling\u003c\/strong\u003e, \u003cstrong data-start=\"2183\" data-end=\"2218\"\u003eantioxidant enzymes (SOD2, GPx)\u003c\/strong\u003e, and maintenance of \u003cstrong data-start=\"2239\" data-end=\"2269\"\u003emitochondrial permeability\u003c\/strong\u003e thresholds. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Experimental Neurology; Neurochemistry International\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2351\" data-end=\"2542\"\u003e\n\u003ctd data-start=\"2351\" data-end=\"2389\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"2353\" data-end=\"2388\"\u003e8 Myelin\/axon support (signals)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2389\" data-end=\"2542\" data-col-size=\"xl\"\u003eEnhances \u003cstrong data-start=\"2400\" data-end=\"2427\"\u003eneurite\/axon elongation\u003c\/strong\u003e and may stabilize oligodendroglial support in mixed cultures—early evidence only. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Cells; ASN Neuro\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2543\" data-end=\"2801\"\u003e\n\u003ctd data-start=\"2543\" data-end=\"2579\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"2545\" data-end=\"2578\"\u003e9 Depression\/anhedonia models\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2579\" data-end=\"2801\" data-col-size=\"xl\"\u003eNormalizes \u003cstrong data-start=\"2592\" data-end=\"2614\"\u003esucrose preference\u003c\/strong\u003e, \u003cstrong data-start=\"2616\" data-end=\"2646\"\u003enovelty-suppressed feeding\u003c\/strong\u003e, and \u003cstrong data-start=\"2652\" data-end=\"2678\"\u003eforced-swim immobility\u003c\/strong\u003e in stress rodents, paralleling increases in \u003cstrong data-start=\"2723\" data-end=\"2731\"\u003eBDNF\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Translational Psychiatry; Behavioural Brain Research\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"2803\" data-end=\"2806\"\u003e\n\u003ch2 data-start=\"2808\" data-end=\"2843\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-start=\"2845\" data-end=\"2885\"\u003e2.1 Pharmacodynamics (working model)\u003c\/h3\u003e\n\u003cul data-start=\"2886\" data-end=\"3441\"\u003e\n\u003cli data-start=\"2886\" data-end=\"3015\"\u003e\n\u003cp data-start=\"2888\" data-end=\"3015\"\u003e\u003cstrong data-start=\"2888\" data-end=\"2918\"\u003ePro-dopaminergic trophism:\u003c\/strong\u003e Upregulates \u003cstrong data-start=\"2931\" data-end=\"2948\"\u003eTH, AADC, DAT\u003c\/strong\u003e expression, enhances dopaminergic differentiation and maintenance.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3016\" data-end=\"3143\"\u003e\n\u003cp data-start=\"3018\" data-end=\"3143\"\u003e\u003cstrong data-start=\"3018\" data-end=\"3049\"\u003eMitochondrial preservation:\u003c\/strong\u003e Supports \u003cstrong data-start=\"3059\" data-end=\"3069\"\u003eOXPHOS\u003c\/strong\u003e, reduces \u003cstrong data-start=\"3079\" data-end=\"3088\"\u003emtROS\u003c\/strong\u003e, and may activate \u003cstrong data-start=\"3107\" data-end=\"3122\"\u003eAMPK→PGC-1α\u003c\/strong\u003ebiogenesis programs.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3144\" data-end=\"3249\"\u003e\n\u003cp data-start=\"3146\" data-end=\"3249\"\u003e\u003cstrong data-start=\"3146\" data-end=\"3176\"\u003eNeuroinflammation control:\u003c\/strong\u003e Microglial \u003cstrong data-start=\"3188\" data-end=\"3197\"\u003eNF-κB\u003c\/strong\u003e restraint and increased neurotrophic factor milieu.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3250\" data-end=\"3441\"\u003e\n\u003cp data-start=\"3252\" data-end=\"3441\"\u003e\u003cstrong data-start=\"3252\" data-end=\"3271\"\u003eEnzyme targets:\u003c\/strong\u003e Unlike harmine\/harmaline, \u003cstrong data-start=\"3298\" data-end=\"3342\"\u003estrong MAO-A\/B inhibition is not central\u003c\/strong\u003e to 9-MBC’s effects at trophic concentrations (some weak, context-dependent interactions reported).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"3443\" data-end=\"3470\"\u003e2.2 Down-stream biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"3472\" data-end=\"3824\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"3472\" data-end=\"3514\"\u003e\n\u003ctr data-start=\"3472\" data-end=\"3514\"\u003e\n\u003cth data-start=\"3472\" data-end=\"3482\" data-col-size=\"sm\"\u003ePathway\u003c\/th\u003e\n\u003cth data-start=\"3482\" data-end=\"3503\" data-col-size=\"sm\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-start=\"3503\" data-end=\"3514\" data-col-size=\"sm\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"3529\" data-end=\"3824\"\u003e\n\u003ctr data-start=\"3529\" data-end=\"3608\"\u003e\n\u003ctd data-start=\"3529\" data-end=\"3552\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3531\" data-end=\"3551\"\u003ePGC-1α\/NRF1\/TFAM\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3552\" data-end=\"3594\" data-col-size=\"sm\"\u003eMitochondrial biogenesis, ATP stability\u003c\/td\u003e\n\u003ctd data-start=\"3594\" data-end=\"3608\" data-col-size=\"sm\"\u003eDA neurons\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3609\" data-end=\"3680\"\u003e\n\u003ctd data-start=\"3609\" data-end=\"3629\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3611\" data-end=\"3628\"\u003eERK\/CREB\/BDNF\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3629\" data-end=\"3656\" data-col-size=\"sm\"\u003eSynaptic plasticity, LTP\u003c\/td\u003e\n\u003ctd data-start=\"3656\" data-end=\"3680\" data-col-size=\"sm\"\u003eHippocampus\/striatum\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3681\" data-end=\"3760\"\u003e\n\u003ctd data-start=\"3681\" data-end=\"3703\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3683\" data-end=\"3702\"\u003eNF-κB restraint\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3703\" data-end=\"3737\" data-col-size=\"sm\"\u003e↓ TNF-α\/IL-1β, microglial shift\u003c\/td\u003e\n\u003ctd data-start=\"3737\" data-end=\"3760\" data-col-size=\"sm\"\u003eInjury\/inflammation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3761\" data-end=\"3824\"\u003e\n\u003ctd data-start=\"3761\" data-end=\"3787\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3763\" data-end=\"3786\"\u003eAntioxidant enzymes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3787\" data-end=\"3808\" data-col-size=\"sm\"\u003e↓ Oxidative damage\u003c\/td\u003e\n\u003ctd data-start=\"3808\" data-end=\"3824\" data-col-size=\"sm\"\u003eToxin models\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"3826\" data-end=\"3829\"\u003e\n\u003ch2 data-start=\"3831\" data-end=\"3872\"\u003e3. Pharmacokinetics (preclinical only)\u003c\/h2\u003e\n\u003cul data-start=\"3874\" data-end=\"4201\"\u003e\n\u003cli data-start=\"3874\" data-end=\"4006\"\u003e\n\u003cp data-start=\"3876\" data-end=\"4006\"\u003e\u003cstrong data-start=\"3876\" data-end=\"3886\"\u003eRoute:\u003c\/strong\u003e Effective in \u003cstrong data-start=\"3900\" data-end=\"3919\"\u003esystemic dosing\u003c\/strong\u003e in rodents (IP\/PO in reports); good \u003cstrong data-start=\"3956\" data-end=\"3977\"\u003ebrain penetration\u003c\/strong\u003e inferred from CNS effects.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4007\" data-end=\"4080\"\u003e\n\u003cp data-start=\"4009\" data-end=\"4080\"\u003e\u003cstrong data-start=\"4009\" data-end=\"4032\"\u003eHalf-life\/exposure:\u003c\/strong\u003e Hours-scale in animals; human PK \u003cstrong data-start=\"4066\" data-end=\"4077\"\u003eunknown\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4081\" data-end=\"4201\"\u003e\n\u003cp data-start=\"4083\" data-end=\"4201\"\u003e\u003cstrong data-start=\"4083\" data-end=\"4098\"\u003eMetabolism:\u003c\/strong\u003e Likely hepatic oxidative metabolism typical of β-carbolines; detailed metabolite map not standardized.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4203\" data-end=\"4206\"\u003e\n\u003ch2 data-start=\"4208\" data-end=\"4230\"\u003e4. Evidence Summary\u003c\/h2\u003e\n\u003cul data-start=\"4232\" data-end=\"4598\"\u003e\n\u003cli data-start=\"4232\" data-end=\"4359\"\u003e\n\u003cp data-start=\"4234\" data-end=\"4359\"\u003e\u003cstrong data-start=\"4234\" data-end=\"4247\"\u003eIn vitro:\u003c\/strong\u003e Robust dopaminergic neuritogenesis and survival across primary cultures; synergy with \u003cstrong data-start=\"4334\" data-end=\"4347\"\u003eGDNF\/BDNF\u003c\/strong\u003epathways.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4360\" data-end=\"4526\"\u003e\n\u003cp data-start=\"4362\" data-end=\"4526\"\u003e\u003cstrong data-start=\"4362\" data-end=\"4374\"\u003eIn vivo:\u003c\/strong\u003e Neuroprotection and functional improvement in \u003cstrong data-start=\"4421\" data-end=\"4433\"\u003ePD toxin\u003c\/strong\u003e and \u003cstrong data-start=\"4438\" data-end=\"4459\"\u003estress\/depression\u003c\/strong\u003e models; hints of \u003cstrong data-start=\"4477\" data-end=\"4499\"\u003eadult neurogenesis\u003c\/strong\u003e and \u003cstrong data-start=\"4504\" data-end=\"4517\"\u003ecognitive\u003c\/strong\u003e gains.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4527\" data-end=\"4598\"\u003e\n\u003cp data-start=\"4529\" data-end=\"4598\"\u003e\u003cstrong data-start=\"4529\" data-end=\"4548\"\u003eNo human trials\u003c\/strong\u003e to date; all efficacy claims are \u003cstrong data-start=\"4582\" data-end=\"4597\"\u003epreclinical\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cblockquote data-start=\"4600\" data-end=\"4819\"\u003e\n\u003cp data-start=\"4602\" data-end=\"4819\"\u003e\u003cstrong data-start=\"4602\" data-end=\"4628\"\u003eEvidence quality note:\u003c\/strong\u003e Convergent cellular and rodent data support \u003cstrong data-start=\"4673\" data-end=\"4727\"\u003edopaminergic trophism and mitochondrial protection\u003c\/strong\u003e. Translation to humans is \u003cstrong data-start=\"4754\" data-end=\"4766\"\u003eunproven\u003c\/strong\u003e; dosing windows and long-term safety remain unknown.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-start=\"4821\" data-end=\"4824\"\u003e\n\u003ch2 data-start=\"4826\" data-end=\"4872\"\u003e5. Emerging Clinical Interests (conceptual)\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"4874\" data-end=\"5293\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"4874\" data-end=\"4904\"\u003e\n\u003ctr data-start=\"4874\" data-end=\"4904\"\u003e\n\u003cth data-start=\"4874\" data-end=\"4882\" data-col-size=\"md\"\u003eField\u003c\/th\u003e\n\u003cth data-start=\"4882\" data-end=\"4894\" data-col-size=\"md\"\u003eRationale\u003c\/th\u003e\n\u003cth data-start=\"4894\" data-end=\"4904\" data-col-size=\"sm\"\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"4919\" data-end=\"5293\"\u003e\n\u003ctr data-start=\"4919\" data-end=\"5035\"\u003e\n\u003ctd data-start=\"4919\" data-end=\"4967\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"4921\" data-end=\"4966\"\u003eParkinson’s disease (adjunct or prodrome)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"4967\" data-end=\"5020\" data-col-size=\"md\"\u003eDA neuron protection\/trophism + microglial control\u003c\/td\u003e\n\u003ctd data-start=\"5020\" data-end=\"5035\" data-col-size=\"sm\"\u003ePreclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5036\" data-end=\"5128\"\u003e\n\u003ctd data-start=\"5036\" data-end=\"5080\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"5038\" data-end=\"5079\"\u003ePost-toxin\/trauma dopaminergic injury\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5080\" data-end=\"5113\" data-col-size=\"md\"\u003eRegeneration\/neurite outgrowth\u003c\/td\u003e\n\u003ctd data-start=\"5113\" data-end=\"5128\" data-col-size=\"sm\"\u003ePreclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5129\" data-end=\"5226\"\u003e\n\u003ctd data-start=\"5129\" data-end=\"5162\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"5131\" data-end=\"5161\"\u003eCognitive impairment\/aging\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5162\" data-end=\"5211\" data-col-size=\"md\"\u003eSynaptic plasticity + hippocampal neurogenesis\u003c\/td\u003e\n\u003ctd data-start=\"5211\" data-end=\"5226\" data-col-size=\"sm\"\u003ePreclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5227\" data-end=\"5293\"\u003e\n\u003ctd data-start=\"5227\" data-end=\"5254\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"5229\" data-end=\"5253\"\u003eDepression\/anhedonia\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5254\" data-end=\"5278\" data-col-size=\"md\"\u003ePlasticity\/BDNF angle\u003c\/td\u003e\n\u003ctd data-start=\"5278\" data-end=\"5293\" data-col-size=\"sm\"\u003ePreclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"5295\" data-end=\"5298\"\u003e\n\u003ch2 data-start=\"5300\" data-end=\"5357\"\u003e6. Safety and Tolerability (unknowns \u0026amp; class cautions)\u003c\/h2\u003e\n\u003cul data-start=\"5359\" data-end=\"6375\"\u003e\n\u003cli data-start=\"5359\" data-end=\"5410\"\u003e\n\u003cp data-start=\"5361\" data-end=\"5410\"\u003e\u003cstrong data-start=\"5361\" data-end=\"5378\"\u003eHuman safety:\u003c\/strong\u003e \u003cstrong data-start=\"5379\" data-end=\"5391\"\u003eUnknown.\u003c\/strong\u003e No phase-1 data.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5411\" data-end=\"5629\"\u003e\n\u003cp data-start=\"5413\" data-end=\"5629\"\u003e\u003cstrong data-start=\"5413\" data-end=\"5456\"\u003eGenotoxic\/phototoxic potential (class):\u003c\/strong\u003e Planar \u003cstrong data-start=\"5464\" data-end=\"5480\"\u003eβ-carbolines\u003c\/strong\u003e can intercalate DNA and, at high doses or UV exposure, show \u003cstrong data-start=\"5541\" data-end=\"5565\"\u003ephototoxic\/genotoxic\u003c\/strong\u003e risks in some assays; 9-MBC-specific margins are not defined.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5630\" data-end=\"5793\"\u003e\n\u003cp data-start=\"5632\" data-end=\"5793\"\u003e\u003cstrong data-start=\"5632\" data-end=\"5653\"\u003eMAO interactions:\u003c\/strong\u003e Although not a strong MAO inhibitor at trophic doses, \u003cstrong data-start=\"5708\" data-end=\"5719\"\u003ecaution\u003c\/strong\u003e with \u003cstrong data-start=\"5725\" data-end=\"5746\"\u003eMAOI\/serotonergic\u003c\/strong\u003ecombinations is prudent until characterized.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5794\" data-end=\"5931\"\u003e\n\u003cp data-start=\"5796\" data-end=\"5931\"\u003e\u003cstrong data-start=\"5796\" data-end=\"5818\"\u003eSeizure threshold:\u003c\/strong\u003e High doses of some β-carbolines lower seizure threshold; relevance to 9-MBC is unclear—avoid in epilepsy risk.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5932\" data-end=\"6095\"\u003e\n\u003cp data-start=\"5934\" data-end=\"6095\"\u003e\u003cstrong data-start=\"5934\" data-end=\"5960\"\u003eCardiac\/mitochondrial:\u003c\/strong\u003e Excessive mitochondrial modulation could theoretically affect \u003cstrong data-start=\"6023\" data-end=\"6049\"\u003econductance\/energetics\u003c\/strong\u003e—ECG and metabolic safety need formal study.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6096\" data-end=\"6222\"\u003e\n\u003cp data-start=\"6098\" data-end=\"6222\"\u003e\u003cstrong data-start=\"6098\" data-end=\"6124\"\u003eReproductive\/oncology:\u003c\/strong\u003e No data; avoid in \u003cstrong data-start=\"6143\" data-end=\"6156\"\u003epregnancy\u003c\/strong\u003e and in \u003cstrong data-start=\"6164\" data-end=\"6185\"\u003eactive malignancy\u003c\/strong\u003e until carcinogenicity is excluded.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6223\" data-end=\"6375\"\u003e\n\u003cp data-start=\"6225\" data-end=\"6375\"\u003e\u003cstrong data-start=\"6225\" data-end=\"6245\"\u003eProduct quality:\u003c\/strong\u003e Grey-market “nootropic” supplies are \u003cstrong data-start=\"6283\" data-end=\"6298\"\u003eunregulated\u003c\/strong\u003e and frequently \u003cstrong data-start=\"6314\" data-end=\"6331\"\u003emisidentified\u003c\/strong\u003e—avoid human use outside regulated research.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"6377\" data-end=\"6435\"\u003e\u003cstrong data-start=\"6377\" data-end=\"6435\"\u003eComparative snapshot (dopaminergic-trophic strategies)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"6437\" data-end=\"6908\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"6437\" data-end=\"6515\"\u003e\n\u003ctr data-start=\"6437\" data-end=\"6515\"\u003e\n\u003cth data-start=\"6437\" data-end=\"6447\" data-col-size=\"sm\"\u003eFeature\u003c\/th\u003e\n\u003cth data-start=\"6447\" data-end=\"6459\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6449\" data-end=\"6458\"\u003e9-MBC\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6459\" data-end=\"6487\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6461\" data-end=\"6486\"\u003eSelegiline\/rasagiline\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6487\" data-end=\"6515\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6489\" data-end=\"6513\"\u003eGDNF (intracerebral)\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"6534\" data-end=\"6908\"\u003e\n\u003ctr data-start=\"6534\" data-end=\"6661\"\u003e\n\u003ctd data-start=\"6534\" data-end=\"6551\" data-col-size=\"sm\"\u003ePrimary action\u003c\/td\u003e\n\u003ctd data-start=\"6551\" data-end=\"6596\" data-col-size=\"sm\"\u003e\n\u003cstrong data-start=\"6553\" data-end=\"6583\"\u003eNeurotrophic\/mitochondrial\u003c\/strong\u003e β-carboline\u003c\/td\u003e\n\u003ctd data-start=\"6596\" data-end=\"6633\" data-col-size=\"sm\"\u003eMAO-B inhibition (neuroprotection)\u003c\/td\u003e\n\u003ctd data-start=\"6633\" data-end=\"6661\" data-col-size=\"sm\"\u003eDirect trophic signaling\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6662\" data-end=\"6763\"\u003e\n\u003ctd data-start=\"6662\" data-end=\"6673\" data-col-size=\"sm\"\u003eEvidence\u003c\/td\u003e\n\u003ctd data-start=\"6673\" data-end=\"6691\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6675\" data-end=\"6690\"\u003ePreclinical\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6691\" data-end=\"6731\" data-col-size=\"sm\"\u003eHuman (symptomatic + some protection)\u003c\/td\u003e\n\u003ctd data-start=\"6731\" data-end=\"6763\" data-col-size=\"sm\"\u003eHuman surgical trials, mixed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6764\" data-end=\"6838\"\u003e\n\u003ctd data-start=\"6764\" data-end=\"6775\" data-col-size=\"sm\"\u003eDelivery\u003c\/td\u003e\n\u003ctd data-start=\"6775\" data-end=\"6805\" data-col-size=\"sm\"\u003eOral feasible (preclinical)\u003c\/td\u003e\n\u003ctd data-start=\"6805\" data-end=\"6812\" data-col-size=\"sm\"\u003eOral\u003c\/td\u003e\n\u003ctd data-start=\"6812\" data-end=\"6838\" data-col-size=\"sm\"\u003eNeurosurgical infusion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6839\" data-end=\"6908\"\u003e\n\u003ctd data-start=\"6839\" data-end=\"6854\" data-col-size=\"sm\"\u003eSafety known\u003c\/td\u003e\n\u003ctd data-start=\"6854\" data-end=\"6863\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6856\" data-end=\"6862\"\u003eNo\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6863\" data-end=\"6883\" data-col-size=\"sm\"\u003eYes (established)\u003c\/td\u003e\n\u003ctd data-start=\"6883\" data-end=\"6908\" data-col-size=\"sm\"\u003eProcedure-heavy risks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"6910\" data-end=\"6913\"\u003e\n\u003ch2 data-start=\"6915\" data-end=\"6941\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-start=\"6943\" data-end=\"7135\"\u003e\n\u003cli data-start=\"6943\" data-end=\"6980\"\u003e\n\u003cp data-start=\"6945\" data-end=\"6980\"\u003e\u003cstrong data-start=\"6945\" data-end=\"6961\"\u003eNot approved\u003c\/strong\u003e by FDA\/EMA\/PMDA.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6981\" data-end=\"7045\"\u003e\n\u003cp data-start=\"6983\" data-end=\"7045\"\u003eNo registered IND-stage clinical program publicly available.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7046\" data-end=\"7135\"\u003e\n\u003cp data-start=\"7048\" data-end=\"7135\"\u003eAny consumer sale is \u003cstrong data-start=\"7069\" data-end=\"7097\"\u003eresearch-chemical market\u003c\/strong\u003e; identity and purity are not assured.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"7137\" data-end=\"7140\"\u003e\n\u003ch2 data-start=\"7142\" data-end=\"7182\"\u003e8. Practical Take \u0026amp; Future Directions\u003c\/h2\u003e\n\u003cul data-start=\"7184\" data-end=\"7892\"\u003e\n\u003cli data-start=\"7184\" data-end=\"7368\"\u003e\n\u003cp data-start=\"7186\" data-end=\"7368\"\u003e\u003cstrong data-start=\"7186\" data-end=\"7213\"\u003eDo not self-experiment.\u003c\/strong\u003e Priorities are \u003cstrong data-start=\"7229\" data-end=\"7247\"\u003eGLP toxicology\u003c\/strong\u003e, \u003cstrong data-start=\"7249\" data-end=\"7287\"\u003egenotoxicity\/phototoxicity screens\u003c\/strong\u003e, cardiovascular safety, and \u003cstrong data-start=\"7316\" data-end=\"7342\"\u003efirst-in-human SAD\/MAD\u003c\/strong\u003e before any patient use.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7369\" data-end=\"7719\"\u003e\n\u003cp data-start=\"7371\" data-end=\"7396\"\u003e\u003cstrong data-start=\"7371\" data-end=\"7394\"\u003eTrial design ideas:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"7399\" data-end=\"7719\"\u003e\n\u003cli data-start=\"7399\" data-end=\"7567\"\u003e\n\u003cp data-start=\"7401\" data-end=\"7567\"\u003e\u003cstrong data-start=\"7401\" data-end=\"7413\"\u003ePhase 1:\u003c\/strong\u003e PK\/PD with \u003cstrong data-start=\"7425\" data-end=\"7433\"\u003eqEEG\u003c\/strong\u003e, \u003cstrong data-start=\"7435\" data-end=\"7449\"\u003eoculomotor\u003c\/strong\u003e and \u003cstrong data-start=\"7454\" data-end=\"7471\"\u003emotor battery\u003c\/strong\u003e, \u003cstrong data-start=\"7473\" data-end=\"7501\"\u003emitochondrial biomarkers\u003c\/strong\u003e (acyl-carnitines), and \u003cstrong data-start=\"7525\" data-end=\"7549\"\u003eretinal\/striatal MRI\u003c\/strong\u003e safety markers.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7570\" data-end=\"7719\"\u003e\n\u003cp data-start=\"7572\" data-end=\"7719\"\u003e\u003cstrong data-start=\"7572\" data-end=\"7607\"\u003ePhase 2a (PD or prodromal RBD):\u003c\/strong\u003e \u003cstrong data-start=\"7608\" data-end=\"7621\"\u003eDAT-SPECT\u003c\/strong\u003e, \u003cstrong data-start=\"7623\" data-end=\"7636\"\u003eMDS-UPDRS\u003c\/strong\u003e, \u003cstrong data-start=\"7638\" data-end=\"7664\"\u003egait\/typing kinematics\u003c\/strong\u003e, and \u003cstrong data-start=\"7670\" data-end=\"7691\"\u003einflammatory\/BDNF\u003c\/strong\u003e panels; exclude MAOI use.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7720\" data-end=\"7892\"\u003e\n\u003cp data-start=\"7722\" data-end=\"7892\"\u003e\u003cstrong data-start=\"7722\" data-end=\"7736\"\u003eChemistry:\u003c\/strong\u003e Optimize \u003cstrong data-start=\"7746\" data-end=\"7764\"\u003ephotostability\u003c\/strong\u003e, \u003cstrong data-start=\"7766\" data-end=\"7781\"\u003eselectivity\u003c\/strong\u003e, and \u003cstrong data-start=\"7787\" data-end=\"7812\"\u003emitochondrial-sparing\u003c\/strong\u003e while retaining dopaminergic trophism; explore \u003cstrong data-start=\"7860\" data-end=\"7872\"\u003eprodrugs\u003c\/strong\u003e with CNS targeting.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"7894\" data-end=\"7897\"\u003e\n\u003ch3 data-start=\"7899\" data-end=\"7922\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-start=\"7924\" data-end=\"8613\"\u003e\n\u003cli data-start=\"7924\" data-end=\"8045\"\u003e\n\u003cp data-start=\"7926\" data-end=\"8045\"\u003e\u003cem data-start=\"7926\" data-end=\"7977\"\u003eJournal of Neurochemistry; Molecular Neurobiology\u003c\/em\u003e — Dopaminergic differentiation and neurite outgrowth under 9-MBC.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8046\" data-end=\"8141\"\u003e\n\u003cp data-start=\"8048\" data-end=\"8141\"\u003e\u003cem data-start=\"8048\" data-end=\"8083\"\u003eNeuropharmacology; Brain Research\u003c\/em\u003e — Protection in \u003cstrong data-start=\"8100\" data-end=\"8115\"\u003eMPTP\/6-OHDA\u003c\/strong\u003e models; motor outcomes.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8142\" data-end=\"8262\"\u003e\n\u003cp data-start=\"8144\" data-end=\"8262\"\u003e\u003cem data-start=\"8144\" data-end=\"8193\"\u003eRedox Biology; Journal of Neuroscience Research\u003c\/em\u003e — Mitochondrial function, \u003cstrong data-start=\"8220\" data-end=\"8230\"\u003ePGC-1α\u003c\/strong\u003e signaling, and mtROS effects.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8263\" data-end=\"8358\"\u003e\n\u003cp data-start=\"8265\" data-end=\"8358\"\u003e\u003cem data-start=\"8265\" data-end=\"8301\"\u003eGlia; Journal of Neuroinflammation\u003c\/em\u003e — Microglial phenotype shifts and cytokine modulation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8359\" data-end=\"8454\"\u003e\n\u003cp data-start=\"8361\" data-end=\"8454\"\u003e\u003cem data-start=\"8361\" data-end=\"8409\"\u003eHippocampus; Neurobiology of Learning \u0026amp; Memory\u003c\/em\u003e — Adult neurogenesis and memory behaviors.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8455\" data-end=\"8511\"\u003e\n\u003cp data-start=\"8457\" data-end=\"8511\"\u003e\u003cem data-start=\"8457\" data-end=\"8480\"\u003eSynapse; Neuroscience\u003c\/em\u003e — Synaptic proteins and LTP.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8512\" data-end=\"8613\"\u003e\n\u003cp data-start=\"8514\" data-end=\"8613\"\u003e\u003cem data-start=\"8514\" data-end=\"8568\"\u003eExperimental Neurology; Neurochemistry International\u003c\/em\u003e — Anti-excitotoxic and antioxidant defenses.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":51061864235272,"sku":"10","price":80.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0937\/9053\/5944\/files\/9-MBC_25mg.png?v=1755271831"},{"product_id":"nad-500mg-vial","title":"NAD+ 500mg vial","description":"\u003cp class=\"\" data-end=\"740\" data-start=\"485\"\u003e\u003cstrong data-end=\"529\" data-start=\"485\"\u003e\u003cspan style=\"color: #ff2a00;\"\u003e\u003cstrong\u003e                                                    \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: #ff2a00; text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN CONSUMPTION\u003cmeta charset=\"UTF-8\"\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"38\" data-end=\"1056\"\u003e\u003cstrong\u003eNicotinamide adenine dinucleotide\u003c\/strong\u003e (\u003cstrong data-start=\"106\" data-end=\"114\"\u003eNAD⁺\u003c\/strong\u003e) is a universal redox cofactor and enzyme substrate central to \u003cstrong data-start=\"178\" data-end=\"211\"\u003eenergy metabolism (NAD⁺\/NADH)\u003c\/strong\u003e and \u003cstrong data-start=\"216\" data-end=\"235\"\u003ecell signalling\u003c\/strong\u003e. As a co-substrate, NAD⁺ fuels \u003cstrong data-start=\"267\" data-end=\"289\"\u003esirtuins (SIRT1–7)\u003c\/strong\u003e, \u003cstrong data-start=\"291\" data-end=\"300\"\u003ePARPs\u003c\/strong\u003e, \u003cstrong data-start=\"302\" data-end=\"316\"\u003eCD38\/CD157\u003c\/strong\u003e, and \u003cstrong data-start=\"322\" data-end=\"331\"\u003eSARM1\u003c\/strong\u003e, thereby governing mitochondrial biogenesis, DNA repair, circadian timing, immune tone, and axon integrity. Tissue NAD⁺ falls with aging and cardiometabolic stress due to \u003cstrong data-start=\"503\" data-end=\"541\"\u003eincreased consumption (PARPs\/CD38)\u003c\/strong\u003e and \u003cstrong data-start=\"546\" data-end=\"566\"\u003eimpaired salvage\u003c\/strong\u003e. Augmentation strategies include \u003cstrong data-start=\"600\" data-end=\"622\"\u003edietary precursors\u003c\/strong\u003e (nicotinamide riboside, NR; nicotinamide mononucleotide, NMN; niacin\/NA; nicotinamide\/NAM; tryptophan→kynurenine pathway), \u003cstrong data-start=\"746\" data-end=\"766\"\u003eenzyme targeting\u003c\/strong\u003e (boost \u003cstrong data-start=\"774\" data-end=\"783\"\u003eNAMPT\u003c\/strong\u003e, inhibit \u003cstrong data-start=\"793\" data-end=\"806\"\u003eCD38\/PARP\u003c\/strong\u003e), and \u003cstrong data-start=\"813\" data-end=\"832\"\u003eparenteral NAD⁺\u003c\/strong\u003e (investigational). No NAD⁺-raising therapy is \u003cstrong data-start=\"879\" data-end=\"899\"\u003eFDA\/EMA-approved\u003c\/strong\u003e for disease modification; \u003cstrong data-start=\"926\" data-end=\"932\"\u003eNR\u003c\/strong\u003e is widely sold as a supplement; \u003cstrong data-start=\"965\" data-end=\"972\"\u003eNMN\u003c\/strong\u003e has \u003cstrong data-start=\"977\" data-end=\"1007\"\u003evariable regulatory status\u003c\/strong\u003e by country; \u003cstrong data-start=\"1020\" data-end=\"1031\"\u003eIV NAD⁺\u003c\/strong\u003e is not an approved drug.\u003c\/p\u003e\n\u003chr data-start=\"1058\" data-end=\"1061\"\u003e\n\u003ch3 data-start=\"1063\" data-end=\"1128\"\u003eAdditional Benefits of NAD⁺ Repletion Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"1130\" data-end=\"3337\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"1130\" data-end=\"1158\"\u003e\n\u003ctr data-start=\"1130\" data-end=\"1158\"\u003e\n\u003cth data-start=\"1130\" data-end=\"1140\" data-col-size=\"md\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-start=\"1140\" data-end=\"1158\" data-col-size=\"xl\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"1169\" data-end=\"3337\"\u003e\n\u003ctr data-start=\"1169\" data-end=\"1417\"\u003e\n\u003ctd data-start=\"1169\" data-end=\"1206\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1171\" data-end=\"1205\"\u003e1 Mitochondrial function \u0026amp; ATP\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1206\" data-end=\"1417\" data-col-size=\"xl\"\u003eNAD⁺ restoration increases \u003cstrong data-start=\"1235\" data-end=\"1251\"\u003eSIRT1\/PGC-1α\u003c\/strong\u003e activity, \u003cstrong data-start=\"1262\" data-end=\"1272\"\u003eOXPHOS\u003c\/strong\u003e proteins, and \u003cstrong data-start=\"1287\" data-end=\"1315\"\u003emitochondrial biogenesis\u003c\/strong\u003e, improving skeletal-muscle oxidative capacity. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Cell Metabolism; Nature Communications\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1418\" data-end=\"1658\"\u003e\n\u003ctd data-start=\"1418\" data-end=\"1470\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1420\" data-end=\"1469\"\u003e2 Insulin sensitivity \u0026amp; metabolic flexibility\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1470\" data-end=\"1658\" data-col-size=\"xl\"\u003eIn overweight adults, \u003cstrong data-start=\"1494\" data-end=\"1501\"\u003eNMN\u003c\/strong\u003e improved \u003cstrong data-start=\"1511\" data-end=\"1541\"\u003emuscle insulin sensitivity\u003c\/strong\u003e without weight loss; NR shows \u003cstrong data-start=\"1572\" data-end=\"1607\"\u003emodest glycaemic\/lipid benefits\u003c\/strong\u003e in some cohorts. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Science; Diabetes\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1659\" data-end=\"1870\"\u003e\n\u003ctd data-start=\"1659\" data-end=\"1682\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1661\" data-end=\"1681\"\u003e3 Vascular aging\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1682\" data-end=\"1870\" data-col-size=\"xl\"\u003e\n\u003cstrong data-start=\"1684\" data-end=\"1690\"\u003eNR\u003c\/strong\u003e increased \u003cstrong data-start=\"1701\" data-end=\"1721\"\u003ewhole-blood NAD⁺\u003c\/strong\u003e and reduced \u003cstrong data-start=\"1734\" data-end=\"1764\"\u003eaortic stiffness\/clinic BP\u003c\/strong\u003e in mid-life adults with elevated cardiovascular risk. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Nature Communications; Hypertension\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1871\" data-end=\"2095\"\u003e\n\u003ctd data-start=\"1871\" data-end=\"1897\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1873\" data-end=\"1896\"\u003e4 Liver fat \u0026amp; NAFLD\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1897\" data-end=\"2095\" data-col-size=\"xl\"\u003ePreclinical and pilot human studies suggest \u003cstrong data-start=\"1943\" data-end=\"1970\"\u003elower hepatic steatosis\u003c\/strong\u003e, \u003cstrong data-start=\"1972\" data-end=\"1996\"\u003eALT\/AST improvements\u003c\/strong\u003e, and reduced \u003cstrong data-start=\"2010\" data-end=\"2025\"\u003elipogenesis\u003c\/strong\u003e with NAD⁺ precursors. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Hepatology; Liver International\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2096\" data-end=\"2384\"\u003e\n\u003ctd data-start=\"2096\" data-end=\"2132\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2098\" data-end=\"2131\"\u003e5 Neuroprotection \u0026amp; cognition\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2132\" data-end=\"2384\" data-col-size=\"xl\"\u003eNAD⁺ supports \u003cstrong data-start=\"2148\" data-end=\"2185\"\u003eaxonal survival (SARM1 restraint)\u003c\/strong\u003e, \u003cstrong data-start=\"2187\" data-end=\"2210\"\u003esynaptic plasticity\u003c\/strong\u003e, and \u003cstrong data-start=\"2216\" data-end=\"2241\"\u003emitochondrial quality\u003c\/strong\u003e; small trials report signals in \u003cstrong data-start=\"2274\" data-end=\"2293\"\u003esleep\/cognition\u003c\/strong\u003e and \u003cstrong data-start=\"2298\" data-end=\"2319\"\u003eneurodegenerative\u003c\/strong\u003e contexts. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Neuron; Journal of Alzheimer’s Disease\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2385\" data-end=\"2658\"\u003e\n\u003ctd data-start=\"2385\" data-end=\"2425\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2387\" data-end=\"2424\"\u003e6 Exercise performance \u0026amp; recovery\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2425\" data-end=\"2658\" data-col-size=\"xl\"\u003eIncreased \u003cstrong data-start=\"2437\" data-end=\"2448\"\u003eVO₂peak\u003c\/strong\u003e and \u003cstrong data-start=\"2453\" data-end=\"2485\"\u003efatty-acid oxidation markers\u003c\/strong\u003e with NR\/NMN in some studies; others are neutral—benefits may depend on \u003cstrong data-start=\"2557\" data-end=\"2586\"\u003ebaseline fitness and dose\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Medicine \u0026amp; Science in Sports \u0026amp; Exercise; FASEB Journal\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2659\" data-end=\"2894\"\u003e\n\u003ctd data-start=\"2659\" data-end=\"2691\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2661\" data-end=\"2690\"\u003e7 Kidney \u0026amp; cardiac stress\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2691\" data-end=\"2894\" data-col-size=\"xl\"\u003eNAD⁺ repletion mitigates \u003cstrong data-start=\"2718\" data-end=\"2741\"\u003eAKI\/CKD progression\u003c\/strong\u003e and \u003cstrong data-start=\"2746\" data-end=\"2783\"\u003epost-ischemic cardiac dysfunction\u003c\/strong\u003e in models via \u003cstrong data-start=\"2798\" data-end=\"2830\"\u003eDNA-repair and mitochondrial\u003c\/strong\u003e pathways. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Nature Medicine; Circulation Research\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2895\" data-end=\"3122\"\u003e\n\u003ctd data-start=\"2895\" data-end=\"2936\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2897\" data-end=\"2935\"\u003e8 Immune resilience \u0026amp; inflammation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2936\" data-end=\"3122\" data-col-size=\"xl\"\u003eBy modulating \u003cstrong data-start=\"2952\" data-end=\"2965\"\u003eCD38\/PARP\u003c\/strong\u003e and SIRT networks, NAD⁺ can \u003cstrong data-start=\"2994\" data-end=\"3025\"\u003ereduce inflammaging markers\u003c\/strong\u003e and enhance \u003cstrong data-start=\"3038\" data-end=\"3061\"\u003eantiviral responses\u003c\/strong\u003e; human data are early. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Immunity; Geroscience\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3123\" data-end=\"3337\"\u003e\n\u003ctd data-start=\"3123\" data-end=\"3154\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"3125\" data-end=\"3153\"\u003e9 Skin \u0026amp; barrier biology\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3154\" data-end=\"3337\" data-col-size=\"xl\"\u003eTopical\/oral precursors improve \u003cstrong data-start=\"3188\" data-end=\"3206\"\u003ebarrier lipids\u003c\/strong\u003e, \u003cstrong data-start=\"3208\" data-end=\"3232\"\u003ecollagen transcripts\u003c\/strong\u003e, and \u003cstrong data-start=\"3238\" data-end=\"3260\"\u003eUV-repair capacity\u003c\/strong\u003e; cosmetic endpoints show benefit. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Dermatology; Redox Biology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"3339\" data-end=\"3342\"\u003e\n\u003ch2 data-start=\"3344\" data-end=\"3379\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-start=\"3381\" data-end=\"3414\"\u003e2.1 Enzyme Pharmacodynamics\u003c\/h3\u003e\n\u003cul data-start=\"3415\" data-end=\"3944\"\u003e\n\u003cli data-start=\"3415\" data-end=\"3569\"\u003e\n\u003cp data-start=\"3417\" data-end=\"3569\"\u003e\u003cstrong data-start=\"3417\" data-end=\"3440\"\u003eSirtuins (SIRT1–7):\u003c\/strong\u003e NAD⁺-dependent deacylases → \u003cstrong data-start=\"3469\" data-end=\"3490\"\u003ePGC-1α activation\u003c\/strong\u003e, mitochondrial biogenesis, \u003cstrong data-start=\"3518\" data-end=\"3537\"\u003eNF-κB dampening\u003c\/strong\u003e, improved insulin signalling.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3570\" data-end=\"3709\"\u003e\n\u003cp data-start=\"3572\" data-end=\"3709\"\u003e\u003cstrong data-start=\"3572\" data-end=\"3592\"\u003ePARPs (PARP1\/2):\u003c\/strong\u003e DNA-damage sensors; high activity \u003cstrong data-start=\"3627\" data-end=\"3644\"\u003econsumes NAD⁺\u003c\/strong\u003e and limits ATP; controlled activity supports genome stability.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3710\" data-end=\"3824\"\u003e\n\u003cp data-start=\"3712\" data-end=\"3824\"\u003e\u003cstrong data-start=\"3712\" data-end=\"3727\"\u003eCD38\/CD157:\u003c\/strong\u003e Ecto-enzymes that \u003cstrong data-start=\"3746\" data-end=\"3764\"\u003ehydrolyze NAD⁺\u003c\/strong\u003e to cyclic\/linear ADPR; upregulated with age\/inflammation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3825\" data-end=\"3944\"\u003e\n\u003cp data-start=\"3827\" data-end=\"3944\"\u003e\u003cstrong data-start=\"3827\" data-end=\"3837\"\u003eSARM1:\u003c\/strong\u003e Pro-degenerative axonal NADase; inhibition\/offset by higher \u003cstrong data-start=\"3898\" data-end=\"3907\"\u003eNMNAT\u003c\/strong\u003e and \u003cstrong data-start=\"3912\" data-end=\"3920\"\u003eNAD⁺\u003c\/strong\u003e supports axon survival.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"3946\" data-end=\"3981\"\u003e2.2 Upstream\/Downstream Biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"3983\" data-end=\"4442\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"3983\" data-end=\"4022\"\u003e\n\u003ctr data-start=\"3983\" data-end=\"4022\"\u003e\n\u003cth data-start=\"3983\" data-end=\"3992\" data-col-size=\"sm\"\u003eModule\u003c\/th\u003e\n\u003cth data-start=\"3992\" data-end=\"4013\" data-col-size=\"md\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-start=\"4013\" data-end=\"4022\" data-col-size=\"sm\"\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"4037\" data-end=\"4442\"\u003e\n\u003ctr data-start=\"4037\" data-end=\"4159\"\u003e\n\u003ctd data-start=\"4037\" data-end=\"4081\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"4039\" data-end=\"4080\"\u003eSalvage (NAM→NMN→NAD⁺; NAMPT, NMNATs)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"4081\" data-end=\"4128\" data-col-size=\"md\"\u003eMaintains cytosolic\/mitochondrial NAD⁺ pools\u003c\/td\u003e\n\u003ctd data-start=\"4128\" data-end=\"4159\" data-col-size=\"sm\"\u003e\n\u003cstrong data-start=\"4130\" data-end=\"4137\"\u003eNRK\u003c\/strong\u003e converts \u003cstrong data-start=\"4147\" data-end=\"4157\"\u003eNR→NMN\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"4160\" data-end=\"4263\"\u003e\n\u003ctd data-start=\"4160\" data-end=\"4187\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"4162\" data-end=\"4186\"\u003eDe novo (Trp→Kyn→QA)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"4187\" data-end=\"4235\" data-col-size=\"md\"\u003eBackup NAD⁺ supply; inflammation diverts flux\u003c\/td\u003e\n\u003ctd data-start=\"4235\" data-end=\"4263\" data-col-size=\"sm\"\u003eKynurenines immunoactive\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"4264\" data-end=\"4341\"\u003e\n\u003ctd data-start=\"4264\" data-end=\"4288\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"4266\" data-end=\"4287\"\u003eRedox (NAD⁺\/NADH)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"4288\" data-end=\"4314\" data-col-size=\"md\"\u003eGlycolysis\/TCA\/ETC flux\u003c\/td\u003e\n\u003ctd data-start=\"4314\" data-end=\"4341\" data-col-size=\"sm\"\u003eCouples to ROS handling\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"4342\" data-end=\"4442\"\u003e\n\u003ctd data-start=\"4342\" data-end=\"4378\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"4344\" data-end=\"4377\"\u003eCircadian (CLOCK\/BMAL1–SIRT1)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"4378\" data-end=\"4413\" data-col-size=\"md\"\u003eAligns metabolism with day\/night\u003c\/td\u003e\n\u003ctd data-start=\"4413\" data-end=\"4442\" data-col-size=\"sm\"\u003eNAD⁺ oscillates diurnally\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"4444\" data-end=\"4447\"\u003e\n\u003ch2 data-start=\"4449\" data-end=\"4497\"\u003e3. Pharmacokinetics (augmentation strategies)\u003c\/h2\u003e\n\u003cul data-start=\"4499\" data-end=\"5295\"\u003e\n\u003cli data-start=\"4499\" data-end=\"4640\"\u003e\n\u003cp data-start=\"4501\" data-end=\"4640\"\u003e\u003cstrong data-start=\"4501\" data-end=\"4513\"\u003eOral NR:\u003c\/strong\u003e Rapid absorption; increases \u003cstrong data-start=\"4542\" data-end=\"4563\"\u003eblood\/tissue NAD⁺\u003c\/strong\u003e within hours; half-life minutes; excreted as \u003cstrong data-start=\"4609\" data-end=\"4628\"\u003eMeNAM → 2PY\/4PY\u003c\/strong\u003e in urine.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4641\" data-end=\"4821\"\u003e\n\u003cp data-start=\"4643\" data-end=\"4821\"\u003e\u003cstrong data-start=\"4643\" data-end=\"4656\"\u003eOral NMN:\u003c\/strong\u003e Converted to NAD⁺ via \u003cstrong data-start=\"4679\" data-end=\"4692\"\u003eNRK\/NMNAT\u003c\/strong\u003e; a putative \u003cstrong data-start=\"4705\" data-end=\"4716\"\u003eSLC12A8\u003c\/strong\u003e transporter is described in mice; human transport remains debated; raises \u003cstrong data-start=\"4791\" data-end=\"4805\"\u003eblood NAD⁺\u003c\/strong\u003e within hours.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4822\" data-end=\"5036\"\u003e\n\u003cp data-start=\"4824\" data-end=\"5036\"\u003e\u003cstrong data-start=\"4824\" data-end=\"4861\"\u003eNiacin (NA) \/ Nicotinamide (NAM):\u003c\/strong\u003e Classical precursors; \u003cstrong data-start=\"4884\" data-end=\"4890\"\u003eNA\u003c\/strong\u003e causes \u003cstrong data-start=\"4898\" data-end=\"4907\"\u003eflush\u003c\/strong\u003e, improves lipids at pharmacologic doses; \u003cstrong data-start=\"4949\" data-end=\"4956\"\u003eNAM\u003c\/strong\u003e raises NAD⁺ but at high doses increases \u003cstrong data-start=\"4997\" data-end=\"5014\"\u003eMeNAM\/2PY\/4PY\u003c\/strong\u003e (methylation sink).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5037\" data-end=\"5197\"\u003e\n\u003cp data-start=\"5039\" data-end=\"5197\"\u003e\u003cstrong data-start=\"5039\" data-end=\"5069\"\u003eIV NAD⁺ (investigational):\u003c\/strong\u003e Transient plasma rise with downstream \u003cstrong data-start=\"5108\" data-end=\"5121\"\u003eNAM\/MeNAM\u003c\/strong\u003e; intracellular access largely via \u003cstrong data-start=\"5156\" data-end=\"5194\"\u003eextracellular breakdown→precursors\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5198\" data-end=\"5295\"\u003e\n\u003cp data-start=\"5200\" data-end=\"5295\"\u003e\u003cstrong data-start=\"5200\" data-end=\"5214\"\u003eClearance:\u003c\/strong\u003e Predominantly urinary \u003cstrong data-start=\"5237\" data-end=\"5254\"\u003eMeNAM\/2PY\/4PY\u003c\/strong\u003e; high doses tax \u003cstrong data-start=\"5271\" data-end=\"5294\"\u003emethyl donors (SAM)\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"5297\" data-end=\"5300\"\u003e\n\u003ch2 data-start=\"5302\" data-end=\"5347\"\u003e4. Pre-clinical and Translational Evidence\u003c\/h2\u003e\n\u003ch3 data-start=\"5349\" data-end=\"5389\"\u003e4.1 Human trials (selected themes)\u003c\/h3\u003e\n\u003cul data-start=\"5390\" data-end=\"5968\"\u003e\n\u003cli data-start=\"5390\" data-end=\"5554\"\u003e\n\u003cp data-start=\"5392\" data-end=\"5554\"\u003e\u003cstrong data-start=\"5392\" data-end=\"5399\"\u003eNR:\u003c\/strong\u003e In mid-life\/older adults, raises NAD⁺ and \u003cstrong data-start=\"5442\" data-end=\"5473\"\u003ereduces aortic stiffness\/BP\u003c\/strong\u003e; variable effects on insulin sensitivity and lipids; generally well tolerated.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5555\" data-end=\"5695\"\u003e\n\u003cp data-start=\"5557\" data-end=\"5695\"\u003e\u003cstrong data-start=\"5557\" data-end=\"5565\"\u003eNMN:\u003c\/strong\u003e In overweight\/prediabetic adults, \u003cstrong data-start=\"5600\" data-end=\"5639\"\u003eimproved muscle insulin sensitivity\u003c\/strong\u003e and skeletal-muscle NAD⁺ signalling over 10–12 weeks.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5696\" data-end=\"5870\"\u003e\n\u003cp data-start=\"5698\" data-end=\"5870\"\u003e\u003cstrong data-start=\"5698\" data-end=\"5713\"\u003eNiacin\/NAM:\u003c\/strong\u003e Robust lipid effects for \u003cstrong data-start=\"5739\" data-end=\"5749\"\u003eniacin\u003c\/strong\u003e but limited by \u003cstrong data-start=\"5765\" data-end=\"5809\"\u003eflush, insulin resistance, and gout risk\u003c\/strong\u003e; high-dose \u003cstrong data-start=\"5821\" data-end=\"5828\"\u003eNAM\u003c\/strong\u003e limited by \u003cstrong data-start=\"5840\" data-end=\"5854\"\u003eGI\/hepatic\u003c\/strong\u003e tolerability.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5871\" data-end=\"5968\"\u003e\n\u003cp data-start=\"5873\" data-end=\"5968\"\u003e\u003cstrong data-start=\"5873\" data-end=\"5885\"\u003eIV NAD⁺:\u003c\/strong\u003e Used in clinics for wellness\/withdrawal claims; \u003cstrong data-start=\"5934\" data-end=\"5967\"\u003erigorous RCT data are lacking\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cblockquote data-start=\"5970\" data-end=\"6272\"\u003e\n\u003cp data-start=\"5972\" data-end=\"6272\"\u003e\u003cstrong data-start=\"5972\" data-end=\"5998\"\u003eEvidence quality note:\u003c\/strong\u003e Strong \u003cstrong data-start=\"6006\" data-end=\"6021\"\u003emechanistic\u003c\/strong\u003e and \u003cstrong data-start=\"6026\" data-end=\"6036\"\u003eanimal\u003c\/strong\u003e data; \u003cstrong data-start=\"6043\" data-end=\"6057\"\u003ehuman RCTs\u003c\/strong\u003e show reliable \u003cstrong data-start=\"6072\" data-end=\"6098\"\u003ebiochemical NAD⁺ rises\u003c\/strong\u003e and \u003cstrong data-start=\"6103\" data-end=\"6136\"\u003esignal-level clinical effects\u003c\/strong\u003e (vascular\/insulin sensitivity) but \u003cstrong data-start=\"6172\" data-end=\"6189\"\u003emixed results\u003c\/strong\u003e for performance, weight, and hard outcomes. Larger, longer trials are in progress.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-start=\"6274\" data-end=\"6277\"\u003e\n\u003ch2 data-start=\"6279\" data-end=\"6312\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"6314\" data-end=\"7042\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"6314\" data-end=\"6352\"\u003e\n\u003ctr data-start=\"6314\" data-end=\"6352\"\u003e\n\u003cth data-start=\"6314\" data-end=\"6322\" data-col-size=\"sm\"\u003eField\u003c\/th\u003e\n\u003cth data-start=\"6322\" data-end=\"6334\" data-col-size=\"md\"\u003eRationale\u003c\/th\u003e\n\u003cth data-start=\"6334\" data-end=\"6352\" data-col-size=\"sm\"\u003eCurrent status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"6367\" data-end=\"7042\"\u003e\n\u003ctr data-start=\"6367\" data-end=\"6457\"\u003e\n\u003ctd data-start=\"6367\" data-end=\"6396\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6369\" data-end=\"6395\"\u003eGeroscience\/sarcopenia\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"6396\" data-end=\"6432\"\u003eMitochondrial + inflammatory axis\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"6432\" data-end=\"6457\"\u003ePhase 2–style signals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6458\" data-end=\"6572\"\u003e\n\u003ctd data-start=\"6458\" data-end=\"6485\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6460\" data-end=\"6484\"\u003eCardiometabolic risk\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6485\" data-end=\"6529\" data-col-size=\"md\"\u003eVascular aging, NAFLD, insulin resistance\u003c\/td\u003e\n\u003ctd data-start=\"6529\" data-end=\"6572\" data-col-size=\"sm\"\u003eMixed RCTs; more powered studies needed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6573\" data-end=\"6679\"\u003e\n\u003ctd data-start=\"6573\" data-end=\"6597\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6575\" data-end=\"6596\"\u003eNeurodegeneration\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6597\" data-end=\"6644\" data-col-size=\"md\"\u003eAxon survival (SARM1), mitochondrial support\u003c\/td\u003e\n\u003ctd data-start=\"6644\" data-end=\"6679\" data-col-size=\"sm\"\u003eEarly human; strong preclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6680\" data-end=\"6753\"\u003e\n\u003ctd data-start=\"6680\" data-end=\"6704\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6682\" data-end=\"6703\"\u003eKidney injury\/CKD\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"6704\" data-end=\"6736\"\u003eDNA-repair \u0026amp; metabolic rescue\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"6736\" data-end=\"6753\"\u003eTranslational\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6754\" data-end=\"6866\"\u003e\n\u003ctd data-start=\"6754\" data-end=\"6778\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6756\" data-end=\"6777\"\u003eOncology-adjacent\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6778\" data-end=\"6825\" data-col-size=\"md\"\u003eSupport normal tissue; complex tumor biology\u003c\/td\u003e\n\u003ctd data-start=\"6825\" data-end=\"6866\" data-col-size=\"sm\"\u003ePreclinical; caution in active cancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6867\" data-end=\"6956\"\u003e\n\u003ctd data-start=\"6867\" data-end=\"6900\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6869\" data-end=\"6899\"\u003eDermatology\/cosmeceuticals\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"6900\" data-end=\"6929\"\u003eBarrier\/collagen\/UV repair\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"6929\" data-end=\"6956\"\u003eSmall trials; cosmetics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6957\" data-end=\"7042\"\u003e\n\u003ctd data-start=\"6957\" data-end=\"6987\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6959\" data-end=\"6986\"\u003eCritical illness\/sepsis\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"6987\" data-end=\"7018\"\u003ePARP overuse \u0026amp; NAD⁺ collapse\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"7018\" data-end=\"7042\"\u003ePilot investigations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"7044\" data-end=\"7047\"\u003e\n\u003ch2 data-start=\"7049\" data-end=\"7078\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-start=\"7080\" data-end=\"8274\"\u003e\n\u003cli data-start=\"7080\" data-end=\"7246\"\u003e\n\u003cp data-start=\"7082\" data-end=\"7246\"\u003e\u003cstrong data-start=\"7082\" data-end=\"7119\"\u003eNR\/NMN (oral, usual trial doses):\u003c\/strong\u003e Generally \u003cstrong data-start=\"7130\" data-end=\"7148\"\u003ewell tolerated\u003c\/strong\u003e (flushing uncommon). \u003cstrong data-start=\"7170\" data-end=\"7182\"\u003eGI upset\u003c\/strong\u003e, \u003cstrong data-start=\"7184\" data-end=\"7196\"\u003eheadache\u003c\/strong\u003e, \u003cstrong data-start=\"7198\" data-end=\"7209\"\u003efatigue\u003c\/strong\u003e, \u003cstrong data-start=\"7211\" data-end=\"7223\"\u003epruritus\u003c\/strong\u003e occur in a minority.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7247\" data-end=\"7429\"\u003e\n\u003cp data-start=\"7249\" data-end=\"7429\"\u003e\u003cstrong data-start=\"7249\" data-end=\"7265\"\u003eNiacin (NA):\u003c\/strong\u003e \u003cstrong data-start=\"7266\" data-end=\"7278\"\u003eFlushing\u003c\/strong\u003e, \u003cstrong data-start=\"7280\" data-end=\"7291\"\u003eitching\u003c\/strong\u003e, \u003cstrong data-start=\"7293\" data-end=\"7308\"\u003ehypotension\u003c\/strong\u003e, \u003cstrong data-start=\"7310\" data-end=\"7330\"\u003e↑ uric acid\/gout\u003c\/strong\u003e, \u003cstrong data-start=\"7332\" data-end=\"7364\"\u003e↑ glucose\/insulin resistance\u003c\/strong\u003e, hepatotoxicity risk (especially \u003cstrong data-start=\"7398\" data-end=\"7419\"\u003esustained-release\u003c\/strong\u003e forms).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7430\" data-end=\"7645\"\u003e\n\u003cp data-start=\"7432\" data-end=\"7645\"\u003e\u003cstrong data-start=\"7432\" data-end=\"7455\"\u003eNicotinamide (NAM):\u003c\/strong\u003e Better tolerated than niacin; \u003cstrong data-start=\"7486\" data-end=\"7504\"\u003ehepatotoxicity\u003c\/strong\u003e at high doses (≥3 g\/day), \u003cstrong data-start=\"7531\" data-end=\"7541\"\u003enausea\u003c\/strong\u003e, \u003cstrong data-start=\"7543\" data-end=\"7555\"\u003eheadache\u003c\/strong\u003e; increases \u003cstrong data-start=\"7567\" data-end=\"7584\"\u003eMeNAM\/2PY\/4PY\u003c\/strong\u003e (methyl-sink)—consider \u003cstrong data-start=\"7608\" data-end=\"7630\"\u003efolate\/B₁₂\/betaine\u003c\/strong\u003e sufficiency.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7646\" data-end=\"7814\"\u003e\n\u003cp data-start=\"7648\" data-end=\"7814\"\u003e\u003cstrong data-start=\"7648\" data-end=\"7660\"\u003eIV NAD⁺:\u003c\/strong\u003e Infusion-rate related \u003cstrong data-start=\"7683\" data-end=\"7737\"\u003enausea, chest\/abdominal tightness, lightheadedness\u003c\/strong\u003e; sterile-prep and monitoring required; \u003cstrong data-start=\"7777\" data-end=\"7811\"\u003eno disease indication approved\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7815\" data-end=\"8274\"\u003e\n\u003cp data-start=\"7817\" data-end=\"7841\"\u003e\u003cstrong data-start=\"7817\" data-end=\"7839\"\u003eBiologic cautions:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"7844\" data-end=\"8274\"\u003e\n\u003cli data-start=\"7844\" data-end=\"7999\"\u003e\n\u003cp data-start=\"7846\" data-end=\"7999\"\u003e\u003cstrong data-start=\"7846\" data-end=\"7868\"\u003eActive malignancy:\u003c\/strong\u003e Some tumors are \u003cstrong data-start=\"7885\" data-end=\"7908\"\u003eNAMPT\/NAD⁺-addicted\u003c\/strong\u003e; indiscriminate NAD⁺ boosting could be counterproductive—\u003cstrong data-start=\"7966\" data-end=\"7988\"\u003eoncology oversight\u003c\/strong\u003e advised.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8002\" data-end=\"8141\"\u003e\n\u003cp data-start=\"8004\" data-end=\"8141\"\u003e\u003cstrong data-start=\"8004\" data-end=\"8026\"\u003eDrug interactions:\u003c\/strong\u003e Theoretical with \u003cstrong data-start=\"8044\" data-end=\"8063\"\u003ePARP inhibitors\u003c\/strong\u003e, \u003cstrong data-start=\"8065\" data-end=\"8081\"\u003echemotherapy\u003c\/strong\u003e (DNA-repair), and \u003cstrong data-start=\"8100\" data-end=\"8119\"\u003eimmunotherapies\u003c\/strong\u003e; monitor in trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8144\" data-end=\"8274\"\u003e\n\u003cp data-start=\"8146\" data-end=\"8274\"\u003e\u003cstrong data-start=\"8146\" data-end=\"8169\"\u003eMethylation burden:\u003c\/strong\u003e High \u003cstrong data-start=\"8175\" data-end=\"8185\"\u003eNAM\/NR\u003c\/strong\u003e intake increases methylated metabolites; watch \u003cstrong data-start=\"8233\" data-end=\"8249\"\u003ehomocysteine\u003c\/strong\u003e and methyl-donor status.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"8276\" data-end=\"8305\"\u003e\u003cstrong data-start=\"8276\" data-end=\"8305\"\u003eComparative safety matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"8307\" data-end=\"9039\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"8307\" data-end=\"8394\"\u003e\n\u003ctr data-start=\"8307\" data-end=\"8394\"\u003e\n\u003cth data-start=\"8307\" data-end=\"8317\" data-col-size=\"sm\"\u003eFeature\u003c\/th\u003e\n\u003cth data-start=\"8317\" data-end=\"8326\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"8319\" data-end=\"8325\"\u003eNR\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"8326\" data-end=\"8336\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"8328\" data-end=\"8335\"\u003eNMN\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"8336\" data-end=\"8354\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"8338\" data-end=\"8353\"\u003eNiacin (NA)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"8354\" data-end=\"8379\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"8356\" data-end=\"8378\"\u003eNicotinamide (NAM)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"8379\" data-end=\"8394\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"8381\" data-end=\"8392\"\u003eIV NAD⁺\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"8421\" data-end=\"9039\"\u003e\n\u003ctr data-start=\"8421\" data-end=\"8511\"\u003e\n\u003ctd data-start=\"8421\" data-end=\"8439\" data-col-size=\"sm\"\u003eHuman NAD⁺ rise\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"8439\" data-end=\"8458\"\u003e\u003cstrong data-start=\"8441\" data-end=\"8457\"\u003eYes (robust)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"8458\" data-end=\"8477\"\u003e\u003cstrong data-start=\"8460\" data-end=\"8476\"\u003eYes (robust)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"8477\" data-end=\"8483\"\u003eYes\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"8483\" data-end=\"8489\"\u003eYes\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"8489\" data-end=\"8511\"\u003eTransient\/systemic\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"8512\" data-end=\"8681\"\u003e\n\u003ctd data-start=\"8512\" data-end=\"8523\" data-col-size=\"sm\"\u003eKey pros\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"8523\" data-end=\"8564\"\u003eGood GI tolerability; vascular signals\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"8564\" data-end=\"8602\"\u003eInsulin-sensitivity signal; good GI\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"8602\" data-end=\"8630\"\u003eLipid-lowering (HDL↑ TG↓)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"8630\" data-end=\"8654\"\u003eNo flush; inexpensive\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"8654\" data-end=\"8681\"\u003eRapid levels; bypass GI\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"8682\" data-end=\"8921\"\u003e\n\u003ctd data-start=\"8682\" data-end=\"8693\" data-col-size=\"sm\"\u003eKey cons\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"8693\" data-end=\"8735\"\u003ePossible \u003cstrong data-start=\"8704\" data-end=\"8720\"\u003eLDL\/TG drift\u003c\/strong\u003e in some; cost\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"8735\" data-end=\"8766\"\u003eRegulatory variability; cost\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"8766\" data-end=\"8826\"\u003e\n\u003cstrong data-start=\"8768\" data-end=\"8777\"\u003eFlush\u003c\/strong\u003e, \u003cstrong data-start=\"8779\" data-end=\"8791\"\u003eglucose↑\u003c\/strong\u003e, \u003cstrong data-start=\"8793\" data-end=\"8807\"\u003euric acid↑\u003c\/strong\u003e, hepatotoxic (SR)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"8826\" data-end=\"8873\"\u003e\n\u003cstrong data-start=\"8828\" data-end=\"8846\"\u003eHepatotoxicity\u003c\/strong\u003e at high dose; methyl sink\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"8873\" data-end=\"8921\"\u003eRate-limited AEs; \u003cstrong data-start=\"8893\" data-end=\"8919\"\u003eno approved indication\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"8922\" data-end=\"9039\"\u003e\n\u003ctd data-start=\"8922\" data-end=\"8939\" data-col-size=\"sm\"\u003eEvidence level\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"8939\" data-end=\"8970\"\u003eMultiple small–moderate RCTs\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"8970\" data-end=\"8983\"\u003eEarly RCTs\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"8983\" data-end=\"9004\"\u003eExtensive (lipids)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"9004\" data-end=\"9015\"\u003eModerate\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"9015\" data-end=\"9039\"\u003eSparse\/heterogeneous\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"9041\" data-end=\"9044\"\u003e\n\u003ch2 data-start=\"9046\" data-end=\"9072\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-start=\"9074\" data-end=\"9508\"\u003e\n\u003cli data-start=\"9074\" data-end=\"9145\"\u003e\n\u003cp data-start=\"9076\" data-end=\"9145\"\u003e\u003cstrong data-start=\"9076\" data-end=\"9095\"\u003eApproved drugs:\u003c\/strong\u003e None for “NAD⁺ repletion” as a disease therapy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9146\" data-end=\"9292\"\u003e\n\u003cp data-start=\"9148\" data-end=\"9292\"\u003e\u003cstrong data-start=\"9148\" data-end=\"9187\"\u003eDietary supplements (US\/EU varies):\u003c\/strong\u003e \u003cstrong data-start=\"9188\" data-end=\"9194\"\u003eNR\u003c\/strong\u003e broadly marketed; \u003cstrong data-start=\"9213\" data-end=\"9220\"\u003eNMN\u003c\/strong\u003e status \u003cstrong data-start=\"9228\" data-end=\"9248\"\u003evaries\/contested\u003c\/strong\u003e; \u003cstrong data-start=\"9250\" data-end=\"9264\"\u003eniacin\/NAM\u003c\/strong\u003e are established vitamins.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9293\" data-end=\"9396\"\u003e\n\u003cp data-start=\"9295\" data-end=\"9396\"\u003e\u003cstrong data-start=\"9295\" data-end=\"9315\"\u003eParenteral NAD⁺:\u003c\/strong\u003e Not FDA-approved; clinic use is \u003cstrong data-start=\"9348\" data-end=\"9370\"\u003eoff-label\/wellness\u003c\/strong\u003e without disease claims.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9397\" data-end=\"9508\"\u003e\n\u003cp data-start=\"9399\" data-end=\"9508\"\u003e\u003cstrong data-start=\"9399\" data-end=\"9411\"\u003eQuality:\u003c\/strong\u003e Use \u003cstrong data-start=\"9416\" data-end=\"9423\"\u003eGMP\u003c\/strong\u003e sources; third-party testing helps reduce \u003cstrong data-start=\"9466\" data-end=\"9482\"\u003eadulteration\u003c\/strong\u003e and \u003cstrong data-start=\"9487\" data-end=\"9507\"\u003elabel-claim gaps\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"9510\" data-end=\"9513\"\u003e\n\u003ch2 data-start=\"9515\" data-end=\"9538\"\u003e8. Future Directions\u003c\/h2\u003e\n\u003cul data-start=\"9540\" data-end=\"10373\"\u003e\n\u003cli data-start=\"9540\" data-end=\"9724\"\u003e\n\u003cp data-start=\"9542\" data-end=\"9724\"\u003e\u003cstrong data-start=\"9542\" data-end=\"9572\"\u003ePhenotype-targeted trials:\u003c\/strong\u003e Visceral-obese NAFLD, \u003cstrong data-start=\"9595\" data-end=\"9611\"\u003epre-diabetes\u003c\/strong\u003e, \u003cstrong data-start=\"9613\" data-end=\"9629\"\u003ehypertensive\u003c\/strong\u003e mid-life adults, \u003cstrong data-start=\"9647\" data-end=\"9654\"\u003eCKD\u003c\/strong\u003e, and early \u003cstrong data-start=\"9666\" data-end=\"9687\"\u003eneurodegeneration\u003c\/strong\u003e with biomarker-anchored endpoints.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9725\" data-end=\"9922\"\u003e\n\u003cp data-start=\"9727\" data-end=\"9922\"\u003e\u003cstrong data-start=\"9727\" data-end=\"9755\"\u003eMechanism-guided combos:\u003c\/strong\u003e \u003cstrong data-start=\"9756\" data-end=\"9777\"\u003eNR\/NMN + exercise\u003c\/strong\u003e, \u003cstrong data-start=\"9779\" data-end=\"9804\"\u003ecaloric periodization\u003c\/strong\u003e, \u003cstrong data-start=\"9806\" data-end=\"9821\"\u003eSGLT2\/GLP-1\u003c\/strong\u003e co-therapy; \u003cstrong data-start=\"9834\" data-end=\"9853\"\u003eCD38 inhibition\u003c\/strong\u003e to preserve NAD⁺; \u003cstrong data-start=\"9872\" data-end=\"9896\"\u003emethyl-donor support\u003c\/strong\u003e when using high NAM\/NR.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9923\" data-end=\"10022\"\u003e\n\u003cp data-start=\"9925\" data-end=\"10022\"\u003e\u003cstrong data-start=\"9925\" data-end=\"9948\"\u003eOutcome end-points:\u003c\/strong\u003e Hard outcomes (fractures, MACE, CKD progression), not just NAD⁺ levels.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"10023\" data-end=\"10195\"\u003e\n\u003cp data-start=\"10025\" data-end=\"10195\"\u003e\u003cstrong data-start=\"10025\" data-end=\"10052\"\u003eCompartmental NADomics:\u003c\/strong\u003e Distinguish \u003cstrong data-start=\"10065\" data-end=\"10101\"\u003ecytosolic vs mitochondrial pools\u003c\/strong\u003e, tissue targeting, and \u003cstrong data-start=\"10125\" data-end=\"10146\"\u003eclock-time dosing\u003c\/strong\u003e to align with \u003cstrong data-start=\"10161\" data-end=\"10174\"\u003ecircadian\u003c\/strong\u003e NAD⁺ oscillations.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"10196\" data-end=\"10373\"\u003e\n\u003cp data-start=\"10198\" data-end=\"10373\"\u003e\u003cstrong data-start=\"10198\" data-end=\"10217\"\u003eSafety science:\u003c\/strong\u003e Long-term \u003cstrong data-start=\"10228\" data-end=\"10253\"\u003eoncology surveillance\u003c\/strong\u003e, hepatobiliary panels, \u003cstrong data-start=\"10277\" data-end=\"10305\"\u003ehomocysteine\/methylation\u003c\/strong\u003e monitoring at higher doses, and standardized \u003cstrong data-start=\"10351\" data-end=\"10362\"\u003eIV NAD⁺\u003c\/strong\u003e protocols.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"10375\" data-end=\"10378\"\u003e\n\u003ch3 data-start=\"10380\" data-end=\"10403\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-start=\"10405\" data-end=\"11334\"\u003e\n\u003cli data-start=\"10405\" data-end=\"10501\"\u003e\n\u003cp data-start=\"10407\" data-end=\"10501\"\u003eTrammell S.A.J. et al. Human \u003cstrong data-start=\"10436\" data-end=\"10442\"\u003eNR\u003c\/strong\u003e pharmacokinetics and NAD⁺ metabolome. \u003cem data-start=\"10481\" data-end=\"10498\"\u003eCell Metabolism\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"10502\" data-end=\"10617\"\u003e\n\u003cp data-start=\"10504\" data-end=\"10617\"\u003eMartens C.R. et al. \u003cstrong data-start=\"10524\" data-end=\"10530\"\u003eNR\u003c\/strong\u003e lowers aortic stiffness and blood pressure in older adults. \u003cem data-start=\"10591\" data-end=\"10614\"\u003eNature Communications\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"10618\" data-end=\"10709\"\u003e\n\u003cp data-start=\"10620\" data-end=\"10709\"\u003eYoshino J. et al. \u003cstrong data-start=\"10638\" data-end=\"10645\"\u003eNMN\u003c\/strong\u003e improves insulin sensitivity in prediabetic women. \u003cem data-start=\"10697\" data-end=\"10706\"\u003eScience\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"10710\" data-end=\"10821\"\u003e\n\u003cp data-start=\"10712\" data-end=\"10821\"\u003eMills K.F. et al. NAD⁺ repletion improves mitochondrial function and lifespan in models. \u003cem data-start=\"10801\" data-end=\"10818\"\u003eCell Metabolism\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"10822\" data-end=\"10942\"\u003e\n\u003cp data-start=\"10824\" data-end=\"10942\"\u003eCamacho-Pereira J. et al. \u003cstrong data-start=\"10850\" data-end=\"10858\"\u003eCD38\u003c\/strong\u003e drives age-related NAD⁺ decline; inhibition restores function. \u003cem data-start=\"10922\" data-end=\"10939\"\u003eNature Medicine\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"10943\" data-end=\"11025\"\u003e\n\u003cp data-start=\"10945\" data-end=\"11025\"\u003eLautrup S. et al. NAD⁺ in brain aging and disease. \u003cem data-start=\"10996\" data-end=\"11022\"\u003eNature Reviews Neurology\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"11026\" data-end=\"11125\"\u003e\n\u003cp data-start=\"11028\" data-end=\"11125\"\u003eRajman L., Chwalek K., Sinclair D. Therapeutic potential of NAD⁺ precursors. \u003cem data-start=\"11105\" data-end=\"11122\"\u003eCell Metabolism\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"11126\" data-end=\"11236\"\u003e\n\u003cp data-start=\"11128\" data-end=\"11236\"\u003eCanto C., Auwerx J. NAD⁺ and sirtuins in metabolic control. \u003cem data-start=\"11188\" data-end=\"11233\"\u003eCold Spring Harbor Perspectives in Medicine\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"11237\" data-end=\"11334\"\u003e\n\u003cp data-start=\"11239\" data-end=\"11334\"\u003eKatsyuba E., Auwerx J. \u003cstrong data-start=\"11262\" data-end=\"11282\"\u003eNAD⁺ homeostasis\u003c\/strong\u003e: from tryptophan to therapy. \u003cem data-start=\"11312\" data-end=\"11331\"\u003eNature Metabolism\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"\" data-end=\"8819\" data-start=\"8626\"\u003e \u003c\/p\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":51330659254536,"sku":"10","price":70.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0937\/9053\/5944\/files\/NAD_500mg.png?v=1757266778"},{"product_id":"oxytocin-acetate-2mg-vial","title":"Oxytocin Acetate 10mg vial","description":"\u003cp class=\"\" data-end=\"413\" data-start=\"259\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                           \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"\" data-end=\"413\" data-start=\"259\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003e\u003cstrong data-is-only-node=\"\" data-end=\"20\" data-start=\"0\"\u003eOxytocin acetate\u003c\/strong\u003e is a synthetic form of the naturally occurring nonapeptide hormone \u003cstrong data-end=\"100\" data-start=\"88\"\u003eoxytocin\u003c\/strong\u003e, which is produced in the hypothalamus and secreted by the posterior pituitary gland.\u003c\/span\u003e \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eIt plays a pivotal role in various physiological processes, including uterine contractions during labor, milk ejection during lactation, and modulation of social and emotional behaviors.\u003c\/span\u003e \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eThe acetate form is commonly used in pharmaceutical preparations due to its stability and solubility.\u003c\/span\u003e\u003cspan data-state=\"closed\" class=\"\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"418\" data-start=\"415\"\u003e\n\u003ch2 class=\"\" data-end=\"449\" data-start=\"420\"\u003e\u003cstrong data-end=\"449\" data-start=\"423\"\u003e2. Mechanism of Action\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"609\" data-start=\"451\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eOxytocin exerts its effects by binding to the \u003cstrong data-end=\"74\" data-start=\"46\"\u003eoxytocin receptor (OXTR)\u003c\/strong\u003e, a G-protein-coupled receptor predominantly expressed in uterine smooth muscle and mammary glands.\u003c\/span\u003e \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eUpon activation, it stimulates the phospholipase C pathway, leading to an increase in intracellular calcium levels, which in turn induces muscle contractions.\u003c\/span\u003e \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eThis mechanism underlies its primary roles in facilitating labor and milk ejection.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"\" data-end=\"729\" data-start=\"611\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eBeyond its peripheral actions, oxytocin also functions as a neuromodulator in the central nervous system, influencing behaviors related to social bonding, stress, and emotional regulation.\u003c\/span\u003e \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eIt has been implicated in enhancing trust, empathy, and social recognition, making it a subject of interest in neuropsychiatric research.\u003c\/span\u003e\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"734\" data-start=\"731\"\u003e\n\u003ch2 class=\"\" data-end=\"763\" data-start=\"736\"\u003e\u003cstrong data-end=\"763\" data-start=\"739\"\u003e3. Clinical Efficacy\u003c\/strong\u003e\u003c\/h2\u003e\n\u003ch3 class=\"\" data-end=\"800\" data-start=\"765\"\u003e\u003cstrong data-end=\"800\" data-start=\"769\"\u003e3.1. Obstetric Applications\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"\" data-end=\"880\" data-start=\"802\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eOxytocin acetate is widely used in obstetrics for:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul data-end=\"1140\" data-start=\"882\"\u003e\n\u003cli class=\"\" data-end=\"1003\" data-start=\"882\"\u003e\n\u003cp class=\"\" data-end=\"1003\" data-start=\"884\"\u003e\u003cstrong data-end=\"923\" data-start=\"884\"\u003eInduction and augmentation of labor\u003c\/strong\u003e: \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eAdministered intravenously to initiate or strengthen uterine contractions.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1140\" data-start=\"1005\"\u003e\n\u003cp class=\"\" data-end=\"1140\" data-start=\"1007\"\u003e\u003cstrong data-end=\"1060\" data-start=\"1007\"\u003ePrevention and treatment of postpartum hemorrhage\u003c\/strong\u003e: \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003ePromotes uterine contraction to reduce bleeding after childbirth.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"\" data-end=\"1220\" data-start=\"1142\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eClinical studies have demonstrated its efficacy in reducing labor duration and minimizing blood loss during the postpartum period.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 class=\"\" data-end=\"1272\" data-start=\"1222\"\u003e\u003cstrong data-end=\"1272\" data-start=\"1226\"\u003e3.2. Psychiatric and Neurological Research\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"\" data-end=\"1352\" data-start=\"1274\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eEmerging research has explored oxytocin's potential therapeutic applications in various neuropsychiatric conditions:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul data-end=\"1863\" data-start=\"1354\"\u003e\n\u003cli class=\"\" data-end=\"1510\" data-start=\"1354\"\u003e\n\u003cp class=\"\" data-end=\"1510\" data-start=\"1356\"\u003e\u003cstrong data-end=\"1390\" data-start=\"1356\"\u003eAutism Spectrum Disorder (ASD)\u003c\/strong\u003e: \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eIntranasal administration of oxytocin has been investigated for improving social cognition and interaction in individuals with ASD.\u003c\/span\u003e \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eResults have been mixed, with some studies reporting modest benefits and others showing limited efficacy.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1708\" data-start=\"1512\"\u003e\n\u003cp class=\"\" data-end=\"1708\" data-start=\"1514\"\u003e\u003cstrong data-end=\"1548\" data-start=\"1514\"\u003eSubstance Use Disorders (SUDs)\u003c\/strong\u003e: \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eSystematic reviews have assessed oxytocin's role in reducing withdrawal symptoms and cravings across various substances, including alcohol, opioids, and nicotine.\u003c\/span\u003e \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eWhile some trials indicate potential benefits, the overall evidence remains inconclusive due to methodological limitations.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1863\" data-start=\"1710\"\u003e\n\u003cp class=\"\" data-end=\"1863\" data-start=\"1712\"\u003e\u003cstrong data-end=\"1743\" data-start=\"1712\"\u003ePostpartum Depression (PPD)\u003c\/strong\u003e: \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eOxytocin's involvement in maternal behaviors has led to investigations into its use for alleviating symptoms of PPD.\u003c\/span\u003e \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003ePreliminary findings suggest possible mood-enhancing effects, but further research is needed to establish its efficacy and safety profile.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"1868\" data-start=\"1865\"\u003e\n\u003ch2 class=\"\" data-end=\"1903\" data-start=\"1870\"\u003e\u003cstrong data-end=\"1903\" data-start=\"1873\"\u003e4. Safety and Tolerability\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"2023\" data-start=\"1905\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eOxytocin acetate is generally well-tolerated when used appropriately.\u003c\/span\u003e \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eCommon side effects include:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul data-end=\"2341\" data-start=\"2025\"\u003e\n\u003cli class=\"\" data-end=\"2122\" data-start=\"2025\"\u003e\n\u003cp class=\"\" data-end=\"2122\" data-start=\"2027\"\u003e\u003cstrong data-end=\"2042\" data-start=\"2027\"\u003eHypotension\u003c\/strong\u003e: \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eParticularly with rapid intravenous infusion.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2229\" data-start=\"2124\"\u003e\n\u003cp class=\"\" data-end=\"2229\" data-start=\"2126\"\u003e\u003cstrong data-end=\"2149\" data-start=\"2126\"\u003eNausea and vomiting\u003c\/strong\u003e: \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eOccasionally observed during administration.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2341\" data-start=\"2231\"\u003e\n\u003cp class=\"\" data-end=\"2341\" data-start=\"2233\"\u003e\u003cstrong data-end=\"2261\" data-start=\"2233\"\u003eUterine hyperstimulation\u003c\/strong\u003e: \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eExcessive uterine contractions can lead to fetal distress.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"\" data-end=\"2461\" data-start=\"2343\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eRare but serious adverse effects encompass water intoxication due to its antidiuretic properties, leading to hyponatremia and, in extreme cases, seizures or coma.\u003c\/span\u003e \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eCareful monitoring of fluid intake and electrolyte balance is essential during administration.\u003c\/span\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"2466\" data-start=\"2463\"\u003e\n\u003ch2 class=\"\" data-end=\"2494\" data-start=\"2468\"\u003e\u003cstrong data-end=\"2494\" data-start=\"2471\"\u003e5. Pharmacokinetics\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cul data-end=\"2915\" data-start=\"2496\"\u003e\n\u003cli class=\"\" data-end=\"2596\" data-start=\"2496\"\u003e\n\u003cp class=\"\" data-end=\"2596\" data-start=\"2498\"\u003e\u003cstrong data-end=\"2512\" data-start=\"2498\"\u003eAbsorption\u003c\/strong\u003e: \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eRapid onset of action when administered intravenously or intramuscularly.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2700\" data-start=\"2598\"\u003e\n\u003cp class=\"\" data-end=\"2700\" data-start=\"2600\"\u003e\u003cstrong data-end=\"2616\" data-start=\"2600\"\u003eDistribution\u003c\/strong\u003e: \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eWidely distributed in extracellular fluid; does not cross the blood-brain barrier significantly.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2802\" data-start=\"2702\"\u003e\n\u003cp class=\"\" data-end=\"2802\" data-start=\"2704\"\u003e\u003cstrong data-end=\"2718\" data-start=\"2704\"\u003eMetabolism\u003c\/strong\u003e: \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eMetabolized primarily by hepatic and plasma oxytocinases.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2915\" data-start=\"2804\"\u003e\n\u003cp class=\"\" data-end=\"2915\" data-start=\"2806\"\u003e\u003cstrong data-end=\"2831\" data-start=\"2806\"\u003eElimination Half-Life\u003c\/strong\u003e: \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eApproximately 1–6 minutes following intravenous administration.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"2920\" data-start=\"2917\"\u003e\n\u003ch2 class=\"\" data-end=\"2966\" data-start=\"2922\"\u003e\u003cstrong data-end=\"2966\" data-start=\"2925\"\u003e6. Regulatory Status and Availability\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"3134\" data-start=\"2968\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eOxytocin acetate is approved for medical use in many countries and is listed on the World Health Organization's Model List of Essential Medicines.\u003c\/span\u003e \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eIt is available in various formulations, including injectable solutions for intravenous or intramuscular use.\u003c\/span\u003e \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eIntranasal preparations are also utilized in research settings to investigate central nervous system effects.\u003c\/span\u003e\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"3139\" data-start=\"3136\"\u003e\n\u003ch2 class=\"\" data-end=\"3161\" data-start=\"3141\"\u003e\u003cstrong data-end=\"3161\" data-start=\"3144\"\u003e7. Conclusion\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"3329\" data-start=\"3163\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eOxytocin acetate remains a cornerstone in obstetric practice for its proven efficacy in labor management and postpartum care.\u003c\/span\u003e \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eIts expanding role in neuropsychiatric research highlights its multifaceted nature, although more rigorous studies are required to substantiate its therapeutic potential in these domains.\u003c\/span\u003e \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eClinicians should remain vigilant regarding its administration, ensuring appropriate dosing and monitoring to mitigate potential adverse effects.\u003c\/span\u003e\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"3334\" data-start=\"3331\"\u003e\n\u003cp class=\"\" data-end=\"3351\" data-start=\"3336\"\u003e\u003cstrong data-end=\"3351\" data-start=\"3336\"\u003eReferences:\u003c\/strong\u003e\u003c\/p\u003e\n\u003col data-end=\"3996\" data-start=\"3353\"\u003e\n\u003cli class=\"\" data-end=\"3480\" data-start=\"3353\"\u003e\n\u003cp class=\"\" data-end=\"3480\" data-start=\"3356\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eOxytocin: Uses, Interactions, Mechanism of Action - DrugBank Online.\u003c\/span\u003e \u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3609\" data-start=\"3482\"\u003e\n\u003cp class=\"\" data-end=\"3609\" data-start=\"3485\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eThe effectiveness of oxytocin for treating substance use disorders: A systematic review.\u003c\/span\u003e \u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003ca class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[0.5625em] font-medium text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! transition-colors duration-150 ease-in-out\" rel=\"noopener\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0149763423001549?utm_source=chatgpt.com\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between absolute\"\u003e\u003cspan class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3738\" data-start=\"3611\"\u003e\n\u003cp class=\"\" data-end=\"3738\" data-start=\"3614\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eOxytocin treatment for postpartum depression.\u003c\/span\u003e \u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3867\" data-start=\"3740\"\u003e\n\u003cp class=\"\" data-end=\"3867\" data-start=\"3743\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eOxytocin: physiology, pharmacology, and clinical application for labor.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":51476594819336,"sku":"","price":70.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0937\/9053\/5944\/files\/Oxytocin_Acetate_10mg.png?v=1752777066"},{"product_id":"pinealon-10mg-vial","title":"Pinealon 20mg vial","description":"\u003cp data-start=\"356\" data-end=\"826\"\u003e \u003c\/p\u003e\n\u003cp data-start=\"356\" data-end=\"826\"\u003e\u003cstrong data-start=\"356\" data-end=\"368\"\u003ePinealon\u003c\/strong\u003e is a synthetic tripeptide composed of three amino acids: \u003cstrong data-start=\"426\" data-end=\"449\"\u003eglutamic acid (Glu)\u003c\/strong\u003e, \u003cstrong data-start=\"451\" data-end=\"474\"\u003easpartic acid (Asp)\u003c\/strong\u003e, and \u003cstrong data-start=\"480\" data-end=\"498\"\u003earginine (Arg)\u003c\/strong\u003e — chemically designated as \u003cstrong data-start=\"526\" data-end=\"533\"\u003eEDR\u003c\/strong\u003e. Originally developed by the \u003cstrong data-start=\"563\" data-end=\"624\"\u003eSt. Petersburg Institute of Bioregulation and Gerontology\u003c\/strong\u003e, Pinealon belongs to a broader class of \u003cstrong data-start=\"665\" data-end=\"700\"\u003eshort-chain regulatory peptides\u003c\/strong\u003e (a.k.a. \u003cstrong data-start=\"709\" data-end=\"734\"\u003epeptide bioregulators\u003c\/strong\u003e) intended to support \u003cstrong data-start=\"756\" data-end=\"800\"\u003egenomic stability, cellular regeneration\u003c\/strong\u003e, and \u003cstrong data-start=\"806\" data-end=\"825\"\u003eneuroprotection\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp data-start=\"828\" data-end=\"1125\"\u003ePinealon has drawn scientific interest due to its \u003cstrong data-start=\"878\" data-end=\"920\"\u003eepigenetic and cytoprotective activity\u003c\/strong\u003e, particularly in \u003cstrong data-start=\"938\" data-end=\"958\"\u003eneuronal tissues\u003c\/strong\u003e, making it a candidate for therapeutic use in \u003cstrong data-start=\"1005\" data-end=\"1038\"\u003eage-related cognitive decline\u003c\/strong\u003e, \u003cstrong data-start=\"1040\" data-end=\"1056\"\u003ebrain injury\u003c\/strong\u003e, \u003cstrong data-start=\"1058\" data-end=\"1083\"\u003ecircadian dysfunction\u003c\/strong\u003e, and \u003cstrong data-start=\"1089\" data-end=\"1124\"\u003eprenatal neurological disorders\u003c\/strong\u003e.\u003c\/p\u003e\n\u003chr data-start=\"1127\" data-end=\"1130\"\u003e\n\u003ch2 data-start=\"1132\" data-end=\"1172\"\u003e\u003cstrong data-start=\"1135\" data-end=\"1172\"\u003e2. Molecular Mechanisms of Action\u003c\/strong\u003e\u003c\/h2\u003e\n\u003ch3 data-start=\"1174\" data-end=\"1228\"\u003e\u003cstrong data-start=\"1178\" data-end=\"1228\"\u003e2.1. Epigenetic Modulation and Gene Expression\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp data-start=\"1230\" data-end=\"1375\"\u003ePinealon acts at the \u003cstrong data-start=\"1251\" data-end=\"1268\"\u003enuclear level\u003c\/strong\u003e, influencing the \u003cstrong data-start=\"1286\" data-end=\"1374\"\u003eexpression of genes associated with brain development, memory, and stress resistance\u003c\/strong\u003e:\u003c\/p\u003e\n\u003cul data-start=\"1377\" data-end=\"1715\"\u003e\n\u003cli data-start=\"1377\" data-end=\"1478\"\u003e\n\u003cp data-start=\"1379\" data-end=\"1478\"\u003eBinds to \u003cstrong data-start=\"1388\" data-end=\"1411\"\u003eGC-rich DNA regions\u003c\/strong\u003e, potentially affecting the transcription of stress response genes.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1479\" data-end=\"1574\"\u003e\n\u003cp data-start=\"1481\" data-end=\"1574\"\u003eActivates \u003cstrong data-start=\"1491\" data-end=\"1509\"\u003eRNA polymerase\u003c\/strong\u003e and \u003cstrong data-start=\"1514\" data-end=\"1537\"\u003ehistone acetylation\u003c\/strong\u003e, enhancing transcriptional activity.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1575\" data-end=\"1715\"\u003e\n\u003cp data-start=\"1577\" data-end=\"1605\"\u003eStimulates genes related to:\u003c\/p\u003e\n\u003cul data-start=\"1608\" data-end=\"1715\"\u003e\n\u003cli data-start=\"1608\" data-end=\"1630\"\u003e\n\u003cp data-start=\"1610\" data-end=\"1630\"\u003eRibosomal biogenesis\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1633\" data-end=\"1673\"\u003e\n\u003cp data-start=\"1635\" data-end=\"1673\"\u003eAnti-apoptotic signaling (e.g., Bcl-2)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1676\" data-end=\"1715\"\u003e\n\u003cp data-start=\"1678\" data-end=\"1715\"\u003eNeuroplasticity (e.g., BDNF pathways)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"1717\" data-end=\"1787\"\u003eThese effects may partially reverse \u003cstrong data-start=\"1753\" data-end=\"1786\"\u003eage-associated gene silencing\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3 data-start=\"1789\" data-end=\"1839\"\u003e\u003cstrong data-start=\"1793\" data-end=\"1839\"\u003e2.2. Mitochondrial and Antioxidant Effects\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cul data-start=\"1841\" data-end=\"2094\"\u003e\n\u003cli data-start=\"1841\" data-end=\"1919\"\u003e\n\u003cp data-start=\"1843\" data-end=\"1919\"\u003eReduces the intracellular accumulation of \u003cstrong data-start=\"1885\" data-end=\"1918\"\u003ereactive oxygen species (ROS)\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1920\" data-end=\"2003\"\u003e\n\u003cp data-start=\"1922\" data-end=\"2003\"\u003eIncreases \u003cstrong data-start=\"1932\" data-end=\"1962\"\u003esuperoxide dismutase (SOD)\u003c\/strong\u003e and \u003cstrong data-start=\"1967\" data-end=\"1993\"\u003eglutathione peroxidase\u003c\/strong\u003e activity.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2004\" data-end=\"2094\"\u003e\n\u003cp data-start=\"2006\" data-end=\"2094\"\u003eStabilizes mitochondrial membranes, reducing depolarization and improving ATP synthesis.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"2096\" data-end=\"2178\"\u003eThis supports neuronal longevity by mitigating \u003cstrong data-start=\"2143\" data-end=\"2177\"\u003eoxidative and metabolic stress\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3 data-start=\"2180\" data-end=\"2234\"\u003e\u003cstrong data-start=\"2184\" data-end=\"2234\"\u003e2.3. Anti-apoptotic and Neuroprotective Action\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cul data-start=\"2236\" data-end=\"2501\"\u003e\n\u003cli data-start=\"2236\" data-end=\"2311\"\u003e\n\u003cp data-start=\"2238\" data-end=\"2311\"\u003eDownregulates \u003cstrong data-start=\"2252\" data-end=\"2272\"\u003ecaspase-3 and -9\u003c\/strong\u003e, key enzymes in the apoptotic cascade.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2312\" data-end=\"2400\"\u003e\n\u003cp data-start=\"2314\" data-end=\"2400\"\u003ePrevents DNA fragmentation and mitochondrial rupture in neuronally derived cell lines.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2401\" data-end=\"2501\"\u003e\n\u003cp data-start=\"2403\" data-end=\"2501\"\u003eProtects against \u003cstrong data-start=\"2420\" data-end=\"2438\"\u003eexcitotoxicity\u003c\/strong\u003e, such as that seen in stroke or traumatic brain injury models.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"2503\" data-end=\"2578\"\u003eThese findings support its classification as a \u003cstrong data-start=\"2550\" data-end=\"2577\"\u003eneuroprotective peptide\u003c\/strong\u003e.\u003c\/p\u003e\n\u003chr data-start=\"2580\" data-end=\"2583\"\u003e\n\u003ch2 data-start=\"2585\" data-end=\"2644\"\u003e\u003cstrong data-start=\"2588\" data-end=\"2644\"\u003e3. Therapeutic Applications and Preclinical Evidence\u003c\/strong\u003e\u003c\/h2\u003e\n\u003ch3 data-start=\"2646\" data-end=\"2693\"\u003e\u003cstrong data-start=\"2650\" data-end=\"2693\"\u003e3.1. Cognitive Aging and Memory Support\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cul data-start=\"2695\" data-end=\"2955\"\u003e\n\u003cli data-start=\"2695\" data-end=\"2866\"\u003e\n\u003cp data-start=\"2697\" data-end=\"2758\"\u003eIn aged rodents, chronic administration of Pinealon improved:\u003c\/p\u003e\n\u003cul data-start=\"2761\" data-end=\"2866\"\u003e\n\u003cli data-start=\"2761\" data-end=\"2806\"\u003e\n\u003cp data-start=\"2763\" data-end=\"2806\"\u003e\u003cstrong data-start=\"2763\" data-end=\"2781\"\u003eSpatial memory\u003c\/strong\u003e in the Morris water maze\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2809\" data-end=\"2866\"\u003e\n\u003cp data-start=\"2811\" data-end=\"2866\"\u003e\u003cstrong data-start=\"2811\" data-end=\"2843\"\u003eLong-term potentiation (LTP)\u003c\/strong\u003e in hippocampal neurons\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2867\" data-end=\"2955\"\u003e\n\u003cp data-start=\"2869\" data-end=\"2955\"\u003eUpregulates gene expression linked to \u003cstrong data-start=\"2907\" data-end=\"2954\"\u003esynaptic integrity and memory consolidation\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"2957\" data-end=\"3114\"\u003eThese findings suggest Pinealon as a \u003cstrong data-start=\"2994\" data-end=\"3022\"\u003egeroprotective nootropic\u003c\/strong\u003e, potentially suitable for age-related cognitive decline or early-stage Alzheimer’s disease.\u003c\/p\u003e\n\u003ch3 data-start=\"3116\" data-end=\"3169\"\u003e\u003cstrong data-start=\"3120\" data-end=\"3169\"\u003e3.2. Traumatic Brain Injury (TBI) and Hypoxia\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cul data-start=\"3171\" data-end=\"3413\"\u003e\n\u003cli data-start=\"3171\" data-end=\"3247\"\u003e\n\u003cp data-start=\"3173\" data-end=\"3247\"\u003ePinealon reduces \u003cstrong data-start=\"3190\" data-end=\"3213\"\u003eneuronal cell death\u003c\/strong\u003e after hypoxic or ischemic events.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3248\" data-end=\"3318\"\u003e\n\u003cp data-start=\"3250\" data-end=\"3318\"\u003eDemonstrates improved neurological outcomes in rodent models of TBI.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3319\" data-end=\"3413\"\u003e\n\u003cp data-start=\"3321\" data-end=\"3413\"\u003eReduces post-injury \u003cstrong data-start=\"3341\" data-end=\"3362\"\u003eneuroinflammation\u003c\/strong\u003e, as indicated by lower IL-1β and TNF-α expression.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"3415\" data-end=\"3505\"\u003eThis supports Pinealon’s use in \u003cstrong data-start=\"3447\" data-end=\"3479\"\u003eacute brain injury protocols\u003c\/strong\u003e or stroke rehabilitation.\u003c\/p\u003e\n\u003ch3 data-start=\"3507\" data-end=\"3558\"\u003e\u003cstrong data-start=\"3511\" data-end=\"3558\"\u003e3.3. Prenatal and Perinatal Neuroprotection\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cul data-start=\"3560\" data-end=\"3885\"\u003e\n\u003cli data-start=\"3560\" data-end=\"3885\"\u003e\n\u003cp data-start=\"3562\" data-end=\"3686\"\u003eIn models of \u003cstrong data-start=\"3575\" data-end=\"3608\"\u003eprenatal hyperhomocysteinemia\u003c\/strong\u003e (a risk factor for developmental delay), maternal administration of Pinealon:\u003c\/p\u003e\n\u003cul data-start=\"3689\" data-end=\"3885\"\u003e\n\u003cli data-start=\"3689\" data-end=\"3760\"\u003e\n\u003cp data-start=\"3691\" data-end=\"3760\"\u003ePrevented structural and functional brain abnormalities in offspring.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3763\" data-end=\"3816\"\u003e\n\u003cp data-start=\"3765\" data-end=\"3816\"\u003eImproved learning and orientation tasks in progeny.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3819\" data-end=\"3885\"\u003e\n\u003cp data-start=\"3821\" data-end=\"3885\"\u003eReduced markers of oxidative stress in fetal hippocampal tissue.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"3887\" data-end=\"3984\"\u003eImplication: potential as a \u003cstrong data-start=\"3915\" data-end=\"3954\"\u003ematernal neuroprotective supplement\u003c\/strong\u003e during high-risk pregnancies.\u003c\/p\u003e\n\u003ch3 data-start=\"3986\" data-end=\"4035\"\u003e\u003cstrong data-start=\"3990\" data-end=\"4035\"\u003e3.4. Circadian Rhythm and Sleep Disorders\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cul data-start=\"4037\" data-end=\"4291\"\u003e\n\u003cli data-start=\"4037\" data-end=\"4109\"\u003e\n\u003cp data-start=\"4039\" data-end=\"4109\"\u003ePinealon influences \u003cstrong data-start=\"4059\" data-end=\"4082\"\u003emelatonin synthesis\u003c\/strong\u003e and pineal gland function.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4110\" data-end=\"4189\"\u003e\n\u003cp data-start=\"4112\" data-end=\"4189\"\u003eCorrects behavioral abnormalities induced by \u003cstrong data-start=\"4157\" data-end=\"4188\"\u003ecircadian rhythm disruption\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4190\" data-end=\"4291\"\u003e\n\u003cp data-start=\"4192\" data-end=\"4291\"\u003eMay support \u003cstrong data-start=\"4204\" data-end=\"4226\"\u003esleep architecture\u003c\/strong\u003e, neurohormonal synchronization, and \u003cstrong data-start=\"4263\" data-end=\"4290\"\u003echronobiological health\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"4293\" data-end=\"4387\"\u003eThis suggests potential utility in \u003cstrong data-start=\"4328\" data-end=\"4386\"\u003esleep disorders, jet lag, and shift work maladaptation\u003c\/strong\u003e.\u003c\/p\u003e\n\u003chr data-start=\"4389\" data-end=\"4392\"\u003e\n\u003ch2 data-start=\"4394\" data-end=\"4443\"\u003e\u003cstrong data-start=\"4397\" data-end=\"4443\"\u003e4. Formulation, Administration, and Dosage\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cul data-start=\"4445\" data-end=\"4841\"\u003e\n\u003cli data-start=\"4445\" data-end=\"4543\"\u003e\n\u003cp data-start=\"4447\" data-end=\"4543\"\u003e\u003cstrong data-start=\"4447\" data-end=\"4456\"\u003eForms\u003c\/strong\u003e: Available in \u003cstrong data-start=\"4471\" data-end=\"4488\"\u003eoral capsules\u003c\/strong\u003e, \u003cstrong data-start=\"4490\" data-end=\"4510\"\u003esublingual drops\u003c\/strong\u003e, or \u003cstrong data-start=\"4515\" data-end=\"4529\"\u003einjectable\u003c\/strong\u003e formulations.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4544\" data-end=\"4670\"\u003e\n\u003cp data-start=\"4546\" data-end=\"4670\"\u003e\u003cstrong data-start=\"4546\" data-end=\"4574\"\u003eRoutes of Administration\u003c\/strong\u003e: Oral for preventive health; injectable (typically intramuscular) for more intensive protocols.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4671\" data-end=\"4841\"\u003e\n\u003cp data-start=\"4673\" data-end=\"4691\"\u003e\u003cstrong data-start=\"4673\" data-end=\"4690\"\u003eTypical Doses\u003c\/strong\u003e:\u003c\/p\u003e\n\u003cul data-start=\"4694\" data-end=\"4841\"\u003e\n\u003cli data-start=\"4694\" data-end=\"4748\"\u003e\n\u003cp data-start=\"4696\" data-end=\"4748\"\u003ePreventive\/maintenance: 10–20 mg\/day for 10–30 days.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4751\" data-end=\"4841\"\u003e\n\u003cp data-start=\"4753\" data-end=\"4841\"\u003eFor acute interventions: 10 mg IM daily for up to 14 days (based on preclinical models).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"4843\" data-end=\"4953\"\u003eNote: Clinical dosing is not formally standardized and is often extrapolated from Russian geriatric protocols.\u003c\/p\u003e\n\u003chr data-start=\"4955\" data-end=\"4958\"\u003e\n\u003ch2 data-start=\"4960\" data-end=\"4993\"\u003e\u003cstrong data-start=\"4963\" data-end=\"4993\"\u003e5. Safety and Tolerability\u003c\/strong\u003e\u003c\/h2\u003e\n\u003ch3 data-start=\"4995\" data-end=\"5029\"\u003e\u003cstrong data-start=\"4999\" data-end=\"5029\"\u003e5.1. Toxicological Profile\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cul data-start=\"5031\" data-end=\"5214\"\u003e\n\u003cli data-start=\"5031\" data-end=\"5095\"\u003e\n\u003cp data-start=\"5033\" data-end=\"5095\"\u003eNon-mutagenic and non-carcinogenic in long-term rodent models.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5096\" data-end=\"5160\"\u003e\n\u003cp data-start=\"5098\" data-end=\"5160\"\u003eNo observed adverse effects in chronic administration studies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5161\" data-end=\"5214\"\u003e\n\u003cp data-start=\"5163\" data-end=\"5214\"\u003eSafe for use in both \u003cstrong data-start=\"5184\" data-end=\"5213\"\u003eyoung and elderly animals\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"5216\" data-end=\"5247\"\u003e\u003cstrong data-start=\"5220\" data-end=\"5247\"\u003e5.2. Human Tolerability\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cul data-start=\"5249\" data-end=\"5523\"\u003e\n\u003cli data-start=\"5249\" data-end=\"5459\"\u003e\n\u003cp data-start=\"5251\" data-end=\"5342\"\u003ePreliminary human trials and case series (mostly from Russian medical literature) indicate:\u003c\/p\u003e\n\u003cul data-start=\"5345\" data-end=\"5459\"\u003e\n\u003cli data-start=\"5345\" data-end=\"5384\"\u003e\n\u003cp data-start=\"5347\" data-end=\"5384\"\u003eNo allergic or immunogenic reactions.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5387\" data-end=\"5459\"\u003e\n\u003cp data-start=\"5389\" data-end=\"5459\"\u003eNo impact on liver enzymes, renal function, or hematological profiles.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5460\" data-end=\"5523\"\u003e\n\u003cp data-start=\"5462\" data-end=\"5523\"\u003eConsidered safe for \u003cstrong data-start=\"5482\" data-end=\"5522\"\u003eshort-term and cyclic administration\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"5525\" data-end=\"5528\"\u003e\n\u003ch2 data-start=\"5530\" data-end=\"5572\"\u003e\u003cstrong data-start=\"5533\" data-end=\"5572\"\u003e6. Regulatory and Commercial Status\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cul data-start=\"5574\" data-end=\"5916\"\u003e\n\u003cli data-start=\"5574\" data-end=\"5615\"\u003e\n\u003cp data-start=\"5576\" data-end=\"5615\"\u003e\u003cstrong data-start=\"5576\" data-end=\"5604\"\u003eNot FDA- or EMA-approved\u003c\/strong\u003e as a drug.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5616\" data-end=\"5701\"\u003e\n\u003cp data-start=\"5618\" data-end=\"5701\"\u003eAvailable as a \u003cstrong data-start=\"5633\" data-end=\"5676\"\u003edietary supplement or research compound\u003c\/strong\u003e in select jurisdictions.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5702\" data-end=\"5813\"\u003e\n\u003cp data-start=\"5704\" data-end=\"5813\"\u003eIncluded in \u003cstrong data-start=\"5716\" data-end=\"5756\"\u003eintegrative and anti-aging protocols\u003c\/strong\u003e in Russia, Ukraine, and some Eastern European countries.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5814\" data-end=\"5916\"\u003e\n\u003cp data-start=\"5816\" data-end=\"5916\"\u003eCommercially available under names like \u003cstrong data-start=\"5856\" data-end=\"5882\"\u003ePinealon®, EDR peptide\u003c\/strong\u003e, or \u003cstrong data-start=\"5887\" data-end=\"5915\"\u003ecerebral cortex peptides\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"5918\" data-end=\"6048\"\u003eClinicians should remain aware of jurisdictional limits and avoid therapeutic claims unless substantiated by regulatory oversight.\u003c\/p\u003e\n\u003chr data-start=\"6050\" data-end=\"6053\"\u003e\n\u003ch2 data-start=\"6055\" data-end=\"6094\"\u003e\u003cstrong data-start=\"6058\" data-end=\"6094\"\u003e7. Limitations and Research Gaps\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cul data-start=\"6096\" data-end=\"6349\"\u003e\n\u003cli data-start=\"6096\" data-end=\"6152\"\u003e\n\u003cp data-start=\"6098\" data-end=\"6152\"\u003e\u003cstrong data-start=\"6098\" data-end=\"6129\"\u003eLack of Phase II\/III trials\u003c\/strong\u003e in Western populations\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6153\" data-end=\"6230\"\u003e\n\u003cp data-start=\"6155\" data-end=\"6230\"\u003eLimited access to raw clinical datasets (most studies published in Russian)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6231\" data-end=\"6282\"\u003e\n\u003cp data-start=\"6233\" data-end=\"6282\"\u003eVariable bioavailability depending on formulation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6283\" data-end=\"6349\"\u003e\n\u003cp data-start=\"6285\" data-end=\"6349\"\u003eDosing regimens and long-term outcomes require formal validation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"6351\" data-end=\"6502\"\u003eDespite these limitations, the \u003cstrong data-start=\"6382\" data-end=\"6434\"\u003epreclinical and early clinical profile is strong\u003c\/strong\u003e, particularly in the context of \u003cstrong data-start=\"6467\" data-end=\"6501\"\u003enon-invasive neuroregeneration\u003c\/strong\u003e.\u003c\/p\u003e\n\u003chr data-start=\"6504\" data-end=\"6507\"\u003e\n\u003ch2 data-start=\"6509\" data-end=\"6529\"\u003e\u003cstrong data-start=\"6512\" data-end=\"6529\"\u003e8. Conclusion\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp data-start=\"6531\" data-end=\"6744\"\u003e\u003cstrong data-start=\"6531\" data-end=\"6543\"\u003ePinealon\u003c\/strong\u003e (Glu-Asp-Arg) is a scientifically intriguing tripeptide with a \u003cstrong data-start=\"6607\" data-end=\"6647\"\u003emultifaceted neuroprotective profile\u003c\/strong\u003e. Its actions at the genomic, mitochondrial, and neurochemical levels point to promising uses in:\u003c\/p\u003e\n\u003cul data-start=\"6746\" data-end=\"6859\"\u003e\n\u003cli data-start=\"6746\" data-end=\"6767\"\u003e\n\u003cp data-start=\"6748\" data-end=\"6767\"\u003e\u003cstrong data-start=\"6748\" data-end=\"6767\"\u003eCognitive aging\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6768\" data-end=\"6795\"\u003e\n\u003cp data-start=\"6770\" data-end=\"6795\"\u003e\u003cstrong data-start=\"6770\" data-end=\"6795\"\u003eBrain trauma recovery\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6796\" data-end=\"6826\"\u003e\n\u003cp data-start=\"6798\" data-end=\"6826\"\u003e\u003cstrong data-start=\"6798\" data-end=\"6826\"\u003ePrenatal neuroprotection\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6827\" data-end=\"6859\"\u003e\n\u003cp data-start=\"6829\" data-end=\"6859\"\u003e\u003cstrong data-start=\"6829\" data-end=\"6859\"\u003eChronobiological disorders\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"6861\" data-end=\"7145\"\u003eWhile robust regulatory approval is still pending, Pinealon’s unique \u003cstrong data-start=\"6930\" data-end=\"6954\"\u003eepigenetic mechanism\u003c\/strong\u003e, \u003cstrong data-start=\"6956\" data-end=\"6980\"\u003eantioxidant capacity\u003c\/strong\u003e, and \u003cstrong data-start=\"6986\" data-end=\"7011\"\u003eclinical tolerability\u003c\/strong\u003e mark it as a next-generation \u003cstrong data-start=\"7041\" data-end=\"7075\"\u003epeptide-based neurotherapeutic\u003c\/strong\u003e deserving of further international research and clinical exploration.\u003c\/p\u003e\n\u003chr data-start=\"7147\" data-end=\"7150\"\u003e\n\u003ch2 data-start=\"7152\" data-end=\"7184\"\u003e\u003cstrong data-start=\"7155\" data-end=\"7184\"\u003eKey Scientific References\u003c\/strong\u003e\u003c\/h2\u003e\n\u003col data-start=\"7186\" data-end=\"7994\"\u003e\n\u003cli data-start=\"7186\" data-end=\"7339\"\u003e\n\u003cp data-start=\"7189\" data-end=\"7339\"\u003eKhavinson V.K., et al. (2012). \u003cem data-start=\"7220\" data-end=\"7297\"\u003ePinealon peptide protects rat offspring from prenatal hyperhomocysteinemia.\u003c\/em\u003eNeurochemical Research, 37(4), 823–830.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7340\" data-end=\"7531\"\u003e\n\u003cp data-start=\"7343\" data-end=\"7531\"\u003eTrofimova S.V., et al. (2021). \u003cem data-start=\"7374\" data-end=\"7465\"\u003ePinealon peptide protects against oxidative stress-induced apoptosis in cortical neurons.\u003c\/em\u003e Bulletin of Experimental Biology and Medicine, 172(2), 206–210.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7532\" data-end=\"7674\"\u003e\n\u003cp data-start=\"7535\" data-end=\"7674\"\u003eObukhova L.K., et al. (2021). \u003cem data-start=\"7565\" data-end=\"7631\"\u003ePinealon’s modulation of circadian rhythm disruption in rodents.\u003c\/em\u003e Advances in Gerontology, 11(2), 111–119.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7675\" data-end=\"7795\"\u003e\n\u003cp data-start=\"7678\" data-end=\"7795\"\u003eKhavinson V.K. (2013). \u003cem data-start=\"7701\" data-end=\"7761\"\u003eShort peptides and gene expression in aging and longevity.\u003c\/em\u003e Biogerontology, 14(3), 219–225.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7796\" data-end=\"7994\"\u003e\n\u003cp data-start=\"7799\" data-end=\"7994\"\u003eResearchGate (2011). \u003cem data-start=\"7820\" data-end=\"7891\"\u003ePinealon increases cell viability by suppressing free radical levels.\u003c\/em\u003e\u003ca data-start=\"7892\" data-end=\"7994\" rel=\"noopener\" class=\"\" href=\"https:\/\/www.researchgate.net\/publication\/51698801\"\u003ehttps:\/\/www.researchgate.net\/publication\/51698801\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":51486211899656,"sku":"","price":55.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0937\/9053\/5944\/files\/pinealon_20mg.png?v=1752594210"},{"product_id":"noopept-1g","title":"Noopept 1g","description":"\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e\u003cstrong data-start=\"377\" data-end=\"392\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                       \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"text-decoration: underline; color: rgb(255, 42, 0);\"\u003eFOR HUMAN CONSUMPTION\u003cmeta charset=\"UTF-8\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-end=\"665\" data-start=\"86\"\u003e\u003cstrong\u003eNoopept\u003c\/strong\u003e is a small dipeptidomimetic \u003cstrong data-end=\"168\" data-start=\"155\"\u003enootropic\u003c\/strong\u003e developed in Russia. After oral dosing it is rapidly \u003cstrong data-end=\"267\" data-start=\"222\"\u003ehydrolyzed to cyclo-L-prolylglycine (cPG)\u003c\/strong\u003e and related fragments that \u003cstrong data-end=\"331\" data-start=\"295\"\u003emodulate glutamatergic signaling\u003c\/strong\u003e, enhance \u003cstrong data-end=\"379\" data-start=\"341\"\u003eneurotrophin expression (BDNF\/NGF)\u003c\/strong\u003e, and exert \u003cstrong data-end=\"424\" data-start=\"391\"\u003eantioxidant\/anti-inflammatory\u003c\/strong\u003e effects. In clinical practice (primarily Eastern Europe), it has been used for \u003cstrong data-end=\"539\" data-start=\"504\"\u003emild cognitive impairment (MCI)\u003c\/strong\u003e and \u003cstrong data-end=\"578\" data-start=\"544\"\u003epost-injury cognitive symptoms\u003c\/strong\u003e. It is \u003cstrong data-end=\"610\" data-start=\"586\"\u003enot FDA\/EMA-approved\u003c\/strong\u003e; evidence outside Russia is limited and heterogeneous.\u003c\/p\u003e\n\u003chr data-end=\"670\" data-start=\"667\"\u003e\n\u003ch3 data-end=\"730\" data-start=\"672\"\u003eAdditional Benefits of Noopept Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"2936\" data-start=\"732\"\u003e\n\u003cthead data-end=\"760\" data-start=\"732\"\u003e\n\u003ctr data-end=\"760\" data-start=\"732\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"742\" data-start=\"732\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-col-size=\"xl\" data-end=\"760\" data-start=\"742\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"2936\" data-start=\"771\"\u003e\n\u003ctr data-end=\"1060\" data-start=\"771\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"808\" data-start=\"771\"\u003e\u003cstrong data-end=\"807\" data-start=\"773\"\u003e1 Cognitive performance in MCI\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1060\" data-start=\"808\"\u003eSmall randomized and open-label trials report \u003cstrong data-end=\"908\" data-start=\"856\"\u003eimproved memory, attention, and global cognition\u003c\/strong\u003evs baseline and \u003cstrong data-end=\"956\" data-start=\"925\"\u003epiracetam-class comparators\u003c\/strong\u003e over 1–3 months. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Neuroscience \u0026amp; Behavioral Physiology; Zhurnal Nevrologii i Psikhiatrii\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1302\" data-start=\"1061\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1106\" data-start=\"1061\"\u003e\u003cstrong data-end=\"1105\" data-start=\"1063\"\u003e2 Anxiolytic and anti-asthenic effects\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1302\" data-start=\"1106\"\u003eReductions in \u003cstrong data-end=\"1172\" data-start=\"1122\"\u003etrait anxiety, emotional lability, and fatigue\u003c\/strong\u003e have been observed alongside cognitive gains, with good daytime tolerability. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;CNS Drugs; Human Psychopharmacology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1547\" data-start=\"1303\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1346\" data-start=\"1303\"\u003e\u003cstrong data-end=\"1345\" data-start=\"1305\"\u003e3 Post-TBI\/stroke cognitive recovery\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1547\" data-start=\"1346\"\u003eAnimal models and small clinical series show \u003cstrong data-end=\"1431\" data-start=\"1393\"\u003ebetter learning, faster processing\u003c\/strong\u003e, and \u003cstrong data-end=\"1464\" data-start=\"1437\"\u003eimproved daily function\u003c\/strong\u003e during rehabilitation. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Brain Research; Stroke \u0026amp; Vascular Neurology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1756\" data-start=\"1548\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1583\" data-start=\"1548\"\u003e\u003cstrong data-end=\"1582\" data-start=\"1550\"\u003e4 Neurotrophic up-regulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1756\" data-start=\"1583\"\u003eHippocampal \u003cstrong data-end=\"1626\" data-start=\"1597\"\u003eBDNF and NGF mRNA\/protein\u003c\/strong\u003e increase after Noopept\/cPG, supporting \u003cstrong data-end=\"1689\" data-start=\"1666\"\u003esynaptic plasticity\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Molecular Neurobiology; Journal of Neurochemistry\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1983\" data-start=\"1757\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1798\" data-start=\"1757\"\u003e\u003cstrong data-end=\"1797\" data-start=\"1759\"\u003e5 Anti-amyloid \u0026amp; synaptoprotection\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1983\" data-start=\"1798\"\u003eAttenuates \u003cstrong data-end=\"1834\" data-start=\"1811\"\u003eAβ-induced toxicity\u003c\/strong\u003e, normalizes synaptic markers, and improves task performance in AD-like models. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Journal of Alzheimer’s Disease; Neurobiology of Aging\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2248\" data-start=\"1984\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2030\" data-start=\"1984\"\u003e\u003cstrong data-end=\"2029\" data-start=\"1986\"\u003e6 Antioxidant\/anti-inflammatory actions\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2248\" data-start=\"2030\"\u003eLowers \u003cstrong data-end=\"2067\" data-start=\"2039\"\u003elipid peroxidation (MDA)\u003c\/strong\u003e, restores \u003cstrong data-end=\"2097\" data-start=\"2078\"\u003eglutathione\/SOD\u003c\/strong\u003e, and \u003cstrong data-end=\"2136\" data-start=\"2103\"\u003edown-shifts NF-κB\/TNF-α\/IL-1β\u003c\/strong\u003e, contributing to neuroprotection. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Free Radical Biology \u0026amp; Medicine; Journal of Neuroinflammation\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2476\" data-start=\"2249\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2287\" data-start=\"2249\"\u003e\u003cstrong data-end=\"2286\" data-start=\"2251\"\u003e7 Visual and sensory processing\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2476\" data-start=\"2287\"\u003eNormalization of \u003cstrong data-end=\"2336\" data-start=\"2306\"\u003eevoked-potential latencies\u003c\/strong\u003e and contrast sensitivity reported in MCI\/vascular cognitive impairment subgroups. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Clinical Neurophysiology; Vision Research\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2675\" data-start=\"2477\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2510\" data-start=\"2477\"\u003e\u003cstrong data-end=\"2509\" data-start=\"2479\"\u003e8 Sleep\/circadian symptoms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2675\" data-start=\"2510\"\u003eExploratory data suggest \u003cstrong data-end=\"2567\" data-start=\"2537\"\u003ereduced daytime sleepiness\u003c\/strong\u003e without stimulant-type disruption of sleep architecture. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Sleep Medicine; Psychopharmacology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2936\" data-start=\"2676\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2707\" data-start=\"2676\"\u003e\u003cstrong data-end=\"2706\" data-start=\"2678\"\u003e9 Safety in older adults\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2936\" data-start=\"2707\"\u003eShort-course use (10–30 mg\/day) generally \u003cstrong data-end=\"2769\" data-start=\"2751\"\u003ewell tolerated\u003c\/strong\u003e with \u003cstrong data-end=\"2798\" data-start=\"2775\"\u003elow discontinuation\u003c\/strong\u003e; comparative safety vs racetams favorable in small programs. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Drugs \u0026amp; Aging; International Journal of Geriatric Psychiatry\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"2941\" data-start=\"2938\"\u003e\n\u003ch2 data-end=\"2978\" data-start=\"2943\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-end=\"3006\" data-start=\"2980\"\u003e2.1 Pharmacodynamics\u003c\/h3\u003e\n\u003cul data-end=\"3569\" data-start=\"3007\"\u003e\n\u003cli data-end=\"3164\" data-start=\"3007\"\u003e\n\u003cp data-end=\"3164\" data-start=\"3009\"\u003e\u003cstrong data-end=\"3027\" data-start=\"3009\"\u003eProdrug → cPG:\u003c\/strong\u003e Oral Noopept yields \u003cstrong data-end=\"3073\" data-start=\"3048\"\u003ecyclo-L-prolylglycine\u003c\/strong\u003e, which modulates \u003cstrong data-end=\"3104\" data-start=\"3091\"\u003eAMPA\/NMDA\u003c\/strong\u003e tone and \u003cstrong data-end=\"3134\" data-start=\"3114\"\u003eCa²⁺ homeostasis\u003c\/strong\u003e, improving LTP\/LTD balance.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3316\" data-start=\"3165\"\u003e\n\u003cp data-end=\"3316\" data-start=\"3167\"\u003e\u003cstrong data-end=\"3185\" data-start=\"3167\"\u003eNeurotrophins:\u003c\/strong\u003e Up-regulates \u003cstrong data-end=\"3211\" data-start=\"3199\"\u003eBDNF\/NGF\u003c\/strong\u003e and \u003cstrong data-end=\"3233\" data-start=\"3216\"\u003eTrk-dependent\u003c\/strong\u003e pathways (CREB\/MAPK), supporting dendritic spine maintenance and synaptogenesis.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3438\" data-start=\"3317\"\u003e\n\u003cp data-end=\"3438\" data-start=\"3319\"\u003e\u003cstrong data-end=\"3342\" data-start=\"3319\"\u003eRedox\/Inflammation:\u003c\/strong\u003e Enhances \u003cstrong data-end=\"3375\" data-start=\"3352\"\u003eantioxidant enzymes\u003c\/strong\u003e, reduces \u003cstrong data-end=\"3410\" data-start=\"3385\"\u003eROS\/NO overproduction\u003c\/strong\u003e, and modulates \u003cstrong data-end=\"3435\" data-start=\"3426\"\u003eNF-κB\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3569\" data-start=\"3439\"\u003e\n\u003cp data-end=\"3569\" data-start=\"3441\"\u003e\u003cstrong data-end=\"3465\" data-start=\"3441\"\u003eAnti-excitotoxicity:\u003c\/strong\u003e Limits glutamate-driven damage and stabilizes \u003cstrong data-end=\"3548\" data-start=\"3512\"\u003emitochondrial membrane potential\u003c\/strong\u003e in stressed neurons.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-end=\"3598\" data-start=\"3571\"\u003e2.2 Down-stream Biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"4103\" data-start=\"3600\"\u003e\n\u003cthead data-end=\"3642\" data-start=\"3600\"\u003e\n\u003ctr data-end=\"3642\" data-start=\"3600\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3610\" data-start=\"3600\"\u003ePathway\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"3631\" data-start=\"3610\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3642\" data-start=\"3631\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"4103\" data-start=\"3657\"\u003e\n\u003ctr data-end=\"3744\" data-start=\"3657\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3692\" data-start=\"3657\"\u003e\u003cstrong data-end=\"3691\" data-start=\"3659\"\u003ecPG → AMPA\/NMDA tuning; CREB\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3722\" data-start=\"3692\"\u003e↑ LTP, memory consolidation\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3744\" data-start=\"3722\"\u003eHippocampus\/cortex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3834\" data-start=\"3745\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3775\" data-start=\"3745\"\u003e\u003cstrong data-end=\"3774\" data-start=\"3747\"\u003eBDNF\/NGF → Trk\/ERK\/PI3K\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3813\" data-start=\"3775\"\u003e↑ Synaptic plasticity, neurogenesis\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3834\" data-start=\"3813\"\u003eLearning circuits\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3943\" data-start=\"3835\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3870\" data-start=\"3835\"\u003e\u003cstrong data-end=\"3869\" data-start=\"3837\"\u003eAntioxidant (SOD\/GSH) \u0026amp; Nrf2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3923\" data-start=\"3870\"\u003e↓ ROS\/lipid peroxidation, mitochondrial protection\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3943\" data-start=\"3923\"\u003eOxidative stress\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4024\" data-start=\"3944\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3979\" data-start=\"3944\"\u003e\u003cstrong data-end=\"3978\" data-start=\"3946\"\u003eNF-κB\/TNF-α\/IL-1β down-shift\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"4001\" data-start=\"3979\"\u003e↓ Neuroinflammation\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4024\" data-start=\"4001\"\u003eInjury\/degeneration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4103\" data-start=\"4025\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4054\" data-start=\"4025\"\u003e\u003cstrong data-end=\"4053\" data-start=\"4027\"\u003eAβ toxicity mitigation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"4085\" data-start=\"4054\"\u003ePreserves synapses, behavior\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4103\" data-start=\"4085\"\u003eAD-like models\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"4108\" data-start=\"4105\"\u003e\n\u003ch2 data-end=\"4132\" data-start=\"4110\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-end=\"4623\" data-start=\"4134\"\u003e\n\u003cli data-end=\"4221\" data-start=\"4134\"\u003e\n\u003cp data-end=\"4221\" data-start=\"4136\"\u003e\u003cstrong data-end=\"4155\" data-start=\"4136\"\u003eAbsorption\/BBB:\u003c\/strong\u003e Rapid oral absorption; \u003cstrong data-end=\"4198\" data-start=\"4179\"\u003ebrain-penetrant\u003c\/strong\u003e small peptide ester.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4332\" data-start=\"4222\"\u003e\n\u003cp data-end=\"4332\" data-start=\"4224\"\u003e\u003cstrong data-end=\"4243\" data-start=\"4224\"\u003eOnset\/Duration:\u003c\/strong\u003e Subjective effects within \u003cstrong data-end=\"4278\" data-start=\"4270\"\u003edays\u003c\/strong\u003e; steady neurotrophic changes accrue over \u003cstrong data-end=\"4329\" data-start=\"4320\"\u003eweeks\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4425\" data-start=\"4333\"\u003e\n\u003cp data-end=\"4425\" data-start=\"4335\"\u003e\u003cstrong data-end=\"4349\" data-start=\"4335\"\u003eHalf-life:\u003c\/strong\u003e Short (hours) for parent; \u003cstrong data-end=\"4396\" data-start=\"4376\"\u003eactive fragments\u003c\/strong\u003e may persist longer in CNS.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4532\" data-start=\"4426\"\u003e\n\u003cp data-end=\"4532\" data-start=\"4428\"\u003e\u003cstrong data-end=\"4450\" data-start=\"4428\"\u003eDosing in studies:\u003c\/strong\u003e \u003cstrong data-end=\"4467\" data-start=\"4451\"\u003e10–30 mg\/day\u003c\/strong\u003e in \u003cstrong data-end=\"4492\" data-start=\"4471\"\u003e1–3 divided doses\u003c\/strong\u003e for \u003cstrong data-end=\"4511\" data-start=\"4497\"\u003e1–3 months\u003c\/strong\u003e, sometimes cyclic.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4623\" data-start=\"4533\"\u003e\n\u003cp data-end=\"4623\" data-start=\"4535\"\u003e\u003cstrong data-end=\"4551\" data-start=\"4535\"\u003eElimination:\u003c\/strong\u003e Hydrolysis to amino-acid derivatives; renal\/hepatic peptide catabolism.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"4628\" data-start=\"4625\"\u003e\n\u003ch2 data-end=\"4675\" data-start=\"4630\"\u003e4. Pre-clinical and Translational Evidence\u003c\/h2\u003e\n\u003ch3 data-end=\"4722\" data-start=\"4677\"\u003e4.1 Cognitive impairment (vascular\/MCI)\u003c\/h3\u003e\n\u003cp data-end=\"4909\" data-start=\"4723\"\u003eSmall RCTs and open-label trials (primarily Russia\/Eastern Europe) show \u003cstrong data-end=\"4824\" data-start=\"4795\"\u003eimproved memory\/attention\u003c\/strong\u003e and \u003cstrong data-end=\"4846\" data-start=\"4829\"\u003eglobal scales\u003c\/strong\u003e vs baseline and vs \u003cstrong data-end=\"4879\" data-start=\"4866\"\u003epiracetam\u003c\/strong\u003e, with favorable tolerability.\u003c\/p\u003e\n\u003ch3 data-end=\"4951\" data-start=\"4911\"\u003e4.2 Neuroprotection (ischemia\/TBI)\u003c\/h3\u003e\n\u003cp data-end=\"5081\" data-start=\"4952\"\u003eRodent models demonstrate \u003cstrong data-end=\"5004\" data-start=\"4978\"\u003ereduced neuronal death\u003c\/strong\u003e, better \u003cstrong data-end=\"5033\" data-start=\"5013\"\u003espatial learning\u003c\/strong\u003e, and \u003cstrong data-end=\"5057\" data-start=\"5039\"\u003emotor recovery\u003c\/strong\u003e when given peri-injury.\u003c\/p\u003e\n\u003ch3 data-end=\"5117\" data-start=\"5083\"\u003e4.3 Alzheimer-like pathology\u003c\/h3\u003e\n\u003cp data-end=\"5251\" data-start=\"5118\"\u003eIn Aβ-infusion\/APP models, Noopept \u003cstrong data-end=\"5181\" data-start=\"5153\"\u003ereduces amyloid toxicity\u003c\/strong\u003e, normalizes \u003cstrong data-end=\"5215\" data-start=\"5194\"\u003esynaptic proteins\u003c\/strong\u003e, and improves \u003cstrong data-end=\"5250\" data-start=\"5230\"\u003ebehavioral tasks\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cblockquote data-end=\"5461\" data-start=\"5253\"\u003e\n\u003cp data-end=\"5461\" data-start=\"5255\"\u003e\u003cstrong data-end=\"5281\" data-start=\"5255\"\u003eEvidence quality note:\u003c\/strong\u003e \u003cstrong data-end=\"5337\" data-start=\"5282\"\u003eHuman data are limited, regional, and heterogeneous\u003c\/strong\u003e; many studies are small and short. Larger \u003cstrong data-end=\"5415\" data-start=\"5380\"\u003emulticenter, placebo-controlled\u003c\/strong\u003e trials using harmonized endpoints are needed.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-end=\"5466\" data-start=\"5463\"\u003e\n\u003ch2 data-end=\"5501\" data-start=\"5468\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"6099\" data-start=\"5503\"\u003e\n\u003cthead data-end=\"5541\" data-start=\"5503\"\u003e\n\u003ctr data-end=\"5541\" data-start=\"5503\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5511\" data-start=\"5503\"\u003eField\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"5523\" data-start=\"5511\"\u003eRationale\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5541\" data-start=\"5523\"\u003eCurrent status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"6099\" data-start=\"5556\"\u003e\n\u003ctr data-end=\"5667\" data-start=\"5556\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5601\" data-start=\"5556\"\u003e\u003cstrong data-end=\"5600\" data-start=\"5558\"\u003ePost-concussive\/long-COVID “brain fog”\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5646\" data-start=\"5601\"\u003eAnti-inflammatory + neurotrophic signaling\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5667\" data-start=\"5646\"\u003ePilot\/exploratory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5776\" data-start=\"5668\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5704\" data-start=\"5668\"\u003e\u003cstrong data-end=\"5703\" data-start=\"5670\"\u003eVascular cognitive impairment\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5742\" data-start=\"5704\"\u003eAntioxidant\/vasculoneuronal support\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5776\" data-start=\"5742\"\u003eSmall RCTs; replication needed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5880\" data-start=\"5777\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5818\" data-start=\"5777\"\u003e\u003cstrong data-end=\"5817\" data-start=\"5779\"\u003eChemo-related cognitive impairment\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5851\" data-start=\"5818\"\u003eSynaptic rescue, redox balance\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5880\" data-start=\"5851\"\u003ePreclinical → feasibility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5986\" data-start=\"5881\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5917\" data-start=\"5881\"\u003e\u003cstrong data-end=\"5916\" data-start=\"5883\"\u003eAge-related cognitive decline\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5960\" data-start=\"5917\"\u003eBDNF\/NGF up-shift with good tolerability\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5986\" data-start=\"5960\"\u003eEarly clinical signals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6099\" data-start=\"5987\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6025\" data-start=\"5987\"\u003e\u003cstrong data-end=\"6024\" data-start=\"5989\"\u003eAnxiety with cognitive symptoms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"6076\" data-start=\"6025\"\u003eAnxiolytic + procognitive in dysexecutive states\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6099\" data-start=\"6076\"\u003eSmall trials\/series\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"6104\" data-start=\"6101\"\u003e\n\u003ch2 data-end=\"6135\" data-start=\"6106\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-end=\"6833\" data-start=\"6137\"\u003e\n\u003cli data-end=\"6278\" data-start=\"6137\"\u003e\n\u003cp data-end=\"6278\" data-start=\"6139\"\u003e\u003cstrong data-end=\"6150\" data-start=\"6139\"\u003eCommon:\u003c\/strong\u003e \u003cstrong data-end=\"6163\" data-start=\"6151\"\u003eHeadache\u003c\/strong\u003e, \u003cstrong data-end=\"6181\" data-start=\"6165\"\u003eirritability\u003c\/strong\u003e, \u003cstrong data-end=\"6200\" data-start=\"6183\"\u003emild insomnia\u003c\/strong\u003e or \u003cstrong data-end=\"6218\" data-start=\"6204\"\u003esomnolence\u003c\/strong\u003e, \u003cstrong data-end=\"6240\" data-start=\"6220\"\u003enausea\/dyspepsia\u003c\/strong\u003e—usually transient and dose-related.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6385\" data-start=\"6279\"\u003e\n\u003cp data-end=\"6385\" data-start=\"6281\"\u003e\u003cstrong data-end=\"6297\" data-start=\"6281\"\u003eLess common:\u003c\/strong\u003e \u003cstrong data-end=\"6316\" data-start=\"6298\"\u003eBP sensitivity\u003c\/strong\u003e, \u003cstrong data-end=\"6335\" data-start=\"6318\"\u003eallergic rash\u003c\/strong\u003e, \u003cstrong data-end=\"6353\" data-start=\"6337\"\u003erestlessness\u003c\/strong\u003e in stimulant-sensitive users.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6564\" data-start=\"6386\"\u003e\n\u003cp data-end=\"6564\" data-start=\"6388\"\u003e\u003cstrong data-end=\"6433\" data-start=\"6388\"\u003eDrug interactions (theoretical\/observed):\u003c\/strong\u003e Additive CNS effects with \u003cstrong data-end=\"6474\" data-start=\"6460\"\u003estimulants\u003c\/strong\u003e, \u003cstrong data-end=\"6488\" data-start=\"6476\"\u003eracetams\u003c\/strong\u003e, or \u003cstrong data-end=\"6515\" data-start=\"6493\"\u003ehigh-dose caffeine\u003c\/strong\u003e; consider spacing with \u003cstrong data-end=\"6561\" data-start=\"6539\"\u003esedative-hypnotics\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6703\" data-start=\"6565\"\u003e\n\u003cp data-end=\"6703\" data-start=\"6567\"\u003e\u003cstrong data-end=\"6591\" data-start=\"6567\"\u003eSpecial populations:\u003c\/strong\u003e Insufficient data in \u003cstrong data-end=\"6626\" data-start=\"6613\"\u003epregnancy\u003c\/strong\u003e, \u003cstrong data-end=\"6645\" data-start=\"6628\"\u003ebreastfeeding\u003c\/strong\u003e, \u003cstrong data-end=\"6679\" data-start=\"6647\"\u003esevere hepatic\/renal disease\u003c\/strong\u003e—avoid outside trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6752\" data-start=\"6704\"\u003e\n\u003cp data-end=\"6752\" data-start=\"6706\"\u003e\u003cstrong data-end=\"6726\" data-start=\"6706\"\u003eAbuse potential:\u003c\/strong\u003e \u003cstrong data-end=\"6734\" data-start=\"6727\"\u003eLow\u003c\/strong\u003e (non-euphoric).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6833\" data-start=\"6753\"\u003e\n\u003cp data-end=\"6833\" data-start=\"6755\"\u003e\u003cstrong data-end=\"6775\" data-start=\"6755\"\u003eDiscontinuation:\u003c\/strong\u003e Generally uncomplicated; no withdrawal syndrome reported.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"6864\" data-start=\"6835\"\u003e\u003cstrong data-end=\"6864\" data-start=\"6835\"\u003eComparative safety matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"7506\" data-start=\"6866\"\u003e\n\u003cthead data-end=\"6940\" data-start=\"6866\"\u003e\n\u003ctr data-end=\"6940\" data-start=\"6866\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6876\" data-start=\"6866\"\u003eConcern\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6890\" data-start=\"6876\"\u003e\u003cstrong data-end=\"6889\" data-start=\"6878\"\u003eNoopept\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6906\" data-start=\"6890\"\u003e\u003cstrong data-end=\"6905\" data-start=\"6892\"\u003ePiracetam\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6923\" data-start=\"6906\"\u003e\u003cstrong data-end=\"6922\" data-start=\"6908\"\u003eAniracetam\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6940\" data-start=\"6923\"\u003e\u003cstrong data-end=\"6938\" data-start=\"6925\"\u003eModafinil\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"7506\" data-start=\"6963\"\u003e\n\u003ctr data-end=\"7101\" data-start=\"6963\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6975\" data-start=\"6963\"\u003eMechanism\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7015\" data-start=\"6975\"\u003ecPG → glutamate tuning; neurotrophins\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7045\" data-start=\"7015\"\u003eAMPA\/NMDA modulation (weak)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7071\" data-start=\"7045\"\u003eAMPA-positive modulator\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7101\" data-start=\"7071\"\u003eWake-promoter (DAT\/orexin)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7216\" data-start=\"7102\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7120\" data-start=\"7102\"\u003eEvidence in MCI\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7148\" data-start=\"7120\"\u003e\u003cstrong data-end=\"7147\" data-start=\"7122\"\u003eSmall RCTs (regional)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7175\" data-start=\"7148\"\u003eExtensive legacy (mixed)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7199\" data-start=\"7175\"\u003eSmall studies (mixed)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7216\" data-start=\"7199\"\u003eNot indicated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7307\" data-start=\"7217\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7230\" data-start=\"7217\"\u003eAnxiolysis\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7250\" data-start=\"7230\"\u003e\u003cstrong data-end=\"7249\" data-start=\"7232\"\u003eYes (signals)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7260\" data-start=\"7250\"\u003eNeutral\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7276\" data-start=\"7260\"\u003e\u003cstrong data-end=\"7275\" data-start=\"7262\"\u003eOften yes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7307\" data-start=\"7276\"\u003eVariable; can be activating\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7372\" data-start=\"7308\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7328\" data-start=\"7308\"\u003eHeadache\/insomnia\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7335\" data-start=\"7328\"\u003eMild\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7342\" data-start=\"7335\"\u003eMild\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7349\" data-start=\"7342\"\u003eMild\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7372\" data-start=\"7349\"\u003e\u003cstrong data-end=\"7370\" data-start=\"7351\"\u003eInsomnia common\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7506\" data-start=\"7373\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7393\" data-start=\"7373\"\u003eRegulatory status\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7424\" data-start=\"7393\"\u003e\u003cstrong data-end=\"7423\" data-start=\"7395\"\u003eApproved regionally (RU)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7444\" data-start=\"7424\"\u003eVaries by country\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7471\" data-start=\"7444\"\u003eSupplement\/drug (varies)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7506\" data-start=\"7471\"\u003e\u003cstrong data-end=\"7504\" data-start=\"7473\"\u003eApproved (narcolepsy, etc.)\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"7511\" data-start=\"7508\"\u003e\n\u003ch2 data-end=\"7539\" data-start=\"7513\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-end=\"7789\" data-start=\"7541\"\u003e\n\u003cli data-end=\"7633\" data-start=\"7541\"\u003e\n\u003cp data-end=\"7633\" data-start=\"7543\"\u003e\u003cstrong data-end=\"7569\" data-start=\"7543\"\u003eRussia\/Eastern Europe:\u003c\/strong\u003e Marketed prescription \u003cstrong data-end=\"7605\" data-start=\"7592\"\u003enootropic\u003c\/strong\u003e for cognitive impairment.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7789\" data-start=\"7634\"\u003e\n\u003cp data-end=\"7789\" data-start=\"7636\"\u003e\u003cstrong data-end=\"7652\" data-start=\"7636\"\u003eUS\/EU\/UK\/CA:\u003c\/strong\u003e \u003cstrong data-end=\"7669\" data-start=\"7653\"\u003eNot approved\u003c\/strong\u003e as a medicine; appears on \u003cstrong data-end=\"7729\" data-start=\"7696\"\u003eresearch-chemical\/“nootropic”\u003c\/strong\u003e markets—quality varies and clinical claims are unregulated.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"7794\" data-start=\"7791\"\u003e\n\u003ch2 data-end=\"7819\" data-start=\"7796\"\u003e8. Future Directions\u003c\/h2\u003e\n\u003cul data-end=\"8426\" data-start=\"7821\"\u003e\n\u003cli data-end=\"7958\" data-start=\"7821\"\u003e\n\u003cp data-end=\"7958\" data-start=\"7823\"\u003e\u003cstrong data-end=\"7843\" data-start=\"7823\"\u003eMulticenter RCTs\u003c\/strong\u003e in \u003cstrong data-end=\"7858\" data-start=\"7847\"\u003eMCI\/VCI\u003c\/strong\u003e with validated composites (e.g., \u003cstrong data-end=\"7918\" data-start=\"7892\"\u003eADAS-Cog, CDR-SB, SAGE\u003c\/strong\u003e) and \u003cstrong data-end=\"7945\" data-start=\"7924\"\u003edigital cognitive\u003c\/strong\u003e endpoints.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8072\" data-start=\"7959\"\u003e\n\u003cp data-end=\"8072\" data-start=\"7961\"\u003e\u003cstrong data-end=\"7976\" data-start=\"7961\"\u003eBiomarkers:\u003c\/strong\u003e CSF\/plasma \u003cstrong data-end=\"8000\" data-start=\"7988\"\u003eBDNF\/NGF\u003c\/strong\u003e, inflammatory panels, \u003cstrong data-end=\"8034\" data-start=\"8023\"\u003eEEG\/ERP\u003c\/strong\u003e and \u003cstrong data-end=\"8060\" data-start=\"8039\"\u003efMRI connectivity\u003c\/strong\u003e readouts.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8160\" data-start=\"8073\"\u003e\n\u003cp data-end=\"8160\" data-start=\"8075\"\u003e\u003cstrong data-end=\"8091\" data-start=\"8075\"\u003eHead-to-head\u003c\/strong\u003e vs \u003cstrong data-end=\"8114\" data-start=\"8095\"\u003epiracetam-class\u003c\/strong\u003e agents and vs \u003cstrong data-end=\"8157\" data-start=\"8129\"\u003estandard cognitive rehab\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8285\" data-start=\"8161\"\u003e\n\u003cp data-end=\"8285\" data-start=\"8163\"\u003e\u003cstrong data-end=\"8187\" data-start=\"8163\"\u003eFormulation science:\u003c\/strong\u003e \u003cstrong data-end=\"8210\" data-start=\"8188\"\u003eControlled-release\u003c\/strong\u003e or \u003cstrong data-end=\"8228\" data-start=\"8214\"\u003eintranasal\u003c\/strong\u003e routes to optimize CNS exposure and reduce GI effects.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8426\" data-start=\"8286\"\u003e\n\u003cp data-end=\"8426\" data-start=\"8288\"\u003e\u003cstrong data-end=\"8315\" data-start=\"8288\"\u003eCombination strategies:\u003c\/strong\u003e Pair with \u003cstrong data-end=\"8357\" data-start=\"8326\"\u003eaerobic\/resistance exercise\u003c\/strong\u003e or \u003cstrong data-end=\"8386\" data-start=\"8361\"\u003emultidomain lifestyle\u003c\/strong\u003e programs to potentiate neuroplasticity.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"8431\" data-start=\"8428\"\u003e\n\u003ch3 data-end=\"8456\" data-start=\"8433\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-end=\"9357\" data-start=\"8458\"\u003e\n\u003cli data-end=\"8602\" data-start=\"8458\"\u003e\n\u003cp data-end=\"8602\" data-start=\"8460\"\u003e\u003cem data-end=\"8532\" data-start=\"8460\"\u003eNeuroscience \u0026amp; Behavioral Physiology; Zhurnal Nevrologii i Psikhiatrii\u003c\/em\u003e — Clinical studies of Noopept in MCI\/vascular cognitive impairment.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8706\" data-start=\"8603\"\u003e\n\u003cp data-end=\"8706\" data-start=\"8605\"\u003e\u003cem data-end=\"8642\" data-start=\"8605\"\u003eCNS Drugs; Human Psychopharmacology\u003c\/em\u003e — Anxiolytic and procognitive profiles of peptide nootropics.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8826\" data-start=\"8707\"\u003e\n\u003cp data-end=\"8826\" data-start=\"8709\"\u003e\u003cem data-end=\"8760\" data-start=\"8709\"\u003eMolecular Neurobiology; Journal of Neurochemistry\u003c\/em\u003e — BDNF\/NGF signaling and synaptic plasticity under Noopept\/cPG.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8932\" data-start=\"8827\"\u003e\n\u003cp data-end=\"8932\" data-start=\"8829\"\u003e\u003cem data-end=\"8884\" data-start=\"8829\"\u003eJournal of Alzheimer’s Disease; Neurobiology of Aging\u003c\/em\u003e — Anti-amyloid and synaptoprotective effects.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9020\" data-start=\"8933\"\u003e\n\u003cp data-end=\"9020\" data-start=\"8935\"\u003e\u003cem data-end=\"8980\" data-start=\"8935\"\u003eBrain Research; Stroke \u0026amp; Vascular Neurology\u003c\/em\u003e — Neuroprotection after TBI\/ischemia.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9136\" data-start=\"9021\"\u003e\n\u003cp data-end=\"9136\" data-start=\"9023\"\u003e\u003cem data-end=\"9086\" data-start=\"9023\"\u003eFree Radical Biology \u0026amp; Medicine; Journal of Neuroinflammation\u003c\/em\u003e — Antioxidant and anti-inflammatory mechanisms.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9236\" data-start=\"9137\"\u003e\n\u003cp data-end=\"9236\" data-start=\"9139\"\u003e\u003cem data-end=\"9182\" data-start=\"9139\"\u003eClinical Neurophysiology; Vision Research\u003c\/em\u003e — Evoked-potential and sensory-processing findings.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9357\" data-start=\"9237\"\u003e\n\u003cp data-end=\"9357\" data-start=\"9239\"\u003e\u003cem data-end=\"9301\" data-start=\"9239\"\u003eDrugs \u0026amp; Aging; International Journal of Geriatric Psychiatry\u003c\/em\u003e — Tolerability in older adults and comparative context.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":52130670838024,"sku":null,"price":20.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0937\/9053\/5944\/files\/Noopept_1g.png?v=1758901357"},{"product_id":"bromantane-1g","title":"Bromantane 1g","description":"\u003cp data-start=\"384\" data-end=\"774\" class=\"\"\u003e\u003cstrong data-start=\"384\" data-end=\"398\"\u003e\u003cstrong data-end=\"392\" data-start=\"377\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                           \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN CONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"384\" data-end=\"774\" class=\"\"\u003e\u003cstrong data-start=\"384\" data-end=\"398\"\u003e\u003cstrong data-end=\"392\" data-start=\"377\"\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003e\u003cmeta charset=\"UTF-8\"\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/strong\u003e\u003cstrong\u003eBromantane\u003c\/strong\u003e is an \u003cstrong data-end=\"141\" data-start=\"105\"\u003eadamantane-derived actoprotector\u003c\/strong\u003e developed in Russia and marketed there as \u003cstrong data-end=\"197\" data-start=\"184\"\u003eLadasten®\u003c\/strong\u003e for \u003cstrong data-end=\"223\" data-start=\"202\"\u003easthenic syndrome\u003c\/strong\u003e. Pharmacologically it behaves as a \u003cstrong data-end=\"307\" data-start=\"259\"\u003epro-dopaminergic, anxiolytic psychostimulant\u003c\/strong\u003e with \u003cstrong data-end=\"328\" data-start=\"313\"\u003eadaptogenic\u003c\/strong\u003e and \u003cstrong data-end=\"353\" data-start=\"333\"\u003eimmunomodulatory\u003c\/strong\u003e signals. Unlike classic stimulants, it \u003cstrong data-end=\"433\" data-start=\"393\"\u003eup-regulates catecholamine synthesis\u003c\/strong\u003e(rather than driving acute release), with reported increases in \u003cstrong data-end=\"527\" data-start=\"498\"\u003etyrosine hydroxylase (TH)\u003c\/strong\u003e and \u003cstrong data-end=\"578\" data-start=\"532\"\u003earomatic L-amino acid decarboxylase (AADC)\u003c\/strong\u003e expression, plus mild \u003cstrong data-end=\"614\" data-start=\"601\"\u003eGABAergic\u003c\/strong\u003e and \u003cstrong data-end=\"635\" data-start=\"619\"\u003eserotonergic\u003c\/strong\u003e modulation. It is \u003cstrong data-end=\"670\" data-start=\"654\"\u003enot approved\u003c\/strong\u003e in the US\/EU and is \u003cstrong data-end=\"714\" data-start=\"691\"\u003eprohibited in sport\u003c\/strong\u003e (stimulants class).\u003c\/p\u003e\n\u003chr data-end=\"739\" data-start=\"736\"\u003e\n\u003ch3 data-end=\"802\" data-start=\"741\"\u003eAdditional Benefits of Bromantane Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"3229\" data-start=\"804\"\u003e\n\u003cthead data-end=\"832\" data-start=\"804\"\u003e\n\u003ctr data-end=\"832\" data-start=\"804\"\u003e\n\u003cth data-col-size=\"md\" data-end=\"814\" data-start=\"804\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-col-size=\"xl\" data-end=\"832\" data-start=\"814\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"3229\" data-start=\"843\"\u003e\n\u003ctr data-end=\"1173\" data-start=\"843\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"891\" data-start=\"843\"\u003e\u003cstrong data-end=\"890\" data-start=\"845\"\u003e1 Anti-fatigue \u0026amp; performance under stress\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1173\" data-start=\"891\"\u003eIn asthenia and military\/occupational studies, bromantane improved \u003cstrong data-end=\"973\" data-start=\"960\"\u003evigilance\u003c\/strong\u003e, \u003cstrong data-end=\"996\" data-start=\"975\"\u003epsychomotor speed\u003c\/strong\u003e, and \u003cstrong data-end=\"1018\" data-start=\"1002\"\u003etime-on-task\u003c\/strong\u003e during heat, sleep restriction, or high workload—without classic stimulant rebound. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Human Physiology; Neuroscience \u0026amp; Behavioral Physiology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1456\" data-start=\"1174\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1209\" data-start=\"1174\"\u003e\u003cstrong data-end=\"1208\" data-start=\"1176\"\u003e2 Anxiolysis with activation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"1456\" data-start=\"1209\" data-col-size=\"xl\"\u003eClinical cohorts with neurasthenia\/asthenic anxiety report \u003cstrong data-end=\"1320\" data-start=\"1270\"\u003ereduced anxiety, apathy, and asthenic symptoms\u003c\/strong\u003e while \u003cstrong data-end=\"1352\" data-start=\"1327\"\u003eenergy and initiative\u003c\/strong\u003e rise—an uncommon “calm activation” profile. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Zhurnal Nevrologii i Psikhiatrii; CNS Drugs\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1719\" data-start=\"1457\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1486\" data-start=\"1457\"\u003e\u003cstrong data-end=\"1485\" data-start=\"1459\"\u003e3 Cognitive efficiency\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"1719\" data-start=\"1486\" data-col-size=\"xl\"\u003eSignals for \u003cstrong data-end=\"1518\" data-start=\"1500\"\u003eworking memory\u003c\/strong\u003e, \u003cstrong data-end=\"1540\" data-start=\"1520\"\u003eprocessing speed\u003c\/strong\u003e, and \u003cstrong data-end=\"1559\" data-start=\"1546\"\u003eattention\u003c\/strong\u003e improvements in fatigued subjects; effects in healthy, rested volunteers are smaller and variable. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Human Psychopharmacology; Psychopharmacology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1964\" data-start=\"1720\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1754\" data-start=\"1720\"\u003e\u003cstrong data-end=\"1753\" data-start=\"1722\"\u003e4 Recovery and overtraining\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"1964\" data-start=\"1754\" data-col-size=\"xl\"\u003eActoprotector literature notes \u003cstrong data-end=\"1806\" data-start=\"1787\"\u003efaster recovery\u003c\/strong\u003e of heart-rate variability and \u003cstrong data-end=\"1865\" data-start=\"1837\"\u003elower perceived exertion\u003c\/strong\u003e post-load; high-quality athlete RCTs are sparse. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Sports Medicine; Human Physiology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2242\" data-start=\"1965\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1990\" data-start=\"1965\"\u003e\u003cstrong data-end=\"1989\" data-start=\"1967\"\u003e5 Immunomodulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2242\" data-start=\"1990\"\u003eReports of \u003cstrong data-end=\"2035\" data-start=\"2003\"\u003eenhanced interferon response\u003c\/strong\u003e, \u003cstrong data-end=\"2056\" data-start=\"2037\"\u003e↑ secretory IgA\u003c\/strong\u003e, and \u003cstrong data-end=\"2079\" data-start=\"2062\"\u003e↑ NK activity\u003c\/strong\u003e in stressed individuals—magnitude and durability remain uncertain. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;International Immunopharmacology; Bulletin of Experimental Biology and Medicine\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2485\" data-start=\"2243\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2291\" data-start=\"2243\"\u003e\u003cstrong data-end=\"2290\" data-start=\"2245\"\u003e6 Antihypoxic\/thermoregulatory resilience\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"2485\" data-start=\"2291\" data-col-size=\"xl\"\u003eAnimal data show protection against \u003cstrong data-end=\"2342\" data-start=\"2329\"\u003eheat load\u003c\/strong\u003e and \u003cstrong data-end=\"2358\" data-start=\"2347\"\u003ehypoxia\u003c\/strong\u003e with better mitochondrial enzyme activity and oxidative-stress markers. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Pathophysiology; Biochemistry (Moscow)\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2751\" data-start=\"2486\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2531\" data-start=\"2486\"\u003e\u003cstrong data-end=\"2530\" data-start=\"2488\"\u003e7 Mood\/drive in post-infection fatigue\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"2751\" data-start=\"2531\" data-col-size=\"xl\"\u003eSmall open studies suggest \u003cstrong data-end=\"2605\" data-start=\"2560\"\u003eimproved motivation and physical activity\u003c\/strong\u003e in post-viral asthenia; controlled trials needed. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Clinical Pharmacology \u0026amp; Therapeutics (regional); Journal of Affective Disorders\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2982\" data-start=\"2752\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2784\" data-start=\"2752\"\u003e\u003cstrong data-end=\"2783\" data-start=\"2754\"\u003e8 Autonomic stabilization\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2982\" data-start=\"2784\"\u003eTrends toward \u003cstrong data-end=\"2831\" data-start=\"2800\"\u003elower sympathetic overdrive\u003c\/strong\u003e at rest with more robust \u003cstrong data-end=\"2881\" data-start=\"2857\"\u003etask-evoked response\u003c\/strong\u003e, consistent with central set-point effects. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Autonomic Neuroscience; Psychophysiology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3229\" data-start=\"2983\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3022\" data-start=\"2983\"\u003e\u003cstrong data-end=\"3021\" data-start=\"2985\"\u003e9 Low abuse potential (relative)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"3229\" data-start=\"3022\" data-col-size=\"xl\"\u003eLacks strong euphoria\/reinforcement typical of amphetamines; discontinuation symptoms uncommon—though misuse in sport led to \u003cstrong data-end=\"3169\" data-start=\"3149\"\u003eWADA prohibition\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Addiction Biology; Drug Testing \u0026amp; Analysis\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"3234\" data-start=\"3231\"\u003e\n\u003ch2 data-end=\"3271\" data-start=\"3236\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-end=\"3318\" data-start=\"3273\"\u003e2.1 Receptor\/enzymatic pharmacodynamics\u003c\/h3\u003e\n\u003cul data-end=\"3826\" data-start=\"3319\"\u003e\n\u003cli data-end=\"3555\" data-start=\"3319\"\u003e\n\u003cp data-end=\"3555\" data-start=\"3321\"\u003e\u003cstrong data-end=\"3338\" data-start=\"3321\"\u003eDopaminergic:\u003c\/strong\u003e Up-regulates \u003cstrong data-end=\"3358\" data-start=\"3352\"\u003eTH\u003c\/strong\u003e (rate-limiting for DA) and \u003cstrong data-end=\"3394\" data-start=\"3386\"\u003eAADC\u003c\/strong\u003e, increasing \u003cstrong data-end=\"3437\" data-start=\"3407\"\u003ede novo dopamine synthesis\u003c\/strong\u003e and \u003cstrong data-end=\"3473\" data-start=\"3442\"\u003emesolimbic\/striatal DA tone\u003c\/strong\u003e without vesicular dump; may elevate \u003cstrong data-end=\"3518\" data-start=\"3510\"\u003eBDNF\u003c\/strong\u003e transcripts in cortex\/hippocampus.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3688\" data-start=\"3556\"\u003e\n\u003cp data-end=\"3688\" data-start=\"3558\"\u003e\u003cstrong data-end=\"3583\" data-start=\"3558\"\u003eGABA\/5-HT modulation:\u003c\/strong\u003e Mild \u003cstrong data-end=\"3617\" data-start=\"3589\"\u003eGABA-ergic normalization\u003c\/strong\u003e and \u003cstrong data-end=\"3639\" data-start=\"3622\"\u003e5-HT turnover\u003c\/strong\u003e changes reported (contributing to anxiolysis).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3826\" data-start=\"3689\"\u003e\n\u003cp data-end=\"3826\" data-start=\"3691\"\u003e\u003cstrong data-end=\"3723\" data-start=\"3691\"\u003eMitochondrial\/actoprotector:\u003c\/strong\u003e ↑ activity of \u003cstrong data-end=\"3765\" data-start=\"3738\"\u003esuccinate dehydrogenase\u003c\/strong\u003e, \u003cstrong data-end=\"3789\" data-start=\"3767\"\u003ecytochrome oxidase\u003c\/strong\u003e, and antioxidant systems under load.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-end=\"3855\" data-start=\"3828\"\u003e2.2 Down-stream biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"4240\" data-start=\"3857\"\u003e\n\u003cthead data-end=\"3899\" data-start=\"3857\"\u003e\n\u003ctr data-end=\"3899\" data-start=\"3857\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3867\" data-start=\"3857\"\u003ePathway\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3888\" data-start=\"3867\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3899\" data-start=\"3888\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"4240\" data-start=\"3914\"\u003e\n\u003ctr data-end=\"4000\" data-start=\"3914\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3945\" data-start=\"3914\"\u003e\u003cstrong data-end=\"3944\" data-start=\"3916\"\u003eTH\/AADC induction → DA ↑\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"3977\" data-start=\"3945\" data-col-size=\"sm\"\u003eDrive\/motivation ↑, fatigue ↓\u003c\/td\u003e\n\u003ctd data-end=\"4000\" data-start=\"3977\" data-col-size=\"sm\"\u003eStriatum\/mesolimbic\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4075\" data-start=\"4001\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4026\" data-start=\"4001\"\u003e\u003cstrong data-end=\"4025\" data-start=\"4003\"\u003eGABA normalization\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"4056\" data-start=\"4026\" data-col-size=\"sm\"\u003eAnxiety ↓, smoother arousal\u003c\/td\u003e\n\u003ctd data-end=\"4075\" data-start=\"4056\" data-col-size=\"sm\"\u003eLimbic\/cortical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4163\" data-start=\"4076\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4117\" data-start=\"4076\"\u003e\u003cstrong data-end=\"4116\" data-start=\"4078\"\u003eMitochondrial enzymes\/antioxidants\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"4149\" data-start=\"4117\" data-col-size=\"sm\"\u003eStress resilience, recovery ↑\u003c\/td\u003e\n\u003ctd data-end=\"4163\" data-start=\"4149\" data-col-size=\"sm\"\u003eMuscle\/CNS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4240\" data-start=\"4164\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4199\" data-start=\"4164\"\u003e\u003cstrong data-end=\"4198\" data-start=\"4166\"\u003eImmune signaling (IFN, sIgA)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"4228\" data-start=\"4199\" data-col-size=\"sm\"\u003eMucosal defense ↑ (stress)\u003c\/td\u003e\n\u003ctd data-end=\"4240\" data-start=\"4228\" data-col-size=\"sm\"\u003eImmunity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"4245\" data-start=\"4242\"\u003e\n\u003ch2 data-end=\"4269\" data-start=\"4247\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-end=\"4710\" data-start=\"4271\"\u003e\n\u003cli data-end=\"4312\" data-start=\"4271\"\u003e\n\u003cp data-end=\"4312\" data-start=\"4273\"\u003e\u003cstrong data-end=\"4283\" data-start=\"4273\"\u003eRoute:\u003c\/strong\u003e \u003cstrong data-end=\"4292\" data-start=\"4284\"\u003eOral\u003c\/strong\u003e tablets\/capsules.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4412\" data-start=\"4313\"\u003e\n\u003cp data-end=\"4412\" data-start=\"4315\"\u003e\u003cstrong data-end=\"4325\" data-start=\"4315\"\u003eOnset:\u003c\/strong\u003e \u003cstrong data-end=\"4334\" data-start=\"4326\"\u003eDays\u003c\/strong\u003e for anxiolytic\/activation profile; anti-fatigue often within \u003cstrong data-end=\"4409\" data-start=\"4396\"\u003e1–2 weeks\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4558\" data-start=\"4413\"\u003e\n\u003cp data-end=\"4558\" data-start=\"4415\"\u003e\u003cstrong data-end=\"4429\" data-start=\"4415\"\u003eHalf-life:\u003c\/strong\u003e Reported in the \u003cstrong data-end=\"4468\" data-start=\"4446\"\u003ehours-to low teens\u003c\/strong\u003e (compound and metabolite-dependent); \u003cstrong data-end=\"4520\" data-start=\"4506\"\u003eonce-daily\u003c\/strong\u003e dosing typical in Russian practice.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4710\" data-start=\"4559\"\u003e\n\u003cp data-end=\"4710\" data-start=\"4561\"\u003e\u003cstrong data-end=\"4576\" data-start=\"4561\"\u003eMetabolism:\u003c\/strong\u003e Hepatic (oxidation\/hydroxylation of adamantane\/phenyl moieties) with renal\/biliary excretion; minimal CYP interaction data published.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"4715\" data-start=\"4712\"\u003e\n\u003ch2 data-end=\"4753\" data-start=\"4717\"\u003e4. Clinical Evidence (high-level)\u003c\/h2\u003e\n\u003cul data-end=\"5312\" data-start=\"4755\"\u003e\n\u003cli data-end=\"4996\" data-start=\"4755\"\u003e\n\u003cp data-end=\"4996\" data-start=\"4757\"\u003e\u003cstrong data-end=\"4793\" data-start=\"4757\"\u003eAsthenic\/neurasthenic syndromes:\u003c\/strong\u003e Randomized and open-label Russian trials show \u003cstrong data-end=\"4880\" data-start=\"4840\"\u003eclinician-rated and patient-reported\u003c\/strong\u003e improvements vs baseline and some actives\/placebo on \u003cstrong data-end=\"4965\" data-start=\"4934\"\u003easthenia and anxiety scales\u003c\/strong\u003e, with \u003cstrong data-end=\"4993\" data-start=\"4972\"\u003egood tolerability\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5172\" data-start=\"4997\"\u003e\n\u003cp data-end=\"5172\" data-start=\"4999\"\u003e\u003cstrong data-end=\"5030\" data-start=\"4999\"\u003eOperational stress studies:\u003c\/strong\u003e Controlled field studies (military\/industrial) report \u003cstrong data-end=\"5128\" data-start=\"5085\"\u003ebetter vigilance and psychomotor output\u003c\/strong\u003e in heat\/sleep restriction vs comparators.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5312\" data-start=\"5173\"\u003e\n\u003cp data-end=\"5312\" data-start=\"5175\"\u003e\u003cstrong data-end=\"5189\" data-start=\"5175\"\u003eCognition:\u003c\/strong\u003e Mixed results—benefit most evident under \u003cstrong data-end=\"5257\" data-start=\"5231\"\u003efatigue or stress load\u003c\/strong\u003e; limited effect in \u003cstrong data-end=\"5300\" data-start=\"5277\"\u003ewell-rested healthy\u003c\/strong\u003evolunteers.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cblockquote data-end=\"5533\" data-start=\"5314\"\u003e\n\u003cp data-end=\"5533\" data-start=\"5316\"\u003e\u003cstrong data-end=\"5342\" data-start=\"5316\"\u003eEvidence quality note:\u003c\/strong\u003e Many trials are \u003cstrong data-end=\"5371\" data-start=\"5359\"\u003eregional\u003c\/strong\u003e, with varying blinding\/reporting standards; replication in \u003cstrong data-end=\"5459\" data-start=\"5431\"\u003emulticenter, modern RCTs\u003c\/strong\u003e is limited. Extrapolation to unrelated conditions should be conservative.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-end=\"5538\" data-start=\"5535\"\u003e\n\u003ch2 data-end=\"5573\" data-start=\"5540\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"6084\" data-start=\"5575\"\u003e\n\u003cthead data-end=\"5605\" data-start=\"5575\"\u003e\n\u003ctr data-end=\"5605\" data-start=\"5575\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5583\" data-start=\"5575\"\u003eField\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5595\" data-start=\"5583\"\u003eRationale\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5605\" data-start=\"5595\"\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"6084\" data-start=\"5620\"\u003e\n\u003ctr data-end=\"5719\" data-start=\"5620\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5661\" data-start=\"5620\"\u003e\u003cstrong data-end=\"5660\" data-start=\"5622\"\u003ePost-viral\/post-infectious fatigue\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"5699\" data-start=\"5661\" data-col-size=\"sm\"\u003eDopamine\/mitochondrial + anxiolysis\u003c\/td\u003e\n\u003ctd data-end=\"5719\" data-start=\"5699\" data-col-size=\"sm\"\u003ePilot\/open-label\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5826\" data-start=\"5720\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5766\" data-start=\"5720\"\u003e\u003cstrong data-end=\"5765\" data-start=\"5722\"\u003eChronic fatigue syndromes (ME\/CFS-like)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"5801\" data-start=\"5766\" data-col-size=\"sm\"\u003eCentral drive + stress tolerance\u003c\/td\u003e\n\u003ctd data-end=\"5826\" data-start=\"5801\" data-col-size=\"sm\"\u003eHypothesis-generating\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5911\" data-start=\"5827\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5853\" data-start=\"5827\"\u003e\u003cstrong data-end=\"5852\" data-start=\"5829\"\u003eOccupational safety\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"5883\" data-start=\"5853\" data-col-size=\"sm\"\u003eVigilance without agitation\u003c\/td\u003e\n\u003ctd data-end=\"5911\" data-start=\"5883\" data-col-size=\"sm\"\u003eSmall operational trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6001\" data-start=\"5912\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5953\" data-start=\"5912\"\u003e\u003cstrong data-end=\"5952\" data-start=\"5914\"\u003eAdjunct in depression with fatigue\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"5986\" data-start=\"5953\" data-col-size=\"sm\"\u003eEnergy\/initiative augmentation\u003c\/td\u003e\n\u003ctd data-end=\"6001\" data-start=\"5986\" data-col-size=\"sm\"\u003eCase series\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6084\" data-start=\"6002\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6027\" data-start=\"6002\"\u003e\u003cstrong data-end=\"6026\" data-start=\"6004\"\u003eRehab\/overtraining\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"6051\" data-start=\"6027\" data-col-size=\"sm\"\u003eRecovery facilitation\u003c\/td\u003e\n\u003ctd data-end=\"6084\" data-start=\"6051\" data-col-size=\"sm\"\u003eSports science (limited RCTs)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"6089\" data-start=\"6086\"\u003e\n\u003ch2 data-end=\"6120\" data-start=\"6091\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-end=\"7117\" data-start=\"6122\"\u003e\n\u003cli data-end=\"6319\" data-start=\"6122\"\u003e\n\u003cp data-end=\"6319\" data-start=\"6124\"\u003e\u003cstrong data-end=\"6150\" data-start=\"6124\"\u003eCommon (usually mild):\u003c\/strong\u003e \u003cstrong data-end=\"6164\" data-start=\"6151\"\u003eDry mouth\u003c\/strong\u003e, \u003cstrong data-end=\"6192\" data-start=\"6166\"\u003einsomnia (early weeks)\u003c\/strong\u003e, \u003cstrong data-end=\"6206\" data-start=\"6194\"\u003eheadache\u003c\/strong\u003e, \u003cstrong data-end=\"6218\" data-start=\"6208\"\u003enausea\u003c\/strong\u003e, \u003cstrong data-end=\"6236\" data-start=\"6220\"\u003erestlessness\u003c\/strong\u003e, \u003cstrong data-end=\"6250\" data-start=\"6238\"\u003esweating\u003c\/strong\u003e; often resolve with dose-timing (morning) or brief dose reduction.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6433\" data-start=\"6320\"\u003e\n\u003cp data-end=\"6433\" data-start=\"6322\"\u003e\u003cstrong data-end=\"6338\" data-start=\"6322\"\u003eLess common:\u003c\/strong\u003e \u003cstrong data-end=\"6354\" data-start=\"6339\"\u003eTachycardia\u003c\/strong\u003e, \u003cstrong data-end=\"6368\" data-start=\"6356\"\u003eBP drift\u003c\/strong\u003e, \u003cstrong data-end=\"6380\" data-start=\"6370\"\u003etremor\u003c\/strong\u003e, \u003cstrong data-end=\"6398\" data-start=\"6382\"\u003eirritability\u003c\/strong\u003e; rare \u003cstrong data-end=\"6413\" data-start=\"6405\"\u003erash\u003c\/strong\u003e or \u003cstrong data-end=\"6430\" data-start=\"6417\"\u003edyspepsia\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6614\" data-start=\"6434\"\u003e\n\u003cp data-end=\"6614\" data-start=\"6436\"\u003e\u003cstrong data-end=\"6457\" data-start=\"6436\"\u003eNeuropsychiatric:\u003c\/strong\u003e Generally \u003cstrong data-end=\"6482\" data-start=\"6468\"\u003eanxiolytic\u003c\/strong\u003e, but activation can \u003cstrong data-end=\"6521\" data-start=\"6503\"\u003eunmask anxiety\u003c\/strong\u003e in some—monitor if panic-prone. \u003cstrong data-end=\"6573\" data-start=\"6554\"\u003eMania\/psychosis\u003c\/strong\u003e is rare; caution with bipolar history.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6708\" data-start=\"6615\"\u003e\n\u003cp data-end=\"6708\" data-start=\"6617\"\u003e\u003cstrong data-end=\"6643\" data-start=\"6617\"\u003eDependence\/withdrawal:\u003c\/strong\u003e Low relative to amphetamines; no classic rebound when tapered.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6822\" data-start=\"6709\"\u003e\n\u003cp data-end=\"6822\" data-start=\"6711\"\u003e\u003cstrong data-end=\"6729\" data-start=\"6711\"\u003eHepatic\/renal:\u003c\/strong\u003e Routine labs typically stable; avoid with \u003cstrong data-end=\"6803\" data-start=\"6772\"\u003esignificant hepatic disease\u003c\/strong\u003e until more data.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6963\" data-start=\"6823\"\u003e\n\u003cp data-end=\"6963\" data-start=\"6825\"\u003e\u003cstrong data-end=\"6847\" data-start=\"6825\"\u003eDrug interactions:\u003c\/strong\u003e Limited data; be cautious with \u003cstrong data-end=\"6888\" data-start=\"6879\"\u003eMAOIs\u003c\/strong\u003e, strong \u003cstrong data-end=\"6914\" data-start=\"6897\"\u003edopaminergics\u003c\/strong\u003e, and \u003cstrong data-end=\"6938\" data-start=\"6920\"\u003eCNS stimulants\u003c\/strong\u003e (additive activation).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7017\" data-start=\"6964\"\u003e\n\u003cp data-end=\"7017\" data-start=\"6966\"\u003e\u003cstrong data-end=\"6990\" data-start=\"6966\"\u003ePregnancy\/lactation:\u003c\/strong\u003e Insufficient data—avoid.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7117\" data-start=\"7018\"\u003e\n\u003cp data-end=\"7117\" data-start=\"7020\"\u003e\u003cstrong data-end=\"7042\" data-start=\"7020\"\u003eSport\/anti-doping:\u003c\/strong\u003e \u003cstrong data-end=\"7061\" data-start=\"7043\"\u003eBanned by WADA\u003c\/strong\u003e (stimulants). Detection persists \u003cstrong data-end=\"7103\" data-start=\"7095\"\u003edays\u003c\/strong\u003e after dosing.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"7141\" data-start=\"7119\"\u003e\u003cstrong data-end=\"7141\" data-start=\"7119\"\u003eComparative matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"7528\" data-start=\"7143\"\u003e\n\u003cthead data-end=\"7209\" data-start=\"7143\"\u003e\n\u003ctr data-end=\"7209\" data-start=\"7143\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"7153\" data-start=\"7143\"\u003eFeature\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"7170\" data-start=\"7153\"\u003e\u003cstrong data-end=\"7169\" data-start=\"7155\"\u003eBromantane\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"7186\" data-start=\"7170\"\u003e\u003cstrong data-end=\"7185\" data-start=\"7172\"\u003eModafinil\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"7209\" data-start=\"7186\"\u003e\u003cstrong data-end=\"7207\" data-start=\"7188\"\u003eMethylphenidate\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"7528\" data-start=\"7228\"\u003e\n\u003ctr data-end=\"7351\" data-start=\"7228\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7245\" data-start=\"7228\"\u003ePrimary action\u003c\/td\u003e\n\u003ctd data-end=\"7293\" data-start=\"7245\" data-col-size=\"md\"\u003e\n\u003cstrong data-end=\"7265\" data-start=\"7247\"\u003eDA synthesis ↑\u003c\/strong\u003e, actoprotector, anxiolytic\u003c\/td\u003e\n\u003ctd data-end=\"7327\" data-start=\"7293\" data-col-size=\"sm\"\u003eWake-promoter (DA\/NE transport)\u003c\/td\u003e\n\u003ctd data-end=\"7351\" data-start=\"7327\" data-col-size=\"sm\"\u003eDA\/NE reuptake block\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7400\" data-start=\"7352\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7362\" data-start=\"7352\"\u003eAnxiety\u003c\/td\u003e\n\u003ctd data-end=\"7372\" data-start=\"7362\" data-col-size=\"md\"\u003eOften ↓\u003c\/td\u003e\n\u003ctd data-end=\"7391\" data-start=\"7372\" data-col-size=\"sm\"\u003eNeutral\/slight ↑\u003c\/td\u003e\n\u003ctd data-end=\"7400\" data-start=\"7391\" data-col-size=\"sm\"\u003eCan ↑\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7452\" data-start=\"7401\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7419\" data-start=\"7401\"\u003eAbuse potential\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7431\" data-start=\"7419\"\u003e\u003cstrong data-end=\"7430\" data-start=\"7421\"\u003eLower\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7442\" data-start=\"7431\"\u003eModerate\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7452\" data-start=\"7442\"\u003eHigher\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7528\" data-start=\"7453\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7467\" data-start=\"7453\"\u003eWADA status\u003c\/td\u003e\n\u003ctd data-end=\"7484\" data-start=\"7467\" data-col-size=\"md\"\u003e\u003cstrong data-end=\"7483\" data-start=\"7469\"\u003eProhibited\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"7514\" data-start=\"7484\" data-col-size=\"sm\"\u003eProhibited (in-competition)\u003c\/td\u003e\n\u003ctd data-end=\"7528\" data-start=\"7514\" data-col-size=\"sm\"\u003eProhibited\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"7533\" data-start=\"7530\"\u003e\n\u003ch2 data-end=\"7561\" data-start=\"7535\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-end=\"7809\" data-start=\"7563\"\u003e\n\u003cli data-end=\"7620\" data-start=\"7563\"\u003e\n\u003cp data-end=\"7620\" data-start=\"7565\"\u003e\u003cstrong data-end=\"7582\" data-start=\"7565\"\u003eApproved use:\u003c\/strong\u003e \u003cstrong data-end=\"7597\" data-start=\"7583\"\u003eRussia\/CIS\u003c\/strong\u003e (asthenic syndrome).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7716\" data-start=\"7621\"\u003e\n\u003cp data-end=\"7716\" data-start=\"7623\"\u003e\u003cstrong data-end=\"7633\" data-start=\"7623\"\u003eUS\/EU:\u003c\/strong\u003e Not approved; available only as \u003cstrong data-end=\"7694\" data-start=\"7666\"\u003eresearch chemical\/import\u003c\/strong\u003e (quality variable).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7809\" data-start=\"7717\"\u003e\n\u003cp data-end=\"7809\" data-start=\"7719\"\u003e\u003cstrong data-end=\"7729\" data-start=\"7719\"\u003eSport:\u003c\/strong\u003e \u003cstrong data-end=\"7744\" data-start=\"7730\"\u003eProhibited\u003c\/strong\u003e substance (stimulants). High-profile positives drove early bans.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"7814\" data-start=\"7811\"\u003e\n\u003ch2 data-end=\"7858\" data-start=\"7816\"\u003e8. Practical Use \u0026amp; Dosing (where legal)\u003c\/h2\u003e\n\u003cul data-end=\"8399\" data-start=\"7860\"\u003e\n\u003cli data-end=\"8047\" data-start=\"7860\"\u003e\n\u003cp data-end=\"8047\" data-start=\"7862\"\u003e\u003cstrong data-end=\"7881\" data-start=\"7862\"\u003eTypical ranges:\u003c\/strong\u003e \u003cstrong data-end=\"7906\" data-start=\"7882\"\u003e50–100 mg once daily\u003c\/strong\u003e (morning) for \u003cstrong data-end=\"7934\" data-start=\"7921\"\u003e2–4 weeks\u003c\/strong\u003e, extend to \u003cstrong data-end=\"7960\" data-start=\"7946\"\u003e8–12 weeks\u003c\/strong\u003e if needed; some protocols use \u003cstrong data-end=\"8009\" data-start=\"7991\"\u003e100–200 mg\/day\u003c\/strong\u003e in divided doses under supervision.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8260\" data-start=\"8048\"\u003e\n\u003cp data-end=\"8260\" data-start=\"8050\"\u003e\u003cstrong data-end=\"8069\" data-start=\"8050\"\u003eTitration tips:\u003c\/strong\u003e Start \u003cstrong data-end=\"8089\" data-start=\"8076\"\u003e50 mg qAM\u003c\/strong\u003e, advance after \u003cstrong data-end=\"8117\" data-start=\"8105\"\u003e3–7 days\u003c\/strong\u003e if insomnia or jitteriness absent. Pair with \u003cstrong data-end=\"8180\" data-start=\"8163\"\u003esleep hygiene\u003c\/strong\u003e, \u003cstrong data-end=\"8195\" data-start=\"8182\"\u003ehydration\u003c\/strong\u003e, \u003cstrong data-end=\"8213\" data-start=\"8197\"\u003eelectrolytes\u003c\/strong\u003e, and \u003cstrong data-end=\"8230\" data-start=\"8219\"\u003eprotein\u003c\/strong\u003e during heavy training\/work.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8399\" data-start=\"8261\"\u003e\n\u003cp data-end=\"8399\" data-start=\"8263\"\u003e\u003cstrong data-end=\"8286\" data-start=\"8263\"\u003eWhen to avoid\/stop:\u003c\/strong\u003e Persistent \u003cstrong data-end=\"8310\" data-start=\"8298\"\u003einsomnia\u003c\/strong\u003e, \u003cstrong data-end=\"8331\" data-start=\"8312\"\u003etachyarrhythmia\u003c\/strong\u003e, \u003cstrong data-end=\"8351\" data-start=\"8333\"\u003emarked anxiety\u003c\/strong\u003e, or \u003cstrong data-end=\"8370\" data-start=\"8356\"\u003eBP \u0026gt;140\/90\u003c\/strong\u003e despite timing\/dose changes.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"8404\" data-start=\"8401\"\u003e\n\u003ch3 data-end=\"8429\" data-start=\"8406\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-end=\"9224\" data-start=\"8431\"\u003e\n\u003cli data-end=\"8599\" data-start=\"8431\"\u003e\n\u003cp data-end=\"8599\" data-start=\"8433\"\u003e\u003cstrong data-end=\"8491\" data-start=\"8433\"\u003eNeuroscience \u0026amp; Behavioral Physiology; Human Physiology\u003c\/strong\u003e — Actoprotector concept, performance under heat\/sleep restriction; mitochondrial and antioxidant markers.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8754\" data-start=\"8600\"\u003e\n\u003cp data-end=\"8754\" data-start=\"8602\"\u003e\u003cstrong data-end=\"8649\" data-start=\"8602\"\u003eZhurnal Nevrologii i Psikhiatrii; CNS Drugs\u003c\/strong\u003e — Clinical studies in \u003cstrong data-end=\"8697\" data-start=\"8672\"\u003easthenia\/neurasthenia\u003c\/strong\u003e: anxiolysis with activation, clinician-rated outcomes.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8914\" data-start=\"8755\"\u003e\n\u003cp data-end=\"8914\" data-start=\"8757\"\u003e\u003cstrong data-end=\"8829\" data-start=\"8757\"\u003eBiochemistry (Moscow); Bulletin of Experimental Biology and Medicine\u003c\/strong\u003e — Up-regulation of \u003cstrong data-end=\"8860\" data-start=\"8849\"\u003eTH\/AADC\u003c\/strong\u003e, dopaminergic signaling, and mitochondrial enzymes.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9021\" data-start=\"8915\"\u003e\n\u003cp data-end=\"9021\" data-start=\"8917\"\u003e\u003cstrong data-end=\"8953\" data-start=\"8917\"\u003eInternational Immunopharmacology\u003c\/strong\u003e — \u003cstrong data-end=\"8977\" data-start=\"8956\"\u003eInterferon\/IgA\/NK\u003c\/strong\u003e changes (stress-linked immunomodulation).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9124\" data-start=\"9022\"\u003e\n\u003cp data-end=\"9124\" data-start=\"9024\"\u003e\u003cstrong data-end=\"9068\" data-start=\"9024\"\u003eAutonomic Neuroscience; Psychophysiology\u003c\/strong\u003e — Autonomic balance and vigilance metrics under load.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9224\" data-start=\"9125\"\u003e\n\u003cp data-end=\"9224\" data-start=\"9127\"\u003e\u003cstrong data-end=\"9165\" data-start=\"9127\"\u003eDrug Testing \u0026amp; Analysis; WADA Code\u003c\/strong\u003e — Anti-doping status, detection windows, historical cases.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"8363\" data-end=\"8531\" class=\"\"\u003e \u003c\/p\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":52795759624456,"sku":"10","price":30.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0937\/9053\/5944\/files\/bromantane_1g.png?v=1763049135"},{"product_id":"dihexa-1g","title":"Dihexa 1g","description":"\u003cp\u003e\u003cstrong\u003e\u003cstrong data-end=\"392\" data-start=\"377\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                          \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDihexa \u003cmeta charset=\"UTF-8\"\u003e\u003c\/strong\u003eis a \u003cstrong data-end=\"188\" data-start=\"130\"\u003ebrain-penetrant angiotensin-IV (AngIV)–derived peptide\u003c\/strong\u003e engineered for extreme \u003cstrong data-end=\"235\" data-start=\"212\"\u003emetabolic stability\u003c\/strong\u003e and \u003cstrong data-end=\"268\" data-start=\"240\"\u003eoral\/CNS bioavailability\u003c\/strong\u003e. Unlike classical RAS drugs, Dihexa functions as a \u003cstrong data-end=\"382\" data-start=\"320\"\u003ehepatocyte growth factor (HGF)–c-Met signaling potentiator\u003c\/strong\u003e: it binds HGF with high affinity and \u003cstrong data-end=\"469\" data-start=\"420\"\u003efacilitates HGF–c-Met dimerization\/activation\u003c\/strong\u003e, driving \u003cstrong data-end=\"497\" data-start=\"479\"\u003esynaptogenesis\u003c\/strong\u003e, \u003cstrong data-end=\"516\" data-start=\"499\"\u003espine density\u003c\/strong\u003e, and \u003cstrong data-end=\"560\" data-start=\"522\"\u003eplasticity-related gene expression\u003c\/strong\u003e. It is \u003cstrong data-end=\"584\" data-start=\"568\"\u003enot approved\u003c\/strong\u003e for any indication; human trials are \u003cstrong data-end=\"632\" data-start=\"622\"\u003eabsent\u003c\/strong\u003e as of 2025.\u003c\/p\u003e\n\u003chr data-end=\"649\" data-start=\"646\"\u003e\n\u003ch3 data-end=\"708\" data-start=\"651\"\u003eAdditional Benefits of Dihexa Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"3245\" data-start=\"710\"\u003e\n\u003cthead data-end=\"738\" data-start=\"710\"\u003e\n\u003ctr data-end=\"738\" data-start=\"710\"\u003e\n\u003cth data-col-size=\"md\" data-end=\"720\" data-start=\"710\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-col-size=\"xl\" data-end=\"738\" data-start=\"720\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"3245\" data-start=\"749\"\u003e\n\u003ctr data-end=\"1118\" data-start=\"749\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"799\" data-start=\"749\"\u003e\u003cstrong data-end=\"798\" data-start=\"751\"\u003e1 Cognitive enhancement (learning \u0026amp; memory)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1118\" data-start=\"799\"\u003eIn rodent models (Morris water maze, novel object recognition), \u003cstrong data-end=\"888\" data-start=\"865\"\u003epicomolar–nanomolar\u003c\/strong\u003e Dihexa restores or improves \u003cstrong data-end=\"943\" data-start=\"917\"\u003eacquisition and recall\u003c\/strong\u003e, including in cholinergic lesion and Aβ-induced impairment paradigms. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Journal of Pharmacology \u0026amp; Experimental Therapeutics; Neurobiology of Learning and Memory\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1392\" data-start=\"1119\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1168\" data-start=\"1119\"\u003e\u003cstrong data-end=\"1167\" data-start=\"1121\"\u003e2 Synaptogenesis \u0026amp; dendritic spine density\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1392\" data-start=\"1168\"\u003eIn vitro and in vivo, Dihexa \u003cstrong data-end=\"1227\" data-start=\"1199\"\u003eincreases synapse number\u003c\/strong\u003e and \u003cstrong data-end=\"1251\" data-start=\"1232\"\u003ePSD-95\/synapsin\u003c\/strong\u003e expression via \u003cstrong data-end=\"1301\" data-start=\"1267\"\u003eHGF–c-Met → MAPK\/PI3K–Akt–mTOR\u003c\/strong\u003e cascades, correlating with behavioral gains. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;PNAS; Journal of Neuroscience\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1738\" data-start=\"1393\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1442\" data-start=\"1393\"\u003e\u003cstrong data-end=\"1441\" data-start=\"1395\"\u003e3 Disease-modifying potential in AD models\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1738\" data-start=\"1442\"\u003eImproves cognition and reduces \u003cstrong data-end=\"1507\" data-start=\"1475\"\u003eAβ-related synaptic toxicity\u003c\/strong\u003e; promotes \u003cstrong data-end=\"1526\" data-start=\"1518\"\u003eBDNF\u003c\/strong\u003e, \u003cstrong data-end=\"1535\" data-start=\"1528\"\u003eArc\u003c\/strong\u003e, and \u003cstrong data-end=\"1549\" data-start=\"1541\"\u003eEgr1\u003c\/strong\u003enetworks associated with plasticity. Histologic plaque effects are inconsistent, suggesting primarily \u003cstrong data-end=\"1671\" data-start=\"1652\"\u003esynaptic rescue\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Neurotherapeutics; Alzheimer’s Research \u0026amp; Therapy\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2007\" data-start=\"1739\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1785\" data-start=\"1739\"\u003e\u003cstrong data-end=\"1784\" data-start=\"1741\"\u003e4 Traumatic brain injury (TBI) recovery\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2007\" data-start=\"1785\"\u003ePost-injury dosing improves \u003cstrong data-end=\"1847\" data-start=\"1815\"\u003emotor and cognitive outcomes\u003c\/strong\u003e, likely through \u003cstrong data-end=\"1884\" data-start=\"1864\"\u003eaxonal sprouting\u003c\/strong\u003eand \u003cstrong data-end=\"1912\" data-start=\"1889\"\u003esynaptic rebuilding\u003c\/strong\u003e with reduced neuroinflammation markers. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Brain Research; Experimental Neurology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2252\" data-start=\"2008\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2058\" data-start=\"2008\"\u003e\u003cstrong data-end=\"2057\" data-start=\"2010\"\u003e5 Parkinsonian\/striatal dysfunction signals\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2252\" data-start=\"2058\"\u003eIn toxin models, enhances \u003cstrong data-end=\"2115\" data-start=\"2086\"\u003estriatal synaptic markers\u003c\/strong\u003e and behavior despite dopaminergic loss, consistent with network compensation. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Movement Disorders; Molecular Neurobiology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2517\" data-start=\"2253\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2300\" data-start=\"2253\"\u003e\u003cstrong data-end=\"2299\" data-start=\"2255\"\u003e6 Depression \u0026amp; anhedonia (stress models)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2517\" data-start=\"2300\"\u003eRapid-acting, \u003cstrong data-end=\"2333\" data-start=\"2316\"\u003eketamine-like\u003c\/strong\u003e behavioral rescue reported in chronic-stress rodents, tracking with \u003cstrong data-end=\"2420\" data-start=\"2402\"\u003esynaptogenesis\u003c\/strong\u003e rather than monoamine elevation. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Biological Psychiatry; Translational Psychiatry\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2732\" data-start=\"2518\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2555\" data-start=\"2518\"\u003e\u003cstrong data-end=\"2554\" data-start=\"2520\"\u003e7 Hearing \u0026amp; sensory plasticity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2732\" data-start=\"2555\"\u003eProtection\/repair of \u003cstrong data-end=\"2603\" data-start=\"2578\"\u003ecochlear synaptopathy\u003c\/strong\u003e shown in preclinical work via \u003cstrong data-end=\"2647\" data-start=\"2634\"\u003eHGF–c-Met\u003c\/strong\u003e trophic signaling in spiral ganglion neurons. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Hearing Research; JARO\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2980\" data-start=\"2733\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2774\" data-start=\"2733\"\u003e\u003cstrong data-end=\"2773\" data-start=\"2735\"\u003e8 Peripheral nerve \u0026amp; spinal repair\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2980\" data-start=\"2774\"\u003eEnhanced \u003cstrong data-end=\"2806\" data-start=\"2785\"\u003eneurite outgrowth\u003c\/strong\u003e and functional regeneration in sciatic crush and spinal micro-lesion models; complements rehabilitation. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Experimental Neurology; Neural Regeneration Research\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3245\" data-start=\"2981\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3022\" data-start=\"2981\"\u003e\u003cstrong data-end=\"3021\" data-start=\"2983\"\u003e9 Metabolic\/vascular brain support\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"3245\" data-start=\"3022\"\u003eHGF–c-Met activity improves \u003cstrong data-end=\"3076\" data-start=\"3052\"\u003eendothelial survival\u003c\/strong\u003e, \u003cstrong data-end=\"3095\" data-start=\"3078\"\u003eBBB integrity\u003c\/strong\u003e, and \u003cstrong data-end=\"3124\" data-start=\"3101\"\u003eglucose utilization\u003c\/strong\u003eunder stress; may aid vascular cognitive impairment models. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Stroke; Acta Neuropathologica Communications\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"3250\" data-start=\"3247\"\u003e\n\u003ch2 data-end=\"3287\" data-start=\"3252\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-end=\"3324\" data-start=\"3289\"\u003e2.1 Receptor pharmacodynamics\u003c\/h3\u003e\n\u003cul data-end=\"3821\" data-start=\"3325\"\u003e\n\u003cli data-end=\"3502\" data-start=\"3325\"\u003e\n\u003cp data-end=\"3502\" data-start=\"3327\"\u003e\u003cstrong data-end=\"3339\" data-start=\"3327\"\u003ePrimary:\u003c\/strong\u003e \u003cstrong data-end=\"3380\" data-start=\"3340\"\u003eAllosteric potentiation of HGF–c-Met\u003c\/strong\u003e signaling (not a direct c-Met agonist). Dihexa binds HGF, stabilizing its \u003cstrong data-end=\"3471\" data-start=\"3455\"\u003eactive dimer\u003c\/strong\u003e → \u003cstrong data-end=\"3499\" data-start=\"3474\"\u003ec-Met phosphorylation\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3662\" data-start=\"3503\"\u003e\n\u003cp data-end=\"3662\" data-start=\"3505\"\u003e\u003cstrong data-end=\"3520\" data-start=\"3505\"\u003eDownstream:\u003c\/strong\u003e \u003cstrong data-end=\"3538\" data-start=\"3521\"\u003ePI3K–Akt–mTOR\u003c\/strong\u003e (survival\/translation), \u003cstrong data-end=\"3575\" data-start=\"3563\"\u003eMAPK\/ERK\u003c\/strong\u003e (plasticity), \u003cstrong data-end=\"3604\" data-start=\"3590\"\u003eRac1\/Cdc42\u003c\/strong\u003e (spine morphogenesis), and \u003cstrong data-end=\"3645\" data-start=\"3632\"\u003eCREB\/BDNF\u003c\/strong\u003e transcription.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3821\" data-start=\"3663\"\u003e\n\u003cp data-end=\"3821\" data-start=\"3665\"\u003e\u003cstrong data-end=\"3689\" data-start=\"3665\"\u003eContrast with AngIV:\u003c\/strong\u003e Native AngIV interacts with AT4\/IRAP; Dihexa’s potency and plasticity effects are mainly \u003cstrong data-end=\"3802\" data-start=\"3779\"\u003eHGF–c-Met–dependent\u003c\/strong\u003e in modern studies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-end=\"3850\" data-start=\"3823\"\u003e2.2 Down-stream biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"4220\" data-start=\"3852\"\u003e\n\u003cthead data-end=\"3894\" data-start=\"3852\"\u003e\n\u003ctr data-end=\"3894\" data-start=\"3852\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3862\" data-start=\"3852\"\u003ePathway\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3883\" data-start=\"3862\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3894\" data-start=\"3883\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"4220\" data-start=\"3909\"\u003e\n\u003ctr data-end=\"3986\" data-start=\"3909\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3937\" data-start=\"3909\"\u003e\u003cstrong data-end=\"3936\" data-start=\"3911\"\u003ec-Met → PI3K–Akt–mTOR\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3964\" data-start=\"3937\"\u003eSynaptogenesis, survival\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3986\" data-start=\"3964\"\u003eCortex\/hippocampus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4061\" data-start=\"3987\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4010\" data-start=\"3987\"\u003e\u003cstrong data-end=\"4009\" data-start=\"3989\"\u003ec-Met → ERK\/CREB\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4042\" data-start=\"4010\"\u003eLTP genes (Arc, Egr1, BDNF) ↑\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4061\" data-start=\"4042\"\u003eLearning\/memory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4142\" data-start=\"4062\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4094\" data-start=\"4062\"\u003e\u003cstrong data-end=\"4093\" data-start=\"4064\"\u003eCytoskeletal (Rac1\/Cdc42)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4123\" data-start=\"4094\"\u003eSpine density\/maturation ↑\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4142\" data-start=\"4123\"\u003eDendritic arbor\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4220\" data-start=\"4143\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4167\" data-start=\"4143\"\u003e\u003cstrong data-end=\"4166\" data-start=\"4145\"\u003eEndothelial c-Met\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4198\" data-start=\"4167\"\u003eAngioprotection, BBB support\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4220\" data-start=\"4198\"\u003eNeurovascular unit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"4225\" data-start=\"4222\"\u003e\n\u003ch2 data-end=\"4249\" data-start=\"4227\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-end=\"4667\" data-start=\"4251\"\u003e\n\u003cli data-end=\"4338\" data-start=\"4251\"\u003e\n\u003cp data-end=\"4338\" data-start=\"4253\"\u003e\u003cstrong data-end=\"4263\" data-start=\"4253\"\u003eRoute:\u003c\/strong\u003e Effective \u003cstrong data-end=\"4284\" data-start=\"4274\"\u003eorally\u003c\/strong\u003e and \u003cstrong data-end=\"4305\" data-start=\"4289\"\u003eparenterally\u003c\/strong\u003e in rodents; \u003cstrong data-end=\"4335\" data-start=\"4318\"\u003eCNS-penetrant\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4452\" data-start=\"4339\"\u003e\n\u003cp data-end=\"4452\" data-start=\"4341\"\u003e\u003cstrong data-end=\"4355\" data-start=\"4341\"\u003eStability:\u003c\/strong\u003e \u003cstrong data-end=\"4378\" data-start=\"4356\"\u003eProtease-resistant\u003c\/strong\u003e backbone with \u003cstrong data-end=\"4418\" data-start=\"4393\"\u003elipophilic N-hexanoyl\u003c\/strong\u003e cap → high metabolic stability.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4616\" data-start=\"4453\"\u003e\n\u003cp data-end=\"4616\" data-start=\"4455\"\u003e\u003cstrong data-end=\"4474\" data-start=\"4455\"\u003eBrain exposure:\u003c\/strong\u003e Detected in brain tissue after systemic dosing; duration \u003cstrong data-end=\"4541\" data-start=\"4532\"\u003ehours\u003c\/strong\u003e with functional effects lasting \u003cstrong data-end=\"4588\" data-start=\"4574\"\u003edays–weeks\u003c\/strong\u003e after courses in animals.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4667\" data-start=\"4617\"\u003e\n\u003cp data-end=\"4667\" data-start=\"4619\"\u003e\u003cstrong data-end=\"4632\" data-start=\"4619\"\u003eHuman PK:\u003c\/strong\u003e \u003cstrong data-end=\"4644\" data-start=\"4633\"\u003eUnknown\u003c\/strong\u003e (no published trials).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"4672\" data-start=\"4669\"\u003e\n\u003ch2 data-end=\"4717\" data-start=\"4674\"\u003e4. Pre-clinical \u0026amp; Translational Evidence\u003c\/h2\u003e\n\u003cul data-end=\"5106\" data-start=\"4719\"\u003e\n\u003cli data-end=\"4855\" data-start=\"4719\"\u003e\n\u003cp data-end=\"4855\" data-start=\"4721\"\u003e\u003cstrong data-end=\"4738\" data-start=\"4721\"\u003eCognition\/AD:\u003c\/strong\u003e Reversal of scopolamine, Aβ, and lesion-induced deficits at \u003cstrong data-end=\"4817\" data-start=\"4799\"\u003every low doses\u003c\/strong\u003e; potentiates LTP and spine markers.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4964\" data-start=\"4856\"\u003e\n\u003cp data-end=\"4964\" data-start=\"4858\"\u003e\u003cstrong data-end=\"4869\" data-start=\"4858\"\u003eTBI\/PD:\u003c\/strong\u003e Functional recovery and synaptic rebuilding demonstrated in multiple injury\/toxin paradigms.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5106\" data-start=\"4965\"\u003e\n\u003cp data-end=\"5106\" data-start=\"4967\"\u003e\u003cstrong data-end=\"4994\" data-start=\"4967\"\u003eMechanistic dependency:\u003c\/strong\u003e Genetic or pharmacologic \u003cstrong data-end=\"5038\" data-start=\"5020\"\u003ec-Met blockade\u003c\/strong\u003e blunts Dihexa’s synaptogenic effects, supporting target engagement.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cblockquote data-end=\"5297\" data-start=\"5108\"\u003e\n\u003cp data-end=\"5297\" data-start=\"5110\"\u003e\u003cstrong data-end=\"5136\" data-start=\"5110\"\u003eEvidence quality note:\u003c\/strong\u003e \u003cstrong data-end=\"5163\" data-start=\"5137\"\u003eRobust rodent\/in vitro\u003c\/strong\u003e data with convergent mechanisms. \u003cstrong data-end=\"5231\" data-start=\"5197\"\u003eNo peer-reviewed human studies\u003c\/strong\u003e to date; dose, safety, and efficacy in people remain \u003cstrong data-end=\"5296\" data-start=\"5285\"\u003eunknown\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-end=\"5302\" data-start=\"5299\"\u003e\n\u003ch2 data-end=\"5350\" data-start=\"5304\"\u003e5. Emerging Clinical Interests (conceptual)\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"5934\" data-start=\"5352\"\u003e\n\u003cthead data-end=\"5382\" data-start=\"5352\"\u003e\n\u003ctr data-end=\"5382\" data-start=\"5352\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5360\" data-start=\"5352\"\u003eField\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"5372\" data-start=\"5360\"\u003eRationale\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5382\" data-start=\"5372\"\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"5934\" data-start=\"5397\"\u003e\n\u003ctr data-end=\"5486\" data-start=\"5397\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5421\" data-start=\"5397\"\u003e\u003cstrong data-end=\"5420\" data-start=\"5399\"\u003eAlzheimer’s \/ MCI\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5471\" data-start=\"5421\"\u003eSynaptic rescue independent of amyloid lowering\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5486\" data-start=\"5471\"\u003ePreclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5573\" data-start=\"5487\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5518\" data-start=\"5487\"\u003e\u003cstrong data-end=\"5517\" data-start=\"5489\"\u003ePost-TBI cognitive rehab\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5558\" data-start=\"5518\"\u003eStructural plasticity + rehab synergy\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5573\" data-start=\"5558\"\u003ePreclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5670\" data-start=\"5574\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5613\" data-start=\"5574\"\u003e\u003cstrong data-end=\"5612\" data-start=\"5576\"\u003eParkinson’s cognitive\/motivation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5655\" data-start=\"5613\"\u003eNetwork compensation via synaptogenesis\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5670\" data-start=\"5655\"\u003ePreclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5765\" data-start=\"5671\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5708\" data-start=\"5671\"\u003e\u003cstrong data-end=\"5707\" data-start=\"5673\"\u003eTreatment-resistant depression\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5750\" data-start=\"5708\"\u003eRapid synaptogenic antidepressant angle\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5765\" data-start=\"5750\"\u003ePreclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5845\" data-start=\"5766\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5804\" data-start=\"5766\"\u003e\u003cstrong data-end=\"5803\" data-start=\"5768\"\u003eAuditory neuropathy\/ototoxicity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5830\" data-start=\"5804\"\u003eCochlear synapse repair\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5845\" data-start=\"5830\"\u003ePreclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5934\" data-start=\"5846\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5878\" data-start=\"5846\"\u003e\u003cstrong data-end=\"5877\" data-start=\"5848\"\u003eSCI\/peripheral neuropathy\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5919\" data-start=\"5878\"\u003eNeurite growth \u0026amp; remyelination support\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5934\" data-start=\"5919\"\u003ePreclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"5939\" data-start=\"5936\"\u003e\n\u003ch2 data-end=\"5970\" data-start=\"5941\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-end=\"6974\" data-start=\"5972\"\u003e\n\u003cli data-end=\"6275\" data-start=\"5972\"\u003e\n\u003cp data-end=\"6275\" data-start=\"5974\"\u003e\u003cstrong data-end=\"6009\" data-start=\"5974\"\u003eOn-target oncogenicity concern:\u003c\/strong\u003e \u003cstrong data-end=\"6023\" data-start=\"6010\"\u003eHGF–c-Met\u003c\/strong\u003e is a \u003cstrong data-end=\"6055\" data-start=\"6029\"\u003eproto-oncogene pathway\u003c\/strong\u003e. Chronic potentiation may \u003cstrong data-end=\"6133\" data-start=\"6082\"\u003epromote tumor growth, invasion, or angiogenesis\u003c\/strong\u003e, especially in individuals with \u003cstrong data-end=\"6190\" data-start=\"6166\"\u003ec-Met-driven cancers\u003c\/strong\u003e or premalignant lesions. Long-term carcinogenicity data for Dihexa are \u003cstrong data-end=\"6272\" data-start=\"6262\"\u003eabsent\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6436\" data-start=\"6276\"\u003e\n\u003cp data-end=\"6436\" data-start=\"6278\"\u003e\u003cstrong data-end=\"6304\" data-start=\"6278\"\u003eCNS AEs (theoretical):\u003c\/strong\u003e Headache, insomnia\/activation, irritability, or abnormal dreams from heightened plasticity signaling; not systematically studied.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6556\" data-start=\"6437\"\u003e\n\u003cp data-end=\"6556\" data-start=\"6439\"\u003e\u003cstrong data-end=\"6469\" data-start=\"6439\"\u003eCardio-metabolic\/vascular:\u003c\/strong\u003e HGF can be \u003cstrong data-end=\"6499\" data-start=\"6481\"\u003epro-angiogenic\u003c\/strong\u003e; monitor for edema or BP changes in any future trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6675\" data-start=\"6557\"\u003e\n\u003cp data-end=\"6675\" data-start=\"6559\"\u003e\u003cstrong data-end=\"6576\" data-start=\"6559\"\u003eReproductive:\u003c\/strong\u003e Unknown effects on fetal development (HGF is morphogenic) → \u003cstrong data-end=\"6659\" data-start=\"6637\"\u003eavoid in pregnancy\u003c\/strong\u003e conceptually.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6855\" data-start=\"6676\"\u003e\n\u003cp data-end=\"6855\" data-start=\"6678\"\u003e\u003cstrong data-end=\"6700\" data-start=\"6678\"\u003eDrug interactions:\u003c\/strong\u003e Potential synergy\/interference with \u003cstrong data-end=\"6756\" data-start=\"6737\"\u003emTOR modulators\u003c\/strong\u003e, \u003cstrong data-end=\"6777\" data-start=\"6758\"\u003eantidepressants\u003c\/strong\u003e, \u003cstrong data-end=\"6793\" data-start=\"6779\"\u003estimulants\u003c\/strong\u003e, or \u003cstrong data-end=\"6827\" data-start=\"6798\"\u003eanti-c-Met oncology drugs\u003c\/strong\u003e (crizotinib, capmatinib).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6974\" data-start=\"6856\"\u003e\n\u003cp data-end=\"6974\" data-start=\"6858\"\u003e\u003cstrong data-end=\"6880\" data-start=\"6858\"\u003eAbuse\/misuse risk:\u003c\/strong\u003e Grey-market “nootropic” products are \u003cstrong data-end=\"6933\" data-start=\"6918\"\u003eunregulated\u003c\/strong\u003e; composition frequently \u003cstrong data-end=\"6973\" data-start=\"6958\"\u003emislabelled\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"7005\" data-start=\"6976\"\u003e\u003cstrong data-end=\"7005\" data-start=\"6976\"\u003eComparative safety matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"7401\" data-start=\"7007\"\u003e\n\u003cthead data-end=\"7073\" data-start=\"7007\"\u003e\n\u003ctr data-end=\"7073\" data-start=\"7007\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"7017\" data-start=\"7007\"\u003eConcern\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"7030\" data-start=\"7017\"\u003e\u003cstrong data-end=\"7029\" data-start=\"7019\"\u003eDihexa\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"7056\" data-start=\"7030\"\u003e\u003cstrong data-end=\"7055\" data-start=\"7032\"\u003eKetamine\/esketamine\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"7073\" data-start=\"7056\"\u003e\u003cstrong data-end=\"7071\" data-start=\"7058\"\u003eDonepezil\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"7401\" data-start=\"7092\"\u003e\n\u003ctr data-end=\"7201\" data-start=\"7092\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7104\" data-start=\"7092\"\u003eMechanism\u003c\/td\u003e\n\u003ctd data-end=\"7133\" data-start=\"7104\" data-col-size=\"sm\"\u003e\u003cstrong data-end=\"7132\" data-start=\"7106\"\u003eHGF–c-Met synaptogenic\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"7168\" data-start=\"7133\" data-col-size=\"sm\"\u003eNMDA modulation → synaptogenesis\u003c\/td\u003e\n\u003ctd data-end=\"7201\" data-start=\"7168\" data-col-size=\"sm\"\u003eAChE inhibition (symptomatic)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7273\" data-start=\"7202\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7219\" data-start=\"7202\"\u003eHuman evidence\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7230\" data-start=\"7219\"\u003e\u003cstrong data-end=\"7229\" data-start=\"7221\"\u003eNone\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"7247\" data-start=\"7230\" data-col-size=\"sm\"\u003eStrong for TRD\u003c\/td\u003e\n\u003ctd data-end=\"7273\" data-start=\"7247\" data-col-size=\"sm\"\u003eStrong for AD symptoms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7340\" data-start=\"7274\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7291\" data-start=\"7274\"\u003eOncogenic risk\u003c\/td\u003e\n\u003ctd data-end=\"7319\" data-start=\"7291\" data-col-size=\"sm\"\u003e\u003cstrong data-end=\"7318\" data-start=\"7293\"\u003eTheoretical ↑ (c-Met)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"7329\" data-start=\"7319\" data-col-size=\"sm\"\u003eNeutral\u003c\/td\u003e\n\u003ctd data-end=\"7340\" data-start=\"7329\" data-col-size=\"sm\"\u003eNeutral\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7401\" data-start=\"7341\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7365\" data-start=\"7341\"\u003eAcute psychotomimesis\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7385\" data-start=\"7365\"\u003eLow (theoretical)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7395\" data-start=\"7385\"\u003e\u003cstrong data-end=\"7394\" data-start=\"7387\"\u003eYes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"7401\" data-start=\"7395\" data-col-size=\"sm\"\u003eNo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"7406\" data-start=\"7403\"\u003e\n\u003ch2 data-end=\"7434\" data-start=\"7408\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-end=\"7683\" data-start=\"7436\"\u003e\n\u003cli data-end=\"7492\" data-start=\"7436\"\u003e\n\u003cp data-end=\"7492\" data-start=\"7438\"\u003e\u003cstrong data-end=\"7454\" data-start=\"7438\"\u003eNot approved\u003c\/strong\u003e by FDA\/EMA\/PMDA for any indication.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7580\" data-start=\"7493\"\u003e\n\u003cp data-end=\"7580\" data-start=\"7495\"\u003eExists in \u003cstrong data-end=\"7542\" data-start=\"7505\"\u003epatents and academic publications\u003c\/strong\u003e; no registered therapeutic product.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7683\" data-start=\"7581\"\u003e\n\u003cp data-end=\"7683\" data-start=\"7583\"\u003e\u003cstrong data-end=\"7600\" data-start=\"7583\"\u003eCompounded\/RC\u003c\/strong\u003e versions online are \u003cstrong data-end=\"7644\" data-start=\"7621\"\u003enot quality-assured\u003c\/strong\u003e and carry \u003cstrong data-end=\"7682\" data-start=\"7655\"\u003eunknown identity\/purity\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"7688\" data-start=\"7685\"\u003e\n\u003ch2 data-end=\"7730\" data-start=\"7690\"\u003e8. Practical Take \u0026amp; Future Directions\u003c\/h2\u003e\n\u003cul data-end=\"8638\" data-start=\"7732\"\u003e\n\u003cli data-end=\"7906\" data-start=\"7732\"\u003e\n\u003cp data-end=\"7906\" data-start=\"7734\"\u003e\u003cstrong data-end=\"7761\" data-start=\"7734\"\u003eDo not self-experiment.\u003c\/strong\u003e Until \u003cstrong data-end=\"7786\" data-start=\"7768\"\u003eGLP toxicology\u003c\/strong\u003e, \u003cstrong data-end=\"7807\" data-start=\"7788\"\u003ecarcinogenicity\u003c\/strong\u003e, \u003cstrong data-end=\"7823\" data-start=\"7809\"\u003efull PK\/PD\u003c\/strong\u003e, and \u003cstrong data-end=\"7847\" data-start=\"7829\"\u003ephase-1 safety\u003c\/strong\u003e are completed, Dihexa should remain \u003cstrong data-end=\"7903\" data-start=\"7884\"\u003elaboratory-only\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8484\" data-start=\"7907\"\u003e\n\u003cp data-end=\"7940\" data-start=\"7909\"\u003e\u003cstrong data-end=\"7938\" data-start=\"7909\"\u003eClinical trial blueprint:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"8484\" data-start=\"7943\"\u003e\n\u003cli data-end=\"8142\" data-start=\"7943\"\u003e\n\u003cp data-end=\"8142\" data-start=\"7945\"\u003e\u003cstrong data-end=\"7957\" data-start=\"7945\"\u003ePhase 1:\u003c\/strong\u003e SAD\/MAD in healthy adults with \u003cstrong data-end=\"8011\" data-start=\"7989\"\u003eoncology screening\u003c\/strong\u003e, cutaneous\/thyroid exams, and \u003cstrong data-end=\"8067\" data-start=\"8042\"\u003ecirculating tumor DNA\u003c\/strong\u003e exploratory safety markers; \u003cstrong data-end=\"8124\" data-start=\"8096\"\u003eqEEG\/cognitive batteries\u003c\/strong\u003e for PD signals.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8339\" data-start=\"8145\"\u003e\n\u003cp data-end=\"8339\" data-start=\"8147\"\u003e\u003cstrong data-end=\"8187\" data-start=\"8147\"\u003ePhase 2a (MCI\/early AD or post-TBI):\u003c\/strong\u003e Biomarker-anchored (functional connectivity MRI, plasma p-tau\/Aβ, neurofilament light), \u003cstrong data-end=\"8297\" data-start=\"8276\"\u003edigital cognition\u003c\/strong\u003e, and \u003cstrong data-end=\"8326\" data-start=\"8303\"\u003espeech\/eye-tracking\u003c\/strong\u003e endpoints.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8484\" data-start=\"8342\"\u003e\n\u003cp data-end=\"8484\" data-start=\"8344\"\u003e\u003cstrong data-end=\"8364\" data-start=\"8344\"\u003eRisk mitigation:\u003c\/strong\u003e Exclude \u003cstrong data-end=\"8390\" data-start=\"8373\"\u003eactive cancer\u003c\/strong\u003e, mandate \u003cstrong data-end=\"8426\" data-start=\"8400\"\u003eoncologic surveillance\u003c\/strong\u003e, and cap exposure duration until risk is characterized.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8638\" data-start=\"8485\"\u003e\n\u003cp data-end=\"8638\" data-start=\"8487\"\u003e\u003cstrong data-end=\"8501\" data-start=\"8487\"\u003eChemistry:\u003c\/strong\u003e Explore \u003cstrong data-end=\"8539\" data-start=\"8510\"\u003ebiased c-Met potentiation\u003c\/strong\u003e, \u003cstrong data-end=\"8569\" data-start=\"8541\"\u003ebrain-selective delivery\u003c\/strong\u003e, or \u003cstrong data-end=\"8605\" data-start=\"8574\"\u003eactivity-dependent prodrugs\u003c\/strong\u003e to minimize peripheral exposure.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"8643\" data-start=\"8640\"\u003e\n\u003ch3 data-end=\"8668\" data-start=\"8645\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-end=\"9574\" data-start=\"8670\"\u003e\n\u003cli data-end=\"8848\" data-start=\"8670\"\u003e\n\u003cp data-end=\"8848\" data-start=\"8672\"\u003e\u003cem data-end=\"8764\" data-start=\"8672\"\u003eJournal of Pharmacology and Experimental Therapeutics; Neurobiology of Learning and Memory\u003c\/em\u003e — Dihexa’s memory enhancement in rodent models and dose–response characteristics.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9014\" data-start=\"8849\"\u003e\n\u003cp data-end=\"9014\" data-start=\"8851\"\u003e\u003cem data-end=\"8925\" data-start=\"8851\"\u003eProceedings of the National Academy of Sciences; Journal of Neuroscience\u003c\/em\u003e — HGF–c-Met–mediated synaptogenesis and downstream signaling (ERK\/Akt, spine density).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9151\" data-start=\"9015\"\u003e\n\u003cp data-end=\"9151\" data-start=\"9017\"\u003e\u003cem data-end=\"9068\" data-start=\"9017\"\u003eNeurotherapeutics; Alzheimer’s Research \u0026amp; Therapy\u003c\/em\u003e — Synaptic rescue frameworks in AD models; plasticity gene programs (BDNF, Arc).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9258\" data-start=\"9152\"\u003e\n\u003cp data-end=\"9258\" data-start=\"9154\"\u003e\u003cem data-end=\"9194\" data-start=\"9154\"\u003eBrain Research; Experimental Neurology\u003c\/em\u003e — Traumatic brain injury recovery and neurite outgrowth data.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9353\" data-start=\"9259\"\u003e\n\u003cp data-end=\"9353\" data-start=\"9261\"\u003e\u003cem data-end=\"9305\" data-start=\"9261\"\u003eMovement Disorders; Molecular Neurobiology\u003c\/em\u003e — Parkinsonian model plasticity and behavior.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9448\" data-start=\"9354\"\u003e\n\u003cp data-end=\"9448\" data-start=\"9356\"\u003e\u003cem data-end=\"9380\" data-start=\"9356\"\u003eHearing Research; JARO\u003c\/em\u003e — Cochlear synaptopathy protection\/repair under HGF potentiation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9574\" data-start=\"9449\"\u003e\n\u003cp data-end=\"9574\" data-start=\"9451\"\u003e\u003cem data-end=\"9491\" data-start=\"9451\"\u003eCancer Research; Nature Reviews Cancer\u003c\/em\u003e — Biology and oncogenic potential of \u003cstrong data-end=\"9542\" data-start=\"9529\"\u003eHGF–c-Met\u003c\/strong\u003e signaling (context for safety).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":52800697958664,"sku":null,"price":100.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0937\/9053\/5944\/files\/Dihexa_1g.png?v=1763139515"},{"product_id":"9-mbc-1g","title":"9-MBC 1g","description":"\u003cp class=\"\" data-end=\"467\" data-start=\"0\"\u003e\u003cstrong\u003e\u003cstrong data-start=\"377\" data-end=\"392\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                         \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"\" data-end=\"467\" data-start=\"0\"\u003e\u003cstrong\u003e9-Methyl-β-carboline \u003cmeta charset=\"UTF-8\"\u003e\u003c\/strong\u003e(9-MBC) is a synthetic \u003cstrong data-start=\"116\" data-end=\"131\"\u003eβ-carboline\u003c\/strong\u003e derivative investigated as a \u003cstrong data-start=\"161\" data-end=\"195\"\u003eneurotrophic, pro-dopaminergic\u003c\/strong\u003e research compound. In cell and rodent models it promotes \u003cstrong data-start=\"253\" data-end=\"325\"\u003edopaminergic neuron survival, differentiation, and neurite outgrowth\u003c\/strong\u003e, with signals of \u003cstrong data-start=\"343\" data-end=\"368\"\u003emitochondrial support\u003c\/strong\u003e and \u003cstrong data-start=\"373\" data-end=\"419\"\u003eanti-inflammatory microglial reprogramming\u003c\/strong\u003e. It is \u003cstrong data-start=\"427\" data-end=\"443\"\u003enot approved\u003c\/strong\u003e for human use; evidence is \u003cstrong data-start=\"471\" data-end=\"486\"\u003epreclinical\u003c\/strong\u003e.\u003c\/p\u003e\n\u003chr data-start=\"489\" data-end=\"492\"\u003e\n\u003ch3 data-start=\"494\" data-end=\"550\"\u003eAdditional Benefits of 9-MBC Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"552\" data-end=\"2801\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"552\" data-end=\"580\"\u003e\n\u003ctr data-start=\"552\" data-end=\"580\"\u003e\n\u003cth data-start=\"552\" data-end=\"562\" data-col-size=\"sm\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-start=\"562\" data-end=\"580\" data-col-size=\"xl\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"591\" data-end=\"2801\"\u003e\n\u003ctr data-start=\"591\" data-end=\"906\"\u003e\n\u003ctd data-start=\"591\" data-end=\"624\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"593\" data-end=\"623\"\u003e1 Dopaminergic neurotrophy\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"624\" data-end=\"906\" data-col-size=\"xl\"\u003eIn primary midbrain cultures and lesion models, 9-MBC increases \u003cstrong data-start=\"690\" data-end=\"711\"\u003eTH⁺ neuron counts\u003c\/strong\u003e, \u003cstrong data-start=\"713\" data-end=\"731\"\u003eneurite length\u003c\/strong\u003e, and \u003cstrong data-start=\"737\" data-end=\"765\"\u003edopamine synthesis genes\u003c\/strong\u003e (TH, DAT), suggesting true trophic action rather than mere MAO inhibition. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Journal of Neurochemistry; Molecular Neurobiology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"907\" data-end=\"1167\"\u003e\n\u003ctd data-start=\"907\" data-end=\"945\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"909\" data-end=\"944\"\u003e2 Protection in PD toxin models\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"945\" data-end=\"1167\" data-col-size=\"xl\"\u003eAttenuates loss of dopaminergic neurons and motor deficits after \u003cstrong data-start=\"1012\" data-end=\"1022\"\u003e6-OHDA\u003c\/strong\u003e or \u003cstrong data-start=\"1026\" data-end=\"1039\"\u003eMPTP\/MPP⁺\u003c\/strong\u003e, linked to \u003cstrong data-start=\"1051\" data-end=\"1081\"\u003emitochondrial preservation\u003c\/strong\u003e and \u003cstrong data-start=\"1086\" data-end=\"1116\"\u003eoxidative-stress buffering\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Neuropharmacology; Brain Research\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1168\" data-end=\"1426\"\u003e\n\u003ctd data-start=\"1168\" data-end=\"1198\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1170\" data-end=\"1197\"\u003e3 Mitochondrial support\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1198\" data-end=\"1426\" data-col-size=\"xl\"\u003eImproves \u003cstrong data-start=\"1209\" data-end=\"1235\"\u003ecomplex I\/III activity\u003c\/strong\u003e and \u003cstrong data-start=\"1240\" data-end=\"1262\"\u003emembrane potential\u003c\/strong\u003e, raises \u003cstrong data-start=\"1271\" data-end=\"1291\"\u003ePGC-1α\/NRF1\/TFAM\u003c\/strong\u003esignaling, and lowers \u003cstrong data-start=\"1314\" data-end=\"1323\"\u003emtROS\u003c\/strong\u003e, pointing to a bioenergetic mechanism. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Redox Biology; Journal of Neuroscience Research\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1427\" data-end=\"1668\"\u003e\n\u003ctd data-start=\"1427\" data-end=\"1457\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1429\" data-end=\"1456\"\u003e4 Microglial modulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1457\" data-end=\"1668\" data-col-size=\"xl\"\u003eShifts microglia toward a \u003cstrong data-start=\"1485\" data-end=\"1512\"\u003epro-resolving phenotype\u003c\/strong\u003e, lowering \u003cstrong data-start=\"1523\" data-end=\"1538\"\u003eTNF-α\/IL-1β\u003c\/strong\u003e and increasing trophic cues (e.g., \u003cstrong data-start=\"1574\" data-end=\"1587\"\u003eBDNF\/GDNF\u003c\/strong\u003e signals) in injured striatum. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Glia; Journal of Neuroinflammation\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1669\" data-end=\"1933\"\u003e\n\u003ctd data-start=\"1669\" data-end=\"1704\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1671\" data-end=\"1703\"\u003e5 Adult neurogenesis signals\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1704\" data-end=\"1933\" data-col-size=\"xl\"\u003eIn hippocampal paradigms, increases \u003cstrong data-start=\"1742\" data-end=\"1756\"\u003eDCX⁺\/BrdU⁺\u003c\/strong\u003e indices and dendritic maturation; behavioral readouts suggest \u003cstrong data-start=\"1819\" data-end=\"1843\"\u003ememory consolidation\u003c\/strong\u003e benefits in stress models. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Hippocampus; Neurobiology of Learning \u0026amp; Memory\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1934\" data-end=\"2093\"\u003e\n\u003ctd data-start=\"1934\" data-end=\"1962\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1936\" data-end=\"1961\"\u003e6 Synaptic plasticity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1962\" data-end=\"2093\" data-col-size=\"xl\"\u003eUpregulates \u003cstrong data-start=\"1976\" data-end=\"1996\"\u003ePSD-95, synapsin\u003c\/strong\u003e, and \u003cstrong data-start=\"2002\" data-end=\"2014\"\u003eCREB\/ERK\u003c\/strong\u003e pathways; improves LTP readouts ex vivo. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Synapse; Neuroscience\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2094\" data-end=\"2350\"\u003e\n\u003ctd data-start=\"2094\" data-end=\"2122\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"2096\" data-end=\"2121\"\u003e7 Anti-excitotoxicity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2122\" data-end=\"2350\" data-col-size=\"xl\"\u003eMitigates \u003cstrong data-start=\"2134\" data-end=\"2152\"\u003eglutamate\/NMDA\u003c\/strong\u003e injury via \u003cstrong data-start=\"2164\" data-end=\"2181\"\u003eCa²⁺ handling\u003c\/strong\u003e, \u003cstrong data-start=\"2183\" data-end=\"2218\"\u003eantioxidant enzymes (SOD2, GPx)\u003c\/strong\u003e, and maintenance of \u003cstrong data-start=\"2239\" data-end=\"2269\"\u003emitochondrial permeability\u003c\/strong\u003e thresholds. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Experimental Neurology; Neurochemistry International\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2351\" data-end=\"2542\"\u003e\n\u003ctd data-start=\"2351\" data-end=\"2389\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"2353\" data-end=\"2388\"\u003e8 Myelin\/axon support (signals)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2389\" data-end=\"2542\" data-col-size=\"xl\"\u003eEnhances \u003cstrong data-start=\"2400\" data-end=\"2427\"\u003eneurite\/axon elongation\u003c\/strong\u003e and may stabilize oligodendroglial support in mixed cultures—early evidence only. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Cells; ASN Neuro\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2543\" data-end=\"2801\"\u003e\n\u003ctd data-start=\"2543\" data-end=\"2579\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"2545\" data-end=\"2578\"\u003e9 Depression\/anhedonia models\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2579\" data-end=\"2801\" data-col-size=\"xl\"\u003eNormalizes \u003cstrong data-start=\"2592\" data-end=\"2614\"\u003esucrose preference\u003c\/strong\u003e, \u003cstrong data-start=\"2616\" data-end=\"2646\"\u003enovelty-suppressed feeding\u003c\/strong\u003e, and \u003cstrong data-start=\"2652\" data-end=\"2678\"\u003eforced-swim immobility\u003c\/strong\u003e in stress rodents, paralleling increases in \u003cstrong data-start=\"2723\" data-end=\"2731\"\u003eBDNF\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Translational Psychiatry; Behavioural Brain Research\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"2803\" data-end=\"2806\"\u003e\n\u003ch2 data-start=\"2808\" data-end=\"2843\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-start=\"2845\" data-end=\"2885\"\u003e2.1 Pharmacodynamics (working model)\u003c\/h3\u003e\n\u003cul data-start=\"2886\" data-end=\"3441\"\u003e\n\u003cli data-start=\"2886\" data-end=\"3015\"\u003e\n\u003cp data-start=\"2888\" data-end=\"3015\"\u003e\u003cstrong data-start=\"2888\" data-end=\"2918\"\u003ePro-dopaminergic trophism:\u003c\/strong\u003e Upregulates \u003cstrong data-start=\"2931\" data-end=\"2948\"\u003eTH, AADC, DAT\u003c\/strong\u003e expression, enhances dopaminergic differentiation and maintenance.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3016\" data-end=\"3143\"\u003e\n\u003cp data-start=\"3018\" data-end=\"3143\"\u003e\u003cstrong data-start=\"3018\" data-end=\"3049\"\u003eMitochondrial preservation:\u003c\/strong\u003e Supports \u003cstrong data-start=\"3059\" data-end=\"3069\"\u003eOXPHOS\u003c\/strong\u003e, reduces \u003cstrong data-start=\"3079\" data-end=\"3088\"\u003emtROS\u003c\/strong\u003e, and may activate \u003cstrong data-start=\"3107\" data-end=\"3122\"\u003eAMPK→PGC-1α\u003c\/strong\u003ebiogenesis programs.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3144\" data-end=\"3249\"\u003e\n\u003cp data-start=\"3146\" data-end=\"3249\"\u003e\u003cstrong data-start=\"3146\" data-end=\"3176\"\u003eNeuroinflammation control:\u003c\/strong\u003e Microglial \u003cstrong data-start=\"3188\" data-end=\"3197\"\u003eNF-κB\u003c\/strong\u003e restraint and increased neurotrophic factor milieu.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3250\" data-end=\"3441\"\u003e\n\u003cp data-start=\"3252\" data-end=\"3441\"\u003e\u003cstrong data-start=\"3252\" data-end=\"3271\"\u003eEnzyme targets:\u003c\/strong\u003e Unlike harmine\/harmaline, \u003cstrong data-start=\"3298\" data-end=\"3342\"\u003estrong MAO-A\/B inhibition is not central\u003c\/strong\u003e to 9-MBC’s effects at trophic concentrations (some weak, context-dependent interactions reported).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"3443\" data-end=\"3470\"\u003e2.2 Down-stream biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"3472\" data-end=\"3824\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"3472\" data-end=\"3514\"\u003e\n\u003ctr data-start=\"3472\" data-end=\"3514\"\u003e\n\u003cth data-start=\"3472\" data-end=\"3482\" data-col-size=\"sm\"\u003ePathway\u003c\/th\u003e\n\u003cth data-start=\"3482\" data-end=\"3503\" data-col-size=\"sm\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-start=\"3503\" data-end=\"3514\" data-col-size=\"sm\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"3529\" data-end=\"3824\"\u003e\n\u003ctr data-start=\"3529\" data-end=\"3608\"\u003e\n\u003ctd data-start=\"3529\" data-end=\"3552\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3531\" data-end=\"3551\"\u003ePGC-1α\/NRF1\/TFAM\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3552\" data-end=\"3594\" data-col-size=\"sm\"\u003eMitochondrial biogenesis, ATP stability\u003c\/td\u003e\n\u003ctd data-start=\"3594\" data-end=\"3608\" data-col-size=\"sm\"\u003eDA neurons\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3609\" data-end=\"3680\"\u003e\n\u003ctd data-start=\"3609\" data-end=\"3629\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3611\" data-end=\"3628\"\u003eERK\/CREB\/BDNF\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3629\" data-end=\"3656\" data-col-size=\"sm\"\u003eSynaptic plasticity, LTP\u003c\/td\u003e\n\u003ctd data-start=\"3656\" data-end=\"3680\" data-col-size=\"sm\"\u003eHippocampus\/striatum\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3681\" data-end=\"3760\"\u003e\n\u003ctd data-start=\"3681\" data-end=\"3703\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3683\" data-end=\"3702\"\u003eNF-κB restraint\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3703\" data-end=\"3737\" data-col-size=\"sm\"\u003e↓ TNF-α\/IL-1β, microglial shift\u003c\/td\u003e\n\u003ctd data-start=\"3737\" data-end=\"3760\" data-col-size=\"sm\"\u003eInjury\/inflammation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3761\" data-end=\"3824\"\u003e\n\u003ctd data-start=\"3761\" data-end=\"3787\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3763\" data-end=\"3786\"\u003eAntioxidant enzymes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3787\" data-end=\"3808\" data-col-size=\"sm\"\u003e↓ Oxidative damage\u003c\/td\u003e\n\u003ctd data-start=\"3808\" data-end=\"3824\" data-col-size=\"sm\"\u003eToxin models\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"3826\" data-end=\"3829\"\u003e\n\u003ch2 data-start=\"3831\" data-end=\"3872\"\u003e3. Pharmacokinetics (preclinical only)\u003c\/h2\u003e\n\u003cul data-start=\"3874\" data-end=\"4201\"\u003e\n\u003cli data-start=\"3874\" data-end=\"4006\"\u003e\n\u003cp data-start=\"3876\" data-end=\"4006\"\u003e\u003cstrong data-start=\"3876\" data-end=\"3886\"\u003eRoute:\u003c\/strong\u003e Effective in \u003cstrong data-start=\"3900\" data-end=\"3919\"\u003esystemic dosing\u003c\/strong\u003e in rodents (IP\/PO in reports); good \u003cstrong data-start=\"3956\" data-end=\"3977\"\u003ebrain penetration\u003c\/strong\u003e inferred from CNS effects.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4007\" data-end=\"4080\"\u003e\n\u003cp data-start=\"4009\" data-end=\"4080\"\u003e\u003cstrong data-start=\"4009\" data-end=\"4032\"\u003eHalf-life\/exposure:\u003c\/strong\u003e Hours-scale in animals; human PK \u003cstrong data-start=\"4066\" data-end=\"4077\"\u003eunknown\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4081\" data-end=\"4201\"\u003e\n\u003cp data-start=\"4083\" data-end=\"4201\"\u003e\u003cstrong data-start=\"4083\" data-end=\"4098\"\u003eMetabolism:\u003c\/strong\u003e Likely hepatic oxidative metabolism typical of β-carbolines; detailed metabolite map not standardized.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4203\" data-end=\"4206\"\u003e\n\u003ch2 data-start=\"4208\" data-end=\"4230\"\u003e4. Evidence Summary\u003c\/h2\u003e\n\u003cul data-start=\"4232\" data-end=\"4598\"\u003e\n\u003cli data-start=\"4232\" data-end=\"4359\"\u003e\n\u003cp data-start=\"4234\" data-end=\"4359\"\u003e\u003cstrong data-start=\"4234\" data-end=\"4247\"\u003eIn vitro:\u003c\/strong\u003e Robust dopaminergic neuritogenesis and survival across primary cultures; synergy with \u003cstrong data-start=\"4334\" data-end=\"4347\"\u003eGDNF\/BDNF\u003c\/strong\u003epathways.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4360\" data-end=\"4526\"\u003e\n\u003cp data-start=\"4362\" data-end=\"4526\"\u003e\u003cstrong data-start=\"4362\" data-end=\"4374\"\u003eIn vivo:\u003c\/strong\u003e Neuroprotection and functional improvement in \u003cstrong data-start=\"4421\" data-end=\"4433\"\u003ePD toxin\u003c\/strong\u003e and \u003cstrong data-start=\"4438\" data-end=\"4459\"\u003estress\/depression\u003c\/strong\u003e models; hints of \u003cstrong data-start=\"4477\" data-end=\"4499\"\u003eadult neurogenesis\u003c\/strong\u003e and \u003cstrong data-start=\"4504\" data-end=\"4517\"\u003ecognitive\u003c\/strong\u003e gains.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4527\" data-end=\"4598\"\u003e\n\u003cp data-start=\"4529\" data-end=\"4598\"\u003e\u003cstrong data-start=\"4529\" data-end=\"4548\"\u003eNo human trials\u003c\/strong\u003e to date; all efficacy claims are \u003cstrong data-start=\"4582\" data-end=\"4597\"\u003epreclinical\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cblockquote data-start=\"4600\" data-end=\"4819\"\u003e\n\u003cp data-start=\"4602\" data-end=\"4819\"\u003e\u003cstrong data-start=\"4602\" data-end=\"4628\"\u003eEvidence quality note:\u003c\/strong\u003e Convergent cellular and rodent data support \u003cstrong data-start=\"4673\" data-end=\"4727\"\u003edopaminergic trophism and mitochondrial protection\u003c\/strong\u003e. Translation to humans is \u003cstrong data-start=\"4754\" data-end=\"4766\"\u003eunproven\u003c\/strong\u003e; dosing windows and long-term safety remain unknown.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-start=\"4821\" data-end=\"4824\"\u003e\n\u003ch2 data-start=\"4826\" data-end=\"4872\"\u003e5. Emerging Clinical Interests (conceptual)\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"4874\" data-end=\"5293\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"4874\" data-end=\"4904\"\u003e\n\u003ctr data-start=\"4874\" data-end=\"4904\"\u003e\n\u003cth data-start=\"4874\" data-end=\"4882\" data-col-size=\"md\"\u003eField\u003c\/th\u003e\n\u003cth data-start=\"4882\" data-end=\"4894\" data-col-size=\"md\"\u003eRationale\u003c\/th\u003e\n\u003cth data-start=\"4894\" data-end=\"4904\" data-col-size=\"sm\"\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"4919\" data-end=\"5293\"\u003e\n\u003ctr data-start=\"4919\" data-end=\"5035\"\u003e\n\u003ctd data-start=\"4919\" data-end=\"4967\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"4921\" data-end=\"4966\"\u003eParkinson’s disease (adjunct or prodrome)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"4967\" data-end=\"5020\" data-col-size=\"md\"\u003eDA neuron protection\/trophism + microglial control\u003c\/td\u003e\n\u003ctd data-start=\"5020\" data-end=\"5035\" data-col-size=\"sm\"\u003ePreclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5036\" data-end=\"5128\"\u003e\n\u003ctd data-start=\"5036\" data-end=\"5080\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"5038\" data-end=\"5079\"\u003ePost-toxin\/trauma dopaminergic injury\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5080\" data-end=\"5113\" data-col-size=\"md\"\u003eRegeneration\/neurite outgrowth\u003c\/td\u003e\n\u003ctd data-start=\"5113\" data-end=\"5128\" data-col-size=\"sm\"\u003ePreclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5129\" data-end=\"5226\"\u003e\n\u003ctd data-start=\"5129\" data-end=\"5162\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"5131\" data-end=\"5161\"\u003eCognitive impairment\/aging\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5162\" data-end=\"5211\" data-col-size=\"md\"\u003eSynaptic plasticity + hippocampal neurogenesis\u003c\/td\u003e\n\u003ctd data-start=\"5211\" data-end=\"5226\" data-col-size=\"sm\"\u003ePreclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5227\" data-end=\"5293\"\u003e\n\u003ctd data-start=\"5227\" data-end=\"5254\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"5229\" data-end=\"5253\"\u003eDepression\/anhedonia\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5254\" data-end=\"5278\" data-col-size=\"md\"\u003ePlasticity\/BDNF angle\u003c\/td\u003e\n\u003ctd data-start=\"5278\" data-end=\"5293\" data-col-size=\"sm\"\u003ePreclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"5295\" data-end=\"5298\"\u003e\n\u003ch2 data-start=\"5300\" data-end=\"5357\"\u003e6. Safety and Tolerability (unknowns \u0026amp; class cautions)\u003c\/h2\u003e\n\u003cul data-start=\"5359\" data-end=\"6375\"\u003e\n\u003cli data-start=\"5359\" data-end=\"5410\"\u003e\n\u003cp data-start=\"5361\" data-end=\"5410\"\u003e\u003cstrong data-start=\"5361\" data-end=\"5378\"\u003eHuman safety:\u003c\/strong\u003e \u003cstrong data-start=\"5379\" data-end=\"5391\"\u003eUnknown.\u003c\/strong\u003e No phase-1 data.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5411\" data-end=\"5629\"\u003e\n\u003cp data-start=\"5413\" data-end=\"5629\"\u003e\u003cstrong data-start=\"5413\" data-end=\"5456\"\u003eGenotoxic\/phototoxic potential (class):\u003c\/strong\u003e Planar \u003cstrong data-start=\"5464\" data-end=\"5480\"\u003eβ-carbolines\u003c\/strong\u003e can intercalate DNA and, at high doses or UV exposure, show \u003cstrong data-start=\"5541\" data-end=\"5565\"\u003ephototoxic\/genotoxic\u003c\/strong\u003e risks in some assays; 9-MBC-specific margins are not defined.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5630\" data-end=\"5793\"\u003e\n\u003cp data-start=\"5632\" data-end=\"5793\"\u003e\u003cstrong data-start=\"5632\" data-end=\"5653\"\u003eMAO interactions:\u003c\/strong\u003e Although not a strong MAO inhibitor at trophic doses, \u003cstrong data-start=\"5708\" data-end=\"5719\"\u003ecaution\u003c\/strong\u003e with \u003cstrong data-start=\"5725\" data-end=\"5746\"\u003eMAOI\/serotonergic\u003c\/strong\u003ecombinations is prudent until characterized.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5794\" data-end=\"5931\"\u003e\n\u003cp data-start=\"5796\" data-end=\"5931\"\u003e\u003cstrong data-start=\"5796\" data-end=\"5818\"\u003eSeizure threshold:\u003c\/strong\u003e High doses of some β-carbolines lower seizure threshold; relevance to 9-MBC is unclear—avoid in epilepsy risk.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5932\" data-end=\"6095\"\u003e\n\u003cp data-start=\"5934\" data-end=\"6095\"\u003e\u003cstrong data-start=\"5934\" data-end=\"5960\"\u003eCardiac\/mitochondrial:\u003c\/strong\u003e Excessive mitochondrial modulation could theoretically affect \u003cstrong data-start=\"6023\" data-end=\"6049\"\u003econductance\/energetics\u003c\/strong\u003e—ECG and metabolic safety need formal study.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6096\" data-end=\"6222\"\u003e\n\u003cp data-start=\"6098\" data-end=\"6222\"\u003e\u003cstrong data-start=\"6098\" data-end=\"6124\"\u003eReproductive\/oncology:\u003c\/strong\u003e No data; avoid in \u003cstrong data-start=\"6143\" data-end=\"6156\"\u003epregnancy\u003c\/strong\u003e and in \u003cstrong data-start=\"6164\" data-end=\"6185\"\u003eactive malignancy\u003c\/strong\u003e until carcinogenicity is excluded.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6223\" data-end=\"6375\"\u003e\n\u003cp data-start=\"6225\" data-end=\"6375\"\u003e\u003cstrong data-start=\"6225\" data-end=\"6245\"\u003eProduct quality:\u003c\/strong\u003e Grey-market “nootropic” supplies are \u003cstrong data-start=\"6283\" data-end=\"6298\"\u003eunregulated\u003c\/strong\u003e and frequently \u003cstrong data-start=\"6314\" data-end=\"6331\"\u003emisidentified\u003c\/strong\u003e—avoid human use outside regulated research.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"6377\" data-end=\"6435\"\u003e\u003cstrong data-start=\"6377\" data-end=\"6435\"\u003eComparative snapshot (dopaminergic-trophic strategies)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"6437\" data-end=\"6908\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"6437\" data-end=\"6515\"\u003e\n\u003ctr data-start=\"6437\" data-end=\"6515\"\u003e\n\u003cth data-start=\"6437\" data-end=\"6447\" data-col-size=\"sm\"\u003eFeature\u003c\/th\u003e\n\u003cth data-start=\"6447\" data-end=\"6459\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6449\" data-end=\"6458\"\u003e9-MBC\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6459\" data-end=\"6487\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6461\" data-end=\"6486\"\u003eSelegiline\/rasagiline\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6487\" data-end=\"6515\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6489\" data-end=\"6513\"\u003eGDNF (intracerebral)\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"6534\" data-end=\"6908\"\u003e\n\u003ctr data-start=\"6534\" data-end=\"6661\"\u003e\n\u003ctd data-start=\"6534\" data-end=\"6551\" data-col-size=\"sm\"\u003ePrimary action\u003c\/td\u003e\n\u003ctd data-start=\"6551\" data-end=\"6596\" data-col-size=\"sm\"\u003e\n\u003cstrong data-start=\"6553\" data-end=\"6583\"\u003eNeurotrophic\/mitochondrial\u003c\/strong\u003e β-carboline\u003c\/td\u003e\n\u003ctd data-start=\"6596\" data-end=\"6633\" data-col-size=\"sm\"\u003eMAO-B inhibition (neuroprotection)\u003c\/td\u003e\n\u003ctd data-start=\"6633\" data-end=\"6661\" data-col-size=\"sm\"\u003eDirect trophic signaling\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6662\" data-end=\"6763\"\u003e\n\u003ctd data-start=\"6662\" data-end=\"6673\" data-col-size=\"sm\"\u003eEvidence\u003c\/td\u003e\n\u003ctd data-start=\"6673\" data-end=\"6691\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6675\" data-end=\"6690\"\u003ePreclinical\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6691\" data-end=\"6731\" data-col-size=\"sm\"\u003eHuman (symptomatic + some protection)\u003c\/td\u003e\n\u003ctd data-start=\"6731\" data-end=\"6763\" data-col-size=\"sm\"\u003eHuman surgical trials, mixed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6764\" data-end=\"6838\"\u003e\n\u003ctd data-start=\"6764\" data-end=\"6775\" data-col-size=\"sm\"\u003eDelivery\u003c\/td\u003e\n\u003ctd data-start=\"6775\" data-end=\"6805\" data-col-size=\"sm\"\u003eOral feasible (preclinical)\u003c\/td\u003e\n\u003ctd data-start=\"6805\" data-end=\"6812\" data-col-size=\"sm\"\u003eOral\u003c\/td\u003e\n\u003ctd data-start=\"6812\" data-end=\"6838\" data-col-size=\"sm\"\u003eNeurosurgical infusion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6839\" data-end=\"6908\"\u003e\n\u003ctd data-start=\"6839\" data-end=\"6854\" data-col-size=\"sm\"\u003eSafety known\u003c\/td\u003e\n\u003ctd data-start=\"6854\" data-end=\"6863\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6856\" data-end=\"6862\"\u003eNo\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6863\" data-end=\"6883\" data-col-size=\"sm\"\u003eYes (established)\u003c\/td\u003e\n\u003ctd data-start=\"6883\" data-end=\"6908\" data-col-size=\"sm\"\u003eProcedure-heavy risks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"6910\" data-end=\"6913\"\u003e\n\u003ch2 data-start=\"6915\" data-end=\"6941\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-start=\"6943\" data-end=\"7135\"\u003e\n\u003cli data-start=\"6943\" data-end=\"6980\"\u003e\n\u003cp data-start=\"6945\" data-end=\"6980\"\u003e\u003cstrong data-start=\"6945\" data-end=\"6961\"\u003eNot approved\u003c\/strong\u003e by FDA\/EMA\/PMDA.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6981\" data-end=\"7045\"\u003e\n\u003cp data-start=\"6983\" data-end=\"7045\"\u003eNo registered IND-stage clinical program publicly available.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7046\" data-end=\"7135\"\u003e\n\u003cp data-start=\"7048\" data-end=\"7135\"\u003eAny consumer sale is \u003cstrong data-start=\"7069\" data-end=\"7097\"\u003eresearch-chemical market\u003c\/strong\u003e; identity and purity are not assured.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"7137\" data-end=\"7140\"\u003e\n\u003ch2 data-start=\"7142\" data-end=\"7182\"\u003e8. Practical Take \u0026amp; Future Directions\u003c\/h2\u003e\n\u003cul data-start=\"7184\" data-end=\"7892\"\u003e\n\u003cli data-start=\"7184\" data-end=\"7368\"\u003e\n\u003cp data-start=\"7186\" data-end=\"7368\"\u003e\u003cstrong data-start=\"7186\" data-end=\"7213\"\u003eDo not self-experiment.\u003c\/strong\u003e Priorities are \u003cstrong data-start=\"7229\" data-end=\"7247\"\u003eGLP toxicology\u003c\/strong\u003e, \u003cstrong data-start=\"7249\" data-end=\"7287\"\u003egenotoxicity\/phototoxicity screens\u003c\/strong\u003e, cardiovascular safety, and \u003cstrong data-start=\"7316\" data-end=\"7342\"\u003efirst-in-human SAD\/MAD\u003c\/strong\u003e before any patient use.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7369\" data-end=\"7719\"\u003e\n\u003cp data-start=\"7371\" data-end=\"7396\"\u003e\u003cstrong data-start=\"7371\" data-end=\"7394\"\u003eTrial design ideas:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"7399\" data-end=\"7719\"\u003e\n\u003cli data-start=\"7399\" data-end=\"7567\"\u003e\n\u003cp data-start=\"7401\" data-end=\"7567\"\u003e\u003cstrong data-start=\"7401\" data-end=\"7413\"\u003ePhase 1:\u003c\/strong\u003e PK\/PD with \u003cstrong data-start=\"7425\" data-end=\"7433\"\u003eqEEG\u003c\/strong\u003e, \u003cstrong data-start=\"7435\" data-end=\"7449\"\u003eoculomotor\u003c\/strong\u003e and \u003cstrong data-start=\"7454\" data-end=\"7471\"\u003emotor battery\u003c\/strong\u003e, \u003cstrong data-start=\"7473\" data-end=\"7501\"\u003emitochondrial biomarkers\u003c\/strong\u003e (acyl-carnitines), and \u003cstrong data-start=\"7525\" data-end=\"7549\"\u003eretinal\/striatal MRI\u003c\/strong\u003e safety markers.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7570\" data-end=\"7719\"\u003e\n\u003cp data-start=\"7572\" data-end=\"7719\"\u003e\u003cstrong data-start=\"7572\" data-end=\"7607\"\u003ePhase 2a (PD or prodromal RBD):\u003c\/strong\u003e \u003cstrong data-start=\"7608\" data-end=\"7621\"\u003eDAT-SPECT\u003c\/strong\u003e, \u003cstrong data-start=\"7623\" data-end=\"7636\"\u003eMDS-UPDRS\u003c\/strong\u003e, \u003cstrong data-start=\"7638\" data-end=\"7664\"\u003egait\/typing kinematics\u003c\/strong\u003e, and \u003cstrong data-start=\"7670\" data-end=\"7691\"\u003einflammatory\/BDNF\u003c\/strong\u003e panels; exclude MAOI use.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7720\" data-end=\"7892\"\u003e\n\u003cp data-start=\"7722\" data-end=\"7892\"\u003e\u003cstrong data-start=\"7722\" data-end=\"7736\"\u003eChemistry:\u003c\/strong\u003e Optimize \u003cstrong data-start=\"7746\" data-end=\"7764\"\u003ephotostability\u003c\/strong\u003e, \u003cstrong data-start=\"7766\" data-end=\"7781\"\u003eselectivity\u003c\/strong\u003e, and \u003cstrong data-start=\"7787\" data-end=\"7812\"\u003emitochondrial-sparing\u003c\/strong\u003e while retaining dopaminergic trophism; explore \u003cstrong data-start=\"7860\" data-end=\"7872\"\u003eprodrugs\u003c\/strong\u003e with CNS targeting.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"7894\" data-end=\"7897\"\u003e\n\u003ch3 data-start=\"7899\" data-end=\"7922\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-start=\"7924\" data-end=\"8613\"\u003e\n\u003cli data-start=\"7924\" data-end=\"8045\"\u003e\n\u003cp data-start=\"7926\" data-end=\"8045\"\u003e\u003cem data-start=\"7926\" data-end=\"7977\"\u003eJournal of Neurochemistry; Molecular Neurobiology\u003c\/em\u003e — Dopaminergic differentiation and neurite outgrowth under 9-MBC.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8046\" data-end=\"8141\"\u003e\n\u003cp data-start=\"8048\" data-end=\"8141\"\u003e\u003cem data-start=\"8048\" data-end=\"8083\"\u003eNeuropharmacology; Brain Research\u003c\/em\u003e — Protection in \u003cstrong data-start=\"8100\" data-end=\"8115\"\u003eMPTP\/6-OHDA\u003c\/strong\u003e models; motor outcomes.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8142\" data-end=\"8262\"\u003e\n\u003cp data-start=\"8144\" data-end=\"8262\"\u003e\u003cem data-start=\"8144\" data-end=\"8193\"\u003eRedox Biology; Journal of Neuroscience Research\u003c\/em\u003e — Mitochondrial function, \u003cstrong data-start=\"8220\" data-end=\"8230\"\u003ePGC-1α\u003c\/strong\u003e signaling, and mtROS effects.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8263\" data-end=\"8358\"\u003e\n\u003cp data-start=\"8265\" data-end=\"8358\"\u003e\u003cem data-start=\"8265\" data-end=\"8301\"\u003eGlia; Journal of Neuroinflammation\u003c\/em\u003e — Microglial phenotype shifts and cytokine modulation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8359\" data-end=\"8454\"\u003e\n\u003cp data-start=\"8361\" data-end=\"8454\"\u003e\u003cem data-start=\"8361\" data-end=\"8409\"\u003eHippocampus; Neurobiology of Learning \u0026amp; Memory\u003c\/em\u003e — Adult neurogenesis and memory behaviors.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8455\" data-end=\"8511\"\u003e\n\u003cp data-start=\"8457\" data-end=\"8511\"\u003e\u003cem data-start=\"8457\" data-end=\"8480\"\u003eSynapse; Neuroscience\u003c\/em\u003e — Synaptic proteins and LTP.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8512\" data-end=\"8613\"\u003e\n\u003cp data-start=\"8514\" data-end=\"8613\"\u003e\u003cem data-start=\"8514\" data-end=\"8568\"\u003eExperimental Neurology; Neurochemistry International\u003c\/em\u003e — Anti-excitotoxic and antioxidant defenses.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":52801023508744,"sku":"10","price":25.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0937\/9053\/5944\/files\/9-MBC_1g.png?v=1763140626"},{"product_id":"nsi-189-1g","title":"NSI-189 1g","description":"\u003cp class=\"\" data-end=\"920\" data-start=\"352\"\u003e\u003cstrong\u003e\u003cstrong data-start=\"377\" data-end=\"392\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                         \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"\" data-end=\"920\" data-start=\"352\"\u003e\u003cstrong\u003eNSI-189 \u003cmeta charset=\"UTF-8\"\u003e\u003c\/strong\u003eis an \u003cstrong data-start=\"98\" data-end=\"168\"\u003eorally bioavailable, benzylpiperazine-aminopyridine small molecule\u003c\/strong\u003e originally developed to \u003cstrong data-start=\"193\" data-end=\"231\"\u003estimulate hippocampal neurogenesis\u003c\/strong\u003e and improve \u003cstrong data-start=\"244\" data-end=\"266\"\u003emood and cognition\u003c\/strong\u003e. It is \u003cstrong data-start=\"274\" data-end=\"290\"\u003enot approved\u003c\/strong\u003e by any regulator. After \u003cstrong data-start=\"315\" data-end=\"326\"\u003ePhase 1\u003c\/strong\u003e safety and signal-finding studies in \u003cstrong data-start=\"364\" data-end=\"399\"\u003emajor depressive disorder (MDD)\u003c\/strong\u003e, a \u003cstrong data-start=\"403\" data-end=\"414\"\u003ePhase 2\u003c\/strong\u003e program did \u003cstrong data-start=\"427\" data-end=\"439\"\u003enot meet\u003c\/strong\u003e its primary endpoint; development has largely \u003cstrong data-start=\"486\" data-end=\"497\"\u003estalled\u003c\/strong\u003e. Preclinical data indicate \u003cstrong data-start=\"525\" data-end=\"575\"\u003epro-neurogenic, synaptogenic, and neurotrophic\u003c\/strong\u003e effects in hippocampus with downstream impacts on \u003cstrong data-start=\"626\" data-end=\"646\"\u003estress circuitry\u003c\/strong\u003e and \u003cstrong data-start=\"651\" data-end=\"664\"\u003ecognition\u003c\/strong\u003e.\u003c\/p\u003e\n\u003chr data-start=\"667\" data-end=\"670\"\u003e\n\u003ch3 data-start=\"672\" data-end=\"730\"\u003eAdditional Benefits of NSI-189 Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"732\" data-end=\"2832\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"732\" data-end=\"760\"\u003e\n\u003ctr data-start=\"732\" data-end=\"760\"\u003e\n\u003cth data-start=\"732\" data-end=\"742\" data-col-size=\"md\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-start=\"742\" data-end=\"760\" data-col-size=\"xl\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"771\" data-end=\"2832\"\u003e\n\u003ctr data-start=\"771\" data-end=\"1028\"\u003e\n\u003ctd data-start=\"771\" data-end=\"804\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"773\" data-end=\"803\"\u003e1 Hippocampal neurogenesis\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"804\" data-end=\"1028\"\u003eIn vitro and rodent studies show \u003cstrong data-start=\"839\" data-end=\"872\"\u003eproliferation\/differentiation\u003c\/strong\u003e of hippocampal precursors and \u003cstrong data-start=\"903\" data-end=\"920\"\u003espine density\u003c\/strong\u003e increases; memory behaviors improve in stress\/lesion models. \u003cem data-start=\"982\" data-end=\"1026\"\u003eStem Cell Reports; Journal of Neuroscience\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1029\" data-end=\"1306\"\u003e\n\u003ctd data-start=\"1029\" data-end=\"1065\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1031\" data-end=\"1064\"\u003e2 Antidepressant signal (MDD)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"1065\" data-end=\"1306\"\u003eEarly Phase 1b showed \u003cstrong data-start=\"1089\" data-end=\"1117\"\u003eexploratory improvements\u003c\/strong\u003e on depression scales; the \u003cstrong data-start=\"1144\" data-end=\"1155\"\u003ePhase 2\u003c\/strong\u003eRCT failed its primary endpoint but suggested \u003cstrong data-start=\"1202\" data-end=\"1224\"\u003esubset\/time-course\u003c\/strong\u003e signals—insufficient for approval. \u003cem data-start=\"1260\" data-end=\"1304\"\u003eMolecular Psychiatry; Depression \u0026amp; Anxiety\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1307\" data-end=\"1566\"\u003e\n\u003ctd data-start=\"1307\" data-end=\"1371\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1309\" data-end=\"1370\"\u003e3 Cognitive enhancement (processing speed\/working memory)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"1371\" data-end=\"1566\"\u003eRodent data and small human exploratory tasks suggested \u003cstrong data-start=\"1429\" data-end=\"1458\"\u003emodest cognitive benefits\u003c\/strong\u003e, especially in \u003cstrong data-start=\"1474\" data-end=\"1494\"\u003eprocessing speed\u003c\/strong\u003e and \u003cstrong data-start=\"1499\" data-end=\"1518\"\u003everbal learning\u003c\/strong\u003e domains. \u003cem data-start=\"1528\" data-end=\"1564\"\u003eNeuropsychopharmacology; CNS Drugs\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1567\" data-end=\"1790\"\u003e\n\u003ctd data-start=\"1567\" data-end=\"1598\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1569\" data-end=\"1597\"\u003e4 Anhedonia \u0026amp; motivation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1598\" data-end=\"1790\" data-col-size=\"xl\"\u003ePreclinical stress paradigms show \u003cstrong data-start=\"1634\" data-end=\"1656\"\u003esucrose preference\u003c\/strong\u003e and \u003cstrong data-start=\"1661\" data-end=\"1683\"\u003eeffort-based tasks\u003c\/strong\u003eimprovements consistent with mesolimbic normalization. \u003cem data-start=\"1739\" data-end=\"1788\"\u003eBiological Psychiatry; Translational Psychiatry\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1791\" data-end=\"2002\"\u003e\n\u003ctd data-start=\"1791\" data-end=\"1834\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1793\" data-end=\"1833\"\u003e5 Neuroprotection after ischemia\/TBI\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"1834\" data-end=\"2002\"\u003eIn stroke\/TBI models, NSI-189 \u003cstrong data-start=\"1866\" data-end=\"1915\"\u003ereduced lesion-associated behavioral deficits\u003c\/strong\u003e and supported \u003cstrong data-start=\"1930\" data-end=\"1949\"\u003eneurite\/synapse\u003c\/strong\u003e recovery. \u003cem data-start=\"1960\" data-end=\"2000\"\u003eBrain Research; Experimental Neurology\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2003\" data-end=\"2222\"\u003e\n\u003ctd data-start=\"2003\" data-end=\"2052\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2005\" data-end=\"2051\"\u003e6 Anti-inflammatory\/neuroimmune modulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"2052\" data-end=\"2222\"\u003eDown-shift of \u003cstrong data-start=\"2068\" data-end=\"2088\"\u003emicroglial NF-κB\u003c\/strong\u003e and cytokines (IL-1β, TNF-α) reported alongside neurogenesis; causal links remain exploratory. \u003cem data-start=\"2184\" data-end=\"2220\"\u003eGlia; Journal of Neuroinflammation\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2223\" data-end=\"2419\"\u003e\n\u003ctd data-start=\"2223\" data-end=\"2257\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2225\" data-end=\"2256\"\u003e7 Stress-axis normalization\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"2257\" data-end=\"2419\"\u003eRodent work shows \u003cstrong data-start=\"2277\" data-end=\"2289\"\u003eHPA-axis\u003c\/strong\u003e re-tuning with lower corticosterone reactivity and improved \u003cstrong data-start=\"2350\" data-end=\"2374\"\u003ehippocampal feedback\u003c\/strong\u003e. \u003cem data-start=\"2376\" data-end=\"2417\"\u003eEndocrinology; Psychoneuroendocrinology\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2420\" data-end=\"2599\"\u003e\n\u003ctd data-start=\"2420\" data-end=\"2453\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2422\" data-end=\"2452\"\u003e8 Neuroplasticity in aging\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2453\" data-end=\"2599\" data-col-size=\"xl\"\u003eSignals for \u003cstrong data-start=\"2467\" data-end=\"2489\"\u003ehippocampal volume\u003c\/strong\u003e preservation and memory tasks in aged rodents; human aging data absent. \u003cem data-start=\"2562\" data-end=\"2597\"\u003eAging Cell; Neurobiology of Aging\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2600\" data-end=\"2832\"\u003e\n\u003ctd data-start=\"2600\" data-end=\"2644\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2602\" data-end=\"2643\"\u003e9 Adjunct in PTSD\/cognitive syndromes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"2644\" data-end=\"2832\"\u003eConcept: pair neurogenesis with psychotherapy\/rehab to consolidate learning; only preclinical or hypothesis-driven studies so far. \u003cem data-start=\"2777\" data-end=\"2830\"\u003eFrontiers in Psychiatry; Behavioural Brain Research\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"2834\" data-end=\"2837\"\u003e\n\u003ch2 data-start=\"2839\" data-end=\"2874\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-start=\"2876\" data-end=\"2918\"\u003e2.1 Pharmacodynamics (working model)\u003c\/h3\u003e\n\u003cul data-start=\"2919\" data-end=\"3427\"\u003e\n\u003cli data-start=\"2919\" data-end=\"3144\"\u003e\n\u003cp data-start=\"2921\" data-end=\"3144\"\u003e\u003cstrong data-start=\"2921\" data-end=\"2955\"\u003eNeurogenesis \u0026amp; synaptogenesis:\u003c\/strong\u003e Up-regulates \u003cstrong data-start=\"2969\" data-end=\"2977\"\u003eBDNF\u003c\/strong\u003e, \u003cstrong data-start=\"2979\" data-end=\"2987\"\u003eCREB\u003c\/strong\u003e, \u003cstrong data-start=\"2989\" data-end=\"3001\"\u003eMAPK\/ERK\u003c\/strong\u003e, and \u003cstrong data-start=\"3007\" data-end=\"3024\"\u003ePI3K–Akt–mTOR\u003c\/strong\u003e pathways → \u003cstrong data-start=\"3036\" data-end=\"3064\"\u003eprogenitor proliferation\u003c\/strong\u003e, \u003cstrong data-start=\"3066\" data-end=\"3095\"\u003edendritic spine formation\u003c\/strong\u003e, and \u003cstrong data-start=\"3101\" data-end=\"3122\"\u003esynaptic proteins\u003c\/strong\u003e (PSD-95, synapsin).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3145\" data-end=\"3292\"\u003e\n\u003cp data-start=\"3147\" data-end=\"3292\"\u003e\u003cstrong data-start=\"3147\" data-end=\"3180\"\u003eNeuroimmune \u0026amp; HPA modulation:\u003c\/strong\u003e Restraint of \u003cstrong data-start=\"3194\" data-end=\"3203\"\u003eNF-κB\u003c\/strong\u003e signaling and improved \u003cstrong data-start=\"3227\" data-end=\"3254\"\u003eglucocorticoid feedback\u003c\/strong\u003e in hippocampus → stress resilience.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3293\" data-end=\"3427\"\u003e\n\u003cp data-start=\"3295\" data-end=\"3427\"\u003e\u003cstrong data-start=\"3295\" data-end=\"3343\"\u003eNot a monoaminergic reuptake inhibitor\/MAOI.\u003c\/strong\u003e Any serotonergic\/dopaminergic effects appear \u003cstrong data-start=\"3389\" data-end=\"3403\"\u003edownstream\u003c\/strong\u003e of plasticity cascades.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"3429\" data-end=\"3456\"\u003e2.2 Down-stream biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"3458\" data-end=\"3797\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"3458\" data-end=\"3500\"\u003e\n\u003ctr data-start=\"3458\" data-end=\"3500\"\u003e\n\u003cth data-start=\"3458\" data-end=\"3468\" data-col-size=\"sm\"\u003ePathway\u003c\/th\u003e\n\u003cth data-start=\"3468\" data-end=\"3489\" data-col-size=\"md\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-start=\"3489\" data-end=\"3500\" data-col-size=\"sm\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"3515\" data-end=\"3797\"\u003e\n\u003ctr data-start=\"3515\" data-end=\"3601\"\u003e\n\u003ctd data-start=\"3515\" data-end=\"3542\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3517\" data-end=\"3541\"\u003eBDNF–TrkB → ERK\/CREB\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3542\" data-end=\"3586\" data-col-size=\"md\"\u003ePlasticity gene induction, mood\/cognition\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"3586\" data-end=\"3601\"\u003eHippocampus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3602\" data-end=\"3672\"\u003e\n\u003ctd data-start=\"3602\" data-end=\"3622\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3604\" data-end=\"3621\"\u003ePI3K–Akt–mTOR\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3622\" data-end=\"3656\" data-col-size=\"md\"\u003eCell survival, dendritic growth\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"3656\" data-end=\"3672\"\u003eHippo\/cortex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3673\" data-end=\"3739\"\u003e\n\u003ctd data-start=\"3673\" data-end=\"3695\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3675\" data-end=\"3694\"\u003eNF-κB restraint\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3695\" data-end=\"3726\" data-col-size=\"md\"\u003e↓ Pro-inflammatory cytokines\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"3726\" data-end=\"3739\"\u003eMicroglia\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3740\" data-end=\"3797\"\u003e\n\u003ctd data-start=\"3740\" data-end=\"3760\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3742\" data-end=\"3759\"\u003eHPA re-tuning\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"3760\" data-end=\"3782\"\u003eStress reactivity ↓\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"3782\" data-end=\"3797\"\u003eLimbic loop\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"3799\" data-end=\"3802\"\u003e\n\u003ch2 data-start=\"3804\" data-end=\"3826\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-start=\"3828\" data-end=\"4260\"\u003e\n\u003cli data-start=\"3828\" data-end=\"3869\"\u003e\n\u003cp data-start=\"3830\" data-end=\"3869\"\u003e\u003cstrong data-start=\"3830\" data-end=\"3840\"\u003eRoute:\u003c\/strong\u003e \u003cstrong data-start=\"3841\" data-end=\"3849\"\u003eOral\u003c\/strong\u003e (phosphate salt).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3870\" data-end=\"3953\"\u003e\n\u003cp data-start=\"3872\" data-end=\"3953\"\u003e\u003cstrong data-start=\"3872\" data-end=\"3894\"\u003eBrain penetration:\u003c\/strong\u003e Demonstrated in animals; human CNS levels not published.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3954\" data-end=\"4074\"\u003e\n\u003cp data-start=\"3956\" data-end=\"4074\"\u003e\u003cstrong data-start=\"3956\" data-end=\"3983\"\u003eHalf-life\/steady state:\u003c\/strong\u003e \u003cstrong data-start=\"3984\" data-end=\"4016\"\u003eHours to low-teens half-life\u003c\/strong\u003e reported; once- or twice-daily regimens used in trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4075\" data-end=\"4170\"\u003e\n\u003cp data-start=\"4077\" data-end=\"4170\"\u003e\u003cstrong data-start=\"4077\" data-end=\"4092\"\u003eMetabolism:\u003c\/strong\u003e Hepatic oxidative pathways (exact CYP liabilities not fully characterized).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4171\" data-end=\"4260\"\u003e\n\u003cp data-start=\"4173\" data-end=\"4260\"\u003e\u003cstrong data-start=\"4173\" data-end=\"4202\"\u003eFood effect\/interactions:\u003c\/strong\u003e Limited public data; not a classic CYP inducer\/inhibitor.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4262\" data-end=\"4265\"\u003e\n\u003ch2 data-start=\"4267\" data-end=\"4303\"\u003e4. Clinical Evidence (high-level)\u003c\/h2\u003e\n\u003cul data-start=\"4305\" data-end=\"4735\"\u003e\n\u003cli data-start=\"4305\" data-end=\"4435\"\u003e\n\u003cp data-start=\"4307\" data-end=\"4435\"\u003e\u003cstrong data-start=\"4307\" data-end=\"4327\"\u003ePhase 1b in MDD:\u003c\/strong\u003e Generally \u003cstrong data-start=\"4338\" data-end=\"4356\"\u003ewell tolerated\u003c\/strong\u003e; exploratory antidepressant and cognitive \u003cstrong data-start=\"4399\" data-end=\"4410\"\u003esignals\u003c\/strong\u003e across several scales.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4436\" data-end=\"4619\"\u003e\n\u003cp data-start=\"4438\" data-end=\"4619\"\u003e\u003cstrong data-start=\"4438\" data-end=\"4457\"\u003ePhase 2 in MDD:\u003c\/strong\u003e \u003cstrong data-start=\"4458\" data-end=\"4491\"\u003eDid not meet primary endpoint\u003c\/strong\u003e vs placebo; some \u003cstrong data-start=\"4509\" data-end=\"4534\"\u003esecondary\/exploratory\u003c\/strong\u003e outcomes hinted at benefit in subgroups\/time windows—insufficient for advancement.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4620\" data-end=\"4735\"\u003e\n\u003cp data-start=\"4622\" data-end=\"4735\"\u003e\u003cstrong data-start=\"4622\" data-end=\"4645\"\u003eImaging\/biomarkers:\u003c\/strong\u003e Small datasets explored \u003cstrong data-start=\"4670\" data-end=\"4697\"\u003ehippocampal volumetrics\u003c\/strong\u003e and peripheral \u003cstrong data-start=\"4713\" data-end=\"4721\"\u003eBDNF\u003c\/strong\u003e—inconclusive.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cblockquote data-start=\"4737\" data-end=\"4952\"\u003e\n\u003cp data-start=\"4739\" data-end=\"4952\"\u003e\u003cstrong data-start=\"4739\" data-end=\"4765\"\u003eEvidence quality note:\u003c\/strong\u003e Strong \u003cstrong data-start=\"4773\" data-end=\"4801\"\u003epreclinical plausibility\u003c\/strong\u003e with \u003cstrong data-start=\"4807\" data-end=\"4831\"\u003eneurogenesis\/circuit\u003c\/strong\u003e biology; \u003cstrong data-start=\"4841\" data-end=\"4868\"\u003ehuman efficacy unproven\u003c\/strong\u003e after a negative Phase 2. Any clinical use should be confined to research settings.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-start=\"4954\" data-end=\"4957\"\u003e\n\u003ch2 data-start=\"4959\" data-end=\"5005\"\u003e5. Emerging Clinical Interests (conceptual)\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"5007\" data-end=\"5377\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"5007\" data-end=\"5037\"\u003e\n\u003ctr data-start=\"5007\" data-end=\"5037\"\u003e\n\u003cth data-start=\"5007\" data-end=\"5015\" data-col-size=\"sm\"\u003eField\u003c\/th\u003e\n\u003cth data-start=\"5015\" data-end=\"5027\" data-col-size=\"sm\"\u003eRationale\u003c\/th\u003e\n\u003cth data-start=\"5027\" data-end=\"5037\" data-col-size=\"sm\"\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"5052\" data-end=\"5377\"\u003e\n\u003ctr data-start=\"5052\" data-end=\"5131\"\u003e\n\u003ctd data-start=\"5052\" data-end=\"5089\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5054\" data-end=\"5088\"\u003eTreatment-resistant depression\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5089\" data-end=\"5120\" data-col-size=\"sm\"\u003ePlasticity beyond monoamines\u003c\/td\u003e\n\u003ctd data-start=\"5120\" data-end=\"5131\" data-col-size=\"sm\"\u003eConcept\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5132\" data-end=\"5237\"\u003e\n\u003ctd data-start=\"5132\" data-end=\"5170\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5134\" data-end=\"5169\"\u003ePost-stroke\/TBI cognitive rehab\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5170\" data-end=\"5208\" data-col-size=\"sm\"\u003ePairing synaptogenesis with therapy\u003c\/td\u003e\n\u003ctd data-start=\"5208\" data-end=\"5237\" data-col-size=\"sm\"\u003ePreclinical\/early concept\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5238\" data-end=\"5290\"\u003e\n\u003ctd data-start=\"5238\" data-end=\"5249\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5240\" data-end=\"5248\"\u003ePTSD\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5249\" data-end=\"5279\" data-col-size=\"sm\"\u003eExtinction learning support\u003c\/td\u003e\n\u003ctd data-start=\"5279\" data-end=\"5290\" data-col-size=\"sm\"\u003eConcept\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5291\" data-end=\"5377\"\u003e\n\u003ctd data-start=\"5291\" data-end=\"5327\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5293\" data-end=\"5326\"\u003eAge-related cognitive decline\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5327\" data-end=\"5354\" data-col-size=\"sm\"\u003eHippocampal neurogenesis\u003c\/td\u003e\n\u003ctd data-start=\"5354\" data-end=\"5377\" data-col-size=\"sm\"\u003ePreclinical concept\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"5379\" data-end=\"5382\"\u003e\n\u003ch2 data-start=\"5384\" data-end=\"5413\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-start=\"5415\" data-end=\"6166\"\u003e\n\u003cli data-start=\"5415\" data-end=\"5554\"\u003e\n\u003cp data-start=\"5417\" data-end=\"5554\"\u003e\u003cstrong data-start=\"5417\" data-end=\"5442\"\u003eCommon AEs in trials:\u003c\/strong\u003e \u003cstrong data-start=\"5443\" data-end=\"5455\"\u003eHeadache\u003c\/strong\u003e, \u003cstrong data-start=\"5457\" data-end=\"5470\"\u003edizziness\u003c\/strong\u003e, \u003cstrong data-start=\"5472\" data-end=\"5495\"\u003esomnolence\/insomnia\u003c\/strong\u003e, \u003cstrong data-start=\"5497\" data-end=\"5507\"\u003enausea\u003c\/strong\u003e, \u003cstrong data-start=\"5509\" data-end=\"5520\"\u003efatigue\u003c\/strong\u003e—generally \u003cstrong data-start=\"5531\" data-end=\"5551\"\u003emild to moderate\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5555\" data-end=\"5630\"\u003e\n\u003cp data-start=\"5557\" data-end=\"5630\"\u003e\u003cstrong data-start=\"5557\" data-end=\"5577\"\u003eVitals\/labs\/ECG:\u003c\/strong\u003e No consistent safety signal in short-term studies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5631\" data-end=\"5743\"\u003e\n\u003cp data-start=\"5633\" data-end=\"5743\"\u003e\u003cstrong data-start=\"5633\" data-end=\"5654\"\u003eNeuropsychiatric:\u003c\/strong\u003e Activation\/insomnia in a subset; monitor for \u003cstrong data-start=\"5700\" data-end=\"5724\"\u003eanxiety or agitation\u003c\/strong\u003e early in dosing.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5744\" data-end=\"5875\"\u003e\n\u003cp data-start=\"5746\" data-end=\"5875\"\u003e\u003cstrong data-start=\"5746\" data-end=\"5773\"\u003eSuicidality monitoring:\u003c\/strong\u003e Standard for antidepressant investigations—no clear excess signal reported, but vigilance required.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5876\" data-end=\"5941\"\u003e\n\u003cp data-start=\"5878\" data-end=\"5941\"\u003e\u003cstrong data-start=\"5878\" data-end=\"5899\"\u003eLong-term safety:\u003c\/strong\u003e Unknown (no lengthy exposure datasets).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5942\" data-end=\"6166\"\u003e\n\u003cp data-start=\"5944\" data-end=\"6166\"\u003e\u003cstrong data-start=\"5944\" data-end=\"5966\"\u003eDrug interactions:\u003c\/strong\u003e Limited data; because the MOA is \u003cstrong data-start=\"6000\" data-end=\"6021\"\u003enon-monoaminergic\u003c\/strong\u003e, risk of \u003cstrong data-start=\"6031\" data-end=\"6053\"\u003eserotonin syndrome\u003c\/strong\u003e appears low when combined with SSRIs\/SNRIs, but combination evidence is sparse—use caution in research settings.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"6168\" data-end=\"6235\"\u003e\u003cstrong data-start=\"6168\" data-end=\"6235\"\u003eComparative snapshot (neuroplasticity-oriented antidepressants)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"6237\" data-end=\"6654\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"6237\" data-end=\"6306\"\u003e\n\u003ctr data-start=\"6237\" data-end=\"6306\"\u003e\n\u003cth data-start=\"6237\" data-end=\"6247\" data-col-size=\"sm\"\u003eFeature\u003c\/th\u003e\n\u003cth data-start=\"6247\" data-end=\"6261\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6249\" data-end=\"6260\"\u003eNSI-189\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6261\" data-end=\"6287\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6263\" data-end=\"6286\"\u003eKetamine\/Esketamine\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6287\" data-end=\"6306\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6289\" data-end=\"6304\"\u003eSSRIs\/SNRIs\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"6325\" data-end=\"6654\"\u003e\n\u003ctr data-start=\"6325\" data-end=\"6438\"\u003e\n\u003ctd data-start=\"6325\" data-end=\"6342\" data-col-size=\"sm\"\u003ePrimary action\u003c\/td\u003e\n\u003ctd data-start=\"6342\" data-end=\"6382\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6344\" data-end=\"6381\"\u003eNeurogenesis\/BDNF–CREB (putative)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6382\" data-end=\"6415\" data-col-size=\"sm\"\u003eRapid glutamatergic plasticity\u003c\/td\u003e\n\u003ctd data-start=\"6415\" data-end=\"6438\" data-col-size=\"sm\"\u003eMonoamine transport\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6439\" data-end=\"6499\"\u003e\n\u003ctd data-start=\"6439\" data-end=\"6447\" data-col-size=\"sm\"\u003eOnset\u003c\/td\u003e\n\u003ctd data-start=\"6447\" data-end=\"6465\" data-col-size=\"sm\"\u003eGradual (weeks)\u003c\/td\u003e\n\u003ctd data-start=\"6465\" data-end=\"6490\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6467\" data-end=\"6489\"\u003eRapid (hours–days)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6490\" data-end=\"6499\" data-col-size=\"sm\"\u003eWeeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6500\" data-end=\"6587\"\u003e\n\u003ctd data-start=\"6500\" data-end=\"6511\" data-col-size=\"sm\"\u003eEvidence\u003c\/td\u003e\n\u003ctd data-start=\"6511\" data-end=\"6542\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6513\" data-end=\"6541\"\u003eNegative Phase 2 primary\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6542\" data-end=\"6564\" data-col-size=\"sm\"\u003eRobust TRD efficacy\u003c\/td\u003e\n\u003ctd data-start=\"6564\" data-end=\"6587\" data-col-size=\"sm\"\u003eRobust MDD efficacy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6588\" data-end=\"6654\"\u003e\n\u003ctd data-start=\"6588\" data-end=\"6606\" data-col-size=\"sm\"\u003eAbuse liability\u003c\/td\u003e\n\u003ctd data-start=\"6606\" data-end=\"6623\" data-col-size=\"sm\"\u003eLow (expected)\u003c\/td\u003e\n\u003ctd data-start=\"6623\" data-end=\"6647\" data-col-size=\"sm\"\u003eModerate (controlled)\u003c\/td\u003e\n\u003ctd data-start=\"6647\" data-end=\"6654\" data-col-size=\"sm\"\u003eLow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"6656\" data-end=\"6659\"\u003e\n\u003ch2 data-start=\"6661\" data-end=\"6687\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-start=\"6689\" data-end=\"6916\"\u003e\n\u003cli data-start=\"6689\" data-end=\"6759\"\u003e\n\u003cp data-start=\"6691\" data-end=\"6759\"\u003e\u003cstrong data-start=\"6691\" data-end=\"6707\"\u003eNot approved\u003c\/strong\u003e (no active late-stage programs publicly ongoing).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6760\" data-end=\"6916\"\u003e\n\u003cp data-start=\"6762\" data-end=\"6916\"\u003eAny availability is via \u003cstrong data-start=\"6786\" data-end=\"6807\"\u003eresearch channels\u003c\/strong\u003e; consumer “nootropic” products are \u003cstrong data-start=\"6843\" data-end=\"6858\"\u003eunregulated\u003c\/strong\u003e and may be \u003cstrong data-start=\"6870\" data-end=\"6887\"\u003emisidentified\u003c\/strong\u003e—avoid outside formal trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"6918\" data-end=\"6921\"\u003e\n\u003ch2 data-start=\"6923\" data-end=\"6963\"\u003e8. Practical Take \u0026amp; Future Directions\u003c\/h2\u003e\n\u003cul data-start=\"6965\" data-end=\"7635\"\u003e\n\u003cli data-start=\"6965\" data-end=\"7062\"\u003e\n\u003cp data-start=\"6967\" data-end=\"7062\"\u003e\u003cstrong data-start=\"6967\" data-end=\"6986\"\u003eCurrent stance:\u003c\/strong\u003e NSI-189 remains \u003cstrong data-start=\"7003\" data-end=\"7019\"\u003eexperimental\u003c\/strong\u003e with \u003cstrong data-start=\"7025\" data-end=\"7059\"\u003einsufficient clinical efficacy\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7063\" data-end=\"7333\"\u003e\n\u003cp data-start=\"7065\" data-end=\"7333\"\u003e\u003cstrong data-start=\"7065\" data-end=\"7095\"\u003eIf pursued scientifically:\u003c\/strong\u003e Target \u003cstrong data-start=\"7103\" data-end=\"7123\"\u003ebiotype-enriched\u003c\/strong\u003e populations (low hippocampal volume, high inflammation, high anhedonia), use \u003cstrong data-start=\"7201\" data-end=\"7227\"\u003eadaptive trial designs\u003c\/strong\u003e, and anchor outcomes with \u003cstrong data-start=\"7254\" data-end=\"7277\"\u003eobjective cognition\u003c\/strong\u003e, \u003cstrong data-start=\"7279\" data-end=\"7302\"\u003edigital phenotyping\u003c\/strong\u003e, and \u003cstrong data-start=\"7308\" data-end=\"7319\"\u003eMRI\/EEG\u003c\/strong\u003e biomarkers.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7334\" data-end=\"7489\"\u003e\n\u003cp data-start=\"7336\" data-end=\"7489\"\u003e\u003cstrong data-start=\"7336\" data-end=\"7363\"\u003eCombination hypotheses:\u003c\/strong\u003e Pair with \u003cstrong data-start=\"7374\" data-end=\"7397\"\u003epsychotherapy\/rehab\u003c\/strong\u003e, \u003cstrong data-start=\"7399\" data-end=\"7411\"\u003eexercise\u003c\/strong\u003e, or \u003cstrong data-start=\"7416\" data-end=\"7452\"\u003esleep-based plasticity protocols\u003c\/strong\u003e to exploit a pro-neurogenic state.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7490\" data-end=\"7635\"\u003e\n\u003cp data-start=\"7492\" data-end=\"7635\"\u003e\u003cstrong data-start=\"7492\" data-end=\"7516\"\u003eTranslational needs:\u003c\/strong\u003e Clear \u003cstrong data-start=\"7523\" data-end=\"7555\"\u003etarget engagement biomarkers\u003c\/strong\u003e, refined \u003cstrong data-start=\"7565\" data-end=\"7574\"\u003ePK\/PD\u003c\/strong\u003e, and \u003cstrong data-start=\"7580\" data-end=\"7605\"\u003elonger blinded trials\u003c\/strong\u003e in precisely defined cohorts.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"7637\" data-end=\"7640\"\u003e\n\u003ch3 data-start=\"7642\" data-end=\"7665\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-start=\"7667\" data-end=\"8312\"\u003e\n\u003cli data-start=\"7667\" data-end=\"7782\"\u003e\n\u003cp data-start=\"7669\" data-end=\"7782\"\u003e\u003cem data-start=\"7669\" data-end=\"7713\"\u003eStem Cell Reports; Journal of Neuroscience\u003c\/em\u003e — NSI-189-driven neurogenesis and synaptogenesis in vitro\/in vivo.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7783\" data-end=\"7923\"\u003e\n\u003cp data-start=\"7785\" data-end=\"7923\"\u003e\u003cem data-start=\"7785\" data-end=\"7840\"\u003eMolecular Psychiatry; Depression \u0026amp; Anxiety; CNS Drugs\u003c\/em\u003e — Phase 1\/2 clinical results in MDD (safety, exploratory signals, Phase 2 miss).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7924\" data-end=\"8039\"\u003e\n\u003cp data-start=\"7926\" data-end=\"8039\"\u003e\u003cem data-start=\"7926\" data-end=\"7977\"\u003eNeuropsychopharmacology; Translational Psychiatry\u003c\/em\u003e — Plasticity markers, cognition, and stress-model outcomes.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8040\" data-end=\"8132\"\u003e\n\u003cp data-start=\"8042\" data-end=\"8132\"\u003e\u003cem data-start=\"8042\" data-end=\"8078\"\u003eGlia; Journal of Neuroinflammation\u003c\/em\u003e — Neuroimmune modulation accompanying neurogenesis.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8133\" data-end=\"8231\"\u003e\n\u003cp data-start=\"8135\" data-end=\"8231\"\u003e\u003cem data-start=\"8135\" data-end=\"8176\"\u003eEndocrinology; Psychoneuroendocrinology\u003c\/em\u003e — HPA-axis changes linked to hippocampal plasticity.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8232\" data-end=\"8312\"\u003e\n\u003cp data-start=\"8234\" data-end=\"8312\"\u003e\u003cem data-start=\"8234\" data-end=\"8274\"\u003eBrain Research; Experimental Neurology\u003c\/em\u003e — Post-stroke\/TBI recovery paradigms.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":52801081508104,"sku":null,"price":27.5,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0937\/9053\/5944\/files\/NSI-189_1g.png?v=1763140957"},{"product_id":"p21-with-adamantane-10mg-vial","title":"P21 with adamantane 10mg vial","description":"\u003cp data-start=\"106\" data-end=\"480\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                            \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"106\" data-end=\"480\"\u003e\u003cstrong data-start=\"106\" data-end=\"129\"\u003eP21 with adamantane\u003c\/strong\u003e most commonly refers to \u003cstrong data-start=\"154\" data-end=\"176\"\u003ePeptide 021 (P021)\u003c\/strong\u003e—a \u003cstrong data-start=\"179\" data-end=\"224\"\u003esmall, CNS-directed, neurotrophic peptide\u003c\/strong\u003eengineered from a \u003cstrong data-start=\"243\" data-end=\"306\"\u003eshort active fragment of ciliary neurotrophic factor (CNTF)\u003c\/strong\u003e and \u003cstrong data-start=\"311\" data-end=\"367\"\u003echemically modified with an adamantane-based residue\u003c\/strong\u003e to increase lipophilicity, metabolic stability, and \u003cstrong data-start=\"420\" data-end=\"441\"\u003ebrain penetration\u003c\/strong\u003e. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"482\" data-end=\"753\"\u003eIn the original medicinal-chemistry \/ behavioral neuroscience line of work, \u003cstrong data-start=\"558\" data-end=\"565\"\u003eP21\u003c\/strong\u003e is described as an \u003cstrong data-start=\"585\" data-end=\"634\"\u003eadamantane-incorporating peptidergic compound\u003c\/strong\u003e that improved learning and memory and promoted hippocampal neurogenesis in mice. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"755\" data-end=\"1119\"\u003e\u003cstrong data-start=\"755\" data-end=\"783\"\u003eImportant naming caveat:\u003c\/strong\u003e “P21” is also used in biology to mean \u003cstrong data-start=\"822\" data-end=\"838\"\u003ep21 (CDKN1A)\u003c\/strong\u003e, a cell-cycle protein—completely unrelated to the CNTF-derived nootropic peptide. When you say “P21 with adamantine,” the CNTF-derived \u003cstrong data-start=\"974\" data-end=\"982\"\u003eP021\u003c\/strong\u003einterpretation is the one that matches the published “adamantane neurotrophic peptide” literature. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"1121\" data-end=\"1124\"\u003e\n\u003ch3 data-start=\"1126\" data-end=\"1162\"\u003e2) Chemical design and rationale\u003c\/h3\u003e\n\u003ch4 data-start=\"1164\" data-end=\"1191\"\u003e2.1 Structural concept\u003c\/h4\u003e\n\u003cp data-start=\"1192\" data-end=\"1387\"\u003eThe design principle is: \u003cstrong data-start=\"1217\" data-end=\"1265\"\u003eretain a minimal CNTF-derived “active” motif\u003c\/strong\u003e but add a \u003cstrong data-start=\"1276\" data-end=\"1323\"\u003ehighly lipophilic adamantane building block\u003c\/strong\u003e (or adamantane-containing amino acid\/terminal substitution) to:\u003c\/p\u003e\n\u003cul data-start=\"1388\" data-end=\"1552\"\u003e\n\u003cli data-start=\"1388\" data-end=\"1429\"\u003e\n\u003cp data-start=\"1390\" data-end=\"1429\"\u003eincrease \u003cstrong data-start=\"1399\" data-end=\"1428\"\u003eresistance to proteolysis\u003c\/strong\u003e,\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1430\" data-end=\"1465\"\u003e\n\u003cp data-start=\"1432\" data-end=\"1465\"\u003eimprove \u003cstrong data-start=\"1440\" data-end=\"1460\"\u003epharmacokinetics\u003c\/strong\u003e, and\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1466\" data-end=\"1552\"\u003e\n\u003cp data-start=\"1468\" data-end=\"1552\"\u003eenhance \u003cstrong data-start=\"1476\" data-end=\"1513\"\u003eblood–brain barrier (BBB) passage\u003c\/strong\u003e. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 data-start=\"1554\" data-end=\"1578\"\u003e2.2 Why adamantane?\u003c\/h4\u003e\n\u003cp data-start=\"1579\" data-end=\"1913\"\u003eAdamantane is a rigid hydrophobic scaffold frequently used in CNS medicinal chemistry to improve membrane partitioning and stability. In this peptide program, the \u003cstrong data-start=\"1742\" data-end=\"1770\"\u003eadamantane incorporation\u003c\/strong\u003e is explicitly framed as a \u003cstrong data-start=\"1797\" data-end=\"1837\"\u003ebrain-delivery enabling modification\u003c\/strong\u003e for a very small peptide therapeutic. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"1915\" data-end=\"1918\"\u003e\n\u003ch3 data-start=\"1920\" data-end=\"1956\"\u003e3) Molecular mechanism of action\u003c\/h3\u003e\n\u003ch4 data-start=\"1958\" data-end=\"2034\"\u003e3.1 Target pathway: CNTF\/LIF-like signaling (IL-6 family cytokine axis)\u003c\/h4\u003e\n\u003cp data-start=\"2035\" data-end=\"2553\"\u003eCNTF belongs to the \u003cstrong data-start=\"2055\" data-end=\"2079\"\u003eIL-6 cytokine family\u003c\/strong\u003e and signals via receptor complexes that converge on \u003cstrong data-start=\"2132\" data-end=\"2144\"\u003eJAK\/STAT\u003c\/strong\u003e pathways (notably \u003cstrong data-start=\"2163\" data-end=\"2172\"\u003eSTAT3\u003c\/strong\u003e). One mechanistic analysis of this peptide program describes P21 as acting relative to its parent motif by \u003cstrong data-start=\"2280\" data-end=\"2343\"\u003epartially inhibiting LIF activity through the STAT3 pathway\u003c\/strong\u003e in a cellular model—consistent with the idea that these small CNTF-derived peptides can modulate cytokine-linked signaling rather than acting as classic receptor agonists. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch4 data-start=\"2555\" data-end=\"2620\"\u003e3.2 Downstream neurotrophic biology (disease-relevant nodes)\u003c\/h4\u003e\n\u003cp data-start=\"2621\" data-end=\"2742\"\u003eAcross summaries and preclinical discussions, P021 is repeatedly connected to neurodegeneration-relevant nodes including:\u003c\/p\u003e\n\u003cul data-start=\"2743\" data-end=\"3020\"\u003e\n\u003cli data-start=\"2743\" data-end=\"2875\"\u003e\n\u003cp data-start=\"2745\" data-end=\"2875\"\u003e\u003cstrong data-start=\"2745\" data-end=\"2768\"\u003eBDNF-linked effects\u003c\/strong\u003e and downstream reduction of \u003cstrong data-start=\"2797\" data-end=\"2816\"\u003eGSK-3β activity\u003c\/strong\u003e, a major tau kinase (→ \u003cstrong data-start=\"2840\" data-end=\"2873\"\u003etau phosphorylation decreases\u003c\/strong\u003e),\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2876\" data-end=\"2938\"\u003e\n\u003cp data-start=\"2878\" data-end=\"2938\"\u003echanges consistent with \u003cstrong data-start=\"2902\" data-end=\"2933\"\u003esynaptic plasticity support\u003c\/strong\u003e, and\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2939\" data-end=\"3020\"\u003e\n\u003cp data-start=\"2941\" data-end=\"3020\"\u003eneurogenic effects in hippocampal niches. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cblockquote data-start=\"3022\" data-end=\"3342\"\u003e\n\u003cp data-start=\"3024\" data-end=\"3342\"\u003eInterpretive note: Some of these pathway claims are synthesized from multiple preclinical reports and reviews; the field’s most consistent “direct” signal is \u003cstrong data-start=\"3182\" data-end=\"3230\"\u003eneurogenesis + cognitive performance in mice\u003c\/strong\u003e plus mechanistic work implicating cytokine\/STAT and tau-related pathways. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-start=\"3344\" data-end=\"3347\"\u003e\n\u003ch3 data-start=\"3349\" data-end=\"3425\"\u003e4) Pharmacokinetics and CNS exposure (what can be stated scientifically)\u003c\/h3\u003e\n\u003cp data-start=\"3426\" data-end=\"3578\"\u003eBecause P021 is \u003cstrong data-start=\"3442\" data-end=\"3486\"\u003enot an approved drug with a public label\u003c\/strong\u003e, PK details are largely derived from the design rationale and preclinical characterization:\u003c\/p\u003e\n\u003cul data-start=\"3580\" data-end=\"4162\"\u003e\n\u003cli data-start=\"3580\" data-end=\"3746\"\u003e\n\u003cp data-start=\"3582\" data-end=\"3746\"\u003e\u003cstrong data-start=\"3582\" data-end=\"3602\"\u003eBBB penetration:\u003c\/strong\u003e adamantane substitution is specifically described as facilitating BBB transport (lipophilicity-driven). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3747\" data-end=\"3940\"\u003e\n\u003cp data-start=\"3749\" data-end=\"3940\"\u003e\u003cstrong data-start=\"3749\" data-end=\"3763\"\u003eStability:\u003c\/strong\u003e adamantane incorporation is used to improve resistance to enzymatic breakdown (common goal in peptide optimization for systemic dosing). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3941\" data-end=\"4162\"\u003e\n\u003cp data-start=\"3943\" data-end=\"4162\"\u003e\u003cstrong data-start=\"3943\" data-end=\"3980\"\u003eRoute flexibility in animal work:\u003c\/strong\u003e published work includes \u003cstrong data-start=\"4005\" data-end=\"4034\"\u003eperipheral administration\u003c\/strong\u003e in mice with CNS effects, implying sufficient exposure to impact hippocampal biology. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4164\" data-end=\"4167\"\u003e\n\u003ch3 data-start=\"4169\" data-end=\"4214\"\u003e5) Preclinical and translational evidence\u003c\/h3\u003e\n\u003ch4 data-start=\"4216\" data-end=\"4272\"\u003e5.1 Cognition and neurogenesis in normal adult mice\u003c\/h4\u003e\n\u003cp data-start=\"4273\" data-end=\"4338\"\u003eA key preclinical report describes P21 administration leading to:\u003c\/p\u003e\n\u003cul data-start=\"4339\" data-end=\"4594\"\u003e\n\u003cli data-start=\"4339\" data-end=\"4452\"\u003e\n\u003cp data-start=\"4341\" data-end=\"4452\"\u003eimproved learning and memory (including \u003cstrong data-start=\"4381\" data-end=\"4403\"\u003eobject recognition\u003c\/strong\u003e and \u003cstrong data-start=\"4408\" data-end=\"4436\"\u003espatial reference memory\u003c\/strong\u003e paradigms), and\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4453\" data-end=\"4594\"\u003e\n\u003cp data-start=\"4455\" data-end=\"4594\"\u003eincreased neurogenesis and maturation of newborn neurons in the \u003cstrong data-start=\"4519\" data-end=\"4553\"\u003edentate gyrus\/subgranular zone\u003c\/strong\u003e. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"4596\" data-end=\"4708\"\u003eThis is one of the more concrete, behavior + histology linked datasets supporting “nootropic\/neurogenic” claims.\u003c\/p\u003e\n\u003ch4 data-start=\"4710\" data-end=\"4788\"\u003e5.2 Disease-model positioning (Alzheimer’s and related neurodegeneration)\u003c\/h4\u003e\n\u003cp data-start=\"4789\" data-end=\"4913\"\u003eA peptide society monograph-style overview describes P21\/P021 as promising in preclinical AD-oriented contexts, emphasizing:\u003c\/p\u003e\n\u003cul data-start=\"4914\" data-end=\"5176\"\u003e\n\u003cli data-start=\"4914\" data-end=\"4984\"\u003e\n\u003cp data-start=\"4916\" data-end=\"4984\"\u003ereduction of abnormal tau phosphorylation (via BDNF\/GSK-3β framing),\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4985\" data-end=\"5066\"\u003e\n\u003cp data-start=\"4987\" data-end=\"5066\"\u003ereduction in amyloid-associated pathology signals (in preclinical reports), and\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5067\" data-end=\"5176\"\u003e\n\u003cp data-start=\"5069\" data-end=\"5176\"\u003ea general neuroprotective profile relative to larger neurotrophins. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"5178\" data-end=\"5263\"\u003e\u003cem data-start=\"5178\" data-end=\"5263\"\u003e(This is still preclinical positioning; it does not substitute for human efficacy.)\u003c\/em\u003e\u003c\/p\u003e\n\u003ch4 data-start=\"5265\" data-end=\"5356\"\u003e5.3 More recent translational use: neurodevelopmental disease model (CDKL5 deficiency)\u003c\/h4\u003e\n\u003cp data-start=\"5357\" data-end=\"5695\"\u003eA 2024 open-access paper reports chronic oral \u003cstrong data-start=\"5403\" data-end=\"5411\"\u003eP021\u003c\/strong\u003e treatment in \u003cstrong data-start=\"5425\" data-end=\"5442\"\u003eCdkl5−\/Y mice\u003c\/strong\u003e, evaluating behavioral and related outcomes after extended dosing. This is relevant because it shows continued scientific interest beyond AD, using modern translational endpoints in a distinct CNS disorder model. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"5697\" data-end=\"5700\"\u003e\n\u003ch3 data-start=\"5702\" data-end=\"5752\"\u003e6) Safety, tolerability, and key uncertainties\u003c\/h3\u003e\n\u003ch4 data-start=\"5754\" data-end=\"5776\"\u003e6.1 What is known\u003c\/h4\u003e\n\u003cul data-start=\"5777\" data-end=\"6083\"\u003e\n\u003cli data-start=\"5777\" data-end=\"5943\"\u003e\n\u003cp data-start=\"5779\" data-end=\"5943\"\u003eThe peptide is repeatedly described as designed to avoid limitations of full-length neurotrophins (size, delivery), but \u003cstrong data-start=\"5899\" data-end=\"5942\"\u003ethat does not establish clinical safety\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5944\" data-end=\"6083\"\u003e\n\u003cp data-start=\"5946\" data-end=\"6083\"\u003ePublished work is predominantly \u003cstrong data-start=\"5978\" data-end=\"6002\"\u003eanimal + mechanistic\u003c\/strong\u003e; there is no widely cited, definitive human safety dataset in the sources above.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 data-start=\"6085\" data-end=\"6154\"\u003e6.2 What remains uncertain (high priority in any serious review)\u003c\/h4\u003e\n\u003cul data-start=\"6155\" data-end=\"6657\"\u003e\n\u003cli data-start=\"6155\" data-end=\"6248\"\u003e\n\u003cp data-start=\"6157\" data-end=\"6248\"\u003e\u003cstrong data-start=\"6157\" data-end=\"6190\"\u003eHuman safety and tolerability\u003c\/strong\u003e (dose-dependent adverse effects, chronic exposure risks).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6249\" data-end=\"6403\"\u003e\n\u003cp data-start=\"6251\" data-end=\"6403\"\u003e\u003cstrong data-start=\"6251\" data-end=\"6269\"\u003eImmunogenicity\u003c\/strong\u003e risk is generally lower for very small peptides than large proteins, but not zero—especially depending on formulation and impurities.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6404\" data-end=\"6657\"\u003e\n\u003cp data-start=\"6406\" data-end=\"6657\"\u003e\u003cstrong data-start=\"6406\" data-end=\"6437\"\u003eCytokine-pathway modulation\u003c\/strong\u003e (STAT3-related signaling) could, in principle, have wide-ranging effects depending on exposure and tissue context; this is one reason controlled clinical development is essential. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"6659\" data-end=\"6662\"\u003e\n\u003ch3 data-start=\"6664\" data-end=\"6713\"\u003e7) Regulatory and clinical-development status\u003c\/h3\u003e\n\u003cul data-start=\"6714\" data-end=\"6982\"\u003e\n\u003cli data-start=\"6714\" data-end=\"6827\"\u003e\n\u003cp data-start=\"6716\" data-end=\"6827\"\u003e\u003cstrong data-start=\"6716\" data-end=\"6735\"\u003eInvestigational\u003c\/strong\u003e: P021\/P21 (adamantane-modified CNTF fragment) is \u003cstrong data-start=\"6785\" data-end=\"6809\"\u003enot FDA\/EMA-approved\u003c\/strong\u003e as a therapeutic.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6828\" data-end=\"6982\"\u003e\n\u003cp data-start=\"6830\" data-end=\"6982\"\u003eCurrent evidence base is \u003cstrong data-start=\"6855\" data-end=\"6870\"\u003epreclinical\u003c\/strong\u003e, with ongoing academic\/translational exploration (e.g., mouse studies). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"6984\" data-end=\"6987\"\u003e\n\u003ch3 data-start=\"6989\" data-end=\"7065\"\u003e8) How P21\/P021 fits within the broader “neurotrophic peptide” landscape\u003c\/h3\u003e\n\u003ch4 data-start=\"7067\" data-end=\"7100\"\u003e8.1 What makes it attractive\u003c\/h4\u003e\n\u003cul data-start=\"7101\" data-end=\"7331\"\u003e\n\u003cli data-start=\"7101\" data-end=\"7235\"\u003e\n\u003cp data-start=\"7103\" data-end=\"7235\"\u003e\u003cstrong data-start=\"7103\" data-end=\"7144\"\u003eSmall size + CNS delivery engineering\u003c\/strong\u003e (adamantane) tackles the classic neurotrophin problem: “great biology, poor druggability.”\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7236\" data-end=\"7331\"\u003e\n\u003cp data-start=\"7238\" data-end=\"7331\"\u003eTargets \u003cstrong data-start=\"7246\" data-end=\"7267\"\u003erepair\/plasticity\u003c\/strong\u003e mechanisms rather than single-symptom neurotransmitter effects.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 data-start=\"7333\" data-end=\"7375\"\u003e8.2 What typically blocks translation\u003c\/h4\u003e\n\u003cul data-start=\"7376\" data-end=\"7688\"\u003e\n\u003cli data-start=\"7376\" data-end=\"7554\"\u003e\n\u003cp data-start=\"7378\" data-end=\"7554\"\u003eMany compounds improve \u003cstrong data-start=\"7401\" data-end=\"7420\"\u003emouse cognition\u003c\/strong\u003e but fail in humans because of endpoint sensitivity, heterogeneity of disease biology, and insufficient target engagement measurement.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7555\" data-end=\"7688\"\u003e\n\u003cp data-start=\"7557\" data-end=\"7688\"\u003eFor neurogenic strategies, functional benefit often depends on \u003cstrong data-start=\"7620\" data-end=\"7687\"\u003etiming, circuit context, and concurrent rehabilitation\/training\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"7690\" data-end=\"7693\"\u003e\n\u003ch3 data-start=\"7695\" data-end=\"7766\"\u003e9) Future directions (what would make the science “clinical-grade”)\u003c\/h3\u003e\n\u003cp data-start=\"7767\" data-end=\"7855\"\u003eIf this were being advanced as a serious therapeutic, the critical experiments would be:\u003c\/p\u003e\n\u003col data-start=\"7857\" data-end=\"8464\"\u003e\n\u003cli data-start=\"7857\" data-end=\"8067\"\u003e\n\u003cp data-start=\"7860\" data-end=\"8067\"\u003e\u003cstrong data-start=\"7860\" data-end=\"7884\"\u003eHuman PK\/PD bridging\u003c\/strong\u003e: confirm CNS exposure and measurable target engagement biomarkers (STAT3 pathway modulation, BDNF\/tau-related signatures where appropriate). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8068\" data-end=\"8217\"\u003e\n\u003cp data-start=\"8071\" data-end=\"8217\"\u003e\u003cstrong data-start=\"8071\" data-end=\"8102\"\u003eRobust functional endpoints\u003c\/strong\u003e: beyond memory tasks—include attention\/executive function batteries, digital biomarkers, and imaging correlates.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8218\" data-end=\"8368\"\u003e\n\u003cp data-start=\"8221\" data-end=\"8368\"\u003e\u003cstrong data-start=\"8221\" data-end=\"8242\"\u003eDisease selection\u003c\/strong\u003e: pick indications with clear mechanistic alignment (tauopathies, synaptic dysfunction disorders) and measurable biomarkers.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8369\" data-end=\"8464\"\u003e\n\u003cp data-start=\"8372\" data-end=\"8464\"\u003e\u003cstrong data-start=\"8372\" data-end=\"8392\"\u003eLong-term safety\u003c\/strong\u003e: given neurotrophic pathway modulation, chronic safety is not optional.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003chr data-start=\"8466\" data-end=\"8469\"\u003e\n\u003ch2 data-start=\"8471\" data-end=\"8513\"\u003eSelected references (most load-bearing)\u003c\/h2\u003e\n\u003cul data-start=\"8514\" data-end=\"9098\"\u003e\n\u003cli data-start=\"8514\" data-end=\"8654\"\u003e\n\u003cp data-start=\"8516\" data-end=\"8654\"\u003e\u003cstrong data-start=\"8516\" data-end=\"8593\"\u003eAdamantane neurotrophic peptide program; cognition + neurogenesis in mice\u003c\/strong\u003e (Li et al., 2010): \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8655\" data-end=\"8762\"\u003e\n\u003cp data-start=\"8657\" data-end=\"8762\"\u003e\u003cstrong data-start=\"8657\" data-end=\"8719\"\u003ePatent describing P21\/P22 and adamantane-containing design\u003c\/strong\u003e: \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8763\" data-end=\"8894\"\u003e\n\u003cp data-start=\"8765\" data-end=\"8894\"\u003e\u003cstrong data-start=\"8765\" data-end=\"8851\"\u003ePeptide 021 (P021) description including adamantane substitution for BBB transport\u003c\/strong\u003e: \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8895\" data-end=\"8991\"\u003e\n\u003cp data-start=\"8897\" data-end=\"8991\"\u003e\u003cstrong data-start=\"8897\" data-end=\"8935\"\u003eSTAT3\/LIF pathway mechanistic note\u003c\/strong\u003e (cell-based): \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8992\" data-end=\"9098\"\u003e\n\u003cp data-start=\"8994\" data-end=\"9098\"\u003e\u003cstrong data-start=\"8994\" data-end=\"9055\"\u003eModern translational mouse study using P021 (CDKL5 model)\u003c\/strong\u003e: \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":53196178981128,"sku":null,"price":70.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0937\/9053\/5944\/files\/P21_10mg.png?v=1769444382"},{"product_id":"pe-22-28-10mg-vial","title":"PE-22-28 10mg vial","description":"\u003cp data-start=\"104\" data-end=\"433\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                          \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"104\" data-end=\"433\"\u003e\u003cstrong data-start=\"104\" data-end=\"116\"\u003ePE-22-28\u003c\/strong\u003e is a \u003cstrong data-start=\"122\" data-end=\"138\"\u003eheptapeptide\u003c\/strong\u003e with the sequence \u003cstrong data-start=\"157\" data-end=\"198\"\u003eGVSWGLR (Gly–Val–Ser–Trp–Gly–Leu–Arg)\u003c\/strong\u003e. It is widely described as the \u003cstrong data-start=\"230\" data-end=\"258\"\u003esmallest active fragment\u003c\/strong\u003e derived from the endogenous peptide \u003cstrong data-start=\"295\" data-end=\"305\"\u003espadin\u003c\/strong\u003e, retaining potent antagonism of the \u003cstrong data-start=\"342\" data-end=\"394\"\u003eTREK-1 (KCNK2) two-pore domain potassium channel\u003c\/strong\u003e. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"435\" data-end=\"734\"\u003e\u003cstrong data-start=\"435\" data-end=\"459\"\u003eNomenclature origin:\u003c\/strong\u003e “PE(22-28)” refers to a peptide fragment numbering used in the parent propeptide context described in patents\/literature; the peptide is associated with \u003cstrong data-start=\"613\" data-end=\"672\"\u003esortilin\/NTSR3 propeptide → spadin → PE-22-28 fragments\u003c\/strong\u003e in the discovery chain. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"736\" data-end=\"739\"\u003e\n\u003ch3 data-start=\"741\" data-end=\"782\"\u003e2) Target biology: why TREK-1 matters\u003c\/h3\u003e\n\u003cp data-start=\"783\" data-end=\"1123\"\u003e\u003cstrong data-start=\"783\" data-end=\"801\"\u003eTREK-1 (KCNK2)\u003c\/strong\u003e is a background\/leak K⁺ channel that helps set \u003cstrong data-start=\"849\" data-end=\"879\"\u003eresting membrane potential\u003c\/strong\u003e and dampens excitability. In many neuron types, \u003cstrong data-start=\"928\" data-end=\"980\"\u003einhibiting TREK-1 tends to increase excitability\u003c\/strong\u003e and can shift network activity in ways that have been explored for \u003cstrong data-start=\"1048\" data-end=\"1079\"\u003eantidepressant-like effects\u003c\/strong\u003e, neuroplasticity, and post-injury recovery.\u003c\/p\u003e\n\u003cp data-start=\"1125\" data-end=\"1374\"\u003ePE-22-28’s importance is that it is a \u003cstrong data-start=\"1163\" data-end=\"1196\"\u003ehigh-potency TREK-1 inhibitor\u003c\/strong\u003e reported at \u003cstrong data-start=\"1209\" data-end=\"1242\"\u003esub-nanomolar IC₅₀ (~0.12 nM)\u003c\/strong\u003e in vendor-compiled pharmacology summaries (which typically trace back to primary literature). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"1376\" data-end=\"1379\"\u003e\n\u003ch2 data-start=\"1381\" data-end=\"1416\"\u003e3) Molecular mechanism of action\u003c\/h2\u003e\n\u003ch3 data-start=\"1418\" data-end=\"1459\"\u003e3.1 Receptor\/channel pharmacodynamics\u003c\/h3\u003e\n\u003cul data-start=\"1460\" data-end=\"1775\"\u003e\n\u003cli data-start=\"1460\" data-end=\"1576\"\u003e\n\u003cp data-start=\"1462\" data-end=\"1576\"\u003e\u003cstrong data-start=\"1462\" data-end=\"1481\"\u003ePrimary target:\u003c\/strong\u003e \u003cstrong data-start=\"1482\" data-end=\"1500\"\u003eTREK-1 (KCNK2)\u003c\/strong\u003e inhibition (functional antagonism). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1577\" data-end=\"1775\"\u003e\n\u003cp data-start=\"1579\" data-end=\"1775\"\u003e\u003cstrong data-start=\"1579\" data-end=\"1637\"\u003eImmediate electrophysiologic consequence (conceptual):\u003c\/strong\u003e reduced K⁺ leak conductance → \u003cstrong data-start=\"1668\" data-end=\"1704\"\u003emembrane depolarization tendency\u003c\/strong\u003e → \u003cstrong data-start=\"1707\" data-end=\"1742\"\u003egreater neuronal responsiveness\u003c\/strong\u003e (cell-type and state dependent).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"1777\" data-end=\"1825\"\u003e3.2 Downstream neurobiology (hypothesis map)\u003c\/h3\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"1826\" data-end=\"2715\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"1826\" data-end=\"1883\"\u003e\n\u003ctr data-start=\"1826\" data-end=\"1883\"\u003e\n\u003cth data-start=\"1826\" data-end=\"1835\" data-col-size=\"sm\"\u003eDomain\u003c\/th\u003e\n\u003cth data-start=\"1835\" data-end=\"1858\" data-col-size=\"md\"\u003ePutative consequence\u003c\/th\u003e\n\u003cth data-start=\"1858\" data-end=\"1883\" data-col-size=\"lg\"\u003eMechanistic rationale\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"1898\" data-end=\"2715\"\u003e\n\u003ctr data-start=\"1898\" data-end=\"2094\"\u003e\n\u003ctd data-start=\"1898\" data-end=\"1935\" data-col-size=\"sm\"\u003eMood \/ antidepressant-like effects\u003c\/td\u003e\n\u003ctd data-start=\"1935\" data-end=\"1980\" data-col-size=\"md\"\u003efaster-acting behavioral effects in models\u003c\/td\u003e\n\u003ctd data-start=\"1980\" data-end=\"2094\" data-col-size=\"lg\"\u003eTREK-1 inhibition increases excitability\/plasticity in relevant circuits \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2095\" data-end=\"2293\"\u003e\n\u003ctd data-start=\"2095\" data-end=\"2110\" data-col-size=\"sm\"\u003eNeurogenesis\u003c\/td\u003e\n\u003ctd data-start=\"2110\" data-end=\"2157\" data-col-size=\"md\"\u003e↑ hippocampal neurogenesis signals in models\u003c\/td\u003e\n\u003ctd data-start=\"2157\" data-end=\"2293\" data-col-size=\"lg\"\u003eplasticity\/BDNF-linked pathways often rise downstream of excitability shifts (model dependent) \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2294\" data-end=\"2509\"\u003e\n\u003ctd data-start=\"2294\" data-end=\"2323\" data-col-size=\"sm\"\u003eStroke \/ ischemia recovery\u003c\/td\u003e\n\u003ctd data-start=\"2323\" data-end=\"2383\" data-col-size=\"md\"\u003eimproved motor\/cognitive outcomes in rodent stroke models\u003c\/td\u003e\n\u003ctd data-start=\"2383\" data-end=\"2509\" data-col-size=\"lg\"\u003eexcitability + plasticity + potentially reduced apoptosis in injured tissue contexts \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2510\" data-end=\"2715\"\u003e\n\u003ctd data-start=\"2510\" data-end=\"2541\" data-col-size=\"sm\"\u003eβ-cell survival under stress\u003c\/td\u003e\n\u003ctd data-start=\"2541\" data-end=\"2593\" data-col-size=\"md\"\u003ereduced apoptotic β-cell death in ischemia models\u003c\/td\u003e\n\u003ctd data-start=\"2593\" data-end=\"2715\" data-col-size=\"lg\"\u003eTREK-1 is expressed beyond brain; protection signals reported in rodent contexts \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp data-start=\"2717\" data-end=\"2963\"\u003e\u003cstrong data-start=\"2717\" data-end=\"2757\"\u003eImportant interpretation constraint:\u003c\/strong\u003e Many of the “downstream” benefits are \u003cstrong data-start=\"2796\" data-end=\"2811\"\u003epreclinical\u003c\/strong\u003e outcomes; PE-22-28 is best thought of as a \u003cstrong data-start=\"2855\" data-end=\"2881\"\u003eresearch tool compound\u003c\/strong\u003e for TREK-1 biology and related phenotypes, not as a clinically validated therapy.\u003c\/p\u003e\n\u003chr data-start=\"2965\" data-end=\"2968\"\u003e\n\u003ch2 data-start=\"2970\" data-end=\"2999\"\u003e4) Chemistry and structure\u003c\/h2\u003e\n\u003cul data-start=\"3000\" data-end=\"3427\"\u003e\n\u003cli data-start=\"3000\" data-end=\"3067\"\u003e\n\u003cp data-start=\"3002\" data-end=\"3067\"\u003e\u003cstrong data-start=\"3002\" data-end=\"3015\"\u003eSequence:\u003c\/strong\u003e \u003cstrong data-start=\"3016\" data-end=\"3027\"\u003eGVSWGLR\u003c\/strong\u003e\u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3068\" data-end=\"3175\"\u003e\n\u003cp data-start=\"3070\" data-end=\"3175\"\u003e\u003cstrong data-start=\"3070\" data-end=\"3078\"\u003eCAS:\u003c\/strong\u003e commonly listed as \u003cstrong data-start=\"3098\" data-end=\"3114\"\u003e1801959-12-5\u003c\/strong\u003e in reagent catalogs. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3176\" data-end=\"3427\"\u003e\n\u003cp data-start=\"3178\" data-end=\"3427\"\u003e\u003cstrong data-start=\"3178\" data-end=\"3195\"\u003eDesign notes:\u003c\/strong\u003e Patents describe PE(22-28) as a \u003cstrong data-start=\"3228\" data-end=\"3244\"\u003ebase peptide\u003c\/strong\u003e used to design analogs (e.g., N-terminal modifications, substitutions, C-terminal derivatizations) to tune activity, stability, or labeling. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"3429\" data-end=\"3742\"\u003e\u003cstrong data-start=\"3429\" data-end=\"3466\"\u003eQuality-control note (practical):\u003c\/strong\u003e marketplace listings are not always consistent (some sites misreport the sequence). When writing professionally, it’s worth stating that \u003cstrong data-start=\"3604\" data-end=\"3637\"\u003eauthentic PE-22-28 is GVSWGLR\u003c\/strong\u003e, consistent with multiple reagent suppliers and patent language. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"3744\" data-end=\"3747\"\u003e\n\u003ch2 data-start=\"3749\" data-end=\"3799\"\u003e5) Pharmacokinetics and exposure considerations\u003c\/h2\u003e\n\u003cp data-start=\"3800\" data-end=\"3934\"\u003eThere is \u003cstrong data-start=\"3809\" data-end=\"3829\"\u003eno drug-label PK\u003c\/strong\u003e because PE-22-28 is not an approved medicine. As a \u003cstrong data-start=\"3881\" data-end=\"3897\"\u003e7-aa peptide\u003c\/strong\u003e, key PK realities typically include:\u003c\/p\u003e\n\u003cul data-start=\"3935\" data-end=\"4155\"\u003e\n\u003cli data-start=\"3935\" data-end=\"4004\"\u003e\n\u003cp data-start=\"3937\" data-end=\"4004\"\u003e\u003cstrong data-start=\"3937\" data-end=\"3958\"\u003erapid proteolysis\u003c\/strong\u003e in plasma\/tissues unless formulated\/modified,\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4005\" data-end=\"4090\"\u003e\n\u003cp data-start=\"4007\" data-end=\"4090\"\u003e\u003cstrong data-start=\"4007\" data-end=\"4027\"\u003eroute dependence\u003c\/strong\u003e (systemic exposure and CNS exposure can differ substantially),\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4091\" data-end=\"4155\"\u003e\n\u003cp data-start=\"4093\" data-end=\"4155\"\u003epossible \u003cstrong data-start=\"4102\" data-end=\"4121\"\u003eshort half-life\u003c\/strong\u003e without stabilization strategies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"4157\" data-end=\"4363\"\u003ePatents explicitly discuss chemical modifications\/analogs, which is often a sign that \u003cstrong data-start=\"4243\" data-end=\"4284\"\u003enative peptide stability and delivery\u003c\/strong\u003eare important development constraints. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"4365\" data-end=\"4368\"\u003e\n\u003ch2 data-start=\"4370\" data-end=\"4417\"\u003e6) Evidence base (what’s actually supported)\u003c\/h2\u003e\n\u003ch3 data-start=\"4419\" data-end=\"4460\"\u003e6.1 Strongest, most “anchored” claims\u003c\/h3\u003e\n\u003cul data-start=\"4461\" data-end=\"4832\"\u003e\n\u003cli data-start=\"4461\" data-end=\"4590\"\u003e\n\u003cp data-start=\"4463\" data-end=\"4590\"\u003e\u003cstrong data-start=\"4463\" data-end=\"4491\"\u003ePotent TREK-1 inhibition\u003c\/strong\u003e (IC₅₀ around 0.12 nM) and use as a pharmacological tool. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4591\" data-end=\"4832\"\u003e\n\u003cp data-start=\"4593\" data-end=\"4832\"\u003e\u003cstrong data-start=\"4593\" data-end=\"4617\"\u003ePreclinical outcomes\u003c\/strong\u003e reported in rodent models (stroke recovery, hippocampal neurogenesis; β-cell apoptosis reduction in ischemia contexts) in supplier summaries referencing underlying studies. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"4834\" data-end=\"4867\"\u003e6.2 What is \u003cem data-start=\"4850\" data-end=\"4855\"\u003enot\u003c\/em\u003e established\u003c\/h3\u003e\n\u003cul data-start=\"4868\" data-end=\"5052\"\u003e\n\u003cli data-start=\"4868\" data-end=\"4984\"\u003e\n\u003cp data-start=\"4870\" data-end=\"4984\"\u003eRobust, replicated \u003cstrong data-start=\"4889\" data-end=\"4916\"\u003ehuman clinical efficacy\u003c\/strong\u003e for depression, cognition, stroke recovery, or metabolic endpoints.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4985\" data-end=\"5052\"\u003e\n\u003cp data-start=\"4987\" data-end=\"5052\"\u003eLong-term safety in humans at therapeutically relevant exposures.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"5054\" data-end=\"5057\"\u003e\n\u003ch2 data-start=\"5059\" data-end=\"5108\"\u003e7) Safety and tolerability: scientific framing\u003c\/h2\u003e\n\u003cp data-start=\"5109\" data-end=\"5224\"\u003eBecause PE-22-28 is \u003cstrong data-start=\"5129\" data-end=\"5157\"\u003einvestigational\/research\u003c\/strong\u003e, safety is best discussed as \u003cem data-start=\"5187\" data-end=\"5223\"\u003emechanism-informed risk hypotheses\u003c\/em\u003e:\u003c\/p\u003e\n\u003cp data-start=\"5226\" data-end=\"5278\"\u003ePotential risks to consider in research translation:\u003c\/p\u003e\n\u003cul data-start=\"5279\" data-end=\"5852\"\u003e\n\u003cli data-start=\"5279\" data-end=\"5506\"\u003e\n\u003cp data-start=\"5281\" data-end=\"5506\"\u003e\u003cstrong data-start=\"5281\" data-end=\"5309\"\u003eCNS excitability shifts:\u003c\/strong\u003e TREK-1 inhibition can alter neuronal firing thresholds; depending on circuits, this can theoretically increase risk of adverse neuropsychiatric or sleep effects (speculative without human trials).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5507\" data-end=\"5661\"\u003e\n\u003cp data-start=\"5509\" data-end=\"5661\"\u003e\u003cstrong data-start=\"5509\" data-end=\"5535\"\u003eOff-tissue physiology:\u003c\/strong\u003e TREK-1 is expressed in multiple tissues; systemic dosing may have \u003cstrong data-start=\"5602\" data-end=\"5640\"\u003enon-CNS electrophysiologic effects\u003c\/strong\u003e (context dependent).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5662\" data-end=\"5852\"\u003e\n\u003cp data-start=\"5664\" data-end=\"5852\"\u003e\u003cstrong data-start=\"5664\" data-end=\"5694\"\u003eImmunogenicity\/impurities:\u003c\/strong\u003e small peptides are generally less immunogenic than proteins, but \u003cstrong data-start=\"5760\" data-end=\"5790\"\u003eimpurities and formulation\u003c\/strong\u003e can drive reactions—especially outside GMP medicine pathways.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"5854\" data-end=\"5857\"\u003e\n\u003ch2 data-start=\"5859\" data-end=\"5909\"\u003e8) Regulatory status and real-world positioning\u003c\/h2\u003e\n\u003cp data-start=\"5910\" data-end=\"6055\"\u003ePE-22-28 is sold primarily as a \u003cstrong data-start=\"5942\" data-end=\"5962\"\u003eresearch reagent\u003c\/strong\u003e and is \u003cstrong data-start=\"5970\" data-end=\"5994\"\u003enot FDA\/EMA-approved\u003c\/strong\u003e for therapeutic use. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"6057\" data-end=\"6060\"\u003e\n\u003ch2 data-start=\"6062\" data-end=\"6129\"\u003e9) Future directions (what would make PE-22-28 “clinical-grade”)\u003c\/h2\u003e\n\u003col data-start=\"6130\" data-end=\"6662\"\u003e\n\u003cli data-start=\"6130\" data-end=\"6250\"\u003e\n\u003cp data-start=\"6133\" data-end=\"6250\"\u003e\u003cstrong data-start=\"6133\" data-end=\"6152\"\u003eValidated PK\/PD\u003c\/strong\u003e: demonstrate exposure and target engagement (TREK-1 occupancy\/functional biomarkers) in humans.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6251\" data-end=\"6425\"\u003e\n\u003cp data-start=\"6254\" data-end=\"6425\"\u003e\u003cstrong data-start=\"6254\" data-end=\"6288\"\u003eRoute\/formulation optimization\u003c\/strong\u003e: stabilizing analogs and delivery approaches (already implied by patent-driven analog design). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6426\" data-end=\"6662\"\u003e\n\u003cp data-start=\"6429\" data-end=\"6662\"\u003e\u003cstrong data-start=\"6429\" data-end=\"6466\"\u003eFunction-first clinical endpoints\u003c\/strong\u003e: if pursued for mood or recovery, trials should prioritize clinically meaningful outcomes (e.g., depressive symptom scales, functional recovery metrics) plus mechanistic neuroplasticity readouts.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003chr data-start=\"6664\" data-end=\"6667\"\u003e\n\u003ch2 data-start=\"6669\" data-end=\"6711\"\u003eSelected references (most load-bearing)\u003c\/h2\u003e\n\u003cul data-start=\"6712\" data-end=\"7160\"\u003e\n\u003cli data-start=\"6712\" data-end=\"6814\"\u003e\n\u003cp data-start=\"6714\" data-end=\"6814\"\u003eTREK-1 inhibition potency and preclinical effects summary: \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6815\" data-end=\"6927\"\u003e\n\u003cp data-start=\"6817\" data-end=\"6927\"\u003eSequence\/identity and “smallest active spadin fragment” description: \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6928\" data-end=\"7044\"\u003e\n\u003cp data-start=\"6930\" data-end=\"7044\"\u003ePatent text specifying \u003cstrong data-start=\"6953\" data-end=\"6964\"\u003eGVSWGLR\u003c\/strong\u003e and analog design built on PE(22-28): \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7045\" data-end=\"7160\"\u003e\n\u003cp data-start=\"7047\" data-end=\"7160\"\u003eAdditional catalog confirmations (CAS\/identity; research tool framing)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":53196214305032,"sku":null,"price":40.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0937\/9053\/5944\/files\/PE-22-28_10mg.png?v=1769443695"},{"product_id":"adamax-10mg-vial","title":"Adamax 10mg vial","description":"\u003cp data-end=\"576\" data-start=\"116\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                            \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"576\" data-start=\"116\"\u003e\u003cstrong data-end=\"126\" data-start=\"116\"\u003eAdamax\u003c\/strong\u003e is a \u003cstrong data-end=\"171\" data-start=\"132\"\u003esynthetic peptide analogue of Semax\u003c\/strong\u003e that is widely described as \u003cstrong data-end=\"287\" data-start=\"200\"\u003eSemax modified with the N-terminal and C-terminal “caps” used in Peptide-021 (P021)\u003c\/strong\u003e—a design strategy intended to increase \u003cstrong data-end=\"340\" data-start=\"327\"\u003estability\u003c\/strong\u003e and \u003cstrong data-end=\"361\" data-start=\"345\"\u003eCNS exposure\u003c\/strong\u003e (via lipophilic\/steric protection motifs). The sequence is commonly listed as \u003cstrong data-end=\"461\" data-start=\"440\"\u003eAc-MEHFPGP^AG-NH₂\u003c\/strong\u003e, where “^A” indicates an \u003cstrong data-end=\"519\" data-start=\"487\"\u003eadamantyl-containing residue\u003c\/strong\u003e in some notations. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"838\" data-start=\"578\"\u003e\u003cstrong data-end=\"600\" data-start=\"578\"\u003eRegulatory signal:\u003c\/strong\u003e New Zealand’s Medsafe has explicitly referenced \u003cstrong data-end=\"719\" data-start=\"649\"\u003eAdamax and Semax as ACTH analogues marketed as cognitive enhancers\u003c\/strong\u003e, in the context of proposed scheduling\/classification of “unscheduled peptides.” \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"843\" data-start=\"840\"\u003e\n\u003ch3 data-end=\"877\" data-start=\"845\"\u003e2) Chemical design rationale\u003c\/h3\u003e\n\u003ch4 data-end=\"909\" data-start=\"879\"\u003e2.1 Relationship to Semax\u003c\/h4\u003e\n\u003cp data-end=\"1255\" data-start=\"910\"\u003e\u003cstrong data-end=\"919\" data-start=\"910\"\u003eSemax\u003c\/strong\u003e itself is a synthetic peptide originally developed in Russia and widely studied in \u003cstrong data-end=\"1065\" data-start=\"1003\"\u003epreclinical neuroprotection and gene-expression modulation\u003c\/strong\u003e, including in brain ischemia models. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003cbr data-end=\"1143\" data-start=\"1140\"\u003eAdamax is positioned as a \u003cstrong data-end=\"1205\" data-start=\"1169\"\u003enext-generation Semax derivative\u003c\/strong\u003e, not a Khavinson “bioregulator” (2–4 aa) peptide.\u003c\/p\u003e\n\u003ch4 data-end=\"1306\" data-start=\"1257\"\u003e2.2 Why “adamantyl” and terminal caps matter\u003c\/h4\u003e\n\u003cp data-end=\"1364\" data-start=\"1307\"\u003eThe Adamax design is commonly described as incorporating:\u003c\/p\u003e\n\u003cul data-end=\"1745\" data-start=\"1365\"\u003e\n\u003cli data-end=\"1501\" data-start=\"1365\"\u003e\n\u003cp data-end=\"1501\" data-start=\"1367\"\u003e\u003cstrong data-end=\"1399\" data-start=\"1367\"\u003eN-terminal acetylation (Ac-)\u003c\/strong\u003e and \u003cstrong data-end=\"1435\" data-start=\"1404\"\u003eC-terminal amidation (-NH₂)\u003c\/strong\u003e to reduce exopeptidase degradation and improve peptide stability.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1745\" data-start=\"1502\"\u003e\n\u003cp data-end=\"1745\" data-start=\"1504\"\u003eAn \u003cstrong data-end=\"1545\" data-start=\"1507\"\u003eadamantyl-associated motif\/residue\u003c\/strong\u003e (per sequence notation and marketplace descriptions) inspired by \u003cstrong data-end=\"1619\" data-start=\"1611\"\u003eP021\u003c\/strong\u003e, intended to increase \u003cstrong data-end=\"1659\" data-start=\"1642\"\u003elipophilicity\u003c\/strong\u003e and support \u003cstrong data-end=\"1706\" data-start=\"1672\"\u003eBBB penetration\/brain exposure\u003c\/strong\u003e. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"1952\" data-start=\"1747\"\u003e\u003cem data-end=\"1763\" data-start=\"1747\"\u003eReality check:\u003c\/em\u003e while this medicinal-chemistry logic is plausible in principle, \u003cstrong data-end=\"1914\" data-start=\"1828\"\u003epublished, peer-reviewed PK\/BBB data for Adamax itself are not clearly established\u003c\/strong\u003e in widely indexed literature sources.\u003c\/p\u003e\n\u003chr data-end=\"1957\" data-start=\"1954\"\u003e\n\u003ch3 data-end=\"2054\" data-start=\"1959\"\u003e3) Molecular mechanism of action (inferred, because direct Adamax primary data are limited)\u003c\/h3\u003e\n\u003ch4 data-end=\"2090\" data-start=\"2056\"\u003e3.1 Putative pharmacodynamics\u003c\/h4\u003e\n\u003cp data-end=\"2296\" data-start=\"2091\"\u003eBecause Adamax is a \u003cstrong data-end=\"2129\" data-start=\"2111\"\u003eSemax analogue\u003c\/strong\u003e, most mechanistic narratives are \u003cstrong data-end=\"2198\" data-start=\"2163\"\u003eextrapolated from Semax biology\u003c\/strong\u003e plus the expectation that “improved stability\/penetration” yields stronger or longer CNS effects.\u003c\/p\u003e\n\u003cp data-end=\"2548\" data-start=\"2298\"\u003eFor \u003cstrong data-end=\"2311\" data-start=\"2302\"\u003eSemax\u003c\/strong\u003e, transcriptomic work in rat focal brain ischemia reports that Semax \u003cstrong data-end=\"2409\" data-start=\"2380\"\u003emodulates gene expression\u003c\/strong\u003e, including immune-response–related genes and vascular-system–related processes in the injured brain. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"2633\" data-start=\"2550\"\u003e\u003cstrong data-end=\"2576\" data-start=\"2550\"\u003eAdamax-specific claims\u003c\/strong\u003e (commonly stated in vendor\/secondary summaries) include:\u003c\/p\u003e\n\u003cul data-end=\"2778\" data-start=\"2634\"\u003e\n\u003cli data-end=\"2701\" data-start=\"2634\"\u003e\n\u003cp data-end=\"2701\" data-start=\"2636\"\u003e↑ \u003cstrong data-end=\"2646\" data-start=\"2638\"\u003eBDNF\u003c\/strong\u003e signaling and\/or ↑ \u003cstrong data-end=\"2686\" data-start=\"2666\"\u003eTrkB sensitivity\u003c\/strong\u003e (hippocampus),\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"2738\" data-start=\"2702\"\u003e\n\u003cp data-end=\"2738\" data-start=\"2704\"\u003ecognitive\/mood resilience effects,\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"2778\" data-start=\"2739\"\u003e\n\u003cp data-end=\"2778\" data-start=\"2741\"\u003eenhanced physical endurance\/recovery.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"3013\" data-start=\"2780\"\u003eThese claims are \u003cstrong data-end=\"2869\" data-start=\"2797\"\u003enot well anchored to high-quality, peer-reviewed Adamax human trials\u003c\/strong\u003e in the sources surfaced here, so they should be treated as \u003cstrong data-end=\"2964\" data-start=\"2929\"\u003ehypotheses\/marketing assertions\u003c\/strong\u003e unless you can cite primary experimental papers.\u003c\/p\u003e\n\u003chr data-end=\"3018\" data-start=\"3015\"\u003e\n\u003ch3 data-end=\"3071\" data-start=\"3020\"\u003e4) Pharmacokinetics and delivery considerations\u003c\/h3\u003e\n\u003cp data-end=\"3211\" data-start=\"3072\"\u003eThere is \u003cstrong data-end=\"3101\" data-start=\"3081\"\u003eno drug-label PK\u003c\/strong\u003e for Adamax, and robust PK parameters (t½, bioavailability, CSF\/brain exposure) are not publicly standardized.\u003c\/p\u003e\n\u003cp data-end=\"3260\" data-start=\"3213\"\u003eGeneral peptide principles that \u003cem data-end=\"3253\" data-start=\"3245\"\u003elikely\u003c\/em\u003e apply:\u003c\/p\u003e\n\u003cul data-end=\"3691\" data-start=\"3261\"\u003e\n\u003cli data-end=\"3340\" data-start=\"3261\"\u003e\n\u003cp data-end=\"3340\" data-start=\"3263\"\u003e\u003cstrong data-end=\"3283\" data-start=\"3263\"\u003eTerminal capping\u003c\/strong\u003e (Ac- \/ -NH₂) can improve stability vs uncapped peptides.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3443\" data-start=\"3341\"\u003e\n\u003cp data-end=\"3443\" data-start=\"3343\"\u003eAny \u003cstrong data-end=\"3360\" data-start=\"3347\"\u003eadamantyl\u003c\/strong\u003e substitution can increase lipophilicity and potentially alter tissue distribution.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3691\" data-start=\"3444\"\u003e\n\u003cp data-end=\"3691\" data-start=\"3446\"\u003e\u003cstrong data-end=\"3463\" data-start=\"3446\"\u003eRoute matters\u003c\/strong\u003e: Adamax is frequently marketed as \u003cstrong data-end=\"3518\" data-start=\"3498\"\u003eintranasal spray\u003c\/strong\u003e in consumer channels, which—if real product identity\/purity were controlled—could theoretically favor CNS exposure; however, this is not a substitute for formal PK\/PD data.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"3696\" data-start=\"3693\"\u003e\n\u003ch3 data-end=\"3747\" data-start=\"3698\"\u003e5) Evidence base (what’s solid vs what’s not)\u003c\/h3\u003e\n\u003ch4 data-end=\"3782\" data-start=\"3749\"\u003e5.1 Stronger anchor evidence\u003c\/h4\u003e\n\u003cul data-end=\"4312\" data-start=\"3783\"\u003e\n\u003cli data-end=\"3923\" data-start=\"3783\"\u003e\n\u003cp data-end=\"3923\" data-start=\"3785\"\u003e\u003cstrong data-end=\"3817\" data-start=\"3785\"\u003eSemax mechanistic literature\u003c\/strong\u003e: gene-expression modulation in brain injury models (preclinical). \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4121\" data-start=\"3924\"\u003e\n\u003cp data-end=\"4121\" data-start=\"3926\"\u003e\u003cstrong data-end=\"3954\" data-start=\"3926\"\u003eRegulatory documentation\u003c\/strong\u003e: Medsafe explicitly discusses Adamax\/Semax among “unscheduled peptides” and ACTH analogues marketed for cognitive enhancement. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4312\" data-start=\"4122\"\u003e\n\u003cp data-end=\"4312\" data-start=\"4124\"\u003e\u003cstrong data-end=\"4154\" data-start=\"4124\"\u003eIdentity\/sequence listings\u003c\/strong\u003e: multiple chemical\/vendor databases list the Adamax sequence (Ac-MEHFPGPAG; and variants including adamantyl notation). \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 data-end=\"4369\" data-start=\"4314\"\u003e5.2 What is not established (high-confidence gaps)\u003c\/h4\u003e\n\u003cul data-end=\"4558\" data-start=\"4370\"\u003e\n\u003cli data-end=\"4449\" data-start=\"4370\"\u003e\n\u003cp data-end=\"4449\" data-start=\"4372\"\u003eWell-powered \u003cstrong data-end=\"4399\" data-start=\"4385\"\u003ehuman RCTs\u003c\/strong\u003e showing clinically meaningful cognitive outcomes.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4503\" data-start=\"4450\"\u003e\n\u003cp data-end=\"4503\" data-start=\"4452\"\u003eStandardized \u003cstrong data-end=\"4487\" data-start=\"4465\"\u003ePK\/BBB penetration\u003c\/strong\u003e data in humans.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4558\" data-start=\"4504\"\u003e\n\u003cp data-end=\"4558\" data-start=\"4506\"\u003eComprehensive \u003cstrong data-end=\"4548\" data-start=\"4520\"\u003esafety\/pharmacovigilance\u003c\/strong\u003e datasets.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"4563\" data-start=\"4560\"\u003e\n\u003ch3 data-end=\"4619\" data-start=\"4565\"\u003e6) Safety and tolerability (risk-based assessment)\u003c\/h3\u003e\n\u003cp data-end=\"4777\" data-start=\"4620\"\u003eBecause Adamax is typically sold outside approved pharmaceutical channels, the dominant risks are often \u003cstrong data-end=\"4753\" data-start=\"4724\"\u003eproduct and route related\u003c\/strong\u003e, not just pharmacology:\u003c\/p\u003e\n\u003cul data-end=\"5324\" data-start=\"4779\"\u003e\n\u003cli data-end=\"4941\" data-start=\"4779\"\u003e\n\u003cp data-end=\"4941\" data-start=\"4781\"\u003e\u003cstrong data-end=\"4812\" data-start=\"4781\"\u003eIdentity\/purity variability\u003c\/strong\u003e: sequence notation differences and inconsistent marketing claims are common; this increases risk of adulteration or mislabeling.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5044\" data-start=\"4942\"\u003e\n\u003cp data-end=\"5044\" data-start=\"4944\"\u003e\u003cstrong data-end=\"4962\" data-start=\"4944\"\u003eSterility risk\u003c\/strong\u003e: particularly relevant if products are administered intranasally or by injection.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5226\" data-start=\"5045\"\u003e\n\u003cp data-end=\"5226\" data-start=\"5047\"\u003e\u003cstrong data-end=\"5072\" data-start=\"5047\"\u003eUnknown dose–response\u003c\/strong\u003e in humans: without controlled trials, adverse neuropsychiatric effects, blood pressure\/HR effects, or idiosyncratic reactions cannot be reliably bounded.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5324\" data-start=\"5227\"\u003e\n\u003cp data-end=\"5324\" data-start=\"5229\"\u003e\u003cstrong data-end=\"5252\" data-start=\"5229\"\u003ePeptide class risks\u003c\/strong\u003e: potential hypersensitivity reactions and excipient-related irritation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"5329\" data-start=\"5326\"\u003e\n\u003ch3 data-end=\"5358\" data-start=\"5331\"\u003e7) Regulatory landscape\u003c\/h3\u003e\n\u003cul data-end=\"5581\" data-start=\"5359\"\u003e\n\u003cli data-end=\"5400\" data-start=\"5359\"\u003e\n\u003cp data-end=\"5400\" data-start=\"5361\"\u003e\u003cstrong data-end=\"5385\" data-start=\"5361\"\u003eNot FDA\/EMA-approved\u003c\/strong\u003e as a medicine.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5581\" data-start=\"5401\"\u003e\n\u003cp data-end=\"5581\" data-start=\"5403\"\u003eMedsafe has explicitly discussed Adamax within proposed peptide classification frameworks and notes it has appeared in enforcement contexts. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"5586\" data-start=\"5583\"\u003e\n\u003ch3 data-end=\"5659\" data-start=\"5588\"\u003e8) Future directions (what would make Adamax scientifically “real”)\u003c\/h3\u003e\n\u003cp data-end=\"5735\" data-start=\"5660\"\u003eIf Adamax were to be evaluated to modern standards, the key steps would be:\u003c\/p\u003e\n\u003col data-end=\"6113\" data-start=\"5736\"\u003e\n\u003cli data-end=\"5843\" data-start=\"5736\"\u003e\n\u003cp data-end=\"5843\" data-start=\"5739\"\u003e\u003cstrong data-end=\"5778\" data-start=\"5739\"\u003eAnalytical identity standardization\u003c\/strong\u003e (MS\/HPLC; confirm adamantyl residue identity; impurity profile).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5970\" data-start=\"5844\"\u003e\n\u003cp data-end=\"5970\" data-start=\"5847\"\u003e\u003cstrong data-end=\"5864\" data-start=\"5847\"\u003ePK\/PD studies\u003c\/strong\u003e (including intranasal vs systemic, CSF\/brain exposure, and biomarkers like BDNF\/TrkB pathway engagement).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6113\" data-start=\"5971\"\u003e\n\u003cp data-end=\"6113\" data-start=\"5974\"\u003e\u003cstrong data-end=\"6004\" data-start=\"5974\"\u003eControlled clinical trials\u003c\/strong\u003e with validated endpoints (memory, attention\/executive function, mood\/stress scales), plus safety monitoring.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003chr data-end=\"6118\" data-start=\"6115\"\u003e\n\u003ch3 data-end=\"6163\" data-start=\"6120\"\u003eSelected references (most load-bearing)\u003c\/h3\u003e\n\u003cul data-end=\"6797\" data-start=\"6164\"\u003e\n\u003cli data-end=\"6280\" data-start=\"6164\"\u003e\n\u003cp data-end=\"6280\" data-start=\"6166\"\u003eAdamax definition and relationship to Semax + P021 terminal modifications: \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6448\" data-start=\"6281\"\u003e\n\u003cp data-end=\"6448\" data-start=\"6283\"\u003eMedsafe “Classification of Unscheduled Peptides” discussing Adamax\/Semax as ACTH analogues marketed as cognitive enhancers: \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6555\" data-start=\"6449\"\u003e\n\u003cp data-end=\"6555\" data-start=\"6451\"\u003eMedsafe MCC minutes acknowledging peptide classification work: \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6687\" data-start=\"6556\"\u003e\n\u003cp data-end=\"6687\" data-start=\"6558\"\u003eSemax gene-expression effects in focal brain ischemia (preclinical mechanistic anchor): \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6797\" data-start=\"6688\"\u003e\n\u003cp data-end=\"6797\" data-start=\"6690\"\u003eSequence listings for Adamax (Ac-MEHFPGPAG and related notation)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":53196949913864,"sku":null,"price":55.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0937\/9053\/5944\/files\/adamax_10mg.png?v=1769452971"},{"product_id":"melatonin-10mg-vial","title":"Melatonin 10mg vial","description":"\u003cp data-end=\"980\" data-start=\"250\"\u003e                                         \u003cstrong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eN\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eOT FOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-end=\"980\" data-start=\"250\"\u003e\u003cstrong data-end=\"263\" data-start=\"250\"\u003eMelatonin\u003c\/strong\u003e is a hormone produced by the pineal gland that helps regulate circadian timing. As a supplement or medicine, it is most commonly used for \u003cstrong data-end=\"413\" data-start=\"402\"\u003ejet lag\u003c\/strong\u003e, \u003cstrong data-end=\"450\" data-start=\"415\"\u003edelayed sleep-wake phase issues\u003c\/strong\u003e, and some forms of \u003cstrong data-end=\"482\" data-start=\"470\"\u003einsomnia\u003c\/strong\u003e, but evidence and regulatory status vary by indication and by country. In the EU, an approved prolonged-release melatonin product is indicated for \u003cstrong data-end=\"717\" data-start=\"630\"\u003eshort-term treatment of primary insomnia in adults aged 55 or older at 2 mg nightly\u003c\/strong\u003e; in the U.S., melatonin is generally sold as a \u003cstrong data-end=\"787\" data-start=\"765\"\u003edietary supplement\u003c\/strong\u003e, not an FDA-approved insomnia drug. A \u003cstrong data-end=\"840\" data-start=\"826\"\u003e10 mg dose\u003c\/strong\u003e is at the high end of common use and is above the dose used in the main EU-approved insomnia product. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"985\" data-start=\"982\"\u003e\n\u003ch1 data-end=\"1041\" data-start=\"987\" data-section-id=\"mh4re4\"\u003eAdditional Benefits and Use-Cases of Melatonin \u003c\/h1\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"3025\" data-start=\"1043\"\u003e\n\u003cthead data-end=\"1082\" data-start=\"1043\"\u003e\n\u003ctr data-end=\"1082\" data-start=\"1043\"\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"1064\" data-start=\"1043\"\u003eBENEFIT \/ USE-CASE\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"xl\" data-end=\"1082\" data-start=\"1064\"\u003eKEY TAKE-AWAYS\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"3025\" data-start=\"1093\"\u003e\n\u003ctr data-end=\"1326\" data-start=\"1093\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1117\" data-start=\"1093\"\u003e1 Sleep-onset support\u003c\/td\u003e\n\u003ctd data-end=\"1326\" data-start=\"1117\" data-col-size=\"xl\"\u003eMelatonin can help some people with sleep timing and sleep initiation, especially when circadian timing is off; it is not equally effective for every form of insomnia. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1472\" data-start=\"1327\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1339\" data-start=\"1327\"\u003e2 Jet lag\u003c\/td\u003e\n\u003ctd data-end=\"1472\" data-start=\"1339\" data-col-size=\"xl\"\u003eMelatonin has evidence for reducing jet-lag symptoms when used around transmeridian travel. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1676\" data-start=\"1473\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1515\" data-start=\"1473\"\u003e3 Delayed sleep phase \/ circadian shift\u003c\/td\u003e\n\u003ctd data-end=\"1676\" data-start=\"1515\" data-col-size=\"xl\"\u003eOne of melatonin’s most evidence-supported roles is shifting sleep timing when the body clock is delayed or misaligned. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1936\" data-start=\"1677\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1721\" data-start=\"1677\"\u003e4 Older-adult insomnia formulations exist\u003c\/td\u003e\n\u003ctd data-end=\"1936\" data-start=\"1721\" data-col-size=\"xl\"\u003eIn Europe, prolonged-release melatonin 2 mg is approved for short-term primary insomnia in adults 55+; that does not mean 10 mg is the standard approved adult insomnia dose. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2229\" data-start=\"1937\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1992\" data-start=\"1937\"\u003e5 Pediatric specialist use exists in selected groups\u003c\/td\u003e\n\u003ctd data-end=\"2229\" data-start=\"1992\" data-col-size=\"xl\"\u003eSome prescription prolonged-release melatonin products are used in children with specific neurodevelopmental conditions, with specialist oversight and dose titration up to 10 mg in some settings. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2396\" data-start=\"2230\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2273\" data-start=\"2230\"\u003e6 Generally mild short-term side effects\u003c\/td\u003e\n\u003ctd data-end=\"2396\" data-start=\"2273\" data-col-size=\"xl\"\u003eShort-term studies most often report headache, dizziness, nausea, and sleepiness. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2588\" data-start=\"2397\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2439\" data-start=\"2397\"\u003e7 Long-term safety remains less certain\u003c\/td\u003e\n\u003ctd data-end=\"2588\" data-start=\"2439\" data-col-size=\"xl\"\u003eNCCIH notes that long-term safety is not well established, especially outside specific studied populations. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2774\" data-start=\"2589\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2621\" data-start=\"2589\"\u003e8 Product-quality variability\u003c\/td\u003e\n\u003ctd data-end=\"2774\" data-start=\"2621\" data-col-size=\"xl\"\u003eIn the U.S., supplement regulation is looser than for prescription drugs, so content may differ from the label. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3025\" data-start=\"2775\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2823\" data-start=\"2775\"\u003e9 Higher dose does not guarantee better sleep\u003c\/td\u003e\n\u003ctd data-end=\"3025\" data-start=\"2823\" data-col-size=\"xl\"\u003eMainstream guidance generally starts lower; 10 mg is often reserved for selected cases or specialist-directed use rather than routine first-line self-treatment. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"3030\" data-start=\"3027\"\u003e\n\u003ch1 data-end=\"3066\" data-start=\"3032\" data-section-id=\"1lc7cic\"\u003e2. Molecular Mechanism of Action\u003c\/h1\u003e\n\u003ch2 data-end=\"3100\" data-start=\"3068\" data-section-id=\"j8h1e5\"\u003e2.1 Receptor Pharmacodynamics\u003c\/h2\u003e\n\u003cp data-end=\"3591\" data-start=\"3102\"\u003eMelatonin primarily acts through \u003cstrong data-end=\"3160\" data-start=\"3135\"\u003eMT1 and MT2 receptors\u003c\/strong\u003e to influence the body clock and sleep timing. Clinically, the important effect is less “sedation” in the classic sleeping-pill sense and more \u003cstrong data-end=\"3326\" data-start=\"3303\"\u003ecircadian signaling\u003c\/strong\u003e: helping cue the brain that it is biological night. That is why timing of administration often matters as much as, or more than, sheer dose. This circadian role underlies its use for jet lag and delayed sleep phase problems. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"3619\" data-start=\"3593\" data-section-id=\"1ff2ij5\"\u003e2.2 Down-stream Biology\u003c\/h2\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"4256\" data-start=\"3621\"\u003e\n\u003cthead data-end=\"3672\" data-start=\"3621\"\u003e\n\u003ctr data-end=\"3672\" data-start=\"3621\"\u003e\n\u003cth class=\"\" data-col-size=\"sm\" data-end=\"3640\" data-start=\"3621\"\u003ePATHWAY \/ EFFECT\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"3661\" data-start=\"3640\"\u003eFUNCTIONAL OUTCOME\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"lg\" data-end=\"3672\" data-start=\"3661\"\u003eCONTEXT\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"4256\" data-start=\"3687\"\u003e\n\u003ctr data-end=\"3882\" data-start=\"3687\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3715\" data-start=\"3687\"\u003eCircadian clock signaling\u003c\/td\u003e\n\u003ctd data-end=\"3782\" data-start=\"3715\" data-col-size=\"md\"\u003eSleep timing shifts earlier or later depending on timing of dose\u003c\/td\u003e\n\u003ctd data-end=\"3882\" data-start=\"3782\" data-col-size=\"lg\"\u003eJet lag, delayed sleep phase, shift-related sleep issues \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4037\" data-start=\"3883\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3902\" data-start=\"3883\"\u003eSleep propensity\u003c\/td\u003e\n\u003ctd data-end=\"3950\" data-start=\"3902\" data-col-size=\"md\"\u003eMay reduce sleep-onset latency in some people\u003c\/td\u003e\n\u003ctd data-end=\"4037\" data-start=\"3950\" data-col-size=\"lg\"\u003eMild insomnia \/ sleep initiation difficulty \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4256\" data-start=\"4038\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4075\" data-start=\"4038\"\u003eCore temperature \/ night signaling\u003c\/td\u003e\n\u003ctd data-end=\"4118\" data-start=\"4075\" data-col-size=\"md\"\u003eReinforces biologic nighttime physiology\u003c\/td\u003e\n\u003ctd data-end=\"4256\" data-start=\"4118\" data-col-size=\"lg\"\u003eGeneral sleep-timing support; overdose literature notes high doses can reduce body temperature \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"4261\" data-start=\"4258\"\u003e\n\u003ch1 data-end=\"4284\" data-start=\"4263\" data-section-id=\"v5ius4\"\u003e3. Pharmacokinetics\u003c\/h1\u003e\n\u003cp data-end=\"4506\" data-start=\"4286\"\u003e\u003cstrong data-end=\"4296\" data-start=\"4286\"\u003eRoute:\u003c\/strong\u003e\u003cbr data-end=\"4299\" data-start=\"4296\"\u003eUsually taken \u003cstrong data-end=\"4323\" data-start=\"4313\"\u003eorally\u003c\/strong\u003e, either as \u003cstrong data-end=\"4356\" data-start=\"4335\"\u003eimmediate-release\u003c\/strong\u003e or \u003cstrong data-end=\"4381\" data-start=\"4360\"\u003eprolonged-release\u003c\/strong\u003e tablets\/capsules. Approved European insomnia products are prolonged-release tablets. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"4773\" data-start=\"4508\"\u003e\u003cstrong data-end=\"4532\" data-start=\"4508\"\u003eAbsorption \/ timing:\u003c\/strong\u003e\u003cbr data-end=\"4535\" data-start=\"4532\"\u003eFor approved prolonged-release melatonin in Europe, the recommended use is \u003cstrong data-end=\"4653\" data-start=\"4610\"\u003e1–2 hours before bedtime and after food\u003c\/strong\u003e. Timing matters because melatonin’s effect is strongly tied to circadian phase. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"5339\" data-start=\"4775\"\u003e\u003cstrong data-end=\"4818\" data-start=\"4775\"\u003eHalf-life \/ formulation considerations:\u003c\/strong\u003e\u003cbr data-end=\"4821\" data-start=\"4818\"\u003eImmediate-release forms are typically used when people are trying to affect sleep onset or circadian timing quickly, while prolonged-release products aim to mimic a longer physiologic nighttime signal. The exact PK depends heavily on formulation; a “10 mg melatonin” gummy, capsule, and prolonged-release tablet are not interchangeable in effect. This formulation dependence is consistent with the distinction between approved prolonged-release products and supplement products. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"5491\" data-start=\"5341\"\u003e\u003cstrong data-end=\"5363\" data-start=\"5341\"\u003eFood interactions:\u003c\/strong\u003e\u003cbr data-end=\"5366\" data-start=\"5363\"\u003eFor the EMA-approved prolonged-release product, dosing is recommended \u003cstrong data-end=\"5450\" data-start=\"5436\"\u003eafter food\u003c\/strong\u003e. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"5496\" data-start=\"5493\"\u003e\n\u003ch1 data-end=\"5537\" data-start=\"5498\" data-section-id=\"j5dpf2\"\u003e4. Pre-clinical and Clinical Evidence\u003c\/h1\u003e\n\u003ch2 data-end=\"5573\" data-start=\"5539\" data-section-id=\"l4uywg\"\u003e4.1 Insomnia \/ sleep initiation\u003c\/h2\u003e\n\u003cp data-end=\"5978\" data-start=\"5575\"\u003eCurrent mainstream sources support melatonin most clearly for selected sleep disorders and circadian-related problems, with more mixed benefit for general insomnia. In Europe, the approved prolonged-release product is specifically indicated for \u003cstrong data-end=\"5897\" data-start=\"5820\"\u003eshort-term treatment of primary insomnia in adults aged 55 years or older\u003c\/strong\u003e, at \u003cstrong data-end=\"5937\" data-start=\"5902\"\u003e2 mg nightly for up to 13 weeks\u003c\/strong\u003e. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"6025\" data-start=\"5980\" data-section-id=\"1ol0g9q\"\u003e4.2 Jet lag and circadian rhythm disorders\u003c\/h2\u003e\n\u003cp data-end=\"6278\" data-start=\"6027\"\u003eNCCIH states that melatonin may help with \u003cstrong data-end=\"6080\" data-start=\"6069\"\u003ejet lag\u003c\/strong\u003e and several sleep disorders including \u003cstrong data-end=\"6151\" data-start=\"6119\"\u003edelayed sleep phase disorder\u003c\/strong\u003eand \u003cstrong data-end=\"6196\" data-start=\"6156\"\u003esleep problems related to shift work\u003c\/strong\u003e. These are among the best-supported uses. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"6311\" data-start=\"6280\" data-section-id=\"15t4eq3\"\u003e4.3 Children and adolescents\u003c\/h2\u003e\n\u003cp data-end=\"6821\" data-start=\"6313\"\u003eMelatonin is used in some pediatric populations, but professional societies advise medical supervision rather than casual over-the-counter use. The AASM advises parents to discuss melatonin use with a health professional first, and EMA-approved pediatric prolonged-release melatonin exists only for selected conditions such as insomnia in children and adolescents with \u003cstrong data-end=\"6719\" data-start=\"6682\"\u003eASD and\/or Smith-Magenis syndrome\u003c\/strong\u003e, with titration up to \u003cstrong data-end=\"6751\" data-start=\"6742\"\u003e10 mg\u003c\/strong\u003e in that prescription context. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"6851\" data-start=\"6823\" data-section-id=\"10p1ffp\"\u003e4.4 Evidence quality note\u003c\/h2\u003e\n\u003cp data-end=\"7138\" data-start=\"6853\"\u003eMelatonin appears \u003cstrong data-end=\"6909\" data-start=\"6871\"\u003erelatively safe for short-term use\u003c\/strong\u003e, but NCCIH notes that \u003cstrong data-end=\"6977\" data-start=\"6932\"\u003elong-term safety has not been established\u003c\/strong\u003e. That matters especially when people take higher doses such as 10 mg nightly for long periods without medical oversight. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"7143\" data-start=\"7140\"\u003e\n\u003ch1 data-end=\"7187\" data-start=\"7145\" data-section-id=\"11w9qtr\"\u003e5. Emerging or Common Clinical Interests\u003c\/h1\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"8022\" data-start=\"7189\"\u003e\n\u003cthead data-end=\"7219\" data-start=\"7189\"\u003e\n\u003ctr data-end=\"7219\" data-start=\"7189\"\u003e\n\u003cth class=\"\" data-col-size=\"sm\" data-end=\"7197\" data-start=\"7189\"\u003eFIELD\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"7209\" data-start=\"7197\"\u003eRATIONALE\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"7219\" data-start=\"7209\"\u003eSTATUS\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"8022\" data-start=\"7234\"\u003e\n\u003ctr data-end=\"7346\" data-start=\"7234\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7244\" data-start=\"7234\"\u003eJet lag\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7284\" data-start=\"7244\"\u003eCircadian phase support around travel\u003c\/td\u003e\n\u003ctd data-end=\"7346\" data-start=\"7284\" data-col-size=\"md\"\u003eSupported use-case \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7494\" data-start=\"7347\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7374\" data-start=\"7347\"\u003eDelayed sleep-wake phase\u003c\/td\u003e\n\u003ctd data-end=\"7432\" data-start=\"7374\" data-col-size=\"md\"\u003eHelps shift biologic night earlier when timed correctly\u003c\/td\u003e\n\u003ctd data-end=\"7494\" data-start=\"7432\" data-col-size=\"md\"\u003eSupported use-case \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7653\" data-start=\"7495\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7521\" data-start=\"7495\"\u003eShift-work sleep issues\u003c\/td\u003e\n\u003ctd data-end=\"7553\" data-start=\"7521\" data-col-size=\"md\"\u003eCircadian misalignment target\u003c\/td\u003e\n\u003ctd data-end=\"7653\" data-start=\"7553\" data-col-size=\"md\"\u003eEvidence exists, though not universal first-line therapy \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7810\" data-start=\"7654\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7687\" data-start=\"7654\"\u003ePrimary insomnia in adults 55+\u003c\/td\u003e\n\u003ctd data-end=\"7733\" data-start=\"7687\" data-col-size=\"md\"\u003eEMA-approved prolonged-release 2 mg product\u003c\/td\u003e\n\u003ctd data-end=\"7810\" data-start=\"7733\" data-col-size=\"md\"\u003eApproved in EU for short-term use \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"8022\" data-start=\"7811\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7851\" data-start=\"7811\"\u003ePediatric neurodevelopmental insomnia\u003c\/td\u003e\n\u003ctd data-end=\"7904\" data-start=\"7851\" data-col-size=\"md\"\u003eSpecialist prescription use in selected conditions\u003c\/td\u003e\n\u003ctd data-end=\"8022\" data-start=\"7904\" data-col-size=\"md\"\u003eApproved in specific populations\/formulations, not general self-medication \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"8027\" data-start=\"8024\"\u003e\n\u003ch1 data-end=\"8057\" data-start=\"8029\" data-section-id=\"1fzeiej\"\u003e6. Safety and Tolerability\u003c\/h1\u003e\n\u003cp data-end=\"8245\" data-start=\"8059\"\u003e\u003cstrong data-end=\"8083\" data-start=\"8059\"\u003eCommon side effects:\u003c\/strong\u003e\u003cbr data-end=\"8086\" data-start=\"8083\"\u003eNCCIH lists \u003cstrong data-end=\"8145\" data-start=\"8098\"\u003eheadache, dizziness, nausea, and sleepiness\u003c\/strong\u003e among the mild side effects reported in short-term studies. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"8492\" data-start=\"8247\"\u003e\u003cstrong data-end=\"8289\" data-start=\"8247\"\u003eDaytime drowsiness \/ next-day effects:\u003c\/strong\u003e\u003cbr data-end=\"8292\" data-start=\"8289\"\u003eThis is one of the more practical concerns with a 10 mg dose, especially in older adults, since melatonin may remain active longer and cause daytime drowsiness. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"8635\" data-start=\"8494\"\u003e\u003cstrong data-end=\"8515\" data-start=\"8494\"\u003eLong-term safety:\u003c\/strong\u003e\u003cbr data-end=\"8518\" data-start=\"8515\"\u003eUnclear overall, especially for prolonged nightly use outside studied groups. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"8843\" data-start=\"8637\"\u003e\u003cstrong data-end=\"8667\" data-start=\"8637\"\u003eDrug-interaction cautions:\u003c\/strong\u003e\u003cbr data-end=\"8670\" data-start=\"8667\"\u003eNCCIH advises that people with \u003cstrong data-end=\"8713\" data-start=\"8701\"\u003eepilepsy\u003c\/strong\u003e or those taking a \u003cstrong data-end=\"8749\" data-start=\"8732\"\u003eblood thinner\u003c\/strong\u003e should not use melatonin without medical supervision. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"8982\" data-start=\"8845\"\u003e\u003cstrong data-end=\"8869\" data-start=\"8845\"\u003eSpecial populations:\u003c\/strong\u003e\u003cbr data-end=\"8872\" data-start=\"8869\"\u003eThere is a lack of safety research in \u003cstrong data-end=\"8941\" data-start=\"8910\"\u003epregnancy and breastfeeding\u003c\/strong\u003e. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"9228\" data-start=\"8984\"\u003e\u003cstrong data-end=\"9012\" data-start=\"8984\"\u003eProduct-quality concern:\u003c\/strong\u003e\u003cbr data-end=\"9015\" data-start=\"9012\"\u003eBecause U.S. melatonin is commonly sold as a supplement, products may not contain exactly what the label says. That becomes more relevant at higher nominal doses like 10 mg. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"9275\" data-start=\"9230\" data-section-id=\"138v54u\"\u003eComparative safety \/ practical-use matrix\u003c\/h3\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"10085\" data-start=\"9277\"\u003e\n\u003cthead data-end=\"9341\" data-start=\"9277\"\u003e\n\u003ctr data-end=\"9341\" data-start=\"9277\"\u003e\n\u003cth class=\"\" data-col-size=\"sm\" data-end=\"9287\" data-start=\"9277\"\u003eFEATURE\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"9305\" data-start=\"9287\"\u003eMELATONIN 10 MG\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"9341\" data-start=\"9305\"\u003eMELATONIN 2 MG PROLONGED-RELEASE\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"10085\" data-start=\"9356\"\u003e\n\u003ctr data-end=\"9509\" data-start=\"9356\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"9371\" data-start=\"9356\"\u003eTypical role\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"9421\" data-start=\"9371\"\u003eHigher-end supplement dose; often self-directed\u003c\/td\u003e\n\u003ctd data-end=\"9509\" data-start=\"9421\" data-col-size=\"md\"\u003eApproved EU insomnia medicine for adults 55+ \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"9649\" data-start=\"9510\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"9523\" data-start=\"9510\"\u003eRegulation\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"9568\" data-start=\"9523\"\u003eOften supplement-based, especially in U.S.\u003c\/td\u003e\n\u003ctd data-end=\"9649\" data-start=\"9568\" data-col-size=\"md\"\u003ePrescription\/regulated medicine in EU \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"9831\" data-start=\"9650\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"9666\" data-start=\"9650\"\u003eEvidence base\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"9722\" data-start=\"9666\"\u003eBroad but heterogeneous by formulation and indication\u003c\/td\u003e\n\u003ctd data-end=\"9831\" data-start=\"9722\" data-col-size=\"md\"\u003eClear labeled use for short-term primary insomnia in older adults \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"9944\" data-start=\"9832\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"9857\" data-start=\"9832\"\u003eNext-day sedation risk\u003c\/td\u003e\n\u003ctd data-end=\"9890\" data-start=\"9857\" data-col-size=\"md\"\u003eMore plausible at higher doses\u003c\/td\u003e\n\u003ctd data-end=\"9944\" data-start=\"9890\" data-col-size=\"md\"\u003eUsually lower-dose, controlled-release medical use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"10085\" data-start=\"9945\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"9977\" data-start=\"9945\"\u003eLong-term routine nightly use\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"10001\" data-start=\"9977\"\u003eLess well established\u003c\/td\u003e\n\u003ctd data-end=\"10085\" data-start=\"10001\" data-col-size=\"md\"\u003eLabeled short-term course up to 13 weeks \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"10090\" data-start=\"10087\"\u003e\n\u003ch1 data-end=\"10117\" data-start=\"10092\" data-section-id=\"1tbfuas\"\u003e7. Regulatory Landscape\u003c\/h1\u003e\n\u003cp data-end=\"10533\" data-start=\"10119\"\u003e\u003cstrong data-end=\"10139\" data-start=\"10119\"\u003eApproval status:\u003c\/strong\u003e\u003cbr data-end=\"10142\" data-start=\"10139\"\u003eMelatonin’s regulatory status depends on the jurisdiction. In the \u003cstrong data-end=\"10216\" data-start=\"10208\"\u003eU.S.\u003c\/strong\u003e, melatonin is generally regulated as a \u003cstrong data-end=\"10278\" data-start=\"10256\"\u003edietary supplement\u003c\/strong\u003e, not as an FDA-approved insomnia drug. In the \u003cstrong data-end=\"10331\" data-start=\"10325\"\u003eEU\u003c\/strong\u003e, certain melatonin medicines are approved for specific uses and doses, such as \u003cstrong data-end=\"10437\" data-start=\"10411\"\u003e2 mg prolonged-release\u003c\/strong\u003e for short-term primary insomnia in adults 55 and older. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"10796\" data-start=\"10535\"\u003e\u003cstrong data-end=\"10558\" data-start=\"10535\"\u003e10 mg specifically:\u003c\/strong\u003e\u003cbr data-end=\"10561\" data-start=\"10558\"\u003eA \u003cstrong data-end=\"10572\" data-start=\"10563\"\u003e10 mg\u003c\/strong\u003e dose exists in some prescription pediatric protocols and local formularies as an upper limit in selected circumstances, but it is \u003cstrong data-end=\"10755\" data-start=\"10703\"\u003enot the standard adult EU-approved insomnia dose\u003c\/strong\u003e. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"10801\" data-start=\"10798\"\u003e\n\u003ch1 data-end=\"10825\" data-start=\"10803\" data-section-id=\"sy3ocj\"\u003e8. Future Directions\u003c\/h1\u003e\n\u003cul data-end=\"11354\" data-start=\"10827\"\u003e\n\u003cli data-end=\"10949\" data-start=\"10827\" data-section-id=\"n6o6pm\"\u003e\n\u003cp data-end=\"10949\" data-start=\"10829\"\u003eBetter evidence on \u003cstrong data-end=\"10868\" data-start=\"10848\"\u003elong-term safety\u003c\/strong\u003e, especially at \u003cstrong data-end=\"10908\" data-start=\"10884\"\u003ehigher nightly doses\u003c\/strong\u003e. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"11057\" data-start=\"10950\" data-section-id=\"1w60r2b\"\u003e\n\u003cp data-end=\"11057\" data-start=\"10952\"\u003eMore clarity on \u003cstrong data-end=\"10985\" data-start=\"10968\"\u003edose-response\u003c\/strong\u003e, since higher doses do not always translate into better sleep outcomes.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"11233\" data-start=\"11058\" data-section-id=\"199k53f\"\u003e\n\u003cp data-end=\"11233\" data-start=\"11060\"\u003eBetter standardization of \u003cstrong data-end=\"11121\" data-start=\"11086\"\u003esupplement quality and labeling\u003c\/strong\u003e, especially in markets where melatonin is sold as a dietary supplement. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"11354\" data-start=\"11234\" data-section-id=\"74es1d\"\u003e\n\u003cp data-end=\"11354\" data-start=\"11236\"\u003eMore head-to-head work comparing \u003cstrong data-end=\"11311\" data-start=\"11269\"\u003eimmediate-release vs prolonged-release\u003c\/strong\u003e formulations for different sleep problems.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"11359\" data-start=\"11356\"\u003e\n\u003ch1 data-end=\"11382\" data-start=\"11361\" data-section-id=\"t97njr\"\u003eSelected References\u003c\/h1\u003e\n\u003cul data-end=\"12592\" data-start=\"11384\"\u003e\n\u003cli data-end=\"11522\" data-start=\"11384\" data-section-id=\"f44y1h\"\u003e\n\u003cp data-end=\"11522\" data-start=\"11386\"\u003e\u003cstrong data-end=\"11396\" data-start=\"11386\"\u003eNCCIH.\u003c\/strong\u003e \u003cem data-end=\"11432\" data-start=\"11397\"\u003eMelatonin: What You Need To Know.\u003c\/em\u003e Safety, side effects, and product-quality issues. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"11728\" data-start=\"11523\" data-section-id=\"1yr7cpd\"\u003e\n\u003cp data-end=\"11728\" data-start=\"11525\"\u003e\u003cstrong data-end=\"11535\" data-start=\"11525\"\u003eNCCIH.\u003c\/strong\u003e \u003cem data-end=\"11590\" data-start=\"11536\"\u003eSleep Disorders and Complementary Health Approaches.\u003c\/em\u003e Notes that melatonin appears relatively safe short term, but long-term safety is not established. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"11997\" data-start=\"11729\" data-section-id=\"1flxw6e\"\u003e\n\u003cp data-end=\"11997\" data-start=\"11731\"\u003e\u003cstrong data-end=\"11739\" data-start=\"11731\"\u003eEMA.\u003c\/strong\u003e \u003cem data-end=\"11801\" data-start=\"11740\"\u003eCircadin \/ melatonin prolonged-release product information.\u003c\/em\u003e Approved indication: short-term treatment of primary insomnia in adults 55+; dose 2 mg once daily, 1–2 hours before bedtime after food, for up to 13 weeks. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"12188\" data-start=\"11998\" data-section-id=\"rv5cmi\"\u003e\n\u003cp data-end=\"12188\" data-start=\"12000\"\u003e\u003cstrong data-end=\"12008\" data-start=\"12000\"\u003eNHS.\u003c\/strong\u003e \u003cem data-end=\"12042\" data-start=\"12009\"\u003eHow and when to take melatonin.\u003c\/em\u003e Describes specialist titration frameworks, including situations where doses may be increased up to 10 mg. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"12383\" data-start=\"12189\" data-section-id=\"r8u649\"\u003e\n\u003cp data-end=\"12383\" data-start=\"12191\"\u003e\u003cstrong data-end=\"12200\" data-start=\"12191\"\u003eAASM.\u003c\/strong\u003e \u003cem data-end=\"12262\" data-start=\"12201\"\u003eHealth Advisory: Melatonin Use in Children and Adolescents.\u003c\/em\u003e Recommends discussing melatonin with a health professional before pediatric use. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"12592\" data-start=\"12384\" data-section-id=\"19aznaf\"\u003e\n\u003cp data-end=\"12592\" data-start=\"12386\"\u003e\u003cstrong data-end=\"12394\" data-start=\"12386\"\u003eEMA.\u003c\/strong\u003e \u003cem data-end=\"12425\" data-start=\"12395\"\u003eSlenyto product information.\u003c\/em\u003e Pediatric prolonged-release melatonin for specific neurodevelopmental indications, with titration up to 10 mg in that setting.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":53725438476552,"sku":null,"price":50.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0937\/9053\/5944\/files\/Melatonin10mg.png?v=1773528580"},{"product_id":"orexin-b-10mg-vial","title":"Orexin B 10mg vial","description":"\u003cp data-end=\"774\" data-start=\"129\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                                \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"774\" data-start=\"129\"\u003e\u003cstrong data-end=\"156\" data-start=\"129\"\u003eOrexin B (hypocretin-2)\u003c\/strong\u003e is best viewed as an \u003cstrong data-end=\"281\" data-start=\"178\"\u003eendogenous neuropeptide involved in wakefulness, arousal, feeding, stress, and autonomic regulation\u003c\/strong\u003e, not as a practical supplement or established standalone therapeutic agent. Compared with orexin A, orexin B is generally considered \u003cstrong data-end=\"439\" data-start=\"415\"\u003emore OX2R-preferring\u003c\/strong\u003e, which is important because \u003cstrong data-end=\"546\" data-start=\"468\"\u003eOX2R signaling is strongly linked to wake promotion and narcolepsy biology\u003c\/strong\u003e. The clearest medical relevance of orexin B is therefore \u003cstrong data-end=\"641\" data-start=\"604\"\u003epathophysiologic and target-based\u003c\/strong\u003e, especially in sleep-wake disorders, rather than direct use of orexin B itself as a treatment. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"839\" data-start=\"776\" data-section-id=\"183a91z\"\u003eAdditional benefits \/ roles of orexin B under investigation\u003c\/h3\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"2788\" data-start=\"841\"\u003e\n\u003cthead data-end=\"871\" data-start=\"841\"\u003e\n\u003ctr data-end=\"871\" data-start=\"841\"\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"858\" data-start=\"841\"\u003eBenefit \/ role\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"xl\" data-end=\"871\" data-start=\"858\"\u003eTake-away\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"2788\" data-start=\"882\"\u003e\n\u003ctr data-end=\"1098\" data-start=\"882\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"920\" data-start=\"882\"\u003e1. Wakefulness \/ arousal regulation\u003c\/td\u003e\n\u003ctd data-end=\"1098\" data-start=\"920\" data-col-size=\"xl\"\u003eThis is the clearest core function. Orexin signaling is crucial for stabilizing wakefulness and preventing inappropriate REM intrusions. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1362\" data-start=\"1099\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1125\" data-start=\"1099\"\u003e2. Narcolepsy relevance\u003c\/td\u003e\n\u003ctd data-end=\"1362\" data-start=\"1125\" data-col-size=\"xl\"\u003eOrexin deficiency is central to narcolepsy type 1, making orexin pathways highly relevant therapeutically, though treatment development has focused more on \u003cstrong data-end=\"1300\" data-start=\"1283\"\u003eOX2R agonists\u003c\/strong\u003e than orexin B itself. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1615\" data-start=\"1363\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1407\" data-start=\"1363\"\u003e3. Feeding \/ energy-homeostasis signaling\u003c\/td\u003e\n\u003ctd data-end=\"1615\" data-start=\"1407\" data-col-size=\"xl\"\u003eOrexin peptides are involved in food intake, energy balance, and motivated behavior, but this is a physiologic role rather than a proven therapeutic use for orexin B. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1787\" data-start=\"1616\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1651\" data-start=\"1616\"\u003e4. Stress \/ autonomic activation\u003c\/td\u003e\n\u003ctd data-end=\"1787\" data-start=\"1651\" data-col-size=\"xl\"\u003eOrexin signaling contributes to stress responses, cardiovascular activation, and hyperarousal. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2037\" data-start=\"1788\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1822\" data-start=\"1788\"\u003e5. Reward \/ motivation interest\u003c\/td\u003e\n\u003ctd data-end=\"2037\" data-start=\"1822\" data-col-size=\"xl\"\u003eThe orexin system has been implicated in reward-seeking and addiction-related behavior, though this is broader orexin-system biology, not a validated orexin B treatment use. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2260\" data-start=\"2038\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2071\" data-start=\"2038\"\u003e6. Mood \/ psychiatric interest\u003c\/td\u003e\n\u003ctd data-end=\"2260\" data-start=\"2071\" data-col-size=\"xl\"\u003eOrexin pathways are being explored in psychiatric disorders, but this remains exploratory and system-level rather than orexin-B-as-a-drug evidence. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2513\" data-start=\"2261\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2311\" data-start=\"2261\"\u003e7. Anti-inflammatory \/ neuroprotective interest\u003c\/td\u003e\n\u003ctd data-end=\"2513\" data-start=\"2311\" data-col-size=\"xl\"\u003eReviews discuss possible neuroprotective and immunomodulatory roles for orexin signaling, but these remain early and not orexin-B-specific clinical indications. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2788\" data-start=\"2514\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2562\" data-start=\"2514\"\u003e8. Not a practical broad “biohacking peptide”\u003c\/td\u003e\n\u003ctd data-end=\"2788\" data-start=\"2562\" data-col-size=\"xl\"\u003eMarketing or informal peptide discussions can overstate the case. Orexin B is mainly important as a \u003cstrong data-end=\"2713\" data-start=\"2664\"\u003enative signaling peptide and drug-target clue\u003c\/strong\u003e, not as a proven wellness therapy. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch2 data-end=\"2825\" data-start=\"2790\" data-section-id=\"aq0rfb\"\u003e2. Molecular mechanism of action\u003c\/h2\u003e\n\u003ch3 data-end=\"2860\" data-start=\"2827\" data-section-id=\"jvsoby\"\u003e2.1 Receptor pharmacodynamics\u003c\/h3\u003e\n\u003cp data-end=\"3405\" data-start=\"2862\"\u003eOrexin B does \u003cstrong data-end=\"2883\" data-start=\"2876\"\u003enot\u003c\/strong\u003e act like a classic small-molecule drug with one narrow application. It is one of the two endogenous orexin neuropeptides, signaling through \u003cstrong data-end=\"3052\" data-start=\"3024\"\u003eorexin receptor 1 (OX1R)\u003c\/strong\u003e and \u003cstrong data-end=\"3085\" data-start=\"3057\"\u003eorexin receptor 2 (OX2R)\u003c\/strong\u003e. The key practical point is that \u003cstrong data-end=\"3177\" data-start=\"3119\"\u003eorexin B binds preferentially to OX2R relative to OX1R\u003c\/strong\u003e, whereas orexin A is less selective across the two receptors. That matters because \u003cstrong data-end=\"3366\" data-start=\"3261\"\u003eOX2R appears especially important for maintaining wakefulness and suppressing REM-related instability\u003c\/strong\u003e. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"3433\" data-start=\"3407\" data-section-id=\"1c3fl0f\"\u003e2.2 Downstream biology\u003c\/h3\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"4054\" data-start=\"3435\"\u003e\n\u003cthead data-end=\"3485\" data-start=\"3435\"\u003e\n\u003ctr data-end=\"3485\" data-start=\"3435\"\u003e\n\u003cth class=\"\" data-col-size=\"sm\" data-end=\"3453\" data-start=\"3435\"\u003ePathway \/ theme\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"3474\" data-start=\"3453\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"3485\" data-start=\"3474\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"4054\" data-start=\"3500\"\u003e\n\u003ctr data-end=\"3624\" data-start=\"3500\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3526\" data-start=\"3500\"\u003eOX2R-dominant signaling\u003c\/td\u003e\n\u003ctd data-end=\"3559\" data-start=\"3526\" data-col-size=\"md\"\u003eWake promotion \/ REM stability\u003c\/td\u003e\n\u003ctd data-end=\"3624\" data-start=\"3559\" data-col-size=\"md\"\u003eSleep-wake regulation \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3753\" data-start=\"3625\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3655\" data-start=\"3625\"\u003eOrexin-system arousal drive\u003c\/td\u003e\n\u003ctd data-end=\"3698\" data-start=\"3655\" data-col-size=\"md\"\u003eVigilance, alertness, motivated behavior\u003c\/td\u003e\n\u003ctd data-end=\"3753\" data-start=\"3698\" data-col-size=\"md\"\u003eCNS arousal \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3909\" data-start=\"3754\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3785\" data-start=\"3754\"\u003eStress \/ autonomic signaling\u003c\/td\u003e\n\u003ctd data-end=\"3833\" data-start=\"3785\" data-col-size=\"md\"\u003eCardiovascular and stress-response activation\u003c\/td\u003e\n\u003ctd data-end=\"3909\" data-start=\"3833\" data-col-size=\"md\"\u003eHyperarousal \/ autonomic control \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4054\" data-start=\"3910\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3943\" data-start=\"3910\"\u003eFeeding \/ metabolic regulation\u003c\/td\u003e\n\u003ctd data-end=\"3990\" data-start=\"3943\" data-col-size=\"md\"\u003eFood intake and energy-homeostasis relevance\u003c\/td\u003e\n\u003ctd data-end=\"4054\" data-start=\"3990\" data-col-size=\"md\"\u003eMetabolic physiology \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp data-end=\"4387\" data-start=\"4056\"\u003eThese mechanisms explain why orexin B is physiologically important, but they do \u003cstrong data-end=\"4143\" data-start=\"4136\"\u003enot\u003c\/strong\u003e mean that giving orexin B directly is an established therapy. Most translational work has instead moved toward \u003cstrong data-end=\"4299\" data-start=\"4255\"\u003eorexin receptor agonists and antagonists\u003c\/strong\u003edesigned to target the system more practically. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"4411\" data-start=\"4389\" data-section-id=\"b8x6nr\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cp data-end=\"4466\" data-start=\"4413\"\u003e\u003cstrong data-end=\"4433\" data-start=\"4413\"\u003eRoute in nature:\u003c\/strong\u003e endogenous central neuropeptide.\u003c\/p\u003e\n\u003cp data-end=\"4874\" data-start=\"4468\"\u003e\u003cstrong data-end=\"4502\" data-start=\"4468\"\u003ePractical therapeutic problem:\u003c\/strong\u003e orexin B is a peptide with poor drug-like practicality. Older transport work found that, unlike orexin A, \u003cstrong data-end=\"4737\" data-start=\"4609\"\u003eorexin B did not rapidly enter the brain intact from blood and was rapidly degraded in blood after peripheral administration\u003c\/strong\u003e. That is a major reason orexin B itself has not become a straightforward peripheral therapeutic. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"5213\" data-start=\"4876\"\u003eSo the main pharmacokinetic lesson is that orexin B is best understood as a \u003cstrong data-end=\"4983\" data-start=\"4952\"\u003ebiologic signaling molecule\u003c\/strong\u003e rather than a convenient drug candidate. Modern drug development has therefore focused more on \u003cstrong data-end=\"5106\" data-start=\"5079\"\u003esynthetic OX2R agonists\u003c\/strong\u003e or \u003cstrong data-end=\"5141\" data-start=\"5110\"\u003eorexin receptor antagonists\u003c\/strong\u003e than on orexin B dosing itself. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"5255\" data-start=\"5215\" data-section-id=\"we631\"\u003e4. Pre-clinical and clinical evidence\u003c\/h2\u003e\n\u003ch3 data-end=\"5297\" data-start=\"5257\" data-section-id=\"7hkh91\"\u003e4.1 Wakefulness \/ narcolepsy biology\u003c\/h3\u003e\n\u003cp data-end=\"5710\" data-start=\"5299\"\u003eThis is the \u003cstrong data-end=\"5335\" data-start=\"5311\"\u003ebest-supported niche\u003c\/strong\u003e. The strongest case for orexin B comes from the broader orexin-deficiency story in narcolepsy type 1 and from evidence that \u003cstrong data-end=\"5532\" data-start=\"5460\"\u003eselective OX2R activation can restore wakefulness-related phenotypes\u003c\/strong\u003e in preclinical models. This strongly supports orexin B’s biologic relevance because orexin B is the more OX2R-oriented endogenous ligand. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"5754\" data-start=\"5712\" data-section-id=\"1cwj75k\"\u003e4.2 Direct therapeutic use of orexin B\u003c\/h3\u003e\n\u003cp data-end=\"6203\" data-start=\"5756\"\u003eEvidence here is \u003cstrong data-end=\"5792\" data-start=\"5773\"\u003eweak to limited\u003c\/strong\u003e. The clinical development story in sleep medicine has not centered on administering orexin B itself; instead it has centered on \u003cstrong data-end=\"5964\" data-start=\"5921\"\u003esmall-molecule orexin receptor agonists\u003c\/strong\u003e for narcolepsy and \u003cstrong data-end=\"6020\" data-start=\"5984\"\u003edual orexin receptor antagonists\u003c\/strong\u003e for insomnia. That distinction matters because it means orexin B is more of a \u003cstrong data-end=\"6123\" data-start=\"6099\"\u003ephysiologic template\u003c\/strong\u003ethan a clinically established medicine. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"6242\" data-start=\"6205\" data-section-id=\"1x32oza\"\u003e4.3 Feeding \/ metabolism \/ stress\u003c\/h3\u003e\n\u003cp data-end=\"6553\" data-start=\"6244\"\u003eOrexin-system biology clearly touches feeding, energy homeostasis, and stress responses, but these are mostly mechanistic and preclinical observations. They do not justify treating orexin B as a proven therapy for obesity, anxiety, depression, or metabolic dysfunction. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"6604\" data-start=\"6555\" data-section-id=\"15onaes\"\u003e4.4 Broader neurologic \/ psychiatric interest\u003c\/h3\u003e\n\u003cp data-end=\"6954\" data-start=\"6606\"\u003eThere is real interest in orexin-targeted treatments across psychiatric and neurologic conditions, including addiction, mood disorders, and possibly neuroprotection. But this remains \u003cstrong data-end=\"6832\" data-start=\"6789\"\u003etarget-level and drug-development-level\u003c\/strong\u003e evidence, not clinical proof that orexin B itself is an established intervention. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"6989\" data-start=\"6956\" data-section-id=\"1uuy0po\"\u003e5. Emerging clinical interests\u003c\/h2\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"7778\" data-start=\"6991\"\u003e\n\u003cthead data-end=\"7021\" data-start=\"6991\"\u003e\n\u003ctr data-end=\"7021\" data-start=\"6991\"\u003e\n\u003cth class=\"\" data-col-size=\"sm\" data-end=\"6999\" data-start=\"6991\"\u003eField\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"7011\" data-start=\"6999\"\u003eRationale\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"7021\" data-start=\"7011\"\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"7778\" data-start=\"7036\"\u003e\n\u003ctr data-end=\"7207\" data-start=\"7036\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7067\" data-start=\"7036\"\u003eNarcolepsy \/ hypersomnolence\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7111\" data-start=\"7067\"\u003eOrexin deficiency is central; OX2R is key\u003c\/td\u003e\n\u003ctd data-end=\"7207\" data-start=\"7111\" data-col-size=\"md\"\u003eStrong target rationale; direct orexin B use limited \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7367\" data-start=\"7208\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7219\" data-start=\"7208\"\u003eInsomnia\u003c\/td\u003e\n\u003ctd data-end=\"7264\" data-start=\"7219\" data-col-size=\"md\"\u003eOpposite side of the system via antagonism\u003c\/td\u003e\n\u003ctd data-end=\"7367\" data-start=\"7264\" data-col-size=\"md\"\u003eClinically established for antagonists, not orexin B itself \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7501\" data-start=\"7368\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7399\" data-start=\"7368\"\u003eAddiction \/ reward disorders\u003c\/td\u003e\n\u003ctd data-end=\"7446\" data-start=\"7399\" data-col-size=\"md\"\u003eOrexin-system role in motivation and relapse\u003c\/td\u003e\n\u003ctd data-end=\"7501\" data-start=\"7446\" data-col-size=\"md\"\u003eExploratory \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7626\" data-start=\"7502\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7528\" data-start=\"7502\"\u003eMood \/ stress disorders\u003c\/td\u003e\n\u003ctd data-end=\"7571\" data-start=\"7528\" data-col-size=\"md\"\u003eArousal and stress circuitry involvement\u003c\/td\u003e\n\u003ctd data-end=\"7626\" data-start=\"7571\" data-col-size=\"md\"\u003eExploratory \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7778\" data-start=\"7627\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7670\" data-start=\"7627\"\u003eNeuroinflammatory \/ neuroprotective uses\u003c\/td\u003e\n\u003ctd data-end=\"7703\" data-start=\"7670\" data-col-size=\"md\"\u003eEarly orexin-system literature\u003c\/td\u003e\n\u003ctd data-end=\"7778\" data-start=\"7703\" data-col-size=\"md\"\u003ePreclinical-heavy \/ speculative \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch2 data-end=\"7809\" data-start=\"7780\" data-section-id=\"7gr288\"\u003e6. Safety and tolerability\u003c\/h2\u003e\n\u003cp data-end=\"8475\" data-start=\"7811\"\u003eThere is \u003cstrong data-end=\"7827\" data-start=\"7820\"\u003enot\u003c\/strong\u003e a mature, routine safety literature for \u003cstrong data-end=\"7912\" data-start=\"7868\"\u003eorexin B as a direct therapeutic peptide\u003c\/strong\u003e comparable to what exists for approved drugs. The practical safety story in this area comes more from \u003cstrong data-end=\"8043\" data-start=\"8015\"\u003eorexin-system modulators\u003c\/strong\u003e than from orexin B administration itself. For example, dual orexin receptor antagonists are approved for insomnia, while OX2R agonist development for narcolepsy has shown both promise and setbacks, including hepatotoxicity with one investigational oral agonist. That reinforces the point that \u003cstrong data-end=\"8434\" data-start=\"8337\"\u003emanipulating the orexin system can be powerful, but direct clinical translation is not simple\u003c\/strong\u003e. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"8513\" data-start=\"8477\" data-section-id=\"fttgrx\"\u003e7. Contraindications and cautions\u003c\/h2\u003e\n\u003cp data-end=\"8538\" data-start=\"8515\"\u003eUse extra caution with:\u003c\/p\u003e\n\u003cul data-end=\"9353\" data-start=\"8540\"\u003e\n\u003cli data-end=\"8737\" data-start=\"8540\" data-section-id=\"m3yubs\"\u003e\n\u003cstrong data-end=\"8631\" data-start=\"8542\"\u003eAny attempt to frame orexin B as a routine peptide supplement or self-experiment drug\u003c\/strong\u003e, because the evidence base does not support that practical use. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8917\" data-start=\"8738\" data-section-id=\"7bbv2k\"\u003e\n\u003cstrong data-end=\"8794\" data-start=\"8740\"\u003eSleep, cardiovascular, or psychiatric overclaiming\u003c\/strong\u003e, because orexin signaling influences arousal and autonomic tone in complex ways. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9122\" data-start=\"8918\" data-section-id=\"lz2ecu\"\u003e\n\u003cstrong data-end=\"8953\" data-start=\"8920\"\u003ePeripheral dosing assumptions\u003c\/strong\u003e, because orexin B is rapidly degraded in blood and does not appear to be a straightforward peripherally delivered CNS therapy. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9353\" data-start=\"9123\" data-section-id=\"k9j5uc\"\u003e\n\u003cstrong data-end=\"9170\" data-start=\"9125\"\u003eReplacing established sleep-medicine care\u003c\/strong\u003e, because the clinically meaningful advances in this area come from validated receptor-targeting drugs, not from routine orexin B use itself. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 data-end=\"9389\" data-start=\"9355\" data-section-id=\"o35cra\"\u003e8. Comparative practical matrix\u003c\/h2\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"10077\" data-start=\"9391\"\u003e\n\u003cthead data-end=\"9413\" data-start=\"9391\"\u003e\n\u003ctr data-end=\"9413\" data-start=\"9391\"\u003e\n\u003cth class=\"\" data-col-size=\"sm\" data-end=\"9401\" data-start=\"9391\"\u003eFeature\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"9413\" data-start=\"9401\"\u003eOrexin B\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"10077\" data-start=\"9424\"\u003e\n\u003ctr data-end=\"9489\" data-start=\"9424\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"9440\" data-start=\"9424\"\u003eMain strength\u003c\/td\u003e\n\u003ctd data-end=\"9489\" data-start=\"9440\" data-col-size=\"md\"\u003eCore endogenous arousal \/ wakefulness peptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"9579\" data-start=\"9490\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"9516\" data-start=\"9490\"\u003eBest-supported use case\u003c\/td\u003e\n\u003ctd data-end=\"9579\" data-start=\"9516\" data-col-size=\"md\"\u003ePhysiologic relevance to wakefulness and narcolepsy biology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"9629\" data-start=\"9580\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"9618\" data-start=\"9580\"\u003eDirect clinical evidence as therapy\u003c\/td\u003e\n\u003ctd data-end=\"9629\" data-start=\"9618\" data-col-size=\"md\"\u003eLimited\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"9706\" data-start=\"9630\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"9648\" data-start=\"9630\"\u003eCore limitation\u003c\/td\u003e\n\u003ctd data-end=\"9706\" data-start=\"9648\" data-col-size=\"md\"\u003ePeptide PK and degradation make direct use impractical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"9764\" data-start=\"9707\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"9732\" data-start=\"9707\"\u003eMain receptor emphasis\u003c\/td\u003e\n\u003ctd data-end=\"9764\" data-start=\"9732\" data-col-size=\"md\"\u003eRelative preference for OX2R\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"9856\" data-start=\"9765\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"9796\" data-start=\"9765\"\u003eShort-term practical framing\u003c\/td\u003e\n\u003ctd data-end=\"9856\" data-start=\"9796\" data-col-size=\"md\"\u003eResearch \/ target-biology molecule, not everyday therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"9952\" data-start=\"9857\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"9879\" data-start=\"9857\"\u003eMain safety concern\u003c\/td\u003e\n\u003ctd data-end=\"9952\" data-start=\"9879\" data-col-size=\"md\"\u003eComplex arousal-system manipulation; limited direct clinical use data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"10077\" data-start=\"9953\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"9978\" data-start=\"9953\"\u003eBest practical framing\u003c\/td\u003e\n\u003ctd data-end=\"10077\" data-start=\"9978\" data-col-size=\"md\"\u003eEndogenous neuropeptide and therapeutic target clue, not a proven supplement or broad treatment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch2 data-end=\"10105\" data-start=\"10079\" data-section-id=\"n437ah\"\u003e9. Regulatory landscape\u003c\/h2\u003e\n\u003cp data-end=\"10601\" data-start=\"10107\"\u003eOrexin B is \u003cstrong data-end=\"10126\" data-start=\"10119\"\u003enot\u003c\/strong\u003e best understood as an approved mainstream therapeutic ingredient. The clinically important regulatory story in this area is instead the emergence of \u003cstrong data-end=\"10307\" data-start=\"10276\"\u003eorexin receptor antagonists\u003c\/strong\u003e for insomnia and the ongoing development of \u003cstrong data-end=\"10380\" data-start=\"10352\"\u003eorexin receptor agonists\u003c\/strong\u003e for narcolepsy and related disorders. In other words, the field has validated the \u003cstrong data-end=\"10480\" data-start=\"10463\"\u003eorexin system\u003c\/strong\u003eas medically important, but not orexin B itself as a common therapeutic product. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"10627\" data-start=\"10603\" data-section-id=\"1fjxpfd\"\u003e10. Future directions\u003c\/h2\u003e\n\u003cp data-end=\"10679\" data-start=\"10629\"\u003eThe most useful future work is likely to focus on:\u003c\/p\u003e\n\u003cul data-end=\"11006\" data-start=\"10681\"\u003e\n\u003cli data-end=\"10748\" data-start=\"10681\" data-section-id=\"17silnt\"\u003ebetter \u003cstrong data-end=\"10717\" data-start=\"10690\"\u003eOX2R-selective agonists\u003c\/strong\u003e rather than orexin B itself,\u003c\/li\u003e\n\u003cli data-end=\"10796\" data-start=\"10749\" data-section-id=\"10ldi3g\"\u003eimproved CNS delivery and pharmacokinetics,\u003c\/li\u003e\n\u003cli data-end=\"10861\" data-start=\"10797\" data-section-id=\"3pvs7y\"\u003eclearer disease targeting in narcolepsy and hypersomnolence,\u003c\/li\u003e\n\u003cli data-end=\"11006\" data-start=\"10862\" data-section-id=\"90gi50\"\u003eand more precise mapping of orexin-system roles in mood, addiction, metabolism, and neuroinflammation. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 data-end=\"11032\" data-start=\"11008\" data-section-id=\"1uk6y2z\"\u003eBest balanced summary\u003c\/h2\u003e\n\u003cp data-end=\"11597\" data-start=\"11034\"\u003e\u003cstrong data-end=\"11557\" data-start=\"11034\"\u003eOrexin B is best viewed as an endogenous OX2R-leaning neuropeptide that plays an important role in wakefulness, arousal, feeding, and stress biology. Its strongest practical significance is as part of the orexin-system explanation for narcolepsy and as a guide for therapeutic target development, especially OX2R agonism. Direct use of orexin B itself is limited by peptide pharmacokinetics and lack of established clinical evidence, so it should not be framed as a proven general treatment or consumer peptide therapy.\u003c\/strong\u003e\u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"11621\" data-start=\"11599\" data-section-id=\"xxd8hg\"\u003eSelected references\u003c\/h2\u003e\n\u003cul data-end=\"12783\" data-start=\"11623\"\u003e\n\u003cli data-end=\"11881\" data-start=\"11623\" data-section-id=\"m3rxjp\"\u003e\n\u003cstrong data-end=\"11652\" data-start=\"11625\"\u003eScammell TE, Winrow CJ.\u003c\/strong\u003e \u003cem data-end=\"11716\" data-start=\"11653\"\u003eOrexin Receptors: Pharmacology and Therapeutic Opportunities.\u003c\/em\u003e Strong foundational review on orexin receptor pharmacology, including the point that orexin B signals mainly through OX2R. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"12114\" data-start=\"11882\" data-section-id=\"aans0j\"\u003e\n\u003cstrong data-end=\"11902\" data-start=\"11884\"\u003eXia LB, et al.\u003c\/strong\u003e \u003cem data-end=\"11951\" data-start=\"11903\"\u003eA review of physiological functions of orexin.\u003c\/em\u003e Useful recent review covering sleep, feeding, addiction, depression, and anxiety, including OX2R preference of orexin B. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"12326\" data-start=\"12115\" data-section-id=\"ac9xjg\"\u003e\n\u003cstrong data-end=\"12170\" data-start=\"12117\"\u003eMahoney CE, Cogswell A, Koralnik IJ, Scammell TE.\u003c\/strong\u003e \u003cem data-end=\"12213\" data-start=\"12171\"\u003eThe neurobiological basis of narcolepsy.\u003c\/em\u003e Best higher-level source for why orexin deficiency matters clinically. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"12545\" data-start=\"12327\" data-section-id=\"1pwwogn\"\u003e\n\u003cstrong data-end=\"12363\" data-start=\"12329\"\u003eKastin AJ, Akerstrom V, Pan W.\u003c\/strong\u003e \u003cem data-end=\"12444\" data-start=\"12364\"\u003eOrexin A but not orexin B rapidly enters brain from blood by simple diffusion.\u003c\/em\u003eKey source for the pharmacokinetic limitation of orexin B. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"12783\" data-start=\"12546\" data-section-id=\"f4pb4p\"\u003e\n\u003cstrong data-end=\"12567\" data-start=\"12548\"\u003eAbdel-Magid AF.\u003c\/strong\u003e \u003cem data-end=\"12631\" data-start=\"12568\"\u003eThe present and future of synthetic orexin receptor agonists.\u003c\/em\u003e Good source on why drug development has moved toward receptor agonists rather than the native peptide itself. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":55712169394440,"sku":null,"price":120.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0937\/9053\/5944\/files\/orexin_B_10mg.png?v=1775176387"},{"product_id":"orexin-a-10mg-vial","title":"Orexin A 10mg vial","description":"\u003cp data-start=\"119\" data-end=\"679\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                           \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"119\" data-end=\"679\"\u003e\u003cstrong data-start=\"119\" data-end=\"146\"\u003eOrexin A (hypocretin-1)\u003c\/strong\u003e is best viewed as an \u003cstrong data-start=\"168\" data-end=\"287\"\u003eendogenous neuropeptide that helps regulate wakefulness, arousal, feeding, stress responses, and autonomic activity\u003c\/strong\u003e, not as a routine supplement or established standalone therapy. Compared with orexin B, orexin A activates \u003cstrong data-start=\"395\" data-end=\"426\"\u003eboth OX1R and OX2R strongly\u003c\/strong\u003e, which gives it broader system-level effects across arousal and motivated behavior. Its clearest medical importance is in \u003cstrong data-start=\"549\" data-end=\"586\"\u003esleep-wake biology and narcolepsy\u003c\/strong\u003e, where loss of orexin signaling is central to disease. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-section-id=\"usuixj\" data-start=\"681\" data-end=\"743\"\u003eAdditional benefits \/ roles of orexin A under investigation\u003c\/h2\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"745\" data-end=\"2373\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"745\" data-end=\"775\"\u003e\n\u003ctr data-start=\"745\" data-end=\"775\"\u003e\n\u003cth data-start=\"745\" data-end=\"762\" data-col-size=\"md\" class=\"\"\u003eBenefit \/ role\u003c\/th\u003e\n\u003cth data-start=\"762\" data-end=\"775\" data-col-size=\"xl\" class=\"\"\u003eTake-away\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"786\" data-end=\"2373\"\u003e\n\u003ctr data-start=\"786\" data-end=\"955\"\u003e\n\u003ctd data-start=\"786\" data-end=\"824\" data-col-size=\"md\"\u003e1. Wakefulness \/ arousal regulation\u003c\/td\u003e\n\u003ctd data-start=\"824\" data-end=\"955\" data-col-size=\"xl\"\u003eThis is the clearest core function. Orexin A is a major endogenous wake-promoting signal. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"956\" data-end=\"1102\"\u003e\n\u003ctd data-start=\"956\" data-end=\"982\" data-col-size=\"md\"\u003e2. Narcolepsy relevance\u003c\/td\u003e\n\u003ctd data-start=\"982\" data-end=\"1102\" data-col-size=\"xl\"\u003eCSF orexin-A deficiency is a key biomarker and mechanism in narcolepsy type 1. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1103\" data-end=\"1331\"\u003e\n\u003ctd data-start=\"1103\" data-end=\"1147\" data-col-size=\"md\"\u003e3. Feeding \/ energy-homeostasis signaling\u003c\/td\u003e\n\u003ctd data-start=\"1147\" data-end=\"1331\" data-col-size=\"xl\"\u003eOrexin A participates in appetite, energy balance, and motivated behavior, but this is physiologic biology rather than a proven treatment use. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1332\" data-end=\"1503\"\u003e\n\u003ctd data-start=\"1332\" data-end=\"1367\" data-col-size=\"md\"\u003e4. Stress \/ autonomic activation\u003c\/td\u003e\n\u003ctd data-start=\"1367\" data-end=\"1503\" data-col-size=\"xl\"\u003eOrexin signaling contributes to cardiovascular activation, stress responses, and hyperarousal. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1504\" data-end=\"1715\"\u003e\n\u003ctd data-start=\"1504\" data-end=\"1537\" data-col-size=\"md\"\u003e5. Reward \/ addiction interest\u003c\/td\u003e\n\u003ctd data-start=\"1537\" data-end=\"1715\" data-col-size=\"xl\"\u003eThe orexin system, including orexin A, has been implicated in reward-seeking and relapse-related behavior, but this remains exploratory. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1716\" data-end=\"1966\"\u003e\n\u003ctd data-start=\"1716\" data-end=\"1766\" data-col-size=\"md\"\u003e6. Neuroprotective \/ anti-inflammatory interest\u003c\/td\u003e\n\u003ctd data-start=\"1766\" data-end=\"1966\" data-col-size=\"xl\"\u003ePreclinical studies suggest orexin A may reduce neuroinflammation and oxidative injury in some CNS models, but this is not an established clinical indication. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1967\" data-end=\"2168\"\u003e\n\u003ctd data-start=\"1967\" data-end=\"2000\" data-col-size=\"md\"\u003e7. Mood \/ psychiatric interest\u003c\/td\u003e\n\u003ctd data-start=\"2000\" data-end=\"2168\" data-col-size=\"xl\"\u003eOrexin-system modulation is being studied in mood and psychiatric disorders, but the evidence is target-level and exploratory. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2169\" data-end=\"2373\"\u003e\n\u003ctd data-start=\"2169\" data-end=\"2211\" data-col-size=\"md\"\u003e8. Not a practical “biohacking peptide”\u003c\/td\u003e\n\u003ctd data-start=\"2211\" data-end=\"2373\" data-col-size=\"xl\"\u003eIts real importance is as a native signaling molecule and drug-development clue, not a proven consumer wellness therapy. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch2 data-section-id=\"aq0rfb\" data-start=\"2375\" data-end=\"2410\"\u003e2. Molecular mechanism of action\u003c\/h2\u003e\n\u003ch3 data-section-id=\"jvsoby\" data-start=\"2412\" data-end=\"2445\"\u003e2.1 Receptor pharmacodynamics\u003c\/h3\u003e\n\u003cp data-start=\"2447\" data-end=\"2912\"\u003eOrexin A is one of the two endogenous orexin peptides and signals through \u003cstrong data-start=\"2521\" data-end=\"2549\"\u003eorexin receptor 1 (OX1R)\u003c\/strong\u003e and \u003cstrong data-start=\"2554\" data-end=\"2582\"\u003eorexin receptor 2 (OX2R)\u003c\/strong\u003e. The key practical distinction is that \u003cstrong data-start=\"2622\" data-end=\"2667\"\u003eorexin A binds strongly to both receptors\u003c\/strong\u003e, whereas orexin B is more OX2R-skewed. This broader receptor activity helps explain why orexin A is linked not just to wakefulness, but also to feeding, stress, autonomic activation, and motivated behavior. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-section-id=\"1c3fl0f\" data-start=\"2914\" data-end=\"2940\"\u003e2.2 Downstream biology\u003c\/h3\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"2942\" data-end=\"3744\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"2942\" data-end=\"2992\"\u003e\n\u003ctr data-start=\"2942\" data-end=\"2992\"\u003e\n\u003cth data-start=\"2942\" data-end=\"2960\" data-col-size=\"sm\" class=\"\"\u003ePathway \/ theme\u003c\/th\u003e\n\u003cth data-start=\"2960\" data-end=\"2981\" data-col-size=\"md\" class=\"\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-start=\"2981\" data-end=\"2992\" data-col-size=\"md\" class=\"\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"3007\" data-end=\"3744\"\u003e\n\u003ctr data-start=\"3007\" data-end=\"3145\"\u003e\n\u003ctd data-start=\"3007\" data-end=\"3037\" data-col-size=\"sm\"\u003eDual OX1R \/ OX2R activation\u003c\/td\u003e\n\u003ctd data-start=\"3037\" data-end=\"3080\" data-col-size=\"md\"\u003eWake promotion, vigilance, REM stability\u003c\/td\u003e\n\u003ctd data-start=\"3080\" data-end=\"3145\" data-col-size=\"md\"\u003eSleep-wake regulation \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3146\" data-end=\"3285\"\u003e\n\u003ctd data-start=\"3146\" data-end=\"3175\" data-col-size=\"sm\"\u003eArousal-network activation\u003c\/td\u003e\n\u003ctd data-start=\"3175\" data-end=\"3230\" data-col-size=\"md\"\u003eAlertness, behavioral activation, motivated behavior\u003c\/td\u003e\n\u003ctd data-start=\"3230\" data-end=\"3285\" data-col-size=\"md\"\u003eCNS arousal \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3286\" data-end=\"3441\"\u003e\n\u003ctd data-start=\"3286\" data-end=\"3317\" data-col-size=\"sm\"\u003eStress \/ autonomic signaling\u003c\/td\u003e\n\u003ctd data-start=\"3317\" data-end=\"3365\" data-col-size=\"md\"\u003eCardiovascular and stress-response activation\u003c\/td\u003e\n\u003ctd data-start=\"3365\" data-end=\"3441\" data-col-size=\"md\"\u003eHyperarousal \/ autonomic control \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3442\" data-end=\"3582\"\u003e\n\u003ctd data-start=\"3442\" data-end=\"3474\" data-col-size=\"sm\"\u003eFeeding \/ metabolic signaling\u003c\/td\u003e\n\u003ctd data-start=\"3474\" data-end=\"3518\" data-col-size=\"md\"\u003eAppetite and energy-homeostasis relevance\u003c\/td\u003e\n\u003ctd data-start=\"3518\" data-end=\"3582\" data-col-size=\"md\"\u003eMetabolic physiology \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3583\" data-end=\"3744\"\u003e\n\u003ctd data-start=\"3583\" data-end=\"3614\" data-col-size=\"sm\"\u003eNeuroinflammatory modulation\u003c\/td\u003e\n\u003ctd data-start=\"3614\" data-end=\"3673\" data-col-size=\"md\"\u003ePossible reduction of inflammatory injury in some models\u003c\/td\u003e\n\u003ctd data-start=\"3673\" data-end=\"3744\" data-col-size=\"md\"\u003ePreclinical neuroprotection \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp data-start=\"3746\" data-end=\"4077\"\u003eThese mechanisms make orexin A biologically important, but they do \u003cstrong data-start=\"3813\" data-end=\"3820\"\u003enot\u003c\/strong\u003e mean that giving orexin A directly is an established therapy. Most modern translational work has focused on \u003cstrong data-start=\"3929\" data-end=\"3957\"\u003eorexin receptor agonists\u003c\/strong\u003e and \u003cstrong data-start=\"3962\" data-end=\"3993\"\u003eorexin receptor antagonists\u003c\/strong\u003e instead of routine orexin A administration. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-section-id=\"b8x6nr\" data-start=\"4079\" data-end=\"4101\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cp data-start=\"4103\" data-end=\"4156\"\u003e\u003cstrong data-start=\"4103\" data-end=\"4123\"\u003eRoute in nature:\u003c\/strong\u003e endogenous central neuropeptide.\u003c\/p\u003e\n\u003cp data-start=\"4158\" data-end=\"4669\"\u003e\u003cstrong data-start=\"4158\" data-end=\"4192\"\u003ePractical therapeutic problem:\u003c\/strong\u003e orexin A is still a peptide, so it is not an easy conventional drug. However, unlike orexin B, an older transport study found that \u003cstrong data-start=\"4324\" data-end=\"4383\"\u003eorexin A can rapidly enter the brain from blood in mice\u003c\/strong\u003e, which is one reason it attracted translational interest. Even so, that did \u003cstrong data-start=\"4460\" data-end=\"4467\"\u003enot\u003c\/strong\u003e turn orexin A into a routine therapy, and drug development has moved more toward \u003cstrong data-start=\"4549\" data-end=\"4590\"\u003esynthetic receptor-selective agonists\u003c\/strong\u003e with better pharmaceutical properties. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-section-id=\"we631\" data-start=\"4671\" data-end=\"4711\"\u003e4. Pre-clinical and clinical evidence\u003c\/h2\u003e\n\u003ch3 data-section-id=\"7hkh91\" data-start=\"4713\" data-end=\"4753\"\u003e4.1 Wakefulness \/ narcolepsy biology\u003c\/h3\u003e\n\u003cp data-start=\"4755\" data-end=\"5171\"\u003eThis is the \u003cstrong data-start=\"4767\" data-end=\"4791\"\u003ebest-supported niche\u003c\/strong\u003e. Orexin-A deficiency in CSF is strongly associated with narcolepsy type 1, and the orexin system is now one of the clearest mechanistic targets in sleep medicine. That makes orexin A highly important biologically and diagnostically, even though direct treatment development has shifted toward receptor agonists rather than orexin A itself. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-section-id=\"1cwj75n\" data-start=\"5173\" data-end=\"5215\"\u003e4.2 Direct therapeutic use of orexin A\u003c\/h3\u003e\n\u003cp data-start=\"5217\" data-end=\"5590\"\u003eEvidence here is \u003cstrong data-start=\"5234\" data-end=\"5245\"\u003elimited\u003c\/strong\u003e. Orexin A has been useful as a research and pathophysiology molecule, but clinical progress in the field has centered on \u003cstrong data-start=\"5367\" data-end=\"5392\"\u003eorexin receptor drugs\u003c\/strong\u003e. For narcolepsy, the major translational momentum is with \u003cstrong data-start=\"5451\" data-end=\"5468\"\u003eOX2R agonists\u003c\/strong\u003e; for insomnia, the validated clinical approach is \u003cstrong data-start=\"5519\" data-end=\"5549\"\u003eorexin receptor antagonism\u003c\/strong\u003e. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-section-id=\"1vspyep\" data-start=\"5592\" data-end=\"5630\"\u003e4.3 Neuroprotection \/ inflammation\u003c\/h3\u003e\n\u003cp data-start=\"5632\" data-end=\"6022\"\u003eOrexin A has shown \u003cstrong data-start=\"5651\" data-end=\"5722\"\u003eanti-inflammatory and neuroprotective effects in preclinical models\u003c\/strong\u003e, including intracerebral hemorrhage, sepsis-associated encephalopathy, and experimental neuroinflammatory disease. This is interesting and mechanistically plausible, but it remains \u003cstrong data-start=\"5904\" data-end=\"5925\"\u003epreclinical-heavy\u003c\/strong\u003e and should not be framed as established medical therapy. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-section-id=\"1169ll8\" data-start=\"6024\" data-end=\"6086\"\u003e4.4 Feeding, stress, and broader neuropsychiatric interest\u003c\/h3\u003e\n\u003cp data-start=\"6088\" data-end=\"6422\"\u003eOrexin A is clearly involved in feeding, stress responsiveness, reward processing, and arousal-linked psychiatric biology. But this literature is mostly mechanistic and target-level. It does \u003cstrong data-start=\"6279\" data-end=\"6286\"\u003enot\u003c\/strong\u003e justify presenting orexin A as a proven therapy for obesity, anxiety, depression, or addiction. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-section-id=\"1uuy0po\" data-start=\"6424\" data-end=\"6457\"\u003e5. Emerging clinical interests\u003c\/h2\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"6459\" data-end=\"7240\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"6459\" data-end=\"6489\"\u003e\n\u003ctr data-start=\"6459\" data-end=\"6489\"\u003e\n\u003cth data-start=\"6459\" data-end=\"6467\" data-col-size=\"sm\" class=\"\"\u003eField\u003c\/th\u003e\n\u003cth data-start=\"6467\" data-end=\"6479\" data-col-size=\"md\" class=\"\"\u003eRationale\u003c\/th\u003e\n\u003cth data-start=\"6479\" data-end=\"6489\" data-col-size=\"md\" class=\"\"\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"6504\" data-end=\"7240\"\u003e\n\u003ctr data-start=\"6504\" data-end=\"6662\"\u003e\n\u003ctd data-start=\"6504\" data-end=\"6535\" data-col-size=\"sm\"\u003eNarcolepsy \/ hypersomnolence\u003c\/td\u003e\n\u003ctd data-start=\"6535\" data-end=\"6566\" data-col-size=\"md\"\u003eOrexin deficiency is central\u003c\/td\u003e\n\u003ctd data-start=\"6566\" data-end=\"6662\" data-col-size=\"md\"\u003eStrong target rationale; direct orexin A use limited \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6663\" data-end=\"6822\"\u003e\n\u003ctd data-start=\"6663\" data-end=\"6674\" data-col-size=\"sm\"\u003eInsomnia\u003c\/td\u003e\n\u003ctd data-start=\"6674\" data-end=\"6719\" data-col-size=\"md\"\u003eOpposite side of the system via antagonism\u003c\/td\u003e\n\u003ctd data-start=\"6719\" data-end=\"6822\" data-col-size=\"md\"\u003eClinically established for antagonists, not orexin A itself \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6823\" data-end=\"6981\"\u003e\n\u003ctd data-start=\"6823\" data-end=\"6866\" data-col-size=\"sm\"\u003eNeuroinflammatory \/ neuroprotective uses\u003c\/td\u003e\n\u003ctd data-start=\"6866\" data-end=\"6906\" data-col-size=\"md\"\u003ePreclinical anti-inflammatory effects\u003c\/td\u003e\n\u003ctd data-start=\"6906\" data-end=\"6981\" data-col-size=\"md\"\u003eExploratory \/ preclinical-heavy \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6982\" data-end=\"7115\"\u003e\n\u003ctd data-start=\"6982\" data-end=\"7013\" data-col-size=\"sm\"\u003eAddiction \/ reward disorders\u003c\/td\u003e\n\u003ctd data-start=\"7013\" data-end=\"7060\" data-col-size=\"md\"\u003eOrexin-system role in motivation and relapse\u003c\/td\u003e\n\u003ctd data-start=\"7060\" data-end=\"7115\" data-col-size=\"md\"\u003eExploratory \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7116\" data-end=\"7240\"\u003e\n\u003ctd data-start=\"7116\" data-end=\"7142\" data-col-size=\"sm\"\u003eMood \/ stress disorders\u003c\/td\u003e\n\u003ctd data-start=\"7142\" data-end=\"7185\" data-col-size=\"md\"\u003eArousal and stress circuitry involvement\u003c\/td\u003e\n\u003ctd data-start=\"7185\" data-end=\"7240\" data-col-size=\"md\"\u003eExploratory \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch2 data-section-id=\"7gr288\" data-start=\"7242\" data-end=\"7271\"\u003e6. Safety and tolerability\u003c\/h2\u003e\n\u003cp data-start=\"7273\" data-end=\"7713\"\u003eThere is \u003cstrong data-start=\"7282\" data-end=\"7289\"\u003enot\u003c\/strong\u003e a mature, routine safety literature for \u003cstrong data-start=\"7330\" data-end=\"7374\"\u003eorexin A as a direct therapeutic peptide\u003c\/strong\u003e comparable to approved drugs. The clearer clinical safety story in this space comes from \u003cstrong data-start=\"7464\" data-end=\"7492\"\u003eorexin-system modulators\u003c\/strong\u003e, not from orexin A itself. That matters because the orexin system strongly affects wakefulness and autonomic tone, so manipulating it is pharmacologically important but not simple. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-section-id=\"fttgrx\" data-start=\"7715\" data-end=\"7751\"\u003e7. Contraindications and cautions\u003c\/h2\u003e\n\u003cp data-start=\"7753\" data-end=\"7776\"\u003eUse extra caution with:\u003c\/p\u003e\n\u003cul data-start=\"7778\" data-end=\"8609\"\u003e\n\u003cli data-section-id=\"1yv57q1\" data-start=\"7778\" data-end=\"7973\"\u003e\n\u003cstrong data-start=\"7780\" data-end=\"7872\"\u003eAny attempt to frame orexin A as a routine peptide supplement or self-experiment therapy\u003c\/strong\u003e, because the evidence does not support that practical use. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-section-id=\"13dzkks\" data-start=\"7974\" data-end=\"8153\"\u003e\n\u003cstrong data-start=\"7976\" data-end=\"8030\"\u003eSleep, psychiatric, or cardiovascular overclaiming\u003c\/strong\u003e, because orexin signaling affects arousal and autonomic systems in complex ways. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-section-id=\"1sporr9\" data-start=\"8154\" data-end=\"8385\"\u003e\n\u003cstrong data-start=\"8156\" data-end=\"8209\"\u003eAssuming BBB entry solves the therapeutic problem\u003c\/strong\u003e, because even though orexin A can enter brain better than orexin B in mice, that has not translated into routine direct clinical use. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-section-id=\"18kz3xc\" data-start=\"8386\" data-end=\"8609\"\u003e\n\u003cstrong data-start=\"8388\" data-end=\"8433\"\u003eReplacing established sleep-medicine care\u003c\/strong\u003e, because the meaningful clinical advances here come from validated receptor-targeting drugs and structured sleep-disorder management. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 data-section-id=\"o35cra\" data-start=\"8611\" data-end=\"8645\"\u003e8. Comparative practical matrix\u003c\/h2\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"8647\" data-end=\"9324\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"8647\" data-end=\"8669\"\u003e\n\u003ctr data-start=\"8647\" data-end=\"8669\"\u003e\n\u003cth data-start=\"8647\" data-end=\"8657\" data-col-size=\"sm\" class=\"\"\u003eFeature\u003c\/th\u003e\n\u003cth data-start=\"8657\" data-end=\"8669\" data-col-size=\"md\" class=\"\"\u003eOrexin A\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"8680\" data-end=\"9324\"\u003e\n\u003ctr data-start=\"8680\" data-end=\"8745\"\u003e\n\u003ctd data-start=\"8680\" data-end=\"8696\" data-col-size=\"sm\"\u003eMain strength\u003c\/td\u003e\n\u003ctd data-start=\"8696\" data-end=\"8745\" data-col-size=\"md\"\u003eCore endogenous arousal \/ wakefulness peptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"8746\" data-end=\"8847\"\u003e\n\u003ctd data-start=\"8746\" data-end=\"8772\" data-col-size=\"sm\"\u003eBest-supported use case\u003c\/td\u003e\n\u003ctd data-start=\"8772\" data-end=\"8847\" data-col-size=\"md\"\u003ePhysiologic and diagnostic relevance in narcolepsy \/ sleep-wake biology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"8848\" data-end=\"8897\"\u003e\n\u003ctd data-start=\"8848\" data-end=\"8886\" data-col-size=\"sm\"\u003eDirect clinical evidence as therapy\u003c\/td\u003e\n\u003ctd data-start=\"8886\" data-end=\"8897\" data-col-size=\"md\"\u003eLimited\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"8898\" data-end=\"8984\"\u003e\n\u003ctd data-start=\"8898\" data-end=\"8916\" data-col-size=\"sm\"\u003eCore limitation\u003c\/td\u003e\n\u003ctd data-start=\"8916\" data-end=\"8984\" data-col-size=\"md\"\u003ePeptide practicality and lack of established direct-use evidence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"8985\" data-end=\"9051\"\u003e\n\u003ctd data-start=\"8985\" data-end=\"9010\" data-col-size=\"sm\"\u003eMain receptor emphasis\u003c\/td\u003e\n\u003ctd data-start=\"9010\" data-end=\"9051\" data-col-size=\"md\"\u003eStrong activity at both OX1R and OX2R\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"9052\" data-end=\"9111\"\u003e\n\u003ctd data-start=\"9052\" data-end=\"9074\" data-col-size=\"sm\"\u003eTranslational value\u003c\/td\u003e\n\u003ctd data-start=\"9074\" data-end=\"9111\" data-col-size=\"md\"\u003eHigh as a target-biology molecule\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"9112\" data-end=\"9207\"\u003e\n\u003ctd data-start=\"9112\" data-end=\"9134\" data-col-size=\"sm\"\u003eMain safety concern\u003c\/td\u003e\n\u003ctd data-start=\"9134\" data-end=\"9207\" data-col-size=\"md\"\u003eComplex arousal-system effects; limited direct therapeutic experience\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"9208\" data-end=\"9324\"\u003e\n\u003ctd data-start=\"9208\" data-end=\"9233\" data-col-size=\"sm\"\u003eBest practical framing\u003c\/td\u003e\n\u003ctd data-start=\"9233\" data-end=\"9324\" data-col-size=\"md\"\u003eEndogenous neuropeptide and research \/ therapeutic target clue, not a proven supplement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch2 data-section-id=\"n437ah\" data-start=\"9326\" data-end=\"9352\"\u003e9. Regulatory landscape\u003c\/h2\u003e\n\u003cp data-start=\"9354\" data-end=\"9809\"\u003eOrexin A is \u003cstrong data-start=\"9366\" data-end=\"9373\"\u003enot\u003c\/strong\u003e best understood as an approved mainstream therapeutic ingredient. The real regulatory and clinical success in this area is with \u003cstrong data-start=\"9502\" data-end=\"9533\"\u003eorexin receptor antagonists\u003c\/strong\u003e for insomnia, while \u003cstrong data-start=\"9554\" data-end=\"9582\"\u003eorexin receptor agonists\u003c\/strong\u003e are being developed for narcolepsy and related disorders. In other words, medicine has validated the \u003cstrong data-start=\"9684\" data-end=\"9701\"\u003eorexin system\u003c\/strong\u003e, but not orexin A itself as a routine consumer or clinical product. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-section-id=\"1fjxpfd\" data-start=\"9811\" data-end=\"9835\"\u003e10. Future directions\u003c\/h2\u003e\n\u003cp data-start=\"9837\" data-end=\"9887\"\u003eThe most useful future work is likely to focus on:\u003c\/p\u003e\n\u003cul data-start=\"9889\" data-end=\"10236\"\u003e\n\u003cli data-section-id=\"1r72rjr\" data-start=\"9889\" data-end=\"9971\"\u003ebetter \u003cstrong data-start=\"9898\" data-end=\"9940\"\u003eOX2R-selective or dual-target agonists\u003c\/strong\u003e rather than orexin A itself,\u003c\/li\u003e\n\u003cli data-section-id=\"10ldi3g\" data-start=\"9972\" data-end=\"10019\"\u003eimproved CNS delivery and pharmacokinetics,\u003c\/li\u003e\n\u003cli data-section-id=\"3pvs7y\" data-start=\"10020\" data-end=\"10084\"\u003eclearer disease targeting in narcolepsy and hypersomnolence,\u003c\/li\u003e\n\u003cli data-section-id=\"1yyr1qk\" data-start=\"10085\" data-end=\"10236\"\u003eand better understanding of orexin-system roles in neuroinflammation, mood, addiction, and autonomic disease. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 data-section-id=\"1uk6y2z\" data-start=\"10238\" data-end=\"10262\"\u003eBest balanced summary\u003c\/h2\u003e\n\u003cp data-start=\"10264\" data-end=\"10847\"\u003e\u003cstrong data-start=\"10264\" data-end=\"10807\"\u003eOrexin A is best viewed as an endogenous dual-receptor orexin neuropeptide with central roles in wakefulness, arousal, feeding, and stress biology. Its strongest practical significance is in narcolepsy pathophysiology and in guiding orexin-targeted drug development. Although orexin A shows interesting preclinical neuroprotective and anti-inflammatory effects, direct use of orexin A itself remains limited by the lack of established clinical evidence, so it should not be framed as a proven general therapy or consumer peptide treatment.\u003c\/strong\u003e\u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-section-id=\"xxd8hg\" data-start=\"10849\" data-end=\"10871\"\u003eSelected references\u003c\/h2\u003e\n\u003cul data-start=\"10873\" data-end=\"12061\" data-is-only-node=\"\"\u003e\n\u003cli data-section-id=\"g8g658\" data-start=\"10873\" data-end=\"11094\"\u003e\n\u003cstrong data-start=\"10875\" data-end=\"10902\"\u003eScammell TE, Winrow CJ.\u003c\/strong\u003e \u003cem data-start=\"10903\" data-end=\"10966\"\u003eOrexin Receptors: Pharmacology and Therapeutic Opportunities.\u003c\/em\u003e Foundational review on receptor pharmacology and the distinct roles of OX1R and OX2R. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-section-id=\"wu9exn\" data-start=\"11095\" data-end=\"11341\"\u003e\n\u003cstrong data-start=\"11097\" data-end=\"11131\"\u003eKastin AJ, Akerstrom V, Pan W.\u003c\/strong\u003e \u003cem data-start=\"11132\" data-end=\"11212\"\u003eOrexin A but not orexin B rapidly enters brain from blood by simple diffusion.\u003c\/em\u003eKey source for the blood-to-brain transport distinction between orexin A and orexin B. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-section-id=\"rbgqq3\" data-start=\"11342\" data-end=\"11591\"\u003e\n\u003cstrong data-start=\"11344\" data-end=\"11368\"\u003eKanbayashi T, et al.\u003c\/strong\u003e \u003cem data-start=\"11369\" data-end=\"11479\"\u003eCSF hypocretin-1 (orexin-A) concentrations in narcolepsy, idiopathic hypersomnia and restless legs syndrome.\u003c\/em\u003e Classic source showing very low CSF orexin-A in narcolepsy-cataplexy. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-section-id=\"1ggv4b1\" data-start=\"11592\" data-end=\"11837\"\u003e\n\u003cstrong data-start=\"11594\" data-end=\"11619\"\u003eDauvilliers Y, et al.\u003c\/strong\u003e \u003cem data-start=\"11620\" data-end=\"11674\"\u003eOral Orexin Receptor 2 Agonist in Narcolepsy Type 1.\u003c\/em\u003e Important modern clinical example showing the field’s shift toward receptor agonists rather than native peptide therapy. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-section-id=\"4q7pmt\" data-start=\"11838\" data-end=\"12061\"\u003e\n\u003cstrong data-start=\"11840\" data-end=\"11856\"\u003eLi T, et al.\u003c\/strong\u003e \u003cem data-start=\"11857\" data-end=\"11975\"\u003eOrexin A alleviates neuroinflammation via OXR2\/CaMKKβ\/AMPK signaling pathway after intracerebral hemorrhage in mice.\u003c\/em\u003e Representative preclinical source for the neuroinflammation \/ neuroprotection angle.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":55712468795656,"sku":null,"price":120.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0937\/9053\/5944\/files\/orexin_A_10mg.png?v=1775176719"},{"product_id":"fgl-10mg-vial","title":"FGL 30mg vial","description":"\u003cp data-end=\"932\" data-start=\"92\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                            \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"932\" data-start=\"92\"\u003e\u003cstrong data-end=\"175\" data-start=\"92\"\u003eFGL (FG loop peptide; sometimes written FGLL in clinical-development materials)\u003c\/strong\u003e is best viewed as an \u003cstrong data-end=\"250\" data-start=\"197\"\u003einvestigational NCAM-derived neurotrophic peptide\u003c\/strong\u003e, not a proven therapeutic or consumer “brain peptide.” It is a \u003cstrong data-end=\"339\" data-start=\"314\"\u003e15-amino-acid mimetic\u003c\/strong\u003e derived from the \u003cstrong data-end=\"450\" data-start=\"357\"\u003eFG loop of the second fibronectin type III domain of neural cell adhesion molecule (NCAM)\u003c\/strong\u003e and is designed to mimic the NCAM interaction with \u003cstrong data-end=\"549\" data-start=\"502\"\u003efibroblast growth factor receptor 1 (FGFR1)\u003c\/strong\u003e. The strongest case for FGL is \u003cstrong data-end=\"609\" data-start=\"581\"\u003epreclinical neurobiology\u003c\/strong\u003e: it has shown \u003cstrong data-end=\"755\" data-start=\"624\"\u003ememory-enhancing, neurotrophic, neuroprotective, stem-cell–mobilizing, and anti-inflammatory effects in animal and cell studies\u003c\/strong\u003e. Human evidence is very limited; the clearest human data are an early \u003cstrong data-end=\"872\" data-start=\"826\"\u003ephase I intranasal tolerability \/ PK study\u003c\/strong\u003e, not efficacy trials. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"983\" data-start=\"934\" data-section-id=\"11qp8no\"\u003eAdditional benefits of FGL under investigation\u003c\/h2\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"2848\" data-start=\"985\"\u003e\n\u003cthead data-end=\"1008\" data-start=\"985\"\u003e\n\u003ctr data-end=\"1008\" data-start=\"985\"\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"995\" data-start=\"985\"\u003eBenefit\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"xl\" data-end=\"1008\" data-start=\"995\"\u003eTake-away\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"2848\" data-start=\"1019\"\u003e\n\u003ctr data-end=\"1300\" data-start=\"1019\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1055\" data-start=\"1019\"\u003e1. Cognitive \/ memory enhancement\u003c\/td\u003e\n\u003ctd data-end=\"1300\" data-start=\"1055\" data-col-size=\"xl\"\u003eThis is one of the main reasons FGL became interesting. Rodent studies reported improved learning or memory-related outcomes, but this remains preclinical rather than established human cognitive therapy. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1507\" data-start=\"1301\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1347\" data-start=\"1301\"\u003e2. Neurotrophic \/ neurite outgrowth effects\u003c\/td\u003e\n\u003ctd data-end=\"1507\" data-start=\"1347\" data-col-size=\"xl\"\u003eFGL has been reported to promote neurite outgrowth and neuronal survival in vitro through NCAM-FGFR-related signaling. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1696\" data-start=\"1508\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1529\" data-start=\"1508\"\u003e3. Neuroprotection\u003c\/td\u003e\n\u003ctd data-end=\"1696\" data-start=\"1529\" data-col-size=\"xl\"\u003eAnimal and cell studies suggest neuroprotective effects in injury and degeneration models, but this is still investigational. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1933\" data-start=\"1697\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1741\" data-start=\"1697\"\u003e4. Anti-inflammatory \/ microglial effects\u003c\/td\u003e\n\u003ctd data-end=\"1933\" data-start=\"1741\" data-col-size=\"xl\"\u003eThis is a meaningful secondary theme. FGL has been reported to reduce inflammatory cytokine-related changes and microglial activation in aging models. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2181\" data-start=\"1934\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1993\" data-start=\"1934\"\u003e5. Neural stem-cell mobilization \/ regeneration interest\u003c\/td\u003e\n\u003ctd data-end=\"2181\" data-start=\"1993\" data-col-size=\"xl\"\u003ePreclinical work suggests FGL can mobilize endogenous neural stem cells and support regenerative responses after CNS injury models such as stroke. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2379\" data-start=\"2182\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2229\" data-start=\"2182\"\u003e6. Oligodendroglial \/ repair-related effects\u003c\/td\u003e\n\u003ctd data-end=\"2379\" data-start=\"2229\" data-col-size=\"xl\"\u003eSome preclinical studies suggest support for oligodendroglial differentiation and repair-associated biology. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2608\" data-start=\"2380\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2425\" data-start=\"2380\"\u003e7. Schizophrenia-relevant cognitive models\u003c\/td\u003e\n\u003ctd data-end=\"2608\" data-start=\"2425\" data-col-size=\"xl\"\u003eIn a neonatal PCP rat model, chronic FGL improved working-memory-type deficits, which helped drive interest in neuropsychiatric applications. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2848\" data-start=\"2609\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2646\" data-start=\"2609\"\u003e8. Not a proven clinical nootropic\u003c\/td\u003e\n\u003ctd data-end=\"2848\" data-start=\"2646\" data-col-size=\"xl\"\u003eMarketing or peptide-for-sale descriptions tend to outrun the evidence. The evidence base remains mostly preclinical, with limited early human safety data only. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch2 data-end=\"2885\" data-start=\"2850\" data-section-id=\"aq0rfb\"\u003e2. Molecular mechanism of action\u003c\/h2\u003e\n\u003ch3 data-end=\"2920\" data-start=\"2887\" data-section-id=\"jvsoby\"\u003e2.1 Receptor pharmacodynamics\u003c\/h3\u003e\n\u003cp data-end=\"3373\" data-start=\"2922\"\u003eFGL does \u003cstrong data-end=\"2938\" data-start=\"2931\"\u003enot\u003c\/strong\u003e act like a classic small-molecule nootropic. It is an \u003cstrong data-end=\"3017\" data-start=\"2993\"\u003eNCAM mimetic peptide\u003c\/strong\u003e designed to reproduce part of the NCAM interaction with \u003cstrong data-end=\"3083\" data-start=\"3074\"\u003eFGFR1\u003c\/strong\u003e. In the literature, FGL is described as an \u003cstrong data-end=\"3175\" data-start=\"3127\"\u003eFGFR agonist \/ activator in the NCAM context\u003c\/strong\u003e, promoting downstream signaling involved in neurite outgrowth, survival, and synaptic plasticity. That target logic is the core of its neurotrophic reputation. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"3401\" data-start=\"3375\" data-section-id=\"1c3fl0f\"\u003e2.2 Downstream biology\u003c\/h3\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"4089\" data-start=\"3403\"\u003e\n\u003cthead data-end=\"3453\" data-start=\"3403\"\u003e\n\u003ctr data-end=\"3453\" data-start=\"3403\"\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"3421\" data-start=\"3403\"\u003ePathway \/ theme\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"3442\" data-start=\"3421\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"3453\" data-start=\"3442\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"4089\" data-start=\"3468\"\u003e\n\u003ctr data-end=\"3625\" data-start=\"3468\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3499\" data-start=\"3468\"\u003eNCAM–FGFR1 mimetic signaling\u003c\/td\u003e\n\u003ctd data-end=\"3550\" data-start=\"3499\" data-col-size=\"md\"\u003eNeurite outgrowth, neuronal survival, plasticity\u003c\/td\u003e\n\u003ctd data-end=\"3625\" data-start=\"3550\" data-col-size=\"md\"\u003eNeurotrophic \/ synaptic biology \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3764\" data-start=\"3626\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3653\" data-start=\"3626\"\u003ePKC \/ synaptic signaling\u003c\/td\u003e\n\u003ctd data-end=\"3692\" data-start=\"3653\" data-col-size=\"md\"\u003eMemory-related synaptic facilitation\u003c\/td\u003e\n\u003ctd data-end=\"3764\" data-start=\"3692\" data-col-size=\"md\"\u003eCognitive-enhancement models \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3927\" data-start=\"3765\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3804\" data-start=\"3765\"\u003eMicroglial \/ inflammatory modulation\u003c\/td\u003e\n\u003ctd data-end=\"3858\" data-start=\"3804\" data-col-size=\"md\"\u003eReduced neuroinflammatory activation in some models\u003c\/td\u003e\n\u003ctd data-end=\"3927\" data-start=\"3858\" data-col-size=\"md\"\u003eAging \/ neuroinflammation \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4089\" data-start=\"3928\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3972\" data-start=\"3928\"\u003eStem-cell mobilization \/ repair signaling\u003c\/td\u003e\n\u003ctd data-end=\"4013\" data-start=\"3972\" data-col-size=\"md\"\u003eRegenerative and post-injury relevance\u003c\/td\u003e\n\u003ctd data-end=\"4089\" data-start=\"4013\" data-col-size=\"md\"\u003eStroke \/ regenerative CNS models \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp data-end=\"4282\" data-start=\"4091\"\u003eThese mechanisms are biologically interesting and internally coherent, but they still do \u003cstrong data-end=\"4187\" data-start=\"4180\"\u003enot\u003c\/strong\u003e amount to strong proof of clinical efficacy in humans. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"4306\" data-start=\"4284\" data-section-id=\"b8x6nr\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cp data-end=\"4885\" data-start=\"4308\"\u003e\u003cstrong data-end=\"4327\" data-start=\"4308\"\u003eRoutes studied:\u003c\/strong\u003e mainly experimental systemic dosing in animals and \u003cstrong data-end=\"4408\" data-start=\"4379\"\u003eintranasal administration\u003c\/strong\u003e in the phase I human study. The key practical point is that FGL is a \u003cstrong data-end=\"4489\" data-start=\"4478\"\u003epeptide\u003c\/strong\u003e, so delivery and stability matter. Early clinical work tested \u003cstrong data-end=\"4602\" data-start=\"4552\"\u003esingle intranasal doses of 25, 100, and 200 mg\u003c\/strong\u003e in healthy volunteers and found a generally dose-related PK profile with acceptable tolerability, which is why intranasal delivery became a notable development route. But that is still early-stage clinical pharmacology, not proof of efficacy. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"4927\" data-start=\"4887\" data-section-id=\"we631\"\u003e4. Pre-clinical and clinical evidence\u003c\/h2\u003e\n\u003ch3 data-end=\"4955\" data-start=\"4929\" data-section-id=\"1oekvw3\"\u003e4.1 Cognition \/ memory\u003c\/h3\u003e\n\u003cp data-end=\"5361\" data-start=\"4957\"\u003eThis is the \u003cstrong data-end=\"5001\" data-start=\"4969\"\u003ebest-known preclinical niche\u003c\/strong\u003e. Early rodent work found that FGL increased memory strength and enhanced presynaptic function, and later studies reported benefits in model systems with cognitive impairment. That is enough to explain FGL’s reputation as a cognition-oriented peptide, but it remains an \u003cstrong data-end=\"5298\" data-start=\"5271\"\u003eanimal-literature story\u003c\/strong\u003e more than a human one. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"5420\" data-start=\"5363\" data-section-id=\"17e2w5z\"\u003e4.2 Neuroprotection \/ aging-related neuroinflammation\u003c\/h3\u003e\n\u003cp data-end=\"5763\" data-start=\"5422\"\u003eFGL has also shown \u003cstrong data-end=\"5490\" data-start=\"5441\"\u003eanti-inflammatory and neuroprotective effects\u003c\/strong\u003e in aging and degeneration-related models. Studies reported reduced microglial activation and changes in inflammatory markers, which suggests a broader CNS-repair rationale beyond cognition alone. Still, this is preclinical evidence. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"5805\" data-start=\"5765\" data-section-id=\"ehsps3\"\u003e4.3 Regenerative \/ stem-cell effects\u003c\/h3\u003e\n\u003cp data-end=\"6131\" data-start=\"5807\"\u003eAnother notable line of research is that FGL may \u003cstrong data-end=\"5897\" data-start=\"5856\"\u003emobilize endogenous neural stem cells\u003c\/strong\u003e and support regenerative capacity after stroke-related injury. This is one of the more interesting mechanistic angles, but again it remains experimental and not an established clinical therapy. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"6155\" data-start=\"6133\" data-section-id=\"cnwh1g\"\u003e4.4 Human evidence\u003c\/h3\u003e\n\u003cp data-end=\"6639\" data-start=\"6157\"\u003eHuman evidence is \u003cstrong data-end=\"6191\" data-start=\"6175\"\u003every limited\u003c\/strong\u003e. The clearest published human study is the 2007 phase I trial of intranasal FGLL in healthy male volunteers, which found the peptide \u003cstrong data-end=\"6343\" data-start=\"6325\"\u003ewell tolerated\u003c\/strong\u003e with no major safety concerns in that small short-term setting and a roughly dose-related PK profile. The abstract noted that further studies were planned, but this should not be mistaken for proven efficacy in Alzheimer’s disease or any other indication. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"6674\" data-start=\"6641\" data-section-id=\"1uuy0po\"\u003e5. Emerging clinical interests\u003c\/h2\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"7477\" data-start=\"6676\"\u003e\n\u003cthead data-end=\"6706\" data-start=\"6676\"\u003e\n\u003ctr data-end=\"6706\" data-start=\"6676\"\u003e\n\u003cth class=\"\" data-col-size=\"sm\" data-end=\"6684\" data-start=\"6676\"\u003eField\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"6696\" data-start=\"6684\"\u003eRationale\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"6706\" data-start=\"6696\"\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"7477\" data-start=\"6721\"\u003e\n\u003ctr data-end=\"6879\" data-start=\"6721\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6763\" data-start=\"6721\"\u003eCognitive impairment \/ memory disorders\u003c\/td\u003e\n\u003ctd data-end=\"6793\" data-start=\"6763\" data-col-size=\"md\"\u003eStrongest historic interest\u003c\/td\u003e\n\u003ctd data-end=\"6879\" data-start=\"6793\" data-col-size=\"md\"\u003ePreclinical-heavy; human efficacy unproven \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7009\" data-start=\"6880\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6914\" data-start=\"6880\"\u003eNeuroinflammation \/ aging brain\u003c\/td\u003e\n\u003ctd data-end=\"6954\" data-start=\"6914\" data-col-size=\"md\"\u003eAnti-inflammatory microglial findings\u003c\/td\u003e\n\u003ctd data-end=\"7009\" data-start=\"6954\" data-col-size=\"md\"\u003eExploratory \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7156\" data-start=\"7010\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7041\" data-start=\"7010\"\u003eStroke \/ neural regeneration\u003c\/td\u003e\n\u003ctd data-end=\"7085\" data-start=\"7041\" data-col-size=\"md\"\u003eStem-cell mobilization and repair biology\u003c\/td\u003e\n\u003ctd data-end=\"7156\" data-start=\"7085\" data-col-size=\"md\"\u003ePreclinical \/ translational \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7294\" data-start=\"7157\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7191\" data-start=\"7157\"\u003eSchizophrenia-related cognition\u003c\/td\u003e\n\u003ctd data-end=\"7227\" data-start=\"7191\" data-col-size=\"md\"\u003eBenefit in PCP-based animal model\u003c\/td\u003e\n\u003ctd data-end=\"7294\" data-start=\"7227\" data-col-size=\"md\"\u003eExploratory preclinical \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7477\" data-start=\"7295\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7317\" data-start=\"7295\"\u003eAlzheimer’s disease\u003c\/td\u003e\n\u003ctd data-end=\"7372\" data-start=\"7317\" data-col-size=\"md\"\u003eDevelopment interest signaled by early trial context\u003c\/td\u003e\n\u003ctd data-end=\"7477\" data-start=\"7372\" data-col-size=\"md\"\u003eNo established clinical benefit shown in the sources reviewed \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch2 data-end=\"7508\" data-start=\"7479\" data-section-id=\"7gr288\"\u003e6. Safety and tolerability\u003c\/h2\u003e\n\u003cp data-end=\"7988\" data-start=\"7510\"\u003eThe main direct human safety data come from the \u003cstrong data-end=\"7592\" data-start=\"7558\"\u003esmall phase I intranasal study\u003c\/strong\u003e, where FGL(L) was reported as \u003cstrong data-end=\"7641\" data-start=\"7623\"\u003ewell tolerated\u003c\/strong\u003e with no major safety concerns in healthy male volunteers after single ascending doses. That is encouraging, but it is still \u003cstrong data-end=\"7806\" data-start=\"7766\"\u003eshort-term, early-stage, and limited\u003c\/strong\u003e. It does \u003cstrong data-end=\"7823\" data-start=\"7816\"\u003enot\u003c\/strong\u003e establish long-term safety, repeated-dose safety, or efficacy. Beyond that, most of the literature is animal or mechanistic. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"8026\" data-start=\"7990\" data-section-id=\"fttgrx\"\u003e7. Contraindications and cautions\u003c\/h2\u003e\n\u003cp data-end=\"8051\" data-start=\"8028\"\u003eUse extra caution with:\u003c\/p\u003e\n\u003cul data-end=\"8749\" data-start=\"8053\"\u003e\n\u003cli data-end=\"8227\" data-start=\"8053\" data-section-id=\"p5dwck\"\u003e\n\u003cstrong data-end=\"8128\" data-start=\"8055\"\u003eAny claim that FGL is a proven nootropic or neuroregenerative therapy\u003c\/strong\u003e, because the evidence base is predominantly preclinical. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8416\" data-start=\"8228\" data-section-id=\"14qvk1\"\u003e\n\u003cstrong data-end=\"8281\" data-start=\"8230\"\u003eSelf-experimentation or peptide-market products\u003c\/strong\u003e, because the formal human literature is sparse and not equivalent to approved-drug evidence. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8578\" data-start=\"8417\" data-section-id=\"1saobc9\"\u003e\n\u003cstrong data-end=\"8485\" data-start=\"8419\"\u003eAssuming animal cognition results translate directly to humans\u003c\/strong\u003e, because that leap has not been demonstrated here. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8749\" data-start=\"8579\" data-section-id=\"negh10\"\u003e\n\u003cstrong data-end=\"8637\" data-start=\"8581\"\u003eReplacing established neurologic or psychiatric care\u003c\/strong\u003e, because FGL remains investigational rather than validated treatment. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 data-end=\"8785\" data-start=\"8751\" data-section-id=\"o35cra\"\u003e8. Comparative practical matrix\u003c\/h2\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"9432\" data-start=\"8787\"\u003e\n\u003cthead data-end=\"8804\" data-start=\"8787\"\u003e\n\u003ctr data-end=\"8804\" data-start=\"8787\"\u003e\n\u003cth class=\"\" data-col-size=\"sm\" data-end=\"8797\" data-start=\"8787\"\u003eFeature\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"8804\" data-start=\"8797\"\u003eFGL\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"9432\" data-start=\"8815\"\u003e\n\u003ctr data-end=\"8895\" data-start=\"8815\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8831\" data-start=\"8815\"\u003eMain strength\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"8895\" data-start=\"8831\"\u003eInvestigational neurotrophic \/ cognitive-enhancement peptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"8988\" data-start=\"8896\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8922\" data-start=\"8896\"\u003eBest-supported use case\u003c\/td\u003e\n\u003ctd data-end=\"8988\" data-start=\"8922\" data-col-size=\"md\"\u003ePreclinical cognition, neuroprotection, and CNS repair biology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"9042\" data-start=\"8989\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"9015\" data-start=\"8989\"\u003eClinical evidence depth\u003c\/td\u003e\n\u003ctd data-end=\"9042\" data-start=\"9015\" data-col-size=\"md\"\u003eVery limited human data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"9103\" data-start=\"9043\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"9061\" data-start=\"9043\"\u003eCore limitation\u003c\/td\u003e\n\u003ctd data-end=\"9103\" data-start=\"9061\" data-col-size=\"md\"\u003eMostly animal and mechanistic evidence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"9175\" data-start=\"9104\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"9121\" data-start=\"9104\"\u003eMain mechanism\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"9175\" data-start=\"9121\"\u003eNCAM mimetic that activates FGFR-related signaling\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"9261\" data-start=\"9176\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"9202\" data-start=\"9176\"\u003eShort-term tolerability\u003c\/td\u003e\n\u003ctd data-end=\"9261\" data-start=\"9202\" data-col-size=\"md\"\u003eEarly intranasal phase I tolerability looked acceptable\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"9338\" data-start=\"9262\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"9284\" data-start=\"9262\"\u003eMain safety concern\u003c\/td\u003e\n\u003ctd data-end=\"9338\" data-start=\"9284\" data-col-size=\"md\"\u003eSparse human data and lack of established efficacy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"9432\" data-start=\"9339\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"9364\" data-start=\"9339\"\u003eBest practical framing\u003c\/td\u003e\n\u003ctd data-end=\"9432\" data-start=\"9364\" data-col-size=\"md\"\u003eResearch peptide, not a proven therapeutic or consumer nootropic\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch2 data-end=\"9460\" data-start=\"9434\" data-section-id=\"n437ah\"\u003e9. Regulatory landscape\u003c\/h2\u003e\n\u003cp data-end=\"9883\" data-start=\"9462\"\u003eFGL is best understood as an \u003cstrong data-end=\"9541\" data-start=\"9491\"\u003einvestigational research \/ development peptide\u003c\/strong\u003e, not an approved mainstream drug or validated supplement. The literature supports serious biologic interest, but not a recognized clinical role. The existence of a phase I intranasal study shows translational interest, yet the absence of established later-stage efficacy evidence is just as important. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"9909\" data-start=\"9885\" data-section-id=\"1fjxpfd\"\u003e10. Future directions\u003c\/h2\u003e\n\u003cp data-end=\"9948\" data-start=\"9911\"\u003eThe most useful future work would be:\u003c\/p\u003e\n\u003cul data-end=\"10363\" data-start=\"9950\"\u003e\n\u003cli data-end=\"10029\" data-start=\"9950\" data-section-id=\"q9yahd\"\u003elarger \u003cstrong data-end=\"9984\" data-start=\"9959\"\u003ehuman efficacy trials\u003c\/strong\u003e in clearly defined neurologic indications,\u003c\/li\u003e\n\u003cli data-end=\"10103\" data-start=\"10030\" data-section-id=\"1esmr2i\"\u003ebetter \u003cstrong data-end=\"10066\" data-start=\"10039\"\u003edose \/ schedule \/ route\u003c\/strong\u003e optimization for peptide delivery,\u003c\/li\u003e\n\u003cli data-end=\"10189\" data-start=\"10104\" data-section-id=\"1j6aj4c\"\u003eclearer separation of \u003cstrong data-end=\"10178\" data-start=\"10128\"\u003ecognitive vs anti-inflammatory vs regenerative\u003c\/strong\u003e effects,\u003c\/li\u003e\n\u003cli data-end=\"10363\" data-start=\"10190\" data-section-id=\"kfjn74\"\u003eand more modern translational work testing whether the promising FGFR-related biology translates into meaningful clinical outcomes. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 data-end=\"10389\" data-start=\"10365\" data-section-id=\"1uk6y2z\"\u003eBest balanced summary\u003c\/h2\u003e\n\u003cp data-end=\"10928\" data-start=\"10391\"\u003e\u003cstrong data-end=\"10888\" data-start=\"10391\"\u003eFGL is best viewed as an NCAM-derived investigational neurotrophic peptide with promising preclinical effects on cognition, neuronal survival, neuroinflammation, and regenerative CNS biology. Its mechanism, centered on mimicking NCAM interaction with FGFR1, is biologically credible and has produced substantial animal data. But human evidence remains limited to early safety \/ PK work, so FGL should not be framed as a proven nootropic, neuroregenerative therapy, or consumer peptide product.\u003c\/strong\u003e\u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"10952\" data-start=\"10930\" data-section-id=\"xxd8hg\"\u003eSelected references\u003c\/h2\u003e\n\u003cul data-end=\"12124\" data-start=\"10954\"\u003e\n\u003cli data-end=\"11189\" data-start=\"10954\" data-section-id=\"o7mlqe\"\u003e\n\u003cstrong data-end=\"11004\" data-start=\"10956\"\u003eKiselyov \/ NCAM-FGL literature summarized in\u003c\/strong\u003e \u003cem data-end=\"11068\" data-start=\"11005\"\u003ePharmacology of Cell Adhesion Molecules of the Nervous System\u003c\/em\u003e — foundational background on NCAM-derived mimetic peptides and FGFR signaling. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"11471\" data-start=\"11190\" data-section-id=\"1qqbwi0\"\u003e\n\u003cstrong data-end=\"11212\" data-start=\"11192\"\u003eCambon K, et al.\u003c\/strong\u003e \u003cem data-end=\"11361\" data-start=\"11213\"\u003eA Synthetic Neural Cell Adhesion Molecule Mimetic Peptide Enhances Function of the Glutamatergic Synapse and Improves Learning and Memory in Rats.\u003c\/em\u003e Strong classic source for the memory-enhancement reputation of FGL. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"11708\" data-start=\"11472\" data-section-id=\"w9nkxc\"\u003e\n\u003cstrong data-end=\"11493\" data-start=\"11474\"\u003eAnand R, et al.\u003c\/strong\u003e \u003cem data-end=\"11616\" data-start=\"11494\"\u003eTolerability, safety and pharmacokinetics of the FGLL peptide following intranasal administration in healthy volunteers.\u003c\/em\u003e Best direct human source for safety \/ PK framing. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"11903\" data-start=\"11709\" data-section-id=\"66c6ss\"\u003e\n\u003cstrong data-end=\"11732\" data-start=\"11711\"\u003eDowner EJ, et al.\u003c\/strong\u003e \u003cem data-end=\"11803\" data-start=\"11733\"\u003eA novel anti-inflammatory role of NCAM-derived mimetic peptide, FGL.\u003c\/em\u003e Best source for the anti-inflammatory \/ microglial angle. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"12124\" data-start=\"11904\" data-section-id=\"1mxjo0x\"\u003e\n\u003cstrong data-end=\"11925\" data-start=\"11906\"\u003eKlein R, et al.\u003c\/strong\u003e \u003cem data-end=\"11994\" data-start=\"11926\"\u003eThe synthetic NCAM mimetic peptide FGL mobilizes neural stem cells\u003c\/em\u003e and related stroke-regeneration work. Best source for the regenerative \/ stem-cell angle.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":55714444738824,"sku":null,"price":200.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0937\/9053\/5944\/files\/FGL_30mg.png?v=1775240794"},{"product_id":"dnsp-11-10mg-vial","title":"DNSP-11 10mg vial","description":"\u003cp data-end=\"743\" data-start=\"100\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                           \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"743\" data-start=\"100\"\u003e\u003cstrong data-end=\"111\" data-start=\"100\"\u003eDNSP-11\u003c\/strong\u003e is best viewed as an \u003cstrong data-end=\"253\" data-start=\"133\"\u003einvestigational neuroactive peptide derived from the proregion of GDNF (glial cell line-derived neurotrophic factor)\u003c\/strong\u003e, not a proven therapeutic or consumer neuroregenerative peptide. Its strongest evidence is in \u003cstrong data-end=\"398\" data-start=\"348\"\u003epreclinical Parkinson’s-disease-related models\u003c\/strong\u003e, where it has shown \u003cstrong data-end=\"509\" data-start=\"419\"\u003edopaminergic trophic-like activity, neurochemical effects, and some behavioral benefit\u003c\/strong\u003e, plus the ability to be delivered \u003cstrong data-end=\"560\" data-start=\"544\"\u003eintranasally\u003c\/strong\u003e in animals. Human evidence is \u003cstrong data-end=\"607\" data-start=\"591\"\u003every limited\u003c\/strong\u003e and centers mainly on an early \u003cstrong data-end=\"690\" data-start=\"639\"\u003ephase I intranasal safety\/pharmacokinetic study\u003c\/strong\u003e, not efficacy. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"798\" data-start=\"745\" data-section-id=\"1ocqt19\"\u003eAdditional benefits of DNSP-11 under investigation\u003c\/h2\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"2624\" data-start=\"800\"\u003e\n\u003cthead data-end=\"823\" data-start=\"800\"\u003e\n\u003ctr data-end=\"823\" data-start=\"800\"\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"810\" data-start=\"800\"\u003eBenefit\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"xl\" data-end=\"823\" data-start=\"810\"\u003eTake-away\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"2624\" data-start=\"834\"\u003e\n\u003ctr data-end=\"1066\" data-start=\"834\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"878\" data-start=\"834\"\u003e1. Dopaminergic neurotrophic-like support\u003c\/td\u003e\n\u003ctd data-end=\"1066\" data-start=\"878\" data-col-size=\"xl\"\u003eThis is the main reason DNSP-11 is studied. Cell and animal studies suggest support for dopaminergic neuron growth, differentiation, and function. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1333\" data-start=\"1067\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1108\" data-start=\"1067\"\u003e2. Parkinson’s disease model relevance\u003c\/td\u003e\n\u003ctd data-end=\"1333\" data-start=\"1108\" data-col-size=\"xl\"\u003eDNSP-11 has shown encouraging effects in rodent PD models, including changes in dopamine turnover, protection of TH-positive neurons, and reduced rotational asymmetry in some studies. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1518\" data-start=\"1334\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1367\" data-start=\"1334\"\u003e3. ERK1\/2 signaling activation\u003c\/td\u003e\n\u003ctd data-end=\"1518\" data-start=\"1367\" data-col-size=\"xl\"\u003eA recurring mechanistic theme is ERK1\/2 phosphorylation, which fits with trophic and neurite-support biology. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1739\" data-start=\"1519\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1549\" data-start=\"1519\"\u003e4. Neuroprotection interest\u003c\/td\u003e\n\u003ctd data-end=\"1739\" data-start=\"1549\" data-col-size=\"xl\"\u003eIn vitro work suggests protection against apoptosis and toxic injury, but in vivo neuroprotection is less clear-cut than marketing language implies. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1991\" data-start=\"1740\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1777\" data-start=\"1740\"\u003e5. Intranasal delivery feasibility\u003c\/td\u003e\n\u003ctd data-end=\"1991\" data-start=\"1777\" data-col-size=\"xl\"\u003eDNSP-11 is notable because repeated intranasal delivery has been shown to reach the CNS and retain neuroactivity in rats, which is a practical advantage over many peptides. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2226\" data-start=\"1992\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2038\" data-start=\"1992\"\u003e6. Better distribution logic than full GDNF\u003c\/td\u003e\n\u003ctd data-end=\"2226\" data-start=\"2038\" data-col-size=\"xl\"\u003eReviews note that DNSP-11 lacks some of the large-molecule delivery limitations of GDNF and does not rely on direct GFRα1 binding in the same way. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2470\" data-start=\"2227\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2269\" data-start=\"2227\"\u003e7. Stable peptide-development candidate\u003c\/td\u003e\n\u003ctd data-end=\"2470\" data-start=\"2269\" data-col-size=\"xl\"\u003eThe peptide has been described as structurally stable and attractive for storage and formulation in preclinical work, but that does not prove clinical success. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2624\" data-start=\"2471\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2506\" data-start=\"2471\"\u003e8. Not a proven human PD therapy\u003c\/td\u003e\n\u003ctd data-end=\"2624\" data-start=\"2506\" data-col-size=\"xl\"\u003eThe evidence remains mostly preclinical, with no established human efficacy. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch2 data-end=\"2661\" data-start=\"2626\" data-section-id=\"aq0rfb\"\u003e2. Molecular mechanism of action\u003c\/h2\u003e\n\u003ch3 data-end=\"2696\" data-start=\"2663\" data-section-id=\"jvsoby\"\u003e2.1 Receptor pharmacodynamics\u003c\/h3\u003e\n\u003cp data-end=\"3146\" data-start=\"2698\"\u003eDNSP-11 does \u003cstrong data-end=\"2718\" data-start=\"2711\"\u003enot\u003c\/strong\u003e appear to work as a simple miniature GDNF replacement through the standard \u003cstrong data-end=\"2807\" data-start=\"2794\"\u003eGFRα1\/RET\u003c\/strong\u003e receptor pathway. Preclinical work suggests it has \u003cstrong data-end=\"2907\" data-start=\"2859\"\u003etrophic-like effects on dopaminergic neurons\u003c\/strong\u003e through mechanisms that are at least partly \u003cstrong data-end=\"2991\" data-start=\"2952\"\u003eindependent of direct GFRα1 binding\u003c\/strong\u003e, which is one of the reasons it attracted interest as a distinct peptide rather than just a truncated GDNF fragment. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"3174\" data-start=\"3148\" data-section-id=\"1c3fl0f\"\u003e2.2 Downstream biology\u003c\/h3\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"3835\" data-start=\"3176\"\u003e\n\u003cthead data-end=\"3226\" data-start=\"3176\"\u003e\n\u003ctr data-end=\"3226\" data-start=\"3176\"\u003e\n\u003cth class=\"\" data-col-size=\"sm\" data-end=\"3194\" data-start=\"3176\"\u003ePathway \/ theme\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"3215\" data-start=\"3194\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"3226\" data-start=\"3215\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"3835\" data-start=\"3241\"\u003e\n\u003ctr data-end=\"3375\" data-start=\"3241\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3261\" data-start=\"3241\"\u003eERK1\/2 activation\u003c\/td\u003e\n\u003ctd data-end=\"3306\" data-start=\"3261\" data-col-size=\"md\"\u003eSupports trophic\/neuroplasticity signaling\u003c\/td\u003e\n\u003ctd data-end=\"3375\" data-start=\"3306\" data-col-size=\"md\"\u003eDopaminergic cell studies \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3523\" data-start=\"3376\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3414\" data-start=\"3376\"\u003eDopaminergic neurite\/growth effects\u003c\/td\u003e\n\u003ctd data-end=\"3451\" data-start=\"3414\" data-col-size=\"md\"\u003eGrowth and differentiation support\u003c\/td\u003e\n\u003ctd data-end=\"3523\" data-start=\"3451\" data-col-size=\"md\"\u003eIn vitro dopaminergic models \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3682\" data-start=\"3524\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3551\" data-start=\"3524\"\u003eNeurochemical modulation\u003c\/td\u003e\n\u003ctd data-end=\"3608\" data-start=\"3551\" data-col-size=\"md\"\u003eIncreased dopamine metabolism\/release in some settings\u003c\/td\u003e\n\u003ctd data-end=\"3682\" data-start=\"3608\" data-col-size=\"md\"\u003eNigrostriatal function studies \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3835\" data-start=\"3683\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3724\" data-start=\"3683\"\u003eAnti-apoptotic\/cell-protective effects\u003c\/td\u003e\n\u003ctd data-end=\"3764\" data-start=\"3724\" data-col-size=\"md\"\u003eProtection from toxic injury in vitro\u003c\/td\u003e\n\u003ctd data-end=\"3835\" data-start=\"3764\" data-col-size=\"md\"\u003ePreclinical neuroprotection \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp data-end=\"4045\" data-start=\"3837\"\u003eThese mechanisms are biologically plausible and fit the peptide’s reputation, but they still do \u003cstrong data-end=\"3940\" data-start=\"3933\"\u003enot\u003c\/strong\u003e amount to strong proof of meaningful clinical benefit in humans. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"4069\" data-start=\"4047\" data-section-id=\"b8x6nr\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cp data-end=\"4615\" data-start=\"4071\"\u003e\u003cstrong data-end=\"4090\" data-start=\"4071\"\u003eRoutes studied:\u003c\/strong\u003e direct brain infusion in animal work and \u003cstrong data-end=\"4155\" data-start=\"4132\"\u003eintranasal delivery\u003c\/strong\u003e in both animals and early human testing. The practical point is that DNSP-11 was developed partly to overcome the delivery and biodistribution problems of larger trophic factors like GDNF. Repeated intranasal rat studies found CNS distribution and maintained neuroactivity, while review literature still notes uncertainty about whether it can adequately penetrate and reach targets under clinically relevant conditions. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"4657\" data-start=\"4617\" data-section-id=\"we631\"\u003e4. Pre-clinical and clinical evidence\u003c\/h2\u003e\n\u003ch3 data-end=\"4702\" data-start=\"4659\" data-section-id=\"12bh5zx\"\u003e4.1 Parkinson’s \/ dopaminergic function\u003c\/h3\u003e\n\u003cp data-end=\"5171\" data-start=\"4704\"\u003eThis is the \u003cstrong data-end=\"4740\" data-start=\"4716\"\u003ebest-supported niche\u003c\/strong\u003e. In cell systems and rodent studies, DNSP-11 has been associated with \u003cstrong data-end=\"4940\" data-start=\"4811\"\u003eneuronal growth, differentiation, ERK1\/2 activation, altered dopamine turnover, and some preservation of dopaminergic markers\u003c\/strong\u003e. In rat PD-related models, repeated intranasal administration reduced rotational behavior and showed evidence of sparing of \u003cstrong data-end=\"5106\" data-start=\"5065\"\u003etyrosine hydroxylase-positive neurons\u003c\/strong\u003e in the substantia nigra. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"5217\" data-start=\"5173\" data-section-id=\"1pwqezr\"\u003e4.2 Neurochemical and behavioral effects\u003c\/h3\u003e\n\u003cp data-end=\"5604\" data-start=\"5219\"\u003eThe picture is \u003cstrong data-end=\"5259\" data-start=\"5234\"\u003eencouraging but mixed\u003c\/strong\u003e. One in vivo study found region-specific increases in potassium-evoked dopamine release after a single treatment, but no change in spontaneous locomotor activity. That supports \u003cstrong data-end=\"5454\" data-start=\"5437\"\u003eneuroactivity\u003c\/strong\u003e, but it also shows that the leap from neurochemical effects to broad functional improvement is not automatic. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"5629\" data-start=\"5606\" data-section-id=\"wkzcgf\"\u003e4.3 Neuroprotection\u003c\/h3\u003e\n\u003cp data-end=\"5983\" data-start=\"5631\"\u003eDNSP-11 has shown \u003cstrong data-end=\"5680\" data-start=\"5649\"\u003eprotective effects in vitro\u003c\/strong\u003e against toxic injury and apoptosis-related insults, but review literature has cautioned that in vivo results look more \u003cstrong data-end=\"5815\" data-start=\"5800\"\u003eneuroactive\u003c\/strong\u003e than robustly \u003cstrong data-end=\"5849\" data-start=\"5830\"\u003eneuroprotective\u003c\/strong\u003e. That is an important distinction, because a lot of peptide marketing blurs those categories. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"6007\" data-start=\"5985\" data-section-id=\"cnwh1g\"\u003e4.4 Human evidence\u003c\/h3\u003e\n\u003cp data-end=\"6420\" data-start=\"6009\"\u003eHuman evidence is \u003cstrong data-end=\"6043\" data-start=\"6027\"\u003every limited\u003c\/strong\u003e. The main published clinical signal is an early \u003cstrong data-end=\"6147\" data-start=\"6092\"\u003ephase I intranasal FGLL\/DNSP-11 safety and PK study\u003c\/strong\u003e in healthy volunteers, which is useful for tolerability framing but \u003cstrong data-end=\"6244\" data-start=\"6216\"\u003enot evidence of efficacy\u003c\/strong\u003e in Parkinson’s disease or any other neurologic disorder. The absence of established later-stage clinical benefit is a major limitation. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"6455\" data-start=\"6422\" data-section-id=\"1uuy0po\"\u003e5. Emerging clinical interests\u003c\/h2\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"7121\" data-start=\"6457\"\u003e\n\u003cthead data-end=\"6487\" data-start=\"6457\"\u003e\n\u003ctr data-end=\"6487\" data-start=\"6457\"\u003e\n\u003cth class=\"\" data-col-size=\"sm\" data-end=\"6465\" data-start=\"6457\"\u003eField\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"6477\" data-start=\"6465\"\u003eRationale\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"6487\" data-start=\"6477\"\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"7121\" data-start=\"6502\"\u003e\n\u003ctr data-end=\"6661\" data-start=\"6502\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6524\" data-start=\"6502\"\u003eParkinson’s disease\u003c\/td\u003e\n\u003ctd data-end=\"6575\" data-start=\"6524\" data-col-size=\"md\"\u003eMain development target via dopaminergic support\u003c\/td\u003e\n\u003ctd data-end=\"6661\" data-start=\"6575\" data-col-size=\"md\"\u003ePreclinical-heavy; human efficacy unproven \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6815\" data-start=\"6662\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6696\" data-start=\"6662\"\u003eIntranasal CNS peptide delivery\u003c\/td\u003e\n\u003ctd data-end=\"6739\" data-start=\"6696\" data-col-size=\"md\"\u003ePractical route for bypassing BBB issues\u003c\/td\u003e\n\u003ctd data-end=\"6815\" data-start=\"6739\" data-col-size=\"md\"\u003eTechnically promising in animals \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6971\" data-start=\"6816\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6853\" data-start=\"6816\"\u003eNeuroprotection \/ neurorestoration\u003c\/td\u003e\n\u003ctd data-end=\"6896\" data-start=\"6853\" data-col-size=\"md\"\u003eTrophic-like and anti-apoptotic findings\u003c\/td\u003e\n\u003ctd data-end=\"6971\" data-start=\"6896\" data-col-size=\"md\"\u003eExploratory, especially in vivo \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7121\" data-start=\"6972\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7000\" data-start=\"6972\"\u003eGeneral neurodegeneration\u003c\/td\u003e\n\u003ctd data-end=\"7041\" data-start=\"7000\" data-col-size=\"md\"\u003eExtension of dopaminergic repair logic\u003c\/td\u003e\n\u003ctd data-end=\"7121\" data-start=\"7041\" data-col-size=\"md\"\u003eSpeculative beyond PD-focused models \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch2 data-end=\"7152\" data-start=\"7123\" data-section-id=\"7gr288\"\u003e6. Safety and tolerability\u003c\/h2\u003e\n\u003cp data-end=\"7587\" data-start=\"7154\"\u003eThe most reassuring safety information is \u003cstrong data-end=\"7217\" data-start=\"7196\"\u003eearly and limited\u003c\/strong\u003e. Preclinical work supports reasonable experimental tolerability, and the human development literature provides some early intranasal safety\/PK experience, but this is far from the kind of safety database expected for an established drug. So the correct framing is \u003cstrong data-end=\"7522\" data-start=\"7482\"\u003epreliminarily encouraging but sparse\u003c\/strong\u003e, not well characterized. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"7625\" data-start=\"7589\" data-section-id=\"fttgrx\"\u003e7. Contraindications and cautions\u003c\/h2\u003e\n\u003cp data-end=\"7650\" data-start=\"7627\"\u003eUse extra caution with:\u003c\/p\u003e\n\u003cul data-end=\"8357\" data-start=\"7652\"\u003e\n\u003cli data-end=\"7837\" data-start=\"7652\" data-section-id=\"1cvtolh\"\u003e\n\u003cstrong data-end=\"7733\" data-start=\"7654\"\u003eAny claim that DNSP-11 is a proven PD treatment or neurorestorative therapy\u003c\/strong\u003e, because the evidence base remains mostly animal\/preclinical. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8010\" data-start=\"7838\" data-section-id=\"12qi7b2\"\u003e\n\u003cstrong data-end=\"7896\" data-start=\"7840\"\u003eSelf-experimentation or gray-market peptide sourcing\u003c\/strong\u003e, because formal human efficacy and longer-term safety data are lacking. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8200\" data-start=\"8011\" data-section-id=\"1mkz3ep\"\u003e\n\u003cstrong data-end=\"8076\" data-start=\"8013\"\u003eAssuming intranasal delivery solves the translation problem\u003c\/strong\u003e, because promising animal delivery does not automatically equal clinical success. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8357\" data-start=\"8201\" data-section-id=\"1o91pf4\"\u003e\n\u003cstrong data-end=\"8241\" data-start=\"8203\"\u003eReplacing standard neurologic care\u003c\/strong\u003e, because DNSP-11 remains investigational rather than validated treatment. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 data-end=\"8393\" data-start=\"8359\" data-section-id=\"o35cra\"\u003e8. Comparative practical matrix\u003c\/h2\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"8959\" data-start=\"8395\"\u003e\n\u003cthead data-end=\"8416\" data-start=\"8395\"\u003e\n\u003ctr data-end=\"8416\" data-start=\"8395\"\u003e\n\u003cth class=\"\" data-col-size=\"sm\" data-end=\"8405\" data-start=\"8395\"\u003eFeature\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"8416\" data-start=\"8405\"\u003eDNSP-11\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"8959\" data-start=\"8427\"\u003e\n\u003ctr data-end=\"8495\" data-start=\"8427\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8443\" data-start=\"8427\"\u003eMain strength\u003c\/td\u003e\n\u003ctd data-end=\"8495\" data-start=\"8443\" data-col-size=\"md\"\u003eInvestigational dopaminergic neuroactive peptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"8578\" data-start=\"8496\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8522\" data-start=\"8496\"\u003eBest-supported use case\u003c\/td\u003e\n\u003ctd data-end=\"8578\" data-start=\"8522\" data-col-size=\"md\"\u003ePreclinical Parkinson’s-related dopaminergic support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"8621\" data-start=\"8579\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8605\" data-start=\"8579\"\u003eClinical evidence depth\u003c\/td\u003e\n\u003ctd data-end=\"8621\" data-start=\"8605\" data-col-size=\"md\"\u003eVery limited\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"8693\" data-start=\"8622\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8640\" data-start=\"8622\"\u003eCore limitation\u003c\/td\u003e\n\u003ctd data-end=\"8693\" data-start=\"8640\" data-col-size=\"md\"\u003eMostly animal data; no established human efficacy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"8783\" data-start=\"8694\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8711\" data-start=\"8694\"\u003eMain mechanism\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"8783\" data-start=\"8711\"\u003eGDNF-proregion-derived trophic-like signaling with ERK1\/2 activation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"8843\" data-start=\"8784\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8804\" data-start=\"8784\"\u003eDelivery interest\u003c\/td\u003e\n\u003ctd data-end=\"8843\" data-start=\"8804\" data-col-size=\"md\"\u003eIntranasal CNS delivery feasibility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"8887\" data-start=\"8844\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8866\" data-start=\"8844\"\u003eMain safety concern\u003c\/td\u003e\n\u003ctd data-end=\"8887\" data-start=\"8866\" data-col-size=\"md\"\u003eSparse human data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"8959\" data-start=\"8888\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8913\" data-start=\"8888\"\u003eBest practical framing\u003c\/td\u003e\n\u003ctd data-end=\"8959\" data-start=\"8913\" data-col-size=\"md\"\u003eResearch peptide, not a proven therapeutic\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch2 data-end=\"8987\" data-start=\"8961\" data-section-id=\"n437ah\"\u003e9. Regulatory landscape\u003c\/h2\u003e\n\u003cp data-end=\"9388\" data-start=\"8989\"\u003eDNSP-11 is best understood as an \u003cstrong data-end=\"9058\" data-start=\"9022\"\u003einvestigational research peptide\u003c\/strong\u003e, not an approved mainstream therapy or validated supplement. Reviews of GDNF-targeting strategies still discuss it as an interesting attempt to capture trophic benefits with a smaller peptide, but they also emphasize that clinically meaningful translation has \u003cstrong data-end=\"9347\" data-start=\"9319\"\u003enot yet been established\u003c\/strong\u003e. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"9414\" data-start=\"9390\" data-section-id=\"1fjxpfd\"\u003e10. Future directions\u003c\/h2\u003e\n\u003cp data-end=\"9453\" data-start=\"9416\"\u003eThe most useful future work would be:\u003c\/p\u003e\n\u003cul data-end=\"9794\" data-start=\"9455\"\u003e\n\u003cli data-end=\"9504\" data-start=\"9455\" data-section-id=\"1g6986s\"\u003elarger and clearer \u003cstrong data-end=\"9501\" data-start=\"9476\"\u003ehuman efficacy trials\u003c\/strong\u003e,\u003c\/li\u003e\n\u003cli data-end=\"9597\" data-start=\"9505\" data-section-id=\"1eamxrf\"\u003ebetter demonstration of \u003cstrong data-end=\"9555\" data-start=\"9531\"\u003edisease modification\u003c\/strong\u003e rather than just neurochemical changes,\u003c\/li\u003e\n\u003cli data-end=\"9650\" data-start=\"9598\" data-section-id=\"1w08m4r\"\u003efurther optimization of \u003cstrong data-end=\"9647\" data-start=\"9624\"\u003eintranasal delivery\u003c\/strong\u003e,\u003c\/li\u003e\n\u003cli data-end=\"9794\" data-start=\"9651\" data-section-id=\"1tzg10b\"\u003eand more direct mechanistic clarification of how DNSP-11 differs from classic \u003cstrong data-end=\"9743\" data-start=\"9731\"\u003eGDNF\/RET\u003c\/strong\u003e signaling. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 data-end=\"9820\" data-start=\"9796\" data-section-id=\"1uk6y2z\"\u003eBest balanced summary\u003c\/h2\u003e\n\u003cp data-end=\"10296\" data-start=\"9822\"\u003e\u003cstrong data-end=\"10256\" data-start=\"9822\"\u003eDNSP-11 is best viewed as a GDNF-proregion-derived investigational peptide with promising preclinical effects on dopaminergic neuron function, Parkinson’s-related animal models, and intranasal CNS delivery. Its biology is credible and more practically attractive than full GDNF in some respects, but the evidence remains mostly preclinical and does not establish DNSP-11 as a proven human neuroregenerative or Parkinson’s therapy.\u003c\/strong\u003e\u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"10320\" data-start=\"10298\" data-section-id=\"xxd8hg\"\u003eSelected references\u003c\/h2\u003e\n\u003cul data-end=\"11542\" data-start=\"10322\"\u003e\n\u003cli data-end=\"10565\" data-start=\"10322\" data-section-id=\"erprgz\"\u003e\n\u003cstrong data-end=\"10344\" data-start=\"10324\"\u003eKelps KA, et al.\u003c\/strong\u003e \u003cem data-end=\"10448\" data-start=\"10345\"\u003eEvaluation of the Physical and In Vitro Protective Activity of a Dopamine Neuron Stimulating Peptide.\u003c\/em\u003e Good source for peptide characterization and in-vitro protective activity. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"10764\" data-start=\"10566\" data-section-id=\"4m9dma\"\u003e\n\u003cstrong data-end=\"10588\" data-start=\"10568\"\u003eFuqua JL, et al.\u003c\/strong\u003e \u003cem data-end=\"10659\" data-start=\"10589\"\u003eDynamic Changes in Dopamine Neuron Function after DNSP-11 Treatment.\u003c\/em\u003e Best source for in vivo dopamine-function and ERK1\/2 findings. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"10988\" data-start=\"10765\" data-section-id=\"1jto18l\"\u003e\n\u003cstrong data-end=\"10790\" data-start=\"10767\"\u003eStenslik MJ, et al.\u003c\/strong\u003e \u003cem data-end=\"10886\" data-start=\"10791\"\u003eMethodology and effects of repeated intranasal delivery of DNSP-11 in normal and 6-OHDA rats.\u003c\/em\u003e Best source for intranasal delivery and PD-model relevance. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"11272\" data-start=\"10989\" data-section-id=\"r5tpma\"\u003e\n\u003cstrong data-end=\"11014\" data-start=\"10991\"\u003eSidorova YA, et al.\u003c\/strong\u003e \u003cem data-end=\"11149\" data-start=\"11015\"\u003eSmall Molecules and Peptides Targeting Glial Cell Line-Derived Neurotrophic Factor Receptors for the Treatment of Neurodegeneration.\u003c\/em\u003e Best review-level source placing DNSP-11 in the broader translational landscape. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"11542\" data-start=\"11273\" data-section-id=\"1ejhz7v\"\u003e\n\u003cstrong data-end=\"11296\" data-start=\"11275\"\u003eConway JA, et al.\u003c\/strong\u003e \u003cem data-end=\"11394\" data-start=\"11297\"\u003eIs activation of GDNF\/RET signaling the answer for successful treatment of Parkinson’s disease?\u003c\/em\u003e Useful cautionary review noting that DNSP-11 appears neuroactive in vivo but not clearly neuroprotective.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":55716577607944,"sku":null,"price":125.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0937\/9053\/5944\/files\/DNSP-11_10mg.png?v=1775179215"},{"product_id":"hng-10mg-vial","title":"HNG 10mg vial","description":"\u003cp data-end=\"763\" data-start=\"92\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                          \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"763\" data-start=\"92\"\u003e\u003cstrong data-end=\"99\" data-start=\"92\"\u003eHNG\u003c\/strong\u003e usually refers to \u003cstrong data-end=\"134\" data-start=\"118\"\u003eS14G-humanin\u003c\/strong\u003e, a synthetic analog of the mitochondrial-derived peptide \u003cstrong data-end=\"203\" data-start=\"192\"\u003ehumanin\u003c\/strong\u003e in which serine at position 14 is replaced with glycine. It is best viewed as an \u003cstrong data-end=\"345\" data-start=\"285\"\u003einvestigational cytoprotective \/ neuroprotective peptide\u003c\/strong\u003e, not a proven therapeutic or consumer anti-aging treatment. The strongest case for HNG is still \u003cstrong data-end=\"457\" data-start=\"442\"\u003epreclinical\u003c\/strong\u003e, especially in \u003cstrong data-end=\"579\" data-start=\"473\"\u003eneuroprotection, metabolic disease models, cardiovascular injury, and other stress-resistance settings\u003c\/strong\u003e. Human therapeutic evidence is essentially absent or extremely limited, so the right framing is \u003cstrong data-end=\"724\" data-start=\"676\"\u003epromising biology, unproven clinical utility\u003c\/strong\u003e. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"814\" data-start=\"765\" data-section-id=\"11nvmm0\"\u003eAdditional benefits of HNG under investigation\u003c\/h2\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"2755\" data-start=\"816\"\u003e\n\u003cthead data-end=\"839\" data-start=\"816\"\u003e\n\u003ctr data-end=\"839\" data-start=\"816\"\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"826\" data-start=\"816\"\u003eBenefit\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"xl\" data-end=\"839\" data-start=\"826\"\u003eTake-away\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"2755\" data-start=\"850\"\u003e\n\u003ctr data-end=\"1090\" data-start=\"850\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"871\" data-start=\"850\"\u003e1. Neuroprotection\u003c\/td\u003e\n\u003ctd data-end=\"1090\" data-start=\"871\" data-col-size=\"xl\"\u003eThis is the clearest and oldest HNG niche. Animal and cell studies support protection against ischemic, excitotoxic, and neurodegenerative insults, but this remains preclinical. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1357\" data-start=\"1091\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1135\" data-start=\"1091\"\u003e2. Alzheimer’s \/ amyloid-related interest\u003c\/td\u003e\n\u003ctd data-end=\"1357\" data-start=\"1135\" data-col-size=\"xl\"\u003eHNG has been studied for protection against amyloid-related injury and protein-misfolding toxicity, but this is still model-based evidence rather than established clinical therapy. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1620\" data-start=\"1358\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1394\" data-start=\"1358\"\u003e3. Metabolic \/ diabetes relevance\u003c\/td\u003e\n\u003ctd data-end=\"1620\" data-start=\"1394\" data-col-size=\"xl\"\u003eHNG and related mitochondrial-derived peptides have shown interesting effects in models relevant to insulin resistance, beta-cell stress, and amyloid toxicity, but this is exploratory. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1871\" data-start=\"1621\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1643\" data-start=\"1621\"\u003e4. Cardioprotection\u003c\/td\u003e\n\u003ctd data-end=\"1871\" data-start=\"1643\" data-col-size=\"xl\"\u003ePreclinical studies suggest HNG can reduce injury in myocardial ischemia\/reperfusion models, including a large-animal MI study, but this has not translated into established clinical use. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2064\" data-start=\"1872\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1919\" data-start=\"1872\"\u003e5. Anti-apoptotic \/ cytoprotective signaling\u003c\/td\u003e\n\u003ctd data-end=\"2064\" data-start=\"1919\" data-col-size=\"xl\"\u003eA major theme across tissues is protection from oxidative stress, hypoxia, toxic injury, and apoptosis. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2289\" data-start=\"2065\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2091\" data-start=\"2065\"\u003e6. Hair-growth interest\u003c\/td\u003e\n\u003ctd data-end=\"2289\" data-start=\"2091\" data-col-size=\"xl\"\u003eHNG has shown pro-anagen and anti-apoptotic effects in hair-follicle models, but this is a niche preclinical application, not a validated hair-loss therapy. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2530\" data-start=\"2290\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2343\" data-start=\"2290\"\u003e7. Healthy-aging \/ “metabolic healthspan” interest\u003c\/td\u003e\n\u003ctd data-end=\"2530\" data-start=\"2343\" data-col-size=\"xl\"\u003eAnimal work suggests HNG can improve some metabolic and inflammatory aging markers, but that is far from proving it as a human longevity therapy. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2755\" data-start=\"2531\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2569\" data-start=\"2531\"\u003e8. Not a proven anti-aging medicine\u003c\/td\u003e\n\u003ctd data-end=\"2755\" data-start=\"2569\" data-col-size=\"xl\"\u003eMarketing around humanin analogs often runs ahead of the evidence. HNG remains a research peptide with no established broad clinical indication. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch2 data-end=\"2792\" data-start=\"2757\" data-section-id=\"aq0rfb\"\u003e2. Molecular mechanism of action\u003c\/h2\u003e\n\u003ch3 data-end=\"2827\" data-start=\"2794\" data-section-id=\"jvsoby\"\u003e2.1 Receptor pharmacodynamics\u003c\/h3\u003e\n\u003cp data-end=\"3450\" data-start=\"2829\"\u003eHNG does \u003cstrong data-end=\"2845\" data-start=\"2838\"\u003enot\u003c\/strong\u003e behave like a classic small-molecule drug with one clean receptor story. Humanin-family peptides signal through both \u003cstrong data-end=\"2997\" data-start=\"2963\"\u003eextracellular receptor systems\u003c\/strong\u003e and \u003cstrong data-end=\"3047\" data-start=\"3002\"\u003eintracellular anti-apoptotic interactions\u003c\/strong\u003e. Reviews describe signaling through a \u003cstrong data-end=\"3133\" data-start=\"3086\"\u003etrimeric CNTFR\/WSX-1\/gp130 receptor complex\u003c\/strong\u003e with downstream \u003cstrong data-end=\"3162\" data-start=\"3150\"\u003eJAK\/STAT\u003c\/strong\u003e activation, while other work highlights intracellular interactions with pro-apoptotic proteins such as \u003cstrong data-end=\"3273\" data-start=\"3266\"\u003eBAX\u003c\/strong\u003e and related cell-death machinery. HNG is generally treated as a \u003cstrong data-end=\"3360\" data-start=\"3338\"\u003emore potent analog\u003c\/strong\u003e of native humanin in these cytoprotective pathways. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"3478\" data-start=\"3452\" data-section-id=\"1c3fl0f\"\u003e2.2 Downstream biology\u003c\/h3\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"4211\" data-start=\"3480\"\u003e\n\u003cthead data-end=\"3530\" data-start=\"3480\"\u003e\n\u003ctr data-end=\"3530\" data-start=\"3480\"\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"3498\" data-start=\"3480\"\u003ePathway \/ theme\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"3519\" data-start=\"3498\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"3530\" data-start=\"3519\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"4211\" data-start=\"3545\"\u003e\n\u003ctr data-end=\"3698\" data-start=\"3545\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3581\" data-start=\"3545\"\u003eJAK2\/STAT3 and PI3K\/AKT signaling\u003c\/td\u003e\n\u003ctd data-end=\"3619\" data-start=\"3581\" data-col-size=\"md\"\u003eSurvival \/ anti-apoptotic signaling\u003c\/td\u003e\n\u003ctd data-end=\"3698\" data-start=\"3619\" data-col-size=\"md\"\u003eNeuroprotection and ischemia models \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3833\" data-start=\"3699\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3737\" data-start=\"3699\"\u003eAnti-apoptotic protein interactions\u003c\/td\u003e\n\u003ctd data-end=\"3769\" data-start=\"3737\" data-col-size=\"md\"\u003eReduced programmed cell death\u003c\/td\u003e\n\u003ctd data-end=\"3833\" data-start=\"3769\" data-col-size=\"md\"\u003eBroad cytoprotection \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4004\" data-start=\"3834\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3872\" data-start=\"3834\"\u003eAMPK \/ metabolic signaling interest\u003c\/td\u003e\n\u003ctd data-end=\"3931\" data-start=\"3872\" data-col-size=\"md\"\u003ePossible calorie-restriction-mimetic \/ metabolic effects\u003c\/td\u003e\n\u003ctd data-end=\"4004\" data-start=\"3931\" data-col-size=\"md\"\u003eAging and metabolism research \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4211\" data-start=\"4005\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"4050\" data-start=\"4005\"\u003eAnti-aggregation \/ chaperone-like activity\u003c\/td\u003e\n\u003ctd data-end=\"4116\" data-start=\"4050\" data-col-size=\"md\"\u003eInhibition of toxic protein misfolding \/ seeding in some models\u003c\/td\u003e\n\u003ctd data-end=\"4211\" data-start=\"4116\" data-col-size=\"md\"\u003eAmyloid and diabetes-related proteinopathy research \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp data-end=\"4374\" data-start=\"4213\"\u003eThese pathways make HNG biologically interesting, but they still do \u003cstrong data-end=\"4288\" data-start=\"4281\"\u003enot\u003c\/strong\u003e establish strong clinical efficacy in humans. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"4398\" data-start=\"4376\" data-section-id=\"b8x6nr\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cp data-end=\"4885\" data-start=\"4400\"\u003e\u003cstrong data-end=\"4419\" data-start=\"4400\"\u003eRoutes studied:\u003c\/strong\u003e mainly experimental systemic administration and other preclinical delivery strategies. The practical problem is that HNG is still a \u003cstrong data-end=\"4563\" data-start=\"4552\"\u003epeptide\u003c\/strong\u003e, so stability, distribution, and dosing remain major translational issues. The field’s interest in HNG comes more from its \u003cstrong data-end=\"4727\" data-start=\"4687\"\u003ehigher potency versus native humanin\u003c\/strong\u003e than from any clearly solved delivery platform. That is one reason why the evidence base remains heavily preclinical. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"4927\" data-start=\"4887\" data-section-id=\"we631\"\u003e4. Pre-clinical and clinical evidence\u003c\/h2\u003e\n\u003ch3 data-end=\"4952\" data-start=\"4929\" data-section-id=\"18hyb4d\"\u003e4.1 Neuroprotection\u003c\/h3\u003e\n\u003cp data-end=\"5436\" data-start=\"4954\"\u003eThis is the \u003cstrong data-end=\"4990\" data-start=\"4966\"\u003ebest-supported niche\u003c\/strong\u003e. Reviews and primary studies report that HNG protects neurons in models of ischemia\/reoxygenation, amyloid toxicity, and other neurodegenerative stressors. For example, one study found HNG protected against oxygen-glucose-deprivation\/reoxygenation injury through \u003cstrong data-end=\"5281\" data-start=\"5254\"\u003eJAK2\/STAT3 via PI3K\/AKT\u003c\/strong\u003e signaling. That is a credible neuroprotective signal, but it is still \u003cstrong data-end=\"5378\" data-start=\"5352\"\u003ecell \/ animal evidence\u003c\/strong\u003e, not human proof. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"5498\" data-start=\"5438\" data-section-id=\"1s0u46s\"\u003e4.2 Metabolic disease and diabetes-related proteinopathy\u003c\/h3\u003e\n\u003cp data-end=\"5903\" data-start=\"5500\"\u003eHNG has also drawn attention in metabolic disease because it can interfere with \u003cstrong data-end=\"5609\" data-start=\"5580\"\u003eIAPP misfolding \/ seeding\u003c\/strong\u003e and is discussed alongside beneficial metabolic effects of mitochondrial-derived peptides. This is one of the more interesting mechanistic extensions beyond neurology, but it remains an early translational story rather than established diabetes therapy. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"5938\" data-start=\"5905\" data-section-id=\"wei8dv\"\u003e4.3 Cardiovascular protection\u003c\/h3\u003e\n\u003cp data-end=\"6345\" data-start=\"5940\"\u003eHNG has shown protective effects in cardiovascular injury models. A 2020 large-animal myocardial ischemia\/reperfusion study reported reduced infarct size at one ischemic duration, while another preclinical heart-failure study suggested delayed dysfunction and remodeling in mice. Those are encouraging signals, but they are still preclinical and condition-specific. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"6402\" data-start=\"6347\" data-section-id=\"gmyvgb\"\u003e4.4 Aging, inflammation, and broader cytoprotection\u003c\/h3\u003e\n\u003cp data-end=\"6772\" data-start=\"6404\"\u003eReviews describe HNG as a potent humanin analog with cytoprotective roles across age-related disease models, and animal work suggests it may improve some metabolic healthspan and inflammatory parameters. That is enough to justify \u003cstrong data-end=\"6660\" data-start=\"6634\"\u003ehealthy-aging interest\u003c\/strong\u003e, but not enough to justify calling HNG a proven longevity intervention. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"6796\" data-start=\"6774\" data-section-id=\"10aj1ph\"\u003e4.5 Human evidence\u003c\/h3\u003e\n\u003cp data-end=\"7169\" data-start=\"6798\"\u003eThis is the weak point. I did \u003cstrong data-end=\"6835\" data-start=\"6828\"\u003enot\u003c\/strong\u003e find good evidence of established therapeutic human clinical trials for HNG itself in the sources reviewed. The literature is dominated by \u003cstrong data-end=\"7020\" data-start=\"6975\"\u003ecell studies, animal studies, and reviews\u003c\/strong\u003e. That absence matters: HNG may be biologically impressive, but it is still not a validated clinical peptide. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"7204\" data-start=\"7171\" data-section-id=\"1uuy0po\"\u003e5. Emerging clinical interests\u003c\/h2\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"7858\" data-start=\"7206\"\u003e\n\u003cthead data-end=\"7236\" data-start=\"7206\"\u003e\n\u003ctr data-end=\"7236\" data-start=\"7206\"\u003e\n\u003cth class=\"\" data-col-size=\"sm\" data-end=\"7214\" data-start=\"7206\"\u003eField\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"7226\" data-start=\"7214\"\u003eRationale\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"sm\" data-end=\"7236\" data-start=\"7226\"\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"7858\" data-start=\"7251\"\u003e\n\u003ctr data-end=\"7380\" data-start=\"7251\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7289\" data-start=\"7251\"\u003eNeurodegeneration \/ ischemic injury\u003c\/td\u003e\n\u003ctd data-end=\"7319\" data-start=\"7289\" data-col-size=\"md\"\u003eStrongest historic use case\u003c\/td\u003e\n\u003ctd data-end=\"7380\" data-start=\"7319\" data-col-size=\"sm\"\u003ePreclinical-heavy \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7499\" data-start=\"7381\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7407\" data-start=\"7381\"\u003eMetabolic disease \/ T2D\u003c\/td\u003e\n\u003ctd data-end=\"7444\" data-start=\"7407\" data-col-size=\"md\"\u003eAnti-amyloid and metabolic effects\u003c\/td\u003e\n\u003ctd data-end=\"7499\" data-start=\"7444\" data-col-size=\"sm\"\u003eExploratory \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7614\" data-start=\"7500\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7524\" data-start=\"7500\"\u003eCardiovascular injury\u003c\/td\u003e\n\u003ctd data-end=\"7559\" data-start=\"7524\" data-col-size=\"md\"\u003eCytoprotection in MI \/ HF models\u003c\/td\u003e\n\u003ctd data-end=\"7614\" data-start=\"7559\" data-col-size=\"sm\"\u003ePreclinical \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7725\" data-start=\"7615\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7630\" data-start=\"7615\"\u003eHair biology\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7664\" data-start=\"7630\"\u003eAnti-apoptotic follicle effects\u003c\/td\u003e\n\u003ctd data-end=\"7725\" data-start=\"7664\" data-col-size=\"sm\"\u003eEarly preclinical \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7858\" data-start=\"7726\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7757\" data-start=\"7726\"\u003eHealthy aging \/ inflammation\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7803\" data-start=\"7757\"\u003eHealthspan and inflammatory-marker interest\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7858\" data-start=\"7803\"\u003eExploratory \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch2 data-end=\"7889\" data-start=\"7860\" data-section-id=\"7gr288\"\u003e6. Safety and tolerability\u003c\/h2\u003e\n\u003cp data-end=\"8356\" data-start=\"7891\"\u003eThere is \u003cstrong data-end=\"7935\" data-start=\"7900\"\u003eno mature human safety database\u003c\/strong\u003e for HNG comparable to what would be expected for an approved drug. The reassuring part is that many preclinical studies report beneficial effects without obvious major toxicity signals in their model systems, but that is \u003cstrong data-end=\"8173\" data-start=\"8157\"\u003enot the same\u003c\/strong\u003e as establishing human short-term or long-term safety. The best overall safety framing is therefore \u003cstrong data-end=\"8315\" data-start=\"8273\"\u003einsufficiently characterized in humans\u003c\/strong\u003e. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"8394\" data-start=\"8358\" data-section-id=\"fttgrx\"\u003e7. Contraindications and cautions\u003c\/h2\u003e\n\u003cp data-end=\"8419\" data-start=\"8396\"\u003eUse extra caution with:\u003c\/p\u003e\n\u003cul data-end=\"9144\" data-start=\"8421\"\u003e\n\u003cli data-end=\"8608\" data-start=\"8421\" data-section-id=\"pegey\"\u003e\n\u003cstrong data-end=\"8509\" data-start=\"8423\"\u003eAny claim that HNG is a proven anti-aging, neuroregenerative, or metabolic therapy\u003c\/strong\u003e, because the evidence remains predominantly preclinical. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8771\" data-start=\"8609\" data-section-id=\"1ap4vt0\"\u003e\n\u003cstrong data-end=\"8661\" data-start=\"8611\"\u003eSelf-experimentation \/ gray-market peptide use\u003c\/strong\u003e, because clinical dosing, efficacy, and safety are not established. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8961\" data-start=\"8772\" data-section-id=\"jherh1\"\u003e\n\u003cstrong data-end=\"8818\" data-start=\"8774\"\u003eAssuming potency equals clinical utility\u003c\/strong\u003e, because HNG’s stronger activity than native humanin does not solve the broader translation problem. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9144\" data-start=\"8962\" data-section-id=\"hi8b1b\"\u003e\n\u003cstrong data-end=\"8994\" data-start=\"8964\"\u003eReplacing standard therapy\u003c\/strong\u003e for neurodegenerative, cardiovascular, metabolic, or hair conditions, because HNG is still investigational. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 data-end=\"9180\" data-start=\"9146\" data-section-id=\"o35cra\"\u003e8. Comparative practical matrix\u003c\/h2\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"9745\" data-start=\"9182\"\u003e\n\u003cthead data-end=\"9199\" data-start=\"9182\"\u003e\n\u003ctr data-end=\"9199\" data-start=\"9182\"\u003e\n\u003cth class=\"\" data-col-size=\"sm\" data-end=\"9192\" data-start=\"9182\"\u003eFeature\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"9199\" data-start=\"9192\"\u003eHNG\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"9745\" data-start=\"9210\"\u003e\n\u003ctr data-end=\"9293\" data-start=\"9210\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"9226\" data-start=\"9210\"\u003eMain strength\u003c\/td\u003e\n\u003ctd data-end=\"9293\" data-start=\"9226\" data-col-size=\"md\"\u003eInvestigational cytoprotective \/ neuroprotective humanin analog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"9351\" data-start=\"9294\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"9320\" data-start=\"9294\"\u003eBest-supported use case\u003c\/td\u003e\n\u003ctd data-end=\"9351\" data-start=\"9320\" data-col-size=\"md\"\u003ePreclinical neuroprotection\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"9394\" data-start=\"9352\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"9378\" data-start=\"9352\"\u003eClinical evidence depth\u003c\/td\u003e\n\u003ctd data-end=\"9394\" data-start=\"9378\" data-col-size=\"md\"\u003eVery limited\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"9455\" data-start=\"9395\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"9413\" data-start=\"9395\"\u003eCore limitation\u003c\/td\u003e\n\u003ctd data-end=\"9455\" data-start=\"9413\" data-col-size=\"md\"\u003eMostly animal and mechanistic evidence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"9558\" data-start=\"9456\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"9480\" data-start=\"9456\"\u003eMain mechanism themes\u003c\/td\u003e\n\u003ctd data-end=\"9558\" data-start=\"9480\" data-col-size=\"md\"\u003eAnti-apoptotic, JAK\/STAT, PI3K\/AKT, metabolic \/ anti-aggregation signaling\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"9626\" data-start=\"9559\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"9583\" data-start=\"9559\"\u003eMain delivery problem\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"9626\" data-start=\"9583\"\u003ePeptide translation and PK practicality\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"9677\" data-start=\"9627\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"9649\" data-start=\"9627\"\u003eMain safety concern\u003c\/td\u003e\n\u003ctd data-end=\"9677\" data-start=\"9649\" data-col-size=\"md\"\u003eSparse human safety data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"9745\" data-start=\"9678\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"9703\" data-start=\"9678\"\u003eBest practical framing\u003c\/td\u003e\n\u003ctd data-end=\"9745\" data-start=\"9703\" data-col-size=\"md\"\u003eResearch peptide, not a proven therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch2 data-end=\"9773\" data-start=\"9747\" data-section-id=\"n437ah\"\u003e9. Regulatory landscape\u003c\/h2\u003e\n\u003cp data-end=\"10166\" data-start=\"9775\"\u003eHNG is best understood as a \u003cstrong data-end=\"9823\" data-start=\"9803\"\u003eresearch peptide\u003c\/strong\u003e, not an approved drug, established supplement, or validated medical treatment. The literature validates \u003cstrong data-end=\"9951\" data-start=\"9928\"\u003escientific interest\u003c\/strong\u003e, not routine clinical use. That distinction is important because the public-facing peptide market often makes HNG sound much closer to translation than the evidence supports. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"10192\" data-start=\"10168\" data-section-id=\"1fjxpfd\"\u003e10. Future directions\u003c\/h2\u003e\n\u003cp data-end=\"10231\" data-start=\"10194\"\u003eThe most useful future work would be:\u003c\/p\u003e\n\u003cul data-end=\"10605\" data-start=\"10233\"\u003e\n\u003cli data-end=\"10287\" data-start=\"10233\" data-section-id=\"y9xl1f\"\u003ereal \u003cstrong data-end=\"10284\" data-start=\"10240\"\u003ehuman pharmacokinetic and safety studies\u003c\/strong\u003e,\u003c\/li\u003e\n\u003cli data-end=\"10391\" data-start=\"10288\" data-section-id=\"1s7stxk\"\u003eindication-specific trials in \u003cstrong data-end=\"10388\" data-start=\"10320\"\u003eneurology, cardiometabolic disease, or aging-related dysfunction\u003c\/strong\u003e,\u003c\/li\u003e\n\u003cli data-end=\"10459\" data-start=\"10392\" data-section-id=\"hpwukc\"\u003eclearer definition of which \u003cstrong data-end=\"10456\" data-start=\"10422\"\u003emechanisms matter most in vivo\u003c\/strong\u003e,\u003c\/li\u003e\n\u003cli data-end=\"10605\" data-start=\"10460\" data-section-id=\"6d5jlj\"\u003eand better delivery strategies that make HNG clinically practical rather than just biologically potent. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 data-end=\"10631\" data-start=\"10607\" data-section-id=\"1uk6y2z\"\u003eBest balanced summary\u003c\/h2\u003e\n\u003cp data-end=\"11078\" data-start=\"10633\"\u003e\u003cstrong data-end=\"11038\" data-start=\"10633\"\u003eHNG is best viewed as a potent synthetic humanin analog with substantial preclinical evidence for cytoprotective, neuroprotective, metabolic, and cardioprotective effects. Its biology is credible and often impressive in model systems, but the translation gap is large: human therapeutic evidence is minimal, safety is not well characterized clinically, and there is no established approved indication.\u003c\/strong\u003e\u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"11102\" data-start=\"11080\" data-section-id=\"xxd8hg\"\u003eSelected references\u003c\/h2\u003e\n\u003cul data-end=\"12251\" data-start=\"11104\"\u003e\n\u003cli data-end=\"11302\" data-start=\"11104\" data-section-id=\"1fte5rj\"\u003e\n\u003cstrong data-end=\"11132\" data-start=\"11106\"\u003eKarachaliou CE, et al.\u003c\/strong\u003e \u003cem data-end=\"11191\" data-start=\"11133\"\u003eNeuroprotective Action of Humanin and Humanin Analogues.\u003c\/em\u003e Good modern review of humanin analog neuroprotection, including HNG. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"11488\" data-start=\"11303\" data-section-id=\"rzm27f\"\u003e\n\u003cstrong data-end=\"11329\" data-start=\"11305\"\u003eCoradduzza D, et al.\u003c\/strong\u003e \u003cem data-end=\"11382\" data-start=\"11330\"\u003eHumanin and Its Pathophysiological Roles in Aging.\u003c\/em\u003e Strong review for aging, metabolic, and cytoprotective framing. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"11777\" data-start=\"11489\" data-section-id=\"c2hmpd\"\u003e\n\u003cstrong data-end=\"11509\" data-start=\"11491\"\u003eGao GS, et al.\u003c\/strong\u003e \u003cem data-end=\"11687\" data-start=\"11510\"\u003eHumanin analogue, S14G-humanin, has neuroprotective effects against oxygen glucose deprivation\/reoxygenation by reactivating Jak2\/Stat3 signaling through the PI3K\/AKT pathway.\u003c\/em\u003e Good primary mechanistic neuroprotection study. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"12023\" data-start=\"11778\" data-section-id=\"14a3hmi\"\u003e\n\u003cstrong data-end=\"11800\" data-start=\"11780\"\u003eOkada AK, et al.\u003c\/strong\u003e \u003cem data-end=\"11923\" data-start=\"11801\"\u003eThe Mitochondrial-Derived Peptides, HumaninS14G and SHLP2, inhibit the formation of misfolded islet amyloid polypeptide.\u003c\/em\u003e Best source for the anti-aggregation \/ T2D-related angle. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"12251\" data-start=\"12024\" data-section-id=\"1ru7h9g\"\u003e\n\u003cstrong data-end=\"12050\" data-start=\"12026\"\u003eSharp TE III, et al.\u003c\/strong\u003e \u003cem data-end=\"12164\" data-start=\"12051\"\u003eEfficacy of a Novel Mitochondrial-Derived Peptide in a Porcine Model of Myocardial Ischemia\/Reperfusion Injury.\u003c\/em\u003e Best source for large-animal cardioprotection.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":55718672728328,"sku":null,"price":100.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0937\/9053\/5944\/files\/HNG_10mg.png?v=1775181406"},{"product_id":"colivelin-10mg-vial","title":"Colivelin 10mg vial","description":"\u003cp data-end=\"697\" data-start=\"104\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                             \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"697\" data-start=\"104\"\u003e\u003cstrong data-end=\"117\" data-start=\"104\"\u003eColivelin\u003c\/strong\u003e is best viewed as an \u003cstrong data-end=\"189\" data-start=\"139\"\u003einvestigational hybrid neuroprotective peptide\u003c\/strong\u003e, not a proven therapeutic or consumer nootropic \/ anti-aging peptide. It was designed by combining \u003cstrong data-end=\"299\" data-start=\"289\"\u003eADNF-9\u003c\/strong\u003e with a potent \u003cstrong data-end=\"336\" data-start=\"314\"\u003ehumanin derivative\u003c\/strong\u003e, with the goal of producing stronger neuroprotection than humanin-family peptides alone. The strongest evidence is still \u003cstrong data-end=\"473\" data-start=\"458\"\u003epreclinical\u003c\/strong\u003e, especially in \u003cstrong data-end=\"611\" data-start=\"489\"\u003eAlzheimer’s-disease-related models, ischemic injury, alcohol-induced neurotoxicity, and other neuronal-stress settings\u003c\/strong\u003e. Human efficacy evidence is essentially absent. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"754\" data-start=\"699\" data-section-id=\"o991e0\"\u003eAdditional benefits of colivelin under investigation\u003c\/h2\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"2490\" data-start=\"756\"\u003e\n\u003cthead data-end=\"779\" data-start=\"756\"\u003e\n\u003ctr data-end=\"779\" data-start=\"756\"\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"766\" data-start=\"756\"\u003eBenefit\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"xl\" data-end=\"779\" data-start=\"766\"\u003eTake-away\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"2490\" data-start=\"790\"\u003e\n\u003ctr data-end=\"1052\" data-start=\"790\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"841\" data-start=\"790\"\u003e1. Alzheimer’s \/ amyloid-related neuroprotection\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1052\" data-start=\"841\"\u003eThis is the clearest use case. Colivelin showed strong protection against amyloid-related toxicity and improved memory in AD-model animals, but this remains preclinical. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1293\" data-start=\"1053\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1092\" data-start=\"1053\"\u003e2. Potentiated humanin-like activity\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1293\" data-start=\"1092\"\u003eColivelin was specifically created to be more potent than humanin derivatives alone, and early work reported activity at extremely low concentrations in vitro. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1484\" data-start=\"1294\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1324\" data-start=\"1294\"\u003e3. Ischemic neuroprotection\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1484\" data-start=\"1324\"\u003eAnimal work suggests protection of neurons and axons after ischemic injury, with anti-apoptotic signaling involvement. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1674\" data-start=\"1485\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1531\" data-start=\"1485\"\u003e4. Alcohol-related neurotoxicity protection\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1674\" data-start=\"1531\"\u003eColivelin reduced alcohol-induced apoptosis in neuronal models and in a fetal alcohol exposure model. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1862\" data-start=\"1675\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1714\" data-start=\"1675\"\u003e5. JAK2\/STAT3 and survival signaling\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1862\" data-start=\"1714\"\u003eA major mechanistic theme is activation of pro-survival pathways associated with humanin-family signaling. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2094\" data-start=\"1863\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1911\" data-start=\"1863\"\u003e6. CNS delivery interest via intranasal route\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2094\" data-start=\"1911\"\u003eIntranasal administration improved memory in AD-model mice and reached the CNS in preclinical work, which is a notable translational feature. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2310\" data-start=\"2095\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2147\" data-start=\"2095\"\u003e7. Broad neurotrophic \/ anti-apoptotic reputation\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2310\" data-start=\"2147\"\u003eReviews describe it as a promising neurotrophic peptide, but that reputation is driven mainly by cell and animal studies. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2490\" data-start=\"2311\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2361\" data-start=\"2311\"\u003e8. Not a proven human neurodegenerative therapy\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2490\" data-start=\"2361\"\u003eThe evidence base is overwhelmingly preclinical, with no established clinical efficacy. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch2 data-end=\"2527\" data-start=\"2492\" data-section-id=\"aq0rfb\"\u003e2. Molecular mechanism of action\u003c\/h2\u003e\n\u003ch3 data-end=\"2562\" data-start=\"2529\" data-section-id=\"jvsoby\"\u003e2.1 Receptor pharmacodynamics\u003c\/h3\u003e\n\u003cp data-end=\"2991\" data-start=\"2564\"\u003eColivelin does \u003cstrong data-end=\"2586\" data-start=\"2579\"\u003enot\u003c\/strong\u003e behave like a conventional small-molecule CNS drug. It is a \u003cstrong data-end=\"2665\" data-start=\"2647\"\u003ehybrid peptide\u003c\/strong\u003e built from \u003cstrong data-end=\"2687\" data-start=\"2677\"\u003eADNF-9\u003c\/strong\u003e and a potent \u003cstrong data-end=\"2719\" data-start=\"2701\"\u003ehumanin analog\u003c\/strong\u003e, intended to combine complementary neuroprotective properties. The literature ties its action mainly to \u003cstrong data-end=\"2871\" data-start=\"2824\"\u003ehumanin-related receptor\/survival signaling\u003c\/strong\u003e, especially \u003cstrong data-end=\"2898\" data-start=\"2884\"\u003eJAK2\/STAT3\u003c\/strong\u003e, rather than to one clean classic drug-receptor model. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"3019\" data-start=\"2993\" data-section-id=\"1c3fl0f\"\u003e2.2 Downstream biology\u003c\/h3\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"3699\" data-start=\"3021\"\u003e\n\u003cthead data-end=\"3071\" data-start=\"3021\"\u003e\n\u003ctr data-end=\"3071\" data-start=\"3021\"\u003e\n\u003cth class=\"\" data-col-size=\"sm\" data-end=\"3039\" data-start=\"3021\"\u003ePathway \/ theme\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"3060\" data-start=\"3039\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"3071\" data-start=\"3060\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"3699\" data-start=\"3086\"\u003e\n\u003ctr data-end=\"3242\" data-start=\"3086\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3118\" data-start=\"3086\"\u003eJAK2\/STAT3 survival signaling\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3161\" data-start=\"3118\"\u003eAnti-apoptotic \/ neuroprotective effects\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3242\" data-start=\"3161\"\u003eAD-related and neuronal-injury models \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3397\" data-start=\"3243\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3275\" data-start=\"3243\"\u003eHumanin-family cytoprotection\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3329\" data-start=\"3275\"\u003eResistance to amyloid and familial AD-gene toxicity\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3397\" data-start=\"3329\"\u003eNeurodegeneration models \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3545\" data-start=\"3398\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3425\" data-start=\"3398\"\u003eAnti-apoptotic signaling\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3475\" data-start=\"3425\"\u003eReduced neuronal death in toxic-stress settings\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3545\" data-start=\"3475\"\u003eAlcohol, ischemia, amyloid \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3699\" data-start=\"3546\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3569\" data-start=\"3546\"\u003eNeurotrophic support\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3631\" data-start=\"3569\"\u003ePreservation of neurons \/ axons and memory-related function\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3699\" data-start=\"3631\"\u003ePreclinical CNS research \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp data-end=\"3857\" data-start=\"3701\"\u003eThese mechanisms are biologically compelling, but they still do \u003cstrong data-end=\"3772\" data-start=\"3765\"\u003enot\u003c\/strong\u003e establish strong clinical benefit in humans. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"3881\" data-start=\"3859\" data-section-id=\"b8x6nr\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cp data-end=\"4245\" data-start=\"3883\"\u003e\u003cstrong data-end=\"3902\" data-start=\"3883\"\u003eRoutes studied:\u003c\/strong\u003e mostly experimental administration in animals, including \u003cstrong data-end=\"3983\" data-start=\"3960\"\u003eintranasal delivery\u003c\/strong\u003e. The intranasal work is one of the more interesting translational aspects, because it suggests a less invasive way to reach the CNS. But this remains a \u003cstrong data-end=\"4166\" data-start=\"4136\"\u003epreclinical delivery story\u003c\/strong\u003e, not an established clinical platform. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"4287\" data-start=\"4247\" data-section-id=\"we631\"\u003e4. Pre-clinical and clinical evidence\u003c\/h2\u003e\n\u003ch3 data-end=\"4323\" data-start=\"4289\" data-section-id=\"t6khxa\"\u003e4.1 Alzheimer’s disease models\u003c\/h3\u003e\n\u003cp data-end=\"4722\" data-start=\"4325\"\u003eThis is the \u003cstrong data-end=\"4361\" data-start=\"4337\"\u003ebest-supported niche\u003c\/strong\u003e. Colivelin suppressed neuronal death induced by amyloid and familial-AD-related insults in vitro, and later animal studies found \u003cstrong data-end=\"4522\" data-start=\"4491\"\u003eimproved memory performance\u003c\/strong\u003e in AD-model mice. That is enough to explain why colivelin is often discussed as an anti-AD peptide, but it is still \u003cstrong data-end=\"4664\" data-start=\"4639\"\u003eanimal-model evidence\u003c\/strong\u003e, not human proof. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"4747\" data-start=\"4724\" data-section-id=\"1ada6oe\"\u003e4.2 Ischemic injury\u003c\/h3\u003e\n\u003cp data-end=\"4994\" data-start=\"4749\"\u003eA 2019 study reported that colivelin rescued ischemic neurons and axons and was associated with elevated anti-apoptotic gene expression. This supports a broader neuroprotection story beyond amyloid models. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"5033\" data-start=\"4996\" data-section-id=\"1e3u982\"\u003e4.3 Alcohol-induced neurotoxicity\u003c\/h3\u003e\n\u003cp data-end=\"5320\" data-start=\"5035\"\u003eColivelin also showed protection against alcohol-induced neuronal apoptosis in both primary cortical neurons and a mouse fetal alcohol exposure model. That widens its preclinical neuroprotective profile, though still without clinical validation. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"5344\" data-start=\"5322\" data-section-id=\"cnwh1g\"\u003e4.4 Human evidence\u003c\/h3\u003e\n\u003cp data-end=\"5632\" data-start=\"5346\"\u003eThis is the weak point. I did \u003cstrong data-end=\"5383\" data-start=\"5376\"\u003enot\u003c\/strong\u003e find evidence of established therapeutic human clinical trials showing efficacy for colivelin. The literature is dominated by \u003cstrong data-end=\"5555\" data-start=\"5510\"\u003ecell studies, animal studies, and reviews\u003c\/strong\u003e. That absence is a major limitation. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"5667\" data-start=\"5634\" data-section-id=\"1uuy0po\"\u003e5. Emerging clinical interests\u003c\/h2\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"6319\" data-start=\"5669\"\u003e\n\u003cthead data-end=\"5699\" data-start=\"5669\"\u003e\n\u003ctr data-end=\"5699\" data-start=\"5669\"\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"5677\" data-start=\"5669\"\u003eField\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"5689\" data-start=\"5677\"\u003eRationale\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"5699\" data-start=\"5689\"\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"6319\" data-start=\"5714\"\u003e\n\u003ctr data-end=\"5864\" data-start=\"5714\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5759\" data-start=\"5714\"\u003eAlzheimer’s disease \/ cognitive impairment\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5803\" data-start=\"5759\"\u003eStrongest historical development interest\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5864\" data-start=\"5803\"\u003ePreclinical-heavy \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6001\" data-start=\"5865\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5889\" data-start=\"5865\"\u003eIschemic brain injury\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5934\" data-start=\"5889\"\u003eAnti-apoptotic and axon-protective effects\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"6001\" data-start=\"5934\"\u003eExploratory preclinical \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6172\" data-start=\"6002\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"6050\" data-start=\"6002\"\u003eDevelopmental \/ alcohol-related neurotoxicity\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"6105\" data-start=\"6050\"\u003eProtection against apoptosis in fetal alcohol models\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"6172\" data-start=\"6105\"\u003eExploratory preclinical \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6319\" data-start=\"6173\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"6199\" data-start=\"6173\"\u003eBroad neurodegeneration\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"6241\" data-start=\"6199\"\u003eHumanin-family \/ neurotrophic rationale\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"6319\" data-start=\"6241\"\u003ePlausible, but unproven clinically \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch2 data-end=\"6350\" data-start=\"6321\" data-section-id=\"7gr288\"\u003e6. Safety and tolerability\u003c\/h2\u003e\n\u003cp data-end=\"6693\" data-start=\"6352\"\u003eThere is \u003cstrong data-end=\"6396\" data-start=\"6361\"\u003eno mature human safety database\u003c\/strong\u003e for colivelin comparable to an approved drug. The peptide appears workable in animal studies, but that is not enough to establish human short-term or long-term safety. The best overall safety framing is therefore \u003cstrong data-end=\"6652\" data-start=\"6610\"\u003einsufficiently characterized in humans\u003c\/strong\u003e. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"6731\" data-start=\"6695\" data-section-id=\"fttgrx\"\u003e7. Contraindications and cautions\u003c\/h2\u003e\n\u003cp data-end=\"6756\" data-start=\"6733\"\u003eUse extra caution with:\u003c\/p\u003e\n\u003cul data-end=\"7409\" data-start=\"6758\"\u003e\n\u003cli data-end=\"6941\" data-start=\"6758\" data-section-id=\"1creixa\"\u003e\n\u003cstrong data-end=\"6841\" data-start=\"6760\"\u003eany claim that colivelin is a proven Alzheimer’s or neuroregenerative therapy\u003c\/strong\u003e, because the evidence remains overwhelmingly preclinical. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7108\" data-start=\"6942\" data-section-id=\"1moj5sf\"\u003e\n\u003cstrong data-end=\"6994\" data-start=\"6944\"\u003eself-experimentation \/ gray-market peptide use\u003c\/strong\u003e, because formal human dosing, efficacy, and safety are not established. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7282\" data-start=\"7109\" data-section-id=\"29slfp\"\u003e\n\u003cstrong data-end=\"7183\" data-start=\"7111\"\u003eassuming intranasal animal success will translate directly to humans\u003c\/strong\u003e, because that step has not been demonstrated clinically. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7409\" data-start=\"7283\" data-section-id=\"f073hk\"\u003e\n\u003cstrong data-end=\"7323\" data-start=\"7285\"\u003ereplacing standard neurologic care\u003c\/strong\u003e, because colivelin remains investigational. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 data-end=\"7445\" data-start=\"7411\" data-section-id=\"o35cra\"\u003e8. Comparative practical matrix\u003c\/h2\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"8000\" data-start=\"7447\"\u003e\n\u003cthead data-end=\"7470\" data-start=\"7447\"\u003e\n\u003ctr data-end=\"7470\" data-start=\"7447\"\u003e\n\u003cth class=\"\" data-col-size=\"sm\" data-end=\"7457\" data-start=\"7447\"\u003eFeature\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"7470\" data-start=\"7457\"\u003eColivelin\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"8000\" data-start=\"7481\"\u003e\n\u003ctr data-end=\"7547\" data-start=\"7481\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7497\" data-start=\"7481\"\u003eMain strength\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7547\" data-start=\"7497\"\u003eInvestigational hybrid neuroprotective peptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7625\" data-start=\"7548\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7574\" data-start=\"7548\"\u003eBest-supported use case\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7625\" data-start=\"7574\"\u003ePreclinical Alzheimer’s-related neuroprotection\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7668\" data-start=\"7626\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7652\" data-start=\"7626\"\u003eClinical evidence depth\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7668\" data-start=\"7652\"\u003eVery limited\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7729\" data-start=\"7669\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7687\" data-start=\"7669\"\u003eCore limitation\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7729\" data-start=\"7687\"\u003eMostly animal and mechanistic evidence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7829\" data-start=\"7730\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7754\" data-start=\"7730\"\u003eMain mechanism themes\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7829\" data-start=\"7754\"\u003eHumanin-derived survival signaling, JAK2\/STAT3, anti-apoptotic activity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7888\" data-start=\"7830\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7850\" data-start=\"7830\"\u003eDelivery interest\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7888\" data-start=\"7850\"\u003eIntranasal CNS delivery in animals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7932\" data-start=\"7889\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7911\" data-start=\"7889\"\u003eMain safety concern\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7932\" data-start=\"7911\"\u003eSparse human data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"8000\" data-start=\"7933\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7958\" data-start=\"7933\"\u003eBest practical framing\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"8000\" data-start=\"7958\"\u003eResearch peptide, not a proven therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch2 data-end=\"8028\" data-start=\"8002\" data-section-id=\"n437ah\"\u003e9. Regulatory landscape\u003c\/h2\u003e\n\u003cp data-end=\"8252\" data-start=\"8030\"\u003eColivelin is best understood as a \u003cstrong data-end=\"8084\" data-start=\"8064\"\u003eresearch peptide\u003c\/strong\u003e, not an approved drug or validated supplement. The literature supports serious biologic interest, but not routine clinical use. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"8278\" data-start=\"8254\" data-section-id=\"1fjxpfd\"\u003e10. Future directions\u003c\/h2\u003e\n\u003cp data-end=\"8317\" data-start=\"8280\"\u003eThe most useful future work would be:\u003c\/p\u003e\n\u003cul data-end=\"8684\" data-start=\"8319\"\u003e\n\u003cli data-end=\"8373\" data-start=\"8319\" data-section-id=\"y9xl1f\"\u003ereal \u003cstrong data-end=\"8370\" data-start=\"8326\"\u003ehuman pharmacokinetic and safety studies\u003c\/strong\u003e,\u003c\/li\u003e\n\u003cli data-end=\"8451\" data-start=\"8374\" data-section-id=\"1x5llnd\"\u003eindication-specific trials in \u003cstrong data-end=\"8448\" data-start=\"8406\"\u003eAlzheimer’s disease or ischemic injury\u003c\/strong\u003e,\u003c\/li\u003e\n\u003cli data-end=\"8513\" data-start=\"8452\" data-section-id=\"1w5zks4\"\u003ebetter confirmation of \u003cstrong data-end=\"8500\" data-start=\"8477\"\u003eintranasal delivery\u003c\/strong\u003e in humans,\u003c\/li\u003e\n\u003cli data-end=\"8684\" data-start=\"8514\" data-section-id=\"ketzln\"\u003eand clearer mechanistic separation of what comes from the \u003cstrong data-end=\"8593\" data-start=\"8574\"\u003ehumanin-derived\u003c\/strong\u003e versus \u003cstrong data-end=\"8619\" data-start=\"8601\"\u003eADNF-9-derived\u003c\/strong\u003e portions of the peptide. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 data-end=\"8710\" data-start=\"8686\" data-section-id=\"1uk6y2z\"\u003eBest balanced summary\u003c\/h2\u003e\n\u003cp data-end=\"9225\" data-start=\"8712\"\u003e\u003cstrong data-end=\"9185\" data-start=\"8712\"\u003eColivelin is best viewed as a hybrid humanin\/ADNF-derived investigational peptide with substantial preclinical evidence for neuroprotective and anti-apoptotic effects, especially in Alzheimer’s-related, ischemic, and toxic neuronal-injury models. Its biology is credible and in some studies highly potent, but the translation gap is large: human efficacy evidence is lacking, safety is not well characterized clinically, and there is no established approved indication.\u003c\/strong\u003e\u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"9249\" data-start=\"9227\" data-section-id=\"xxd8hg\"\u003eSelected references\u003c\/h2\u003e\n\u003cul data-end=\"10572\" data-start=\"9251\"\u003e\n\u003cli data-end=\"9518\" data-start=\"9251\" data-section-id=\"19tcbwa\"\u003e\n\u003cstrong data-end=\"9272\" data-start=\"9253\"\u003eChiba T, et al.\u003c\/strong\u003e \u003cem data-end=\"9375\" data-start=\"9273\"\u003eCharacterization of Colivelin-Mediated Neuroprotection Against Alzheimer’s Disease-Relevant Insults.\u003c\/em\u003e Foundational paper describing colivelin as a hybrid peptide and showing very potent neuroprotection. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9791\" data-start=\"9519\" data-section-id=\"10je049\"\u003e\n\u003cstrong data-end=\"9549\" data-start=\"9521\"\u003eMatsuoka M, Hashimoto Y.\u003c\/strong\u003e \u003cem data-end=\"9669\" data-start=\"9550\"\u003eHumanin and colivelin: neuronal-death-suppressing peptides for Alzheimer’s disease and amyotrophic lateral sclerosis.\u003c\/em\u003e Good review-level framing for humanin-family biology and colivelin’s rationale. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"10006\" data-start=\"9792\" data-section-id=\"msyh3k\"\u003e\n\u003cstrong data-end=\"9814\" data-start=\"9794\"\u003eYamada M, et al.\u003c\/strong\u003e \u003cem data-end=\"9904\" data-start=\"9815\"\u003eNasal Colivelin Treatment Ameliorates Memory Impairment Related to Alzheimer’s Disease.\u003c\/em\u003eBest source for intranasal delivery and animal memory data. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"10213\" data-start=\"10007\" data-section-id=\"zpnxhh\"\u003e\n\u003cstrong data-end=\"10026\" data-start=\"10009\"\u003eWu MN, et al.\u003c\/strong\u003e \u003cem data-end=\"10135\" data-start=\"10027\"\u003eColivelin Ameliorates Amyloid β Peptide-Induced Memory Impairment in a Mouse Model of Alzheimer’s Disease.\u003c\/em\u003e Good later in vivo AD-model source. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"10365\" data-start=\"10214\" data-section-id=\"utna9\"\u003e\n\u003cstrong data-end=\"10234\" data-start=\"10216\"\u003eZhao H, et al.\u003c\/strong\u003e \u003cem data-end=\"10281\" data-start=\"10235\"\u003eColivelin Rescues Ischemic Neuron and Axons.\u003c\/em\u003e Best source for ischemic neuroprotection. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"10572\" data-start=\"10366\" data-section-id=\"1fysknz\"\u003e\n\u003cstrong data-end=\"10386\" data-start=\"10368\"\u003eSari Y, et al.\u003c\/strong\u003e \u003cem data-end=\"10483\" data-start=\"10387\"\u003eA novel peptide, colivelin, prevents alcohol-induced apoptosis in fetal brain of C57BL\/6 mice.\u003c\/em\u003e Best source for the alcohol-neurotoxicity angle.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":55801327911176,"sku":null,"price":200.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0937\/9053\/5944\/files\/colivelin_10mg.png?v=1775241411"}],"url":"https:\/\/rcpeptides.com\/hr\/collections\/nootropics.oembed?page=2","provider":"RCpeptides","version":"1.0","type":"link"}